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Abstract 
Introduction 
This thesis reports a research project with a mixed methods research design 
and a pragmatist worldview.  It documents, analyses and reflects upon the 
evolution of a project, that over nine years, examined the challenges of 
designing and implementing a clinical trial design that could capture the 
effect of using Ovarium compositum to support the outcomes of women 
undergoing infertility treatment at Jersey General Hospital. 
 
Aims 
The initial aim of the research project was to design and conduct a 
randomised clinical trial of a homeopathic product, Ovarium compositum, as 
an additional treatment for women undergoing infertility treatment at Jersey 
General Hospital.  When the trial did not meet it’s recruitment target the focus 
of the project switched to an investigation of the reasons for trial failure.  The 
need for a pragmatist philosophical worldview to bring structure and 
understanding to the process of writing and rewriting the thesis became 
increasingly clear as the project evolved. 
 
The aims are divided into two categories, methodological and outcomes. 
Methodological aims include: 
• To explore the appropriate methodology for designing a clinical trial of 
a homeopathic product. 
• To understand the role of a pragmatist worldview in clinical trial design 
and in rewriting a thesis. 
• To understand the use of Mixed Methods Research in healthcare 
research. 
 
Outcome aims include: 
To understand the conceptualisation of infertility and its treatment by 
homotoxicologists in the UK 
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To explore the effectiveness of using Ovarium compositum to treat infertility 
in women. 
To understand the perspective of the women who are being recruited and 
therefore aid trial recruitment. 
 
Trial Design:  
The four strands of the study follow a sequential design that was firstly 
exploratory and then explanatory; a schematic diagram is included after this 
abstract for the overview and for each strand. 
Strand 1: Qualitative review of homotoxicology treatment for Infertility in the 
UK. 
Strand 2: Qualitative study of the feasibility of working with patients and staff, 
based at The Bridge Centre London 
Strand 3: An RCT of Ovarium compositum.  A double blind placebo 
controlled trial seeking to recruit 90 women undergoing infertility treatment at 
Jersey General Hospital. 
Strand 4:  Qualitative investigation into work related concerns of infertile 
women: 
Results: The results from strand one led to a greater understanding of how 
homotoxicologists conceptualise infertility and their responses were used to 
select the trial medication and to check the model validity of the planned 
RCT.  The results from strand 2 were used to check the feasibility of running 
a trial at an infertility unit.  The results highlighted areas such as patient 
distress, the role of nurses as a link between CAM and conventional 
medicine, the additional time needed during appointments. 
Strand 4 led to a conceptual model of the comparative risks and benefits of 
disclosing treatment status at work. The ethical use of data from Internet 
forums is explored as a source of qualitative data. 
 
Conclusion: Pragmatism and MMR were suitable as an approach for the 
investigation of the two research objectives and the rewriting of a thesis.  
There is a need to consider both qualitative and quantitative data when 
planning and conducting a clinical trial of CAM in order to ensure model 
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validity, successful recruitment and retention of patients and meaningful, 
useful results.  Qualitative data may also include data sourced from patient 
forums on the Internet and there are unique ethical considerations when 
using this kind of data that need to be taken into account. 
 
Infertile women have to balance the risks and benefits of treatment 
disclosure.  Future trials including women undergoing infertility treatment 
should consider providing flexible appointment times, support for their 
psychological identity and use a participatory approach towards including 
nursing staff and patients during trial design.   
 
Homotoxicology as a form of complex homeopathy is suitable for evaluation 
using an RCT model as long as there is an appropriate blinding, control 
groups and randomisation.  It is only suitable if there is a homogeneous 
patient pool with a clinical diagnosis that matches the indications for the 
remedy being tested.   
 
Limitations: It was not possible to assess the effectiveness of Ovarium 
compositum in the treatment of women undergoing infertility treatment.  The 
failure of strand 3 (RCT of Ovarium compositum) to meet it’s recruitment 
target can largely be attributed to the fact that the researcher did not take 
sufficient account of the perspectives of staff at the unit and the pressures 
faced by the women attending as patients.   The differences between a clinic 
in London and a clinic in Jersey were not adequately explored.  The 
importance of using both qualitative and quantitative data to plan a trial and 
attaching equal value to both approaches is acknowledged to be one of the 
major lessons of this thesis.  The need for a systematic approach to the 
literature review was also highlighted during viva examination and addressed 
as part of the corrections submitted. 
 
Funding: This PhD study was funded by educational grants from BioPathica 
Ltd and Heel GmbH. 
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Strand	  1.	  Qualitative	  review	  of	  homotoxicology	  treatment	  for	  Infertility	  in	  the	  UK.	  Method:	  Questionnaire	  sent	  to	  60	  UK	  homotoxicology	  practitioners	  and	  Thematic	  Analysis	  of	  results.	  	  Results:	  33%	  return	  rate,	  16	  analysed	  to	  inform	  study	  with	  theoretical	  framework	  and	  choice	  of	  trial	  medication.	  
Strand	  2.	  Qualitative	  study	  of	  the	  feasiblility	  of	  working	  with	  patients	  and	  staff,	  based	  at	  The	  Bridge	  Centre	  London.	  	  Methods:	  Discussion	  group/questionnaire	  to	  sample	  of	  5	  nurses	  and	  questionnaires	  completed	  by	  24	  patients.	  	  Results	  generated	  links	  to	  nursing	  theory	  and	  insights	  into	  nurse	  and	  patient	  perspectives.	  	  InsufXiciently	  integrated	  into	  trial	  management	  and	  design.	  
Strand	  3.	  Quantitative	  .	  A	  RCT	  of	  Ovarium	  compositum.	  	  A	  double	  blind	  placebo	  controlled	  trial	  seeking	  to	  recruit	  90	  women	  undergoing	  infertility	  treatment	  at	  Jersey	  General	  Hospital.	  	  Results:	  Trial	  closed	  early	  due	  to	  failure	  to	  meet	  recruitment	  targets.	  
Strand	  4.	  	  Qualitative	  investigation	  into	  work	  related	  concerns	  of	  infertile	  women.	  	  Data	  sourced	  from	  Infertility	  Internet	  Forums.	  	  Analysis	  of	  7	  direct	  responses	  and	  213	  postings.	  	  Results:	  the	  Risk	  BeneXit	  Model	  of	  Disclosure	  leading	  to	  improved	  understanding	  of	  trial	  design	  and	  treatment	  delivery.	  
	  	  Road	  Map	  for	  Thesis:	  A	  Schematic	  Overview	  of	  the	  Thesis.	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Strand	  1	  
60	  copies	  of	  the	  questionnaire	  distributed	  to	  homotoxicologists	  in	  the	  UK	  	  
20	  replies	  received	  
17	  considered	  for	  analysis.	  3	  negative	  responses	  and	  1	  potentially	  biased	  response	  excluded.	  
16	  analysed	  =	  33%	  
Thematic	  Analysis	  of	  Q2,3,4	  leading	  to	  insights	  inot	  the	  role	  of	  CAM	  practitioners	  as	  advisors	  and	  the	  exogenous	  and	  endogenous	  inRluences	  on	  Infertility	  
Numerical	  analysis	  of	  Q1	  leading	  to	  a	  choice	  of	  Ovarium	  compositum	  as	  trial	  medication	  
40	  not	  returned.	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Strand	  2	  
The	  Feasibility	  Study	  at	  the	  Bridge	  Centre	  
Matron	  as	  key	  contact	  and	  facilitator	  
Discussion	  group	  of	  5	  nurses.	  
Discussion	  group	  and	  questionnaire	  	  
Thematic	  Analysis	  of	  results	  
Nurses	  seen	  as	  a	  'bridge'	  with	  the	  following	  themes:	  boundaries	  of	  their	  professional	  role,	  the	  need	  for	  a	  theoretical	  perspceive,	  concerns	  about	  practical	  implementation,	  need	  for	  nurse	  involvement	  in	  trial	  design.	  
127	  patient	  questionnaires	  in	  waiting	  room.	  
103	  not	  returned,	  24	  completed	  and	  returned	  (19%).	  	  Results	  indicate	  patients	  are	  likely	  to	  consent	  to	  randomisation	  and	  to	  be	  motivated	  to	  take	  part.	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Strand	  3	  
RCT	  placebo	  controlled	  double	  blind	  trial	  of	  Ovarium	  compositum	  at	  Jersey	  General	  Hospital	  
4	  Patients	  consented	  and	  4	  more	  invited.	  
Recruitment	  Target	  not	  met	  and	  trial	  closed.	   Hypothesis	  regarding	  trial	  closure	  generated	  by	  unit	  staff.	  
INTRODUCTION 
 	  
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   12	  
 
 
Strand	  4	  
The	  work	  related	  concerns	  of	  infertile	  women.	  
Question	  posted	  on	  infertility	  forums	  
Direct	  response	  from	  7	  forum	  users	  
Feedback	  from	  unit	  staff	   Thematic	  Analysis	  of	  data	  and	  initial	  codes	  generated	  
213	  internet	  forum	  posting	  analysed	  for	  themes	  generated	  in	  smaller	  sample	  
Risk	  BeneRit	  model	  of	  disclosure	  developed	  and	  improved	  understanding	  of	  trial	  design	  and	  practice.	  
New	  literature	  searches,	  use	  of	  theory	  and	  new	  world	  view.	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Introduction  
The aim of this thesis is to explore the need for high quality evidence that 
respects the unique features of homotoxicology and the holistic needs of the 
infertile female patient.  The study is also located in the debate around 
homeopathy and the challenge it represents to the traditional model of 
medicine.  Pragmatism is explored as a foundation for reconciling traditional 
dualisms between conventional and humanistic approaches to providing 
medical care and a mixed methods research (MMR) approach chosen as 
suitable for combining the data from qualitative and quantitative sources. 
 
The PhD serves two main objectives. The first is made quite explicit by PhD 
Handbooks (e.g., QUT, 1993, p. 2): the student researcher is required to 
produce "an original and substantial contribution to knowledge." The second, 
which is less explicit, but which is nevertheless implied in the type of thesis 
examination required, is to investigate and become proficient in the process 
of doing research in an ethical manner in one's chosen area (Phillips & Pugh, 
1990). 
(Hanrahan et al., 1999) 
 
Objective One 
This is a mixed methods research project looking at the design of and 
recruitment to a placebo controlled, double blind trial of a complex 
homeopathic product, Ovarium compositum, to treat infertile women at 
Jersey General Hospital.   
 
When recruitment failed to enrol enough women to run the trial, the focus of 
the project moved to a qualitative investigation into the possible reasons for 
trial recruitment failure.  This project therefore is composed of four discrete 
strands and these are explained in more detail in the methodology chapter. 
 
The researcher had successfully used homotoxicology (complex 
homeopathy) in her own practice, with women who had been diagnosed with 
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failure to ovulate, treatment resulting in live births (n= 3) and the PhD study 
grew out of an interest in investigating the apparent efficacy of this approach.   
 
Earlier studies (Gerhard I, 1997, Lai, 2000), (Bergmann et al., 2000) had also 
tried to reproduce their clinical successes as trials but had failed due to 
difficulties with recruitment or are of such poor methodological quality that 
they cannot be used as evidence of a specific effect.  They are discussed in 
more detail in the Literature Review Chapter. 
 
The initial aim of this project was therefore to improve on the existing 
published trials and design a trial that could provide evidence of the specific 
effects of Ovarium compositum.  The first three strands of this study focus on 
the design of a suitable randomised controlled trial (RCT) that also fulfils the 
criteria of model validity for a homeopathic product (Mathie et al., 2012). One 
aim was to find out if homotoxicology as a complementary and alternative 
medicine (CAM) intervention could be evaluated using scientific methods of 
investigation in a positivist framework of evaluation.   
 
The failure of trial recruitment and feedback from the site staff led to a 
second hypothesis, that the social and work concerns of the infertile women 
prevented them participating and so the fourth strand of this study is a 
qualitative investigation of the experiences of infertile women. 
 
It was not possible to have access to the original patient group and as no 
specific support group or forum exists for infertile women in Jersey the 
leading UK infertility websites were used as a source of data.  The specific 
responses of 7 women and the online postings of 213 women were analysed 
thematically (Braun and Clarke, 2006a) to investigate their concerns about 
their work and their treatment. The researcher takes a constructionist 
approach to both the selection of the data, the analysis of the data and the 
approach to writing the thesis and this is consistent with both the worldview 
and the methodology adopted. 
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Objective Two 
I saw my individual production of knowledge as being necessarily shaped by 
my personal place in my own cultural context. This seemed a natural 
extension of the notion that knowledge is context-dependent, and thus 
should be reported in relation to that context (with myself being part of the 
context). 
(Hanrahan et al., 1999) 
 
The researcher moved from an unconscious acceptance of the positivist 
worldview of her social environment towards a more pragmatist 
understanding of using a mixed methods research approach (MMR) and in 
turn to an appreciation of the underlying philosophical worldview and the 
theoretical approach known as constructionism. 
 
The constructed knowledge of the researcher was formed in an iterative 
cycle of action, feedback and reflection leading to a new world view with 
strong pragmatic characteristics and this study therefore makes a 
contribution to the literature on the role of philosophical foundations in trial 
design and in particular how such a world view can emerge from the 
processes of action and reflection, with writing and rewriting as an integral 
part of that cycle. 
 
The study also illustrates how methodology can change in order to address 
an evolving research question, and makes a contribution to the knowledge 
about the use of MMR to investigate a homoeopathic product as treatment 
for infertility.   A recent review found that only 4% of CAM research journals 
articles included MMR studies and noted that the quality could be improved 
(Bishop and Holmes, 2013). 
 
The integration of both the qualitative (1 & 2) and quantitative strands (3) was 
made possible by the philosophical worldview.  Pragmatism which is a 
pluralistic philosophy provides a framework for reconciling the dualistic views 
originating from quantitative and qualitative research traditions (Mesel, 2013).  
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This thesis values the knowledge that can be gained from conducting both 
quantitative and qualitative methods in order to gain a wider, more complete 
perspective on the research question. 
 
The need to report philosophical orientation when writing up a mixed 
methods study was highlighted by (Bishop and Holmes, 2013) who reviewed 
articles from the field of CAM and found that only 5% of studies 
acknowledged or reflected on the limitations of their mixed methods design.   
None of the studies they reviewed acknowledged or addressed the 
philosophical tensions involved in a mixed methods research project.  This 
study seeks to make a contribution to the field by reporting with transparency 
both the pragmatic philosophical framework and the process through which it 
was developed. 
The World View Adopted In This Study 
 
I hold that both qualitative and quantitative forms of knowledge are of value 
and importance and that they need to be judged on their own terms and 
within their own logic.  
 
The worldview adopted in this study underwent transformation as the study 
progressed through the different strands identified in the diagram and 
discussed in more detail in the Methodology Chapter.  It encompasses both 
the philosophy of how we come to know the world (epistemology) and the 
practice of how we come to know the world (ontology). 
 
The transformation was driven by the research questions which changed 
from ‘can we show that this remedy makes a difference? To ‘why is it difficult 
to recruit women to this trial?’ 
 
The initial starting point was a post-positivist worldview characterised by 
reductionism, empirical observation, measurement and theory verification 
(Creswell and Clark, 2007a).  The researcher was inherently biased by the 
cultural experience of studying in a medical school, which has a positivist 
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view of medicine and knowledge. This is a form of critical realism where the 
researcher believes that there is a form of reality independent of our thinking 
about it that science can study.  However it is recognised that all observation 
is fallible and that all theory is revisable.  In other words the researcher is 
critical of their ability to know reality with certainty.  This emphasises the 
need for multiple measurements and observations that can be triangulated to 
try and get a better idea of ‘reality’ (William M.K. Trochim, 2006).   
 
The intention was to design a clinical trial that allowed the effect of a 
medicinal product to be investigated under controlled conditions.  This is a 
top down, or deductive, methodology in which the researcher works from 
theory to hypothesis to data, which adds to or problematizes the theory. 
 
Full integration of qualitative and quantitative methods came about after trial 
recruitment failed and the necessity of solving the problems associated with 
changing the direction of the study led to a Pragmatist worldview 
characterised by a pluralistic approach to research.  This meant that a 
bottom up approach was adopted in order to use the participants’ views to 
build themes and generate a theory.  In the process of writing and rewriting 
the thesis the researcher’s knowledge was constructed, deconstructed and 
reconstructed. 
 
The Researcher’s view of knowledge changed to acknowledge that: 
One might say that as a consequence that there is no single hierarchy of 
knowledge, nor should we give up on hierarchies, but that we should 
acknowledge that there are hierarchies of knowledge for each object of 
knowledge, or there is one world but multiple hierarchies of knowledge. 
(Nairn, 2012) 
 
The other realisation was that inquiry has a sequential nature, this has been 
described (Dewey, 1925) as having its root in conditions of life itself.  There 
is no absolute end to inquiry, it does not solve problems by returning to a 
stable position but creates a new position each time, therefore the learning 
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process in this thesis is summarised and described as a four step model 
(Time point 1 – Time point 4) below: 
Figure	  1	  Model	  to	  show	  the	  development	  of	  the	  researcher	  world	  view 
 
  
T1	   •  Strand	  1.	  	  • Research	  Question	  1	  &	  Trial	  Design	  • Post	  Positivist	  Paradigm	  with	  dualistic	  assumptions	  unchallenged.	  
T2	   •  Strands	  1,	  2	  &	  3	  •  (Action	  leading	  to	  knowledge)	  • Post-­‐Postivism	  and	  Critical	  Realism	  in	  a	  Constructivist	  	  Paradigm	  Dualistic	  assumptions	  unchallenged.	  
T3	   • Strand	  4	  (qualitative	  study)	  • Experience	  leading	  to	  knowledge	  but	  challenge	  to	  dualistic	  view	  point	  begins.	  	  	  • Need	  to	  change	  Methodology	  and	  Research	  Question	  • Unconscious	  Pragmatic	  Approach	  
T4	   • Post	  Viva	  &	  Reglection	  on	  Experience	  • Conscious	  use	  of	  MMR	  • Conscious	  exploration	  of	  Pragmatic	  Philosophical	  Framework	  • Action	  and	  Experience	  leading	  to	  knowledge	  • New	  Pragmatic	  Lens	  &	  Third	  Paradigm	  • More	  'intelligent'	  approach	  to	  study	  design	  and/or	  
practice	  next	  time.	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Time point 1 (T1) 
First Research Question Formulated and Trial Design 
• Strand 1.  
• Research Question 1 & Trial Design 
• Post Positivist Paradigm with ddualistic assumptions 
unchallenged. 
 
Research denotes the deliberate instigation of intelligent experimental 
problem solving in order to generate knowledge and understanding (Biesta 
and Burbules, 2003) 
 
This is the natural starting point where theory (e.g. often from literature 
review in medical research) shapes practice (e.g. trial design) and collection 
of facts of the case, which both help to define the terms of the problem.  The 
research question arises out of a problem in lived professional practice.  The 
research question at time point 1 of this project was ‘Can Ovarium 
compositum make a difference to the fertility outcomes of women undergoing 
treatment at Jersey General Hospital?’ The researcher was working in a 
positivist environment where the expectation of a good trial design was that it 
would create quantitative data for analysis; any qualitative data was intended 
to inform the design of a rigorous quantitative study. 
 
According to pragmatism, the lived experience becomes the ‘cognitive’ mode 
or ‘experience’ when we start inquiry. The stages of inquiry were described 
by Dewey (Dewey, 1925) as: 
The occurrence of the problem 
i. Its specification 
ii. Occurrence of a solving suggestion, supposition, hypothesis 
iii. Elaboration of suggestions or reasoning  
iv. Experimental testing. 
 
The process of inquiry consists of the cooperation of two kinds of operations: 
existential operations (the actual transformation of the situation for example 
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the setting up of a control group in a randomised trial) and conceptual 
operations (reflecting or thinking) in order to transform an indeterminate 
situation into a situation where the elements are recognisable as part of a 
unified whole (Dewey, 1925). 
 
Time point 2 (T2) 
• Strands 1, 2 & 3 
• (Action leading to knowledge) 
• Post-Positivism and Critical Realism in a Constructivist Paradigm 
Dualistic assumptions unchallenged. 
 
The need for a qualitative aspect to the study was seen as contributing to the 
validity of the quantitative study design rather than generating answers to the 
research question.  The dualism between qualitative and quantitative forms 
of knowledge was not being challenged as each domain was seen as 
contributing separately to the inquiry.   Thus, the first qualitative strand was 
the review of homotoxicology treatment for infertility in the UK in order to 
make sure that the protocol chosen for the clinical trial was an accurate 
representation of how homotoxicologists would prescribe for infertile women. 
 
The researcher was conscious of operating simultaneously in two paradigms, 
both the medical and the CAM paradigm of health and disease, but had not 
found a way to reconcile these two aspects of the study.  The study of 
placebo and non-specific effects was contemplated as a link between these 
two paradigms during this phase resulting in a published paper (Haresnape, 
2013b). 
 
The researcher had not yet made the link with pragmatism and the continuity 
between the material world and the world of consciousness, meaning, 
interaction and communication (Dewey, 1928).  Dewey rejected the idea that 
the universe consists of two completely difference substances, ‘mind and 
matter’ (Biesta and Burbules, 2003), taking instead a naturalistic approach 
which claimed there is a continuity between the material and social domains 
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that we experience…In the social world the physical world is taken up into a 
wider and more complex and delicate system of interactions so that it takes 
on new properties (Dewey, 2008). 
 
The second qualitative strand was a feasibility study with patients and staff at 
The Bridge Centre, a private infertility clinic in London.  Here the staff and 
patient perceptions of two paradigms of treatment (CAM and conventional 
medicine) for infertility were explored.   The perception of the two paradigms 
as separate led to the failure of the researcher to fully integrate the 
qualitative findings into the quantitative trial design and probably contributed 
to the eventual failure of the trial recruitment in strand 3 for an RCT of the 
use of Ovarium Compositum as an adjunct treatment for infertile women in 
an assisted reproduction unit. 
 
Time point 3 (T3) 
• Strand 4 (qualitative study of work related concerns of infertile 
women) 
• Experience leading to knowledge but challenge to dualistic 
viewpoint begins.   
• Need to change Methodology and Research Question 
• Unconscious Pragmatic Approach 
 
Dewey’s analysis of the process of inquiry distinguishes between two 
outcomes or types of knowledge: an ‘actual’ and a ‘conceptual’ outcome 
(Biesta and Burbules, 2003).  
 
By recognising that the conceptual outcome is related to the specific situation 
in which it was achieved we recognise that the knowledge gained in this way 
is provisional not absolute.  Dewey preferred to use the expression 
warranted assertion to denote the conceptual outcomes of inquiry rather than 
knowledge or truth (Biesta and Burbules, 2003) 
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In this case the RCT trial led to an actual outcome in that women were 
reluctant to take part in the trial and a conceptual outcome - an 
understanding that qualitative research methods were necessary to find out 
why they were reluctant and to prevent it happening again.  This kind of 
conceptual outcome is a form of knowledge that allow us to criticise, validate 
and improve our work by informing further processes of inquiry.   A new 
research question was generated “Do work related concerns prevent women 
from taking part in an RCT trial?” 
 
The attempt to use qualitative research without fully integrating a mixed 
methods research approach and a philosophical perspective misled the 
researcher to try an impose a positivist approach onto the qualitative data 
using methods such as ranking the frequency of keywords or codes. 
 
Time point 4 (T4) 
• Post Viva  & Reflection on Experience 
• Conscious use of MMR 
• Conscious exploration of Pragmatic Philosophical Framework 
• Experience leading to knowledge 
• Rewrite of Thesis as an active process of de-construction and 
reconstruction 
• Iterative process of thematic data analysis. 
• More 'intelligent' approach to study design and/or practice next 
time. 
 
The feedback from the viva for version 1 of this thesis, and the further study 
of mixed methods research (MMR), led to a realisation that the philosophical 
foundation of Pragmatism which had been unconsciously adopted had much 
greater implications than I had acknowledged for methodology choices, study 
design, and the value placed on the outcomes gained.   The general 
characteristics of Pragmatism have been summarised (Johnson and 
Onwuegbuzie, 2004) and are shown below Error! Reference source not 
found. 
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(Johnson and Onwuegbuzie, 2004) 
Table 1 General Characteristics of Pragmatism 
General Characteristics of Pragmatism 
The project of pragmatism has been to find a middle ground between 
philosophical dogmatisms and scepticism and to find a workable solution 
(sometimes including outright rejection) to many longstanding philosophical 
dualisms about which agreement has not been historically forthcoming. 
Rejects traditional dualisms (e.g. rationalism vs. empiricism, realism vs. anti 
realism, facts vs. values, free will vs. determinism, Platonic appearance vs. 
reality, facts vs. values, subjectivism vs. objectivism) and generally prefers 
more moderate and common sense versions of philosophical dualisms based 
on how well they work in solving problems. 
Recognises the existence and importance of the natural or physical world as 
well as the emergent social and psychological world that includes language, 
culture, human institutions, and subjective thoughts. 
Places high regard for the reality of and influence of the inner world of human 
experience in action. 
Knowledge is viewed as being both constructed and based on the reality of 
the world we experience and live in.  
Replaces the historically popular epistemic distinction between subject and 
external object with the naturalistic and process orientated organism-
environment transaction. 
Endorses fallibilism (current beliefs and research conclusions are rarely, if 
ever, viewed as perfect, certain, or absolute}. 
Justification comes in the form of what Dewey called ‘warranted assertability’ 
According to Pierce, “reasoning should not form a chain which is no stronger 
than it’s weakest link, but a cable whose fibres may be ever so slender, 
provided they are sufficiently numerous and intimately connected” (1868 in 
Menand, 1997, pp 5-6) 
Theories are viewed instrumentally (they become true and they are true to 
different degrees based on how well they currently work; workability is judged 
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especially on the criteria of predictability and applicability). 
Endorses eclecticism and pluralism (e.g. different, even conflicting, theories 
and perspectives can be useful; observation, experience, and experiments 
are all useful ways to gain an understanding of people and the world). 
Human inquiry (i.e. what we do in our day-to-day lives as we interact with our 
environments) is viewed as being analogous to experimental and scientific 
inquiry.  We all try out things to see what works, what solves problems, and 
what helps us to survive.  We obtain warranted evidence that provides us 
with answers that are ultimately tentative (i.e., inquiry provides the best 
answers we can currently muster), but in the long run, use of this “scientific” 
or evolutionary or practical epistemology moves us towards larger Truths. 
Endorses a strong and practical empiricism as the path to determine what 
works. 
Views current truth, meaning and knowledge as tentative and as changing 
over time.  What we obtain on a daily basis in research should be viewed as 
provisional truths. 
Capital “T” Truth (i.e. absolute Truth) is what will be the “final opinion” 
perhaps at the end of history.  Lowercase “t” truths (i.e., the instrumental and 
provisional truths that we obtain and live by in the meantime) are given 
through experience and experimenting. 
Instrumental truths are a matter of degree (i.e., some estimates are more 
true than others).  Instrumental truth is not stagnant and, therefore James 
(1995: 1907) states that we must “be ready tomorrow to call it falsehood.” 
Prefers action to philosophizing (pragmatism is, in a sense, an anti-
philosophy). 
Takes an explicitly value-orientated approach to research that is derived from 
cultural values; specifically endorses shared values such as democracy, 
freedom, equality, and progress. 
Endorses practical theory (theory that informs effective practice: praxis) 
Organisms are constantly adapting to new situations and environments.  Our 
thinking follows a dynamic homeostatic process of belief, doubt, inquiry, 
modified belief, new doubt, new inquiry…in an infinite loop, where the person 
or researcher (and research community) constantly tries to improve upon 
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past understandings in a way that fits and works in the world in which he or 
she operates.  The present is always a new starting point. 
Generally rejects reductionism (e.g. reducing culture, thoughts, and beliefs to 
nothing more than neurobiological processes). 
Offers the “pragmatic method” for solving traditional philosophical dualisms 
as well as for making methodological choices. 
 
 
 
Reconciling Dualisms 
The dualisms between conventional medicine and complementary medicine 
are a central theme in this thesis.  They permeate the social environment of 
the study, the choice of clinical subject, the methodology and the 
philosophical orientation of the project. It is not by coincidence that MMR is 
suitable for reconciling these different and opposing paradigms (Creswell and 
Clark, 2007b) and that pragmatism provides a robust philosophical 
framework for doing so (Shelton, 2013), it is also acknowledged that the 
treatment of fertility involves both the physical and psychological domains of 
health (Fields et al., 2013) and therefore is a suitable condition for a mind-
body medicine intervention. 
 
The Use Of Extracts From The Data 
Quotations from the qualitative data have been used to generate and later to 
illustrate the themes.  The selection of quotations for inclusion followed the 
rule that they captured the essence of the theme, could be understood in 
isolation and were representative of the sample.  Differing or deviant 
quotations were explored as part of the thematic analysis (Braun and Clarke, 
2006a).  Anonymity of the participants has been retained by removing some 
words and by aggregating the quotes (Bond et al., 2013) so that they cannot 
be traced back to an internet forum by pasting them into a search engine. 
 
Definitions And Abbreviations 
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The data from the online forum postings in strand three contain many 
abbreviations that are derived from the either the terminology around their 
treatment or from the social conventions of the online community.  A glossary 
of abbreviations used in this thesis is provided here to aid understanding. 
 
Table 2 A list of abbreviations used in this thesis 
Abbreviation Meaning or Definition 
AF Aunty Flo, menstrual period 
ART Assisted Reproductive Technology 
BFN Big Fat Negative (pregnancy test) 
CAF Critical Appraisal Framework 
CAM Complementary and Alternative Medicine 
DD Dear Donor (Egg or Sperm Donor) 
DH Dear Husband 
DPO Days post ovulation 
DS Donor Sperm 
EHIQ Emotional Health In Infertility Questionnaire 
EMM Evolutionary Medical Model 
EQ-5D 
EQ-5D™ is a standardised instrument for use as a measure 
of health outcome 
ET Embryo Transfer 
FSH Follicle Stimulating Hormone 
GnRH Gonadotropin Releasing Hormone 
GnRHantag Gonadotropin Releasing Hormone Agonist 
GP General Practitioner 
ICSI Intra-Cytoplasmic Sperm Injection 
ICSI Intra-cytoplasmic Sperm Injection 
IM Integrative Medicine 
IUI Intrauterine Insemination 
IUI Intra-uterine Insemination 
IVF In Vitro Fertilization 
LH Luteinizing Hormone 
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LP Luteal-Phase 
MM Mixed Methods 
MMR Mixed Methods Research 
NHS National Health Service 
PCOS Polycystic Ovary Syndrome 
PCT Primary Care Trust 
PG Pregnancy 
PNEI Psycho-Neuro-Endocrine Immunology 
PSS Perceived Stress Score 
RCT Randomised Controlled Trial. 
SA Sperm analysis 
SD Standard Deviation 
SPA Sperm Penetration Assay 
TTC Trying to conceive 
USS Ultrasound Scan 
 
Background 
The Social Environment Of This Study 
The British Medical Journal (BMJ) provided a lens through which to view the 
social environment of this study during its conception and design (1993 – 
2011).   The choice of the BMJ as a portal to view the social and cultural 
context of the study has to take into account the possibility of bias, and this 
issue has been raised by the homeopathic community (Fisher, 2010) who 
would like to see a serious consideration of the evidence for homeopathy, 
rather than an out of hand dismissal or the mere voicing of opinion 
(Colquhoun, 2009). 
 
The BMJ has reported, in both articles and letters, the debate over the 
different controversies around homeopathy: the philosophical basis of 
healing systems (Buckman and Lewith, 1994), (Reilly, 2001); the provision of 
homeopathy of the NHS (Fisher and Eden, 1995b), (Kmietowicz, 2010); the 
need to cast out ‘quacks’ (Fisken, 1996a) and avoid the use of homoeopathy 
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for life threatening illnesses (Delaunay et al., 2000), (Mashta, 2009); and the 
popularity of homeopathy (Fisher and Ward, 1994).  
 
Two perspectives emerged from the reading of the BMJ articles firstly the 
biochemical perspective as a quest for a mechanism of action:  
 ‘Is there a verifiable physical mechanism by which the homeopathic 
remedies themselves affect disease (Buckman and Lewith, 1994)?  
 
And secondly, from a healthcare research perspective, ‘do homeopathic 
remedies make patients feel better (Buckman and Lewith, 1994)?   
 
These two perspectives represent the dual challenge that CAM has faced in 
order to meet the criteria for evidence based medicine (EBM) and retain its 
validity as a pluralistic and holistic practice that can be assessed using 
appropriate methods.  These two perspectives are not valued equally in the 
predominately post-positivist thinking of the medical profession which has 
focused the debate on ways of providing evidence for a mechanism of action 
(Kmietowicz, 2010), or on demonstrating effectiveness (Smith, 1995). 
 
The assumption that an RCT was the best model for evaluating the effects of 
a Ovarium compositum was based on the positivist thinking that was the 
dominant model in the researcher’s social environment (a central London 
Medical School).   Homeopathy was being increasingly subjected to the 
scrutiny of the medical and scientific community who were calling for a 
scientific/experimental model of evaluation (Dobson, 2006), (Oh, 1998). 
 
The suitability of this methodology to evaluate homeopathy was also being 
debated as part of the larger debate around the provision of homeopathy by 
the NHS (Thompson and Feder, 2005).   CAM practitioners, including 
homeopaths, were concerned about the methodological challenges posed by 
treatments that were often highly individualised, characterised by a 
practitioner-patient relationship, that has subtle or long term outcomes and 
may be concurrent with existing mainstream healthcare: 
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As homoeopathic prescribing is highly individualized to a person’s 
“constitutional picture” rather than to specific diseases, future research will 
need to meet this challenge as well as explore a plausible mechanism of 
action for homoeopathy (Baldwin, 2003) 
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Chapter 1 Literature Review 
Introduction	  To	  The	  Literature	  Review	  
This chapter represents a 9-year period of study and covers 9 distinct 
reviews (see Table 3 The nine distinct reviews in Chapter 1), based on the evolution 
of the two hypotheses, the methodology, and the philosophical worldview of 
this thesis (section 1). 
 
The first hypothesis was that a complex homeopathic product called Ovarium 
compositum could be used to improve the fertility outcomes of women 
attending an Assisted Reproduction Unit (ARU) at Jersey General Hospital.  
Section two is concerned with the definitions, prevalence and treatment of 
female infertility by the medical profession.  Section three looks at how 
homotoxicology (complex homeopathy) is defined and evaluates the three 
existing trials of homeopathic products used to treat female infertility.  
Section four reviews the use of Randomised Controlled Trials (RCT) to 
investigate homeopathy. 
 
The failure to recruit sufficient women to the RCT led to the second area of 
research and a new hypothesis, that the work related concerns of infertile 
women prevented them taking part in an RCT trial.  To gain a perspective on 
the reasons for trial failure, section five looks at the concerns of infertile 
women.   
 
The methodological issues raised by the need to design an additional 
qualitative strand to the study are covered in section six which reviews 
thematic analysis, section eight, qualitative research and section nine, mixed 
methods research.  New data had to be sought by using the online infertility 
forums and section seven examines the issues of ethics and privacy raised 
by using such data sources. 
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Table 3 The nine distinct reviews in Chapter 1 
Section  Questions Research Questions Type of Review 
1 Pragmatism What is Pragmatism?  How does it inform 
this thesis? 
 
Narrative review 
2 Infertility How is infertility defined in published 
studies, in working practice, what is the 
estimated prevalence – global and UK?  
What is the accepted medical treatment for 
female infertility? 
Systematic Qualitative Review 
with acknowledged limitations. 
3 Homotoxicology What is homotoxicology?  Are there any 
existing trials of homotoxicology to treat 
infertility? 
 
Systematic Qualitative Review 
with acknowledged limitations. 
  
What is the role of CAM in treating 
infertility? 
Narrative Review 
4 RCT  What steps can be taken to ensure the 
model validity of an RCT to measure the 
efficacy of Ovarium compositum? 
Narrative Review 
5 Infertile women What are the concerns of infertile women?  
Do existing studies offer any insight for trial 
design? 
Narrative Review 
6 Thematic analysis What is thematic analysis and is it an 
appropriate method of analysis for this 
project?  What does good thematic analysis 
look like? 
Narrative Review 
7 Ethics and Internet Data What are the ethics of using data from 
internet forums?   
Narrative Review 
8 Qualitative research What is qualitative research? How can I 
make sure my study is credible and valid? 
Narrative Review 
9 Mixed methods research 
(MMR) 
What is MMR?  How do I describe my study 
and ensure transparency of reporting? 
Narrative Review 
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Reading and  ‘Writing-up’ for both the first and second time was not a 
passive procedure but a more active set of iterative activities and 
approaches:  
‘This set includes de-constructing and re-constructing, disconnecting and re-
connecting, as well as shaping and re-shaping.’(Badley, 2009) 
Writing up was therefore, not an add-on to the existing research or a simple 
summarizing of what has been achieved, it was a creative, reflective and 
critical process, learning and transforming what was known at each stage of 
the project. 
 
The reading of texts across the disciplines of education and medicine, helped 
to construct and re-construct the world view to include Pragmatism, which in 
turn helped meet the aims and purposes of the thesis. Section one looks at 
Pragmatism and how it can be used to inform our study design, our choice of 
methodology and the importance of transparency so that methods from 
different traditions can be integrated in a consistent manner. 
 
Pragmatism became the thread running through the different strands of the 
study and was the framework for the process of learning new knowledge 
through action. 
 
Badley describes this process when he takes a Deweyan approach to 
connecting and re-connecting: 
My interpretation of Dewey here is based on the notion that our reading, 
researching, and writing for academic purposes often forms or ‘grows out of’ 
a series of natural chains or threads or connections (Dewey, 1910a), 1-5).  
When we write reflectively (or re-constructively), we deliberately word and re-
word our claims to new knowledge based on a series of connecting ideas 
and firm reasons (Dewey, 1910a), 6-8)(Badley, 2009) 
The Methodology In This Literature Review 	  
The literature review continued throughout the data analysis and writing up 
process as new and unexpected perspectives were encountered and the use 
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of theory became more developed (Kelly, 2009).  Papers were examined to 
see if they contained ideas that were useful and meant something for the 
particular purpose of this thesis. It is not unusual in qualitative research to go 
backwards and forwards between the literature and the research question 
during the course of a study with a preliminary literature review being 
undertaken at the planning stage (Kelly, 2009) and for the bulk of the reading 
to be done in and around the later stages of data collection and data analysis 
(Silverman, 2013). 
 
The nine sections of the literature review are summarised in as Table 3 The nine 
distinct reviews in Chapter 1 and are a mixture of narrative and systematic 
qualitative reviews depending upon the research question. 
 
Some papers are considered in more depth because they are popular and 
well cited e.g. (Pope et al., 2000), other papers are less well cited but very 
specifically aligned to the ideas or concepts that emerged from the analyses 
in this thesis e.g. (Shelton, 2013).   
 
Critical Reading  
The critical reading process enables us to analyse, collect, evaluate and 
interpret important ideas that can then be used to synthesize, re-evaluate 
and re-interpret our new text (Badley, 2009). 	  	  
The need to include a more critical reading process was highlighted in my 
first viva.  As a response to this need a process a list of questions was 
developed (using an Open University module studied by the author), this 
gave a consistent structure to the appraisal of each article included in this 
chapter when it was rewritten Table	   4:	   Checklist	   of	   questions	   for	   critical	  reading	  of	  selected	  articles: 
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1. What are the underlying philosophical assumptions in this paper?  
2. Are these made explicit?  
3. What methodology is being used?  
4. What methods are being used?  
5. What contr ibution did each of the data col lection methods make to the 
research?  
6. Would I have used different data col lection methods?  
7. Would I have analysed the data differently?  
8. What framework is being used to interpret the data?  
9. How is language being used?  Do we share a common understanding of 
the terms and phases.  
10. Questions: What research questions are being addressed?  
11. Setting: What is the sector and sett ing? (e.g. school, higher education, 
training, informal learning)  
12. Concepts: What theories, concepts and key terms are being used? 
13. Findings: What did this research f ind out?  
14. Do I agree with the authors’ conclusions? 
15. Limitat ions: What are the l imitat ions of the methods used?  
16. Ethics: Are there any ethical issues associated with the research?  
17. Implications: What are the implications ( i f  any) for practice, pol icy or 
further research?  
18. How have subsequent authors buil t  on this research, i f  at al l? 
19. Why did I choose to include this paper?  
	  
Table	  4:	  Checklist	  of	  questions	  for	  critical	  reading	  of	  selected	  articles 
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The use of mixed methods research and the dualities between CAM and 
conventional medicine meant that the nine sections cover a broad spectrum 
of topics.  The articles in each of the nine chapters were reviewed using 
quality assessment tools that varied according to the study design and which 
methodological feature were being examined.    
 
Some excellent textbooks were used to develop an understanding of Mixed 
Methods Research (Creswell and Clark, 2007a), qualitative research 
(Silverman, 2013), the research methods used in healthcare (Bowling, 2011) 
and clinical research in the field of complementary medicine (Lewith et al., 
2010).  The textbooks suggested established papers and authors in each 
field, and helped to ensure consistency of understanding of key concepts and 
definitions, as well as providing a historical perspective of the field. 
 
A balance was sought between being flexible enough to capture the essence 
and the use of methodological guidelines and a consistent approach that 
ensured the validity of the reviews in each section (Sternberg et al., 2011).  
This will now be explained in more detail for each of the nine sections.  It is 
acknowledged that this balance was not always achieved and that the 
absence of a fully systematic approach should temper the conclusions 
reached. 
 
Background - Different Types of Literature Review 
At least three types of literature review can be indentified (Green et al.): 
narrative review, qualitative systematic review and quantitative systematic 
review.  The purpose of a literature review is to objectively report the current 
knowledge on a topic based on previously published research thus providing 
the reader with reliable and comprehensive overview.(Green et al.). 
Narrative literature reviews 
Narrative literature reviews can also be described as three types (Green et 
al.): editorials, commentaries and overview articles. 
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The Qualitative Systematic Literature Review 
This is a type of literature review that employs detailed, rigorous and explicit 
methods (Muir Gray, 1997), (Friedland et al., 1998).  This means that they 
can be employed as an evidence based on which to base clinical decisions 
or for the creation and testing of hypotheses. (Phillips et al., 2001). They are 
characterised by a detailed search of the literature based upon a focused 
question or purpose and a step by step methodology is clearly described.  
Each paper is reviewed in a systematic and consistent manner but these 
reviews do not include a statistical combination of the results.  This is found 
in quantitative systematic reviews. 
 
 
The choice of articles for this chapter was also informed by a pragmatist 
viewpoint of what works and what meets the need?  The pitfalls inherent in 
this approach include the possibility of bias and a lack of credibility and utility 
in the completed article.  As part of the corrections submitted post-viva, this 
has been addressed by a closer attention to theory, a more transparent 
reporting of search strategies and a reflective commentary at the end of each  
of the nine sections. 
 
It was also recognised post-viva that it is especially important to conduct a 
systematic literature review in this field (CAM) because it works as a 
mechanism to facilitate interdisciplinary collaboration and a more integrated 
understanding of health (Karunananthan et al., 2009). 
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Type of 
narrative 
literature 
reviews 
Description Advantages Disadvantages 
Editorials 
Typically written 
by the editor of 
a peer reviewed 
journal or an 
invited guest 
Usually short, 
selected, narrowly 
focused review of only 
a few papers 
May be no 
more than the 
editor’s 
comments 
regarding a 
current issue 
Commentaries 
Usually written 
by an expert in 
the field of the 
commentary 
Draws upon the 
wisdom of the 
commentator,intended 
to provoke scholarly 
discussion 
A biased 
narrative review 
and bias can 
become 
replicated by 
citations. 
Narrative 
overview 
articles, 
(unsystematic 
narrative 
reviews). 
Comprehensive 
narrative 
syntheses of 
previously 
published 
information. 
Provides a useful 
educational tool with  
a broad perspective 
that is readable. Often 
written by an expert in 
the field 
Can become an 
opinion 
orientated 
argument 
based upon 
references. 
 
Table 5 Types of Narrative Literature Reviewed based on Green et al 2006 
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Literature Review - Section 1 – The Pragmatic World 
View  
Methodology 
The articles selected for this chapter were not chosen systematically, they 
are a record of the reading and thinking process that accompanied the 
rewriting of the thesis.  This section of the literature review is more akin to a 
narrative review or commentary (Green et al.).  Another way to describe this 
section would be as an extended memo in the tradition of qualitative 
research, (Charmaz, 2006) in which the writer deconstructs their current 
understanding, synthesises from new information, abstracts and reconstructs 
their worldview.   
 
The framework that was developed allowed the author to make sense of the data and the 
process of rewriting. The utility of this section for other researchers would not be as a 
systematic review of the literature on Pragmatism but as a practical example of how a 
philosophical dimension can inform the development of a research project.  The articles 
selected were read systematically using the critical reading checklist of questions developed by 
the author 	  Table	  4:	  Checklist	  of	  questions	  for	  critical	  reading	  of	  selected	  articles. 
Research Questions: 
What is Pragmatism?  How does it inform this thesis? 
 
What is Pragmatism? 
When we research something we are looking into the ‘truth’ of a situation.  
The ‘truth’ may take the form of a quantitative truth, for example an accurate 
measurement or evidence of cause and effect.  Another kind of ‘truth’ would 
be a qualitative truth such as an empathic understanding of someone else’s 
point of view or discovering the motivation behind their actions. 
 
These two positions will discussed as the two stances of qualitative and 
quantitative researchers and mixed methodology will be suggested as a third 
stance that seeks to balance the benefits and drawbacks of each 
methodology to produce a more complete kind of ‘truth’. 
 
LITERATURE REVIEW 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   49	  
Underlying the choice of each methodology is a set of assumptions about the 
world, knowledge and how we can know things.  It is reasonable to assume 
that as we evolved as a species there has been an evolution in man’s 
thinking about the world and our intellectual tradition has been dominated at 
different times by theology, empiricism and idealism. 
 
Pragmatism as a school of thought emerged over a century ago, as the first 
North American original contribution to philosophy, or ‘thinking about 
thinking.’  It originated in the writings of three American thinkers: the natural 
scientist and philosopher Charles Sanders Peirce (1842-1910), the 
psychologist and philosopher William James (1842-1910) and the 
philosopher, psychologist and educationalist John Dewey (1859-1952) 
(Biesta and Burbules, 2003).  
 
They observed the social, cultural and political changes of their time and felt 
that philosophy should help to solve the real life problems of men rather than 
the abstract problems of philosophers.  They saw an urgent need to balance 
the scientific and political progress being made with values such as 
democracy, justice and equality. 
 
For these early pragmatists the central idea was that nothing is ultimately 
‘True’ or ‘False’. James believed that truth is ‘what works’; Pierce understood 
it to mean ‘something that we will eventually converge upon after a process 
of inquiry’; and Dewey believed that the truth is what you are ‘warranted’ in 
saying is true. 
 
The core of their philosophy lay in their rejection of the Platonic idea of Truth.  
Philosophers, such as Descartes, have carried this conception forward and is 
the idea underlying Realism.  Realism adheres to a correspondence theory 
of truth and maintains that there is a reality ‘behind’ appearances and that 
true knowledge is knowledge which correspondents to that reality (Cornish 
and Gillespie, 2009). 
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After Descartes, philosophy became focused on epistemology, how could a 
subjective living mind come to know or understand the material world?   A 
division was created between the inner-directed world of observation or self 
awareness and the outer directed world of observation of the material world, 
including nature and humans (Tauber, 2009).  This is commonly referred to 
as the mind-body divide where the mind is consigned to the role of a 
scientific spectator and the human body becomes an impersonal object of 
scientific study.  The Descartian viewpoint therefore set the stage for the 
application of the scientific method to all of nature and the rise of modern 
science and technology including medicine (Mehta, 2011). 
 
Pragmatism strongly rejects the correspondence theory of truth.  Pragmatists 
see knowledge not as a mirror of reality, but as a tool for action that also 
mediates our relationships with the physical and social world (Cornish and 
Gillespie, 2009). 
 
The pragmatists did not seek to answer the problems created by the mind-
body divide, instead they sidestepped them by rejecting the traditional 
dualisms such as Platonic appearance versus reality.  Pragmatists prefer 
instead to judge knowledge according to its consequences in action.  
Knowledge is deemed useful if it can help solve problems (Johnson and 
Onwuegbuzie, 2004). 
 
They were able to do this because they saw humans as being in constant 
transaction with their environment. They believed that as a result knowledge 
is a construction, not of the mind, but located in the organism-environment 
transaction itself (Biesta and Burbules, 2003).  For pragmatists it is the 
practical activity that is the bedrock and the test of knowledge.  Knowledge is 
viewed as being both constructed and based on the reality of the world we 
experience and live in (Johnson and Onwuegbuzie, 2004). 
 
Pragmatism does not reject the methods and insights of modern science 
however, they argue that these should be taken into account (Biesta and 
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Burbules, 2003), while avoiding reductionism, seeking instead ‘warranted 
assertability’.  
 
Human inquiry (i.e. what we do in our day-to-day lives as we interact 
with our environments) is viewed as being analogous to experimental 
and scientific inquiry.  We all try out things to see what works, what 
solves problems, and what helps us to survive.  We obtain warranted 
evidence that provides us with answers that are ultimately tentative 
(i.e., inquiry provides the best answers we can currently muster), but 
in the long run, use of this “scientific” or evolutionary or practical 
epistemology moves us towards larger Truths (Johnson and 
Onwuegbuzie, 2004) 
 
Pragmatists, like scientists, also endorse fallibilism, believing that current 
beliefs and research conclusions are rarely, if ever, viewed as perfect, certain 
or absolute.  Instead they view the current truth, meaning and knowledge as 
tentative and changing over time.  This iterative process of belief, doubt, 
inquiry, modified belief, new doubt, new inquiry means that the present is 
always a new starting point for the researcher who constantly tries to improve 
upon past understandings in a way that is congruent with the world in which 
he or she operates (Johnson and Onwuegbuzie, 2004). 
 
All domains of knowledge are recognised and acknowledged as important, 
the natural or physical world as well as the social and psychological spheres 
including language, culture and thought.  As a result of accepting all these 
differing domains of knowledge pragmatists endorse eclecticism and 
pluralism which means that different and even conflicting theories and 
perspectives can be useful and that observations, experiments and 
experiences are all useful ways to gain knowledge (Johnson and 
Onwuegbuzie, 2004). 
 
One of the main critics of Pragmatism was Bertrand Russell, who believed 
that that it cannot simply be right, that what is useful is true.  You may be 
fooled by your practical experience of the world into believing falsehoods 
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such as the Earth looks flat.  His point was that their position was too simple 
and that there are independent hard facts out there which we can genuinely 
discover and call the ‘Truth’ (Johnson and Onwuegbuzie, 2004).   
 
The pragmatist’s answer to this critique was that if we treat the world as if 
these things do exist we can make things work better because for 
pragmatists the only sensible yardstick by which to judge a piece of 
knowledge is whether that knowledge is useful for a given interest (Cornish 
and Gillespie, 2009). 
 
Johnson and Onwuegbuzie have identified other weaknesses of Pragmatism 
(Johnson and Onwuegbuzie, 2004) such as the danger that basic research 
may be neglected in favour of applied research because applied research 
appears to produce more immediate and practical results.  The fact that 
Pragmatism takes a rather ‘moderate and common sense’ approach may 
mean that it promotes incremental change rather than more fundamental, 
structural, or revolutionary changes in society. 
 
Although perhaps not revolutionary, pragmatism takes an explicitly value-
orientated approach to research, that is derived from cultural values; 
specifically endorsing shared values such as democracy, freedom, equality, 
and progress which reflect it’s birth in the western expansion of the United 
States. (Johnson and Onwuegbuzie, 2004). 
The Pragmatism of John Dewey 
John Dewey (1859-1952) was an American philosopher and one of the first 
pragmatists.  He was greatly influenced by the social and cultural changes 
that he observed taking place at the time and went on to gain an international 
reputation for his pragmatic approach to philosophy, psychology and liberal 
politics. His publications in these areas include How We Think (Dewey, 
1910b), Reconstruction in Philosophy (Dewey, 1920), Experience and Nature 
(Dewey, 1958), and Logic: The Theory of Inquiry (Dewey, 1938b). 
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His most enduring influence is in the field of education (Dewey, 1938a) and it 
was in this field that his work first came to the attention of the author.  The 
transferability of his ideas the investigation of CAM therapies using MMR is 
one of the original themes developed in this thesis.   
 
He believed in the unity of theory and practice, not only writing on the subject 
but for a time participating in a progressive ‘laboratory school’ for children 
connected with the University of Chicago (Dewey, 1938a).  
 
The main significance of Dewey’s pragmatism for (educational) research is 
that he deals with questions of knowledge and the acquisition of knowledge 
within the framework of a philosophy of action.   Dewey made it clear that the 
domain of knowledge and the domain of human action are not separate 
domains but are intimately connected; that knowledge emerges from action 
and feeds back into action and that it does not have a separate existence or 
function. 
 
He attempted to reconcile the gulf between traditional and progressive 
education by using a robust philosophical framework to promote a more 
‘intelligent’ way of working.  At the time his writing was hailed as a guiding 
beacon for a society that was experiencing rapid social, cultural and 
economic expansion.   
 
Innovation in schools might be seen as the movement from a traditional 
model of education towards a progressive model.  One of Dewey’s 
contributions was to characterise these two approaches and put forward the 
idea that progression should not be merely a negative reaction to tradition.  
He deplored the necessity for pupils taught in a traditional manner to be 
docile, passive, receptive and obedient (Dewey, 1938a) but did not feel that 
the opposite extreme was desirable either: 
 
Impulses and desires that are not ordered by intelligence are under 
the control of accidental circumstances… A person whose conduct is 
controlled in this way has at most only the illusion of freedom.  
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Actually he is directed by forces over which he has no command. 
(Dewey, 1938a) 
 
Dewey acknowledged that teaching in a way that built on the existing 
experience of the learner, that did not oppress them or impose unnecessary 
restrictions, required a well thought out philosophy and well planned 
activities: 
 
 It is, accordingly, a much more difficult task to work out the kinds of 
materials, of methods, and of social relationships that are appropriate 
to the new education than is the case with traditional education 
(Dewey, 1938a).  
 
If we draw a parallel between progressive education and CAM then we can 
explore the ways in which his ideas about education might be applied to the 
practice and research of CAM. The dualisms between CAM and conventional 
medicine, like the dualisms between progressive and traditional education, 
have their foundation in the philosophical differences that divide qualitative 
and quantitative research methodologies.  CAM, like education, is a complex 
and dynamic system of beliefs and actions that cannot be simply 
characterised by category or without including the perspectives of the 
participants. 
 
CAM therapies are sometimes regarded with mistrust by the conventional 
medical profession because they are not viewed as scientific, for example: 
 
It seems to me that we owe it to our patients, as well as to ourselves, 
to be much more intolerant, aggressive, and demanding in our 
dealings with fringe medicine, quackery, humbug, and deception of all 
kinds.  
 
Any decent, responsible form of medical practice must be based on 
logic, sound science, and well conducted research; if it is not then all 
of the philosophical, social, and political struggles of the 
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Enlightenment and the sacrifices of our forebears have been in vain 
and we might as well give up and turn our patients over to the nearest 
witch doctor. 
(Fisken, 1996b). 
 
CAM therapists, for their part may regard conventional medicine as too 
scientific and dehumanising, putting patients in a position where they are 
‘docile, passive, receptive’. Many of the therapies that make up the spectrum 
of CAM are based on theories of personal development and individual 
autonomy, so that they support patients in their journey to become ‘whole’, 
‘integrated’ and responsible for their own health.  This is sometimes seen in 
terms of a paradigm shift that is currently in progress: 
 
The old paradigm was that the human body functions like a machine.  
The new paradigm focuses on the interconnectedness of body, mind, 
emotions, social factors, and the environment in determining the 
status of health. 
(Murray and Pizzorno, 1998) 
 
Dewey’s pragmatism rejected such dualisms and sought to use scientific 
method to create a more intelligent way of working that integrated both 
scientific method and the way we learn from everyday experiences.  He did 
not reject the scientific method and he was very clear about it’s value and 
importance because “it’s comparative maturity as a form of knowledge 
exemplifies so conspicuously the necessary place and function of 
experimentation” (Biesta and Burbules, 2003) 
 
But his appreciation for the scientific method does not mean that science is 
the only valid form of knowledge and he rejected the idea that knowledge is 
the only way in which we can get in touch with reality.  This broader definition 
of knowledge allows the scientific approach to include the rigorous use of 
both qualitative and quantitative methods to capture what is most 
characteristic of human life and experience. 
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One way to understand Dewey’s project is to see it as an attempt to undo 
this mistake so that those dimensions of our being in the world that cannot be 
traced back to (scientific) knowledge can again be seen as real and rational. 
(Biesta and Burbules, 2003) 
 
He sought to reconnect scientific thought with an appreciation of to the realm 
of values, the realm that had been split off or separated by the dualisms of 
Plato and Descartes.  He argued that the domains of action and knowledge 
were intimately connected and that all knowledge, scientific and non-
scientific, is generated by action and is therefore fallible and subject to 
change.   
 
Like Dewey, researchers using the MMR approach also are attempting to 
reconcile the gulf between traditional and CAM medicine, by using a robust 
pragmatic philosophical framework to promote a more ‘intelligent’ way of 
working.  
 
If we take forward his idea that progression should not be merely a negative 
reaction to tradition, we can look for ways to benefit patients by using the 
best ‘evidence’ from both the quantitative ‘scientific’ approach and the new 
paradigm that recognises the qualitative aspects of health and disease.  The 
articles reviewed next in this section are an exploration of this idea. 
 
 
A New Look at Medicine and the Mind-Body Problem: Can 
Dewey’s Pragmatism Help Medicine Connect with Its Mission? 
(Shelton, 2013) 
 
Shelton has a constructivist and pragmatist world view that acknowledges 
the dualisms of the Cartesian world view and the Faustian pact that medicine 
has made to trade advances in healthcare and scientific understanding for 
the humanist holistic approach to patients and their suffering.  The multiple 
perspectives of patients and practitioners are acknowledged as he discusses 
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the practical implications of the issues for the education of doctors and the 
practice of medicine.     
 
My perspective in that paper was based on Dewey's pragmatism, which 
clearly grounds all philosophical problems and issues in the historical 
process of human culture and society. (Shelton, 2014) 
 
The author describes the changes to the American health care system, and 
medical education system that have taken place in the 20th and 21st century.   
He describes how the medical culture of the United States has been shaped 
by the dominant modern philosophical paradigm and how the cultural and 
institutional life of modern medicine has its source in the modern Cartesian 
legacy of mind-body dualism. 
 
His theory is that Dewey, in 1927 was a prophetic voice who made his 
analysis from a mature philosophical perspective, seeing dualism of mind 
and body as a profound practical problem throughout modern society and 
especially in the cultural life and activity of scientific medicine. 
 
The central element in this crisis is the disintegrating influence of modern 
science on everyday life that has changed our understanding of the world to 
a mechanistic worldview.  The result has been a devaluing of the reality of 
the everyday experiences of men and the noncognitive dimensions of human 
life (Biesta and Burbules, 2003) 
 
Dewey preferred to see the mind and body as an integrated whole with 
nuanced functions and qualities of integrated action.  The narrowly focused 
scientific perspective, taken alone, not only cuts off mind from the individual 
human being, it cuts off the environment from behavior by seeing 
environment as a purely external occasion from which behavior proceeds. 
 
He describes how Dewey also recognized that it is not just the natural 
environment that is important but also the social environment because it is 
the social environment that explains how individual humans engage in 
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speech acts and thinking, the social forms of organized human life of which 
human consciousness is predicated.   
 
That the rise of medical ethics and humanities in the early 1970’s has 
highlighted the value-laden dimensions of medicine and the physician-
practitioner relationship but these are taught and seen as separate from the 
‘hard language of chemistry and physics’.  The values of humanities and 
ethics are still seen as less important that the value of mastering scientific 
knowledge.  The implication of becoming proficient in evidence-based 
medicine is that it directs the attention of learners toward the particular 
disease mechanism and away from the whole person. 
 
Dewey acknowledges that there is an appropriate time for perspectives such 
as detachment and objectivity but the key point is that any one perspective 
necessary to care for some needs of the total patient, will not adequately 
address certain other needs. 
 
Shelton is arguing for a reconnection of medicine with its core mission of 
caring for the whole person.  In line with his pragmatic worldview he is 
looking for practical ways to nurture this standard of excellence into the 
practice habits of new physicians by changing both the taught curriculum and 
the structure of the learning environment. 
 
The use of evidence-based medicine to train doctors is replaced by the 
concept of becoming the ‘virtuous practitioner’ as described on page 437.   
The questions facing the medical education system are ‘what kind of 
practitioners are we striving to educate in a healthcare system driven by 
market forces and a dominant positivist paradigm?  How will these traits be 
nurtured over a lifetime of learning and practice?’ 
 
He quotes the voice of Francis Peabody (1927) who expressed a similar 
perspective that clinical medicine should care for the total needs of the whole 
person and we therefore require a certain kind of physician who can deal 
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with the complex unity of biological, physical, mental, psychological and 
spiritual factors that makes up the whole person. 
 
‘Diagnosing and treating the disease alone is comparable to the work of a 
mechanic.  But managing the illness of the whole human being is the task of 
the physician as a clinical artist.’ 
 
‘Changing this mindset requires a philosophical perspective that gives equal 
epistemic standing to all relevant clinical aspects of patient care and unites 
them into an underlying sense of moral purpose dedicated to provide total 
care for the patient.’ 
 
Shelton provides an insight into the way that the dominant paradigm has 
become embedded in the provision of healthcare and the education of 
doctors.  He provides an argument with a strong philosophical basis for an 
emphasis on a more integrated holistic approach to medicine that recognises 
the needs of society and the individual.   
 
He provides practical suggestions for the way that medicine is taught in order 
to achieve this including a need to create financial framework for practitioners 
who wish to train others in a holistic approach. And need to recruit, train and 
retain ‘virtuous’ practitioners who can balance private gain and public good in 
a healthcare system. This concept of ‘virtue’ is also linked to the Dewey’s 
concept of intelligence, which extends to the crucial importance of self-
reflection in medical education, so that physicians are aware of their own 
attitudes and biases in their encounters with patients. 
 
If this vision is to be achieved then more research into the holistic aspects of 
health and disease will be needed.  This could also be seen as a need for 
mixed methods research including qualitative research approaches to 
measure some of these ‘virtuous’ qualities and their effect on patients. 
 
Shelton recognises the value of both approaches to medicine and healing but 
acknowledges that no one perspective can provide the whole answer.  A 
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pluralistic philosophy such as Pragmatism provides a framework for 
reconciling the dualistic views. 
 
The reconciliation of dichotomies or dualities has been a repeating theme 
through out this literature search, the inherent tension between qualitative 
and quantitative, progression and tradition, medicine and CAM, the interests 
of patients and researchers, the scientific standing of doctors and other 
healthcare providers are all examples of this theme. 
 
It is common to refer to these differences as originating from a different 
paradigm, and this concept has been used in different ways in the literature 
(Morgan, 2007).  Three essential characteristics of a paradigm can be 
identified (Harrits, 2011): Firstly it is a set of ontological and epistemological 
assumptions made about the nature of social reality and the way in which we 
come to know this reality.  Secondly it is a research practice or a specific way 
of conducting research within a research community.  Thirdly, paradigms 
may have different philosophical assumptions, but this does not imply that 
they are necessarily incommensurable, having no common measure or 
fraction.   
 
If they are to be found commensurable then transparency and consistency 
must be employed in the reporting of the philosophical and methodological 
choices made.  Mesel reflects on this when he says, ‘transparency on the 
philosophical level is important for validity and consistency as well as for 
attempts to integrate or establish an interface to other research.’(Mesel, 
2013) 
 
Mesel is writing in the context of his role as an Associate Professor of a 
Department of Religion, Philosophy and History at a Norwegian University 
Hospital.  He is able to argue that the if we make our basic assumptions 
transparent and available for reflection, then we can start to identify the new 
positions and formulations which allow the integration of data from different 
paradigms.  He is working from the ‘bottom up’ starting with the most 
fundamental category, the philosophical worldview. 
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It is interesting to compare his perspective with other pragmatist researchers 
who are working from the other end of the spectrum or ‘top down’.  For 
example, Cornish (Cornish and Gillespie, 2009) who are working in a health 
psychology context in the field of nursing and midwifery. Their challenge is to 
be able to promote speedy and positive social action, that addresses the 
moral, political and social conditions, but they have to make those changes 
based upon choices between opposing forms of knowledge. They see 
Pragmatism as an approach that can reconcile the two traditions in health 
psychology, which can be described at their most basic level, as realism and 
constructivism.   
 
Although at the time of publication MMR is not a common approach in 
Scandinavia, and this would explain why Mesel would say that there is a 
tendency to create dichotomies between qualitative and quantitative 
methodology within healthcare research.   
 
For example qualitative studies have been recognised as making an 
important contribution the scientific knowledge of medical sociology and 
nursing science.  Evidence based research within nursing and medicine has 
concentrated on randomised controlled trials in which quantitative 
methodology has been the main source of knowledge (Mesel, 2013). 
 
He recognises that clinical practice utilizes both quantitative and qualitative 
forms of knowledge and that clinical decisions and choices may be 
influenced by interviews with patients, previous experience as well as data 
from clinical trials.  Cornish rejects the idea of an absolute hierarchy of 
knowledge with randomised controlled trials at the pinnacle and argues 
instead that different forms of knowledge are needed for different audiences 
and purposes. 
 
Knowledge for taking care of oneself (Cornish and Gillespie, 2009) 
• Health education has been criticized for taking biomedical accurate 
information (such as that provided by RCT’s) and assuming that if lay 
LITERATURE REVIEW 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   62	  
people are given this information they will think rationally and act 
accordingly.  While an RCT provides service users with useful 
information it does not help patients make sense of an illness or forge 
a new identity. 
 
• An illness can change the meaning of a person’s life, their 
relationships, their work and their very self.  In creating their health 
identities people may draw on medical and non-medical knowledge. 
 
• Health researchers can use qualitative methodologies such as 
grounded theory or discourse analysis to discover which strategies 
and skills are needed by people to cope with their illnesses.  The 
health researcher could support the construction of knowledge in 
support groups, survivor groups and service user groups. 
 
• Alternatively action research may help create new strategies or 
transform service provision to better reflect the needs of others.  From 
a pragmatist point of view the knowledge needs to be useful or 
actionable from the point of view of the people it is trying to help. 
 
Knowledge for intervention design (Cornish and Gillespie, 2009). 
• Health intervention designers face challenges of implementation.  
They have to work with the complex, real world, everyday practicalities 
of individuals and communities, where familial, financial, political, 
cultural and social dimensions are deeply entwined with health 
behaviours and outcomes. 
 
• Programme success often depends, not only on the evidence base of 
the intervention but on the skills of ensuring acceptability to service 
users, commitment from local healthcare workers, and support of 
managers or powerful stakeholder. 
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• An RCT may offer some confidence that a chosen method has worked 
in the past but a new context will produce uncertainties, exceptions, 
obstacles, and dilemmas that have to be managed. 
 
• Programme designers need generative, adaptive and flexible 
knowledge to guide them through novel situations.  Theories and 
models can provide such flexible knowledge.  Richly detailed case 
studies can support the development of context-sensitive expertise 
and skilled decision-making. 
 
Knowledge for cultural critique (Cornish and Gillespie, 2009) 
• A pragmatist perspective values research activity, which creates new 
ways of thinking and acting and thus creating a richer future.  The 
multiple interests that might be served by health research leads us to 
reject the idea of an absolute hierarchy of evidence although methods 
might be better than others in relation to particular interests. 
 
• Pragmatism does not determine whose interests should be advanced 
through research.  They suggest three means that health researchers 
might use to inform their choice of interest to pursue: 
 
1. Tackle problems defined by people’s experience 
2. Choose problems through public deliberation 
3. Critique the choice of interests being served. 
 
Mesel suggests that a focus on justifying the value of a pluralistic approach 
may be explained by sociological factors such as the power balance between 
groups of professionals.  The professionalism of nurses and their struggle for 
scientific autonomy and status have led to a need for their qualitative 
researchers to have strong arguments in favour of the validity of their 
methods (Mesel, 2013). 
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He argues that the current philosophical landscape is both complex and 
nuanced and therefore to avoid falling into twin pitfalls traps of endless 
debate, or an ‘anything goes’ form of pragmatic action, that transparent and 
consistent philosophical declarations should be make on all sides.  He 
agrees with Cornish that a research community that is creative and pluralistic 
best serves the complex needs of modern healthcare and that mixed 
methods offer a promising asset in healthcare research. 
 
Limitations To This Narrative Review 
The main limitation to this section is that it is not a systematic exploration of 
Pragmatism, it is a personal exploration of the philosophy that emerged from 
the process of rewriting and the application of the new world view to the data, 
methodology, theoretical framework and results of this thesis.   The 
disadvantages of Pragmatism as a worldview are not fully explored and the 
bias towards the usefulness of pragmatism is recognised as a limitation of 
this study. 
 
Conclusion  
Research Questions: 
What is Pragmatism?  How does it inform this thesis? 
 
In this section, the methodology chapter and in the introduction I have written 
about how engaging with pragmatism allowed me to move away from the 
early assumptions that shaped the early phases of this research project.  The 
general characteristics of pragmatism (Johnson and Onwuegbuzie, 2004) 
can be used as a framework here to provide practical examples of this 
change of worldview. 
 
1. Finding a middle ground. 
The initial strands were informed by a dominant medical paradigm as the 
social environment for a study about complementary or alternative medicine.  
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The parallels between progressive education and complementary medicine, 
as explored by Dewey (Dewey, 1910a),(Dewey, 1916), as well as in more 
recent analyses of his work (Shelton, 2013) challenged these assumptions 
and allowed me to find an intellectually valid space in which to work between 
these dualisms. 
 
2. Rejects traditional dualisms. 
An exploration of the dualisms between a purely scientific position and a 
holistic approach to healthcare research and knowledge (Cornish and 
Gillespie, 2009) gave rise to a better understanding of the need for my 
research to see not just the disease but also the person.  The work of Dewey 
on the reflex arch (Dewey, 1896), the regulatory systems of homotoxicology ] 
(Smit et al., 2010) and the medical model of PNEI are explored in this thesis 
to describe the connection between mind and body, stress and infertility. 
 
3. Recognises the existence and importance of the natural or physical world 
as well as the emergent social and psychological world. 
By allowing equal value to be placed on the construction of knowledge from 
qualitative sources as well as the collection of data under controlled 
conditions, I was able to reconcile the tension of working with the two 
paradigms (Mesel, 2013).  
 
4. Places high regard for the reality of and influence of the inner world of 
human experience in action. 
The adoption of a pragmatist perspective allowed me to see that it was worth 
continuing with the project after the failure of the RCT because the 
understanding of why it failed was useful for future trial designs.  If resilience 
and persistence in the face of difficulty are the hallmarks of a good 
researcher then pragmatism is surely the researchers best friend and tool for 
cultivating these traits. 
 
5. Knowledge is viewed as being both constructed and based on the reality 
of the world we experience and live in. 
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Pragmatism provided the philosophical framework for adopting the mixed 
methods research approach and allowed me to include the multiple 
perspectives of staff, patients and researchers into the trial design, results 
and analysis.  Had this taken place earlier then the outcomes of the RCT trial 
might have been improved. 
 
6. Organisms are constantly adapting to new situations and environments.  
Our thinking follows a dynamic homeostatic process of belief, doubt, inquiry, 
modified belief, new doubt, new inquiry…in an infinite loop, where the person 
or researcher (and research community) constantly tries to improve upon 
past understandings in a way that fits and works in the world in which he or 
she operates.  The more intelligent use of theory, and a more intelligent way 
of working (Dewey, 1910b) contributed to the eventual success of the thesis 
in my second viva and will inform my future projects: The present is always a 
new starting point.(Johnson and Onwuegbuzie, 2004) 
 
7. Views current truth, meaning and knowledge as tentative and as changing 
over time.  What we obtain on a daily basis in research should be viewed as 
provisional truths.  The need for philosophical transparency in the reporting 
of the project was highlighted by my reading (Mesel, 2013), (Cornish and 
Gillespie, 2009) and this focus allowed me to improve my writing of the 
methodology as well as helping me to clarify my thinking. 
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Literature Review- Section 2 The Definitions, 
Prevalence and Treatment of Female Infertility 
 
Research	  Questions	  
How	  is	  infertility	  defined	  in	  published	  studies,	  in	  working	  practice,	  what	  is	  
the	  estimated	  prevalence	  –	  global	  and	  UK?	  	  What	  is	  the	  recommended	  
treatment	  for	  female	  infertility?	  
Introduction	  
The site for the planned RCT trial of Ovarium compositum was an assisted 
reproduction unit (ARU) at Jersey General Hospital and the audience for the 
trial protocol was a conventional medical audience.  The trial design and 
choice of literature for this phase of the study reflects the need to work within 
the dominant biomedical paradigm and to have an understanding of the 
recommended treatments.  
 
Infertility is a major, multifaceted issue worldwide whose prevalence is 
increasing in both high- and low-income countries (Petraglia et al., 2013) but 
the specific focus of this search was to find an estimate of global female 
infertility and working definitions of infertility that could be used in this thesis. 
 
Methodology	  
 
The selection of papers can be summarised in four steps as seen in Figure 2. 
 
1. A preliminary search of the literature was performed using MeSH terms 
"Humans" AND "Infertility/epidemiology" AND "Prevalence" NOT "male 
infertility on PubMed, resulting in 110 articles.  The date of the search was 
15th February 2015.  The results were filtered for full text articles on human 
subjects in the last ten years and an additional information source was also 
included (Fields et al., 2013): 
.   
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2. The abstracts for each of these articles were read and sorted into broad 
themes as detailed below Table 6 The results of the preliminary literature 
search and Figure	  3	  Thematic	  Sorting	  of	  Preliminary	  Search	  Results 
 
3. The articles that had the best fit to the research question were shortlisted for critical reading 
and review using the checklist previously described in  	  Table	  4:	  Checklist	  of	  questions	  for	  critical	  reading	  of	  selected	  articles  
 
Selection criteria - These 8 papers ( Table	   8	   Shortlist	   of	   8	   papers	   on	   the	  prevalence	   of	   infertility ) were chosen from the 110 initial candidates to 
provide an up-to-date estimate of the prevalence of global infertility as well as 
exploring the definitions of infertility and the types of data used for such 
estimates. The criteria for including them was that their main focus was on 
the prevalence of infertility on an international or global dimension, that they 
were peer reviewed and published in the last 10 years. 
 
4. Three articles were chosen to review in greater detail for this section and 
the  additional information source was included in this analysis(Fields et al., 
2013): 
 
1. Fertility (update): summary of NICE guidance (Fields et al., 2013) 
 
2. International estimates of infertility prevalence and treatment-seeking: 
potential need and demand for infertility medical care (Boivin et al., 
2007) 
 
3. National, Regional, and Global Trends in Infertility Prevalence Since 
1990: A Systematic Analysis of 277 Health Surveys (Mascarenhas et 
al., 2012b) 
 
4. Defining infertility – a systematic review of prevalence studies 
(Gurunath et al., 2011) 
 
These papers were chosen to provide an up-to-date estimate of the prevalence of global 
infertility as well as exploring the definitions of infertility and the types of data used for such 
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estimates.  The two systematic reviews were chosen as they represented a more complete and 
reliable form of evidenced compared to the papers that were excluded.  The papers were read 
critically using the list of questions for as explained in the methodology section of this chapter 	  Table	   4:	   Checklist	   of	   questions	   for	   critical	   reading	   of	   selected	   articles.  There 
was no quantitative synthesis or meta-analysis of the papers. 
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PRISMA	  2009	  Flow	  Diagram	  
 
Figure 2 Selection Process for Literature Review on Prevalence and Treatment of Infertility 	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Results	  of	  Literature	  Searches	  	  
Table 6 The results of the preliminary literature search 
 
Name and details of paper found using MeSH 
search terms 
Humans 
Infertility/epidemiology* 
Prevalence 
Not male infertility 
 
Reference for 
bibliography 
What is the main focus of the 
paper? 
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Thematic sorting of preliminary search results 
Figure	  3	  Thematic	  Sorting	  of	  Preliminary	  Search	  Results 
Two articles were concerned with the provision and management of 
healthcare provision for infertile patients in developing or low resource 
countries with low access to assisted reproductive technology (ART) 
(Sharma et al., 2009) and (Ombelet et al., 2008).  
 
The diagnosis and treatment of infertility were sometimes constructed in the 
literature as being dependent on the availability or non-availability of ART, 
one article explored the correlation between state funded treatments and 
frequency of diagnosis for diminished ovarian reserve:  
The presence or absence of state-mandated ART coverage could impact 
access to care and the mix of patients that pursue and initiate ART cycles in 
ways that influence these proportions (Butts et al., 2013) 
 
The reproductive technology known as in vitro fertilization (IVF) was the 
subject of eight articles; two were concerned with the therapeutic use of 
specific hormones, gonadotropin-releasing hormone (Xiao et al., 2013) and 
progesterone (Simunic et al., 2007).  Four papers were concerned with the 
implications of singleton or multiple live births in various contexts (Malizia et 
al., 2013, Shapiro et al., 2013, Nakashima et al., 2013, Grunfeld et al., 2008).  
Specific outcomes such as heterotopic pregnancy (Clayton et al., 2007)and 
the role of co-culture were also investigated or subjected to meta-analysis 
(Kattal et al., 2008).  
 
The risks and benefits of specific surgical treatments (Rasheed et al., 2014) 
or drug interventions (Malloch and Rhoton-Vlasak, 2013) (Boots et al., 2013) 
were also the focus of some studies.   
 
Sexually transmitted diseases are major determinant of the prevalence of 
infertility in most latitudes (Petraglia et al., 2013) and eight papers were 
found to cover this topic, ranging from HIV infections (Dhont et al., 2011, 
Larsen et al., 2007) and HPV (Spandorfer et al., 2006) to Chlamydia (Malik et 
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al., 2006) (Datta et al., 2012, Baraitser et al., 2011, Svenstrup et al., 2008) 
and Pelvic Inflammatory Disease (Wiesenfeld et al., 2012). 
 
Another reason for the increasing incidence of infertility is the widespread 
use of contraception, the choice of delaying the first pregnancy until the third 
decade of life which places women at higher risk for uterine fibroids, 
endometriosis, polycystic ovary syndrome, and chronic anovulation (Petraglia 
et al., 2013) and 17 studies reported on aspects of female reproductive 
pathology.  The most commonly reported conditions were adenomyosis and 
endometriosis. 
 
Adenomyosis occurs when endometrial tissue, which normally lines the 
uterus, exists within and grows into the muscular wall of the uterus and may 
be associated with subfertility (Tomassetti et al., 2013).  A systematic review 
(Maheshwari et al., 2012) concluded that  further studies are needed to 
determine the natural history of adenomyosis and implications for fertility and 
reproductive outcomes, with and without treatment.   
 
MRI imaging has been used to estimate the prevalence of adenomyosis in 
endometriosis and it’s impact on fertility (Kunz et al., 2005) Four other 
articles were concerned with the use of imaging techniques in ART (Souter et 
al., 2010, Marci et al., 2013, Moini et al., 2013, Butts et al., 2013, Liberty et 
al., 2010). 
 
Endometriosis is believed to be associated with female infertility in women 
with otherwise normal ovulation (Ilangavan and Kalu, 2010), and can cause a 
reduced responsiveness to the drugs used in IVF (Somigliana et al., 2006).  
Described as an ‘enigmatic’ condition (Ozkan et al., 2008) there have been 
several studies and reviews to try and establish the optimum treatment for 
affected infertile women (Ozkan et al., 2008).  
 
The need for the surgical treatment of minimal to mild endometriosis was 
investigated (Werbrouck et al., 2006) who found no difference in IVF cycle 
pregnancy rates and live births between women affected and women with 
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unexplained infertility. Endometriosis (ENDO) is believed to have increased 
during recent years (Paris and Aris, 2010) in women aged 18 -24 who are 
therefore at a greater risk of infertility.  Hysteroscopic polypectomy and 
removal of endometriotic foci significantly increased the chances of achieving 
a pregnancy compared with those without polyps (Shen et al., 2011).  
 
The other female reproductive pathologies that have been reported include: 
fibroids (Firouznia et al., 2009), polycystic ovary syndrome (McGovern et al., 
2007), luteal phase deficiency (Schliep et al., 2014), utero-tubal infertility 
(Audu et al., 2009), empty follicle syndrome (Aktas et al., 2005), (Stevenson 
and Lashen, 2008) and abnormal cervical cytology (Al-Jaroudi and Hussain, 
2010).   
 
Another reason for the increasing prevalence of infertility may be the 
prolonged exposure to chronic stress and environmental pollutants, which 
may play a critical role (Petraglia et al., 2013).  Published papers in this area 
include: smoking and infertility (2012), (Neal et al., 2005), the reproductive 
life events in a population living in the vicinity of a nuclear waste 
reprocessing plant (Slama et al., 2008) and the effect of chemicals used in a 
hair dressing salon (Ronda et al., 2009). 
 
The psychological and emotional health of infertile women has been reported 
in a range of papers covering topics such as alexithymia (Lamas et al., 
2006), eating disorders (Freizinger et al., 2010), state and trait anxiety 
(Albayrak and Gunay, 2007) and schizophrenia (Svensson et al., 2007). 
Infertile women were found to be at higher risk of developing psychiatric 
disorders if they were housewives rather than working women (Noorbala et 
al., 2009).  Sexual dysfunction either in women or couples was reported in 
three papers (Khademi et al., 2008), (Keskin et al., 2011) and (Pakpour et al., 
2012). 
 
Although gonadotoxic oncologic treatments allow many patients to survive 
cancer, it may be at the cost of their fertility. This consideration may justify 
the development of treatments that preserve fertility (Petraglia et al., 2013), 
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four papers were identified as dealing with these issues (Turan et al., 2013), 
(du Bois et al., 2013), (Balcerek et al., 2012, Hammond et al., 2008). 
 
Papers that dealt specifically with the definition of infertility, and estimates of 
prevalence were examined to see if they could be used to provide a global 
estimate.  Nine papers dealt with a specific geographical area and were 
excluded (Ziller et al., 2013, Thoma et al., 2013, Esmaeilzadeh et al., 2012, 
Bushnik et al., 2012, Bhattacharya et al., 2009, Kumar, 2007, Safarinejad, 
2008, Stephen and Chandra, 2006, Oakley et al., 2008). 
 
One of these papers found that among married women in the United States, 
there has been a significant decline in 12-month infertility, which cannot be 
explained by changes in the composition of the population from 1982-2002 
(Stephen and Chandra, 2006) and this apparent reversal in the global trend 
provoked some methodological debate in response: 
 
Data on trends in fertility and infertility are of significant interest, because 
they may reflect social, behavioral, biological, or environmental changes. The 
conclusion that infertility has declined in the United States, based on data 
from the National Survey of Family Growth, must be interpreted with great 
caution because of definitional and methodological concerns (Guzick and 
Swan, 2006) 
 
Self-reported data have serious limitations, particularly when the outcome is 
constructed from indirect questions. Policy decisions require clearly defined 
issues, validated tools, careful and comprehensive analysis, and cautious 
interpretation (Olive and Pritts, 2006) 
 
Conclusions regarding estimates of infertility may reflect study bias based on 
the definition of infertility used. Careful consideration of how the infertile 
population is defined, as well its use in subgroup analysis that may not be 
generalizable to the population of infertile women as a whole, is needed 
(Thornton and Goldman, 2006).   
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The idea that how we define infertility affects our ability to detect and report 
its prevalence was tested in a Moshi town in northern Tanzania (Larsen, 
2005) where it was found that the infertility definition made a difference. The 
researcher concluded that the World Health Organization definition based on 
24 months of trying to get pregnant was recommended as the definition that 
is useful both in clinical practice and research among different disciplines. 
 
The articles that had the best fit to the research question were shortlisted for critical reading 
and review using the checklist previously described 	  Table	  4:	  Checklist	  of	  questions	  for	  critical	  reading	  of	  selected	  articles  
31: Mascarenhas MN, Flaxman SR, Boerma T, 
Vanderpoel S, Stevens GA. National, 
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since 1990: a systematic 
analysis of 277 health surveys. PLoS Med. 
2012;9(12):e1001356. doi: 
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PubMed PMID: 23271957; PubMed 
Central PMCID: PMC3525527. 
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2012a) 
Systematic review of infertility 
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57: Gurunath S, Pandian Z, Anderson RA, 
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Reprod Update. 2011 
Sep-Oct;17(5):575-88. doi: 10.1093/humupd/dmr015. 
Epub 2011 Apr 14. Review. 
PubMed PMID: 21493634. 
(Gurunath et al., 2011) Systematic Review of prevalence 
72: Dyer SJ. International estimates on infertility 
prevalence and treatment 
seeking: potential need and demand for medical 
care. Hum Reprod. 2009 
Sep;24(9):2379-80; author reply 2380-3. doi: 
10.1093/humrep/dep219. Epub 2009 Jun 
20. PubMed PMID: 19542544. 
(Dyer, 2009) Infertility prevalence 
95: Boivin J, Bunting L, Collins JA, Nygren KG. 
International estimates of 
infertility prevalence and treatment-seeking: potential 
need and demand for 
infertility medical care. Hum Reprod. 2007 
Jun;22(6):1506-12. Epub 2007 Mar 21. 
Erratum in: Hum Reprod. 2007 Oct;22(10):2800. 
PubMed PMID: 17376819. 
(Boivin et al., 2007) Infertility prevalence 
102: Thornton KL, Goldman MB. Impact of subgroup 
analysis on estimates of 
infertility. Fertil Steril. 2006 Sep;86(3):531-3; 
discussion 534. PubMed PMID: 
16952504. 
(Thornton and 
Goldman, 2006) 
Infertility prevalence 
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devil is in the details. 
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(Olive and Pritts, 
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104: Barnhart KT. The challenge and enjoyment of 
the interpretation of 
epidemiologic data. Fertil Steril. 2006 Sep;86(3):527-
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(Barnhart, 2006) Infertility prevalence 
(methodology) 
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Table	  8	  Shortlist	  of	  8	  papers	  on	  the	  prevalence	  of	  infertility 
 
Selection criteria - These papers were chosen from the 110 initial candidates 
to provide an up-to-date estimate of the prevalence of global infertility as well 
as exploring the definitions of infertility and the types of data used for such 
estimates. The criteria for including them was that their main focus was on 
the prevalence of infertility on an international or global dimension, that they 
were peer reviewed and published in the last 10 years. 
 
Three articles were chosen to review in greater detail for this section and an 
additional information source was included (Fields et al., 2013): 
 
5. Fertility (update): summary of NICE guidance (Fields et al., 2013) 
 
6. International estimates of infertility prevalence and treatment-seeking: 
potential need and demand for infertility medical care (Boivin et al., 
2007) 
 
7. National, Regional, and Global Trends in Infertility Prevalence Since 
1990: A Systematic Analysis of 277 Health Surveys (Mascarenhas et 
al., 2012b) 
 
8. Defining infertility – a systematic review of prevalence studies 
(Gurunath et al., 2011) 
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These papers were chosen to provide an up-to-date estimate of the 
prevalence of global infertility as well as exploring the definitions of infertility 
and the types of data used for such estimates.  The two systematic reviews 
were chosen as they represented a more complete and reliable form of 
evidenced compared to the papers that were excluded.  The papers were 
read critically using the list of questions for as explained in the methodology 
section of this chapter. 
 
Analysis	  of	  Literature	  Searches	  
The	  Definition	  And	  Treatment	  Of	  Infertility	  	  
The first choice of guidelines for the diagnosis and treatment of female 
infertility were the updated NICE guidelines because these are the guidelines 
that will be in use at the site of the trial, an assisted reproduction unit at 
Jersey General Hospital.  It is important that the patients, researcher and 
clinicians at the site share a common understanding of the condition and it’s 
treatment.  The guidelines are written from a conventional medical 
perspective and with a post positivist philosophical framework.   
 
NICE recommendations are based on systematic reviews of the best 
available evidence and explicit consideration of cost effectiveness.  When 
minimal evidence is available, recommendations are based on the Guideline 
Development Group’s experience and opinion of what constitutes good 
practice. 
 
These guidelines also recommend that couples should be informed that the 
effectiveness of complementary therapies for fertility problems has not been 
properly evaluated and that further research is needed. 
 
The	  Definition	  Of	  Infertility	  
The way in which we define infertility will influence the way in which data is 
collected and prevalence is measured.  The researcher has to choose 
between demographic and epidemiological data sources; demographic 
definitions provide important data on reproductive outcomes in large 
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populations but may fail to identify couples who need investigation and 
treatment in order to improve their chances of conception (Gurunath et al., 
2011).   
 
Clinical definitions are also useful when determining treatment groups and for 
the purposes of this study infertile woman who fall into the WHO category 2 
and 3 (hypothalamic-pituitary dysfunction and ovarian failure) groups were 
eligible for study recruitment. 
 
The WHO classifies ovulation disorders into three groups: 
Group 1: hypothalamic pituitary failure (hypothalamic amenorrhoea or 
hypogonadotrophic hypogonadism 
Group 2: hypothalamic-pituitary-ovarian dysfunction (predominately 
polycystic ovary syndrome) 
Group 3: ovarian failure. 
 
Both demographic and epidemiological definitions of infertility are important 
in their own contexts and both types of studies are considered in this section. 
  
Infertility is defined by NICE (Fields et al., 2013) as the period of time people 
have been trying to conceive without success after which formal investigation 
is justified and possible treatment implemented.  This new definition replaces 
defining the patient as ‘infertile’ and uses infertility as a unit or status update. 
  
However estimates of prevalence can be affected by our shared 
understanding of the definitions of terms such as ‘infertility’, ’subfertility’, and 
‘sub fecundity’ and how they are used in the data without being clearly 
defined, as well the terms ‘primary permanent infertility’, ‘unresolved 
infertility’, ‘childlessness’ and ‘primary unresolved infertility’ (Gurunath et al., 
2011) 
 
The main challenge in generating global estimates of infertility are the 
scarcity of population-based studies and the inconsistent definitions used in 
the few high-quality studies available (Gurunath et al., 2011). 
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In order to obtain a clearer understanding of these definitions (Gurunath et 
al., 2011) has investigated the way that infertility is defined in prevalence 
studies using a computerised and manual literature search for demographic 
and epidemiological studies. 
  
The studies selected for review were population-based studies of a random 
selection of a representative sample, surveyed by postal questionnaires or 
oral interviews. The 28 epidemiological studies were cross sectional in 
design.   Descriptive cross sectional surveys are based on a representative 
sample or sub-sample of the population of interest who are questioned at 
one point in time.  The aim is usually to assess the prevalence of disease 
and associated factors. 
 
The results highlight the fact that the absence of an established definition of 
infertility results in varying estimates of its prevalence within and between 
populations.  There is considerable heterogeneity in terms of determining 
exposure and outcomes, the nature of the population sampled and the 
denominator used to calculate prevalence rates (Gurunath et al., 2011). 
 
While a systematic review of this kind helps us to search for a universal 
explanation, derived from empirical regularities (Bowling, 2011), it might have 
also been appropriate to use qualitative research methods to investigate the 
differences and similarities in global definitions of the concept of infertility.   
 
The	  Prevalence	  of	  Infertility	  
Estimates of the prevalence of infertility vary slightly between studies, from 
about one in seven couples in the United Kingdom (HFEA, 2008) to a 9% 
global prevalence of infertility of 12 months duration (Boivin et al., 2007).   
 
Boivin et al have taken a post-positivist approach to estimating the 
prevalence of infertility. Population surveys published since 1990 were 
examined for the prevalence of infertility.  A specific Pub Med search yielded 
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28 studies, which they selected for review.  Estimates on population size and 
variables such as age, marital status and contraception use were made using 
data from recognised sources. 
 
No statistical modelling was performed but the main findings of this review 
were that prevalence and demand for infertility treatment were lower than 
typically cited and remarkably similar between more and less developed 
countries.  The potential need for infertility medical services was 
approximately 9% based on a sample of 170 000 women. The evidence 
indicated a 9% prevalence of infertility (of 12 months duration) with 56% of 
couples seeking medical care (Boivin et al., 2007). 
 
Mascarenhas et al commented on the 12-month duration definition of 
infertility used by Boivin finding that it was not long enough to compensate for 
other variables: 
 
We found that a 5-y exposure period is needed to accommodate the time it 
takes to become pregnant and give birth, and helps prevent unreported 
temporary separations, periods of postpartum sexual abstinence, or lactation 
amenorrhea from unduly affecting the infertility measure. Births, rather than 
pregnancies, are the preferred outcome, as information on live births is 
collected more often and reported more accurately: neither pregnancies in 
the first trimester nor voluntary terminations are reliably reported in 
household surveys.(Mascarenhas et al., 2012b) 
 
Mascarenhas (Mascarenhas et al., 2012b) used  an alternative to 
synthesizing data found in the literature  by applying  a consistent definition 
and a statistical model to regularly collected demographic data and 
reproductive health survey data. One of the stated aims of this project was to 
use an agreed definition of infertility. They applied consistent definitions of 
primary infertility (inability to have any live birth) and secondary infertility 
(inability to have an additional live birth).  
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The strength of this study is that few comparative analyses of global infertility 
have been conducted and none have applied a consistent algorithm to 
demographic and reproductive health survey data both from developing and 
developed countries, nor used these data to estimate regional and global 
trends in infertility prevalence.  
 
They estimated the prevalence of primary and secondary infertility trends 
using household survey data consisting of interviews with the female partner.    
However there are challenges associated with inferring prevalence from 
household survey data.  Few household surveys ask how long the 
respondent has tried to get pregnant instead these surveys may collect 
information on births, couple status, fertility preferences and contraceptive 
use (Mascarenhas et al., 2012b).  
 
A previous analysis (Mascarenhas et al., 2012a) performed a sensitivity 
analysis around each of the components (live birth as the outcome and a 5-y 
exposure period based on union status, use of contraceptives, and desire for 
a child.), to identify important biases that may arise when information is 
incomplete . 
 
The scale of this project means that the data collection was appropriate and 
allowed comparison to be made between different countries.  The return 
rates of the surveys used would allow us to judge how representative they 
are of the population sampled.  They did exclude thirteen studies because at 
least one response was missing for more than 15% of respondents. 
 
The methodological quality of the study was improved by the use of cross 
validation to evaluate the predictive validity of their model and a geographical 
framework was used to evaluate results at global, regional and country level.  
Some aspects of social and cultural differences were taken into account such 
as political pressures in China, which may cause underreporting of abortion 
and contraception. 
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Limitations of the study include the narrow definition of child-seeking women 
and data gaps for some countries. This could have been extended, for 
example, by including women in a same sex union or single women who 
desired a child. 
 
They found that by using a larger data set and a different algorithm to 
calculate infertility their estimate of the global number of couples affected by 
infertility was lower than that of (Boivin et al., 2007) in 2006.  They found that 
in 2010 1.9% of child-seeking women aged 20-44 years old were unable to 
have a first live birth (primary infertility) and 10.5% of child-seeking women 
with a prior live birth were unable to have an additional live birth (secondary 
infertility). 
 
Other findings included: 
 
• The prevalence of primary infertility was higher amongst women aged 
20-24 y compared to women aged 25-29y and women aged 30-44y. 
 
• Prevalence of secondary infertility increased sharply with age. 
 
• Both age patterns are less pronounced when calculated as a 
percentage of all women. 
 
 
This study was used as a baseline estimate of global infertility rates in a 
recent paper ‘Fertility drugs, reproductive strategies and cancer risk’ (Tomao 
et al., 2014): 
 
In the world the number of people with problems of infertility has increased 
since 1990, resulting in a consistent increase in the use of strategies to 
improve fertility and reproductive rates. The highest incidence of infertility 
was found in western countries and in these countries a consistent proportion 
of the infertile women receive fertility treatments (Mascarenhas et al., 2012b). 
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Moreover, the clinical use of fertility drugs and other reproductive strategies 
is expected to increase for the large number of women who postpone 
pregnancy for economic and social reasons (Mascarenhas et al., 2012b). 
 
The	  Treatment	  Of	  Infertility	  
There is evidence that more people are having fertility treatment which is 
increasingly successful (HFEA) and so the NICE guidelines from 2004 have 
been updated to provide clinicians with a list of recommendations regarding 
appropriate care (Fields et al., 2013). 
 
NICE recommends that Clinicians should inform people who are concerned 
about their fertility that: 
 
• Over 80% of couples in the general population will conceive within one 
year if the women is aged under 40 years and they have regular 
sexual intercourse without contraception. 
• Of those who do not conceive in the first year, about half will do so in 
the second year (cumulative pregnancy rate over 90%). 
• Vaginal sexual intercourse every two to three days optimises the 
chance of pregnancy. 
• Female fertility declines with age. 
• That they may find it helpful to contact a fertility support group 
• Offer counselling as fertility problems can cause psychological stress. 
• Both partners should be informed that: 
Stress in the male and/or female partner can affect the couple’s 
relationship and is likely to reduce libido and frequency of intercourse, 
in turn contributing to fertility problems (Fields et al., 2013). 
 
Treatment options for women with WHO group 2 annovulatory infertility:  
clinicians should offer one of the following treatments: 
a. Clomiphene citrate for ovulation induction and ovarian 
stimulation. 
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b. Metformin 
c. A combination of the above 
Conclusion	  	  
Research	  Questions	  
How	  is	  infertility	  defined	  in	  published	  studies,	  in	  working	  practice,	  what	  is	  
the	  estimated	  prevalence	  –	  global	  and	  UK?	  	  What	  is	  the	  recommended	  
treatment	  for	  female	  infertility?	  
 
An examination of the literature shows that both systematic reviews of 
prevalence studies, and the systematic analysis of demographic data and 
reproductive health survey data, have been conducted in recent years.  The 
current prevalence of infertility has been calculated at approximately 9% 
globally or 1 in 7 couples in the UK. 
 
Infertility has been defined in various ways including primary infertility 
(inability to have any live birth) and secondary infertility (inability to have an 
additional live birth).  For the purposes of this study it is important to know 
how many couples might be seeking medical help for their infertility and this 
has been estimated at 56% of couples that have infertility problems.  This 
would create a significant opportunity for the use of Ovarium compositum if it 
could be shown to improve fertility outcomes for women undergoing fertility 
treatment. 
 
The age of women seeking to conceive is shown to change their predicted 
fertility outcomes with the prevalence of primary infertility being higher 
amongst women aged 20-24 y compared to women aged 25-29y and women 
aged 30-44y.  The prevalence of secondary infertility increases sharply with 
age and these findings informed the design of the quantitative strand of the 
thesis (an RCT trial of Ovarian compositum).   
 
The treatment and advice given to couples seeking to conceive have been 
updated recently by NICE and will form the basis of the treatment for the 
women who are the focus of this thesis.  Treatment options for women with 
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WHO group 2 annovulatory infertility:  clinicians should offer one of the 
following treatments: 
a. Clomiphene citrate for ovulation induction and ovarian 
stimulation. 
b. Metformin 
c. A combination of the above 
 
The advice given to couples recognises that infertility can cause 
psychological stress, and that in turn, stress can have an impact on fertility 
outcomes.  The current advice from NICE to the medical community is that, 
while counselling or joining a support group may help couples to cope, the 
value and safety of CAM therapies has not yet been adequately researched.   
 
This thesis seeks to make a contribution to that particular field of knowledge 
by evaluating the specific effect of a homeopathic preparation prescribed 
without a homeopathic consultation, as well as questioning the kind of 
research that is needed to establish the value of CAM therapies in the 
treatment of infertility. 
Limitations	  To	  The	  Overview	  
It was not possible in the context of this PhD to work with another reviewer or 
to rate each paper using a scoring system.  The initial search was not 
recorded systematically and the search had to be replicated and recorded in 
a table format post viva. No attempt was made to search for unpublished 
work from other sources and so it cannot be claimed that this is a fully 
systematic qualitative review of the literature on infertility and it’s global 
prevalence.  The only database that was searched was the PubMed 
database. 
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Literature Review - Section 3 The Treatment Of 
Infertility Using Homeopathy Or Homotoxicology  
Research Questions: What is homotoxicology?  Are there any existing trials of 
homotoxicology to treat infertility? What is the role of CAM in treating 
homotoxicology? 
 
Methodology 
A preliminary search using a search engine, using PubMed and by 
contacting suppliers of homoeopathic remedies was supported by personal 
correspondence with the author of a systematic review of randomised 
controlled trials of homeopathy (Mathie et al., 2013) 
 
Selection of papers for review 
At start of the study the philosophical perspective adopted by the author was 
a post positivist stance and the only studies considered for review were 
quantitative in nature and the ideal data being sought was in the form of 
Randomised Controlled Trials, any qualitative strands to the study design 
were intended to inform the design of the quantitative phase 
 
Search Strategy 
PubMed was searched using the MeSH terms (((homeopathy[MeSH Terms]) 
AND female infertility[MeSH Terms])) AND homeopathy  which yielded one 
of the papers selected for review, (Bergmann et al., 2000). 
 
Papers were also sourced from the suppliers of homotoxicological products 
(BioPathica Ltd) and the newsletters from a manufacturer (GUNA srl).  The 
possibility of bias from these sources is acknowledged and this was 
addressed by using Robert Mathies’ systematic list of RCT on homeopathy to 
check for available papers. 
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PRISMA	  2009	  Flow	  Diagram	  to	  show	  the	  selection	  of	  
papers	  on	  female	  infertility	  and	  homeopathy 	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One hallmark of a systematic qualitative review is that the Authors attempt to 
obtain all original (primary) research studies published on the topic under 
study by searching in multiple databases, performing handsearches, and 
contacting authors of previously published research (Green et al.)  I 
contacted Robert Maithie via email (7th November 2014), to discuss his 
systematic search of the RCT literature of homeopathy (Mathie et al., 
2013).to make sure that no papers had been missed from my selection and 
that no translations of papers were available to add to my analysis. 
 
Using this strategy three papers on the use of homotoxicology/homeopathy 
to treat female infertility could be found and no new studies were available on 
Pub Med when writing up in February 2015:   
 
1. Homeopathy Versus Conventional Therapy For Female Infertility: 
Intermediate Report From A Randomised Study.(Gerhard I, 1997) 
2. The Homotoxicological Treatment Of Female Functional Infertility: A 
Clinical Trial.(Lai, 2000) 
3. The Efficacy Of The Complex Medication Phyto-Hypophyson L In 
Female Hormone Related Sterility A Randomized, Placebo-Controlled 
Clinical Double Blind Study.(Bergmann et al., 2000) 
 
Review of Papers Selected. 
Each was evaluated against three frameworks: CONSORT (Hopewell et al., 
2008), RedHot  (Dean et al., 2007) and the MVHT (Mathie et al., 2012).  This 
ensures that the trial is assessed for validity as a randomised controlled trial 
that is suitable for homeopathy and that the methodology chosen is a valid 
model to test the research question for the intervention under investigation.   
 
A table summarising these three evaluations for each study can be found 
APPENDIX 1.  Although the methodological quality of these studies is poor 
they do provide a perspective on both the available literature on treating 
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infertility with homoeopathy and the quality of the research being undertaken 
in that field. 
 
The frameworks being used to evaluate the studies have been developed 
more recently than the publication date and so this is a retrospective 
analysis.  It is acknowledged that the authors would not have had the benefit 
of such guiding frameworks and also demonstrates the evolution that has 
taken, and continues to take place, in the thinking about the appropriate 
methodology for designing and conducting such trials. 
 
Introduction	  
The Definition of Homotoxicology 
The term homotoxicology is derived from three words: Latin homo meaning 
man or self; “toxic” derived from the Greek toxikon, meaning toxin or poison; 
and “logy” derived from the Green logos, meaning study.(Heel, 1986). 
 
The homotoxicological paradigm (Smit A, 2009) is a homeotherapeutic 
system in which a medical diagnosis is made, followed by an individualized 
assessment according to the severity of the patient’s disease.  This takes 
into account the response of the patient’s self-regulatory system to 
exogenous and endogenous stressors.  Treatment is given, using 
predominantly homeopathically prepared medicines, to support the inherent 
self-regulating ability of the body rather than just treat symptoms, which are 
seen as an expression of the body’s own defence that should not be 
suppressed. (Heel, 1986). 
 
Disease and Health are described as a position on a two dimensional scale 
known as the Disease Evolution Table (DET) (Smit et al., 2010), in which 
disease is represented as six successive stages along the horizontal axis 
and the different tissues of the body are shown on the vertical axis according 
to their embryonic origins. 
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The six successive stages of disease refer to the relationship between the 
organism and the presence of ‘toxins’, which cause a reaction.  Initially the 
organism will react with an excretory or inflammatory response and if these 
strategies fail to restore health the organism will compensate with storage or 
deposition of the toxins that may lead to a disruption of cellular metabolism or 
control. (Smit A, 2009) 
 
The Development of Homotoxicology 
Dr. Han-Heinrich Reckeweg (1905-1985) was the primary developer of 
homotoxicology.  He started the development in 1948 but it was only in 1952 
that the first official article was published (RECKEWEG, 1952) in Germany.  
This was followed by the definitive work in 1955 (Reckeweg, 1955). 
 
Some of the influences on Reckeweg’s development of homotoxicology are 
thought to have derived from the teachings of August Bier, a renowned and 
distinguished surgeon and the director of the Surgical University Clinic in the 
Ziegelstrasse in Berlin (Vogeler, 1942), where Reckeweg attended several 
semesters of his medical studies before moving to Bonn, where he received 
his degree. 
 
Major concepts from Bier and his contemporaries that are incorporated into 
homotoxicology are the purposefulness of disease (which is seen as a 
manifestation of the activation of the self-regulation system of the organism), 
the relationship between the cell and the extracellular matrix (ECM), and the 
cardinal concept that inflammation is a physiological process rather than a 
pathological one and a natural response to all stressors (Bier, 1926, Bier, 
1930). 
 
Homotoxicology also integrated the work of Cannon and later Hans Selye.  
Cannon  (Cannon, 1916) showed how the biological organism automatically 
mobilized its physiological and biochemical resources by a built-in "wisdom of 
the body," to defend itself against real or threatened assault (Mittelmann et 
al., 1942) 
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Selye’s theory was that various "stressors" (cold, heat, solar radiation, burns, 
"nervous stimuli") produce a generalized, stereotyped response in the 
biological organism as it works to "perform certain adaptive functions and 
then to reestablish normalcy." (Medicine, 2015) 
 
In homotoxicology, disease is seen as the expression of biologically 
purposeful defence mechanisms against endogenous and exogenous 
stressors (generally described as homotoxins) or the expression of the 
organism’s effort to compensate for the toxic damage it has sustained (Heel, 
1986). 
 
The response to stressors is coordinated by the global autoregulatory 
system, which is seen as the master system that regulates homeodynamics.  
Reckeweg depicted this as the Greater Defence System (Heel, 1986).    
 
The six subsections of the Greater Defence System are 
1. The reticuloendothelial system 
2. The hypothalamus-hypophysis-suprarenal axis 
3. The neural reflex system 
4. Detoxification by the liver 
5. Detoxification of the matrix 
6. The mucous membranes 
 
These systems are seen as closely interconnected and may share mediators 
and receptors.  The ‘cross talk’ between the immune, endocrine, and nervous 
systems is the basis for the science of psychoneuroimmunology. 
 
In homotoxicology symptoms and signs of illness and disease are thought to 
be an activation of this system and are therefore supported rather than 
suppressed.  Symptoms may be treated in order to keep the patient 
comfortable but never just suppressed. 
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Autoregulatory systems are governed by feedback loops, which can be both 
positive and negative, they are often characterised by an oscillating pattern 
that may also include a chronobiological pattern.  The goal of treatment with 
homotoxicology may be to restore and support these autoregulatory patterns  
 
 
 
Table 9 Examples of endogenous and exogenous stressors 
 
Exogenous Stressors Endogenous Stressors 
Pollutants Physiological substances 
Metals Waste products 
Agricultural chemicals Hormones 
Plasticizers Microbial debris 
Food Additives Dental filings and medical implants 
Microbial by-products and molds  
Therapeutic and Recreational Drugs  
 
Source (Heel, 1986) 
 
The Classification of Homotoxicology as a Homeotherapeutic 
System 
The homeotherapeutic schools can be classified according to the 
manufacturing method of the medication and the method by which it is 
prescribed.  The most important schools include classical homeopathy, 
clinical homeopathy, combination product homeopathy, isopathy and 
anthroposophic medicine (Jütte and Riley, 2005).   
 
Homotoxicology has a close connection to clinical homeopathy, combination 
product homeopathy, and isopathy and the rationale for medications used in 
homotoxicology follows some of these principles (Heel, 1986). 
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In classical homeopathy medications are chosen by comparing the 
constellation of symptoms of the diseased individual with the so-called drug 
picture of the single-ingredient medication.  This drug picture is derived from 
pathogenic trials (and eventually published in a Materia Medica).  The 
detailed picture takes into account the physical, emotional, and mental 
pictures of the patient. (Heel, 1986). 
 
In clinical homeopathy the medication is prescribed according to the 
pathological picture of the disease, this is also true in homotoxicology, in 
which a medical diagnosis is made according to the currently accepted 
guidelines.  In addition, the diagnosis will include an assessment of the 
status of the patient’s biological regulatory system and a classification on the 
Disease Evolution Table (DET) (Heel, 2012).   
 
Reckeweg developed combination medications from homeopathically 
prepared ingredients selected according to the literature based on the 
pathogenic trials (therefore based upon the similar principle) and validated by 
his own observations.  He was especially interested in the multi-target 
approach because he believed that disease was caused by several factors 
both exogenous and endogenous and therefore needed a multicomponent 
medication to simultaneously address different targets (Heel, 1986). 
  
 
Homeopathy versus conventional therapy for female infertility: 
Intermediate report from a randomized study.  
(Gerhard et al., 1997) 
 
The setting for this study was a German University Clinic with approval from 
the Federal Ministry for Education and Technological research, and was 
partially funded by the Carl and Veronica Carstens Foundation 
(http://www.kisswin.de/en/funding/funding-organisations/organisation/0/1/karl-and-veronica-
carstens-foundation.html).   
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Key concepts include the view that infertility may have multiple causes that 
homeopathy and acupuncture are a holistic mind-body medicine, and that 
clinical trials are a ‘scientific’ way of providing evidence of efficacy.  The 
context of the study includes the fact that Assisted Reproduction Technology 
(ART) is moving forward and developing new techniques. 
 
This paper attempts to take results observed over a three year period in a 
real life clinical situation, which are acknowledged to be ‘alternative and 
scientifically unrecognised’, and tries to replicate them using a quantitative 
model (randomised two arm study) and a positivist perspective.   The 
conventional medical descriptions of infertility status are used and the 
homeopathic terms are explained for the non-specialist reader. 
 
The authors understanding of the holistic nature of mind-body medicine is 
made clear.  The nature of infertility as a disease is discussed and the 
author’s opinion is that infertility sometimes has a psychological causation 
but this mind-body connection is rarely acknowledged and patients are 
offered medical rather than psychotherapeutic interventions.  The rationale 
for using homeopathy is that by triggering regulatory systems the patient is 
restored to health on both a somatic and psychic level. 
 
This was designed as quantitative clinical trial model using randomised 
patients. 
When evaluated against the CONSORT criteria, Table 29 Gerhard 1997 
evaluated against Consort, the study meets some of the basic criteria but 
because of the failure to recruit sufficient women the outcomes and adverse 
events are not reported.  The general interpretation of the results has been 
replaced by a discussion about the problems of recruitment and a proposal 
for a new study design.  The available literature does not provide a trial 
registration number. 
 
The study was designed as a monocentric, two armed, randomised study. 
Patients agreeing to take part in the trial were divided into two treatment 
groups: 
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1. Single homeopathic remedies prescribed according to repertorisation 
of their symptoms and the selection of a remedy using the similar 
principle. 
2. Normal hormonal therapy tailored to the individual. 
 
 The decision not to use blinding when assigning women to treatment groups 
is justified by the different treatments used in the conventional treatment arm 
and the use of individualised remedies in the homeopathy arm.   
 
The criteria for allocating women to homeopathy or conventional treatment is 
not described but it is clear that women who elected to have homeopathy 
were allocated to a separate group and treated, as they desired.  They were 
not included in the analysis, as this could have created a placebo effect due 
to their positive expectations of homeopathy 
 
Using the REDHOT checklist, Table 30 Gerhard et al 1997 evaluated against 
REDHOT, highlights the issue that the knowledge condition of the patients 
appeared to present an obstacles to recruitment and that the medication, 
although listed by trade name, is not described fully.   
 
Although the setting is a clinic with both conventional and alternative 
practitioners, the details of the experience, accreditation and qualifications of 
the prescribing practitioners are not made clear.  The authors’ position as a 
supporter of the holistic approach to treating infertility is explained and 
reference made to some of the difficulties that occurred when working with 
more conventionally trained medical colleagues. 
 
The MVHT analysis, Table 31 Gerhard et al 1997 evaluated against MVHT, 
confirms that the rationale for the study is appropriate for women with 
amenorrhoea and sterility through hormonal causes, because there have 
been historical successes in the clinic.  However the case is not so clear for 
the third group of women with idiopathic sterility and women with 
simultaneous organic change.  
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The criteria for inclusion and exclusion were appropriate to control for 
variables that would affect the outcome of the trial however the recruitment of 
sufficient numbers of women willing to be randomised was a stumbling block 
for this study.  
 
The choice of 3,6,9 month testing dates to collect data on hormonal change 
and ‘questionnaire of sensitivities’ would be appropriate to monitor on-going 
changes and the patient’s perspective of the experience. 
 
Due to recruitment difficulties the data analysis is not reported in this study, it 
presents instead a detailed break down of the reasons for recruitment failure. 
The framework being used to interpret the data is a mathematic 
(percentages) description of the reasons that women did not recruit.  They 
provided a qualitative answer to what was a quantitative research question: 
Is it possible to show clinical effectiveness of homeopathic treatment vs. 
conventional treatment for female infertility using a randomised two-armed 
clinical trial? 
 
This study found that women might not consent to be randomised to a clinical 
trial of homeopathy for a variety of clinical, practical and financial reasons. A 
preliminary qualitative study exploring women’s attitudes towards taking part 
in a trial might have revealed some of these problems and allowed them to 
generate a model or theory that would have informed the quantitative 
research phase.  This could have improved on the simple model used to 
categorise and select women could not accommodate the complexity of their 
real life situations and choices including the long waiting times for diagnosis 
and treatment which eroded the number of women willing to be recruited.   
 
The limitations of this study include the very small sample size (due to 
multiple difficulties recruiting patients) and the lack of subject blinding which 
would have allowed them to control for placebo. 
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The treatment regime is not standardised, each patient is being treated using 
individualised treatment so we are testing the efficacy of an approach not a 
remedy. 
 
The study is of generally low methodological quality (Dean et al., 2007) 
because it does not include enough detail about the medications, 
prescriptions, practitioners, co-interventions, and adverse effects.  However 
the model is valid because it attempts to investigate a condition that has 
been shown to respond to homeopathic treatment, with sensitive enough 
outcomes, that are prescribed according to homeopathic principles. 
 
The ethics issues associated with the research centre around including a 
group that did not receive allopathic treatment which could be viewed as 
unethical but this is a clinic that women choose to attend because if offers a 
natural form of medicine. If this study were conducted today they would 
probably not have randomised to homeopathy vs. allopathic treatment for 
ethical reasons.  Women who have been trying to conceive for a very long 
time do not want to wait for unnecessary months, as an alternative they could 
have randomised to placebo or homeopathy in addition to conventional 
treatment. 
 
The implication for this thesis is that a mixed methods approach might be a 
better model for researching this kind of field.  Infertility is a highly emotive 
subject and the perspectives of patients need to be taken into account if trial 
recruitment is to succeed.  The findings of this study are particularly relevant 
to this thesis as it was also found that there are difficulties in recruiting 
women to this kind of trial in Jersey.  The author hoped to avoid these 
difficulties by conducting a qualitative strand in London and this will explained 
in more detail later. 
 
It has been cited by 5 other studies two by the same author (Article in 
German) and two are reviews.  One review is a meta analysis of headaches 
and migraines so is not included here but (Van Wassenhoven, 2005)  is of 
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interest as it summarises the thinking about how best to investigate 
homoeopathy in 2005. 
 
The Homotoxicological Treatment Of Female Functional Infertility: 
A Clinical Trial (Lai, 2000). Translated From Italian By Professional 
Translator. 
 
This article was not published as a peer reviewed article but does appear as 
a citation in some reviews of homotoxicology (Van Wassenhoven, 2005).  
Very few papers were available at the time of the original review and this was 
included as it dealt with homotoxicology and female infertility. The research 
question being addressed is: How does treatment with homotoxicology 
compare to allopathic treatment in women with female functional infertility? 
 
The setting appears to be a clinical setting and the results were included in a 
national convention on homeopathy, homotoxicology and biological medicine 
in Italy in 2000.  The paper has a clear bias towards the superiority of 
homotoxicology and describes it as a bridge between allopathy and 
homoeopathy. 
 
Infertility is described using scientific concepts; remedy protocols are 
described using standard homotoxicology products not individualised 
remedies.  Outcomes recorded are standard medical outcomes. This paper 
is written from the perspective of a positivist model, but dualistic nature of 
mind body medicine is accepted and these are made explicit by the author. 
Key concepts covered by this paper include: 
 
• Homoeopathy as an alternative form of medicine that takes the mind-
body connection into account.   
 
• Homotoxicology as a bridge between modern medicine and 
homoeopathy.  Infertility as a disorder that may have different 
causations. 
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• Ethical and generational conflicts that arise because of the 
introduction of new ART approaches and the awaking of public 
opinion.  
 
• Homotoxicology as a third option between passive acceptance of 
infertility and the aggressive technology of ART. 
 
 
Although he uses a quantitative methodology, described as a clinical trial, it 
is of poor methodological quality.  When compared to the criteria on the 
CONSORT checklist it does not include an explanation about how sample 
size was determined, the methods used to generate randomisation 
sequences or a description of the allocation to blinded treatment groups, 
Table 32 Lai 2000 evaluated against CONSORT.  
 
There is a strong rationale for this study as it sought to build on the clinical 
experiences described in earlier studies (Lai, 2000) and the success rate at 
the site clinic.  The remedies used are complex formulations from Heel that 
meet the criteria for inclusion for the Principles domain of the MVHT, Table 
34 Lai, 2000 evaluated against MVHT. 
 
The lead author is qualified to prescribe for the condition under investigation 
but his homeopathic training is not made clear.  The outcome measures 
chosen were suitable to show a clinical effect.  There was no long term follow 
up described but the data was collected over an eight month period which 
would have been long enough to see some changes of function such as 
hormone level or endometrial thickness.  On the whole this trial does 
represent a valid model to answer the research question but it is insufficiently 
reported and cannot therefore be assessed as a high quality clinical trial. 
 
Three subsets of women with different infertility conditions were randomised 
to homotoxicological or allopathic treatment:  
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Subset A: women with irregular anovulation suffering from premature 
luteinisation who were part of the large group entitled Unexplained Infertility. 
(n=29) 
 
Subset B: women with normal ovulation and presumed minor cervical factor 
who were part on the group entitled unexplained infertility. (n=34) 
  
Subset C: women suffering from ovulatory disorders associated with 
Hyperandrogenization (Polycystic Ovary Syndrome). (n=29) 
 
Therapeutic responses were compared in the six resulting groups and the 
outcomes included: monthly monitoring of ovulation and hormonal status, 
pregnancy rate, side effects and ovarian volume. 
 
Women were selected on clinical indications so there is no control for 
practitioner bias, they may have selected women who they thought would do 
well in the trial.  
 
The type of homeopathy used is evidenced by the description of the 
treatments and includes the use of mesotherapy at specific acupuncture 
points, which could confound the results due to the medication.  There is no 
description of which acupuncture points were used or if these were 
individualised to each patient.  
 
As an alternative to describing this as a clinical trial the authors could have 
framed it as a series of case studies or observational studies, and included 
patient questionnaires to gather qualitative data on their perceptions and 
experiences when taking part in the trial.  This data could have then been 
used to compare the two arms of the trial, inform the design of further 
investigations or been triangulated with other analyses as part of a mixed 
methods approach.  
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However it depends upon the research question being asked, in this case 
they were assessing the clinical outcomes between two approaches and in 
order to show a significant difference they would need to collect data from a 
larger sample and analyse it using a statistical analysis.  Some statistical 
analysis of the data would have allowed stronger associations to be made 
between the treatment and the outcome.  The existing data analysis is 
quantitative but is observational/descriptive data that cannot therefore be 
used to make inferences or demonstrate causal relationships. 
 
The authors claim that their results show that patients taking the 
homotoxicology achieved the same therapeutic response as those patients 
on allopathic treatment.  However this data has limited value due to the poor 
methodological quality of the trial so the conclusions are not reliable.  It is, 
however, useful as a model of a trial including the homotoxicological 
approach. 
 
The limitations of this study are highlighted when compared to the REDHOT 
list of criteria, Table 33 Lai, 2000 evaluated against REDHOT.  The author 
provides very few details about the knowledge condition of the participants 
and practitioners involved, or the setting and consultation process.   There is 
no information about how the sample size was determined or how 
randomisation was generated.  This means that the study is not reliable or 
repeatable.  The small sample size and poor control of variables makes this 
study more like a case study or observational study than a clinical trial. 
 
Randomisation of women to a homotoxicology group is not ethical as it 
withholds treatment from this group.  There is no mention of how they have 
obtained informed consent from the women taking part, no details given 
about informed consent to be randomised to the different treatment groups 
and no details about how ethics approval was sought or granted. 
 
Trial design, use of alternative approaches in infertility treatment, ethics of 
working with women being treated for infertility where their age has a big 
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impact on their predicted outcomes.  This paper was included in review of 
homeopathy (Van Wassenhoven, 2005). 
 
The efficacy of the complex medication Phyto-Hypophyson L in 
female, hormone related sterility. A randomized, placebo-
controlled clinical double blind study. (Bergmann et al., 2000) 
This article is only published in German but there is an English abstract 
available.  The setting of the study was a German University Clinic. 
It takes a positivist approach with quantitative clinical trial design and the 
commonly agreed medical definitions of infertility are used. The data analysis 
is appropriate for the intention of the trial; the positivist statistical approach 
would allow the research question to be answered. The research question 
was: How does Phyto-Hypophyson L compare to placebo when measuring 
the clinical outcomes of infertile women taking them both over a three month 
period?  Key concepts include Infertility/Sterility as having a functional cause, 
and that the use of ‘alternative’ treatment can be measured using quantitative 
tools. 
 
Randomised double blind placebo controlled study of 67 women with 
oligomenorrhea and 30 women with amenorrhea received 50 drops of Phyto 
Hypophyson L or placebo three times a day over 3 months or 3 cycles. 
 
Outcomes measured were spontaneous menstruation, improved 
concentration of progesterone in the luteal phase, shortening of the cycle, 
earlier ovulation and pregnancy.  Collection of hormonal status data and 
clinical findings were used to test the difference between remedy and 
placebo in the subjects. 
 
From the information available the trial quality is compromised because there 
is no description of randomisation and blinding or the number of participants 
randomized to each group.  The trial registration number is not provided and 
there is no disclosure of funding sources. 
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The abstract does not include a rationale for undertaking the study and there 
is no information about the knowledge condition of the patients regarding 
homeopathy.  The trial medication is name and the dose is described but the 
whole formula is not discussed in the abstract.  The number of practitioners, 
their qualifications and experience are not given so it is difficult to judge this 
study according to the REDHOT criteria, Table 36 Bergman 2000 evaluated 
against REDHOT.  The use of placebo is mentioned but there are no details 
in the abstract regarding its type or manufacture. 
 
The model validity is uncertain, as the abstract does not contain enough 
information to warrant a ‘yes’ outcome in all the domains contained in the 
MVHT model Table 37 Bergman et al 2000 evaluated against MVHT. 
 
The authors could have improved the trial design if they had included a 
patient well-being questionnaire and conducted interviews to gather 
qualitative data of how patients felt about being randomised, about taking 
remedies daily, and exploring their perceptions of themselves as infertile. 
 
There were no significant effects when viewing the whole group; outcomes 
for women in the oligomenorrhea in the Phyto Hypophyson L group had 
superior outcomes to the placebo group (82 versus 45% p=0.021). 
 
The verum group showed a significant increase in progesterone during the 
luteal phase compared to the placebo group and only a very few undesirable 
drug effects were observed 
 
Details of blinding and randomisation were not reported in abstract, which is 
a limitation of the study.  The original article is only in German, the availability 
of a full English translation was checked with Robert Mathie at the Faculty of 
Homeopathy but he only had access to the same translation as myself. 
 
This study is reviewed in Complementary and Alternative Medicine (CAM) in 
reproductive-age women: a review of randomized controlled trials (Fugh-
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Berman and Kronenberg, 2003) as one of only two studies identified that 
investigate the effectiveness of CAM therapies for female infertility. 
 
It has been noted (Mathie et al., 2012) that some homeopathic trials have 
been broadly criticized for their lack of acceptable model validity e.g. 
homeopathic complex medication in female infertility (Bergmann et al., 2000) 
(Kraft, 2001) and this highlights the need  to investigate the third attribute of 
an RCT, it’s model validity. 
 
Papers that explore the use of CAM to treat infertility 
 
Three additional papers were chosen in a non-systematic way, (as part of an 
iterative cycle of reading and writing) to represent the social context of the 
use of CAM to treat infertility as a narrative form of review. 
Complementary and Alternative Medicine (CAM) in reproductive-
age women: a review of randomized controlled trials (Fugh-
Berman and Kronenberg, 2003) 
 
Set in the context of an American University and published in Reproductive 
Toxicology 2003, this paper seeks to review randomised controlled trials of 
CAM therapies for obstetrical and gynaecologic conditions and presents 
therapies that are likely to be used by women of reproductive age and 
pregnant women. 
 
The research question being investigated is ‘What are the CAM exposures 
that can be expected in women of reproductive age?’  A positivist 
methodology was used with a computer search of databases using search 
term and authors own extensive files.  Clinical information was extracted 
from the articles and summarized in tabular form or in the text. No specific 
definition of infertility is used. 
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The main findings were that limited evidence supports the efficacy of some 
CAM therapies; exposure of women of reproductive age to these therapies 
can be expected. Most trials are small and definitive efficacy studies are 
lacking.  Mechanisms of action are largely unexplored.  Studies are 
described as ‘intriguing’ and ‘encouraging’. 
 
This study does not meet the PRISMA requirements for a systematic review 
(Moher et al., 2009)  as the methodology is especially weak as there is very 
little information on the eligibility criteria, the search strategy or the process of 
selecting studies.   Details of the PRISMA criteria for this study can be found 
in the appendices Table 38 Fugh-Berman and Kronenberg, 2003 evaluated 
against PRISMA 
 
There is no attempt to assess the trials included in the study for model 
validity or bias.  The findings are therefore limited.  It is useful as a list of 
available studies in this field but does not attempt to review them critically. 
 
They warn that healthcare providers and consumers should be aware that 
despite the potential usefulness of many CAM therapies, scientific research 
is limited.  They believe that the harmlessness of ‘sub therapeutic’ doses 
cannot be assumed.  CAM therapies are popular with pregnant women and 
because herbs, vitamins and other natural products have limited patentability 
and because there is no requirement for testing industry sponsored research 
will remain limited.  Federal, private and other alternative funding sources 
must bridge this gap.  Scientific evaluation of both safety and efficacy of 
these therapies is important to public health. 
 
It is cited by 95 studies including a study that attempts to evaluate the quality 
of CAM treatments a few years later: 
 
However, there is still a paucity of well-designed and executed studies [16]. 
We used the Oxford criteria to evaluate the quality of studies of CAM 
treatment (Oxford centre for evidence-based medicine 2001). This system 
places homogeneous systematic reviews of randomized controlled trials 
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(RCTs) at the highest level, followed by single RCT with narrow confidence 
intervals, case-control studies, case series, and expert opinions. In this 
review, we sought to identify systematic reviews, meta-analyses, RCTs and 
prospective cohort studies ahead of case-series and case reports. (Weiss et 
al., 2011) 
 
Complementary therapy and obstetrics and gynaecology: a time 
to integrate (Dooley, 2006) 
 
This study was selected because it is a good example of a Pragmatic 
worldview, it acknowledges the mind-body divide and recognises the 
dualisms between conventional and complementary medicine without 
needing to take a side. 
 
This perspective is made clear in the summary, where he is saying that we 
need to develop an integrated approach to healthcare.  Value is placed on 
both conventional and alternative medicine. 
 
The paper is probably best described as a position paper, the author runs an 
integrated health clinic in London, and is a non-systematic review of 
literature, political and cultural contexts. He offers an opportunity for 
reconciliation between opposing viewpoints by taking a broader view of the 
problem and integrating opinions from both mainstream medical and CAM 
perspectives. 
 
The key concepts covered include: biomedical assumptions, patient choice, 
complex interventions, holistic integrated approach vs. duality, equality of 
access to treatments that are funded by individuals, polypharmacy and 
regulation of CAM.  
 
This paper finds that an integrated approach to infertility may bring some 
benefits, that there is a need for an integrated approach, he acknowledges 
that there is a lack of randomized trials but that patient use is high. 
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He highlights that there is a need to improve patient care and shared 
communication when working in an integrated way, that there is a funding 
imbalance when it comes to research in the area of CAM. 
 
The main limitation of this paper is that it is not a systematic review of 
available data, more of a position paper, but it forms a useful source of 
information when seeking a context for studies such as this thesis. 
 
This paper represents a clear call to policy makers to consider abandoning 
traditional dualisms it has been cited by 16 studies including (Erin et al., 
2014) a study that uses a qualitative approach to investigate how CAM 
practitioners might be integrated into the treatment of infertility. 
 
Perspectives of Complementary and Alternative Medicine (CAM) 
practitioners in the support and treatment of infertility.(Erin et al., 
2014) 
 
The objective of this study was to determine the roles of CAM practitioners in 
the support and treatment of infertility.  Ten semi-structured interviews were 
conducted in Ottawa, Canada in 2011 with CAM practitioners who 
specialized in naturopathy, acupuncture, traditional Chinese medicine, 
hypnotherapy and integrated medicine. 
 
They found that CAM practitioners played an active role in both treatment 
and support of infertility, using a holistic, interdisciplinary and individualized 
approach. CAM practitioners recognized biological but also environmental 
and psychosomatic determinants of infertility. Participants were receptive to 
working with physicians but details of the collaboration were not included. 
 
They concluded that integrated infertility patient care achieved by 
collaboration with CAM practitioners and incorporation of CAM’s holistic, 
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individualized and interdisciplinary approaches would greatly benefit infertility 
patients. 
 
For some patients, ART presents significant financial, psychological, moral 
and ethical challenges, which may lead to discontinuation of treatment [12]. 
As medicine, in particular ART becomes increasingly technological, patients 
are choosing complementary and alternative medicine (CAM); perceived as 
more natural with less side effects.  
 
 
Conclusion  
Research Questions: What is homotoxicology?  Are there any existing trials of 
homotoxicology to treat infertility? What is the role of CAM in treating 
homotoxicology? 
 
The homotoxicological paradigm (Smit A, 2009) is a homeotherapeutic 
system in which a medical diagnosis is made, followed by an individualized 
assessment according to the severity of the patient’s disease.  This takes 
into account the response of the patient’s self-regulatory system to 
exogenous and endogenous stressors.  Treatment is given, using 
predominantly homeopathically prepared medicines, to support the inherent 
self-regulating ability of the body rather than just treat symptoms, which are 
seen as an expression of the body’s own defence that should not be 
suppressed. (Heel, 1986). 
 
A systematic qualitative review of the existing trials has shown that there is a 
gap in the literature for a methodologically sound, well-reported trial, to 
investigate the use of homotoxicology in infertile women.  Earlier trials (Lai, 
2000), (Bergmann et al., 2000) do seem to indicate that homoeopathic 
products can provide improved fertility outcomes to women in a clinical 
setting.   
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Infertility patients are increasingly using complementary and alternative 
medicine (CAM) to supplement or replace conventional fertility treatments 
(Erin et al., 2014) and (Fugh-Berman and Kronenberg, 2003) and therefore 
more information about their safe use is needed. 
 
The difficulty of reproducing clinical success as a randomised controlled trial 
has been dubbed the ‘efficacy paradox’ where the use of quantitative trial 
designs lead to a situation where internal validity is emphasised at the cost of 
external validity.  It is of little benefit to produce methodologically sound 
results if they do not reflect the real-world situation (Lewith et al., 2010). 
 
The position paper (Dooley, 2006) captures the context of this thesis, a time 
where the battle lines between complementary and conventional medicine 
were being drawn up, and the type of evidence that was being called for by 
was very much predicated upon quantitative methods.  The low 
methodological quality of the trials that were available also seemed to make 
it imperative that better RCT trials were needed, whereas by the time this 
thesis was nearing completion it was clear to the author that good evidence 
should capture several domains of knowledge including the perspective of 
the patient and the usefulness of the knowledge to a wider audience or 
population.  A researcher setting out to conduct a similar trial today would 
have access to alternative designs such as pragmatic trial design rather than 
automatically choosing an RCT model. 
 
Limitations	  
At the time that the selected studies were written it was not so common to 
find mixed methods research designs but if researchers were replicating 
those studies today it would perhaps seem more obvious that the views and 
perspectives of the participants needed to be taken into account.  In order to 
improve upon existing studies the trial design for the quantitative phase of 
this thesis is informed by qualitative data collection and analysis. 
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Literature Review - Section 4 The Use Of RCT To 
Investigate Homeopathy/Homotoxicology 	  
Research Question	  	  
What steps can be taken to ensure the model validity of an RCT to measure 
the efficacy of Ovarium compositum? 	  
Introduction  
Open-label randomised controlled trials (RCTs), and blinded, placebo 
controlled RCTs are listed at the top of the hierarchy.  They offer the most 
internal validity and minimization of bias and are considered by many to be 
the most reliable evidence for evaluation of modern medical interventions. 
(Lewith et al., 2010) 
 
The choice of a London Medical School for the author’s PhD studentship led 
to the expectation that her study of Ovarium compositum would be 
quantitative in style.  An RCT is the correct method to use when the 
investigator is aiming to provide unbiased answers to specific hypotheses 
and theories regarding efficacy and harms of interventions on a well-defined 
and measured clinical outcome (Lewith et al., 2010).   
 
The control of variables allows the investigator to attribute observed 
outcomes to the action of the medication.  However by controlling the 
variables the trial situation can become very different from the real life clinical 
situation.  This was not considered to be a problem for Ovarian compositum 
as it was not going to be prescribed on an individualised basis but as a 
routine prescription for women undergoing infertility treatment.  The trial and 
the clinical situation would be very similar in structure; if the outcomes of the 
trial were shown to be beneficial then this would be easily translated into 
routine clinical use. 
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Context 
The debate around the funding of homeopathy by the NHS provides a 
practical example of this problem. In 1995 (Smith, 1995) it was recognised 
that the provision of homoeopathy by the NHS for many years had created a 
political and cultural acceptance of CAM.  However this was increasingly 
being challenged as by 1997 (Wise, 1997) one London health authority had 
decided to stop buying homeopathy on ‘evidence’ based grounds.  The 
vigorous defence of CAM (Fisher and Eden, 1995a) in the medical press has 
been a catalyst for the development of methodologies for investigating 
complex and holistic interventions.  
Methodology 
This section is structured as a narrative overview that reports in a condensed 
format the contents of each article with a critique of each study.  The reasons 
for writing such an overview is to present an up to date overview which can 
be used to encourage scholarly discourse and a participatory approach to 
dynamic knowledge development (Green et al.) 
 
Selection of Papers for Review 
Papers were selected from an acknowledged expert in the field, Robert 
Mathie, PhD who also represents the Faculty of Homeopathy.   
Method for appraising model validity of randomized controlled 
trials of homeopathic treatment: multi-rater concordance study 
(Mathie et al., 2012) 
 
Model validity refers to the fact that the research must be a fair exemplar of 
the practice in use and the method chosen to test it must reflect the goals 
and context of the audience that will use the consequent information.(Lewith 
et al., 2010) 
 
Throughout this thesis the shift of perspective away from positivist 
assumptions towards the use of Mixed Methods Research tools has created 
an awareness of the need to work with transparency, with validated tools and 
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to demonstrate that the papers chosen have been subjected to critical 
appraisal.  The need for a tool to appraise model validity of randomised 
controlled trials of homeopathy has been met by the MVHT (Mathie et al., 
2012).  
 
Internal validity is the extent to which the design, conduct and analysis of a 
trial has minimised or avoided bias in its comparison of treatments.   This can 
be adequately measured with existing well-defined criteria such as 
QUOROM, PRISMA AND CONSORT. 
 
However there are some unique features of homeopathic practice that create 
the need for a model that is valid for it’s investigation so that there is a 
concordance between the trial study design and “state of the art” practice for 
the intervention under investigation. 
 
The existing model RedHot (Dean et al., 2007) does not provide the means 
to define or assess model validity and the high risk of false negative results in 
the systematic review of the current literature is increased by the absence of 
a model to use to assess study validity. 
 
The need to create a new model was addressed by an international group of 
homeopathic practitioners/researchers, who by using an integrative process 
developed six novel judgement domains. These domains, can be used to 
assess the model validity of trials of homeopathy with ‘fair’ to ‘almost perfect 
concordance’ and they have been used in this literature review as well as in 
the review of OVCT-001, the quantitative phase of this thesis. 
 
The domains and their criteria are summarised in the table below which has 
been adapted from (Mathie et al., 2012). 
 
Table 10 Domains of MVHT 
Domain Criteria 
Domain 1 (Rationale) Would a significant body of accredited homeopaths support the 
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rationale for the intervention used in the study? 
Criteria for a judgment of ‘Yes’. 
Both of the following: 
 
Clinical knowledge and practice inform 
that, for the condition under 
investigation, the health of patients may 
be benefited by homeopathic 
intervention. 
A substantial number of experienced 
homeopaths would support the choice of 
this intervention for this type of patient. 
 
Criteria for a judgment of ‘No’. 
One or both of the following: 
Clinical knowledge and practice do not 
inform that, for the condition under 
investigation, the health of patients may 
be benefited by homeopathic 
intervention. 
A substantial number of experienced 
homeopaths would not support the 
choice of this intervention for this type of 
patient. 
Criteria for a judgement of ‘Unclear’. 
One of the following 
There are likely to be important 
differences among experienced 
homeopaths on the rationale for the 
intervention used. 
Insufficient information to permit 
judgment of ‘yes’ or ‘no’. 
Domain 2 (Principles) Is the specific intervention used consistent with 
homeopathic/homotoxicological principles? 
Criteria for a judgement of ‘Yes’. 
One or both of the following: 
The intervention used is based on the 
principle of ‘like treats like’ or is based on 
the principle of isopathy. 
Literature sources (material medica, 
repertory etc.) are available that 
convincingly justify the specific 
intervention. 
Criteria for a judgement of ‘No’. One or both of the following: 
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The intervention used is not based on 
the principle ‘like treats like’ or of 
isopathy 
Literature sources do not convincingly 
justify the specific intervention 
Criteria for a judgment of ‘Unclear’. 
Insufficient information to permit 
judgement of ‘yes’ or ‘no’. 
Domain 3 (Practitioner) Does the study have suitably qualified and experienced 
homeopathic prescriber input? 
Criteria for a judgement of ‘Yes’. 
Either of the following as appropriate: 
Individualised homeopathy: Those who 
have prescribed the homeopathic 
medicine(s) are suitably trained and 
experienced in homeopathy to manage 
the condition under investigation. 
Non-Individualised homeopathy: There is 
evidence that experienced homeopathic 
input (and/or a suitable literature source) 
has been involved in informing the 
choice of medicine(s) used commonly for 
all patients in the study. 
Criteria for a judgement of ‘No’. 
Either of the following as appropriate: 
Individualised homeopathy: Those who 
have prescribed the homeopathic 
medicine(s) are not suitably trained and 
experienced in homeopathy to manage 
the condition under investigation. 
Non-Individualised homeopathy: There is 
evidence that experienced homeopathic 
input (and/or a suitable literature source) 
has not been involved in informing the 
choice of medicine(s) used commonly 
 
Criteria for a judgment of ‘Unclear’. 
Insufficient information to permit 
judgement of ‘yes’ or ‘no’. 
Domain 4 (Outcome Measure) Does the main outcome reflect the main effect expected 
of the intervention used? 
Criteria for a judgement of ‘Yes’. 
The main clinical effect expected of the 
intervention is adequately measured by 
the main outcome used. 
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Criteria for a judgement of ‘No’. 
The main clinical effect expected of the 
intervention is not adequately measured 
by the main outcome used. 
Criteria for a judgment of ‘Unclear’. 
Insufficient information to permit 
judgement of ‘yes’ or ‘no’. 
Domain 5 (Sensitivity) Is the main outcome capable of detecting change? 
Criteria for a judgement of ‘Yes’. 
All of the following: 
The main outcome measure is sensitive 
to changes of the magnitude expected in 
the patients under investigation. 
The main outcome measure is capable 
of determining both improvement and 
deterioration. 
The main outcome measure shows no 
evidence of a ‘floor effect’ and/or ‘ceiling 
effect’. 
Criteria for a judgement of ‘No’. 
Any one or more of the following: 
The main outcome measure is not 
sensitive to changes of the magnitude 
expected in the patients under 
investigation. 
The main outcome measure is not 
capable of determining both 
improvement and deterioration 
The main outcome measure shows 
evidence of a ‘floor effect’ and/or ‘ceiling 
effect’. 
 
Criteria for a judgment of ‘Unclear’. 
Insufficient information to permit 
judgement of ‘yes’ or ‘no’. 
Domain 6 (Follow up) Is the length of follow-up for the main outcome measure 
appropriate to detect the intended effect of the intervention? 
Criteria for a judgement of ‘Yes’. 
The time-point selected for main follow-
up measurement provides sufficient 
opportunity for a clinical change to be 
observed. 
Criteria for a judgement of ‘No’. 
The time-point selected for main follow-
up measurement does not provide 
sufficient opportunity for a clinical 
change to be observed. 
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Criteria for a judgment of ‘Unclear’. 
Insufficient information to permit 
judgement of ‘yes’ or ‘no’. 
  
 
 
 
Since 2012 Researches have had the aid of the MVHT to check the model 
validity of their quantitative studies and although this was not available to the 
author during the planning stage it has been helpful in reflecting on the trial 
design: 
 
Domain I (Rationale)   
Clinical knowledge and practice inform that, for the condition under 
investigation, the health of patients may be benefited by homeopathic 
intervention. 
A substantial number of experienced homeopaths would support the choice 
of this intervention for this type of patient. 
 
The literature review has shown that two studies, although of poor 
methodological quality, seem to indicate that infertility outcomes can be 
improved with the use of complex homeopathic prescribing.   
 
Ovarian compositum was considered suitable for the RCT model because 
the women are part of a clinical group that have been selected due to their 
well-defined diagnosis. The first qualitative strand was the review of 
homotoxicology treatment for infertility in the UK, which sought to established 
support for the choice of intervention for infertile women.  
 
Domain II (Principles). 
One or both of the following: 
The intervention used is based on the principle of ‘like treats like’ or is based 
on the principle of isopathy. 
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Literature sources (material medica, repertory etc.) are available that 
convincingly justify the specific intervention. 
 
Homotoxicology uses complex formulations instead of single remedies and is 
not prescribed on individual indications but instead on clinical indications, 
each ingredient is selected for its targeted homeopathic action on a tissue, 
organ or function. 
 
The clinical indications for Ovarium compositum are listed (Heel, 1986) as: 
"Stimulation of the glandular and defensive functions, as well as those of the 
connective tissue, in dysmenorrhoea, endometritis, metritis, parametritis, 
enuresis (in young girls), in the climacteric, hyperemesis, insufficiency of the 
anterior lobe of the pituitary gland in females, craurosis vulvae, mastodynia, 
osteomalacia, menorrhagia, as well as in various disturbances of 
metabolism, including those arising in geriatrics." 
 
Due to its individual homeopathic constituents Ovarian Compositum has an 
application in the homeopathic treatment of hormonal disturbances, 
menopausal syndromes and insufficiency of the pituitary gland.  The 
individual ingredients are a mixture of different homoeopathic potencies 
ranging from D4 – D18. 
 
Domain III (Practitioner) 
Either of the following as appropriate: 
Individualised homeopathy: Those who have prescribed the homeopathic 
medicine(s) are suitably trained and experienced in homeopathy to manage 
the condition under investigation. 
Non-Individualised homeopathy: There is evidence that experienced 
homeopathic input (and/or a suitable literature source) has been involved in 
informing the choice of medicine(s) used commonly for all patients in the 
study. 
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As chief investigator the author, Claire Haresnape, was qualified and insured 
to prescribe homotoxicological preparations and had also studied classical 
homoeopathy for five years with a practitioner in North Devon. 
 
The choice of Ovarium compostitum to treat female infertility was supported 
by the medical expertise of the manufacturer Heel.   
  
Domain IV (Outcome Measure) 
The main clinical effect expected of the intervention is adequately measured 
by the main outcome used. 
In the opinion of the author the outcomes chosen will allow sensitive 
measurement of the differences between individual responses.  This was 
confirmed by the view of the external peer reviewer: 
 
The study uses a number of measures: experimental (endometrial thickness, 
number of follicles progesterone levels) as well as the Quality of Life 
measure. These measures seem appropriate and adapted to capture any 
significant difference between the two groups, as well as offering room for 
interpretation of the results in terms of possible mechanisms of action. 
The inclusion of a blinded placebo group should allow the difference between 
specific effects due to the remedy and non-specific placebo effects to be 
detected. 
 
Domain V (Sensitivity) 
 
The main outcome measure is sensitive to changes of the magnitude 
expected in the patients under investigation. 
 
The main outcome measure is capable of determining both improvement and 
deterioration. 
 
The main outcome measure shows no evidence of a ‘floor effect’ and/or 
‘ceiling effect’. 
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The outcomes for the quantitative strand of the study are listed below and 
discussed for their sensitivity and appropriateness: 
 
1. Follicular count and Ovarium volume 
2. Follicular stimulating hormone (FSH) levels 
3. Estradiol (E2 or 17β-estradiol, also oestradiol) at day 2 
4. Progesterone Levels at day 21 
5. Pregnancy confirmed with a pregnancy test 
6. Live birth 
Ovarian volume has been shown to be an important tool in the assessment 
of ovarian reserve and the prediction of response to ovulation induction (Lass 
and Brinsden, 1999).  The routine use of trans vaginal scans has led to 
quick, accurate and cost effective assessment of ovarian volume.  Poor 
response to treatment leading to cycle cancellation and failure to retrieve 
oocytes is associated with smaller ovaries (Lass and Brinsden, 1999), 
advancing maternal age is also associated with a decrease in ovarian 
volume and fewer follicles. 
The menstrual cycle is a complex combination of synchronized endocrine 
events involving the release of hormones by the hypothalamus, the anterior 
pituitary and the ovaries.   The measurements of reproductive hormones are 
an important part of the assessment and management of women undergoing 
infertility treatment.  The measurements are capable of detecting both 
increases and decreases in hormonal levels.  
Follicle Stimulating Hormone (FSH) is measured during the follicular phase 
(days 2-3) of the menstrual cycle.  The normal values are 5-20 mIU/L.  FSH 
values >10 IU/L predict a poor response to ovarian stimulation.  FSH values 
>18IU/L are predictive of poor pregnancy outcomes (Delaney, 2012) 
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In a study of 1019 infertile but ovulating women, studied during their first IVF 
cycle of treatment, it was found that serum FSH levels are also a valuable 
prognostic tool for the assessment of oocyte quality and fecundity (Akande et 
al., 2002).  The number of oocytes retrieved and embryo’s available for 
transfer declined with advancing age and basal serum FSH concentrations. 
Estradiol (E2) is a steroid hormone secreted into circulation by granulosa 
cells of developing ovarian follicles.  It is also measured in the follicular 
phase, days 2-3 of the menstrual cycle.  The normal range is 20-400 pg./mL.  
It is helpful in combination with FSH to establish a baseline ovarian reserve, 
and has useful prognostic value in the treatment and counseling of patients 
of advanced reproductive age who are considering ovulation induction and 
IUI therapy (Buyalos et al., 1997). 
Progesterone is a hormone produced mainly in the ovaries by the corpus 
luteum and it helps to prepare the uterus for the implantation of the fertilized 
egg.  If a fertilized egg implants then the progesterone helps the uterine lining 
to maintain the pregnancy.  Women undergoing fertility treatment usually 
have their progesterone levels checked about day 21 of a 28-day cycle 
during the luteal phase.  If the progesterone is elevated within a certain range 
(greater than or equal to 32nmol/L) it means that the woman is ovulating.  
Low progesterone levels may indicate a failure to ovulate.  
The serum progesterone level as been found in some studies to be a better 
predictor of future live births than levels of any of the other hormones (Murto 
et al., 2013).  One problem with using serum progesterone is that it has a 
wide range of concentrations during the menstrual cycle (Follicular phase: 
<3ng/mL, Secretory phase: 5-30ng/mL) so that more than one test is needed.  
Some researchers now favour the use of serum Anti-Mullerian hormone 
(AMH) instead of progesterone as it has very little variation during the 
menstrual cycle (Murto et al., 2013).  At the time of designing the quantitative 
strand of this study AMH testing was not available at Jersey General Hospital 
although the desirability of using this test was discussed. 
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The combination of these different hormonal tests allows the collection of 
data that is sensitive to the individual responses of women to their treatment.  
Small differences in hormonal status may indicate changes in ovulatory 
status or be predictive of treatment success or failure. 
Outcomes such as pregnancy and live birth may have more significance to 
the patient or the clinic as part of their success rate and a qualitative study 
would be an interesting way to further explore the perceptions of women and 
their clinicians towards the different outcomes that can be measured. 
There was no mention found in the literature reviewed of either a floor or 
ceiling effect when measuring these hormonal levels. 
Domain VI (Follow-up) 
 
The time-point selected for main follow-up measurement provides sufficient 
opportunity for a clinical change to be observed. 
 
The women recruited to the study were expected to attend the clinic for 
follow-up appointments every 30 days for up to 12 months.  This timescale 
would allow the capture of data, such as hormonal status, on a monthly cycle 
of treatment and would capture any pregnancies or live births that resulted 
from treatment.  Follow up of live births or pregnancies that occurred after the 
12-month treatment period was agreed with the clinic and with Heel. 
Randomized controlled trials of homeopathy in humans: 
characterizing the research journal literature for systematic 
review (Mathie et al., 2013) 
Mathie et al (2013) showed that a placebo controlled RCT can be used as a 
feasible method for assessing non-individualised homeopathy/ 
homotoxicology.  The context for this paper is the British Homeopathic 
Association, Faculty of Homeopathy, and the audience is a mixed Medical/ 
Homeopathy audience. 
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The research question being investigated is the provision of an up to date 
and comprehensive systematic review of the entire international RCT 
literature in homeopathy.  This new programme needs to distinguish 
important attributes that are unique to RCT trials of homeopathy: (a) 
treatment versus prophylaxis, (b) placebo versus other than placebo (OTP), 
(c) individualised versus non individualised homeopathy, (d) Peer Reviewed 
(PR) versus non peer reviewed (NPR) journal sources. 
 
Written from a post positivist perspective this is a uniquely detailed and 
systematic review of homeopathic randomised controlled trials, searching 
and categorising trials using electronic databases.  The data collection was 
systematic and made sure that all available published trials were considered 
for review.  Translations were employed to make sure that non-English 
papers were also considered. 
 
A pragmatist framework was employed to decide about the appropriate 
categories with which to review RCT trials of homeopathy.  Earlier reviews 
had not considered the need to distinguish between (a) treatment versus 
prophylaxis, (b) placebo versus other than placebo (OTP), (c) individualised 
versus non individualised homeopathy, (d) Peer Reviewed (PR) versus non 
peer reviewed (NPR) journal sources.   
 
This review is of good quality because it is unlikely that important papers 
have not been included.  The conventional clinical trial terminologies are 
used and the search criteria used different spellings and presentations of 
homeopathy and homeopath.  The categories selected for inclusion and 
exclusion were suitable to answer the research question.  The paper 
compares well with the criteria for systematic reviews as defined by PRISMA 
(Moher et al., 2009) and a summary of this can be found in APPENDIX 1 as 
Table 39 Mathie et al 2013 evaluated against PRISMA. 
 
The findings clarify the RCT literature in homeopathy.  The 263 accepted 
journal papers would be the basis for a forthcoming programme of systematic 
reviews. The limitation of this review is that it does not include qualitative 
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studies or MMR, which would capture other important aspects of 
homeopathy and healthcare provision. 96 studies of placebo controlled, non-
individualised homeopathy were identified and included two records for the 
condition of female infertility: A52 (Bergmann et al., 2000); A74 (Gerhard et 
al., 1998).   The Gerhard paper has not been included in my own literature 
review because it is not easily available in English.  The authors of this study 
acknowledge that they had access to optimum resources and that the multi-
language nature of the literature can be problematic for researchers.   
 
Conclusion  
 
What steps can be taken to ensure the model validity of an RCT to measure the 
efficacy of Ovarium compositum? 
 
A systematic review of the literature by an expert in the field (Mathie et al., 
2013) has shown that there are very few RCT trials of homeopathy versus 
placebo for female infertility.  However 96 studies of placebo controlled, non-
individualised homeopathy were identified and so the RCT is shown to be a 
suitable method for investigating the specific effects of a homeopathic 
medicine compared to a placebo. 
 
The MVHT (Mathie et al., 2012) provides homeopathic researchers with an 
appropriate tool to ensure the validity of their own trial designs as well as a 
way of assessing the validity of published work in this field.  It can be used in 
conjunction with existing tools such as CONSORT to ensure that trial design 
meets the criteria necessary for a high methodological quality of a good RCT.   
 
Limitations 
The choice of papers by an expert in the field of RCT for homeopathy could 
potentially lead to a bias in the conclusions of this review.  However the 
methods used by Mathie are transparent, rigorous and systematic and his 
work is therefore considered both credible and reliable as an evidence 
source.   
LITERATURE REVIEW 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   143	  
Literature Review - Section 5 -  The Concerns of 
Infertile Women. 
Research Questions	  
What	  are	  the	  concerns	  of	  infertile	  women?	  	  Do	  existing	  studies	  offer	  any	  
insight	  for	  trial	  design?	  
Methodology	  
The narrative literature review for this section was developed and refined as 
part of an iterative cycle of data collection and review during the fourth 
qualitative strand of the thesis.  Although the papers selected were read 
critically and systematically using a checklist, this was not a systematic view 
of the literature, the work of Charmaz on self identity at work was suggested 
after reading about the methodology of Grounded Theory (Charmaz, 1990).   
The work by Brandes on the dropout rates in IVF (Brandes et al., 2009) was 
first noticed when reading the conference proceedings from ESHRE (The 
European Society of Human Reproduction and Embryology) 2009. 
The paper on the concerns of women undergoing infertility treatment 
(Finamore et al., 2007) was found using ("employment"[MeSH Terms] OR 
"employment"[All Fields]) AND ("infertility"[MeSH Terms] OR "infertility"[All 
Fields])  as a PubMed search (December 2013). 
Another research team were recruiting women during the data collection for 
the fourth strand of this thesis.  This was noticed when they also posted a 
request on same infertility online support group website.  Communication 
was established with Nicola Payne of Middlesex University and some of the 
insights from their preliminary results are also reviewed in this section. Their 
full dataset had not been completely analysed at the time of writing this. 
Introduction	  
Themes that were suggested by the staff at the ARU unit at Jersey General 
Hospital led to a hypothesis that women’s concerns about employment and 
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disclosure were one reason for the failure to recruit sufficient women to the 
trial of Ovarium compositum.   This was surprising as infertile couples are 
usually considered to be highly motivated to undergo investigation and 
treatment (Brandes et al., 2009).  The literature was therefore searched for 
reports of the pressures faced by women who both work and seek infertility 
treatment.   
If an employer is not supportive of the frequent absences necessary for 
treatment then the situation can lead to increased stress level, which in turn 
could affect fertility.  Research suggests that stress, depression, anxiety and 
other negative psychological feelings result in poorer outcomes for patients 
undergoing IVF (Demyttenaere et al., 1994, Stoleru et al., 1997, Gallinelli et 
al., 2001, Boivin and Schmidt, 2005). 
In both Jersey and the UK there is a need for men and women to have time 
off from work to attend appointments at an ARU when couples are 
undergoing infertility treatment.  It has been suggested by the ARU nurse at 
Jersey General Hospital that women may feel considerable pressure when 
deciding whether or not to disclose fertility treatment to their employers as 
few employers have a policy on this and many managers are unsure how to 
deal with these cases (Hawksworth, 2012).   
XpertHR, who offer an online advisory service to HR professionals, 
summarise the position thus: 
‘Fertility treatment is not a "deemed incapacity" for statutory sick pay 
purposes. However, the treatment can affect people in different ways. An 
employee may well be ill due to the treatment, for example through 
depression or stress. If this is the case, it is up to the employer whether or 
not to accept the incapacity as stated on any medical certificate or form, in 
order to consider statutory sick pay entitlement. 
There is no statutory right for an employee to receive time off, with or without 
pay, during normal working hours in order to undertake a course of fertility 
treatment. The maternity pay and rights legislation relates solely to an 
employee being pregnant and not to the causes of pregnancy. 
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The Health and Safety Executive recommends that women should be given a 
reasonable number of paid or unpaid days' absence towards any fertility 
treatment. Women generally require more treatment for in vitro fertilisation 
(IVF) than men do for fertility treatment, so they are more likely to incur 
absences from the workplace to undergo IVF. An employer could be exposed 
to an indirect discrimination claim if its rules on sickness absence adversely 
affect a woman undergoing treatment.’ 
(XpertHR, 2012) 
The Legal Position In Jersey 
 At the time of writing this thesis, working women in Jersey and the UK who 
are undergoing IVF treatment are not afforded any specific employment 
protection, and IVF related sickness absences could be taken into account in 
the same way as other sickness absence for dismissal and disciplinary 
purposes (Hawksworth). 
There have been some developments in European case law in this area 
(Mayr v. Backerei und Konditorei Gerhard Flockner OHG C-506/06 [2008]) 
over the past few years but there are still gaps in the law and women are 
often unsure as to how far they are protected.  The current position is that the 
dismissal of a woman on the grounds of sickness absence due to the later 
stages of IVF will constitute unlawful sex discrimination. 
The Jersey Advisory and Conciliation Service (Patricia Rowan, 2012) offered 
this advice: 
‘Without Prejudice 
The employment legislation currently does not cover maternity, flexible 
working etc., nor do we yet have any discrimination legislation - it is hoped 
that by the end of 2014 this may have changed.  Therefore it would only be 
under individual terms of employment for a business that individuals may be 
allowed some paid maternity break.  It is certainly not uncommon for GP and 
hospital appointments (for any kind of treatment/illness) to be either taken 
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outside of working hours and/or the time made up at a later stage.  If any 
employee exceeds the absence levels set by their employer then a capability 
process can be triggered and therefore jobs can be placed at risk – this 
applies for absence for any reason.’ 
The law therefore offers no protection to women in the early stages of 
infertility treatment such as the women who were being approached for 
recruitment to this study.  Women being treated or evaluated for infertility 
must have a flexible work schedule and be willing and able to go for frequent 
office visits, leading to hours and sometimes days missed at work.   
 
One study (Finamore et al., 2007)  has explored this situation in more detail. 
It used a cross sectional questionnaire and then analysed the results using 
statistical tools.   
Social Concerns of Women Undergoing Infertility Treatment 
(Finamore et al., 2007) 
This quantitative study attempts to prove a link between cause and effect, 
infertility and stress related to needing time off for infertility treatment.  It was 
set in an American University Infertility Treatment Centre and the concepts 
covered include infertility treatment as a stressful life event and recognition of 
the mind body connection in the form of PNEI.  Their hypothesis is that in 
certain women, disclosure may lower stress and therefore increase success 
rate of IVF treatment. 
 
Most women who did disclose did so because they needed a reason to leave 
work for frequent doctor visits.  Among women who did not disclose the main 
reason for nondisclosure was to protect their privacy.  Women who had a 
high school education were more likely to disclose than those with a college 
and postgraduate education.  African, American/Caribbean American women 
were least likely to disclose.  Those who were out of work more often 
because of their infertility were more likely to disclose.  There was not an 
association with disclosure and decreasing stress levels. 
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The method used was a cross sectional questionnaire consisting of 38 
questions and including a validated global measure of stress, a four item 
version of the Perceived Stress Scale (Cohen et al., 1983).  Continuous 
variables such as patient’s age, Perceived Stress Scores were analysed 
using mean and Standard Deviation (SD). 
 
The student’s t test was used to examine differences in characteristics 
between women who did and did not disclose their infertility status.  Interval 
data such as gravidity and the number of people disclosed were analysed as 
proportion of total subjects who responded to the survey.  A chi-squared test 
was applied to compare differences in proportions between women who did 
and did not disclosure their infertility status and evaluated associations based 
on odds ration (OR) with an 95% confidence interval (CI).  All tests of 
hypothesis were two tailed, with a type one-error rate set at 5%.  Incomplete 
surveys were not analysed. 
 
The reason for using a cross sectional study is that it may be the only 
practicable method of studying various problems or where a randomized 
controlled trial might be unethical, or if the condition to be studied is rare. 
Cross sectional studies are used to determine prevalence. They are relatively 
quick and easy but do not permit distinction between cause and effect 
(Mann, 2003).  
 
Cross-sectional studies are sometimes carried out to investigate associations 
between risk factors and the outcome of interest but they are limited by the 
fact that they are carried out at one time point, in this case a 6 month period, 
and give no indication of the sequence of events and therefore it is 
impossible to infer causality (Levin, 2006). They are usually used when the 
purpose of a study is descriptive and there is no hypothesis as such.  In this 
study a hypothesis was being investigated, which was the risk factor of stress 
in infertility treatment. 
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They do have the advantage of being relatively inexpensive and take up little 
time to conduct.  Another advantage is that they can be used to assess many 
outcomes and risk factors in one questionnaire.  
 
The authors acknowledge that there are many confounding factors in their 
data collection including the fact that the survey was given to women who 
sought-first time treatment as well as women who were currently undergoing 
treatment. 
 
The sample frame that was used to select the participants in this study did 
not represent the population as a whole, so the results cannot be generalized 
to a larger population.  There is a concern that women are more likely to 
respond to the survey if they have a particular set of characteristics and 
therefore the responses are biased.  Bias will occur when the characteristic is 
in someway related to the probability of having the outcome (Levin, 2006).  In 
this case the women who are highly stressed may not have wanted to 
participate in the study or may have only partially completed the 
questionnaire. 
 
The authors acknowledge that they were not able to determine how many 
patients refused to participate in the study and they were not able to identify 
any differences between women who did not and did participate in the study.  
They did attempt to limit participation bias by collecting in every 
questionnaire that was given out, however 12% of surveys were incomplete 
and could not be included in the analysis. 
 
The data collection method does allow the calculation of risk factors but it is a 
snapshot in time. If a study wanted to look for risk factors in a wider 
population researchers could have conducted a literature review and possibly 
looked at data that is available from larger samples.  As it stands it has not 
captured any qualitative aspects of the participants.   
 
The authors acknowledge that there are difficulties controlling for 
psychological, behavioural and social differences between groups of 
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participants and perhaps some of these characteristics could have been 
captured using qualitative methods such as interviews or open-ended 
questions requiring a written answer.  The practical concerns about 
conducting such as study have to be taken into account and balanced 
against the possible benefits. 
 
It has generated some useful hypothesis for further study, and these are 
mentioned in the discussion section of the qualitative strand of the thesis, for 
example; the fact that women are more likely to disclose to a female 
supervisor and that women with a higher level of education are less likely to 
disclose their treatment. 
 
The choice of statistical methods appears to be appropriate for the 
calculation of the association between the risk factor and the data collected.  
Demographic data that was collected could also be useful and interesting.  
For example how did women from different educational or racial backgrounds 
perceive their infertility, how did disclosure affect their employment status?  
This author’s study seeks to describe some of those perceptions but because 
it used Internet data, does not distinguish between different ages, races or 
educational backgrounds. 
 
It is acknowledged that women from different cultures may have different 
concerns about privacy and infertility.  The data from this study did not 
address those differences, it observed them but did not describe them due to 
methodological choices.   
 
The perception of stress may also vary between individuals.  The Perceived 
Stress Scale (PSS) (Cohen et al., 1983) attempts to measure stress 
subjectively, or as perceived by the individual in the context of their 
cognitively mediated emotional response to an event.  It is not a measure of 
the intensity or frequency of the event itself.  This scale therefore is 
appropriate to capture the individual’s response to stress in a situation where 
different individuals have different resources, support and coping 
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mechanisms.  The scale was developed in America and the setting of the 
study is also American. 
 
Some of the discussion points are interesting, for example is it possible that 
women with a higher level of education are in better paid jobs with better 
working conditions and are therefore able to be more flexible about taking 
time off work?  How does this fit with their desire for promotion compared to 
their desire for a family?  What is meant by privacy, is that to do with shame 
at being infertile or the desire to appear capable and in control at work? 
 
The limitation of this study is that it is a snapshot in time that can only 
evaluate the risk factors in a small sample with potential bias towards women 
who are less stressed.  It observes but not describes or explains some of the 
concerns of the women undergoing treatment. 
  
The findings of this study have implications for the legal status of infertility 
treatment and the access to time off work, privacy and disclosure.  It has 
been cited 8 times including (Huisman et al., 2009) This multinational, 
interview-based study was conducted to provide insights into participants' 
experiences, behavior, attitudes and emotions towards fertility treatments. 
One study group comprised 185 patients who were undergoing ovarian 
stimulation for IVF while the other comprised 170 physician and nurse fertility 
experts. A key study objective was to identify which aspects of ovarian-
stimulation treatment contribute to the physical and psychological burden on 
patients. 
 
It is cited by a second study that reviews the research exploring which 
psychosocial factors (e.g. personality traits and coping strategies) are 
associated with the emotional adjustment of IVF patients. The aim is to 
reveal what is currently known about risk and protective factors for coping 
with the stress of IVF treatment and where further enquiry would be most 
beneficial (Rockliff et al., 2014).   
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There is a commercial interest from pharmaceutical companies and clinics in 
retaining women for additional cycles of treatment if the first or second IVF 
cycle fails.  This was mentioned in informal discussions with unit staff but has 
not been systematically investigated in this study.  The ethics of such 
decisions and the potential benefits and harms to patients would make an 
interesting further area of research. 
Disclosure at work and self-identity 
Identity, chronic illness and disclosure at work have been investigated by 
Charmaz (Charmaz, 2010).  We can draw valid comparisons between 
infertility and her analysis of chronic disease because of the long lasting 
nature of infertility and infertility treatment which can span several years and 
has a major impact on psychological, emotional and physical health.   
Charmaz highlights the need to use insights from research into chronic 
disease to inform the management of human resources in the international 
workplace and this is directly relevant to the socioeconomic structure of 
Jersey which, as an offshore banking community, hosts offices for many 
multinational corporations: 
‘Managers in global organisations may need additional training that focuses 
on dealing with and facilitating such disclosures, and universities all over the 
world involved in preparing local and international business graduates need 
to consider this issue in designing course content.’ (Charmaz, 2010) 
Infertility, like chronic disease, may remain invisible in the workplace until 
people feel forced to reveal their condition or request special 
accommodations: 
‘What is means to disclose illness and disability depends on a person’s 
health problem, cultural traditions, social values and norms, hierarchical 
arrangements, and specific policies in a given workplace.’ (Charmaz, 2010). 
If visibility does not force disclosure then people see themselves as who they 
have been, not as who they have become.  Workers with a chronic condition 
may experience daily limitations and restrictions but because they have 
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devised ways of organizing their life around them they do not feel a need to 
disclose their condition.  Disclosure is often associated with an episode 
hospitalization and this could be compared with the hospitalization needed 
for IVF procedures or the aftermath of an unsuccessful implantation. 
Charmaz notes that questions about disclosure also involve the relative 
legitimacy granted to the person’s medical condition and as we discussed 
earlier in this chapter fertility treatment is not a "deemed incapacity" for 
statutory sick pay purposes.  She highlights the fact that legitimacy matters to 
validate competent work, adult status and social acceptance.   
‘Experiencing an illness or disability often conflicts with business values that 
assume constant involvement and productivity, speed, coordinated timing, 
regular schedules and predictable performance levels.’ (Charmaz, 2010) 
If as she say; ‘Disability does not reside entirely in the individual’ but also 
‘depends on his or her match with a specific job’ then we can see the 
confusion caused by people switching between two roles: being competent at 
their job and then becoming unable to maintain that level of competency for a 
period of time due to the demands of their treatment regime. 
It is understandable therefore that the positive or negative feedback from a 
manager will become an important validation of that person and their self-
concept as they fluctuate between these two roles. Face-to-face relationships 
with shared interactions also shape how employers view people with 
disabilities (Charmaz, 2010). Employees who spend time face-to-face with 
their employer are more likely to experience a favourable outcome in 
negotiations about time needed for treatment. 
Infertile men and women also face uncertainty about their probability of 
becoming parents and may have experienced loss of social and self-worth.  
In chronic illness this may lead people to struggle with losing their financial 
independence but in infertility this would not necessarily be the case. 
Charmaz provides a model of the dilemmas of disclosure for an employee, 
which includes choosing between honesty, and privacy where cultural 
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stigmas associated with may influence that decision, this can be applied 
directly to infertility because disclosure may result in scrutiny or intrusive 
questions but also allows the person to explain behaviour that might have 
looked odd or suspicious.   
 
Work-Life balance & Medically Assisted Reproduction (MAR): 
MAR users - experiences of workplace support (Payne, 2014) 
 
During the time period that data was being sought on the online infertility 
forums another research group were also posting a request asking women to 
come forward and be interviewed about their work-life balance.  Nicola 
Payne was kind enough to correspond with the author and we exchange 
several emails about our projects.  In March 2014 we discussed our progress 
and she shared her slides for a conference of the European Academy of 
Occupational Health Psychology.  The data analysis is not based on her full 
data (31 women and 6 men) set but on 15 women with a mean age of 35 (SD 
=5).  They used semi-structured interviews to collect the data, which was 
then analysed thematically. 
 
The framework for their literature search used role conflict theory (Greenhaus 
and Beutell, 1985) as this is common approach for research on work-life 
balance.  The aim of their project was to explore the experiences of Medically 
Assisted Reproduction, (MAR), users of combining work and MAR.  They 
hoped to be able to identify barriers as well as support mechanisms that 
people used. 
 
The themes that they identified were presented as summary slides and are 
shown below as a list: 
 
o MAR-Work conflict 
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o Time- and strain-based conflict, which included worrying about the 
results of treatment and the practical issues around taking time off. 
 
o Work providing a distraction from the anxiety and allowing you to carry 
on as ‘normal’ 
 
o The impact of identity 
o A shift in anchor identity to ‘becoming a parent’ and work being 
put on the back burner 
o Resentment towards work if it was perceived to be getting in 
the way. 
 
o Support for MAR use 
 
o Manager support 
o Most women experienced some degree of support from practical only 
to also including emotional support 
o This enabled women to priories MAR, so supported their anchor 
identity and reduced conflict 
 
o Shared understanding of the experience helped 
o Job flexibility also helped reduce conflict 
 
o The pros and cons of a specific policy 
o Policy is needed but few workplaces had a specific policy and where it 
existed it was limited, so policy or guidance is needed. 
o Constraints might include working for a smaller company where the 
absence has a greater impact on the company. 
o There may be mutual benefits to working for a company that has been 
really good to you and therefore created a loyalty. 
(Payne, 2014) 
 
They concluded that MAR users experience a shift in identity to 
parenthood and so experience a ‘spill over’ conflict.  Spillover (is) stress 
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experienced in one domain of life, which results in stress in the other 
domain for the same individual. Spillover is… intra-individual… Thus, 
spillover is a process by which attitudes and behavior carry over from one 
role to another (Westman, 2005) 
 
Line manager support and job flexibility can help to reduce this conflict.   
The existence of a specific policy or guidance is relatively rare but 
necessary and while there are constraints to providing support this may 
be mutually beneficial. 
 
These early results have been included in this literature review because 
they offer a form of triangulation with my own data collection and analysis.  
They occurred during a similar time frame and with a similar target for 
recruitment.  While they had the advantage of a larger sample they have 
not had time to perform a full analysis yet. 
 
The other consideration is that they have used a specific framework for 
grounding the study (role conflict theory) and therefore their codes and 
assumptions are to some extent shaped by this orientation.  
Transparency about their choice of theory is strength of the study:  
 
The benefit of greater attention to theory in qualitative research is that it 
enables a more sophisticated approach to the data so that a range of 
different questions can be asked of the data set. Theory helps to define what 
the strategy for analysis should be, including questions about level of 
analysis, and how to describe the way decisions about analysis have been 
made.(Kelly, 2009) 
 
If the themes that were found in my own study are similar to the themes 
identified by Payne (Payne, 2014)  then this will help to validate my own 
analysis, especially if we are starting from different theoretical perspectives 
and still find some common themes or understandings.  It is important to note 
that her analysis was not available to me during the time that I was coding 
the data that I collected from the Internet forum. 
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When And Where Do Sub fertile Couples Discontinue Their 
Fertility Care? A Longitudinal Cohort Study In A Secondary Care 
Subfertility Population. (Brandes et al., 2009) 
This study was set at The Jeroen Bosch Hospital, which is a large regional 
secondary care teaching clinic, performing almost all modern fertility 
treatments.  GP’s in that region of the Netherlands do not in general perform 
any basic fertility workup and do not prescribe fertility drugs.  They refer 
couples if despite unprotected intercourse for at last 1 year no on-going 
pregnancy has occurred.  In the Netherlands all treatment cycles are fully 
reimbursed as well as a maximum of three IVF or ICSI cycles. 
 
Implicit in the study design are the post positivist values of society that 
acknowledges the emotional and psychological needs of the patient.  Best 
practice is to include a social worker in the care team.  This is an 
observational study that seeks to construct an understanding of a process. 
 
These values and beliefs are explicitly present in the description of the 
context and the methodology.  For example, care is taken that the couples 
that stopped fertility care at the study site were followed up, so that the study 
was performed from the patient’s perspective and not just the investigators’ 
perspective. 
 
The aim of this study is to analyse at which stage couples from an 
unselected secondary care subfertility population discontinue fertility care.  
The reasons for withdrawal and the spontaneous pregnancy rates after 
discontinuation were secondary outcome measures. 
 
Throughout the reporting the medical understanding of the causes and 
treatments of infertility are used and the mind-body connection is 
acknowledged as PNEI.  The key concepts being covered are infertility as a 
medical condition that can be diagnosed and treated.  The process that was 
being observed was divided into six different stages of fertility care: 
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Stage 1 couples who discontinued treatment before fertility workup was even 
started (pre-diagnostic testing) 
Stage 2 couples who discontinued treatment during diagnostic fertility 
workup. 
Stage 3 couples who discontinued treatment after diagnostic fertility workup 
but before fertility treatment was started. 
Stage 4 couples who discontinued treatment during or after conventional 
treatment was performed but before IVF or ICSI was started. 
Stage 5 couples who discontinued treatment before completing three cycles 
of IVF or ICSI 
Stage 6 couples who discontinued treatment after they underwent at least 
three cycles of IVF or ICSI. 
 
The methodology being used was quantitative with some qualitative 
embedded elements. The method was a longitudinal cohort analysis, but it 
included a qualitative follow up stage, all couples who were missing from 
follow up were contacted by telephone and a questionnaire of open-ended 
questions used to investigate their reasons for discontinuation of treatment. 
Statistical analysis was used to describe the demographic characteristics of 
the three groups. 
 
About half of the couples stopped before any fertility treatment was started 
and one-third stopped after at least one IVF cycle.  The main reasons for 
withdrawal were emotional distress and poor prognosis.  
 
The couples who discontinued fertility care were slightly older (33.3 years 
versus 31.0 years), had a higher basal FSH level (8.6 versus 6.8 UI) and 
were more frequently secondary subfertile than couples who continued 
treatment.   
 
Many couples 45.1% had stopped fertility care before starting any form of 
fertility treatment (Stages 1-3) and 68.7% had discontinued before starting 
IVF or ICSI. 
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Before treatment was started couples mainly withdrew because they simply 
rejected treatment.  Couples that discontinued after treatment was started 
mainly stopped because of emotional distress or because of the doctor’s 
refusal to continue in view of the poor prognosis. 
 
The main reasons were ‘emotional distress’ 22% and poor prognosis 18.8% 
and rejection of treatment (17.2%.  For 18 couples the reason of 
discontinuation was not know (5.6%). 
 
Emotional distress was not equally important at all stages in fertility care and 
reflects the fact that it may be due to a variety of causes, stress because of 
subfertility, poor prognosis, female age, the chance of treatment that may not 
result in pregnancy, poor organisational care etc. 
 
This study is transparent and well reported as the numbers of patients that 
were included or lost at each stage are summarised clearly both in the text 
and as a flow diagram.  Efforts were made to find 243 patients who had been 
lost to follow up and this was pursued in an ethical manner.  232 couples 
were found and in total only 44 couples (3.2%) were lost to follow up. 
 
A longitudinal study, like a cross-sectional one, is observational. So, once 
again, researchers do not interfere with their subjects. However, in a 
longitudinal study, researchers conduct several observations of the same 
subjects over a period of time, sometimes lasting many years. 
 
The benefit of a longitudinal study is that researchers are able to detect 
developments or changes in the characteristics of the target population at 
both the group and the individual level. The key here is that longitudinal 
studies extend beyond a single moment in time. As a result, they can 
establish sequences of events (IWH, 2009).  
 
The open ended questionnaires used to follow up couples who had 
discontinued treatment asked whether or not an ongoing pregnancy was 
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achieved in the intervening period and about the reason for discontinuation of 
treatment.  The answers were categorized into 11 groups.  If more than one 
reason was mentioned then the patient was asked to identify the main 
reason and only the main reason was documented and included in the study.  
This would lead to a less nuanced analysis but makes it easier to perform a 
quantitative analysis of the data. 
 
Including a statistical analysis makes the results more credible and less likely 
to have arisen by chance.  The authors could have improved on their 
analysis if they had documented all of the reasons for drop out not just the 
‘main one’ as that introduces a level of bias into the study, and over simplifies 
what may be a complex situation.  Then the reasons for drop out and 
discontinuation could have been explored using a thematic analysis to 
capture the complexity of the situation and how the different elements are 
interrelated. 
 
The Mind Body connection is acknowledged and the stress of infertility is 
acknowledged but looking for a simple reason for drop out may not be the 
most appropriate framework.  This framework is best suited to answer 
question of how many and when but not why.  The difference between 
patients who drop out due to their doctor’s recommendation compared to 
making their own choice to drop out is a valid category to investigate with this 
method. 
 
A strength of this study is the clear and structured approach to the stages of 
infertility treatment, which helps to bring the temporal sequence into focus.  A 
greater understand of which stage is most likely to be stressful or to cause 
drop out is useful and could help future studies select a suitable sample for 
further investigation.  
 
The setting of the trial in a culture where the cost of treatment is not a 
variable means that other reasons for drop out can be investigated.  The 
cultural context that recognises the emotional burden of treatment means 
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that this has appeared as one of the reasons for drop out.  It is culturally 
acceptable for patients to use this as a reason. 
 
The main limitation of this study is that is does not explore the full depth of 
the reasons for drop out but presents an accurate picture of the frequency 
and distribution. 
 
Previous studies had mainly focused on dropout rates in IVF/ICSI patients 
this was the first study in which the focus was on the stage of fertility care at 
which patients dropped out in an unselected group of fertility patients. 
 
As they found that it is likely that the prognosis of the couples that 
discontinued fertility care would have been better if they had continued with 
treatment there are implications for how patients are helped to make well-
informed choices about treatment.   The authors suggest that counselling 
should be offered to couples about the difference in chance of conceiving 
depending on whether they stop or continue treatment.  83 studies have cited 
this paper so it has had a high impact on subsequent research. More recent 
studies such as (Boivin et al., 2012) recognise that in order to retain women 
in treatment cycles the emotional and psychological aspects of infertility 
treatment need to be recognised and addressed:  
 
Reducing the burden of treatment should lead to improved outcomes, namely 
better quality of life during treatment and lower discontinuation rates. (Boivin 
et al., 2012) 
 
Conclusion 
Research Questions 
What are the concerns of infertile women?  Do existing studies offer any 
insight for trial design? 
The social and legal context of infertility treatment means that women may 
have a variety of concerns ranging from personal emotional distress 
(Brandes et al., 2009) to concerns about protecting their privacy at work 
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(Finamore et al., 2007).  Although infertility is not legally recognised as a 
chronic medical condition a comparison can be made with a grounded theory 
derived model on workplace identity and chronic illness (Charmaz, 2010) 
because of the tremendous impact that infertility and infertility treatment has 
on the wellbeing of those afflicted as well as the demanding nature of 
treatment and the practical implications for time off work. 
 
Borrowing from (Charmaz, 2010) and triangulating with another more recent 
qualitative analysis (Payne, 2014) confirms that women have difficulty 
reconciling their two identities as a treatment seeker and as an employee.  
Limiting their disclose may help to keep these two identities separate, 
allowing them to function as normally as possible in the workplace but 
compromising their integrity.  Integrity here having the dual meaning of 
‘wholeness’ and ‘honesty’. The third longed for status of ‘parent’ grants a kind 
of moral legitimacy that would justify time off work or divided priorities for 
working women and this is further strengthened by the protective legal status 
accorded to parents who are allowed time off work for parenthood related 
issues. 
 
The success rate for IVF is greatly influenced by the woman’s age (Fields et 
al., 2013) and therefore age and poor prognosis have been identified as a 
reason for many couples discontinuing treatment that in fact may have been 
successful (Brandes et al., 2009).  The design of the quantitative strand of 
this research project needs to take the age of female participants into 
account when planning the randomisation of patients to placebo and active 
drug.  The concept of supporting the psychological identity of the patient was 
not taken up when planning the trial, this important facet of the study was left 
in the hands of the unit staff and was probably a major contributor to the 
recruitment difficulties experienced in strand 3. 
Limitations  
The narrative literature review for this section was developed and refined as 
part of an iterative cycle of data collection and review during the fourth 
qualitative strand of the thesis.  It is therefore not a systematic review of the 
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literature around the concerns of infertile women.  It provides instead some 
synthesis of ideas from grounded theory, from the research literature and 
from another research project that was taking place at the same time.   
The non systematic nature of this review can also be justified by the literature 
on qualitative research and grounded theory in which there is a debate about 
the need for a literature review when creating new theory because of the 
danger of imposing existing models and interpretations rather than finding 
new patterns and ideas in the data (Wolcott, 1990), (Silverman, 2013). 
The findings in this section should therefore be interpreted within the 
pragmatic framework as an example of: 
‘Current truth, meaning and knowledge as tentative and as changing over 
time.  What we obtain on a daily basis in research should be viewed as 
provisional truths’. (Johnson and Onwuegbuzie, 2004) 
These provisional truths should therefore not be used as an evidence base 
for making clinical decisions, that is the role of the RCT, but can be seen as a 
source of specific and local knowledge regarding trial design for this specific 
group of women.  
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Literature Review - Section 6 - Thematic Analysis 
 
Research	  Questions:	  What	  is	  thematic	  analysis	  and	  is	  it	  an	  appropriate	  
method	  of	  analysis	  for	  this	  project?	  	  What	  does	  good	  thematic	  analysis	  look	  
like?	  
Methodology	  	  
This section is a brief narrative review of the most popular and well known paper on Thematic 
Analysis, it was read critically using a check list of questions, as previously described 	  Table	   4:	   Checklist	   of	   questions	   for	   critical	   reading	   of	   selected	   articles. An 
example of thematic analysis of a CAM therapy was chosen as part of an 
iterative cycle of reading and writing regarding the methodology of this thesis. 
 
Using Thematic Analysis in psychology.   
 
The good practice of thematic analysis (TA) as a qualitative research method 
has been defined by Braun and Clarke in 2006 (Braun and Clarke, 2006a) 
and their article has been widely cited.  A citation check in November 2014 
showed that this article had been cited 10509 times.   
 
Their paper was written from their perspective as psychologists interested in 
qualitative research in the field of same sex and heterosexual relationships. 
Their starting point was that, at that time, TA was both poorly demarcated 
and widely used, because of its ubiquitous use by researchers in so many 
other research traditions.  They argued that people who claimed that they 
were using rigorous theories such as grounded theory or comparative 
analysis were often using thematic analysis because they did not go further 
than a surface level analysis of the data and did not create new theory.   
 
Their aim was to argue convincingly that TA should be regarded as a method 
in its own right, and to provide an article that could be used to reference TA 
as both a research and a teaching tool.  
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This text adds to the existing body of knowledge by locating TA in the 
research literature and tradition and by providing clear guidelines for 
conducting TA as well as criteria for evaluating the quality of studies using 
TA.  Braun and Clarke, by providing us with a standard protocol, have 
opened up the opportunity for the qualitative results of different trials to be 
compared or combined in a larger analysis. 
 
The advantages of this relatively simple, flexible method are explained and 
can be used by researchers to justify their choice of TA as a tool: 
 
• Flexibility. 
• Relatively easy and quick method to learn, and do. 
• Accessible to researchers with little or no experience of qualitative 
work. 
• Results are generally accessible to educated general public. 
• Useful method for working within participatory research paradigm, with 
participants as collaborators. 
• Can usefully summarise similarities and differences across the data 
set. 
• Can generate unanticipated insights. 
• Allows for social as well as psychological interpretation of data. 
• Can be useful for producing qualitative analyses suited to informing 
policy development. 
 
Adapted from Table 3: Advantages of Thematic Analysis (Braun and Clarke, 
2006a) 
 
TA is described as a foundational method for qualitative research that 
provides an opportunity to develop core skills that will be useful in conducting 
other forms of research.  TA had previously been regarded as a tool to use 
within different methods (Boyatzis, 1998) because the creation of themes of 
meanings is a generic skill across qualitative analysis (Holloway and Todres, 
2003). 
LITERATURE REVIEW 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   165	  
 
This plurality of use is the key to understanding TA; it is not automatically 
linked to any pre-existing theoretical framework and so can be used to do 
different things within different frameworks.  The flexibility of TA is it’s 
characteristic feature: 
 
‘Thematic analysis can be an essentialist or realist method, which reports 
experiences, meanings and the reality of participants, or it can be a 
constructionist method, which examines the ways in which events, realities, 
meanings, experiences and so on are the effects of a range of discourses 
operating within society (Braun and Clarke, 2006a)’. 
 
The key to whether it is being used to unpick reality or reflect reality is the 
theoretical position of the researcher.  This text describes how TA differs 
from other approaches such as Grounded Theory (GT) and Discourse 
Analysis (DA).  Both of these require a detailed theoretical and technical 
knowledge where as TA offers a more accessible form of analysis to the 
relatively inexperienced researcher. 
 
The paper provides clear guidelines for such a researcher by explaining the 
need for transparency of theoretical framework and assumptions about 
knowledge.  The actual method for conducting the TA is broken down into six 
stages that are easy to understand and reproduce.  The key terms are well 
defined and in particular the discussion around what constitutes a ‘theme’ is 
helpful.  
 
The distinction is made between inductive and theoretical themes, and at 
another level between semantic or latent themes and allows the researcher 
to describe their analysis, locating it, for example, within constructionist or 
realist paradigm. 
 
The text provides help with the practical application of TA by listing both the 
potential pitfalls and characteristics of good TA. 
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The first of these potential pitfalls is a failure to actually analyse the data at 
all: 
   
‘Thematic analysis is not just a collection of extracts strung together with little 
or no analytic narrative.  Nor is it a selection of extracts with analytic 
comment that simply or primarily paraphrases their content.” (Braun and 
Clarke, 2006a) 
 
The second pitfall to is the use of data collection questions to form the 
themes that are reported and in such a case no analytic work has been done 
to identify themes across the entire data set, or make sense of the patterning 
of responses. 
 
The third pitfall is a weak or unconvincing analysis where the themes do not 
appear to work.  The fourth is a mismatch between the data and the analytic 
claims that are made about it. 
 
In the field of qualitative analysis criteria for conducting good research do 
exist and this paper shows how the issues raised in many general qualitative 
research assessment criteria can be more or less applied to thematic forms 
of analysis. 
 
“As thematic analysis is a flexible method, you will also be clear and explicit 
about what you are doing, and what you say you are doing needs to match 
up with what you actually do.  In this sense, the theory and the method need 
to be applied rigorously, and “rigour lies in devising a systematic method 
whose assumptions are congruent with the way one conceptualises the 
subject matter” (Reicher and Taylor, 2005)549” 
(Braun and Clarke, 2006a) 
 
Their 15-point checklist of Criteria for Good Thematic Analysis is helpful for 
the novice researcher also helps to characterise Thematic Analysis 
compared to other methods: 
Table 11 Checklist of criteria for good thematic analysis 
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Process No. Criteria 
Transcription  The data have been transcribed to an 
appropriate level of detail, and the transcripts 
have been checked against the tapes for 
‘accuracy’. 
Coding 2  Each data item has been given equal attention 
in the coding process 
3 Themes have not been generated from a few 
vivid examples (an anecdotal approach), but 
instead the coding process has been thorough, 
inclusive and comprehensive. 
 
4 All relevant extracts for all each theme have 
been collated 
5 Themes have been checked against each 
other and back to the original data set. 
6 Themes are internally coherent, consistent, 
and distinctive 
Analysis 7 Data have been analysed – interpreted, made 
sense of – rather than just paraphrased or 
described. 
8 Analysis and data match each other – the 
extracts illustrate the analytic claims. 
9 Analysis tells a convincing and well-organised 
story about the data and topic. 
10 A good balance between analytic narrative and 
illustrative extracts is provided. 
Overall 11 Enough time has been allocated to complete 
all phases of the analysis adequately, without 
rushing a phase or giving it a once over lightly. 
Written Report 12 The assumptions about, and specific approach 
to, thematic analysis are clearly explicated. 
 13  There is a good fit between what you claim to 
do, and what you show you have done – i.e. 
described method and reported analysis are 
consistent. 
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14  The language and concepts used in the report 
are consistent with the epistemological position 
of the analysis. 
15 The reporter is positioned as active in the 
research process; themes do not just ‘emerge’. 
 
Adapted from Table 2: 15 point checklist of Criteria for Good Thematic 
Analysis (Braun and Clarke, 2006a)  
 
“We do not subscribe to a naïve realist view of qualitative research where the 
researcher can simply ‘give voice’ see (Fine, 1992) to their participants.  As 
(Fine, 1992) argues, even a ‘giving voice’ approach “involves carving out 
unacknowledged pieces of narrative evidence that we select, edit and deploy 
to border our arguments.  However neither do we think there is one ideal 
theoretical framework for conducting qualitative research, or indeed one ideal 
method?  What is important is that the theoretical framework and methods 
match what the researcher wants to know, and that they acknowledge these 
decisions, and recognise them as decisions.” 
 
In essence their position is that they believe in the plurality of different 
realities and perspectives and therefore the validity of using a plurality of 
methods needed to investigate them.  They do not mention Mixed Methods 
Research perhaps because it would have been at an early stage of 
development in 2006.  This article would have been written and published in 
the time between the first publications that developed the procedures and 
those that advocated and expanded the use of MMR. 
 
Greene et al had identified a classification system of types of mixed methods 
designs (Greene et al., 1989), and (Tashakkori and Teddlie, 1998) had 
provided a comprehensive treatment of many aspects of MMR.  In 2007 
papers that focused on the multiple ways of seeing, hearing and making 
sense of the social world (Greene, 2007) were published and (Creswell and 
Clark, 2007a) were advocating and engaged in disseminating technical 
expertise in this field. 
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The method used in this paper reflects the subject matter; the key themes 
that identify Thematic Analysis are picked out and narrated in a convincing 
manner that provides encouragement as well as guidance.  It is not an 
unbiased, objective opinion but it does provide an overview of the benefits as 
well as the disadvantages of using TA. 
 
It does not depart from general good practice for conducting qualitative 
research and this simplicity reflects the relatively simple analytical tool that is 
TA.  There are quotes and examples from published work in the field of 
sexuality and these are effective in supporting the argument and also provide 
examples of the kind of work that could be analysed using TA. 
 
There is still room to debate the role of TA as a tool utilised in a skilful way 
rather than a distinct methodology in it’s own right but the paper does provide 
a clear explanation of how to use that tool and what good practice would look 
like. 
 
The writing style is clear and accessible for the novice researchers who 
might be interested in using this form of analysis and the text is well 
organised into logical sections and steps. 
 
An Example Of Thematic Analysis 
The Effect Of Acupuncture On Psychosocial Outcomes For Women 
Experiencing Infertility: A Pilot Randomized Controlled Trial. (Smith et 
al., 2011) 
 
This is a mixed method randomised controlled trial, comparing acupuncture 
with a wait list control set at the Centre For Complementary Medicine 
Research, the University Of Western Sydney, Sydney, Australia. Thirty-two 
(32) women aged 20–45 years, with a diagnosis of infertility, or a history of 
unsuccessfully trying to conceive for 12 months or more, were recruited to 
the study using local papers, online forums and a press release. 
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The underlying concept being investigated was that stress has an impact on 
fertility through the HPA axis, and that acupuncture can reduced stress and 
increase well being because Traditional Chinese Medicine is a holistic 
treatment. 
 
The language of the paper includes some technical acupuncture terms that 
need some specialist knowledge to understand their significance.  The 
psychological interventions are described using conventional medical terms.  
The mind body connection is described in terms of PNEI, the statistical 
analysis is described using the conventional statistical language and the trial 
design uses the usual language of clinical trials.  This paper is therefore 
useful to all medically trained readers but some explanation of acupuncture 
would also be helpful.  
 
The authors examine the hypothesis that acupuncture compared to a wait-list 
control would demonstrate improvements in infertility self-efficacy, and 
reductions in anxiety and infertility-related stress and women’s experiences 
of acupuncture are also reported. 
 
A mixed method approach is being used to triangulate data from qualitative 
and quantitative sources.  This approach acknowledges that a plurality of 
methods are necessary to capture the infertility related stress.   
 
The subjects were randomised to acupuncture or wait list, those subjects in 
the treatment group received six sessions of acupuncture over eight weeks. 
Randomisation to treatment or wait list attempts to measure the impact of 
having acupuncture treatment against not having acupuncture treatment 
while on the wait list for treatment. 
 
Both quantitative and qualitative data were collected.   The quantitative data 
were collected as outcome measures of three questionnaires: The Fertility 
Problem Inventory (FPI) (Newton et al., 1999), the Infertility Self-Efficacy 
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Scale (ISE) (Cousineau et al., 2006) and the State-Trait Anxiety Inventory 
(STAI) (Spielberger et al., 1970).  
 
Use of validated questionnaires to measure infertility-related stress.  The FPI 
- Scores are summated into five domains: social concern, sexual concern, 
relationship concern, rejection of childfree lifestyle, and need for parenthood. 
ISE has been specifically validated with infertility patients and is a self-report 
questionnaire consisting of 16 items that probe into the respondents’ 
perceptions about their ability to deal with various aspects of fertility 
treatment.  The results were analysed using statistical methods to ascertain 
their significance of results and to explore any causal relationships. 
 
The qualitative data were 10 in-depth interviews with women who completed 
the 8 weeks of acupuncture.  The Interview data were digitally recorded, 
transcribed and then subjected to a process of coding and thematic analysis 
following established protocols for thematic analysis (Braun and Clarke, 
2006a) 
 
The 10 interviews with women were intended to find out how they felt about 
acupuncture.  The interviews explored the women’s experiences of infertility, 
its psychological impact, and the perceived impact of acupuncture on 
cognitive control.  Women were first asked an open-ended question about 
their fertility treatment and how it affects them, with prompt questions 
including reasons for joining the trial, previous experience of fertility 
treatment, and expectations of treatment. 
 
They were then asked about their sessions with the acupuncturist, including 
what happened, how they felt, whether it made them feel differently, and 
whether their feelings about it changed over time.  Finally, women were 
asked about the effects of acupuncture, including problems and difficulties 
and feelings for the future. 
 
The findings were based upon a sample of 16 who women were allocated to 
the acupuncture treatment group and 14 to the wait-list control.  They found 
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that more research is needed to evaluate the preliminary results, which 
suggest that acupuncture, may be a useful intervention to assist with the 
reduction of infertility-related stress. 
 
The data also show promising trends in relation to improve self-efficacy and 
reduced anxiety.  At the end of the 8-week intervention, women in the 
acupuncture group reported significant changes on two domains on the FPI, 
less social concern defined as sensitivity to comments, reminders of 
infertility, feelings of social isolation, and alienation from family or peers. 
 
The in-depth interviews highlighted a changed perception for women with 
regard to coping, feeling less anxious, feeling physically calm, relaxed and 
overall having achieved a greater sense of well-being.  Women’s responses 
are organised under three themes: “expectations of acupuncture: invoking 
change,” “positive experiences of acupuncture,” and “changes achieved after 
acupuncture.” 
 
The usefulness of this study could have been increased if they had also 
interviewed 10 women from the other group, the wait group, and carried out a 
thematic analysis of the two groups to compare their experiences. 
 
Control groups are usually associated with quantitative research methods 
where in classic experimental design where patients are randomly assigned 
to two or more differently treated groups (experimental and control) (Bowling, 
2011) 
The comparison of two groups, with similar naturalistic settings (Lloyd-Jones, 
2008), could be seen as a pragmatist version of a control group in qualitative 
research and this would have allowed them to see how their experiences 
differed from the treatment group, and in turn that would have made a 
greater contribution to the research question that was inquiring into the effect 
of the acupuncture on infertility related stress compared to no acupuncture. 
 
Discussion 
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The thematic analysis has resulted in themes that are credible and the 
authors acknowledge the limitations of the study, which are a small sample 
size, the lack of participant blinding, and the short follow up time.  Some 
strengths of the thematic analysis can be identified using the criteria from 
Braun and Clarke: 
 
• Interview data were digitally recorded and transcribed verbatim by a 
professional transcribe.  Transcripts of the interviews were de-
identified and checked for transcription accuracy.   
 
• Three researchers read the transcripts independently and subjected 
the data to a process of coding and thematic analysis, based on 
notions of consistency, commonality, and the function and effects of 
specific themes, following established protocols. 
 
• To begin with the data were subject to open coding involving a close 
reading of each transcript to identify first order concepts.  Axial coding 
was employed to develop categories.  In the final stages of selective 
coding a core category was developed which essentially linked all of 
the concepts and categories. 
 
• They report that the research was largely inductive, where the 
concepts and categories came from the data, rather than being 
deductive or informed by existing preconceptions about acupuncture 
and fertility. 
 
It is not clear from reading the paper if the qualitative themes were informed 
by the results of the quantitative surveys, the combining of results could have 
occurred at an early analytical stage in the study or later in the reporting 
stage, and a good study should make this clear.   
 
The structure and quality of mixed methods research designs is explored in 
more detail in a later section.  But before moving away from the experiences 
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of infertile women some time is taken to look into the ethics of using data that 
is mined from their personal postings on infertility Internet forums. 
Conclusion	  
Research Questions: What is thematic analysis and is it an appropriate 
method of analysis for this project?  What does good thematic analysis look 
like? 
 
This account of thematic analysis by acknowledged experts in the field 
(Braun and Clarke, 2006a) helped me to improve on my first submission of 
my thesis which had mistakenly claimed to included grounded theory as an 
analytical tool.  The clear guidelines offered by Braun and Clarke gave me a 
step by step method to follow as I re-analysed my data from strand one and 
strand four, looking for the themes in the data.  My clearer understanding of 
what thematic analysis looks like was also reflected in a clear declaration of 
my methodology and methods in the second submission of the thesis. 
 
The use of thematic analysis is especially suited to researchers in the early 
stages of their career and can be used as a stepping stone to achieve a 
deeper, more abstracted level of analysis leading in time to a full blown 
grounded theory.  It is my intention to continue along this path after 
successful submission of my corrections by working on an article regarding 
my findings in conjunction with another, experienced researcher Dr Carol 
Rivas. 
 
The example of thematic analysis (Smith et al., 2011) as applied to the field 
of CAM and female infertility was included to show that the method is 
appropriate for my research questions, can provide useful results and can be 
reported in a transparent manner.   The criteria for good thematic analysis as 
reported by Braun and Clarke were used to check the credibility of the 
example as well as my own work in strands one and four. 
Limitations	  To	  This	  Section	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This was not a systematic qualitative review of all the literature available on 
Thematic Analysis and cannot therefore be interpreted as an unbiased 
account of the advantages and disadvantages of using this method. 
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Literature Review - Section 7 -  The Ethics of using 
Internet Data Sources 
 
Methodology	  	  
The articles chosen for this narrative review were selected by an internet 
search of articles on PubMed using the search terms ((ethics[MeSH Terms]) 
AND internet[MeSH Terms]) AND data and filtered for articles published in 
the last 5 years.  The results were not systematically selected for review but 
the abstracts of the articles were read before choosing the most relevant and 
up to date paper for critical reading (Bond et al., 2013) 
 
Memos were kept to record this process and they are included in the 
APPENDIX 12 memos written during thematic analysis of strand 4.  Memo 
writing is a technique from the qualitative research method known as 
Grounded Theory (Charmaz, 2006) in which informal analytic notes that 
chart, record and detail the analytic phases of the project. 
 
The characteristics of pragmatism include the idea that our thinking follows a 
dynamic homeostatic process of belief, doubt, inquiry, modified belief, new 
doubt, new inquiry…in an infinite loop, where the person or researcher (and 
research community) constantly tries to improve upon past understandings in 
a way that fits and works in the world in which he or she operates. (Johnson 
and Onwuegbuzie, 2004).  This dynamic model seem particularly appropriate 
for the study of a new and constantly changing field of knowledge such as 
the growth of the internet, the increasing use of patient forum’s and the 
explosion of data available to researchers from this source. 
 
 
Any systematic review would quickly be out of date, for example A PubMed 
seach on 30th December 2015 using the MeSH terms ("internet/ethics"[MeSH 
Terms]) AND patient data privacy [MeSH Terms] returned 55 search results 
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published within the last 5 years, 5 of which have been published since this 
thesis was submitted for  re-examination. 
 
It is anticipated that is section of the thesis will be developed as an article 
intended for publication and that a thorough and up to date qualitative 
literature review will be undertaken at that time. 
 
The narrative review undertaken here is sufficient as an introduction to the 
field but is not intended to be complete or definitive. 
Introduction	  	  
Research	  question:	  What	  are	  the	  ethics	  of	  using	  data	  from	  internet	  forums?	  	  	  	  
When the recruitment to trial OVCT-001 failed, the author was faced with a 
dilemma, the lack of quantitative data made it impossible to write a thesis 
and yet the time and energy already invested made abandoning the project 
altogether an unappealing prospect.  There was also the new research 
question to be answered, ‘Why did recruitment fail?’   
 
In an ideal situation the women who had been approached for recruitment 
phase would have been sampled for a qualitative study to find an answer to 
this question.  It was not possible to gain the support of the ARU staff to carry 
out this strand of the study so the pragmatist solution was to turn to the data 
that was available which found online via the Internet infertility forums.   
 
This data could be viewed as existing in the public domain and yet it to some 
extent ‘belongs’ to the person posting it, a person who may not even be 
identifiable in order to seek informed consent.   The blurring of the traditional 
boundaries between data, subject and researcher has created new questions 
some of which are explored in this section. 
 
The author also sought the opinion of the forum administrators, and her 
supervisors who had experience in this field, and these are documented in 
the methodology section as Strand	  Four	  (2012	  -­‐2015). 
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The Conceptual And Practical Ethical Dilemmas Of Using Health 
Discussion Board Posts As Research Data. 
(Bond et al., 2013) 
 
The use of the Internet in modern society is introduced as the context for this 
study and the introduction charts the evolution of an ethical framework in 
response to technological change.  The online discussion boards of people 
living with the long-term medical condition, diabetes, are the focus of the 
study.  
 
The blurring of the boundary between private and public information is a 
consequence of the rapid expansion of posting in a forum and the views and 
perspectives of the people posting have not been adequately explored. 
 
The scale of personal posting was not anticipated in the early days of this 
debate and some published research provide principles but not specific 
ethical guidelines for researchers who wish to use such data. 
 
To date the views of those people posting health information online in 
relation to how they anticipate the information they post being used has not 
featured significantly in the debate and so this study seeks to bring their 
voices into the knowledge base by examining the views of people living with 
diabetes who share health information online. Four active diabetes forums 
were identified by the PI and chosen as platforms to recruit participants into 
the study. 
 
A qualitative approach was employed using online semi structured 
asynchronous email interviews conducted with the users of an online 
diabetes discussion boards.  Both the primary investigator and the project 
researcher had experience in online interviewing techniques.  The target 
number of 24 participants was set prior to recruitment with the ability to 
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increase this should the need arise.  Drawing on previous experience it was 
correctly anticipated that saturation of data would be reached by this stage. 
 
The Ethics Committee of the School of Health and Social Care, Bournemouth 
University granted ethical approval for this study. Forum Moderators and 
administrators were approached prior to posting on the forum in order to gain 
their approval for posting for research purposes. 
 
Data collection commenced in April 2012 and concluded in May 2012. 
Four active diabetes forums were identified and participants were eligible for 
the study if they were active as a member on at least one of the forums 
identified. CSB and OHA posted in each of the forums on different threads 
within the forum in order to give the recruitment posts more publicity.   
 
The recruitment posts described the study and provided contact details for 
the investigators.  Individuals interested in participating were invited to 
contact them by email for more information.  Once interested individuals had 
made contact with the research team they were sent a brief overview of the 
study along with an information sheet.  Following this, if the participants were 
happy to participate they were sent the first interview questions by email and 
the interview was started. 
 
The data from participants were collected using asynchronous semi 
structured interviews.  The semi structured nature of these interviews meant 
that similarly themed information was collected from the participants, while 
the fact that the interviews were asynchronous enables participants to 
respond to questions in their own time (but within the time constraints of the 
research programme). 
 
Participants were sent several emails during the course of the interview with 
each email containing 1-2 questions.  The questions aimed to ascertain 
whether participants felt it was acceptable for researchers to use information 
on health discussion boards, what permission should be sought prior to using 
this information, and whether the length of time since the post was made 
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influenced the need to obtain permission.  Once the participants had 
answered all of the questions, they were thanked for their contributions and 
their participation in the study was over. 
Following the requests for recruitment posted on the discussion boards, 33 
individuals expressed an interest in participating and were contacted by the 
research team.  30 participants consented and responded to at least one 
question in the interview sequence, while four participants who did not 
complete the interview questions did not respond to further follow-up 
prompts.  The remaining 26 participants completed all of the semi structured 
interview questions and their answers were included for analysis. 
 
All of the interviews were completed in less than 10 days.  Of the 26 
completed interviews 12 participants were identified as being male and 9 as 
female and there were 6 participants who it was not possible to identify. 
 
A qualitative approach using interpretative description methodology (Thorne 
et al., 1997) was used to assess the interview transcript and quotations were 
extracted and anonymised to support each theme. 
 
It is our view that nursing’s uniqueness has gradually shifted the priorities 
within our research enterprise to the point that we can begin to build methods 
that are grounded in our own epistemological foundations, adhere to the 
systematic reasoning of our own discipline, and yield legitimate knowledge 
for our practice. 
 
We put forward interpretive description as one of many possible “generic” 
nursing approaches.  
(Thorne et al., 1997) 
 
Because they address the dialectic between individual cases and common 
patterns, nursing studies can also capitalize on this strategy. Interpretive 
description in nursing requires that nurse researchers come to know 
individual cases intimately, abstract relevant common themes from within 
these individual cases, and produce a species of knowledge that will itself be 
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applied back to individual cases. In order to do this effectively, they must 
engage in both the ethereal abstractions of theorizing and the earthbound 
concrete realities of the practice context in order to produce sound and 
usable knowledge.(Thorne et al., 1997) 
 
Interpretative Description has its roots in qualitative approaches used by 
nurse researchers and therefore has strong connections to practical 
situations.  It is recommended that immersion in the data is interleaved with 
exposure to the field (Thorne et al., 1997) but there is no evidence that these 
researchers have experience of working with this field of chronic illness.  
They do not explain why Diabetes was chosen as the context for this study. 
 
An inductive approach was adopted; allowing the themes to emerge from the 
data rather then testing previously identified themes on the data. 
The analysis of the rigor of this study was based on Guba and Lincoln’s 
principles of credibility, confirmability and dependability (Lincoln, 1989). 
 
Four forums were selected in order to ensure that any particular character or 
interest on a board would not have undue influence on the findings. 
The rigor was achieved through prolonged engagement with sufficient depth 
of data, peer debriefing and analysis of material, linking assertions, findings, 
and interpretations with the data and third party auditing of the data collection 
and analysis process.  The process is set out as a flow chart making the 
study transparent and suitable for replication. 
 
Two investigators read each transcript several times independently and 
loosely attributed themes to the data with no consultation occurring between 
the assessors at this stage.  Discussion was then undertaken to compare the 
themes identified and to resolve any areas of disagreement with theme 
allocation.  Quotations were extracted to support themes and each 
participant was assigned a number when using the supporting quotations.  
Following this process and the identification of themes their findings were 
sent out to the other members of the research team in order to verify the 
themes. 
LITERATURE REVIEW 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   182	  
In view of the lack of consensus on some issues among the study 
participants someone not previously involved in the analysis who reviewed 
the themes and the conclusions to ensure consistency carried out a final 
check. 
 
Four main themes were identified  
1. The views of people living with diabetes are needed. 
2. Posts made are in the public domain 
3. Permission (two subthemes) 
4. Use of citations 
 
1. The views of people living with diabetes are needed. 
There was general support for researchers using information posted on 
discussion boards as this was seen as a way of giving a ‘voice’ to such 
people. 
The use of such data was seen to be altruistic and not for commercial 
gain. 
 
2. Posts made are in the public domain 
There was a general acceptance by the participants in this study that 
once information is posted on a forum it is available to the public and this 
could be accessed and used for research purposes.   Some people felt 
that it could be used unreservedly and some people felt it should be 
restricted. 
 
3. Permission (two subthemes) 
Respondents were asked if they thought researchers need permission to 
use information in their posts and the responses were grouped into two 
subthemes:  Those who felt that their information was in the public 
domain and therefore available to be used did not feel there was any 
need for permission to be sought.  Those who acknowledged the public 
nature of the forum but expressed reservations felt that some sort of 
permission should be sought from the person who posted the information. 
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Site administrators also failed to come to a consensus about their role in 
giving permission. 
 
4. Use of citations 
There was no correlation between the date that the post was made and 
the need to obtain permission. 
Aggregated data was not considered as needing permission however direct 
quotes were seen as needing some sort of citation.  Aggregating quotes also 
helps to protect user anonymity.  Some quotes are included to show the links 
to empirical data and the comparison with concepts from mass media studies 
help to offer insights. 
 
The use of thoughtfully constructed aggregated quotes is discussed as a way 
of providing richly textured and comprehensive data sets and to give depth to 
the participants meaning. This contributes to the debate about ethics and 
methodology but they acknowledge that the findings may not be transferrable 
to other domains outside discussion board-type communications. 
 
Conclusion 
What are the ethics of using data from internet forums?   
The findings of this study were helpful when dealing with the ethical dilemma 
of how to approach the use of data in strand four of this thesis.  The idea that 
the views of people living with a condition can be heard and acknowledged 
needs to be balanced with their desire for privacy.  The choice of an internet 
forum as a form of expression creates an expectation of anonymity combined 
with identify as part of a group.  These results triangulate with  and agree 
well with the findings of my own thematic analysis in the results chapter. 
 
The use of aggregated quotes; the seeking of permission from forum 
administrators and the feedback of results to the forum can all be 
incorporated into my own research design and methodology. 
 
Limitations  
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It is acknowledged that this existing narrative review is not systematic and 
therefore the conclusions need to be interpreted with caution as bias cannot 
be excluded.  
 
Literature Review - Section 8  – Qualitative Research    
 
Research	  question:	  What	  is	  qualitative	  research?	  How	  can	  I	  make	  sure	  my	  
study	  is	  credible	  and	  valid?	  
 
Introduction	  	  
The move towards a mixed methods research design meant that a greater 
emphasis was placed on the qualitative strand of the study, particularly the 
fourth strand, which explores the concerns of infertile women: 
 The use of qualitative techniques to explore this aspect of the study was 
consistent with the development of the pragmatist worldview: 
 
Pragmatism recognises the existence and importance of the natural or 
physical world as well as the emergent social and psychological world that 
includes language, culture, human institutions, and subjective thoughts. 
(Johnson and Onwuegbuzie, 2004) 
 
In order to make sure that this part of the study was written to the required 
standards of credibility and rigor a framework for evaluating qualitative 
research was sought in the literature.  
Methodology	  
This is not a systematic qualitative review but a narrative review that reflects 
the iterative cycle of reading, thinking and rewriting that accompanied the 
development of the pragmatist world view.  Many of the ideas were clarified 
during the reading of (Silverman, 2013) and (Creswell and Clark, 2007b).   
 
Memos were kept to record this process and they are included in the 
APPENDIX 12 memos written during thematic analysis of strand 4.  Memo 
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writing is a technique from the qualitative research method known as 
Grounded Theory (Charmaz, 2006) in which informal analytic notes that 
chart, record and detail the analytic phases of the project.  Memo writing is a 
pivotal intermediate step between data collection and writing drafts of papers 
(Charmaz, 2006).  Memos catch your thoughts, allow you to make 
comparisons and connections leading to new directions for you to explore. 
 
The characteristics of qualitative research are covered in more detail in the 
next section as part of the narrative review of mixed methods research. 
 
The paper selected for critical reading (Pope et al., 2000) was widely cited 
(3772 times on 31/12/15) and was published in the BMJ.  It was therefore 
seen as reliable and credible as a source of information to researchers from 
a quantitative tradition who might need a road map of this unfamiliar territory. 
 
The paper on standards for reporting qualitative research (O’Brien et al., 
2014b) was chosen as an up to date source that had been systematically 
prepared and peer reviewed. 
 
The authors identified guidelines, reporting standards, and critical appraisal 
criteria for qualitative research by searching PubMed, Web of Science, and 
Google through July 2013; reviewing the reference lists of retrieved sources; 
and contacting experts. Specifically, two authors reviewed a sample of 
sources to generate an initial set of items that were potentially important in 
reporting qualitative research. Through an iterative process of reviewing 
sources, modifying the set of items, and coding all sources for items, the 
authors prepared a near-final list of items and descriptions and sent this list 
to five external reviewers for feedback. The final items and descriptions 
included in the reporting standards reflect this feedback. 
(O’Brien et al., 2014b) 
 
Discussion	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A basic framework for describing qualitative research was provided by (Pope 
et al., 2000) who  noted that 
• Qualitative research produces large amounts of textual data in the 
form of transcripts and observational field notes. 
 
• The systematic and rigorous preparation and analysis of these data is 
time consuming and labour intensive. 
 
• Data analysis often takes place alongside data collection to allow 
questions to be refined and new avenues of inquiry to develop. 
 
• Textual data are typically explored inductively using content analysis 
to generate categories and explanations; software packages can help 
with analysis but should not be viewed as short cuts to rigorous and 
systematic analysis. 
 
• High quality analysis of qualitative data depends on the vision, skill 
and integrity of the researcher and should not be left to the novice. 
 
Not all qualitative researchers accept that they need to establish the 
credibility of their research results by using measures of reliability (Pope et 
al., 2000) but as qualitative research has become increasingly common and 
valued in the medical and medical education literature (O’Brien et al., 2014a) 
there is widespread agreement about the need for clear and complete 
reporting.   
 
The Standards for Reporting Qualitative Research (SRQR) (O’Brien et al., 
2014a) is an instrument consisting of 21 items. It has the aim of improving 
the transparency of all aspects of qualitative research by providing clear 
standards for reporting such work.   It has the strength of being grounded in a 
systematic review of previously reported literature and by the diversity of 
experience and perspectives of its authors.   
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Experts in three countries have also critically reviewed it.  It was therefore 
chosen as a suitable framework for reviewing some of the qualitative studies 
referenced in this thesis and for self-evaluation of the methodology section of 
this thesis.  A table detailing the 21 items is included here and in the 
appendix as Table 40 Standards for Reporting Qualitative Research. 	  
 
 
Topic Item 
1 Title Concise description of the nature and topic of the study 
identifying the study as qualitative or quantitative or 
indicating the approach or data collection method is 
recommended. 
2 Abstract Summary of key elements of the study using the abstract 
format of the intended publication; typically includes 
background, purpose, methods, results and conclusions. 
 Introduction  
3  Problem 
formulation 
Description and significance of the problem/phenomenon 
studied; review of relevant theory and empirical work; 
problem state 
4 Purpose or 
Research 
Question 
Purpose of the study and specific objectives or questions 
 Methods  
5 Qualitative 
approach and 
research 
paradigm 
Qualitative approach (e.g. ethnography, grounded 
theory, narrative research) and guiding theory if 
appropriate; identifying the research paradigm (e.g. post 
positivist, constructivist/interpretivist) is also 
recommended; rationale that briefly discusses the 
justification for choosing that approach; the assumptions 
and limitations implicit in that choice and how those 
choices influence study conclusions and transferability. 
6 Researcher 
characteristics 
and reflexivity 
Researchers’ characteristics that may influence the 
research, including personal attributes, 
qualifications/experience, relationships with participants, 
assumptions, and/or presuppositions; potential or actual 
interaction between researchers characteristics and the 
research question, approach, methods, results, and/or 
transferability. 
7 Context Setting/Site and salient contextual factors, rationale. 
8 Sampling strategy How and why research participants, documents and 
events were selected, criteria for deciding when no 
further sampling was necessary (sampling saturation), 
rationale. 
9 Ethical issues 
pertaining to 
Documentation of approval by an appropriate ethics 
review board and participant consent, or explanation for 
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human subjects lack thereof; other confidentiality and data security 
issues. 
 
10  Data collection 
methods 
Types of data collected; details of data collection 
procedures including start and stop dates of data 
collection and analysis, iterative process, triangulation of 
sources/methods, and modification of procedures in 
response to evolving study findings, rationale. 
11 Data collection 
instruments and 
technologies 
Description of instruments (e.g. interview guides, 
questionnaires) and devices (e.g. audio recorders used 
for data collection; if/how the instruments changed over 
the course of the study. 
12 Units of study Number and relevant characteristics of participants, 
documents or events included in the study, level of 
participation (could be recorded in results). 
13  Data processing Methods for processing data prior to and during analysis, 
including transcription, data entry, data management and 
security, verification of data integrity, data coding, and 
anonymization/deidentification of excerpts 
14 Data analysis Process by which inferences, themes, etc. were 
identified and developed including the researchers 
involved in data analysis, usually references to a specific 
paradigm or approach, rationale. 
15 Techniques to 
enhance 
trustworthiness 
Techniques to enhance trustworthiness and credibility of 
data analysis 9e.g member checking, audit trail, 
triangulation), rationale. 
 
 Results/Findings  
16 Synthesis and 
interpretation 
Main findings (e.g. interpretations, inferences, and 
themes); might include development of a theory or 
model, or integration with prior research or theory. 
17 Links to empirical 
data 
Evidence (e.g. quotes, field notes, text excerpts, 
photographs) to substantiate analytic findings. 
 Discussion  
18 Integration with 
prior work, 
implications, 
transferability, 
and contributions 
to the field 
Short summary of main findings; explanation of how 
findings and conclusions connect to, support, elaborate 
on, or challenge conclusions of earlier scholarship; 
discussion of scope of application/generalizability; 
identification of unique contribution(s) to scholarship in a 
discipline or field. 
19 Limitations Trustworthiness and limitations of findings 
20 Conflicts of 
interests 
Potential source of influence or perceived influence on 
study conduct and conclusions, how these were 
managed 
21 Funding Sources of funding and other support; role of funders in 
data collection, interpretation and reporting. 
Table	  12	  21	  Standards	  for	  reporting	  qualitative	  research	  (O’Brien	  et	  al.,	  2014a)	  
LITERATURE REVIEW 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   189	  
Summary	  
Research questions: What is qualitative research? How can I make sure my 
study is credible and valid? 
 
Qualitative research springs from a research paradigm which values 
evidence from a wider variety of sources than quantitative research.  The 
adoption of a pragmatist worldview brings an opportunity to use both 
qualitative and quantitative data and this is discussed in greater detail in the 
next section.   
 
Quantitative purists articulate assumptions that are consistent with what is 
called a positivist philosophy.  That is they believe that social observations 
should be treated as entities in much the same way that physical scientists 
treat physical phenomenon.  Further, they contend that the observer is 
separate from the entities that are subject to observation.  They maintain that 
social science inquiry should be objective.  That is time- and context-free 
generalizations are desirable and possible, and real causes of social science 
outcomes can be determined reliably and validly.   
 
According to this school of thought. Researchers should eliminate their 
biases, remain emotionally detached and uninvolved with the objects of 
study, and test or empirically justify their stated hypotheses. 
 
These researchers have traditionally called for rhetorical neutrality, involving 
a formal writing style using the impersonal passive voice and technical 
terminology, in which establishing and describing social laws is the major 
focus (Tashakkori and Teddlie, 1998) 
 
Qualitative researchers, also called constructivists and interpretivists 
(Johnson and Onwuegbuzie, 2004) they reject positivism and argue for the 
superiority of constructivism, idealism, humanism, hermeneutics and, 
sometimes, postmodernism (Lincoln, 1989) 
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These purists contend that multiple-constructed realities abound, that time- 
and context-free generalizations are neither desirable nor possible, that 
research is value-bound, that it is impossible to differentiate fully cause and 
effect, that logic flows from specific to general (e.g. explanations are 
generated inductively from the data), and that knower and known cannot be 
separated because the subjective knower is the only source of reality (Guba, 
1990). 
 
Qualitative purists are also characterized by a dislike of a detached and 
passive style of writing, preferring, instead, detailed, rich, and thick 
(empathetic) description written directly and somewhat informally (Johnson 
and Onwuegbuzie, 2004). 
 
Conclusion	  	  
The guidelines described by (O’Brien et al., 2014a) ensure that qualitative 
research can be clearly and transparently reported, to satisfy the need for 
credibility and rigour without compromising the unique and characteristic 
qualities of qualitative research. This is necessary in this project as the 
intended audience for my findings includes lay people, medical staff and 
academic mentors, examiners and supervisors.  By making sure that I 
adhere to these guidelines the utility of my findings will be ensured in line 
with my pragmatic worldview. 
 
Pragmatism endorses practical theory (theory that informs effective practice: 
praxis (Johnson and Onwuegbuzie, 2004) 
 
My findings could be used for example to help students writing a PhD thesis, 
medical staff planning a clinical trial design, CAM practitioners planning a 
pragmatic clinical trial, a support group for infertile women or anyone 
interested in how pragmatism can be applied to the research process.   
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Limitations	  
This is a narrative review, not a systematic qualitative review and 
therefore the conclusions should remain provisional.  The iterative use 
of theory, memo’s, data collection and return to theory are partially 
documented in the appendix APPENDIX 12 memos written during 
thematic analysis of strand 4  
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Literature Review Section 9 -  Mixed Methods 
Research  
Research	  question:	  What	  is	  MMR?	  	  How	  do	  I	  describe	  my	  study	  and	  ensure	  
transparency	  of	  reporting?	  	  
Methodology	  	  
This is not a systematic qualitative review but a narrative review that reflects 
the iterative cycle of reading, thinking and rewriting that accompanied the 
development of the pragmatist world view.  Many of the ideas were 
developed during the reading of (Creswell and Clark, 2007b).  Memos were 
kept to record this process and they are included in the APPENDIX 12 
memos written during thematic analysis of strand 4.  The paper by (Bishop 
and Holmes, 2013) was sourced during this process as being closely aligned 
with the focus of this thesis as well as being systematic and up to date. 	  
Introduction	  
This section aims to define mixed methods research, to locate it in the 
literature as a ‘third paradigm’, and to explore the ways in which the critical 
appraisal of such a methodology can be conducted.  The section ends with 
insights into the relationship between using mixed methods research and a 
pragmatist philosophical worldview. 
 
Mixed Methods Researchers may plan to include both qualitative and 
quantitative methods within their design or the design may evolve as their 
study progresses.   Creswell and Clark (Creswell and Clark, 2007a) 
characterise this situation as a continuum with ‘fixed design’ at one end and 
‘emergent design’ at the other. 
 
This thesis is a four strand structure that started as a ‘fixed’ design but 
evolved to become an ‘emergent’ design (Creswell and Clark, 2007a).  The 
use of both qualitative and quantitative methods was planned at the start of 
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the research process but the failure of the quantitative trial to recruit sufficient 
patients led to an additional qualitative analysis as the fourth strand.   
 
The typology adopted in this thesis is a variation of a Mixed Methods 
Sequential Design (Morse and Niehaus, 2009) because the phases are 
sequential.  However we will also be comparing this study to the concept of a 
Multiphase Design  
 
The factors that decided the choice of study design included the intended 
audience, the problem to be addressed and the questions to be answered.  
The intended audience for this thesis has been one of the factors that 
contributed to the choice of study design.  The intended audience consisted 
of both health practitioners, clinical investigators, academics and trial 
participants and each audience required a certain kind of information (Lewith 
et al., 2010). 
 
Health practitioners such as the staff at the Assisted Reproduction Unit 
(study site) wanted to know if Ovarium compositum was safe to use with 
women who may become pregnant, if it is a cost effective treatment and if it 
could improve the outcomes of their patients.   Some of this kind of evidence 
is to be found in the safety data and case studies for Ovarium compositum. 
 
The nurses at the unit will want to know if the treatment is complex or difficult 
to administer or likely to cause their patients additional stress.  This can be 
researched using the quality of life (QoL) questionnaires.  The additional 
workload imposed upon staff as a result of hosting the trial also had to be 
taken into account.  Working from a pragmatist perspective means that the 
trial design must work in practice and not just appear to answer the research 
questions with an appropriate design. 
 
The clinical investigators and academic supervisors will want to know how 
much improvement can be demonstrated in the trial group who received the 
Ovarium compositum compared to another group who received placebo 
which necessitates a quantitative strand of evidence in the form of the RCT. 
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The flexibility of this approach is consistent with the underlying philosophical 
framework of this thesis, pragmatism, which allows the researcher to select 
‘what works’ as the best method to answer the research question.  In this 
case the research question itself also evolved to include an additional 
question about the reasons for poor trial recruitment.  
 Discussion: The Paradigm Wars 
(Johnson and Onwuegbuzie, 2004) 
For more than a century, the advocates of quantitative and qualitative 
research paradigms have engaged in ardent dispute.  From these debates, 
purists have emerged on both sides. 
 
Both sets of purists view their paradigm as the ideal for research and, 
implicitly if not explicitly, advocate the incompatibility thesis (Howe, 1988) 
which posits that qualitative and quantitative research paradigms, including 
their associated methods, cannot and should not be mixed. (Johnson and 
Onwuegbuzie, 2004) 
Table to show the simplified comparison of typical characteristics of 
quantitative and qualitative approaches to research adapted from 
(Bishop and Holmes, 2013). 
Table 13 Typical characteristics of quantitative and qualitative paradigms 
Characteristic Quantitative approaches Qualitative approaches 
Ontology (the nature of 
being) 
Realist Relativist 
Epistemology (theory of 
knowledge) 
Knowledge limited only 
by technologies of 
knowing 
Knowledge is 
embedded in value and 
culture (including the 
research process). 
Aims/intended 
outcomes 
Universal Laws Locally situated and 
contextualised 
understandings 
Relationships between Distant, objective Close, subjective 
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researcher and 
participants 
Scope General, nomothetic Specific, idiographic 
Nature of information Causal, mechanistic 
explanation and 
prediction 
Meaning, understanding 
Relationship between 
theory and data 
Hypothetico-deductive-
data confirms/falsifies 
theory  
Inductive, theory 
emerges from data 
 
 
Johnson and Onwuegbuzie (Johnson and Onwuegbuzie, 2004) presented 
mixed methods research as the third research paradigm which has the goal, 
not of replacing either of the other approaches, but rather to draw from the 
strengths and minimize the weaknesses of both in single research studies 
and across studies.  “If you visualize a continuum with qualitative research 
anchored at one pole and quantitative research anchored at the other, mixed 
methods research covers the large set of points in the middle area.”  
 
Bishop (Bishop and Holmes, 2013) highlights the way that we can  see MMR 
from as both a philosophical perspective (as a methodology) as well as (from 
a technical perspective) a method: 
 
“As a methodology, it involves philosophical assumptions that guide the 
direction of the collection analysis of data and the mixture of qualitative and 
quantitative approaches in the many phases of the research process.  As a 
method it focuses on collecting, analysing, and mixing both quantitative and 
qualitative data in a single study or series of studies.”(Creswell and Clark, 
2007a) 
 
The term methodological eclecticism means MMR practitioners select and 
creatively integrate the most appropriate techniques from a wide variety of 
qualitative, quantitative and mixed strategies in order to thoroughly 
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investigate the phenomenon of interest (Teddlie and Tashakkori, 2010, 
Denzin and Lincoln, 2011).  The researcher is seen as a connoisseur of 
methods who knowledgeably and often intuitively selects the best techniques 
available to answer research questions that may evolve as a study unfolds 
(Teddlie and Tashakkori, 2012). 
 
Methodological eclecticism stems from rejection of the incompatibility of 
methods thesis, which stated that it is inappropriate to mix qualitative and 
quantitative methods due to fundamental philosophical or epistemological 
differences between the paradigms underlying those methods.  This is 
replaced by the compatibility thesis which distinguishes MMR from other 
fields of research (Teddlie and Tashakkori, 2012). 
 
Teddlie and Tashakkori (Teddlie and Tashakkori, 2012) consider that there 
are at least three issues related to the core characteristic of integrating 
qualitative and quantitative research: Firstly there are concerns that 
researchers can adequately develop the diverse skill set’s required.  
Secondly that existing MMR research features relatively unimaginative 
combinations of quantitative and qualitative methods.  Thirdly is the need to 
engage in philosophical discussion with supporters of the incompatibility 
thesis.   
 
In answer to the first and third concerns, the researcher found that in order to 
complete this thesis it was necessary to take extra time to develop the 
qualitative research skills necessary, the real key to integrating the different 
strands of the investigation was the discovery that a strong pragmatic 
philosophical foundation gave the whole project relevance, structure and 
meaning. 
 
In answer to the second point the need to adapt the initial design to include a 
final qualitative strand led to a new typology that falls somewhere between a 
small scale multiphase design and an exploratory sequential design and this 
will be explored in more detail later. 
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Descriptions of MMR 
The methodology employed in this thesis follows a sequential mixed methods 
research (MMR) design and it is helpful to employ the agreed MMR notation 
for the purposes of describing and analysing it. 
 
Table To Show The Summary Of Notations Used To Describe Mixed 
Methods Designs adapted from (Creswell and Clark, 2007a) 
 Table 14 Notations used to describe MMR 
Notation Example Application What the notation indicates 
Key 
Citations 
Shorthand: 
Quan, Qual 
Quan strand Quantitative methods 
Morse 
(1991, 
2003) 
Upper case 
letters: 
QUAN, 
QUAL 
QUAL priority 
The qualitative methods are 
prioritized in the design 
Morse 
(1991, 
2003) 
Lowercase 
letters: quan, 
qual 
qual supplement 
The qualitative methods have a 
lesser priority in the design 
Morse 
(1991, 
2003) 
Plus sign: + QUAN + QUAL 
The QUAN and QUAL methods 
occur concurrently 
Morse 
(1991, 
2003) 
Arrow: è QUAN è 
The methods occur in sequence 
of QUAN followed by qual 
Morse 
(1991, 
2003) 
Parentheses: 
( ) 
QUAN (qual) 
A method is embedded within a 
larger design or procedure or 
mixed within a theoretical or 
program objective framework 
Plano 
Clark 
(2005) 
Double 
arrows è 
QUALèQUAN 
The methods are implemented 
in a recursive process 
(QUALèQUANèQUALèQUAN 
Nastasi 
et al 
(2007) 
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etc. 
Bracket [ ]  
QUALèQUANTè[QUAN 
+qual] 
Mixed methods is used within a 
single study or project within a 
series of studies 
Morse 
& 
Niehaus 
(2009) 
Equal sign:=   
QUAN èqual = explain 
results 
The purpose for mixing 
methods 
Morse 
& 
Niehaus 
(2009) 
 
 
Mixed Methods research is the type of research in which a researcher 
combines elements of qualitative or quantitative research techniques for the 
purpose of breadth and depth of understanding and corroboration. (Creswell 
and Clark, 2007a) 
 
In mixed methods the researcher (Creswell and Clark, 2007a): 
• Collects and analyses persuasively and rigorously both qualitative and 
quantitative data based on research questions. 
• Mixes or integrates the two forms of data by combining them 
sequentially or embedding them one within the other 
• Gives priority to one or to both forms of data 
• Uses these procedures in a single study or in multiple phases of a 
program of study 
• Frames these procedures within philosophical worldviews and 
theoretical lenses and 
• Combines the procedures into specific research designs that direct the 
plan for conducting the study. 
 
There are times when qualitative research may be best, because the 
researcher aims to explore a problem, honour the voices of participants, map 
the complexity of a situation and convey multiple perspectives of participants. 
(Creswell and Clark, 2007a) 
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At other times quantitative research may be best because the researcher 
aims to understand the relationship between variables or determine if one 
group performs better on an outcome than another group (Creswell and 
Clark, 2007a). 
 
We know that qualitative data provides a detailed understanding of a problem 
while quantitative data provides a more general understanding of a problem.  
Both approaches have their limitations and each provides a different 
perspective.  The limitations of one method can be offset by the advantages 
of the other. 
Table to show the Contemporary “Core” Characteristics of 
Mixed Methods Research. (Teddlie and Tashakkori, 2012) 
Table 15 Core characteristics of MMR 
Characteristic 
Number 
Description of Characteristic 
1 Methodological eclecticism 
2 Paradigm pluralism 
3 Iterative cyclical approach to research 
4 
Set of basic “signature” research designs and analytical 
processes 
5 
Focus on the research question (or research problem) in 
determining the methods employed within any given study 
6 Emphasis on continua rather than a set of dichotomies 
7 
Emphasis on diversity at all levels of the research 
enterprise 
8 
Tendency towards balance and compromise that is implicit 
within the “third methodological community” 
9 
Reliance on visual representations (e.g., figures, 
diagrams) and a common notational system 
 
This dynamic approach to study design is characteristic of the evolving field 
of MMR where there are on-going debates about the typology and 
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classification of designs and approaches.  Some researcher are even 
concerned that the field is moving towards a convergence that will stifle the 
expression of diverse perspectives and reduce MMR to a set of techniques 
and procedures (Leech, 2010) but the common characteristics of MMR such 
as eclecticism, diversity and pluralism make this unlikely (Teddlie and 
Tashakkori, 2012). 
Discussion: The Critical Appraisal of Mixed Methods Studies 
How can we ensure that the mixed methods research studies are of 
sufficiently high quality to be included in the evidence base for their field?  If 
the criteria demanded by qualitative and quantitative researchers are based 
upon different understandings of ‘knowledge’ and ‘knowing’, how can such 
trials meet their understandings of ‘good evidence’? 
  
Quality criteria differ for qualitative and quantitative methods because they 
have different underlying assumptions and aims.  Studies using different 
methods are therefore typically subject to quality appraisal using different 
tools.  These tools cannot easily be adapted to assess mixed methods 
studies and so new tools have been developed for systematic reviews which 
include both qualitative and quantitative studies per se (Bishop and Holmes, 
2013). 
 
One research group (Heyvaert et al., 2013) has recently appraised the 
existing critical appraisal frameworks (CAF’s) and their paper is reviewed 
below.  They found 13 unique CAFs that had been developed to evaluate the 
methodological quality of primary MMR articles published between 2004-
2009 (Heyvaert et al., 2013).  Their paper provides an overview of the 
available Critical Appraisal Frameworks (CAFs) developed to evaluate the 
methodological quality of primary MMR articles.  They also compare and 
critically evaluate the quality criteria proposed in these frameworks. 
The Critical Appraisal of Mixed Methods Studies (Heyvaert et al., 2013) 
Because a mixed methods study is more than just the sum of the individual 
qualitative and quantitative strands of the study the combined application of 
qualitative and quantitative critical appraisal criteria is most likely not 
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sufficient to evaluate the methodological quality of a primary MMR article. 
(Heyvaert et al., 2013) 
 
The setting for this study is an Educational Science Research Group, at a 
University in Belgium.  The research question of this paper is ‘Can we 
construct a CAF that provides clear guidelines on how to critically evaluate 
mixed methods research so that they primary MMR studies can be included 
in systematic reviews without compromising review quality?’   
 
The authors take pragmatism as their mixed methods philosophical stance, 
advocating the integration of quantitative and qualitative methods within a 
single study from a question-driven philosophy.  They argue that the 
construction of a critical appraisal framework instrument should include the 
fact that it is easy, quick and clear in it’s use. 
 
This implies that one should apply the best-suited combination of methods 
and modes of analysis to answer the posed research question(s).  
Emphasising processes of abduction, intersubjectivity, and transferability 
(Morgan, 2007), pragmatism offers the researcher alternatives to the 
dichotomous choice between (post) positivism and constructivism, driven by 
the question of utility. 
 
As well as searching academic databases the search was extended by 
focusing on grey literature databases and dissertations and theses 
databases.  In addition they conducted a hand search of 10 journals with a 
tradition of providing information on MMR methodology.  They searched 
backwards by searching the reference lists of all identified relevant articles 
and forwards by searching three citation databases.  Authors of retrieved 
relevant studies and MMR experts were contacted regarding any additional 
published or unpublished work.  There were no restrictions on the language 
of published work and search strings were combined using Boolean logic. 
 
It is unlikely that important relevant studies were missed as by searching 
published and unpublished work across a wide variety of sources they 
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included data that characterised MMR. The first author conducted the search 
for articles.  An agreement check was conducted with a second and third 
author were necessary.  The inter-rater agreement was 99.93% 
 
Only publications reporting on CAFs developed to evaluate the 
methodological quality of primary MMR articles were included.  Studies that 
used the same CAF were excluded.  1,4200 articles were involved in the 
check and from this the 13 unique CAF’s for evaluating the methodological 
quality of primary MMR articles were chosen and their content categorised 
using a constant comparative method.   
 
In the opinion of the investigators they included the criteria that are 
necessary to investigate MMR.  Some are generic for the critical evaluation 
of primary research studies (post positivist assumptions) and some are 
specific to MMR. 
 
Using a constant comparative method they generated 13 headings that 
group similar criteria of the retrieved frameworks: 
 
1. Criteria for the qualitative part of the study 
2. Criteria for the quantitative part of the study 
3. Criteria for mixing and integration of methods 
4. Rationale for mixing methods stated 
5. Theoretical framework 
6. Research aims and questions 
7. Design 
8. Sampling and data collection 
9. Data analysis 
10. Interpretation, conclusions, inferences and implications 
11. Context 
12. Impact of investigator 
13. Transparency 
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They found that there were large differences between the numbers of 
domains included in the respective frameworks.  For all of the CAFs the 
procedures domain was most extensively described 
 
Their analysis of the retrieved CAF’s was an inductive one, generating 
headings that group similar criteria of the retrieved frameworks by applying a 
constant comparative method.  Having done so they then discuss the idea 
that their framework could be used to carry out a deductive analysis. 
 
• Standard protocols turned out to be lacking and the substantial 
differences between the construction of the 13 frameworks and the 
included quality criteria can be observed. 
 
• The two criteria appropriateness of mixing qualitative and quantitative 
research components and providing a rationale for conducting MMR 
should be included in each CAF for evaluating MMR articles. 
 
• It is not sufficient to merely apply critical appraisal instruments for the 
separate qualitative and quantitative strands, the strands should be 
appropriately mixed in order to answer the posed research question 
and the overall study should be coherent and insightful. 
 
There are three possibilities when constructing a CAF: 
 
1. It may not be possible or desirable to construct a Universal CAF due 
to the diversity of published studies. 
 
2. A set of general criteria that should minimally be addressed in each 
primary MMR study could be provided but each secondary researcher 
could add criteria to this set based on the type of the study and their 
philosophical orientation. 
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3. The secondary researcher can pick and choose criteria, from a larger 
pool, to compose a set of criteria and account for this choice based on 
the type of study and their philosophical orientation. 
 
This field is novel and still being developed and this paper makes a 
contribution to that field especially as they acknowledge that their identified 
criteria can be used to continue the dialogue on potential and necessary 
elements to be included in a future check list. 
 
The main limitation of the study was the cut off point for data collection as 
December 31st 2009 and many of the frameworks mentioned are being or 
have been updated for example Pluye et al, whose 2009 framework was 
used in this paper and who have since gone on to produce the MMAT (Pace 
et al., 2012). 
 
Mixed Methods in CAM Research: A Systematic Review of Studies 
Published in 2012 (Bishop and Holmes, 2013). 
 
This recent paper discusses the importance of viewing mixed methods from 
a philosophical perspective, in order to address the tensions inherent in 
mixing qualitative and quantitative methods, but the authors do not make 
their own perspective clear.   It helps to describe the prevalence of MMR for 
CAM in recent years. 
 
A quantitative methodology is used and the method is a systematic review 
with the aim of describing the major mixed methods designs and their use in 
CAM research; to identify the strengths and limitations of mixed methods 
studies published in the CAM journals and to suggest strategies for 
improving the design, conduct and reporting of future MM CAM research. 
 
It is unlikely that important papers were missed although the selection 
procedure was only systematic for the year of publication (2012) selected 
and focused on (then) current mixed methods research.  All the studies 
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published in the top 10 integrative and complementary medicine journals 
were screened. 
  
 Journals were selected according to impact factor assuming that they are 
the most widely read and have the most influence on the literature.  Full texts 
as well as titles and abstracts were searched using a definition of MMR that 
was a quite minimal.  Although only one researcher collected the articles, 
10% were checked by a second researcher to ensure they were suitable for 
inclusion   
 
Ten of the 95 articles reported on studies using a single method but 
described how this related to another study, which used a different method.  
In nine of these cases it was possible to locate and include the article 
reporting the related study. 
 
Studies were also screened for inclusion based on the criteria set out in the 
screening questions of the quality appraisal tool The Mixed Method Appraisal 
Tool (MMAT) (Pace et al., 2012).  This means that the selected studies were 
appraised using a framework that was also used to select them.  It is also 
interesting that the researcher selected this tool although it does not included 
a domain about the philosophical orientation of the study which was an 
important part of the research question and one of the findings of the study. 
 
The MMAT results suggest that some mixed methods elements were of good  
quality and the quantitative components were generally of a higher quality 
than the qualitative components.  In the majority of studies the mixed 
methods design was relevant to the research questions and the qualitative 
and quantitative components were integrated at some stage to address the 
research question.  Often this integration occurred at the interpretation stage 
but sometimes it occurred during data analysis. 
 
• Only 5% of studies acknowledged or reflected on the limitations of 
their mixed methods design and none of the studies acknowledged or 
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addressed the philosophical tensions involved in a mixed methods 
research project. 
 
• Quantitative studies dominated the top 10 CAM journals in 2012 
(84%) of all published papers. 
 
• 4% of papers reported mixed methods studies while just 1% reported 
purely qualitative methods alone.  The remaining 11% of papers did 
not report primary research findings. 
 
• Of the mixed methods studies the most common study design for 
qualitative components was ethnography (65%).  Qualitative studies 
also used phenomenological methods (24%), qualitative description 
(6%), grounded theory (2.5%) and qualitative case study (2.5%). 
 
• The most common study design for quantitative components was an 
incidence or prevalence study (72.5%) following by RCT (12.5%), 
cross-sectional analytical study (6%), case report (4%), cohort study 
(2.5%) and case series (2.5%) 
 
The MMAT distinguishes between four major mixed methods designs: 
sequential exploratory, sequential explanatory, triangulation and embedded.  
These designs have been described in detail by (Creswell and Clark, 2007a). 
 
The insights from this review lead us into the next section which explores the 
way in which a pragmatist philosophical perspective can help to reconcile the 
use of quantitative and qualitative methods within a single study.   
 
In future CAM researchers might consider pragmatism as a way of 
addressing the philosophical challenges of mixed methods research…. in 
essence a pragmatic perspective involves judging a piece of research on the 
extent to which it achieves its stated external goals.  Applying pragmatism, a 
qualitative component might be judged on the extent to which the findings 
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enable an intervention to be delivered in a way that respects and engages 
patients; a quantitative component might be judged on the extent to which it 
provides persuasive evidence that leads to policy makes funding an 
intervention. (Bishop and Holmes, 2013) 
 
Summary	  
What	  is	  MMR?	  	  How	  do	  I	  describe	  my	  study	  and	  ensure	  transparency	  of	  
reporting?	  
 
The application of complementary medicine to a conventional medical fertility 
unit presents challenges regarding the incompatibility of methods thesis, 
which stated that it is inappropriate to mix qualitative and quantitative 
methods due to fundamental philosophical or epistemological differences 
between the paradigms underlying those methods. 
 
Mixed Methods Research based upon a Pragmatist world view offers a way 
to reconcile these dualisms based upon the compatibility thesis (Teddlie and 
Tashakkori, 2012). Mixed Methods research is the type of research in which 
a researcher combines elements of qualitative or quantitative research 
techniques for the purpose of breadth and depth of understanding and 
corroboration. (Creswell and Clark, 2007a) 
 
Bishop (Bishop and Holmes, 2013) highlights the way that we can  see MMR 
from as both a philosophical perspective (as a methodology) as well as (from 
a technical perspective) a method. 
 
In mixed methods the researcher (Creswell and Clark, 2007a): 
• Collects and analyses persuasively and rigorously both qualitative and 
quantitative data based on research questions. 
• Mixes or integrates the two forms of data by combining them 
sequentially or embedding them one within the other 
• Gives priority to one or to both forms of data 
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• Uses these procedures in a single study or in multiple phases of a 
program of study 
• Frames these procedures within philosophical worldviews and 
theoretical lenses and 
• Combines the procedures into specific research designs that direct the 
plan for conducting the study. 
 
The reporting of such studies must include the different quality criteria for 
quantitative and qualitative studies as well as addressing the philosophical 
tensions.  Other concerns that need to be addressed have been identified as,  
the skills needed by the researcher and the tension between the creative and 
imaginative use of MMR, compared to the desire to unify and characterise 
this emerging field  (Teddlie and Tashakkori, 2012) 
 
Guidelines for designing and reporting MMR have been suggested in a 
systematic study (Heyvaert et al., 2013) and they include 13 headings that 
group similar criteria of the retrieved frameworks: 
 
1. Criteria for the qualitative part of the study 
2. Criteria for the quantitative part of the study 
3. Criteria for mixing and integration of methods 
4. Rationale for mixing methods stated 
5. Theoretical framework 
6. Research aims and questions 
7. Design 
8. Sampling and data collection 
9. Data analysis 
10. Interpretation, conclusions, inferences and implications 
11. Context 
12. Impact of investigator 
13. Transparency 
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A study (Bishop and Holmes, 2013) that focused on studies in the field of 
CAM used a quality appraisal tool The Mixed Method Appraisal Tool (MMAT) 
(Pace et al., 2012).  Attention to the criteria used in both these tools should 
be sufficient to ensure the quality and transparency of the MMR in this thesis. 
Conclusion	  
Although MMR is a relatively recent and quickly evolving ‘third paradigm’ of 
methods and methodology there are already some systematic studies of the 
field and thoughtful discussions of the philosophical debate available to guide 
the researcher engaged in this field.  The study of CAM is especially 
compatible with MMR due to the wide range of outcomes being measured 
that can include both quantitative and qualitative domains of knowledge. 
 
Limitations	  	  	  
This section is not a systematic review of the literature on mixed methods 
research and the conclusions reached must be viewed as both tentative and 
provisional. 
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Reflections on The Limitations of the Literature 
Review Chapter 
This literature review has evolved over time to become nine discrete sections 
each one dealing with an aspect of the thesis.  It is a mixture of narrative 
reviews and systematic qualitative reviews as summarised in Table 3 The nine 
distinct reviews in Chapter 1. 
 
It is also a record or narrative of the development of the methodology and 
philosophical foundation of the thesis and this will be further explored in 
Chapter 2. 
 
 There is therefore a tension throughout Chapter 1 between the need for a 
systematic approach to the literature on each topic and the exploratory 
nature of the way the thesis was written in an iterative cycle of reading, 
writing, feedback, response to feedback as writing and this has explained as 
a model in Figure	   1	  Model	   to	   show	   the	   development	   of	   the	   researcher	  world	  view. 
 
Most of the nine sections were not written as systematic qualitative reviews 
and this deficiency as been acknowledged and to some extent addressed 
(post viva) by a closer attention to theory, a more transparent reporting of 
search strategies and a reflective commentary at the end of each  of the nine 
sections. 
 
It was also recognised post-viva that it is especially important to conduct a 
systematic literature review in this field (CAM) because it works as a 
mechanism to facilitate interdisciplinary collaboration and a more integrated 
understanding of health (Karunananthan et al., 2009). 
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The benefits of conducting a more systematic literature review would have 
included a more systematic analysis leading to the generation of credible 
theoretical insights from this thesis.  These theoretical insights would be of 
greater use in the design of clinical trials for CAM therapies if they have been 
generated systematically and that is a primary goal for this field of research. 
 
However this thesis has made different contribution in that it has explored the 
methodological issues around the trial design and philosophical worldview in 
great detail and used the literature reviewed to stimulate theoretical 
sensitivity, to stimulate questions, to direct theoretical sampling (Silverman, 
2013) in order to develop a thematic analysis that differs from the existing 
literature.  
 
On balance the need to incorporate a more systematic approach has been 
acknowledged and will be an important aspect of any published work derived 
from this thesis and it will continue to be combined with the close attention to 
theory and philosophy that I have already begun to develop. 
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Chapter 2 - Methodology 
Introduction 
The quality of work is dependent upon consistent reflection on the dynamics 
between research question, philosophical assumptions and methodology 
(Mesel, 2013). 
 
This section aims to describe the methodology used in this thesis and explain 
the reasons for choosing it.  It will then be evaluated using the appropriate 
frameworks and discussed against suitable criteria for both ‘rigour and 
relevance’ (Lewith et al., 2010).   
 
The pragmatic worldview that became the central theme of this thesis has 
been made explicit, and has four broad features: it is concerned with the 
consequences of actions; it is problem centred, it is pluralistic in its approach 
to methodology and it is orientated towards “what works” and practice 
(Creswell and Clark, 2007a). 
 
The choice of a mixed methods approach and the use of Thematic Analysis 
(TA) (Braun and Clarke, 2006a) were guided by this pragmatic world view.  
However, in an iterative process of reflection and rewriting, the recognition of 
the pragmatic worldview also occurred while researching the theoretical 
foundations of mixed methods research and the use of TA as a method. 
 
Researchers who wish to employ mixed methods in this way need to employ 
a philosophical strategy to clarify their inclusion of data from two different 
paradigms and this section describes the development of that strategy for 
this thesis. 
 
Teddlie and Tashakkori (Teddlie and Tashakkori, 2012) recognise the 
connections between epistemological and ontological assumptions as one of 
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the main challenges for mixed methodologies and advocate what they call 
paradigm pluralism:  
 
‘This implies that mixed methods does not define ownership of a certain 
methodology to a certain paradigm, and second, opens up for multiple 
frameworks or philosophical paradigms even within the same study.’ 
(Mesel, 2013) 
 
This pluralistic approach seemed especially appropriate for this thesis 
because it sought to integrate a complementary medical approach with a 
traditional medical approach and represented a meeting point of two 
paradigms. 
Pragmatism	  As	  The	  Guiding	  Principle	  For	  The	  Study	  	  
Pragmatism does not mean ‘try anything that works’ it should be a 
philosophically informed approach to research. But research seldom begins 
with a set of philosophical assumptions, and rather usually with a defined 
problem and a set of questions that attempt to provide answers for the 
problem at hand (Morgan, 2007).  These research questions determine the 
method that is chosen to answer these questions.   
 
Underlying this process, however, is a set of (acknowledged or 
unacknowledged) philosophical assumptions that indirectly define how the 
research object is viewed, what research questions are asked and what 
methods are chosen.  Mesel believes that acknowledging this bottom-up 
perspective allows for better communication between potentially 
incommensurate positions by adopting a pragmatic approach that is closer to 
everyday research (Mesel, 2013). 
. 
Explicit philosophical reflection is especially important if this bottom up 
pragmatic approach is explicitly adopted in order to ensure transparency and 
internal consistency. 
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Mixed	  Methods	  Research	  And	  The	  Reasons	  For	  Choosing	  MMR	  For	  This	  
Thesis.	  
 
It is necessary to be explicit about the reasons for choosing to use mixed 
methods and the framework chosen here is that of Bryman (Bryman, 2006b) 
because it offers a more detailed list of researchers’ reasons than the earlier 
model developed by Greene et al (Greene et al., 1989).  The Bryman 
typology here is adapted from a table from (Creswell and Clark, 2007a) page 
62-63. 
 
The choice of a framework to evaluate the use of MMR was also guided by 
this author’s philosophical stance.  Researchers (Greene and Hall, 2010) 
have identified five stances on mixing paradigms whilst mixing methods: 
purist, complementary strengths, dialectic, aparadigmatic, and pragmatism 
as an alternative paradigm.  The stance adopted in this thesis is pragmatism. 
 
Therefore the chosen frameworks of Creswell and Clarke (Creswell and 
Clark, 2007a) are used in this study as they are pragmatic frameworks with a 
strong orientation towards philosophical assumptions (Heyvaert et al., 2013). 
Their list is therefore likely to include an emphasis on ‘what works’, ‘what is 
feasible’, ‘what is the most appropriate tool’ and to be driven by the research 
question. 
 
Triangulation  
Triangulation for greater validity refers to the traditional view that quantitative 
and qualitative research might be combined to triangulate findings in order 
than they may be mutually corroborated.   
 
Fielding and Fielding (Fielding and Fielding, 1986) suggest that the use of 
triangulation should operate according to ground rules: 
1. Always begin from a theoretical perspective or model 
2. Choose methods and data that will give you an account of structure 
and meaning from within that perspective. 
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For the current study the chosen methods, if full data sets were available, 
would have provided insights into both the clinical efficacy as well as the 
patient’s experience of quality of life during the trial.   Safety data from the 
trial could have been added to the existing portfolio held by the manufacturer 
and the cost of treating infertile women with Ovarium compositum as an 
additional therapy could be estimated. 
 
It was necessary to establish the external context of the trial, i.e. how do 
homotoxicologists treat infertility? How do patients feel about taking part in a 
trial where they might receive a placebo?  How do clinic staff feel about 
hosting such a trial? Qualitative phases early in the protocol design helped to 
move the project forward.  Some of the problems that were encountered 
during recruitment were predicted in the early qualitative phases and perhaps 
should have alerted the researcher to the need to establish a better line of 
communication with the clinic staff in Jersey. 
 
In the final analysis the triangulation attempted to explore a different 
question, why is it difficult to recruit women who are undergoing infertility 
treatment to a clinical trial? 
 
Offset  
Offset refers to the suggestion that the research methods associated with 
both quantitative and qualitative research have their own strengths and 
weaknesses so that combining them allows the researcher to offset their 
weaknesses to draw on the strengths of both.   
 
In this study the final qualitative strand, (the investigation into the work 
related concerns of women undergoing infertility treatment), seeks to offset 
the weaknesses in the thesis caused by lack of the planned quantitative data.  
The strength of the first and second qualitative strands is that they can help 
us to understand the perceptions of patients and practitioners towards 
infertility and it’s treatment using homoeopathy or homotoxicology. 
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 The methods used in the quantitative strand have the weakness of being 
unable to identify the reasons for recruitment difficulty, that information has to 
be sought using qualitative methods.  
 
The strength of the quantitative strand is that an RCT model can be used to 
measure the difference between the effect of the placebo and active 
medication on the fertility outcomes of trial participants. 
 
Completeness   
Completeness refers to the notion that the researcher can bring together a 
more comprehensive account of the area of inquiry in which he or she is 
interested if both quantitative and qualitative research methods are 
employed.   The pragmatic worldview would be that both forms of knowledge 
are generated through the transactions of all participants with their natural 
and social environment.  To understand that knowledge we need to be able 
to use language and concepts that would be understood by all the 
participants.  As Cornish would say: 
 
Lay people and scientists alike construct knowledge in the context of action: 
knowledge guides action and action feeds back into knowledge construction. 
(Cornish and Gillespie, 2009) 
 
Process 
Quantitative research provides an account of structures in social life but 
qualitative research provides a sense of process.  In this study the 
researcher used qualitative research to explore the patient’s perspective on 
their infertility treatment and how it might reveal a conflict with their identity 
as both a treatment seeker and an employee.   An understanding of the 
process of taking part in infertility treatment is sought in the data from the 
online support forums.  The process of treating infertility with CAM therapists 
was explored using a practitioner questionnaire and the process of taking 
part in a randomised placebo controlled trial was explored using a patient 
questionnaire and by talking to clinic staff at The Bridge Centre. 
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Different Research Question 
This refers to the argument that quantitative and qualitative researches can 
each answer different research questions.  In this study the questions that 
were approached with a quantitative method were related to the clinical 
efficacy of the trial medication: ‘What is the effect of Ovarium compositum as 
an additional treatment on fertility outcomes in infertile women undergoing 
treatment?’ 
 
The questions that were asked from a qualitative perspective included: ‘how 
do homotoxicologists treat infertility?  Will women agree to be randomised?’ 
Why is it difficult to recruit women to a trial when they are already undergoing 
infertility treatment?  How do women experience balancing work with 
infertility treatment?’  
 
Explanation 
Explanation refers to when one line of research is used to help explain 
findings generated by the other.  In this case qualitative research were used 
to seek an explanation for the poor recruitment to the quantitative phases of 
the design. 
 
Unexpected Results 
Surprising results generated by one can be understood by employing the 
other.  In this case it is widely assumed that infertile women are highly 
motivated to seek treatment (Brandes et al., 2009) and therefore it was 
surprising that women were not more willing to participate in the trial of 
Ovarium compositum.  The ideal qualitative follow up would have been 
targeted at those same women but as this was not possible then the internet 
forums provided some data on the experiences of women in a similar 
situation. 
 
Instrument Development 
This refers to contexts in which qualitative research is employed to develop 
questionnaire and scale items – for example, so that better wording or more 
comprehensive closed answers can be generated.  The results of my 
METHODOLOGY 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   218	  
thematic analysis could be used in the future for these purposes.  Also the 
use of the non-validated EHIQ would have provided useful data to its 
authors. 
 
Sampling 
This refers to situations in which one approach is used to facilitate the 
sampling of respondents or cases.  The sample of participants for the 
quantitative strand was dictated by the infertility unit and did not depend upon 
the results of the early qualitative strands. 
  
Credibility 
Refers to suggestions that employing both approaches enhances the 
integrity of findings.  The planned trial design would have provided results or 
an enhanced understanding that would have been of interest to both medical 
and CAM practitioners.  The chosen methodology would have given the 
thesis credibility both as a clinical trial and as a sensitive exploration of the 
participants’ perspectives. 
 
The actual thesis sought to regain credibility (as a thesis) by using qualitative 
research to explore the reasons for poor recruitment. 
 
Illustration 
Refers to the use of qualitative data to illustrate quantitative findings, often 
referred to as “putting meat on the bones” of “dry” quantitative findings.  In 
this thesis the ‘dry bones’ were really the ‘non-findings’ and qualitative 
analysis was needed to make those non-findings useful or any conclusions, 
drawn from the poor recruitment, credible. 
  
Utility Or Improving The Usefulness Of Findings 
The suggestion that combining the two approaches will be more useful to 
practitioners and others.  It is of little use to say that women are reluctant to 
participate in trials about infertility unless we can explain why.   
 
Diversity Of Views 
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Firstly this means to combine the researchers’ and participants’ perspectives, 
and secondly, to reveal meanings amongst research participants through 
qualitative research.  This thesis sought to explore the diversity of views in 
three different contexts: firstly amongst practitioners using homotoxicology to 
treat infertility; secondly the views of patients and staff at a London Infertility 
Unit about treating infertility with CAM or mainstream medicine and about 
being randomised to a trial; thirdly the diversity of views of women about their 
infertility experience were sought in the internet forum. 
 
Enhancement Or Building Upon Quantitative And Qualitative 
Findings 
The enhancement of findings from one methodology by findings from another 
methodology is the unifying theme in the choice of a MMR.   
 
Description	  Of	  The	  Structure	  Of	  MMR	  Used	  In	  This	  Thesis	  
Introduction 
This section aims to further describe the chosen methodology and locate it in 
the field of Mixed Methods Research (MMR). 
This project has four strands, a strand is a component of a study that 
encompasses the basic process of conducting quantitative or qualitative 
research: posing a question, collecting data, analysing data, and interpreting 
results based on that data (Teddlie and Tashakkori, 2009). 
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The four distinct strands that can be identified in this thesis are shown below: 
Strand Methodology Method 
1st Qualitative A questionnaire of practitioners 
2nd Qualitative A questionnaire of patients, a 
discussion group and questionnaire of 
nurses 
3rd QUANTITATIVE 
(qualitative embedded) 
An RCT trial and quality of life 
questionnaire of patients 
 
4th QUALITATIVE A thematic analysis of data from an 
internet forum 
Table 16 The study design 
 
It is important that each strand has clear research objectives or a research 
question and these are found in each strand and are summarised below:  
 
1. A practitioner survey to investigate the choice of medication to use 
in a randomised controlled trial of homotoxicology to treat female 
infertility  
2. To investigate practitioner perceptions of the cause and treatment 
of infertility.  
3. To explore the role of the CAM practitioner in treating infertility 
 
Strand 2 there are two qualitative research objectives: 
1. Will it be possible to recruit women to a double blind randomised 
placebo controlled trial of a homoeopathic product and  
2. What will be the likely attitudes of the staff of the clinic towards such a 
trial? 
Strand 3  - this is framed as a qualitative objective (1 with prior knowledge of 
the outcome) but it could also be framed as a quantitative research question 
(2): 
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1. Is it possible to show that Ovarium compositum can improve the 
fertility outcomes of women undergoing infertility treatment at the 
Assisted Reproduction Unit of Jersey General Hospital? 
2. What is the specific effect of Ovarium compositum on the fertility 
outcomes of women attending an ARU at Jersey General Hospital? 
 
Strand 4 there is a clear qualitative research objective:  
1. The purpose of this study was to further investigate the reasons for 
recruitment failure that were suggested by the nursing staff at the trial 
site.   
 
The first qualitative strand was the review of homotoxicology treatment for 
infertility in the UK and the aim was to check the model validity of the 
quantitative strand.  As a preliminary stage to the design of the trial protocol it 
was deemed necessary to establish the choice of trial medication and 
method for treating female infertility by seeking a consensus of opinion from 
homotoxicologists working in the UK.  These were identified and approached 
via the annual conference of the Society of Homotoxicology, the database of 
a supplier and the British Register of Complementary Therapists.  A 
questionnaire was sent to 60 homotoxicologists and the return rate was 33%. 
Thematic Analysis (TA) was used to analyse the responses. 
 
The second qualitative strand was a feasibility study with patients and staff at 
The Bridge Centre, a private infertility clinic in London.    Gerhard et al 
(Gerhard I, 1997) attempted to design and implement a monocentric, two 
armed, randomised study at the University Hospital of Obstetrics and 
Gynaecology, Heidelberg   The trial proved impossible to implement for a 
number of reasons including the fact that only 14% of patients agreed to be 
randomised instead of the anticipated 60-70%.   
 
Potential obstacles to success were discussed with the discussion group who 
then completed a survey of nine open questions.  Their responses were 
analysed thematically create a qualitative evaluation of the data and their 
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concerns and insights used to generate a patient questionnaire.  127 patient 
questionnaires were distributed at the registration desk over a 9-month 
period.   The results of this survey were used to support the decision to pilot 
a trial at Jersey General Hospital. 
 
The third strand, quantitative with an embedded qualitative aspect, was 
originally conceived as the main focus of the study and consisted of a RCT of 
the use of Ovarium Compositum as an adjunct treatment for infertile women 
in an assisted reproduction unit.  The study was sponsored by Clinical 
Pharmacology, Barts and The London, Queen Mary's School of Medicine 
and Dentistry, Charterhouse Square, London and funded by Biologische 
Heilmittel Heel GmbH Dr. Reckeweg-Straße 2-4 76532 Baden-Baden, 
 Germany.   
 
The primary objective was to assess whether the administration of Ovarium 
Compositum as an adjunct therapy could make a significant difference to 
fertility outcomes in infertile women seeking medical intervention.  The 
second objective was to measure quality of life in women undergoing 
treatment for infertility and using Ovarium compositum.  The study was 
designed as a one centre, double blind placebo randomised controlled trial 
located at the Department of Obstetrics and Gynaecology, Jersey General 
Hospital, Gloucester Street, St Helier, Jersey, JE1 3QS, and the study period 
was intended to be twelve months. 
 
The fourth strand was a qualitative investigation into the work-related 
concerns faced by women seeking infertility treatment in the British Isles to 
investigate themes suggested by the staff at the site of the RCT phase.  This 
stage was theory driven and the choice of data and the method of collection 
were informed by the need to investigate a particular theory or hypothesis.  
The data was approached with a particular research question in mind and the 
source of the data, the online forum, was a pragmatic choice driven by what 
was available and accessible in a realistic timeframe.  It was not possible to 
work with the study site team to collect qualitative data for this stage in spite 
of several attempts to do so. 
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Mixed Methods Designs have been categorised and described (Creswell and 
Clark, 2007a) into six main designs as depending on four key decisions, (1) 
The level of interaction between the strands, (2) the relative priority of the 
strands, (3) the timing of the strands and (4) the procedures for mixing the 
strands.  
 
In this thesis the qualitative and quantitative strands are very interactive and 
the results of one strand feeds directly into the design of the next.  At the 
start of the study priority was given to the importance of the quantitative data 
and the role of the qualitative data was to support the collection of 
quantitative data.  These priorities changed as the trial progressed and 
became explanatory and exploratory in nature. 
 
The timing was sequential rather than concurrent because each strand was a 
distinct phase in the research study.  Mixing of the quantitative and 
qualitative data occurred at the level of design as well as during the final 
conclusions to each strand and the end of the whole project. 
 
This study could be characterised as a variant of two sequential designs, the 
exploratory sequential design followed by the explanatory sequential design, 
(Creswell and Clark, 2007a). 
 
The first two strands begins with and prioritizes the collection and analysis of 
qualitative data and building from those results the researcher conducts a 
second quantitative phase (strand three), however because of the failure of 
trial recruitment the study was not complete and began an explanatory 
sequential design where the quantitative data (or lack thereof) was the 
starting point for a qualitative phase to explain the quantitative findings. 
 
This is congruent with the pragmatist world view of the researcher where: 
Organisms are constantly adapting to new situations and environments.  Our 
thinking follows a dynamic homeostatic process of belief, doubt, inquiry, 
modified belief, new doubt, new inquiry…in an infinite loop, where the person 
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or researcher (and research community) constantly tries to improve upon 
past understandings in a way that fits and works in the world in which he or 
she operates.  The present is always a new starting point.(Johnson and 
Onwuegbuzie, 2004) 
 
The study does not meet the definition of a multiphase design (Creswell and 
Clark, 2007a) because the purpose of those designs is to implement multiple 
phases to address a wider  objective such as large-scale program 
development and education.  Although strongly informed by a philosophical 
worldview this thesis did not employ a transformational design as it was not 
collecting and analysing data within a transformative theoretical framework, 
for example feminism, that guided the methods and decisions.  It might be 
better described as a pragmatic design that views human inquiry as being 
analogous to experimental and scientific inquiry:  
 
We all try out things to see what works, what solves problems, and what 
helps us to survive.  We obtain warranted evidence that provides us with 
answers that are ultimately tentative (i.e., inquiry provides the best answers 
we can currently muster), but in the long run, use of this “scientific” or 
evolutionary or practical epistemology moves us towards larger Truths  
(Johnson and Onwuegbuzie, 2004). 
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The	  Methods	  Used	  In	  Each	  Strand.	  
	  Methodology	  for	  Strand	  One	  	  (2006)	  
Introduction 
The first qualitative strand was the review of homotoxicology treatment for 
infertility in the UK.  As a preliminary stage to the design of the trial protocol it 
was important to establish the choice of trial medication and method for 
treating female infertility by seeking a consensus of opinion from 
homotoxicologists working in the UK.  This approach is also suggested in the 
MVHT (Mathie et al., 2012) in order to ensure that the trial has external 
validity and that it is representative of the way the patients would be treated 
in a homeopathic clinic. 
 
The sample practitioners were identified and approached via the annual 
conference of the Society of Homotoxicology and the British Register of 
Complementary Therapists. At the time that this study was being designed 
homotoxicologists were self-regulating in the UK and the registration body 
was the British Register of Complementary Therapists.  UK practitioners 
using homotoxicology to treat infertility, registered Homotoxicologists and 
practitioners attending an annual symposium were asked to complete a 
questionnaire.  The questionnaire is included in the appendix Figure 4 
Questionnaire for practitioners from strand 1 
 
The primary aim of this questionnaire was to find out how Homotoxicologists 
currently practicing in the UK would treat infertility.  The results were used to 
inform the trial design of a pilot study of Ovarium compositum.  The 
secondary aim of this study was to explore the role of Thematic Analysis as a 
research tool to understand which practices, beliefs and concepts the CAM 
approach shares with the mainstream medical treatment of infertility and 
where it diverges.  
 
 
Problem formulation 
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There are multiple approaches to using homoeopathy and homotoxicology to 
treat infertility and each CAM therapist may also utilise more than one 
therapy or approach.  In order to design a trial with both internal and external 
validity it was necessary to understand three things: How homotoxicology 
might be used to treat infertility in practice?   What is the role of the CAM 
practitioner in the treatment of infertility?  Is there a specific treatment that 
can be given without a consultation and in the absence of an individualised 
prescription? 
 
Purpose or Research Question 
1. A practitioner survey to investigate the choice of medication to use in 
a randomised controlled trial of homotoxicology to treat female 
infertility  
2. To investigate practitioner perceptions of the cause and treatment of 
infertility.  
3. To explore the role of the CAM practitioner in treating infertility 
 
Methods 
A paper questionnaire with both open and closed questions (see Figure 4 
Questionnaire for practitioners from strand 1.) 
 
Data collection methods 
The questionnaire was designed to firstly establish practitioner opinions 
regarding a specific case study and then to investigate their approach 
towards treating infertility in general.  The case study used was characteristic 
of the patient group that will be enrolled in the pilot study. 
The second version of the questionnaire was created when it became 
apparent that the sponsor might be Heel and therefore the Heel products 
needed to be included in the protocol. 
 
The questionnaire was composed of four questions:  
• Question one asked for tick options to five protocols for a case study 
of female infertility, participants were allowed to select more than one 
option.   
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• Question two asked them to recommend a protocol for treating female 
infertility with homotoxicology.    
• Question three asked them to recommend a protocol for treating male 
infertility with homotoxicology.   
• Question four was an open question asking if they had any other 
recommendations. 
 
Data collection instruments and technologies 
The case study was based upon a real life example of a successfully treated 
case of female infertility in the researcher’s own practice.  The choices of the 
five protocols for the case study were based upon the researcher’s personal 
experience of treating female infertility and therefore introduced some 
treatment bias into the questionnaire.  The protocols chosen had to include 
possible trial medications from a list of three manufacturers, Heel, Nelsons 
and Guna.  This bias was balanced by allowing an open response to 
questions two, three and four. 
 
Qualitative approach and research paradigm 
The results of questions 2-4 of the practitioner questionnaire were analysed 
using a qualitative approach, content thematic analysis (Braun and Clarke, 
2006a).  This approach was chosen in order to organise the data into themes 
that can be used to describe the plurality of approaches used by individual 
therapists to treat infertility and to explore their understanding of the causes 
of the condition.  The results are discussed in more detail in the results 
chapter  (see The	  Results	  Of	  The	  Practitioner	  Questionnaire). 
 
This sample of therapists has a spectrum of diagnostic skills ranging from the 
conventional medical approach to alternative systems of healing such as 
acupuncture (for sampling see below).  They will therefore have their own 
individual belief systems regarding the nature of health, disease and healing.  
Qualitative analysis of their responses should reveal some these embedded 
concepts and beliefs. 
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Sampling strategy 
The survey was posted to the 10 registered Homotoxicologists in the UK.  
They were selected from a register supplied by the Institute for 
Complementary Medicine Register or BRCP (British Register of 
Complementary Practitioners). This is the only recognized UK registration 
body for Homotoxicology.   
 
An additional 50 copies were distributed via the mailing list of one of the 
homotoxicology suppliers to target therapists using the products.  The 
mailing list consisted of CAM practitioners supplied by the UK sole 
distributors of products from Germany and Italy.  The details of the mailing 
list were not supplied to the researcher but the questionnaires were sent to 
the distributor to include with a monthly statement posted to practitioners. 
 
Delegates at the annual conference of the Society of Homotoxicology (UK) 
were encouraged to return their copies during a verbal presentation 
explaining the purpose of the study and how their responses would be used.   
 
A letter did not accompany the forms but at the top it stated: 
 
 RESEARCH PROJECT; Homoeopathy and Infertility.  Supervised by Prof 
Atholl Johnston, Clinical Pharmacology, Barts and The London, Queen 
Mary’s School of Medicine and Dentistry. 
 
The return of the form was used as implied consent to include their 
responses in the study.   
 
Researcher characteristics and reflexivity 
The researcher is a qualified homotoxicologist who was acquainted with 
many of the therapists who were participants in the study.  The protocols 
being discussed had also been included in some of the training sessions that 
she had delivered, in her role as a practitioner/teacher, to some of them.  The 
benefit of this closeness is that the researcher had a good understanding of 
the treatments that were suggested by the respondents and there was no 
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need to seek clarification of the technical terms used.  The disadvantage is 
that the researcher cannot free herself of her ‘theoretical and epistemological 
commitments’ to the context of the data (Braun and Clarke, 2006a) .  There 
is also the possibility that knowing me influenced the participants and this 
could have biased the results.  However as many of them were experienced 
CAM practitioners their responses would reflect their experience rather than 
a desire to support the study by selecting a potential sponsor from the 
options offered.   
 
Context 
Homotoxicology was relatively new to the UK at the time and some of the 
therapists were attending the conference to find out more about the use of 
homotoxicology in the UK, some of them were already registered 
homeopaths and homotoxicologists using CAM therapies in the UK 
 
Ethical issues pertaining to human subjects 
Participants in the questionnaire were not asked to reveal any of the details 
of their patients’ identity.  No patients would be identifiable as a result of the 
questionnaire.  
 
Data analysis 
The results of question 1 were counted to give a numerical count of the 
popularity of 5 different protocols.  The results of the questions 2-4 of the 
practitioner questionnaire were analysed by sorting the responses using a 
qualitative approach, content thematic analysis, according to the protocols 
suggested by (Braun and Clarke, 2006a).  The data were read to familiarise 
the researcher with the content and then the responses were printed out as 
individual slips that could be treated as codes.  The slips were then 
organised into themes in an iterative process of reading and sorting until 
coherent themes emerged.  The data was revisited and the themes explored 
and refined as part of the rewriting period in January 2013. 
 
Copy of Questionnaire 
Question One: 
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Please would you read the following summary of an infertility case and 
indicate which of the suggested protocols would, in your opinion, be 
appropriate.  You may tick more than one option. 
Case Details:  
Sex: Female, Date of Birth 13th April 1962, Age at first consultation 42 
years old 
Marital Status: Married (happily) 
Appearance: Dark haired, athletic build. 
Family history: Not available as patient was adopted.  She has 
undertaken psycho-emotional therapy regarding her adoption and is 
actively tracing her birth mother. 
Presenting condition:  Failure to respond to Gonadotrophins injections 
for IVF treatment.  An earlier IVF treatment had resulted in a successful 
pregnancy but the pregnancy was terminated following tests for 
Down’s syndrome. 
General Health is good, no menstrual difficulties, few acute infections, 
and infrequent headaches.  No financial anxieties. Regular exercise 
(horse riding), but some pain from muscles, diagnosed as lactic acid 
build-up. 
Vaccination: Hepatitis; Yellow fever, Typhoid.  Malaria treatment. 1998 
Other Health Choices: Hypnosis and Herbal treatment for high mercury 
levels. 
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Figure 4 Questionnaire for practitioners from strand 1 
Please tick the options that in your opinion are appropriate, you may chose more 
than one: 
QUESTIONNAIRE VERSION ONE 
Option 
number 
Description of Treatment 
Tick 
 
1 
Treatment of the vaccinations using potentised vaccines, 
Silica and Thuja. 
 
2 
Treatment of the hormone balance using potentised 
hormones (GUNA): 
 
FSH D6 20 drops three times a day from the 1st to the 3rd 
day of the menstrual cycle. 
 
Beta Estradiol D6 20 drops three times a day from the 4th 
to the 14th day of the menstrual cycle. 
 
Luteinizing Hormone D6 20 drops three times a day from 
the 4th to the 15th day of the menstrual cycle. 
 
Progesterone D6 20 drops three times a day from the 14th 
to the 24th day of the menstrual cycle. 
 
 
3 
 
Use of the indicated remedies: Nat Mur 6 and Sepia 6 daily 
for two weeks. 
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4 
Treatment of Miasmatic ‘Psoric’ tendency with Psorinum nosode 
and drainages. 
 
 
5 
Treatment of Pituitary-Ovarian feedback mechanism using 
complex remedy ‘G3’ (GUNA): Composition: Ovarium 
D8/D12/D30, Corpus Luteum D8/D12/D30, Pulsatilla 
D6/D8/D30, Kali Carb 6CH/30CH. 
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 QUESTIONNAIRE VERSION TWO 
 
Please tick the options that in your opinion are appropriate, you may chose 
more than one: 
 
 
Option 1:  
Remedy Manufactured by Dosage 
Frequency 
 
Syzygium 
Compositum 
-Heel 
Biologische 
Heilmittel 
Heel GmbH 
www.heel.com 
10 drops 
 
3 times daily 
Galium-heel® 
-Heel 
Biologische 
Heilmittel 
Heel GmbH 
www.heel.com 
10 drops 
 
3 times daily 
Gynäcoheel® 
-Heel 
Biologische 
Heilmittel 
Heel GmbH 
www.heel.com 
10 drops 3 times daily 
 
Option 2: Treatment Of The Declining Hormone Levels Using Potentised 
Hormones (GUNA): 
Remedy Manufactured by Dosage Frequency 
FSH D6 
GUNA srl 
www.guna.it 
20 drops 
3 times daily 
from the 1st to 
the 3rd day of the 
menstrual cycle 
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Β-estradiol D6 
GUNA srl 
www.guna.it 
20 drops 
3 times daily 
from the 4th to 
the 14th day of 
the menstrual 
cycle 
LH D6 
GUNA srl 
www.guna.it 
20 drops 
 
3 times daily 
from the 4th to 
the 15th day of 
the menstrual 
cycle. 
Progesterone 
D6 
GUNA srl 
www.guna.it 
20 drops 
3 times daily 
from the 14th to 
the 24th day of 
the menstrual 
cycle. 
 
Option 3: Constitutional Treatment and Correction of Miasmatic Tendency 
Using Classical Homeopathy 
 
Option 4: Treatment Of Pituitary-Ovarian Feedback Mechanism Using Complex 
Remedy ‘G3’ (GUNA): Composition: Ovarium D8/D12/D30, Corpus Luteum 
D8/D12/D30, Pulsatilla D6/D8/D30, Kali Carb 6CH/30CH. 
Remedy Manufactured by Dosage Frequency 
G3 
GUNA srl 
www.guna.it 
Begin with 5 
drops twice a 
day, and then 
increase by 1 
drop daily up to 
10 drops three 
times a day. 
Daily 
 
Question Two  
METHODOLOGY 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   235	  
What would you use in your practice as a well indicated homoeopathic/ 
homotoxicological protocol for treating female infertility due to declining hormone 
levels? 
 
Question Three 
What would you use in your practice as a well indicated 
homoeopathic/homotoxicological protocol for treating male infertility due to low 
sperm count? 
 
Question Four   
Are there any other lifestyle choices or changes that you would recommend to a 
patient seeking advice regarding infertility? 
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Methodology	  for	  Strand	  Two	  (2006-­‐2007)	  	  
The second strand was a qualitative study with patients and staff at The 
Bridge Centre, a private infertility clinic in London.  Patient and public 
involvement (PPI) was a political and grassroots initiative at the time that this 
study was being designed (Mockford et al., 2012), and under New Labour 
there was a greater emphasis on public and user participation in public 
services (Newman, 2001) which stressed the importance of citizenship as 
well as consumerism, responsibilities as well as rights. 
 
The idea of including the pluralistic perspectives of patients, nurses, 
researcher, practitioner in study design meets this need for research to be 
more responsive to the service users as well as endorsing Pragmatist shared 
values such as democracy, freedom, equality, and progress. 
  
Background: Gerhard et al (Gerhard I, 1997) attempted to design and 
implement a monocentric, two armed, randomised study of single 
homeopathic remedies (prescribed according to repertorisation of their 
symptoms and the selection of a remedy using the similar principle ) at the 
University Hospital of Obstetrics and Gynaecology, Heidelberg   The trial 
proved impossible to implement for a number of reasons including the fact 
that only 14% of patients agreed to be randomised instead of the anticipated 
60-70%.   
The first aim of this PhD project was to design and implement a double blind 
randomised trial of Ovarian Compositum in conjunction with an infertility clinic 
in Jersey.  Before embarking on a trial it was important to try to make sure 
that sufficient numbers of women would agree to take part.  Understanding 
their motivation for agreeing to take part in such a trial would help with the 
recruitment programme. 
Objectives:   
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1. To find out if women undergoing infertility treatment would consent to 
be randomised to a double blind placebo controlled trial and what 
might be their motivation for taking part. 
2. To investigate the attitude of women receiving infertility treatment 
towards homeopathy/homotoxicology 
3. To investigate the attitudes of clinic nursing staff towards the idea of a 
trial of a homeopathic product. 
Research Question:  
Will it be possible to recruit women to a double blind randomised placebo 
controlled trial of a homoeopathic product and what will be the likely attitudes 
of the staff of the clinic towards such a trial? 
Method: Interviews and questionnaires were used to investigate the 
attitudes of staff and patients at the clinic. 
Ethics  
Ethics approval for the patient questionnaire was granted by the Chair of the 
ethics committee at The Bridge Centre based on the understanding that an 
information sheet about homotoxicology accompanied the questionnaire.  
 
The Staff Interviews and Questionnaires 
A group interview was conducted with five nurses who then completed a 
survey of nine open questions.  Their responses were organised using 
MaxQDA and then analysed thematically to create a qualitative evaluation of 
the data.  It is acknowledged that a sample of five nurses is not enough to 
produce sufficient data to achieve saturation of themes but for practical 
reasons this was the maximum number available.  A copy of the 
questionnaire is available in appendix. 
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The Patient Questionnaire 
This patient survey took place at the Bridge Centre, London.  127 
Questionnaires and patient information sheets were distributed to the 
registration desk over a 9-month period and were completed by women who 
were waiting for their treatment.  They were able to post them back to the 
Matron of the clinic in a postage paid envelope or hand them into reception.  
A copy of the questionnaire and patient information sheet is available in 
appendix see Questionnaire for nurses at The Bridge Centre, Questionnaire 
for Patients at The Bridge Centre, and Patient Information Sheet included 
with questionnaires. 
Development	  of	  the	  Patient	  Questionnaire	  	  
The patient questionnaire ( Table 24 Table of results for patient 
questionnaire) was developed by Claire Tyson (as chief investigator of the 
trial), and was designed to investigate possible obstacles to running the trial 
such as previous treatment with homoeopathy, bias against homeopathy, 
willingness to take a placebo, willingness to take their medication at home, 
willingness to give up caffeine and peppermint, willingness to take part in a 
trial that might bring benefit to others in the future rather than immediate 
personal benefit.  	  	  
There were nine closed questions that were intended to yield a simple yes or 
no answer that could be counted rather than rich information for thematic 
analysis.  Questions 3, 4, and 9 were designed to investigate the pitfalls 
encountered in earlier studies of homeopathy for infertility (Gerhard I, 1997)  
in which women declined to be randomised to a placebo group or expressed 
a preference for homeopathy.	  	  
If the questions could be been chosen after conducting the qualitative fourth 
strand of this thesis then the concerns of working women could have been 
explored and the results used to plan the recruitment to the quantitative 
strand three.	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The questionnaire was not used with the patients in Jersey but the results of 
the questionnaire in London were used to assess the feasibility of recruiting 
women to the trial at the Jersey Site.	  	  
An attempt was made to research the social context of public attitudes to 
homeopathy in Jersey by contacting Jersey Citizens Advice Bureau and 
seeking  the contact details for homeopaths registered on the island 
(https://cab.org.je/index.php?option=com_content&view=article&id=535:hom
eopathy-1033&catid=59&Itemid=56).	  	  
Two homeopaths were identified and contact and one of them, Dr Guy Wildy 
communicated via email regarding attitudes towards homeopathy in Jersey 
(Wilding, 2012):	  	  
Q1. How long have you worked as a doctor in Jersey? 
A1: Twenty Eight Years 
 
Q2. Have you seen changes in public perceptions and attitudes towards 
Complementary and Alternative Medicine (CAM) during that time? 
A2: No change they have always been interested. 
 
Q3. Have you heard of Homotoxicology? 
A3: No 
 
Q4.  Have you helped with recruitment to any clinical trials in Jersey and if so 
what were your experiences? 
A4: No. 
 
Q5.  In your experience how often do women seeking infertility treatment 
disclose their treatment to their employers? 
A5: I do not know. 
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Q6.  What is the prevailing public opinion towards clinical trials in Jersey? 
A6: The prevailing public opinion is indifference. 
 
Q7.  What differences do you notice between patient populations in Jersey 
and the mainland UK regarding attitudes towards (i) CAM and (ii) clinical trial 
participation. 
A7: I do not know what these trials are. 
 
Q8. Do you have any insights into obstacles that might prevent patients 
enrolling in a clinical trial in Jersey?	  
A8: No obstacles unique to Jersey.	  	  
Discussion	  
The answers to the questions posed via email seem to indicate that there is 
no hostility towards homeopathy although it is acknowledged that Dr Wildy’s 
experiences may be biased towards patients who seek him out because they 
are supporters of homeopathy.  The answers generated in London were 
therefore assumed to be relevant to the situation that might be expected in 
Jersey. The major limitations of this questionnaire are the assumption that 
patients in Jersey and London will exhibit similar preferences for treatment 
and that the questions only explore practical aspects of implementing a trial 
of a homeopathic product and do not investigate the possible social and 
psychological obstacles to recruitment.	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Researcher characteristics and reflexivity 
As a researcher with a homeopathic background the researcher felt that her 
study might not be viewed as suitable for a clinic that uses assisted 
reproduction technology.   The dualisms which separate conventional from 
complementary medicine might have made it very difficult to build a working 
relationship with the clinic staff.  It was important to find out if they felt 
strongly about the use of homeopathy and if they had experience of their 
patients using it.  A negative attitude from clinic staff would create a bias in 
the study if they were consciously or unconsciously discouraging their 
patients from taking part. 
 
Sampling strategy 
London was chosen for the site of this strand of the study as it was not 
possible to access the clinic in Jersey for regular meetings due to time and 
budget constraints.  There was also an intention of expanding the study to 
include a London site if possible and this qualitative study was seen as a way 
of building a working relationship with the clinic. 
 
The sampling for this strand was pragmatist, the Matron at the Bridge Centre 
invited the nursing staff to attend the group interview and those who were 
willing and available took part.  The sampling for the patient questionnaires 
was a self-selected sample and therefore might be biased towards women 
who are interested in taking part in such a study.   
 
There is no data available on how many women chose not to take a copy of 
the questionnaire and no distinction was made between women who were 
starting treatment or women who had already received treatment and all 
replies were anonymous.  No data was collected on their age or which type 
of treatment they were undergoing. 
 
Data processing 
The data from the nurses’ questionnaires were transcribed by the researcher 
into word documents and then organised into codes using MaxQDA. 
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The data from the nurses’ interviews were transcribed as notes and used to 
supplement the creation of themes from the questionnaire data. 
 
The data from the patient questionnaires were counted manually and 
recorded on a word document in table form. 
 
Data analysis 
Thematic analysis was used to analyse the nurses’ responses into themes 
according to protocols established for that approach as before (Braun and 
Clarke, 2006a). 
 
The nurse questionnaire was deliberately open-ended so as to investigate 
their individual attitudes and understandings about their role, about 
homoeopathy and about their patient’s use of CAM.  It was hoped that new 
or surprising responses would be captured in this way and that the data 
would be rich and qualitative. 
 
The patient questionnaire was more structured and included mostly closed 
questions because it was important to obtain the answers to some very 
specific questions that made the trial feasible.  The use of a pragmatist 
framework means that the trial design is based upon an understanding of 
what is going to work in practice as well as acknowledging that the problems 
to be solved need an empirical solution acceptable to the scientific audience 
of nurses and other medical staff. 
 
 
Techniques to enhance trustworthiness 
No other researchers were approached to analyse the data and so it is 
recognised that the interpretation is subjective and that the context is the 
researchers’ own experience of meeting the nurses and working with infertile 
patients using homotoxicology. 
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The use of both group interviews and questionnaires with the nurses helps to 
make sure that the analysis is trustworthy and that themes found in the 
questionnaire are also reflected in the narrative of the meeting.  
 
By today’s definitions this approach was an example of ‘participation’ where 
people take part in a research study by completing a questionnaire or 
participating in a focus group as part of a research study.    This does not 
meet the criteria for  ‘involvement’, where members of the public 
are actively involved in research projects and in research organisations as 
joint grant holders or co-applicants on a research project.  Involvement may 
include identifying research priorities, commenting and developing patient 
information leaflets or other research materials. (INVOLVE, 2015). 
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Methodology	  for	  Strand	  Three	  (2007	  –	  2012)	  
Title:	  A	  Pilot	  Study	  Of	  Ovarium	  Compositum	  In	  Infertile	  Women.	  
Introduction 
The third strand, quantitative with an embedded qualitative aspect, was 
originally conceived as the main focus of the study and consisted of a RCT of 
the use of Ovarium Compositum as an adjunct treatment for infertile women 
in an assisted reproduction unit.  The small sample size and experimental 
nature of the trial design led to this being designated as a pilot study.  A copy 
of the protocol is included in the appendix (see Protocol	  No.:	  OVCT-­‐001) 
 
A Pilot study is sometimes confused with a feasibility study and recently 
efforts are being made to provide clearer definitions and guidelines for the 
reporting of preliminary studies (London, 2015) 
 
An early report of the findings of the research group cited above states that 
the analysis of pilot studies should be mainly descriptive, outlining well-
defined aims and objectives that highlight methodological rigor and scientific 
validity and most importantly, the lessons learned that could be useful in 
designing the main study (Dolgin, 2013) 
 
A review of the literature (Whitehead et al., 2014) found that the 
distinguishing features of a pilot study from a feasibility study are as follows:  
 
• Stricter study methodology (e.g., a justification of the sample size)  
• An intention for further work  
• Smaller version of the main study (e.g., use of a control  
group and randomisation)  
• A focus on trial processes  
 
 Whitehead believes that researchers should not use the title ‘pilot’ for a trial, 
which evaluates a treatment effect.  It was acknowledged by the trial 
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reviewers that the study was underpowered to demonstrate such an effect 
and that it’s intention but it was to test the feasibility of randomisation, and 
the use of RCT to test a homeopathic intervention.  On balance it would be 
best described as a pilot study because it included a randomised control 
group and feasibility studies do not include this. 
 
Abstract Women who experience infertility may seek help using 
complementary and alternative medicine (CAM).  There is a need for further 
research to provide an evidence base for the safety, efficacy and cost 
effectiveness of CAM.  Ovarium compositum is a preparation of homeopathic 
ingredients purporting to treat female infertility.  It is prescribed in the UK by 
registered Homotoxicologists and other clinicians.  The aim of this pilot study 
is to evaluate the effectiveness of Ovarium compositum vs. placebo in a 
randomised trial of 90 women attending an infertility clinic for ovarian 
stimulation and assisted reproduction.  The outcomes to be evaluated are 
both quantitative (response to ovulation drugs, length of time to pregnancy) 
and qualitative (quality of life).  
 
The study sponsor:  Clinical Pharmacology, Barts and The London, Queen 
Mary's School of Medicine and Dentistry, Charterhouse Square, London, 
EC1M 6BQ, UK, Tel:  +44 (20) 7882 3404, Fax: +44 (20) 7882 3408  
 
Funding:  Heel GmbH 
 
Objectives: The primary objective is to assess whether the administration of 
Ovarium Compositum as an adjunct therapy can make a significant 
difference to fertility outcomes in infertile women seeking medical 
intervention.  The second objective is to measure quality of life in women 
undergoing treatment for infertility and using Ovarium compositum. 
 
Study Design:  One centre, double blind placebo randomised controlled 
exploratory/pilot trial and two QoL questionnaires 
 
METHODOLOGY 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   246	  
Study Location: Department of Obstetrics and Gynaecology, Jersey 
General Hospital, Gloucester Street, St Helier, Jersey, JE1 3QS, Telephone 
01534 622 660 
 
Study Period: 12 Months 
 
Pharmaceutical Agents: Subjects will be randomised to Ovarium 
Compositum vs. Placebo.  Both supplied as white tablets with identical 
appearance for composition see Table 19 Treatment Formulations Table for 
active drug and Table 20 Formulation of Placebo. 
 
Route of Administration: Oral Tablet, one tablet three times a day to be 
dissolved in the mouth 
 
Duration of administration: Daily, on-going until positive pregnancy test or 
trial ends 
 
Study Duration: Expected to take 12 months 
 
Sample Size: 45 active plus 45 placebo N=90 
Non-participating women at clinic to be consented for access to data for 
comparison 
Research Question 
Is it possible to show that Ovarium compositum can improve the fertility 
outcomes of women undergoing infertility treatment at the Assisted 
Reproduction Unit of Jersey General Hospital? 
Methods 
A quantitative method using a randomised, double blind, placebo controlled 
trial design in order to measure the specific effect of Ovarium compostitum 
compared to a placebo.  A comparison group composed of women who did 
not agree to take part in the trial (i.e. a usual care arm) was planned.  If they 
would consent to have their data included in the trial it would also then be 
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possible to compare them to the outcomes in the placebo arm and generate 
a measure of the placebo effect. 
 
One of the characteristics of Pragmatism is that it places high regard for the 
reality of and influence of the inner world of human experience in action 
(Johnson and Onwuegbuzie, 2004).  This aspect can be captured using 
Quality of Life data (QoL) is also of interest and will be collected using a 
validated questionnaire the EQ-5D (Rabin and Charro, 2001) and an 
unvalidated questionnaire, that is specific to infertility,  the  Emotional Health 
in Infertility  Questionnaire (EHIQ) (Farmer, 2007).   
 
A full trial protocol is included in the appendix Protocol	  No.:	  OVCT-­‐001and the 
two QoL tools are considered in more detail in Qualitative	  Data	  Collection	   in	  Strand	  Three, see Qualitative	  Data	  Collection	  in	  Strand	  Three. 
Researcher characteristics and reflexivity 
The researcher is not based in Jersey and is not medically qualified to treat 
infertility.  She has experience of working with infertile women using 
homotoxicology and homeopathy as a CAM modality and has trained in 
clinical trial design.  As a science graduate she is familiar with the medical 
concepts involved and the language used.   
 
The researcher has adopted a Pragmatic worldview in which Pragmatism 
endorses a strong and practical empiricism as the path to determine what 
works. (Johnson and Onwuegbuzie, 2004).  Therefore this strand of the trial 
design is intended to produce data that can be triangulated with the theory 
generated in the qualitative strands (one, two, and four). 
 
As a practitioner in CAM she is familiar with the concept of placebo and the 
possible effects generated by an individualised consultation and prescription.  
The trial is designed to control for these effects by not including a 
consultation with the researcher. 
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Context 
The site for the trial is the Assisted Reproductive Unit at Jersey General 
Hospital.  Jersey is the largest of the Channel Islands and sits in the English 
Channel, closer to France than to England.  It covers 45.5 square miles and 
has a population of 98,000 (Jersey, 2012).  Jersey, Guernsey and the Isle of 
Man are part of the British Isles.  England, Scotland and Wales make up 
Great Britain, while the United Kingdom includes Great Britain and Northern 
Island.  Jersey is a British Crown Dependency.  Jersey is self-governing and 
has its own financial and legal systems and its own court of law.   Jersey was 
chosen as the site of the RCT trial because the researcher had supported the 
treatment of a patient whose treatment had initially been unsuccessful in 
producing a live birth.  After homotoxicology treatment and a successful live 
birth the lead consultant at the clinic had expressed an interest in finding out 
more about homotoxicology and it’s potential to help other patients. 
Ethics 
The researcher encountered a variety of difficulties in obtaining ethics 
approval due to Jersey’s unique legal and constitutional position.  
Clarification of the necessary route of application took some 28 months.  It 
was established that only local ethics approval is required for clinical trials 
taking place in the Channel Islands and that there is no need for MHRA 
approval in the form of Clinical Trials Authorisation (CTA) because Jersey 
falls outside the existing legal and regulatory framework (Haresnape, 2013a).   
 
The initial inquiry to the Medicines and Healthcare products Regulatory 
Agency confirmed that: 
 ‘UK clinical trial legislation does not apply in the Channel Islands.  The 
Channel Islands and the Isle of Man are self-governing dependencies of the 
British Crown, that is, Her Majesty Queen Elizabeth II is their Head of State 
but they are not part of the UK.  They are subject to European Unity 
Directives so far as trade is concerned but the inhabitants are not citizens of 
the EU…. For your clinical trial in sites in Jersey you will need local ethical 
approval and may require local regulatory approval but you do not require 
MHRA approval of a CTA.’ (Ward, 2008) 
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The response from Jersey General Hospital was positive but that they would 
prefer an opinion from an ethics committee in London first followed by a local 
application to Jersey.  Their pharmacy department pointed out that it was 
more than 10 years since they undertook any clinical trials involving 
investigational medical products (IMPs) and that they had their own ‘very out-
dated’ regulations under the Medicines (Jersey) Law 1995 and having an 
opinion from a mainland committee would give them additional confidence. 
(McCabe, 2009). 
 
The National Research Ethics Service (NRES) Queries Line were then 
approached to provide guidance in this dilemma and their response was as 
follows: 
‘Jersey is not part of the UK and the favourable opinion from the UK REC 
would not formally confer ethical approval for the study in Jersey.  Nor would 
the REC undertake any site-specific assessment of the Jersey research site 
as this is outside its remit.  It is entirely a matter for the island authorities to 
determine what process is required to include a site in Jersey.’ (Line, 2009). 
 
The status of homoeopathic and homotoxicological medicines was also an 
issue at this point.  On 18th March Professor Johnston, PhD supervisor, 
queried the position of homeopathic and homotoxicological remedies in the 
European Union (EU) Directive with the MHRA (Johnston, 2008).  Dr 
Malcolm Barratt-Johnson, Medical Assessor at the Clinical Trials Unit and to 
the Licensing Division at the MHRA, confirmed that homoeopathic products 
lie within the scope of a clinical trials authorization (CTA) because they have 
the ability or potential to treat individuals.  According to European Legislation 
(Article 1, paragraph 2 of Directive 65/65 EEC) a preparation constitutes 
medicinal product where:  
‘The substance or combination of substances either prevent or treat disease 
in human beings or are administered to human beings with a view to making 
a medical diagnosis or to restore, correct or modify physiological functions in 
humans.’.(EEC, 1965) 
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On the basis that this was an IMP an application was made to the Guy’s 
Research Ethics Committee for the October 2009 meeting (application 
reference 09/H0804/93). A response was received confirming that: ‘the study 
cannot be reviewed by an NHS REC, as it is a CTIMP happening outside of 
the UK. We are therefore unable to give a legally valid opinion on the 
application and it has been withdrawn with immediate effect.’ (Hill, 2009). 
 
Professor Johnston queried this decision with the local research ethics 
committee (LREC) who in turn escalated it to one of the NRES regional 
managers for guidance.  Maria Robinson, SRES Manager, South West gave 
the following response:  
‘This is an interesting scenario, Although outside the UK and technically 
outside our remit for ethical review, this study being a CTIMP falls under the 
EU regs and therefore must be reviewed by a UKECA recognized REC and 
receive authorization form the MHRA.  This being the case, we would need 
to review this project.’ (Robinson, 2009) 
 
In December 2009 David Neal, Deputy Director (policy), National Research 
Ethics Service, was asked for his opinion.  He agreed that this was an 
unprecedented situation and apologized that it had not been clarified sooner. 
His email of 10th December 2010 is shown below: 
‘I explained that we had sought advice from the Department of Health about 
whether a mainland REC could review the trial on a voluntary basis.   We 
have now been advised as a matter of policy that it should not do so.     
The background is as follows: 
The European Clinical Trials Directive applies to the Crown Dependencies, 
which for purposes of European law are considered to be part of the UK 
Member State, although not part of the UK in domestic law.   The States of 
Jersey were therefore required to transpose the Directive into States law by 1 
May 2004; they have not so far done so.   The Medicines for Human Use 
(Clinical Trials) Regulations 2004 do not apply to Jersey, and under present 
arrangements the United Kingdom Ethics Committee Authority is not able to 
recognise ethics committees to review trials taking place in Jersey, though 
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we understand that the Crown Dependencies have been offered the option of 
UKECA recognition for their ethics committees. 
In these circumstances, it is not considered appropriate for a mainland REC 
to review and give an opinion or otherwise advises on a trial taking place 
solely in Jersey.   Responsibility for the trial lies with the authorities in 
Jersey.  If it were proposed to start the trial at a mainland site, an application 
could then be reviewed by a UKECA recognised REC and an opinion given 
in relation to that site.’(Neale, 2010) 
 
This clarification of the situation allowed the project to proceed with a local 
application to Jersey in September 2009 (Johnston, 2009).  Written 
confirmation that the committee were ‘minded to grant a favourable ethical 
opinion subject to receipt of an amended patient information leaflet’ was 
received on 24th March 2010 in a personal email to the researcher (McCabe, 
March 2010). 
 
Sampling strategy 
Female patients were recruited via the infertility clinic consultant who was in 
charge of their conventional treatment. There were two categories of women 
that were of interest to this trial: firstly those that respond very poorly to 
standard ovulation induction agents and secondly those annovulatory women 
who are being given ovulation induction agents.   
Women presenting at the clinic, because they had been referred by their GP 
for infertility treatment, were offered the opportunity to take part in the trial 
during their consultation and the lead clinician sent out a letter of invitation to 
those who expressed an interest (see appendix Figure 17 Letter of Invitation 
to Trial Participants).   
Those women who fulfilled the selection criteria were consented and then 
allocated a protocol on a randomised basis.  The clinician allocating them to 
a trial protocol was blinded to treatment but not to their age. Chronological 
age is an important predictor of outcome and so each treatment group was to 
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be stratified for chronological age.  A copy of the consent form is included in 
the appendix as Figure 14 Consent forms for participants in pilot study.  It 
was planned to consent women who did not wish to take part so that their 
data could be used as a comparison with the placebo group.  Although the 
consent form was printed and supplied to the clinic (see Figure 15 Consent 
forms for non participants in pilot study) no women were consented in this 
way.  A patient information sheet accompanied the consent form and this is 
also included in the appendix, see Figure 16 Patient Information Sheets for 
Pilot Study. 
Previous use of homeopathic remedies was not considered to be an 
exclusion factor.  However a washout period of one month would be 
necessary if they were taking any homeopathic remedies. 
Data collection methods 
Quantitative data collection was designed to take place during their clinic 
appointments and was captured by their consultant using a Case Report 
Form (CRF) see appendix Figure 18 Case report form for pilot study.  The 
CRF had three carbon copies, one for the patient file, one for the trial master 
file and one for the researcher. 
Data collection instruments and technologies 
The clinic staff received some basic training on the CRF during a site visit but 
they were not involved in the design of the CRF and this has been identified 
as a limitation of the study. The consultant used a case report form (CRF) to 
manually capture the outcome data on: 
1. Follicular count and Ovarium volume 
2. Follicular stimulating hormone (FSH) levels 
3. Estradiol (E2 or 17β-estradiol, also oestradiol) at day 2 
4. Progesterone Levels at day 21 
5. Pregnancy confirmed with a pregnancy test 
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6. Live birth 
For an initial screening visit additional information was requested on the CRF 
that included: 
1. A check on inclusion and exclusion criteria 
2. Demographic data (age, height, weight, BMI) 
3. Smoking and Alcohol consumption 
4. Medication  
5. Previous medical history 
6. Physical Examination and vital signs (repeated on each visit) 
7. Ovarian Function Investigations 
 
Units of study 
 Inclusion Criteria 
In order to be eligible to enter the study, volunteers must meet the following 
criteria: 
1. Female  
2. Age stratified in active and placebo groups (see Table). 
3. Diagnosed with poor response to ovulation induction or annovulatory 
(WHO Group2) 
4. Absence of other significant endocrine dysfunction including diabetes 
5. Absence of other known causes of infertility 
Exclusion Criteria 
Taking medication for other medical conditions that may affect ovulation  
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1. Pregnancy 
2. Tubal infertility or any other cause of infertility 
3. Previous pregnancy 
4. BMI   <20kg/m2 and >35kg/m2  
5. Concomitant use of other CAM therapies 
6. Use of peppermint, caffeine, nicotine, recreational drugs or alcohol 	  
 Treatment Given Plus 
Group one 
N=15 
Clomid Placebo 
Group two 
N=15 
Clomid Ovarium Compositum 
Group three 
N=15 
FSH Placebo 
Group four 
N=15 
FSH 
Ovarium 
Compositum 
Group five 
N =15 
IVF Placebo 
Group six 
N=15 
IVF 
Ovarium 
Compositum 
 
Table 17 Table to Show The Proposed Treatment Groups 
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Recruitment 
Recruitment was started in November 2011 and stopped in July 2012, during 
that time 4 patients were enrolled and 4 more identified as appropriate and 
sent a recruitment invitation letter by the unit.  Further details are discussed 
in the results section (Chapter 3 Results for Strands 1, 2 & 3). 
When the difficulties regarding recruitment became apparent in Jersey the 
literature was searched for existing studies that might offer some insights.  
There are relatively few papers published regarding research conducted in 
the Channel Islands.  A pubmed search using the MeSH terms "Channel 
Islands/epidemiology"[MeSH Terms] AND "humans"[MeSH Terms] returns 
12 studies published between 2012 and 1992 .Table	  43	  Table	   to	  show	  a	  Pub	  Med	  Search	  for	  Published	  Studies	  in	  the	  Channel	  Islands 
 
One of the authors, Dr Ellison, was contacted by email to investigate the 
possible obstacles to conducting a clinical trial in Jersey  (Ellison, 201) as he 
had conducted an epidemiological study of the Jersey population.  His 
opinion was that we should not encounter any particular problems in clinical 
trial recruitment and that it would be worth making contact with Professor Ian 
Fentiman who ran the Breast Cancer Study on the neighbouring Channel 
Island of Guernsey. 
Professor Fentimen was able to offer the following insights: 
Our work involved volunteers on Guernsey which does have a different 
health system from Jersey.  There were 5 studies in all and I was involved 
with the 3rd study and its sequels.  The study aim was to identify risk factors 
for breast cancer in a normal population.  In the 3rd study 5104 women aged 
>35 years recruited between 1977 and 1985.  We involved the surgeons who 
were part of the general practices at the time and paid a fee for each patient 
that the surgeons examined.  We were involved in multiple articles in the 
Guernsey Evening Press and local radio and television.  Additionally we 
METHODOLOGY 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   256	  
employed a local coordinator who was able to network widely and help with 
recruitment.(Fentimen, 2012) 
Discussion	  
The suggestions made by Professor Fentimen were discussed with the clinic 
staff in Jersey but for various reasons they were not implemented as ways of 
supporting our own recruitment drive.  One of the major limitations of this 
thesis was the lack of planning to support the recruitment drive and the 
difficulty of supporting a trial at site that is relatively difficult to visit on a 
regular basis.  
Randomisation and Allocation 
The patients were to be randomised, to treatment, using a randomisation 
sequence designed by Heel, in blocks of four.  They were to be stratified 
according to chronological age and treatment group.  The randomisation 
sequence was designed by Heel (manufacturer) who provided sealed 
envelopes for the codes they had generated.  A template was provided for 
the generation of labels so that clinic staff in Jersey could label patient files.  
Copies of the label templates are included in the appendix Figure 19 
Medication labels for pilot study 
 
The consulting physician who randomised the patient to the next number in 
the appropriate age controlled allocation of the study drug and treatment 
group, the allocation code was passed to pharmacy that held the medication 
labelled with the allocation codes.  The allocation codes are included in the 
appendix see Figure 20 Randomisation Codes for Pilot Study. 
 
The sealed envelope was added to the patient’s file of notes and a sticker 
was attached to the front of the file to identify them as a trial participant and 
included their allocation code.  In the event of an adverse event the envelope 
could be opened and the code broken.  Patients, researchers, doctors and 
pharmacy were all blinded as to the allocation of patients to the active drug 
or placebo. 
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Unit staff and site pharmacy recorded the randomisation of the allocation 
code on a word document provided by the investigator (see appendix Figure 
20 Randomisation Codes for Pilot Study). 
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Medicat
ion 
 
 
Clomi
d 
Vs. 
Place
bo 
Clomi
d 
Vs. 
Place
bo 
Clomi
d 
Vs. 
Place
bo 
FSH 
Vs. 
Place
bo 
FSH 
Vs. 
Place
bo 
FSH 
Vs. 
Place
bo 
IVF 
Vs. 
Place
bo 
IVF 
Vs. 
Place
bo 
IVF 
Vs. 
Place
bo 
Years 
of age 
on date 
of trial 
entry 
<30 30-35 
 
>35 
 
<30 30-35 >35 <30 
 
30-35 
 
>35 
 
Table 18 Table to show Age Stratification Bands  
 
Study Procedures 
Schedule of Visits. 
Visit One:  
• The Volunteers will report to the Study Centre at a pre-agreed time. 
• The active agent will be randomly distributed and 100 tablets 
dispensed to the Subject by the responsible administering Clinician 
with full instructions on frequency and timing of dosages.  
• Dose frequency and timing: one tablet dissolved in the mouth three 
times a day, at least 15 minutes before or after meals.  Dose to be 
taken at 9am, 12 noon and 9pm. 
• Subjects will at all times continue with their conventional infertility 
treatment as prescribed by the Consultant.   
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Visits 2 - 12 
• On completion of this dose for 30 days Subjects are expected to 
attend an evaluation session and if they still fulfil the criteria of the trial 
the dose can be repeated. 
• A further 100 tablets will be dispensed.   
• Volunteers will be evaluated in this way every 30 days. 
• Unused tablets to be returned to the Principal Investigator in a sealed 
bag, labelled with Subjects name and date of birth for counting. 
• Subjects will be instructed to discontinue trial drug after an ART 
intervention and wait until a pregnancy test is performed. 
• The maximum length of trial is 12 months. 
• Patients will be discharged when the trial ends (12 months) or on a 
positive pregnancy test. 
 
Parameters for evaluation 
Demography, Medical History 
Includes initials, date of birth, BMI, race, height and weight.  A full medical 
and surgical history will also be evaluated including previous pregnancies or 
treatments for infertility, to be recorded on the Case Report Form (CRF). 
EHIQ (Emotional Health in Infertility Questionnaire) and the EQ-5D 
Subjects will be asked to complete a QoL questionnaire for infertile women 
The EHIQ and the validated questionnaire The EQ-5D, copies are included in 
the appendix as Figure 11 The Oxford Fertility Questionnaire EHIQ and 
Figure 13 The EQ-5D. 
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 Vital Signs 
Vital signs, including body temperature, sitting radial pulse and blood 
pressure will be performed at the screening visit. 
Clinical Tests Associated With The Trial and Fertility Treatment 
Baseline ultrasound scans every month to assess ovarian follicles, monthly 
blood tests including FSH, E2 at day 2 and Progesterone level at day 21. 
Adverse Events 
Subjects will be monitored for adverse events throughout the study.  Adverse 
events may be spontaneously reported by the subject, observed by the study 
personnel or elicited by the study personnel, who should ask subjects the 
following non-leading question: ‘How do you feel?’ or ‘How have you been 
feeling since I last asked you?’  The same questions will be used throughout 
the study. 
There is a form for reporting SAE included in the CRF see Figure 18 Case 
report form for pilot study 
Serious Adverse Events will be reported to the Sponsor, the COREC 
recognised Research Ethics Committee and the MHRA.  If a Grade 3 r 4 
toxicity (based on the Common Toxicity Criteria (CTCv3.0)) or other serious 
adverse events occurs, no further dosing of the subjects will occur until the 
cause of the event and its relationship to the study drug has been clarified.  
Continuation of the trial will be contingent upon approval by the Sponsor. 
There is a database for ADRs at Heel’s Safety Department (only one ADR 
listed for Ovarium Compositum). 
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Qualitative	  Data	  Collection	  in	  Strand	  Three	  
 
Qualitative data were captured on two questionnaires that the patients were 
asked to complete at each appointment and return to the clinician on their 
next visit.   
 
Infertility is known to cause emotional distress (Finamore et al., 2007) and 
the hormonal treatment regimes can also be difficult for women to manage, 
therefor it is important to include a measurement of their quality of life.   
 
 Infertility and subsequent treatment are acknowledged to have potentially 
detrimental effects on emotional health. Qualitative studies suggest that 
infertility can be a devastating experience, especially for women, but 
empirical findings have tended to be less conclusive. (Weil et al., 2007) 
 
Including a QoL measurement broadens the outcomes to include a 
consideration of the impact of the condition and it’s treatment on the person’s 
emotional, physical and social functioning and life style.   
 
It addresses the question of whether the treatment leads to a life worth living, 
and it provides a subjective, patient-led baseline against which the effects of 
interventions can be evaluated (Bowling, 2011). 
 
In order to measure changes the tool chosen must be valid for the purpose, 
reliable, precise, responsive to change and sensitive enough to capture 
changes (Bowling, 2011).  Disease specific tools will have a narrower focus 
and can pick up small but clinically relevant changes.  In order to capture a 
broad picture of health status, and a narrower focus on the specific impact of 
infertility and its treatment, two different questionnaires were chosen for this 
study. 
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The two forms that were used were the EQ-5D (Mark Oppe, 2007) and the 
EHIQ (Farmer, 2007).   A description of the two tools and the reasons for 
choosing them are discussed in more here. 
 
The EQ-5D 
 A copy of the EQ-5D is included in the appendix see Figure 13 The EQ-
5DThe EQ-5D was chosen because it is relatively simple to print and 
complete and provides a standardized measure of health status appraisal.  It 
is   applicable to a wide range of health conditions and treatments, it provides 
a simple descriptive profile and a single index value for health status that can 
be used in the clinical and economic evaluation of health care as well as in 
population health surveys. (Mark Oppe, 2007) 
 
One advantage of using the EQ-5D is that it is designed for self-completion 
by respondents and the instructions needed to complete it are included in the 
questionnaires, it was therefore suitable for trial subjects to take away with 
them as the clinician did not have time to complete the survey with the 
patients. 
 
It is designed to measure current health on five domains mobility, self-care, 
usual activities, pain/discomfort and anxiety/depression. Each dimension has 
3 levels: no problems, some problems, severe problems. This decision 
results in a 1-digit number expressing the level selected for that dimension.  
The digits for 5 dimensions can be combined in a 5-digit number describing 
the respondent’s health state (Mark Oppe, 2007). 
 
Some disadvantages have been reported by researchers such as a lack of 
sensitivity at the ceiling level, being insensitive to health changes that are 
important to patients, and some inconsistencies in the wording which may 
increase response error (Bowling, 2011).  However the EQ-5D has been 
found to be superior to the other preference-based measures of health 
related quality of life (Brazier et al., 1999) and the possible lack of sensitivity 
is addressed in this study by using a second infertility-specific questionnaire. 
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The EHIQ 
A copy of the EHIQ is included in the appendix see Figure 11 The Oxford 
Fertility Questionnaire EHIQ.  The Emotional Health In Infertility 
Questionnaire was a designed by a nurse researcher, Gail Farmer (Farmer, 
2007), as part of her Masters Degree and was reported in 2007 as oral 
presentation at the ESHRE Lyon conference (Weil et al., 2007).   
 
The existing generic instruments tend to focus on psychological states and 
psychopathy rather than the emotional strain associated with infertility in 
otherwise healthy individuals.  The EHIQ was created in response to a 
perceived need for the construction and validation of a new infertility-specific 
measure of emotional health. 
 
It was designed following a process of qualitative research and statistical 
validation.  Twenty-three, largely unstructured interviews were undertaken 
with males and females separately at different stages of infertility 
investigation and treatment. Qualitative analysis revealed three major 
themes: the effects on self, on relationships and on life plans. This analysis, 
combined with a literature review, formed the basis of the 64 items that made 
up the developmental version of the questionnaire.  
 
The questionnaire was then piloted with a large sample (n = 204 women and 
n = 187 of their male partners) undergoing treatment for infertility at the 
Oxford Fertility Unit, with response rates for those who received 
questionnaires of 79% and 70% respectively.   
 
A 40 item version of the questionnaire was developed in which nine domains 
accounting for 65% of the variance were identified: personal strain; partner 
relationship strain; sexuality; social support; confidence in treatment; guilt 
and blame; financial strain; need for privacy and couple concordance.  
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The EHIQ was chosen for this thesis because it has been rigorously 
developed to quantify emotional health in infertility, measuring emotional 
strain in healthy individuals, rather than psychopathology. It has the potential 
to be a useful tool in studying issues such as the emotional effects of 
infertility, the effectiveness of interventions to reduce emotional distress in 
this population and the influence of emotional health on treatment 
perseverance and treatment outcome.    
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The	  Study	  Drug	  in	  Strand	  3	  
Ovarium Compositum 
Ovarium compositum is manufactured in Germany according to Good 
Manufacturing Standards (Certificate included in appendix see Figure 12 
Certificate of Good Manufacturing Standards for Ovarium compositum).  
Ovarium compositum is on the market in 20 different countries with an import 
licence, a registration or with a marketing authorization (Russia, Poland, 
Latvia). Figures of sales show approximately 700.000 - 900.000 Ampoules 
per year (2008). 
 
Labelling for the trial medication (both placebo and active drug) was 
designed and supplied by Heel with the randomisation codes included and 
these are shown in the appendix see Figure 19 Medication labels for pilot 
study. 
 
Clinical indications are listed (Heel, 1986) as : "Stimulation of the glandular 
and defensive functions, as well as those of the connective tissue, in 
dysmenorrhoea, endometritis, metritis, parametritis, enuresis (in young girls), 
in the climacteric, hyperemesis, insufficiency of the anterior lobe of the 
pituitary gland in females, craurosis vulvae, mastodynia, osteomalacia, 
menorrhagia, as well as in various disturbances of metabolism, including 
those arising in geriatrics." 
 
Due to its individual homeopathic constituents, see Table 19 Treatment 
Formulations Table for active drug, Ovarian Compositum has an application 
in the homeopathic treatment of hormonal disturbances, menopausal 
syndromes and Insufficiency of the pituitary gland. 
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The preparation is formulated as follows: 
Name Potency Amount (mg) 
Ovarium suis D8 1 
Placenta suis D10 1 
Uterus suis D10 1 
Salpinx suis D10 1 
Cypripedium D6 1 
Lilium tigrinum D4 1 
Pulsatilla D18 1 
Aquilegia vulgaris D4 1 
Sepia D10 1 
Lachesis D10 1 
Apisnum D8 1 
Kreosotum D8 1 
Bovista D6 1 
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Name Potency Amount (mg) 
Ipecacuanha D6 1 
Mercurius solubilis Hahnemanni D10 1 
Hydrastis D4 1 
Acidum cis-aconiticum D10 1 
Magnesium phosphoricum D10 1 
Carrier   
Lactose-Monohydrat  297 
Magnesium stearate  1.5mg 
Table 19 Treatment Formulations Table for active drug 
 
 
 
 
Table 20 Formulation of Placebo 
Carrier   
Lactose-Monohydrat  297 
Magnesium stearate  1.5mg 
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Homeopathic Medicinal Products 
Modern definitions of homeopathic remedies tend to focus on what remedies 
are rather than how they are used (Kayne, 2006). The definition given in both 
the EU Directive for Medicinal Products (1992) and UK Statutory Instrument 
(SI 1995/308) is as follows (Kayne, 2006): 
Homeopathic medicinal product means a medicinal product (which may 
contain a number of principles) prepared from products, substances or 
compositions called homeopathic stocks in accordance with a homeopathic 
manufacturing procedure described by the European Pharmacopoeia or, in 
the absence thereof, by any pharmacopoeia used officially in an (EU) 
member state. 
The UK Medicines and Healthcare Products Regulation Authority (MHRA) 
and other European regulatory bodies use the term stocks for the starting 
solutions, usually mother tinctures, from which homeopathic potencies are 
prepared. 
In 1988 The German Health Ministry took the initiative to establish standards 
for the manufacture of homeopathic medicines and this led to the production 
of a European Pharmacopoeia in 2002. 
About 65% of all remedies are prepared from extracts of plant materials, and 
because of this homeopathy is often confused with herbalism by many 
people.  The difference lies in the manner of producing the two types of 
medicine.  Herbal products are generally the result of an aqueous or 
alcoholic extraction alone, whereas in homoeopathy an additional dilution 
process is involved.  Either the whole plant may be used or only the leaves, 
stems, flowers or roots as specified in the pharmacopoeia monographs.  The 
species of plants, the parts taken, the time of collection and the extraction 
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procedures may well differ according to the particular pharmacopoeia being 
consulted (Kayne, 2006). 
Animal and insect material must be obtained from healthy specimens.  
Biological materials from healthy animal or vegetable secretions or from 
bacterial cultures are made into remedies known as sarcodes.  If the remedy 
is derived from diseased tissue then the finished remedy is known as a 
nosode. 
‘Suis organ preparations (sarcodes) are homeopathic attenuations of 
wholesome organs or tissues obtained from healthy animals, in this case 
pigs.’ (Heel) 
Suis organs are said to act like ‘organ specific nosodes’ to create a 
stimulative treatment where damage has occurred to the organs and tissues 
in question.  These medications are claimed to be ‘particularly successful in 
treatment of degenerative damage as well as functional insufficiency of the 
organs.’(Heel, 1986) The Suis organ preparations are said to ‘guide’ other 
active homeopathic substances in their presence to the corresponding 
targeted organ, thereby intensifying their efficacy. 
Preparation of remedies 
Extraction 
Mother tinctures are the liquid preparations resulting from the extraction of 
suitable source material with alcohol/water mixtures, which form the starting 
point for the production of most homeopathic remedies.  Comminution 
followed by standard percolation, maceration and squeezing techniques are 
used on fresh plants and succulents while dried specimens are subjected to 
percolation with alcohol.(Kayne, 2006) 
The resulting solutions are strained and can contain one part drug to three 
parts mother tincture, when the final tincture represents one tenth of the 
concentration of the original drug it is in effect a 1x dilution (Kayne, 2006).  
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With insoluble chemicals such as Aurum (gold), Plumbum (lead) or Sulphur 
the solid material must be triturated and serially diluted with lactose powder 
using a pestle and mortar in a precise and documented manner (Kayne, 
2006).  
Potentization 
Most mother tinctures are subjected to a two stage process involving dilution 
and succession (Kayne, 2006), this process is known as potentization.  The 
Hahnemannian method offers two scales of dilution, centesimal and decimal 
(Kayne, 2006).  The remedies that make up Ovarium Compositum are in the 
decimal scales of dilution.  In modern pharmaceutical practice it is common 
to use a triple distilled alcohol and water system, the strength of which varies 
from 20 – 60%, in the preparation of homeopathic dilutions (Kayne, 2006).  
The solution resulting from a mixture of the two liquids is subjected to the 
vigorous shaking with impact known as succession.   
After the initial processes, successive serial dilutions follow, using fresh glass 
vials at each stage, until the solution reaches 6x for example.  The process 
involves adding one drop to nine drops of diluent.  A number designates the 
potencies with the letter ‘x’ following it.  Thus 6x represents a 1 in 10 dilution 
carried out serially six times, each with a burst of succession. 
In large-scale manufacture homeopathic granules are medicated and then 
compressed to form the tablets in a process similar to allopathic 
manufacture. 
Dilution Concentration Decimal Potency 
1:10 10-1 1x or D1 
1:100 10-2 2x or D2 
1:1 000 10-3 3x or D3 
1:10 000 10-4 4x or D4 
1:100 000 10-5 5x or D5 
1:1 000 000 10-6 6x or D6 
1:1030 10-30 30x or D30 
Table 21 Decimal potencies (Kayne, 2006) 
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Homeopathic Indications for the Individual Constituents of Ovarium 
Compositum 
For a full description of each ingredient please refer to the appendix 
(APPENDIX 6 The Study Drug) a summary is included below as Table 22 
The ingredients of Ovarium compositum 
Table 22 The ingredients of Ovarium compositum 
Ingredient 
Examples of Homeopathic Indications  (Heel, 
1997) 
Ovarium suis (ovary) 
D8 
Disturbances of the ovarian function. 
Placenta suis 
(placenta) D10 
Dysmenorrhea and peripheral circulatory 
disturbances. 
Uterus suis (uterus) 
D10 
Dysmenorrhea. 
Salpinx suis  (fallopian 
tube) D10 
Dysmenorrhea and sterility through inflammatory 
diseases of the salpinx uteri. 
Cypripedium calceolus 
var. pubescens D6 
Conditions of nervous irritation, insomnia with 
restlessness and twitching of the body. 
Lilium tigrinum D4 
Uterus descensus, dysmenorrhea, nervous cardiac 
disturbances with anxiety, fluor albus. Menses early, 
scanty, dark, clotted, offensive; flow only when 
moving about…Pain in ovaries. 
Pulsatilla pratensis 
D18 
Migrating disorders (worse before menses), delayed 
menses, dysmenorrhea, remedy for affectations of 
the mucosa, venous stasis. Amenorrhea, irregular 
menses. 
Aquilegia vulgaris 
(columbine) D4 
Disturbances of the menses, climacteric disorders 
Sepia officinalis 
(cuttlefish) D10 
Climacteric disorders, nervous exhaustion, 
depression, chronic inflammation of the uterus and 
adnexa.  Tendency to abortion from 5th to 7th month, 
sterility, dull heavy pains in ovaries, prolapse, pelvic 
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organs relaxed with bearing down sensation, 
menses too late, too scanty or early and profuse. 
Lachesis mutus 
(bushmaster) D10 
Climacteric disorders (hot flushes), dysmenorrhea, 
left ovary very painful and swollen, ovarian tumors, 
menses irregular. 
Apisinum (bee venom) 
D8 
Oedema, ovarian cysts, dysmenorrhea, ovarialgia, 
metrorrhagia. Severe ovarian pains, Amenorrhea of 
puberty, abortion (miscarriage) during early months, 
pain and enlargement in right ovary during menses. 
Uterine hemorrhage during pregnancy. 
Kreosotum (beech tar 
creosote) D8 
Catarrh of the mucosa with acrid secretions, e.g. 
fluor albus, pruritus vulvae, menorrhagia (excessive 
bleeding at the regular period), metrorrhagia 
(bleeding from the womb otherwise than at the 
proper period. It is usually due to a uterine lesion). 
Hyperemesis (vomiting in pregnancy). 
Bovista D6 
Menorrhagia, dysmenorrhea, venous hemorrhages, 
swelling of the ovaries, depressed before menses, 
chronic ovaritis. 
Ipecacuanha D6 
Uterine haemorrhages, in gushes. Hyperemesis, 
menses too early and too profuse, cutting pain in 
uterus from left to right, prolapse of uterus worse 
during menses, threatened abortion (miscarriage). 
Mercurius solubilis 
Hahnemanni D10 
Suppuration, acute and chronic inflammation of the 
lymphatic system, chronic affections of the 
connective tissue. 
Hydrastis canadensis  
D4 
Remedy for affections of the mucosa; thick ropy, 
yellowish white secretions, menorrhagia, viscid, 
metrorrhagia, myomatous hemorrhages. 
Acidum cis-aconiticum 
D10 
Active factor of the citric acid cycle and of redox 
systems. 
Magnesium 
phosphoricum D10 
Anti spasmodic remedy, Dysmenorrhea, tendency 
towards cramps, neuralgia. 
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Safety & Tolerability 
Global evaluation of toxicity 
The manufacturer (Heel) commissioned an expert report on Ovarium 
Compositum, this report (see Figure 10 The Expert Report on Ovarium 
Compositum) which concluded that ‘The current scientific fundamentals and 
the clinical experiences did not reveal serious signs to suspect the containing 
amount of all homeopathic dilutions for causing toxicological risks.’  
 
The following statements are quoted from the report, which is shown in full in 
the appendix as Figure 10 The Expert Report on Ovarium Compositum: 
 
Reproductive Function  
Results from direct studies of reproductive or teratogenic toxicity as well as 
fetotoxic side effects influencing fertility are not available. Researching the 
literature produced no hint for such risks  
 
Embryo-Foetal and Peri-Postnatal Toxicity  
Results from direct studies of embryo toxic/ fetotoxic or peril-, postnatal 
toxicity are not available. Researching the literature produced no suggestion 
of such risks. 
 
Mutagenic Potential  
Results from direct studies of mutagenic toxicity are not available. 
Researching the literature produced no hint for such risks. 
 
Carcinogenic Potential  
Results from direct studies of carcinogenicity are not available. Researching 
the literature produced no hint for such risks. 
 
Immunotoxicity  
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No indications show that the effects of single components of Ovarium 
Compositum injection are sensitising or will provoke allergic reactions by the 
parenteral application. Possible risks or adverse drug reactions of parts or 
components of the plants have not been observed regarding the 
pharmacovigilance of the compounds of Ovarium Compositum or similar 
composed drugs. 
 
Interactions  
There are no hints that the effects of single components of the incorporated 
homeopathic dilutions and substances may be enhanced or inhibited by 
incorporated drugs or substances which interfere with their characteristic 
pharmacodynamic or toxicological effects. Potential risks or interactive 
effects associated with the combined administration of the incorporated 
homeopathic dilutions have not been substantiated in drug surveillance 
studies and pharmacovigilance on the use of the incorporated drugs in 
human. 
 
Pharmacovigilance 
Observing pharmacovigilance data, which have been determined by a 
dispensing of a formula with the same composition, can also show the drug 
safety of Ovarium Compositum tablet. The components showed identical 
finishing dilutions. Consequently the dispensing carried the same risk 
potential.  
Within the framework of the supervision of drug safety no adverse event was 
reported since 1998 (745.510 ampoules delivered only in Germany), globally 
seen. This result is striking for the good safety profile of Ovarium 
Compositum. This result of the pharmacovigilance points out that adverse 
drug reactions after parenteral application of the homeopathic dilution in 
Ovarium Compositum tablet are a rarity and that this preparation cannot be 
related to an increased risk especially concerning the gastro-intestinal, 
cardiovascular or central-neurogenic body organ system or the skin. 
 
Conclusions 
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The scientific findings material and the clinical experiences do not reveal any 
indications concerning toxicological risks caused by components of the 
homeopathic drug Ovarium Compositum if the speciality is applied according 
to a recommended dosage of the manufacturer.  Components of an 
immunotoxicological potential are included with a very small concentration. 
Consequently, a corresponding risk during treatment does not need to be 
taken into account.  
Discussion 
The Investigators were targeted to enrol up to ninety (90) female volunteers 
who met the trial inclusion criteria and they were to be randomised into six 
treatment groups.  The usual blood tests and clinical evaluations were to be 
made by the fertility clinic.  In order to measure the placebo effect as well as 
the specific effects of Ovarium compositum women who are not taking part in 
the trial were to be asked to consent to allow their data to be used as a 
comparison group.  In order to make sure there is no placebo effect from a 
consultation with a prescribing homotoxicologist the trial design did not 
include such a consultation for any of the trial groups.  
 
The trial protocol was reviewed internally by WHRI Table 42 WHRI internal 
review of trial from strand 3 and externally by Dr Alexander Tournier, who 
found that, as there were no know toxicology issues, the choice of 
medication was suitable for the condition under investigation Table 41 
External peer review of the protocol for strand 3.   Both reviews noted the 
small sample size that was not sufficiently powered for statistical analysis but 
accepted the fact that this was a pilot study designed to test for feasibility of 
study design. 
 
Details of the protocol were sent to Neil MacLachlan at Jersey General 
Hospital in order to ask for his feedback and input.  The Protocol was also 
reviewed by Heel in 200 and Dr Robbert Van Haselen (Haselen, 2007) 
emailed me in September 2007 to say that Heel had had internal discussions 
and that they like the protocol and were happy in principle to support the 
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study.  He made some useful suggestions about trial structure and duration 
and also acknowledged that this was primarily a hypothesis generating-pilot 
trial and therefore it was acceptable to have a variety of outcome 
measurements. 
 
The emotional strain of infertility treatment may affect the decision to 
continue or discontinue treatment (Brandes et al., 2009). If homeopathy 
could be shown to reduce the strain associated with treatment and retain 
women for more cycles of IVF then this would be a desirable outcome for the 
clinic.  Quality of life measurements both specific and general therefore 
formed a part of this phase of the study. 
 
Pragmatism recognises the existence and importance of the natural or 
physical world as well as the emergent social and psychological world that 
includes language, culture, human institutions, and subjective thoughts 
(Johnson and Onwuegbuzie, 2004), by combining a randomised controlled 
trial with quality of life data both perspectives are acknowledged and the 
results triangulated so that they may be mutually corroborated.   
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Methodology	  for	  Strand	  Four	  (2012	  -­‐2015)	  
 
Title An Investigation Into The Work-Related Concerns Faced By 
Women Seeking Infertility Treatment In The British Isles 
 
Introduction 
This was a qualitative investigation into the work-related concerns faced by 
women seeking infertility treatment in the British Isles.  
Objectives- The purpose of this study was to further investigate the reasons 
for recruitment failure that were suggested by the nursing staff at the trial 
site.   
Background – The failure to recruit sufficient women to the planned clinical 
trial was investigated using a qualitative analysis of online infertility forum 
postings. 
Context 
The time constraints of the PhD study meant that there was not time to 
obtain ethical approval for further investigations at Jersey General Hospital 
and it was also apparent that unit staff would not welcome further 
involvement in the study.  As a solution to this dilemma it was decided to use 
the information available on Internet forums for infertility treatment seekers. 
 
Method – Stage 1: A semi-structured questionnaire was posted on the 
research section of two popular infertility Internet forums inviting participants 
to respond (see Figure 5 Details of posting on forum).  The responses were 
organised using MaxQDA and then analysed using a deductive thematic 
analysis to use to construct initial codes. Quotations were extracted, 
aggregated and anonymised to illustrate and support each theme; the data 
segments are included in the appendix (APPENDIX 11 Qualitative Data From 
Strand 4)   
Stage 2: The second stage of analysis was to use naturalistic data in the 
form of the online postings of 213 forum users from the ‘My Story’ section of 
METHODOLOGY 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   278	  
one of the forums.  This data was examined on a line-by-line basis 
(theoretical thematic analysis) for the codes that were generated in stage 1.  
The data is included in the appendix (APPENDIX 11 Qualitative Data From 
Strand 4). 
 
Researcher characteristics and reflexivity 
The reading of the online stories was emotionally disturbing as so many of 
them expressed feelings of grief and loss.  The researcher was able to reflect 
on these during one to one mentoring sessions with Dr Sue Davies who had 
been a mentor for a number of years.  This avoided an unnecessary bias 
towards the themes of emotional distress and helped to develop an 
understanding of the participants’ perspective.  The researcher also kept a 
research diary in which to record her responses to the data, and record the 
process of conducting this strand. 
 
Sampling strategy 
Stage 1: The initial postings were open for anyone to reply to, male and 
female responses were equally welcome and it did not matter if their 
treatment was current or historical.   The only inclusion criterion was that they 
were or had been undergoing infertility treatment. 
 
Stage 2: The principal use of the ‘My Story’ (MS) section of the forum is to 
record the experiences of women during their infertility treatment and the 
sample is a good indication of the range of concerns that they have. At the 
time of posting no specific forums for Jersey so the answers received are not 
specific to Jersey but come from a larger sample of Internet users from the 
British Isles 
 
Ethical issues pertaining to human subjects 
The issue of using Internet forums as a form of data source also raises 
methodological and ethical questions, which are examined in more detail 
here. 
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Stage 1: After seeking permission from site administrators a semi structured 
research question was posted on the research section of two popular 
infertility forum websites.   
 
Stage 2: The second stage of analysis was to use naturalistic data in the 
form of the online postings of 213 forum users from the ‘My Story’ section of 
one of the forums.  Permission was obtained from the site administrators 
before data was used.  
 
This data could be viewed as existing in the public domain and yet it to some 
extent ‘belongs’ to the person posting it, a person who may not even be 
identifiable in order to seek informed consent.  
 
The author also sought the opinion of the forum administrators, and her 
supervisors who had experience in this field.  The consensus of their opinion 
was that the posts were public and could be used without permission as long 
as individuals who were posted were not approached outside of the forum 
(Johnston, 2013). 
 
Data collection methods 
Stage 1: a semi structured research question was posted on the research 
section of two popular infertility forum websites and participants were invited 
to respond by email. 
Stage 2: A manual search of the My Story Section of the Infertility Network 
UK forum.   250 individual stories posted in the ‘MS’ section of the forum of 
INUK (Forum) were examined and 213 stories were found to be of use, the 
other 37 were found to be missing or duplicated and were not included in the 
analysis.   
 
Data collection instruments and technologies 
The Internet was searched using an Apple Mac PC and MacBook Air.  The 
two sites used were selected on the basis that a Google Search would locate 
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the most commonly used sites.  The sites were selected by typing in 
‘Infertility forum UK’ and this resulted in the choice of Fertility Friends and 
Infertility Network UK.  Both site were contacted by email to request 
permission to post a thread on the ‘Research Questions’ section of the 
forum.  When approval was received the following posts were made: 
Details of postings 
Figure 5 Details of posting on forum 
Fertility Friends (Friends, 2012) 
Hi, I am interested in finding out about couples or individuals who have 
chosen or felt forced to reveal their fertility status and treatment at 
work.  How much legitimacy is granted to your condition and have you had to 
choose between being open and privacy?  Are you worried about risking loss 
of promotion? Where does your experience fall on the continuum between 
acceptance and ostracism?  You can email me on 
c.harenape@qmul.ac.uk Thanks and best wishes. 
 
Infertility Network UK. (UK) 
I am currently writing up my PhD research project looking at supporting 
infertility treatment using CAM therapies.  The pilot study I was running in 
Jersey had trouble recruiting enough women to take part and the reason 
given was the stress of telling employers about treatment and needing time 
off to attend appointments.  I would like to collect more data on this topic and 
therefore would like to hear the experiences and stories of women who have 
or have not disclosed their treatment at work.  
 
Units of study 
Stage 1: Seven forum users emailed a direct response with information about 
their personal experiences.   
Stage 2: 213 postings from the My Story section of the Infertility UK forum. 
 
Data processing 
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Stage 1: responses, which were received as emails were transcribed into a 
word document and organised using MaxQDA.  Then the coded sections or 
quotes were printed out and cut into slips so that they could be manually 
sorted into themes. 
 
Stage 2: data was extracted from the forum posting using a cut and paste 
into a word document and then organised using Max QDA. 
 
Data analysis 
Stage 1: The seven responses were read through several times in order to 
familiarise the researcher with their content.   Notes were made of patterns 
and meanings that could lead to codes.  The initial codes reflected ideas that 
seemed to be important to the respondents.  Using MaxQDA allowed the 
data to be coded in a way that it can be retrieved and manipulated to explore 
different themes 
 
The initial quotes, once coded, were printed out and cut into slips so that they 
could be manually sorted into meaningful groups.   The researcher worked 
from a constructionist perspective seeking to understand the socio-cultural 
contexts and structural conditions that generate the observed themes.  Eight 
themes were constructed and these are discussed in the results section (	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Chapter	  4	  Results). 
 
Stage 2: The second stage of analysis was to use naturalistic data in the 
form of the online postings of 213 forum users from the ‘My Story’ section of 
one of the forums. 
 
After familiarisation with the data by repeated reading of the postings the 
data was examined on a line by line basis (deductive thematic analysis) for 
the codes that were generated in stage 1 (Braun and Clarke, 2006a). This 
theoretical or ‘top-down’ approach to coding was driven by the researchers 
theoretical interest in the themes that were generated in the smaller sample. 
 
The rules used to guide the coding were that each code can only be used 
once in each paragraph and that only the initial posting on the forum was 
used not any posts added or comments made at a later date. 
 
The frequency and proximity of codes and keywords were examined (using 
MaxQDA) as part of the development of the themes.  This increasingly used 
‘concordance’ approach was suggested by Carol Rivas and has been used 
by (Seale et al., 2006) to analyse qualitative interview data and forum 
postings of men and women with cancer. The analysis did yield some useful 
insights but in the end was supplementary to the development of the themes 
and the model that was generated. 
 
Stage 3: Writing up the themes was an integral part of the analysis and there 
was an iterative process of reading and writing as patterns of meaning and 
areas of interest were studied.  The early engagement with the literature had 
suggested ‘emotional distress’ as a theme but some reading was left until 
later to avoid narrowing the researchers field of view.   
A mind map of themes was generated (Figure 21 Mind map from early 
coding memo) and this model was discussed with two other researchers who 
helped to refine the themes by contributing their own perspective, for 
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example Dr Carol Rivas suggested the idea that a crisis of identity lay at the 
heart of the themes around disclosure. 
The smaller sample (stage 1) was analysed again by comparing it with the 
Charmaz model of ‘’Forms of Telling” and the results of this analysis used to 
generate the ‘Relative Risk vs. Benefit’ model see Figure 7 Thematic Map. 
 This model was shared with forum users via the Research Section of the 
Infertility Network UK forum for their feedback but no responses were 
received. 
 
Techniques to enhance trustworthiness 
The coding and themes were checked with two other researchers (CR and 
NP) and a bias towards the negative experiences of working and undergoing 
treatment in my forum postings was noted and discussed.   The bias was 
kept in mind when performing the analysis so that it did not unconsciously 
affect the coding of data. The data set was reread after the themes had been 
decided upon to check that the data worked in relation to the themes.  If 
there had been more time to code the 213 stories in a ‘bottom-up’ inductive 
analysis then new themes might also have emerged but nothing occurred on 
the rereading that challenged the validity of the suggested model.   The 
model generated by this researcher was shared with another researcher who 
was working on a similar project at the same time (Payne, 2014) and this 
process of triangulation appeared to confirm the credibility of the themes. 
Conclusions Regarding The Methodology 	  
Many lessons were learned during the evolution of this study and on several 
conceptual levels.  The deeper understanding of the underlying philosophical 
framework grew from an analysis of the mixed methods research approach 
to the methodology.   There were however several points that were specific 
to the methodology and these are listed below.   Attention to these points will 
allow any future projects to yield interesting, credible and authentic results. 
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The main lessons regarding the methodology from Strand One were:   
 
1. That the two versions of the questionnaires for the practitioners should 
have been analysed separately.  The earlier version could have been treated 
as a pilot in order to refine the questions.  The reason for the change of 
questionnaire was the change in potential study sponsor and therefore 
remedy choice but they should not have been combined in the analysis 
stage. 
  
2. The initial analysis claimed to use Grounded Theory but this 
misunderstanding of the depth of analysis needed to meet that claim was 
corrected after the first viva.  During rewriting it was realised that what I had 
actually used was thematic analysis and a section on this method was added 
to the literature review. 
 
3.  The methodology chosen was appropriate to answer the research 
questions but it was not systematic enough in the way it was applied to the 
situation. 
 
The main lessons regarding the  methodology in strand 2 were: 
 
1. Results generated at a clinic in London are not necessarily applicable to a 
clinic in Jersey.  It is always important to take the social and cultural context 
into account, the methodology should have been changed to sample the 
population of infertile women seeking treatment in Jersey and I might have 
done this through my existing private patient network. 
 
2. Patient questionnaires that are returned on a voluntary basis are 
susceptible to bias as only those patients interested are likely to take part 
and return them. 
 
3. The methodology did generate some useful results and greater attention 
could have been paid to these when designing the methodology for Strand 3. 
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The main lessons regarding the methodology in Strand 3 were: 
 
1.  It would have been helpful, prior to study design, to carry out research 
regarding the social and legal implications of choosing Jersey as the study 
site.  A lot of time was spent trying to establish the requirement for mainland 
ethics and this delayed the time available for recruitment before the study 
drug expired. 
 
2. Greater participation from the study site unit staff in the design of the Case 
Report Form would have resulted in a methodology that was easier to 
implement and therefore more ownership, goodwill, and support for 
recruitment. 
 
 
3.  The trial design was appropriate for the research question and had the 
necessary level of model validity for investigating a homeopathic substance.   
 
The main lessons regarding the methodology in Strand 4 were: 
1. From the new perspective of a pragmatist worldview this strand could have 
been carried out as strand one and informed the design of the rest of the 
study.  This would still have been a mixed methods study but greater priority 
could have been given to the role of qualitative data, sourced from the patient 
forums, in an early exploratory phase of the study. 
 
2.  The initial methods (ranking of responses and keyword frequency) used to 
analyse the qualitative patient data were not appropriate to answer the 
research question.  The rewritten thesis used thematic analysis to explore 
the attitudes of women towards disclosing their treatment and this led to 
useful insights that could have been used to plan the methodology in Strand 
3. 
 
3. The questions posted on the forum had a bias towards the difficulties 
experienced by women and it is recognised that biased questions can lead to 
results that are less credible and therefore less useful in trial design. 
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4. The small sample size of the direct responses to the question posted on 
the forum (n=7),  is acknowledged as a limitation, but the close attention to 
theory, adherence to the guidelines for good thematic analysis and cross 
referencing with other researchers/sources of data  helps to improve the 
credibility of the conclusions drawn using this method. 
 
 
RESULTS 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   287	  
  
RESULTS 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   288	  
 
Chapter 3 Results for Strands 1, 2 & 3 
Introduction	  
The purpose of this section is to present the main findings from each of the 
four strands of the study and to expand upon the synthesis of findings into 
themes where appropriate.  The findings from strand four are further 
developed into a model of risk and benefit of disclosure. 
 
The four distinct strands that can be identified in this mixed methods 
research design are: 
qual  è qual èQUAN(qual) èQUAL  
 
The first qualitative strand was the review of homotoxicology treatment for 
infertility in the UK and the aim was to check the model validity of the 
quantitative strand.  A questionnaire was sent to 60 homotoxicologists and 
the return rate was 33%. Thematic Analysis (TA) was used to analyse the 
responses.  
 
The second qualitative strand was a feasibility study with patients and staff at 
The Bridge Centre, a private infertility clinic in London.  Potential obstacles to 
success were discussed with the discussion group who then completed a 
survey of nine open questions.  Their responses were analysed thematically 
create a qualitative evaluation of the data and their concerns and insights 
used to generate a patient questionnaire.  127 patient questionnaires were 
distributed at the registration desk over a 9-month period.    
 
The third strand was a quantitative design with an embedded qualitative 
aspect.  The quantitative element was a RCT of the use of Ovarium 
Compositum as an adjunct treatment for infertile women in an assisted 
reproduction unit.  
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The fourth strand was a qualitative investigation into the work-related 
concerns faced by women seeking infertility treatment in the British Isles to 
investigate themes suggested by the staff at the site of the RCT phase.  Data 
from forum users were analysed thematically (Braun and Clarke, 2006a)  and 
used to create of model of risk and benefits around disclosure of treatment in 
the work place. 
Results	  from	  Strand	  one	  	  
The	  Results	  Of	  The	  Practitioner	  Questionnaire	  
 
Units of study 
60 copies in total were distributed and 20 replies were received (33%). 
Of the two versions sent out the break down was as follows: 
Version One: Replies received 13 
Version Two: Replies received 7 
 
Negative responses (not qualified or have chosen not to complete 
questionnaire) received from 4 practitioners. One participant was excluded 
as she worked for the manufacturer of one of the products being considered 
for trial.  The results therefore included the responses from 16 participants. 
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The returning therapists are characterised in the table below: 
Question one asked the respondents to choose one or more options for the 
treatment of female infertility 
 
 
Table 23 Practitioner response to question 1 
 
 1:V1 1: V2 2: V1 
& V 2 
3: V1 4: V1 3:  V2 5:V1 
and 4: 
V2 
n 
Practitioner         
1 Ticked - - - -   1 
2 Ticked - - - Ticked  Ticked 3 
3 Ticked - Ticked Ticked Ticked   4 
4 - - Ticked - -  Ticked 2 
5 - - - Ticked -   1 
6 - - Ticked - Ticked   2 
7 Ticked - - - Ticked  Ticked 3 
8 - - - - -    
9 - - Ticked - Ticked  Ticked 3 
10 - - Ticked - -  Ticked 2 
11 - Ticked Ticked - - Ticked  3 
12 - Ticked - - - -  1 
13 Ticked Ticked - - Ticked - Ticked 4 
14  - - - - - - -  
15  Ticked -   Ticked Ticked 3 
16 - - - - - - -  
         
Total 5 4 6 2 6 2 7  
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Discussion of results for question 1 
The most popular protocol for treating the case study given was the 
correction of the miasmatic tendency.  This is a homeopathic concept relating 
to constitutional treatment.  The Psoric miasm can be defined as a 
constitutional tendency to ‘hypo functioning’ or lack of reaction.  The Heel 
Remedy Psorinoheel contains nosodes for the psoric, tubercular and sycotic 
miasm and could therefore be used to treat a wide variety of patients in a 
double blind trial setting. 
 
The second most popular option, the choice of 7 therapists, was the use of 
the remedy G3, this is a combination remedy produced by Guna in Milan.  It 
is formulated to stimulate the ovarian-pituitary feedback mechanism.  It 
contains 2 classical homoeopathic remedies (Pulsatilla and Kali Carbonicum) 
and two suis organ preparations (Ovarium and Corpus Luteum).  It is 
indicated in cases of ovarian hypofunction and functional dysregulation.  
Again this remedy does not need to be individualised as the underlying 
physiological mechanisms are common to all women and therefore the 
remedy could be used in a double blind trial. 
 
The use of potentised doses (D6) of the hormones, LH, FSH, Progesterone 
and Beta-estradiol was the third most popular choice, receiving 6 ticks.  
These remedies are universally applicable to all women and could be used in 
a double blind trial but the protocol is more complicated with different drops 
being taken on different days of the month.  This may mean that they are 
unsuitable for use in a trial where the patient is responsible for taking their 
remedies daily at home. 
 
5 therapists supported the view that a vaccination detox was justified, 4 
supported the option of supporting pancreatic function and detoxification 
using Syzygium compositum and Galium heel.  The least popular option was 
the use of the classical homoeopathy and this was congruent with the 
qualifications of the sampled practitioners and their forms of practice. 
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Homotoxicology is characterised by the use of more than one homoeopathic 
remedy at a time, which is why it is sometimes called ‘complex 
homoeopathy’.  5 therapists were happy to tick three options from the list to 
be given together.  2 therapists ticked four of the available options and 3 
therapists were happy to give just one and two of the choices on offer. 
 
3 therapies was the mean average as well as the mode or most frequently 
chosen.  In a real life therapeutic setting this would be feasible but from a 
clinical trial point of view it may be better to test one remedy at a time in 
order to ascertain the specific effect of that one remedy.   
 
The main weakness is the confusion between the two versions of the 
questionnaire, the results are not analysed separately.  The decision to 
include a second version of the questionnaire was due to the fact that the 
funding for trial medication changed half way through the process and so 
some of the Heel products were included in the questions.  After the 
questionnaire had been completed and negotiations with Heel were taking 
place it was clear that the remedy that they would like to trial was the 
Ovarium compositum tablet formula, this is analogous to the Guna G3 
formulation and works on the same principles.  
 
The decision was made that as G3 was the second most popular choice the 
equivalent remedy from Heel, Ovarium compositum, would be an appropriate 
medication for trial.  As a tablet formulation it had the advantage of being 
easy to randomise to placebo in a tablet form and easy to patients to self-
administer. 
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Figure 6 Cluster Diagram showing the emerging themes from analysis of the results 
  
The	  CAM	  practitioner	  as	  'advisor'	  based	  on	  beliefs	  about	  lifestyle,	  diet,	  health,	  toxins.	  
Exogenous	  
Ingluences:	  toxins,	  dental	  amalgam,	  infections.	  	  Electromagnetic	  radiation,	  Stress	  	  and	  Relaxation,	  Allergies,	  Nutrition,	  Diet	  and	  Lifestyle	  
Endogenous	  
Ingluences:	  Miasmatic	  /Consitutional	  type,	  Emotional	  Blockages,	  Basal	  Temperature	  and	  Ovulation	  	  Pathological	  changes	  Deregulation	  of	  Endocrine	  System	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Thematic	  Analysis	  of	  Questions	  2,3,4	  
 
The iterative sorting of the slips led to three main themes being identified: 
 
• The role of the practitioner in patient choice and self-care 
• The role of endogenous influences 
• The role of exogenous influences  
 
These themes are represented in Figure 6 Cluster Diagram showing the 
emerging themes from analysis of the results, the data that was collected is 
included in table form in the appendix: see Table 45 Summary of Practitioner 
Responses to Question Two; Table 46 Summary of Practitioner Responses 
to Question Three; Table 47 Analysis of Practitioner Responses to Question 
Four. 
The Role Of The Practitioner 
 
The practitioners emerged as ‘advisors’ and their advice was based on their 
beliefs about the causes of infertility: 
 
I would seek to find out what is causing the infertility.. 
 
The focus on treating various kinds of ‘toxicity’ is not surprising when the 
sample is targeted at homotoxicologists.  Toxins causing infertility fell into 
two groups, exogenous and endogenous, and the advice given spanned the 
‘whole’ range of mental, emotional, ‘energetic’ (e.g. vitalism), and physical 
domains of health and disease. 
 
Dietary advice was given to avoid processed foods, wheat (an allergen for 
some people), sugar and dairy products and some quotes indicated that this 
treatment would be individualised.  An organic diet, high in vegetables and 
complex carbohydrates was recommended and as well as supplementation 
of deficiencies: 
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Eat only high quality protein, fish, beef and lamb…eat only fresh 
food…organic food if possible…avoid white meats…avoid dairy 
products…minimise wheat and sugar and dairy dependent on further case 
taking….a diet high in vegetables and complex carbohydrates…Male 
supplements: anti-oxidants…vitamin C, ginseng, zinc, flaxseed oil, Females: 
evening primrose oil, copper, zinc, vitamin B complex, fish oils…maca 
supplement.. 
 
Both male and female cases were recommended to avoid nicotine, caffeine, 
alcohol and recreational drugs.   
 
No alcohol, no smoking, no drugs..reduce/eliminate intoxicants, cigarettes, 
alcohol or recreational drugs….avoid caffeine. 
 
The avoidance of plastics, microwaves, chemicals, and mobile phones were 
all recommended as well as the reduction of extreme lifestyles, exercise and 
exhaustive journeys.   
 
Eliminate mercury fillings...remove all toiletries…plus what is individually 
indicated…avoid all chemicals…avoid plastics and microwaves...particular 
emphasis on mobile telephone usage (if in trouser pocket can microwave 
sperm.)…reduce extreme lifestyles…do not fly long haul…de stress 
cortisone cycle.. blood sugar and adrenaline levels… 
 
Male patients were encouraged to avoid overheating in general and 
overheating the testicles in particular by wearing loose fitting underwear. 
 
Abandon Y fronts in favour of boxer shorts to cool the testicles… 
 
The emotional strain of infertility was recognised by practitioners who gave 
advice about counselling and stress reduction techniques.   
 
The emotional freedom technique may release deep emotions…the strain 
that couples go through with IVF is often marriage breaking so to give 
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counselling or advise external counsellor to see this through…reduce 
stress….teach a meditation/visualisation technique to improve positive 
thinking and results…yoga…and relaxation classes…energy and personal 
development work. 
 
The giving of advice in this way implies that by making these lifestyle 
changes the infertility will be ‘treated’. One limitation of the methodology of 
this strand is that the questionnaire does not capture the context of how the 
benefits of giving up and the chances of success would be explained to the 
patient.  This kind of data might have been captured using practitioner 
interview or by observing some consultations. 
 
Some homotoxicologists also recommended other concomitant treatment 
with therapies such as flower essences, reflexology or Chinese herbal 
medicine.   
 
Homotoxicologists who are also holistic dentists recommended the removal 
of crowns on the front teeth because they believe that the front teeth are 
positioned on certain meridians (Chinese medicine) that are influential in 
fertility outcomes. 
 
Some practitioners recognised the limitations of their knowledge or 
qualifications to treat: 
 
I would refer patient as I only treat dental problems.. not qualified to answer..I 
would pass this one, it would all depend on the patient.. 
 
The accuracy and authority of the advice was sometimes based upon a 
diagnostic tool such as Electro acupuncture (EAV) or Vega testing, typically 
recorded by the practitioner as ‘checking’ or ‘testing’: 
 
I would correct any imbalances apparent with vega testing.. the environment 
of the couple needs to be scrutinized with EAV…check miasms… test for 
mumps nosode..this would include checking for genetic inherited toxins, 
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viruses, bacteria (e.g.Chlamydia), amoeba and parasites.. check for NSU, 
check endocrine system for MMR and Scarlet Fever..I have no specific 
protocol under homotoxicology however I work with EAV.. using BFD.. 
 
Another use of technology was general assessment using a biofeedback 
machine for current health status  
Endogenous Influences 
The Deregulated Endocrine System 
Practitioners believed that infertility in both male and female cases was often 
being caused by a deregulated endocrine system, particularly the sub-
optimal functioning of ovaries or testes, although other glands were 
mentioned. Pathologies that can lead to infertility were also suggested as 
causes: 
Test for thyroxine and testosterone levels…Check out 
hyperthyroidism…strengthen liver and pancreas…I would check her 
thyroxine/thyroid level function...Nutri-Thyroid extract 
 
Endometriosis...undiagnosed ovarian cysts… 
   
The predominant therapy chosen to treat male infertility was the use of the 
Suis Organ remedies to stimulate the glandular function of the male gonads.  
Suis Organ remedies are homoeopathic attenuations of wholesome organs 
or tissues obtained from healthy animals, in this case pigs. The pig is 
selected because of the similarity between pig and human tissues.   
 
Homotoxicologists believe that the remedies act like an organ specific 
nosode and are believed to have stimulating properties in accordance with 
the homoeopathic similar principle, rather than being prescribed on individual 
symptom pictures.   
 
K2M…Testis compositum, ductus suis, coenzyme compositum, Testis suis… 
Roy Martina Endocrinotox 2 (General Male Regulation) and 7 (Male Gonad 
Endocrine Type)…  
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Where practitioners suggested that female infertility is due to a deregulated 
endocrine system, basal temperature checking would allow patients to self-
diagnose and the suggested treatment included combinations of classical 
homeopathic remedies, suis organs and potentised hormones: 
 
Thalamus comp..Ovarian compositum…K2F…Hormeel.. Potentised 
Hormones such as Beta-Estradiol, Progesterone D6 (luteal phase deficit), LH 
(D6-D30), FSH (D6-D30) ….Sepia D6..Gynacoheel..single low potencies of 
hormones..G3..Ovarian suis..overall stimulation of pituitary-adrenal axis 
using R29 Dr Reckeweg products.. 
 
Ovarian compositum was a popular choice and was not prescribed on 
individual symptom pictures but on the clinical indications of infertility due to 
ovarian deficiency. 
Exogenous Influences 
Many practitioners believed that environmental toxins were a cause of 
infertility. Some practitioners address these issues using Homotoxicology as 
a treatment.  The theme of exogenous toxins included past and present 
infections, as well as hereditary weaknesses, which were all seen as barriers 
to fertility, that could be treated with nosode therapy.  Some, as evidenced in 
the third extract below, demonstrated a holistic approach:  
 
Would look for endotoxins and exotoxins…High mercury levels..reduce 
external toxins through skin and air and from food..we also need to look for 
exotoxins, lead pipes etc..radiation…I find problems with fungus and 
mycotoxins in people’s houses..occupational hazards..jobs, hobbies, 
activities of both partners, geopathic stress, environmental pollution 
especially electro smog, phone masts,(G3), EMF’s etc…Water and quality of 
water, cosmetics, shampoos, household… endocrine disruptors 
etc…xenoestrogens, plastics etc… 
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Check miasms...test for mumps nosode...past infections particularly 
mumps..treat with Psorinoheel..check and treat miasms… brucella, past 
infections, viruses, bacteria (e.g. Chlamydia), amoeba and parasites..check 
for NSU, check endocrine system for MMR and Scarlet Fever 
 
The herbal treatment for high mercury levels are a concern here, due to 
mercury there may be some candida present 
 
One approach to the treatment of emotional blocks and stress, as an 
exogenous cause of disturbance to fertility, was the use of flower remedies to 
remove emotional ‘blocks’. 
 
Discussion 
 
The sample of practitioners was drawn from the database of UK registered 
homotoxicologists as well as other users of homotoxicology.   The themes 
that developed from the responses were influenced by an understanding of 
infertility as seen through the framework of homotoxicology theory.  The 
homotoxicological paradigm (Smit A, 2009) is a homeotherapeutic system in 
which a medical diagnosis is made, followed by an individualized 
assessment according to the severity of the patient’s disease.  This takes 
into account the response of the patient’s self-regulatory system to 
exogenous and endogenous stressors.   
 
The results show that the practitioners perceive infertility to have both 
exogenous causes such as stress and toxins as well as endogenous causes 
such as reproductive pathology or hormonal imbalance.  The holistic view 
that fertility is an expression of health and infertility is a disturbance of health 
is found in the theoretical framework of homotoxicology where treatment is 
given, to support the inherent self-regulating ability of the body rather than 
just treat symptoms, which are seen as an expression of the body’s own 
defence that should not be suppressed. (Heel, 1986). 
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The coding was also performed by myself, a qualified homotoxicologist and 
so the choice of codes may have been influenced by that same framework.  
The reliability of the coding could perhaps have been improved, if another 
researcher from outside the homotoxicology community had checked it, but 
that might have been at the cost of losing the detailed understanding of the 
concepts from the emic perspective. 
 
One of the aims of this strand was to investigate how homotoxicology might 
be used to treat infertility in practice and the analysis shows that 
homotoxicology may be used alone, or in conjunction with other therapies, to 
support the detoxification of the patient (e.g. Heel detox kit, gallium heel) for 
exogenous toxins and to support the endogenous factors such as regulation 
of the endocrine system (e.g. Testis compositum, Ovarian compositum). 
 
What is the role of the CAM practitioner in the treatment of infertility?  The 
CAM practitioner takes a holistic view of the health of the infertile patient, as 
shown in one of the extracts above in particular, and may advise a range of 
strategies to support their health and fertility including diet, nutritional 
supplementation, stress reduction, detoxification of endogenous and 
exogenous toxins, and stimulation of the endocrine system.  Treatments may 
be individualised by taking case histories or by using diagnostic techniques 
and technologies such as electro-acupuncture (EAV), Vega testing or Bio-
Functional diagnosis (BFD). 
 
Is there a specific treatment that can be given without a consultation and in 
the absence of an individualised prescription?  The use of complex 
homotoxicological preparations such as Ovarium compositum (females) and 
Testis compositum (males) are prescribed on clinical indications rather than 
individual case histories and would be suitable for use in a randomised 
controlled trial where the sample of patients are being recruited by the clinic 
for a specific clinical indication. 
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The results of strand one and the successful negotiation of a funding contract 
with Heel led to the selection of Ovarium compositum as the trial medication 
for the third strand of the study. 
 
Results	  from	  Strand	  2	  -­‐	  The	  Bridge	  Centre	  
Themes	  From	  The	  Staff	  Questionnaire	  And	  Discussion	  Group	  
Units of study 
Five nursing staff attended the interview and completed the questionnaire. 
127 questionnaires were distributed at the reception desk and 24 completed 
forms were returned for analysis. Copies of the questionnaires are included 
in the appendix see Questionnaire for nurses at The Bridge Centre 
 
Theory 
Nursing theory is a pluralistic discipline and the four central concepts of 
person, environment, health and nursing are interpreted in different ways 
according to the theoretical position of the nurse (Masters, 2014).  Some 
theories are more holistic than others, for example the Jean Watson 
philosophy and science of caring model (Watson, 1979) emphasizes the 
integration of mind, body and spirit and is open to the mysterious and 
unknown dimensions of life, death and suffering (Watson, 1979).  
 
Based on humanistic nursing theories such as Callista Roy’s (Roy et al., 
2009) adaptation model,  nursing  may include the concept of caring for the 
holistic man (person), who is on a daily position along a health-illness 
continuum.  This can be compared to the perspective of the doctor, whose 
focus is on disease and whose goal is to move the patient along the 
continuum from ‘illness’ to ‘health’ (Simoni, 1981) 
 
Some nursing theory models, for example (Watson, 1979),  have a focus on 
the principle of ‘caritas’ which means to love or cherish and again this can be 
compared to the principle of ‘virtue’ that has been proposed as the guiding 
principle for a medical training, that has internal norms and values, as well as 
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a technical body of knowledge (Shelton, 2013).  The ‘virtuous doctor’ and the 
‘caring nurse’ would make an interesting area of research, particularly if 
undertaken from a feminist perspective or using a transformative theoretical 
lens.   
 
There is also a philosophical debate around ‘virtue’, as either an Aristotelian 
absolute that exists ‘out there’ to be attained or as Dewey argues, a position 
that is gained by acting reflecting on experience within specific contexts: 
 
Aristotle assumed the embodiment of certain virtues in the polis, such as 
courage, prudence, temperance, and bravery, but in a pluralistic democratic 
and postmodern age, our virtues are not given. If they exist at all, they will be 
determined by conscious agreement and dedication on the basis of insight 
into an understanding of the conditions of life and those actions most 
compatible with life and flourishing, or what Dewey called “intelligence.” 
(Shelton, 2013) 
 
Themes 
The data used to generate the themes is included in the appendix see Coded 
Data from Staff Questionnaire and Discussion Group 
Nurses As A Bridge for patients between CAM and IVF. 
A core theme generated by the eight codes used was the idea that the 
nurses represented a bridge between the CAM therapies and the 
conventional medical perspective.  They could see the potential benefits to 
patients of using homeopathy and this positive attitude was tempered by their 
professionalism and caution.  They were well informed about the practical 
issues of running a trial at the clinic and could anticipate the likely reactions 
of the staff and patients towards such an idea.   
 
Some nurses had experience of homeopathy and CAM that gave them 
confidence as shown in the extract below:  
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As a midwife I’ve cared for many women using remedies so I’ve gained some 
knowledge… Personal use to treat Hay fever… Echinacea with colds, rescue 
remedy with stress, gingko balboa for memory… 
 
Caring For The Patient 
By putting the needs of the patient first nurses could see that homeopathy 
might provide benefits in the form of stress reduction, placebo effect or 
increased well being.   The homeopathy could be seen as ‘more natural’ by 
women who are having invasive assisted reproduction techniques. Caring for 
women undergoing IVF also involves nurses supporting women who are 
emotionally distressed by treatment failure, if their nursing education has 
prepared them to care for the whole person including mental and emotional 
health they may see homeopathy as offering support on a more holistic level: 
 
I think believing in the remedies will make someone to use them with a hope 
of success and belief = success…More pregnancies…More relaxed 
patients… Not a quick cure but something that can help/ease illness… 
General wellbeing, find treatment less stressful, patients able to move on 
with life re deciding not to continue with treatment… For certain patients with 
problems like overweight which may affect their chances of having children I 
think they will benefit from the project…Relaxes the body and minds as well 
as relieves their stresses therefore promote health… I would probably say try 
anything (safe) once if it will help you get pregnant or have another positive 
effect on your health…. It is their choice, if it is beneficial then let them try… 
 
There was also a perceived benefit as a unique selling point for the clinic: 
 
Potentially it could be of great benefit to clinic if we can sell the clinic as 
having an option of IVF or IVF plus homeopathy… 
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Boundaries Of Professional Role 
A conflict arose when trying to balance holistic needs of the patient with their 
role as ‘technical assistants’ to the doctor’s performing the assisted 
reproduction. 
They did not feel that the doctors would agree with them, or share their 
interest, and they recognised that patients may also have concerns about 
taking part in a randomised trial with an unknown drug and the possibility of 
being randomised to placebo: 
 
 Lack of knowledge on Doctors behalf, unwilling to believe, patients not 
wanting to go on a placebo, patients not wanting to delay treatment… Asking 
women if they are willing to delay treatment with a 50% chance they will be 
on a placebo… 
 
Patients not wanting to try the homeopathy…patients getting angry or upset 
because trial hasn’t worked or no benefits…. Professional (concerns), 
patients, drugs not known so tend to stop… 
 
The Need For A Theoretical Perspective 
To balance these concerns the nurses needed to feel that they were well 
informed about the trial drug and it’s possible side effects so that they could 
explain the risks and benefits to the patients or support them in making a 
decision: 
 
Need more information…Fine with more training re homeopathy…To explain 
the mechanism to clients…Knowledge, actually understanding everything I’m 
telling patients before I talk with them… It’s a very good idea but not enough 
training to impart knowledge... Ethical dilemmas – consider!!! 
 
They were happy to take part in the trial because they felt that hosting the 
trial they were helping to provide an evidence base for something that might 
support their patients: 
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I’m interested but sometimes sceptic, I like the idea of research and proof 
and if scientific research can justify then fantastic…Fine with more training re 
homeopathy… positive...Happy (to take part)… 
 
They identified practical difficulties in hosting a trial, such as the appointment 
times that would need to be extended, and the need to get a large sample 
size to create a credible result: 
 
Talk 30 mins to one hour, probably best to organise further talk…Not long 
enough, 5-8 minutes approx….More (time needed)…Not enough with nurses 
talks up to one hour….OK just hope we can recruit enough women to get 
results 
Discussion of Results 
The nurses at the clinic provided a perspective that appeared to bridge the 
dualistic choice between the dismissal of homeopathy by some medical 
practitioners and the personal choice to use homeopathy made by some 
patients 
 
They were open to the idea and potential benefits and could also see 
practical challenges to implementing a trial.  Their support would be 
necessary to run such a trial and would need to be fostered by the 
researcher.  They would like to receive more training and information so that 
they could advise patients and colleagues and this would need to be planned 
into the trial schedules.  They recognised that their patients often suffer 
emotional distress and disappointment at treatment failure and for that 
reason may not wish to take part in a trial where they could be randomised to 
placebo.  The other issue raised was that it would not be ethical to delay any 
conventional treatment as women’s fertility outcomes decline with age. 
 
The sample of nurses in the discussion group were not asked about their 
training or theoretical orientation and that would have provided a conceptual 
level to the analysis if it had been included.  There has been some debate in 
the nursing profession about the need for reflection on theory and the 
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cultivation of metaparadigms in order to raise the professional standing of 
nurses (Lee and Fawcett, 2013) and to avoid ‘burn out’ in the work place.   A 
future research project springing from this study could aim to find out more 
about the influence of nursing theory on the acceptance or rejection of CAM. 
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The Patient Questionnaire from The Bridge Centre 
Table 24 Table of results for patient questionnaire 
 
Question  Yes No 
Question One. 
Have you ever tried Homotoxicology as a therapy? 3 21 
Question Two. 
Have you tried Homotoxicology as part of your 
treatment for infertility? 
1 23 
Question Three. 
Would you consider trying Homotoxicology in 
the future as part of your treatment for 
Infertility? 
22 2 
Question Four. 
Would you be prepared to take part in a clinical trial where you may 
receive a placebo or no medication instead of the active remedy? 
15 9 
Question Five. 
Would you be willing to take your medication 
daily at home, as drops or tablets? 
23 1 
Question Six. 
Would you be willing to give up 
peppermint and coffee? 
24 0 
Question Seven 
What would be your motivation to take part in a clinical trial of 
homotoxicology   
(i) To increase my chances of ovulating? 20 1 
(ii) To help other couples in the future? 22 1 
(iii) To increase knowledge about homeopathy? 20 2 
(iv) Decided to stop trying with IVF/ART 7 7 
Question Eight 
Would you be happy to pay for homotoxicology in the future if this was 
shown to be an effective therapy? 
20 2 
Question Nine 
Would you be prepared to take homotoxicology remedies at the same 
time as your conventional medication? 
21 3 
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Discussion of results from the patient questionnaire 
The patient group that was surveyed is a vulnerable group undergoing 
stressful psychological and physical experiences and therefore sensitivity 
was required when asking for their cooperation.  Postal questionnaire 
response rates are declining in the general population and strategies on how 
to increase them were employed, including the use of a prepaid return 
envelope and a university return address.  The response rate to this 
questionnaire (19%) was average for its type and the patient group 
concerned (Roberts PJ, 2002).   
A high level of altruism was displayed by respondents 91% of whom were 
motivated by the desire to take part in a trial that would help other infertile 
couples in the future, 85% were motivated by the point that a trial of this kind 
would increase our knowledge about homotoxicology and homeopathy. 
It is likely that the respondents who chose to respond will have a positive 
bias towards the subject matter, but as future patient choice would be an 
important factor in integrating CAM this survey can be viewed as a positive 
indicator of potential patient demand.  Nevertheless, homotoxicology 
represents a novel intervention to the respondents, as 88% had not tried this 
therapy before. A high level of interest (92%) was shown in trying 
homotoxicology in the future. A large majority, 83%, would be willing to pay 
for treatment if homotoxicology was shown to be effective. The use of 
homotoxicology is apparently not viewed as an alternative by these patients; 
only 2% indicated that they would consider homotoxicology because they 
were considering stopping IVF/ART. 
The feasibility of setting up a double blind trial is enhanced by the fact that 
62% would be prepared to take part in a trial where they may receive a 
placebo. A high level of participant compliance is indicated by the fact that 
95% would be prepared to take their medication at home and to 100% would 
be happy to give up peppermint and coffee.  
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Limitations 
It was not possible to record the number of patients who did not take a 
questionnaire from reception and therefore the sample of respondents is 
biased towards patients that have some interest in taking part or finding out 
more about the trial. 
Summary 
In conclusion it appeared that a randomised controlled double blind trial was 
a feasible option and that there would be a high level of participant 
compliance and motivation.  The focus group provided some valuable 
insights about trial recruitment and implementation, for example the amount 
of time nurses will have to discuss the trial with potential subjects, the need 
for specialist training in the background information about homotoxicology 
and the ethical dilemma of asking women to consider taking part in a trial 
when they are already undergoing stressful treatment.   
The results of this survey were presented at the William Harvey Research 
Institute Open Day in 2007 and a copy of the abstract and poster are 
included in the appendix Figure 22 Poster. 
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Results	  from	  Strand	  3	  -­‐	  A	  Double	  Blind,	  Randomised	  Controlled	  Trial	  of	  
Ovarian	  Compositum	  in	  Infertile	  Women	  
THE RECRUITMENT TO STUDY OVCT-001 
Introduction 
Recruitment was started in November 2011 and stopped in July 2012, during 
that time 4 patients were enrolled and 4 more identified as appropriate and 
sent a recruitment invitation letter by the unit.  They are summarised in Table 
25 Summary of recruitment below. 
Of the 3 patients that were consented 1 withdrew after initial screening as 
she became pregnant before she started the trial medication.  1 patient 
completed 6 months of treatment, 1 patient withdrew after 1 month due to 
compliance issues and 1 patient withdrew after 2 months also with 
compliance issues. 
Randomisation 
number 
Age 
band 
(years) 
Treatment 
Group 
Trial medication 
group 
Outcome 
1201 30-35 Clomid Ovarium 
compositum 
Treatment stopped 
after 2 months 
1202 30-35  Clomid Ovarium 
compositum 
Treatment stopped 
after 1 months 
1204 30-35 Clomid Placebo Withdrawn from 
trial due to 
pregnancy before 
taking trial 
medication 
1301 >35 Clomid Placebo Completed 6 
months of 
treatment 
 
Table 25 Summary of recruitment 
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Delays To Recruitment Caused By Damage To Trial Medication 
During December 2011 another event delayed recruitment to the trial, the 
Pharmacy in Jersey alerted the researcher to the fact that the trial medication 
was compromised.  There were a number of broken containers and 
containers with broken seals.  A list of the damaged tablet containers is 
shown in the appendix see APPENDIX 9 Damage To Trial Medication 
The recruitment process was suspended pending further investigation and in 
early February 2012 Ms C Haresnape (Researcher and CI), Prof Atholl 
Johnston (PhD supervisor) and Dr Istvan Zatik (Funder- Heel GmBh) flew to 
Jersey for a site visit.  It was ascertained that the trial medication had not 
been examined on arrival at pharmacy and so it may well have been 
damaged during transportation.  Some pots were opened with broken seals 
and there were no security seals on the boxes of pots.  The outer boxes were 
sealed and unopened as so it was decided that the packaging of the tablets 
was at fault and had not been strong enough for the transportation process 
by air. 
Sufficient medication was available for the recruitment targets and so it was 
deemed appropriate to continue with the trial.  The damaged pots were 
removed for secure destruction by pharmacy.  The incident created a further 
two-month delay to recruitment. 
Timeline of recruitment. 
The final feedback during a site visit in September 2012 was that with 
hindsight the set up and design of the project should have been a joint 
consultation with nursing staff as this project had created a strain on the 
department.  
This strain had become evident from the email correspondence during 
November 2011 when the full time nurse in the Assisted Reproduction Unit 
(ARU) found that the time taken to book screening appointments was putting 
pressure on her existing workload (Thomas, 2011).  She described the 
service as ‘small but overstretched’ and suggested that the lead consultant 
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had not fully appreciated the impact that running a trial would have on the 
unit.   
A site visit was arranged for 1st February 2012 to discuss recruitment and 
other issues.  The unit staff suggested that the extra appointments required 
for USS and blood tests were a reason for low recruitment and retention of 
patients to the trial.   The doctors suggested that we started recruiting from 
the pool of patients who had already started their Clomid or FSH treatment. 
The nurse had reported problems with compliance and in order to try and 
boost retention a change to the protocol was proposed which allowed 
patients to take their medication three times a day, morning, afternoon and 
evening but not at a specific time.  These changes were made and the ethics 
committee informed. 
The ARU nurse provided further emailed feedback in February 2012 
(Thomas, 2012) making the  following points:  
There had been no further requests from patients to join the trial. 
Patients feel it is too big a commitment as they have to attend the unit during 
their working day and treatment may persist for several months or even 
years. 
In March 2012 there was again little to report and the message from the unit 
was that subjects ‘don’t like the extra hassle’ (MacLachlan, 2012a) but there 
was the intention of continuing to try and recruit further patients. 
The need to increase recruitment was becoming increasingly urgent as the 
expiry date of the trial medication had to be taken into account.  Any patient 
who did enrol must be guaranteed a 12-month supply of medication and this 
meant that recruitment must stop in July 2012. 
With this in mind the ethics of a campaign of publicity was discussed with 
Heel to include meetings with the local media, meetings with local GP’s, 
meetings with local patient support groups.  These ideas were put forward to 
the Jersey unit but the response (MacLachlan, 2012c) was that the local 
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fertility group is new and very much aimed at IVF; the local GP’s do not 
prescribe Clomid so their patients do not meet the inclusion criteria for the 
trial; and that although approaching the local press was seen as a good idea 
the main problem still appears to be the need to attend additional 
appointments. 
Towards the end of March 2012 a telephone conference with the ARU nurse 
highlighted the following points:  
• If she had been consulted earlier in this process she would have 
predicted the difficulties in recruitment due to her experience and 
knowledge of the patients. 
• She could have helped design the documentation by using existing file 
formats and templates. 
• Patients are stressed by extra appointments because Jersey is such a 
small island and it is difficult to maintain privacy around their 
treatment. 
In April 2012 a telephone conference with Dr Istvan Zatik from Heel GmbH 
confirmed that we would not be able to boost recruitment by looking to move 
this trial to another UK site, as Heel senior management would not support 
that move.  No further trial medication was to be authorised and a meeting 
was arranged with Dr Alta Smit of Heel GmbH in London for early May 2012 
to discuss these points. 
In June 2012 we discussed closing down the trial via email and the response 
from the unit (MacLachlan, 2012b) was that despite their genuine wish for the 
trial to succeed a number of unforeseen circumstances had created 
obstacles to success.  This included a perception by patients that taking part 
in the trial might slow down their transition through the conventional 
treatment modalities and also created extra visits, blood tests and intrusive 
scans. 
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A formal letter of trial closure was sent to all stakeholders in July 2012 and a 
final site visit was made in September 2012 to meet, collect the paperwork 
and discuss the outcome. 
Discussion points arising from recruitment 
The clinical staff at the unit identified the following themes: compliance, 
frequent blood testing and USS, high expectations, coincidental issues. 
Compliance. 
2 out of the 4 patients stopped taking medications because of difficulty taking 
the tablets 3 times daily at a fixed time.  It was also noted that they felt that 
the taking of the trial medication acted as a perpetual reminder that they 
were infertile and this created emotional distress 
Frequent blood testing and USS (Ultrasound Scan). 
In addition to monthly blood tests for FSH, E2 at day 2 and Progesterone at 
day 21, patients needed to have baseline USS every month and this was not 
normal practice for Clomid patients. This added extra appointments to their 
schedule, which were difficult for patients who were working to 
accommodate.  
High Expectations  
The feedback from the clinic was that patients had elevated expectations of 
the success of their treatment because they were taking daily medication and 
having more frequent blood tests and USS. 
Coincidental Issues 
During the autumn/winter of 2011 and spring 2012 the clinic experienced a 
higher pregnancy success rate and this made the recruitment of new trial 
subjects more difficult. 
RESULTS 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   315	  
The Recruitment process - Reflection and feedback from clinic staff. 
A clinic with a higher input of a more homogenous patient group would make 
recruitment easier and they suggested that future trials should focus on one 
subgroup with a specific definition of infertility. 
Some patients were biased against trying CAM, as they were worried it might 
slow down their progress through their conventional treatment.  Patients are 
conscious of the timescale of their fertility treatment, as age is a predictor of 
success. 
There are a high percentage of Portuguese girls in the local population and 
they are expected to bring a friend or translator, this made it more difficult to 
make the additional appointments needed for trial participation. 
The fertility clinic feeds into a mainland IVF unit and they had expressed 
some doubts about patients being involved in a CAM treatment and this was 
based on some evidence about Chinese herbs. 
It would be preferable to have a research Doctor based on site as the lead 
investigator. 
Summary 
Over a period of nine months (November 2011 – July 2012) unit staff 
identified suitable patients who attended the ARU.  Four patients agreed to 
take part and three of them were consented. Of the 3 patients that were 
consented 1 withdrew after initial screening as she became pregnant before 
she started the trial medication.  1 patient completed 6 months of treatment, 
1 patient withdrew after 1 month due to compliance issues and 1 patient 
withdrew after 2 months after compliance issues. 
Recruitment and retention rates were low due to a combination of reported 
circumstances: 
• A higher than expected pregnancy rate at the clinic left fewer eligible 
subjects. 
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• The difficulty of attending additional appointments for working women 
who are wary of disclosing their treatment to colleagues, family or 
friends 
• The burden of extra work on the ARU staff who did not feel any 
‘ownership’ for this trial, as they had not been involved in the planning 
stages. 
• Patient perceptions of the impact of taking part in a trial on their 
treatment progression or outcomes 
• The subjects that were recruited to the trial OVCT-001 are 
summarised as follows: 
 
Randomisation 
number 
Age 
band 
(years) 
Treatment 
Group 
Trial medication 
group 
Outcome 
1201 30-35 Clomid Ovarium 
compositum 
Treatment stopped 
after 2 months 
1202 30-35  Clomid Ovarium 
compositum 
Treatment stopped 
after 1 months 
1204 30-35 Clomid Placebo Withdrawn from trial 
due to pregnancy 
before taking trial 
medication 
1301 >35 Clomid Placebo Completed 6 months 
of treatment 
Table 26 Summary of Recruitment to study OVCT-001 
 
The data for the four subjects who were consented to the study was collected 
from Jersey General Hospital and is included in the appendix as APPENDIX 
10 Data collected from Jersey General Hospital participants in pilot study.  
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The data is described but cannot be subjected to statistical analysis as the 
sample was too small and only one subject attended more than two 
appointments. 
This study failed to meet its recruitment targets for the reasons given above 
and this generated a new hypothesis for further investigation into the work 
related concerns of women seeking infertility treatment, this is investigated in 
strand four of the thesis.  
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Chapter 4 Results for Strand 4 
Results	  for	  Strand	  4	  -­‐	  A	  Qualitative	  Analysis	  Of	  The	  Work	  Related	  Concerns	  
Of	  Infertile	  Women	  
Theory  
Writing up the themes was an integral part of the analysis and there was an 
iterative process of reading and writing as patterns of meaning and areas of 
interest were studied.  The early engagement with the literature had 
suggested ‘emotional distress’ as a theme so emotions but some reading 
was left until later to avoid narrowing the researchers field of view.   
Scientists who study the relationship between emotional health and physical 
health (psychosomatic medicine), have seen several theoretical shifts in the 
last 30 years (Medicine, 2015).  Scientists have moved away from simple 
behavioural models based on theories of stimulus and response in lower 
organisms (Skinner, 2011) towards a concept of an integrated complex and 
dynamic system of two way communication between mind and body 
(Hiramoto et al., 1997) 
 
The early model that was based upon psychoanalysis has been replaced 
with concepts that mostly derive from the work of early twentieth century 
Harvard physiologist Walter B. Cannon.  Cannon’s model was that of the 
biological organism that automatically mobilized its physiological and 
biochemical resources to defend itself against real or threatened assault 
using it’s own innate ‘wisdom’ (Cannon, 1916).  The presence of negative 
emotions such as fear or rage would cause the organism to prepare for fight 
or flight by shutting down energy-storing functions and activating energy-
releasing ones.  Cannon also defined the word homeostasis in 1932, deriving 
it from the Greek words homios (the same) and stasis (stance or posture).  
Homeostasis thus means to stay in the same condition or position (Smit A, 
2009) and this concept will be explored in more detail later in this thesis. 
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These ideas were further developed by Wolff (Wolff, 1953) and then Hans 
Selye who emerged as a leading proponent of stress based theories (Selye, 
1973).  Selye’s theories were based upon the idea that “stressors” such as 
cold, heat, solar radiation, burns and ‘nervous stimuli’ produced a 
generalised response it the biological organism as an adaptive response.  
The stress response was divided into three stages and included both the 
nervous system and endocrine system as part of a cascade of neuro-
hormonal messenger molecules from the hypothalamus to the adrenal 
glands.  The three stages were known as the ‘alarm’, ‘adaptation’ and 
exhaustion phase.   
 
Selye’s work was influential in a wide range of medical and other health 
related fields including the development of Homotoxicology.  Homotoxicology 
theory includes the concept of the role of the Hypothalamus-Hypophysis-
Suprarenal cortex in the Greater Defence System (Smit A, 2009) (INSERT 
CROSS REFERENCE to literature review) 
 
The discovery that the nervous system and the immune system were able to 
share a common language of neuropeptides and neurotransmitters was 
popularised in the 1990’s (Pert, 1997) and more recently the interactions 
between psychological processes and the nervous, immune and endocrine 
systems of the body are being studied as a new branch of medicine called 
Psycho-neuro-endocrine-immunology (PNEI), sometimes referred to as just 
PNI (psychoneuroimmunology). 
 
Psychoneuroimmunology refers to the study of the interactions between the 
behavioural, neural, neuroendocrine, and immunological process of adaption 
Although relationships between the brain and the immune system have been 
suggested for many years, research has now provided mechanisms for how 
these systems may interact (Weigent et al., 2011).   
 
The widely held belief is that it represents a bi directional system.  The 
nervous system not only influences immune function but the immune system 
modifies the nervous system.    (Weigent et al., 2011) 
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Collectively these relationships provide the foundation for behaviourally 
induced alterations of immune function and for immunologically based 
changes in behaviour. (Weigent et al., 2011) 
 
By 1894 Pragmatism had also challenged the dualism that viewed mind and 
body as separate.  Dewey, Tufts, Mead and Angell were forming the basis of 
the so-called "Chicago group" of psychology. 
 
They had a practical emphasis on action and application. In Dewey's article 
"The Reflex Arc Concept in Psychology" (Dewey, 1896) he reasoned against 
the traditional stimulus-response understanding of the reflex arc in favour of 
a "circular" account in which what serves as "stimulus" and what as 
"response" depends on how one considers the situation, and defends the 
unitary nature of the sensory motor circuit 
 
He developed the idea that there is a coordination by which the stimulation is 
enriched by the results of previous experiences. The response is modulated 
by sensorial experience. This article has become a classic in the history of 
modern psychology and is often identified as the beginning of the 
functionalist approach in psychology (Titchener, 1898). 
 
Dewey characterized the organism-environment transaction as a process of 
continuous readjustment, not simply as an external stimulus and then an 
organism’s response.  Through selection and assimilation the organism 
establishes a dynamic coordination with its environment.  The increase of the 
range of coordination is one of the central development processes, leading to 
a new state of intelligence (Biesta and Burbules, 2003). 
 
The idea that environmental and emotional experiences, in conjunction with 
genetic and epigenetic factors, can modify inflammation pathways, brain 
structure and emotional responses is one that the advances in neuroimaging 
and neurochemistry are being used to explore in diverse fields such placebo 
effects (Benedetti et al., 2011), posttraumatic stress disorder (Pace and 
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Heim, 2011),  wound healing (Gouin and Kiecolt-Glaser, 2011) and cancer 
(Lissoni, 2012).  
 
The effects of prenatal maternal stress has been shown to cause immune 
disorders in offspring, psychological stress acts as a programming 
determinant by setting functional parameters to abnormal levels, thus 
inducing postnatal maladaptation (Veru et al., 2014).   
 
Stress promotes inflammation, impairs antibody responses to vaccination, 
slows wound healing, and suppresses cell-mediated immune function, Thus, 
stress-induced immune deregulation during pregnancy has unique 
implications for both maternal and fetal health, particularly preterm birth. The 
application of psychoneuroimmunology research models to the perinatal 
period is being used to elucidate the biological pathways by which stress 
may affect adverse pregnancy outcomes, maternal health, and fetal 
development (Christian, 2012). 
 
Higher levels of stress as measured by salivary alpha-amylase are 
associated with a longer time-to-pregnancy (TTP) and an increased risk of 
infertility (Lynch et al., 2014).  It is thought that stress significantly reduced 
the probability of conception each day during the fertile window, possibly 
exerting its effect through the sympathetic medullar pathway (Louis et al., 
2011). 
 
The mechanisms are thought to include centrally controlled GnRH pulse 
inhibition (Ferin, 1999) (Li et al., 2010) as well as autonomic nervous system 
activation leading to alterations in ovarian and uterine function (Schenker et 
al., 1992) (Rockliff et al., 2014). 
 
The impact of emotional stress upon fertility has been investigated 
(Cousineau and Domar, 2007)  who found that the inability to conceive 
children is experienced as a stressful situation by individuals and couples all 
around the world. The consequences of infertility are manifold and can 
include societal repercussions and personal suffering. Evidence is emerging 
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of an association between stress of fertility treatment and patient drop- out 
and pregnancy rates. (Cousineau and Domar, 2007) 
 
Psychological interventions, especially those emphasizing stress 
management and coping-skills training, have been shown to have beneficial 
effects for infertility patients. Further research is needed to understand the 
association between distress and fertility outcome, as well as effective 
psychosocial interventions (Cousineau and Domar, 2007). 
 
Their findings have been updated by a more recent systematic review of 
psychosocial factors associated with emotional adjustment in in vitro 
fertilization patients (Rockliff et al., 2014) who found that  social support as a 
coping strategy and perceiving one’s social circle as supportive were 
positivity associated with reduced emotional stress. Neuroticism and escapist 
coping strategies were found to be associated with increased distress by 
numerous studies (Rockliff et al., 2014). 
 
They acknowledge that: 
There is also a paucity of research using positive emotional outcome 
measures (e.g. well-being, positive affect, happiness or life satisfaction) to 
quantify psychological adjustment (Rockliff et al., 2014). 
 
The distinction between mind and body is not maintained if PNEI is used as a 
framework for viewing the connection between stress and infertility, they are 
acknowledge to be an integrated system, working together in an adaptive 
manner to overcome disturbances to health. 
 
There does however remain the question of what to measure and how to 
measure it.  If a quantitative perspective is taken of the phenomenon then a 
quantitative answer will be produced, the same phenomenon studied using a 
qualitative technique will produced and the dualism is still present in the 
results and interpretation of the results. 
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It is argued in this thesis that Mixed Methods research would allow both 
perspectives to be integrated and allow a fuller understanding of the 
phenomenon. 
Summary 
The field of PNEI offered an opportunity to research the role of emotional 
stress in female infertility using a scientific post positivist perspective, a 
homotoxicological perspective and a pragmatist philosophical perspective.  
All three models view the organism as dynamic, adaptive and in constant 
transaction with their internal and external environment.  These perspectives 
will be used as a theoretical framework for the explanation of the themes in 
this chapter. 
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Results	  for	  Strand	  4	  
Units of study 
Stage 1: Seven forum users emailed a direct response with information about 
their personal experiences.   
Stage 2: 213 postings from the My Story section of the Infertility UK forum. 
The data used to generate the themes is included in the appendix see 
APPENDIX 11 Qualitative Data From Strand 4 
A mind map of themes was generated (Figure 21 Mind map from early 
coding memo) and this model was discussed with two other researchers. 
This discussion led to refinement of the themes; for example the concept of a 
crisis of identity as lying at the heart of the themes around disclosure resulted 
from this discussion of the data. 
After this talk it was clear that Charmaz’ work on disability disclosure had 
parallels with my own work. This shift in underpinning theory to better fit the 
theoretical framework to the data is common in thematic analyses (Kelly, 
2010) and is recognised in the CASP checklist for quality of qualitative 
analysis. (http://media.wix.com/ugd/dded87_29c5b002d99342f788c6ac670e49f274.pdf) 
 
The smaller sample (stage 1) was then analysed again by comparing it with 
the Charmaz model of ‘’Forms of Telling” as the theoretical underpinning, 
and the results of this analysis used to generate the ‘Relative Risk vs. 
Benefit’ model Figure 7 Thematic Map. 
Charmaz - Disclosure At Work And Self-Identity 
Identity, chronic illness and disclosure at work have been investigated by 
Charmaz (Charmaz, 2010).  We can draw valid comparisons between 
infertility and her analysis of chronic disease because of the long lasting 
nature of infertility and infertility treatment which can span several years and 
has a major impact on psychological, emotional and physical health.   
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Charmaz highlights the need to use insights from research into chronic 
disease to inform the management of human resources in the international 
workplace and this is directly relevant to the socioeconomic structure of 
Jersey which, as an offshore banking community, hosts offices for many 
multinational corporations: 
‘Managers in global organisations may need additional training that focuses 
on dealing with and facilitating such disclosures, and universities all over the 
world involved in preparing local and international business graduates need 
to consider this issue in designing course content.’ (Charmaz, 2010) 
Infertility, like chronic disease, may remain invisible in the workplace until 
people feel forced to reveal their condition or request special 
accommodations: 
‘What is means to disclose illness and disability depends on a person’s 
health problem, cultural traditions, social values and norms, hierarchical 
arrangements, and specific policies in a given workplace.’ (Charmaz, 2010). 
If visibility does not force disclosure then people see themselves as who they 
have been, not as who they have become.  Workers with a chronic condition 
may experience daily limitations and restrictions but because they have 
devised ways of organizing their life around them they do not feel a need to 
disclose their condition.  Disclosure is often associated with an episode 
hospitalization and this could be compared with the hospitalization needed 
for IVF procedures or the aftermath of an unsuccessful implantation. 
Charmaz notes that questions about disclosure also involve the relative 
legitimacy granted to the person’s medical condition and as we discussed 
earlier in this chapter fertility treatment is not a "deemed incapacity" for 
statutory sick pay purposes.  She highlights the fact that legitimacy matters to 
validate competent work, adult status and social acceptance.   
‘Experiencing an illness or disability often conflicts with business values that 
assume constant involvement and productivity, speed, coordinated timing, 
regular schedules and predictable performance levels.’ (Charmaz, 2010) 
RESULTS 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   326	  
If as she say; ‘Disability does not reside entirely in the individual’ but also 
‘depends on his or her match with a specific job’ then we can see the 
confusion caused by people switching between two roles: being competent at 
their job and then becoming unable to maintain that level of competency for a 
period of time due to the demands of their treatment regime. 
It is understandable therefore that the positive or negative feedback from a 
manager will become an important validation of that person and their self-
concept as they fluctuate between these two roles. Face-to-face relationships 
with shared interactions also shape how employers view people with 
disabilities (Charmaz, 2010). Employees who spend time face-to-face with 
their employer are more likely to experience a favourable outcome in 
negotiations about time needed for treatment. 
Infertile men and women also face uncertainty about their probability of 
becoming parents and may have experienced loss of social and self-worth.  
In chronic illness this may lead people to struggle with losing their financial 
independence but in infertility this would not necessarily be the case. 
Charmaz provides a model of the dilemmas of disclosure for an employee, 
which includes choosing between honesty, and privacy where cultural 
stigmas associated with may influence that decision, this can be applied 
directly to infertility because disclosure may result in scrutiny or intrusive 
questions but also allows the person to explain behaviour that might have 
looked odd or suspicious.   
Disclosure may be staged or spontaneous depending upon the felt emotional 
intensity, difficulty in telling, emotional and informational control, amount and 
kind of planning and intended audience effect (Charmaz, 2006).   
Models From HIV Theory 
Additional models for disclosure are provided by the studies that have looked 
at HIV status disclosure in men (Derlega and Chaikin, 1977) and women 
(Serovich et al., 2008), (Serovich, 2001). 
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The findings suggested that women may evaluate the rewards and costs of 
disclosure to family and friends before it occurs but the study design did not 
allow data to be collected on how this processing occurs, how rewards and 
costs are weighed, who is involved. (Serovich et al., 2008). 
The disease progression model has been used in HIV theory to explain 
disclosure that occurs as the disease becomes more visible or requires 
hospitalisation (Crandall and Coleman, 1992).  The parallel could be drawn 
with women who need to ask for time off work in order to attend the infertility 
treatment appointments or whose treatment side effects are making them 
unwell. 
Consequence theory has also been used to explain the decision to disclose 
HIV status (Serovich, 2001) .  The consequence theory of HIV disclosure 
suggests that disease progression influences disclosure through individuals’ 
perception of the consequences anticipated as a result of disclosure.  This 
may include the consequences of disclosing to sexual partners, children and 
friends and the anticipated positive or negative outcomes of disclosure. 
Thematic Analysis 
The analysis of the two samples gives an indication of the concerns faced by 
working women undergoing infertility treatment.  The response to the direct 
request for information was a small one, about 0.18%, considering the size of 
the forums (described 4000 members by the administrator) on which the 
request was posted and may indicate that employment concerns are of low 
importance compared to other challenges faced when trying to conceive.  It 
must also be noted that my request may only have been seen by a small 
percentage of forum users.  The themes identified in the first, smaller sample 
are described in detail here with additional quotes from the forum users.  The 
themes are developed into an analytical interpretation of the relative risks 
and benefits of disclosure at work, to friends and family and on the forum. 
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Themes 
Two main themes were identified, firstly the conflicting identities of the 
respondent as both an employee and an infertile treatment seeker, and 
secondly, the emotional distress caused by infertility and infertility treatment.  
Linking these was a further theme about the legitimacy of their condition. 
 
Consideration of the subthemes within these led to development of a higher 
order thematic map as shown below in Figure 7 Thematic Map: 
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Figure 7 Thematic Map 
!!!!
!
Disclosure!(strategic!or!spontaneous)!Non3disclosure!and!desire!for!privacy!
Sexual'
discrimination'
for'time'taken'off'
work'for'
treatment!
Flexible'
working'
arrangements!
Psychological+
Identity+
Company'has'a'clear'
supportive+policy+
Proximity'from'
clinic,'demands'of'
unpredictable'
treatment'with'
high'failure'rate!
Equality'of'access'
to'treatment!
Emotional+Distress+
Company'has'NO'clear'
supportive+policy+
Isolation!and!Injustice!of!Situation!
Practical!Issues!
Emotional!Support,!from!work,!husband,!family,!friends!or!forum!
RESULTS 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   330	  
 
Theme	  One	  -­‐	  The	  Psychological	  Identity	  Of	  The	  Respondent	  As	  An	  Employee	  
Or	  A	  Treatment	  Seeker	  
 
Psychological Identity 
This theme concerns the inherent tension between the desire for parenthood, 
the requirements of the treatment and the requirements of the work place.   
Women may have difficulty reconciling their identity as an infertile treatment 
seeker with their identity as an employee.  They have to balance the practical 
and psychological aspects of their situation and often in the context of a 
workplace where there is no clear policy for their managers to follow. 
 
I feel very conflicted a lot of the time as in June last year I started a new job 
which is basically my dream job working for a great charity, and don't want to 
be messing them around - or to give it up - but at the same time I know that 
having a child would be the most important thing in my life, much more 
important than any job.. 
 
To top it off I’ve been offered a promotion at work but don't want to accept it if 
im going to start IVF this year… 
Identity as Infertile 
Different Degrees Of Infertility 
Women were able to find hope in their situation when things went wrong if 
they had progressed towards fertility by falling pregnant. 
 
Even though i am devastated I take solace in the fact that i got 
pregnant again...and started to go to the clinic counsellor which was a great 
help… I did not want to have IVF again and be so upset again..It was an 
awful time, but slowly we picked ourselves up and everyone said at least you 
know you can get PG….Even though i am devastated I take solace in the 
fact that i got 
pregnant again… 
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The parents demonstrated a strong attachment to their babies, even at a 
very early stage of the pregnancy, describing them as babies or girls, rather 
than embryo’s or zygotes.  This strong sense of personhood means that they 
have to bear the associated loss when things go wrong at an early stage of 
the pregnancy or when a baby is stillborn:  
 
Our little girl was a frozen embryo, created in the late summer of 2006, and 
so had already overcome being frozen and defrosted. We at least have the 
consolation that we were able to “meet” her when she was only 3 cells old … 
he next day was our scan and the clinic agreed to go ahead even though 
they were reluctant as they feared what I already knew deep down - it was 
over. No picture of a heartbeat and a bean like being on the screen - nothing. 
I have never felt emotional pain like it. DH didn't know what to do, it was 
unbearable. 
 
Women were able to use the forum to share their grief at the loss of a child 
whist protecting their privacy and avoiding the negative reactions of work or 
family: 
 
She was conceived on our third attempt after many years of striving to 
become parents so her loss was particularly difficult to bear….Our little girl 
was born asleep on 25th June and we miss her so very much. She was born 
at 36+6 at 6.45pm and just looked so perfect and beautiful. ..We had lost our 
darling baby 
 
Secondary Infertility 
The isolation and emotional distress of women who suffer from secondary 
infertility, who having had one child are unable to conceive a second one, 
was slightly different as they receive less sympathy and support from friends, 
family and health professionals and feel guilty complaining when they already 
have one child.  They are not able to identify themselves as fertile or infertile: 
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…Grieving for the child I couldn't have, sorrow for my son not having a sibling 
(I am very close to my sibling), pain at my incomplete family and feeling 
totally isolated dangling somewhere between the worlds of the fertile and 
infertile…I just didn't belong or fit in anywhere and feeling totally isolated 
dangling somewhere between the worlds of the fertile and infertile. I just 
didn't belong or fit in anywhere. After 2 solid years of trying every cycle we 
went to our GP who referred us on to a fertility clinic.  It was not a very 
pleasant experience, the first time i turned up to the clinic the consultant 
came out into the waiting room and shouted loudly at me that i could not be 
seen at this clinic as 'I already had one kid, what more did i want?'  It was 
awful, left totally humiliated 
 
Company Has A Clear Supportive Policy 
If a company has no clear policy regarding infertility, treatment decisions are 
often left to the judgment of individual managers and the implementation of 
rules often links to the amount of empathy between manager and employee.  
Managers have the opportunity to make a decision at their individual decision 
rather than upholding a company policy, which takes the decision away from 
them.  This has the effect of blurring the boundary between personal and 
professional domains of decision making for both the employee and the 
employer: 
 
Also not sure how much time to take off from work (very stressful 
workplace!!) What do you think is acceptable?  Does anyone know how long 
after planning how long before treatment starts roughly.  How much time will I 
need off work?  I am a teacher and it obviously has a big impact on the 
children I teach when I am continually out at appointments? …as I am the 
first and only woman I know they haven't had to work out maternity leave 
before, let alone whether they have a policy for people going through IVF 
treatment. 
 
There are several problems with this approach. For example, it was totally 
dependent on the particular relationship and amount of empathy between 
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manager and employee.  In the first extract below for example, the empathy 
was lacking, whereas in the second example below there was empathy: 
 
When i 1st started my journey I was an assistant manager in a well know 
retail store. My store manager and area manager, at first, were quite 
sympathetic. This soon changed when i needed to go for daily bloods and 
scans  Her attitude changed towards my treatment but then from then on i 
thought, stuff it, they don't care about me, Im just a number and instead of 
having the odd day off after embryo transfer etc, i had more time off to suit 
my needs and not of that of the business! Work is incredibly hard at the 
moment, my (female) manager does not really understand and my job is 
extremely stressful….I know I'm teetering on the edge of depression - I 
suffered from it in June 2006 following severe bullying by a senior manager 
at work (I left the organisation as a result but now have my own business).  I 
feel helpless, scared and so desperately sad 
 
 
Any hospital appointments that followed I emailed her about to let her know, 
and she was happy for me to attend…I was honest about my appointments, 
if they were in the middle of the day I took holiday so as not to be a complete 
pain, if they were early or late I worked around them….– I was allowed time 
off for egg collection and embryo transfer…He said he appreciated my being 
open and that I could just let the manager know when my appointments 
were, that was fine…She was fine about it, chatty, agreed the time I needed.. 
he was really pleased… The situation really hit me last October 4 days before 
my Nieces 1st birthday and I turned to our senior leader who was brilliant and 
really made a tough week as easy as it was going to be. 
 
The gender of the manager was in some cases was perceived to affect their 
empathy for the employee, although not all female managers were shown to 
be sympathetic to requests for time off.   For one subject it was less 
embarrassing to discuss the reasons for treatment with a female manager. 
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.Luckily it was a female manager who dealt with it.. .Work is incredibly hard at 
the moment, my (female) manager does not really understand and my job is 
extremely stressful… 
 
The requirements of a business might include commercial and operational 
factors such as the business plans for the company and the need to cover 
busy shifts, as explained in the first example below.  The demanding nature 
of infertility treatment, it’s unpredictability and high failure rate mean that it 
can be difficult to plan time off in advance and this can create additional 
tension between the needs of the company and the needs of the treatment 
seeker. Again this is something that guidelines might have helped to clarify, 
at least reducing the stress on the part of the treatment seeker,  
 
 
‘I was very upset in front of the nurses as I knew that it would be frowned 
upon as Saturdays are our busiest day and my area manager was visiting 
too’…I was made aware that this was very inconvenient to the business and 
sometimes I was made to still let the cleaners in the store at 7 am and wait 
until another manager arrived to relieve me from my duties…She was very 
annoyed and her words were " I am very sympathetic regarding your needs 
but I have a business to run and you’re wanting to leave on a Saturday 
afternoon?! 
 
 
But then the stress levels seem to rise Which clinic? How long to get 
appointment? How much time off work? (as i work as a f/t nanny difficult to 
get time off!) etc.........I'm sure you have all faced the same choices! 
 
Where a company has a clear policy regarding infertility treatment, which 
guides the decisions of managers, and employees then the employees feel 
supported and there is an increase in goodwill, openness and a willingness 
to be flexible in return: 
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Yes, I got the job on merit, I had no problems whatsoever with having time 
off; working for a large organisation, with a terrific foundation on offering staff 
a good work / life balance – I  was allowed time off for egg collection and 
embryo transfer 
We have it written in our t&c that females having Ivf are allowed an extra 5 
days leave in a rolling 12 mths, so if you had 1 cycle every year you can 
claim the extra 5 days leave, men and civil partners are allowed 2 days in a 
rolling 12 mths. 
 
I have requested my 5 days together as I am going abroad and have taken a 
weeks leave before and a weeks leave after. 
 
Women were able to view the dilemma from both sides: 
So just hoping things will work out and I won't need too much time off for 
treatment. I think they would be fine about it - and my line manager has 
young children of his own so should understand - but I wouldn't be pleased if 
I was them so why should they be? 
 
Practical Issues 
Proximity of treatment centre to work 
Another factor is the proximity of the clinic to the workplace, which will dictate 
how long employees need to take off to attend appointments, and may affect 
their choice to disclose or not disclose their treatment.  The choice of clinic 
takes several factors in to account such as proximity, funding and success 
rates: 
 
As we chose a clinic some distance from our home, this led to quite a lot of 
time off 
Luckily my clinic was only 20 minutes from the office and my scans and 
blood tests were always first thing I had a good number of blood tests over 
the next few months. I was a nursery manager and at that point I worked in a 
nursery on a hospital site so didn't really need to say much as it was easy to 
fit in…This made me feel anxious as I had to then travel 8  miles to the 
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hospital, get parked up and be there before 9. Whilst in the waiting area I 
was constantly aware of the time as they needed me back asap. Sometimes 
2 hours would pass waiting from bloods and then onto scans, depending on 
how many patients were in that day.  
 
 
 The waiting lists for NHS funded IVF was outside of our timescales so we 
chose to go privately, made easy by the fact that  the Clinic was about 20 
minutes down the road…We have found a lovely clinic nearby with…Anyway 
fast forward a few months and we have been really lucky we have found a 
clinic 30 mins from home with excellent results and no NHS waiting list…as 
the travelling alone would be a minimum of 2 hours each time. 
 
Flexible working arrangements 
Subjects often showed a willingness to be flexible about time taken off for 
treatment, for example using their annual leave, which often forms the basis 
of a mutual trust in this process. 
 
They let me book the Monday as annual leave for the IUI, and then we 
waited… 
I was honest about my appointments, if they were in the middle of the day I 
took holiday so as not to be a complete pain, if they were early or late I 
worked around them… I was able to take a combination of flexi and holiday 
as I felt necessary 
 
This also means that time off work that should be for rest and relaxation is 
being used for stressful treatment with a high failure rate. 
 
Thanks to Easter I have not had to take too much time off work but have 
been back a week now…April 07 - 1st IVF - this was our private one.  Got 11 
eggs, 8 fertilised.  2 embies transferred 2 days later on 14th November - a 4 
cell b & a 3 cell b. Took the 2ww off & did all I could to optimise 
chances..Again I didn't work during 2ww & I did all I did last time & a few 
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extra things such as acupuncture, a hypnotherapy cd, paraben free shower 
gel etc, no nail polish etc.   
Sexual Discrimination For Time Taken Off 
Taking sick leave can also avoid the need for disclosure unless they work for 
a company that demands evidence of medical treatment.  For some patients 
company policy does not recognise infertility treatment as a valid reason for 
authorised leave and so employees who take time off sick might be 
threatened with disciplinary procedures as a result of time off.  Women also 
used annual leave as a way of avoiding disclosure of treatment 
 
Have now been to Cyprus twice without anyone at work having any idea of 
the reasons behind our trip – just a last minute holiday…We have decided 
though that as we have holiday in April we are going to try and tie everything 
in with that. 
..They have provisionally booked me in for EC and ET for week beginning 
feb 13th and We have both booked off  that week..3th August embryo put 
back, again not a nice experience but copable, like an extended smear 
test...2 weeks of pessaries, 1 week at work the other one on leave at M-I-L 
caravan to relax. 
 
Taking sick leave for stress and anxiety caused by infertility or by infertility 
treatment can also avoid the need for disclosure unless they work for a 
company that demands evidence of medical treatment. 
 
Shortly after this 2nd failed go I took some leave ill as I was suffering from 
anxiety/stress…I had depression and anxiety and had been signed of work 
prior to our IUI commencing, the miscarriage from our IVF just compounded 
that..It was the hardest thing i have ever done.  Dr'ing was horrible, i suffered 
badly emotionally and didnt make it very long into treatment before needing 
to be signed off work….At this point very depressed . Hit rock bottom. Sure 
we would not have children! ..Signed off work for 2 weeks.. We finally saw 
the Cons again whilst I was on sick leave to talk through the treatment 
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options and she told us we could start as soon as possible as there was in 
fact DS available and no waiting list 
 
Disclosure And Non-Disclosure 
The conflict between their identity as a treatment seeker or as an employee 
can make it difficult for women to know when and how much to disclose to 
their family as there are risks and benefits to both positions.  The benefits 
can include increased support when treatment fails and flexible working 
arrangements: 
 
We finally told our families and very close friends what was going on.  We'd 
wanted to keep it private but actually telling others was helpful - especially 
my family.  I eventually also told work too when I requested to go part time 
which helped enormously... Went back to work today, which was hard, but 
everyone has been very sympathetic. A colleague at work, has a sister who 
has gone through IVF too which helps a bit, ….I was intending on working 
right up to EC but I really struggled with the side effects, mainly the hot 
sweats, very emotional and tiredness like i’ve never felt before. I decided to 
take leave from work until after ET – my manager was wonderful, so 
supportive! 
 
For some patients, company policy does not recognise infertility treatment as 
a valid reason for authorised leave, and so employees who take time off sick 
might be anxious about being threatened with disciplinary procedures as a 
result of time off. 
 
I can’t get time off work until July so expect to start down regging June ish 
time. 
I went to my GP last Monday and she signed me off for a week - i do not feel 
ready to go back to work yet but cannot get appointment at docs till 
Tuesday.... so what do i do re work and will docs renew sick note over 
phone? 
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Additional emotional distress may be caused by the financial losses 
associated with the cost of treatment or loss of earnings/promotion due to 
time off for treatment.  
Know I am wasting my time but can't help hoping for a miracle. Just can't 
stop crying so desperate for me and DH to have a baby. Don't know where to 
go from here. We said we wouldn't keep throwing money at this but I just 
can't accept we won't have children… 
 
I had to take a day off one day because I was so upset after a terrible 
appointment with a gynaecologist and having to explain why was awful, so I 
have that stress plus the stress of not getting paid for any time off I take for 
appointments.  
proof to show work, that's also about 4 hours of wages a month I am missing 
out on, which doesn't sound like much but really it's the principle and I don't 
exactly get paid very much anyway 
 
My 1st failed ivf attempt i was that upset that my partner rang in work for me 
to say that i wouldn't be in work the following day. I was hysterical during the 
conversation wouldn't be in work the following day. I was hysterical during 
the conversation and my manager could hear me in the background but 
because the company policy is to ring in yourself I didn't get paid… We 
couldn't afford the amount being asked privately and didn't yet qualify under 
the NHS criteria of 3  yeas ttc, ( we were 2.5 yrs) so we looked into the 
private system to see if we could  in any way afford it possibly with some help 
from family. Things really grim now because we are out of money and my 
hormones are utterly messed up and periods haven't returned.  Need to be 
scanned for cysts.  Feel in quite a low place now as time is ticking, my DD is 
getting older and money is very low 
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Theme	  Two	  -­‐	  Emotional	  Distress	  
This theme explores the emotional and psychological suffering associated 
with treatment, treatment failure and the feelings of loss and grief as 
expressed by the individuals.  This code was applied to text whenever the 
emotion was described directly or whenever emotive language was used.  
The code was not applied to text that merely described treatment without any 
emotional value being assigned to the experience.  Spelling mistakes made 
by the forum posters have not been corrected and a list of infertility acronyms 
is included below to help with understanding the extracts: 
 
AF Aunty Flo, menstrual period 
BNF Big Fat Negative (pregnancy test) 
DD Dear Donar ( Egg or Sperm Donar) 
DH Dear Husband 
DPO Days post ovulation 
DS Donar Sperm 
ET Embryo Transfer 
GP General Practitioner 
ICSI Intra-cytoplamic Sperm Injection 
IUI Intra-uterine Insemination 
IVF  In Vitro Fertilization 
LP  Luteal-Phase 
NHS National Health Service 
PCT Primary Care Trust 
PG Pregnancy 
SA Sperm analysis 
SPA Sperm Penetration Assay 
TTC Trying to conceive 
 
Source: http://www.resolve.org/support/Managing-Infertility-Stress/infertility-
acronyms.html 
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Subtheme Devastation and Injustice 
Women frequently described the discovery of their own or their partner’s 
infertility as ‘devastating’ and often questioned the reason for it happening to 
them: 
 
I couldnt understand why this was happening to me.. to my shock was told I 
had a probable endometrioma on my ovary and most likely had 
endometriosis and would need a Laparoscopy….Unfortunately, I had a BFN 
in June and was utterly devastated…We were devastated. We didn't realise 
how much we wanted the baby until we lost it. If that makes sense! I was so 
shocked and yet again devastated and hurt -..the cycle was abandoned and I 
was devastated…As you can imagine I was devastated, I couldn't get my 
head round why this was happening, I've never been a bad person or hurt 
anyone why was this happening to us! This is the worst experience of my life. 
Every month is a bereavement. The unexplained element is bewildering and 
not understanding why drives me demented. The prospect of facing a future 
without ever experiencing pregnancy and having children of my own, is 
horrific…I have been in a state of panic and shock for most of the last 3 
years… I have deep, deep feelings of failure, anger and incredulousness at 
our situation…The disappointment, injustice, lack of understanding I feel is 
overwhelming…. Of course I can’t help feeling a little resentment, why do 
other people have a baby at the drop of a hat I ask?  
Their sense of injustice might also include distress as a result of having to 
disclose their treatment or condition at work or anger at the way they have 
been treated at work.   
Whilst typing it up i was sobbing as i felt humiliated and in disbelieve that i 
had to do it…She did her floor walk with the store manager looked at me and 
ignored me…I felt hurt and anxious…This made me feel angry and i spoke to 
the store manager about it saying that i felt sick and really upset.. I know I'm 
teetering on the edge of depression - I suffered from it in June 2006 following 
severe bullying by a senior manager at work (I left the organisation as a 
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result but now have my own business)…I feel helpless, scared and so 
desperately sad. 
Women also perceived injustice when they compared the way they were 
treated with the needs of other groups such as parents of children who have 
childcare issues, men and civil partners.   
 
..men and civil partners are allowed 2 days in a rolling 12 mths.. The worst 
thing is that people with children are allowed time off for 'dependant care', I  
know more than a few people who abuse this and take days off pretending 
that they can't  get child care and they're not disciplined for it but when I had 
to take a day off because I  was so distressed it went through as 'sickness' 
and I was given a verbal warning which  stays on my file for a year… but I 
had disciplinary action as a result of being off that day.. 
Subtheme Access To Treatment 
Not all women experience equality of access to infertility treatments and this 
was another source of perceived injustice, and having to fight for treatment 
increased their sense of emotional distress: 
We were told that there was no DS on the NHS, we were told to go to the 
USA, we were told that the wait here would be 5 years...I have had to fight 
and got my MP behind me, harassed my poor GP to death and it went to the 
exceptional case panel. I have just found out that they have approved it and I 
get what I am entitled too. Whoopie doo! I should be grateful for that! I am 
SO angry. We were devastated and with my mum's help we complained to 
the GP and PCT and after 8 months of letters, phone calls, crying and 
appointments, we were transferred to another clinic…. 
Subtheme Treatment Failure 
Women and their partners often felt immense grief at the failure of their 
treatment. The nature of infertility treatment is that success or failure can be 
encountered at every stage from ovulation, sperm production, fertilization, 
implantation, pregnancy test, scans to successful delivery of a live birth.   
These are all significant milestones which are either successfully passed or 
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mark a failure along the way.  The use of language such as ‘cheated’ and 
‘robbed’ implies that women felt that a successful outcome was due to them 
and is somehow being withheld.  This sense of entitlement was also found in 
the extracts of data relating to husbands.  The status of ‘wife’ is assumed to 
include the status of ‘mother’ as in the saying ‘wife and mother’ and when 
this does not come to fruition women experience a tremendous and 
devastating sense of loss. 
Every month the cycle of negative test sticks is quite wearing …had 7th cycle 
using donor eggs, but donor pulled out.  World then fell well and truly apart 
but found that leap of faith to try using donor eggs just once more…Felt like 
the end of the world…At this point i went on to the sales floor and cried my 
heart out…as I just couldn’t cope with the thought of someone else having 
what I longed for and as his wife should be entitled to. 
 
 i started to bleed even before the blood results came so we knew, yet our 
heart broke when we got the phone call with the negative result.. I was given 
the option of waiting or having an injection called methotrexate to end it. I 
chose the injection I could not wait. The next day it happened. I broke my 
heart, I wanted to hide away and I did, the trouble with losing something so 
wanted and precious if it changed you forever, I wasn’t sure I would ever get 
over this but I did with time and understanding 
 
I couldn't believe I could feel so sad and empty.  I couldn't believe that me, 
someone with nothing wrong with them, a youngish age and of good health, 
could get a BFN.  I feel cheated and robbed and all the other horrible horrible 
feelings are that all of us here deal with on a daily basis. 
 
Women were aware that age is an important predictor of success in infertility 
treatment and the loss of available treatment time due to misdiagnosis, failed 
treatment, life events or choices were an additional source of emotional 
distress: 
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I've recently been unsuccessful at ICSI (2nd attempt) and miscarried after a 
short time recently - 1 day before my 39th birthday so hugely disappointed 
and really struggled this time round - I feel a mid-life crisis coming on!  
 
The women characterised their infertility journey using numbers such as 
time, age and quantities as units with which to describe themselves and to 
measure success, failure or progress of their infertility treatment: 
 
We started trying to conceive in 2004 and fell pregnant after about 6 months 
but sadly miscarried at 7 weeks…. The GP told me that most couples will 
conceive within the first 6- 8 months of ttc, and the majority by a year… 
Anyway, things have been awful since then.  Made extra 3 embryoes with 
first round of IVF.  Had frozen cycle a couple of months ago.  2 died and 1 
was 'barely there' on day of ET so no surprises we ended up with a BFN. 
 
I am a 44 yr old woman with endo/cysts and a blocked fallopian tube. I had 
my son with a known donor at 40 using IVF at a London clinic (2nd attempt).. 
Me almost 38, DH almost 44..we have unexplained secondary infertility.. 
6 miscarriages later, and unable to conceive since our last miscarriage in 
2006, a failed IVF and recently a failed ICSI.. 
 
The biological differences between men and women also lead to emotional 
distress caused by women’s sense of time urgency. 
 
If I'm honest DH isn't as worried as me. He's younger and in less of a rush, 
he's more patient, he can't hear his clock ticking, he's more worried 
about money, he's got an exciting new job which he's really enjoying and if 
I'm honest he was quite dismissive and it seemed that he was relieved at the 
start of the year when we didn't get lucky 
 
Subtheme Grief And Loss At Her Infertility 
The women who had lost a baby or whose treatment had failed experienced 
a range of emotions that could also lead them to dislike themselves for 
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becoming jealous or ‘cold’ as in the first extract.  The natural stages of 
grieving for someone who has not yet been born were all experienced and 
described as anger, grief, self pity, jealousy and ultimately exhaustion and 
depression at their failure as in the second extract: 
 
I work in a hospital environment and and have to deal with seeing people 
who are pregnant and with children all the time, I have created a professional 
and cold shell I put up to allow me to function but inside I am screaming, 
tears come late at night after my husband sleeps and when I am alone - 
pathetic I know, I'm doing it again now. I used to like me and I am a good 
person I hope, most of the time -I am a caring person, now all I see is a 
stressed and tired woman looking back at me at odds with the world 
wondering when did all this take over me and when will I ever be able to not 
wake to the thoughts I do and drift off to sleep without a tear stained pillow. 
 
It's like I am grieving for the child that hasn't been born.. I’ve got to the point 
where I have moments when I really struggle and feel utterly consumed with 
sadness at the thought of no baby..I know I have a lot to be grateful for, and I 
am, but I also have this void, this huge emptiness that hits me like a kick in 
the stomach when I least expect.. This news made me feel inadequate, a 
failure and less of a women. The sense of failure that I can’t do something 
that to me is part of being a woman – being able to have children, when 
some people find it so, so easy.  
 
Finding something physical wrong may mean that an explanation of infertility 
is provided and with it the hope of a solution: 
 
Part of me really wanted them to find something physical so we could pin 
point it and fix it! Had a cry after the procedures from all the pent up anxiety, 
frustration and much relief that my body is in working order…So went for the 
scan with DH in tow, & the sonographer asked me if I knew I had ovarian 
cysts. Cue a bit of crying, followed by rational 'at least we know & can deal 
with it'. 
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Emotional Support - Relationship with Partner/Dear 
Husband (DH) 
Some husbands and wives were being able to share their grief work and by 
working to support each other survive the stress of infertility: 
 
 Thankfully my husband was there with me and we grieved together… I 
sobbed and howled, my husband and I were inconsolable, our hearts were 
broken. Seeing my husband cry was also extremely distressing.   It took a 
few weeks to get back to any sense of normality,..  
 
After that appointment we decided just to stop everything  for two months, to 
concentrate on each other again, go on holiday in  the sunshine, see our 
friends and find some joy in our lives again... We've managed to get our 
marriage back on track and despite the ongoing pain of infertility, are 
stronger than ever 
 
A more unusual situation occurred when the husband would like to wife to 
continue with treatment in spite of her own feelings about it: 
 
My husband and I were in shock and disbelief at first, I just felt numb - he 
was clearly devastated and angry. 4 months on my husband wanted me to try 
IVF again. 6 weeks ago I told him that there is no way that I can do this again 
for the moment - if it did not work then this would just destroy me. I don't 
know when we will do it again now, but have said that if we do it again then 
that really is the last time I can go through this god awful process! 
 
Women who felt that their husbands had not supported them emotionally 
blamed this on a variety of reasons, their own anger and grief, their own 
sense of isolation, his family background and their obsession with the need 
to get pregnant: 
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BFN followed and I lost the plot, was on a plane the next day to see my 
parents in Spain and to give my DH a breather from the mad woman... DH 
isn’t coping too well. He is doing the caveman bit and retreating. So I thought 
this would be a good way for me to get off my chest, stuff I know I want to 
say to DH, but cant at the moment.. Successful transfer then spotting 2 days 
before pregnancy test, which was, negative result. My husband and I were 
devastated.. 
 
I am all alone away from my friends and family and honestly don’t know how 
to get through the next few days. My husband is the silent type who says he 
just wants to move on...  When I suggest getting a second opinion (preferably 
in a language we can understand and in a country with few legal restrictions) 
he says I must not get scary and obsessed.  
 
Everything spiralled down, with me pushing Matt away at times, it was easier 
to grieve alone, or so I thought... After the SA results dh and i seriously grew 
apart.  I was a like a demon possessed, desperately searching the web for 
info and stories of ivf and reading every book going.  He on the other hand 
refused to discuss any of it, completely shut me out of everything and stuck 
his head in the sand (plus he didn’t want me to talk to anyone either, got very 
upset if i mentioned wanting to speak to any family or friends and all but 
forbid me to even speak to my mum!!).  Eventually the strain became too 
much and we split.  
 
 
Over the year things have moved on, I've regularly broken down - tears most 
month, the odd hissy fit for no reason and a couple of good heart to hearts. 
I'm still hurt that he never seems upset. Does that make me weird? It's not 
that I was to see him upset but I want to see that he cares. He's being more 
supportive as time goes on and I'm sure it's just a mars venus thing. 
Sometimes it seems he just saying the right thing but doesn't really feel it but 
then his family are dryer than mine emotionally. 
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Subtheme It’s Ok For Him 
Women who have married a man who already has children and then finds 
that they cannot have children together are often in a difficult situation, as 
some PCT’s will not fund their treatment.  The resentment that this inequality 
brings may be added to the feeling that partners with their own children do 
not understand the depth of suffering experienced by the infertile partner: 
My partner had 2 children to a previous relation ship which made things more 
difficult for me to cope with, and at times i thought that he didn't even 
understand, as after all he had 2 children, so how could he?  
 
Picking up my partner's three children and seeing the mother of his children, 
only added insult to injury.  They do not know about what we are going 
through so there have been lots of excuses and brave faces, something I 
could have done without.  My partner has been brilliant and very supportive 
but dare I say, this is very different for him:  he has three children and he is a 
man so I believe his understanding is limited.  No one can understand this 
unless you have been through it yourself. 
 
I was living in ignorance, thinking that I might just need some tablets and now 
I am sterile! My DH is trying to understand but he has and always will have 2 
lovely children. What about me? I have to heal for 3 months now before I 
begin the "real" journey but feel like I have been through the mill already!!! 
It’s His Fault 
Women who found out that their infertility as a couple was caused by a male 
factor were often shocked to discover their husband was not able to produce 
healthy sperm.  Their desire was to have a biological child with their partner 
and alternatives such as sperm donation had to be come to terms with so 
that their treatment could proceed.  Men also experienced the news as a 
tremendous assault on their masculinity: 
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DH is azoospermic (absolutely zilch). He dealt with it as only men can - very 
badly. He was turning 40 as well, and all that turned into a mid-life crisis of 
sorts. Pleased to report he's on the up, just as I lose my optimism and stamp 
my feet about the injustice of it all!..After DH going to pieces initially I think he 
was expecting the negative result but I was, and still am, completely floored. 
My best friend has just had her second child and the fact I will never have 
DH's baby makes me feel sick. I am finding it very, very hard to accept…we 
had bad news that unexpectedly my DH's sperm count and motility had 
drastically reduced so they couldn't go ahead with IUI - we were totally 
devastated and couldn't understand it and neither could the clinic because he 
was fine a month before. It felt like the world was falling apart…I still feel very 
, very sad that I will never have my husbands biological children, I will never 
look at them and think they have his nose / eyes / build etc.  I still feel that I 
don't want another man's baby and feel guilty that my fertility (as far as we 
know) is fine, and cannot imagine how he feel.. 
 
Specialist asked husband to do sp.test - to our shock it came back low - 8ml. 
Advised to do a secondary swim up test.  Returned to the hospital in Nov for 
results, devastated to find DH result was even worse at 5ml…Married in 
1997and started ttc in 1999, after about 9 months we went to the doctors 
and had all the initial blood tests and sperm samples were sent away but to 
be honest we didn’t really think anything of it, therefore it came as a massive 
shock when dh sperm sample came back as no sperm in them, my blood 
tests were all ok… 
 
The use of donor sperm was one of the easier things to come to term with for 
me… 
 
I had to break the news to my DH when he got home from work and he was 
devastated. We then waited two weeks to see a consultant to explain 
things ….As I’m sure most of you will understand we were devasted and my 
DH feels awful - he even told me I should leave him and find myself a 'real 
man'. Felt so bad and no matter how hard I tried I couldn't make him feel 
better. Scary to think of the journey ahead but I want children with my DH not 
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anyone else... My husband has did not really speak about our news and I 
suppose I had to let him come to terms with it in his own way as it's male 
factor infertility, all my tests came back normal. 
Subtheme Isolation 
The sense of isolation caused by infertility may affect relationships with 
family, partner, friends or colleagues.  Some times this is because women 
have not disclosed their treatment and sometimes because they feel that no 
one can understand how they are feeling.   
I am SO unbelievably happy for her but man was it difficult the first few 
months of her starting to show. It was just so hard. I just wanted to hide. With 
time I am getting better about it but it still is just so difficult. She is my best 
friend and we depend on each other so much as our families are far away 
but our friendship is so strained right now.  
Where we live, most of our friends now have children or are expecting, which 
has left us feeling quite isolated - we sometimes joke about the fact that we 
need to find new friends. Of course we still spend time with our friends, but 
their life styles have changed and they cannot do the same things as they 
used to… 
I think the hardest part for me is that three of my four closest friends are all 
pregnant and all became pregnant in the first month of trying.  I feel alienated 
from them as babies and pregnancy is all the talk about with each 
other.  Sadly I feel I am avoiding situations when we are all together.  I know 
it has affected my friendships with them.  It not their fault they are pretty 
sensitive but they can never understand the frustrations having month after 
month of disappointment as then didn't even have one. .. Perhaps I am being 
mean? 
I get very low and because so few people around me are aware of the 
problem, I often feel misunderstood…what I'm struggling with the most is 
how distant I now feel from a lot of my friends who were once in the same 
boat as me but now seem to have got on with their lives with their new 
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families and we just don't see so much of them or it can be a little strained - I 
guess they don't know what to say, others are just plain silent.   
 I can't stand the loneliness anymore. I was initially reluctant to tell anyone 
because I had this idea in my head that I would get pregnant and it would be 
this amazing surprise to everyone 
The pain of infertility is so entrenched, all consuming and inexplicable, it will 
never ever leave me. Unless you have been there, it is really totally 
impossible to understand. I cannot begin to pretend to understand the depth 
of pain of total childlessness, but I have a fair idea of how I felt dealing with 
our infertility. I wouldn't wish it on my worst enemy. Its unfair, cruel and heart-
breaking and nobody should have to suffer it, least of all alone.. Knowing no 
one who has gone through the same thing I have found this a very lonely 
time. 
The experience of being infertile while others are starting families makes it 
difficult to maintain existing friendships because the fertile women take on a 
new identity and wish to celebrate their new status as mothers.  The happy 
new mothers or their families are perceived as insensitive and lacking in 
support, this may be made worse when grandparents are seen to be helping 
fertile siblings or friends with their children, so the lucky mothers who get the 
baby and the support of their families:  
But feel that all other family members are really negative and would rather 
not know what is going on. No support- I get really frustrated by this.... and 
makes me feel worse... especially as my parents are so supportive of my 
sister and her 3 children… 
 
In an ideal world we would be open with those closest to us but people 
struggle with understanding how we feel and find it awkward knowing what to 
say.  Listening to comments like “you’ll be ok in the end” or “relax and stay 
positive” don’t help but can understand why people say them 
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But my husband’s family have found our situation hard. They have (not 
consciously) made it much harder, especially this year since the birth of their 
first grandchild. The comments that have been made, the pressure that’s put 
on us to attend big family get together and the lack of understanding even 
though we've tried to explain is proving really hard to deal with and causing 
us a lot of distress 
 
One of the struggles that infertile women have is to face the fact that fertility 
very visible and is celebrated in our society and that they are constantly 
faced with reminders of their own inability to conceive:  
I cannot stand pregnant women, especially the ones who are oblivious to the 
fact that someone around them may not be as lucky as them and who think 
everyone should fawn all over them and make a fuss of them (a so called 
friend who knew what I was going through thrust her positive pregnancy test 
under my nose a week to show me her success after I had my first failed IVF 
such was her lack of empathy and self absorption). I've had some pregnant 
friends who have been lovely and worked hard to not rub my face in it but I 
really have difficulty being around them. When I cry, the grief comes from so 
deep down in my very depths and I just howl with sorrow 
I´m surrounded (it feels like) by pregnant people and I can´t relate to them 
anymore and more importantly feel  incredibly isolated, as my usual sources 
of help and support are  pregnant and how uncomfortable for all involved to 
pour your heart  out about being childless to someone heavily pregnant!!!! Or  
Im sick of the pregnant people, sick of new mums with babys forcing theirs 
on me and the pitying smile of "it will be you soon dont stress it will happen!" 
Im sick of the announcements and the " i wanted to let you know im pregnant 
and i dont want to upset you because you cant have one!" Ive had enough of 
it all, i hate being the only wife alone. They all group together for mum and 
baby stuff and im left out on the side lines forgotten about because i dont fit 
into their group!  
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Friends around me didn't understand and I felt lost and left out the loop or 
club. every announcement that was made by friends made my isolation 
worse. 
 
Infertile women may also find it very difficult to cope with close relations 
becoming pregnant or finding out that someone has had an abortion because 
that is seen as deliberately throwing away the one thing that they truly desire, 
and as another injustice to add to the situation: 
 
I'm also having to cope with a difficult family situation. My younger (29) sister 
got accidently pregnant last year and chose to have an abortion. She and my 
mother debated not telling me, but did. So I had to bury all my own feelings 
to support her including listening to her complain about her pregnancy 
symptoms before the procedure. Didn't she realise that I'm desperate to feel 
like that? Life is so unfair. That little life was flushed away. My sister is 
incapable of offering support to me so I'm feeling angry at her (for this more 
than the abortion). We've now fallen-out and I don't have the emotional 
energy to sort it out. 
 
then my younger, unmarried, unattached sister announced her pg and it felt 
like a knife in the heart...I cried and cried and think I lost the plot for a while. 
No-one understands as all my family and freinds have kids and if anyone 
else says "at least there is IVF", I think I wil hit them! Lol.. I have to put a 
smile on my face and pretend that I am ok to everyone around me cos I think 
they will get sick of hearing me moaning! It would be great to hear back from 
anyone as I feel so very alone right now 
 
Subtheme Getting Help 
There were two main ways that people sought help for their emotional 
distress, formal counselling and the use of the forum to share their feelings 
and read about others.   The counselling as a support therapy was often 
seen as helpful in coming to terms with their situation and find strength for 
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further treatment.  The use of a professional counselling service allows the 
benefits of disclosure with out the risks associated with disclosing to friends, 
family or work colleagues. 
.I had counselling throughout the first cycle and through our loss, every 
week. Our counsellor was fantastic…From speaking to the fertility counsellor 
I realised my feelings were normal and as a result I haven’t beat myself up 
about whether I’m being irrational…In time counselling helped me to see 
things differently. On reading some of the stories, I decided I was strong 
enough to look to the future and I booked a counciling session for us and an 
appointment with the hospital nurses to discuss the next steps as I wanted to 
again donate my eggs… 
  
The forum was used as a place to tell their story and draw inspiration from 
the strength or successes of other women and men going through the same 
processes.  It was widely reported that they knew that the other posters 
would understand their situation and feelings.  The isolation that women felt 
in their life outside the forum could be assuaged by contact with other women 
in the same situation, they created a new identity as a forum user by 
becoming part of a group or community and described themselves as ‘us’: 
 
Went through IVF in 2007 in Oxford and conceived by beautiful, amazing DD 
first go.  Feel very guilty writing that but hopefully it gives people 
hope.  Dreams can come true. 
 
I’m fairly new on here and joined in the hope that some of you are in similar 
situations with male infertility.  I feel very alone, but know that I'm not alone - 
just don't know anyone who is in the same situation. …Has anybody out 
there, had a similar situation? I really feel like I need to talk about this, but 
like most people on here none of my family or friends understand. New to 
INUK so thought I provide some background to my story and hope to speak 
to individuals who understand the pain I am going through… I joined IFUK to 
remind myself that I’m not alone, and I’m encouraged by the stories on here.  
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It is great to know that I am not alone in this desperate situation but sad that 
there are so many of us out there…This is the first time I have written 
anything about what I’m feeling in relation to our ‘unexplained’ 
infertility.  ..This is my story. I would really like to hear back from anyone who 
is in a similar position as I don't feel there is anyone I know who truly 
understands how I feel. I found out this week that our second attempt at IVF 
didn't work…I’m looking forward to hearing from you lovely ladies, and 
knowing that I’ve got this forum as an outlet.. I’m so glad I’ve finally joined 
this site.  I dipped in and out for so long, but got to the point where I really 
needed someone who properly understood.  Friends and family support, but 
it’s not the same.   
 
Well, I picked up a card for INUK 2 1/2wks ago at the hospital having ET, I 
desperately hoped I'd never have the need to find out what it was all about, 
but here I am so that says alot… It's just nice to have somewhere to put my 
thoughts and feelings. It just helps me to write about it…but would love to 
hear from anyone with words of encouragement to keep my spirits up and to 
hear your own experiences of IVF.. Hopefully, like anyone who may read 
this, one day the longed for result will happen and this constant ache and 
emptiness will go away. 
 
The act of writing their story was seen as a way of acknowledging that their 
situation was real: 
 
I will update this piece by piece as there is just too much to put down in one 
go. I think I am trying to prolong putting it all down as once it is written down 
then it becomes real, our story, something I wouldn't wish on my worst 
enemy... but the loneliness was just too much to bear. So we have gradually 
starting telling people. And this is my next step in reaching out, writing this… 
this the first time I have ever really sat down and tried to tell anyone about all 
of this....sorry if I go on, just don't have anyone I can discuss this with and to 
find this network has opened my eyes so much, hopefully you won't judge 
me. Up until now I felt like the loneliest person in the world! 
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The forum was seen as a safe outlet for disclosing their infertility status 
where they could share their feelings without hurting the feelings of other 
people in their everyday life and where they could be sure of support: 
 
 
Feel very alone with all the worry as my partner gets upset when I get tearful 
about it all, so I try to keep as much of the black mood to myself as possible. 
Most of my friends have kids and say they feel guilty if I tell them how sad I 
get...so - quite isolated and blue. that's why i'm here… I felt something like 
this may help if I had a focus each month where I could talk to others in the 
same situation and we could swap thoughts. I had felt so alone before this. 
 
Sorry to be moaner thanks for listening it's helped just to put this to paper so 
to speak. Better go and put my face on again and pretend everything is OK... 
am getting to be quite the expert…I've been in tears reading some of your 
experiences - thank you all so much for sharing as it must have been really 
difficult… I really just need to be in touch with people who understand and 
can make me feel less lonely…The support and stories on here give me 
hope that miracles can happen. Just so empty at min and finding it had to 
carry on.. We havent told anybody about our if so when we found this 
website it was a godsend and provides the needed support although to 
date we havent come across anyone in the exactly the same position. 
Subtheme Out Of My Control 
Successful professional men or women who are used to feeling in control of 
their destiny may also struggle to come to terms with the loss of control 
associated with infertility and infertility treatment leaving them with a need to 
create new strategies for finding success or coping with failure: 
I had always worked hard with determination and commitment in everything I 
had done in my life...but this..this was different. It didn't matter what i did I 
could not influence the outcome 
l. I would need IVF!! I was devastated, I had been lead to believe I would just 
need some pills?..After a long wait of 25 months, one beautiful wedding and 
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both brothers having 6 children between them and me feeling a complete 
failure 
 
I am 30 in August and DH will be 39, like all of the ladies on this wonderful 
site I dread every birthday and every Christmas as for me it marks yet 
another year of ttc and for me it makes me feel a failure.  I was a successful 
carrer girl and controlled all aspects of my life and this is the one thing I can't 
control or buy!..  
 
And now I feel like I am totally failing and there is absolutely nothing I can do 
to improve the situation – I can’t study harder, I can’t work longer hours, I 
can’t be a better daughter or wife.  Usually I know the answer to things and 
know what I have to do to improve the situation.  But not about this.    I’ve 
always been known as the ‘rational’ friend, the person to turn to in need, the 
person who can work through things logically. 
 
I am a successful professional and I have always held the belief that if you 
want something badly enough you will get it with determination and grit. 
Whilst that may be true of career goals, it doesn't seem to be true of fertility. I 
am used to being in control and calling the shots. This infertility experience 
has left me feeling hopelessly lost and despondent. 
 
The cost to patients of being infertile and undergoing infertility treatment may 
be financial, emotional or psychological 
 
It's not so much the cost of all this treatment but the cost to me emotionally, 
and in time off work….Cycles appeared to return to normal then april to june 
cycle 7 weeks - think this is due to huge stress and unhappiness at work.. 
 
Despite the difficulty in reconciling their identities as treatment seekers or 
employees women viewed the opportunity to conceive and have a family as 
so important that they were prepared to try and balance the demands of both 
roles: 
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In 2009 we started our treatment.  It hasn't been that bad but the emotional 
journey is quite hard.  I spend so much time trying to convince myself that we 
should just accept that we don't have to have children and we can get a dog 
or travel again but the desire for a family has become so great now that I 
can't see how I will accept just being the two of us. 
 
Hoping that it is going to be that week as will be difficult to rearrange the time 
off. Plus found out recently that I am moving to a new department in work 
first week in March around time of end of the 2 week wait (assuming the 
dates don't change). Not the best timing! Will have to get to know new staff, 
new boss, different way of working! Not ideal but hopefully will be ok. 
 
Am just playing the waiting game now- was hoping to start asap while I am 
on summer holidays (I'm a teacher). If period arrives this week, embryo 
collection and transfer would be in the first week of the new term. Not very 
convenient! 
 
Work wise, I am in the middle of an intensive three year training course 
where TTC isn’t the best idea, but at the same time having a family means so 
much to us that we want all the precious time on our side that we can get 
 
In October, it was announced that my office was going to close, this really hit 
me as I moved to this office so that I could have mat leave, return to work 
part time, and be close to home, that made me really sad,  
Work is crazily manic and I worry about my ability to balance the relaxed zen 
that I need to get through the next few weeks with my need to perform and 
not let the side down in work. 
 
 
There were some indications that when one identity failed (ie failure to 
conceive) the alternative identity as an employee provided a solace or a 
distraction: 
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I came off the pill at the same time that I left a busy stressful job in London 
and began working for myself at home.  So we were trying but not trying too 
hard whilst I worked on getting the business off the ground… I am staying 
busy, went straight back to work after the results on monday and havent 
stopped, think thats the best way for me…  
 
When I was having treatment I didn't tell anyone at work although I was 
tempted on several occasions. I'm really glad I didn't. It was hard getting over 
the disappointment privately so dealing with other people too wouldn't have 
suited me. It also meant at work I could temporarily forget about it. 
 
My one good luck story in 3 years has been my new job, which I started 2 
weeks after 1st IVF failure.  So now, at least, DH and myself are both finally 
settled in jobs that we love, so some stability at long last. 
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Conceptual	  Model	  The	  Risks	  and	  Benefits	  of	  Disclosure	  and	  Non-­‐Disclosure	  
 
The infertility ‘journey’ may involve multiple appointments and consultations 
as the subject is passed from his/her GP to a specialist clinic.  There will be 
appointments for ultrasound scans, internal examinations, sperm analysis 
and blood tests before a treatment regime is decided.  In many primary care 
trusts there are waiting lists for treatment.   
 
Infertility treatment is demanding and often unpredictable by nature because 
each stage is controlled by the patient’s responses to the earlier treatment.  
The response to ovulation drugs, the number of sperm or eggs retrieved, the 
number of fertilized eggs, the number of viable embryos, fluctuating hormone 
levels are just some examples of the dependent variables that might 
influence timing of the next step.  This means that women cannot simply plan 
a schedule of treatment and hand this to their manager with a request for 
time off.  
 
Now I'm going to need time off twice a month for ultrasounds and blood tests 
and it will be  extra stressful because these appointments will be made over 
the phone…They said that i may need to go back that day for my treatment… 
This was really frustrating as it is not an exact science and all depends on 
your body clock… 
 
 Ironically women are often told that stress with decrease their chances of 
conception and that they need to stay as calm as possible 
 
Prior to my second cycle I was told that I needed to stay as stress-free as  
possible and ideally reduce my hours of work. 
 
Women had to make a decision about whether to share or withhold 
information about treatment with their friends, family colleagues or managers. 
The decision to disclose or not disclose was seen as central theme in this 
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analysis because it connected the idea of an identity crisis (am I a treatment 
seeker or an employee?) with the risks (emotional distress) and benefits 
(practical and/or emotional support) of  telling work, friends, family or forum 
members about their status (see Table 27 The Risk Benefit Model of 
Disclosure). 
 
The decision to tell work was sometimes prompted by a need to arrange time 
off and gain benefits such as flexible working hours meaning that women 
took a high risk for high reward approach: 
 
I eventually also told work too when I requested to go part time which helped 
enormously…Going to speak to my Fed rep at work tomorrow and advise her 
of what we are doing so I can get some guarantees of support from my 
bosses.. I have to say though that our employers have been fantastic. My 
boss even looked at the INUK site and fact sheets and has been great at 
telling me to take as much time as I need, not to rush back to work etc. I 
couldn't have asked for more, so we have to count our blessings on that 
front. They have been incredibly understanding.. 
 
 
One of the risks that women took was that disclosure at work might 
compromise their identity as an employee with a loss of status, income or 
promotion: 
 
The day after our diagnosis I started the biggest job of my career in a new 
company. I don't tend to do things by halves .. To top it off Ive been offered a 
promotion at work but don't want to accept it if im going to start IVF this year. 
 
The confidentiality gained by not disclosing their treatment status may be 
violated because company policy demands evidence of medical 
appointments: 
 
I had to take a day off one day because I was so upset after a terrible 
appointment with a gynaecologist and having to explain why was awful.. I had 
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no choice but to tell work because I work in a call centre and can't just come 
in and  leave when I like, i have to show proof and they have to photocopy 
everything and time off  has to be approved depending on the staffing  
 
The lack of a clear legal framework to guide managers can mean that there 
is an inequality in the way that subjects were treated in different companies.  
Some were disciplined for taking time off, some decided not to disclose and 
some were supported emotionally and practically by their managers: 
 
Work is incredibly hard at the moment, my (female) manager does not really 
understand and my job is extremely stressful… and hurt i rang the union who 
gave me some really good advise and they told me what she was doing was 
more of sexual discrimination rather than victimisation. .. but I had disciplinary 
action as a result of being off that day. 
 
Compared to: 
 
My company have been fantastic and haven't even asked to see any 
evidence of treatment… possible but that I was taking a drug (clomid) that 
impacts on your hormones and I would need a blood test at day 21. They 
were fine with this and I think appreciated that I could  have completely kept 
this to myself, both the owner and the manager have two young  children… 
 
 A decision not to disclose treatment at work was sometimes the result of a 
desire to protect privacy in an emotionally sensitive situation: 
 
When I was having treatment I didn't tell anyone at work although I was 
tempted on several occasions. I'm really glad I didn't. It was hard getting over 
the disappointment privately so dealing with other people too wouldn't have 
suited me. It also meant at work I could temporarily forget about it… I haven't 
told work anything yet - I think I may have to but very reluctant - especially as 
its such a small team, there are about 10 employees… I am not telling work 
either, my job is quite pressured and I couldn't stand the speculation. They 
already suspect I am pregnant as I put on weight post wedding. The irony of 
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it isn't lost on me!! …So the next step is basically doing it!  We have to keep 
things very quiet here at work, for many reasons, so getting the time/dates to 
do it is proving a bit of a nightmare.. .  
 
Maintaining their identity as an employee sometimes meant that infertility 
distress had to be hidden away behind a professional façade: 
 
I work in a hospital environment and have to deal with seeing people who are 
pregnant and with children all the time, I have created a professional and 
cold shell I put up to allow me to function but inside I am screaming, tears 
come late at night after my husband sleeps and when I am alone - pathetic I 
know, I'm doing it again now. 
 
Confronting this conflict led to some women realising that they had to adopt a 
different position or identity: 
 
I also went on a motivational course with work in January and had to face up 
to some things and be honest with myself that family is more important than 
work for me.  I think I was going for promotions as some sort of displacement 
for how I really feel! 
 
The intimate nature of infertility treatment and the social stigma attached to 
being infertile mean that subjects may wish to keep their treatment a secret.   
 
We have decided not to tell anyone about our situation and over time a lot of 
people have stopped asking us questions. … it took me about 5 weeks to 
pluck up the courage to show  a manager my letter from assisted conception 
with my first appointment on it because I was so embarrassed, my boyfriend 
also works in here so that makes me feel even more embarrassed - I really 
wish that managers in here didn't know so much about my personal life.  
 
In addition to this the high failure rate and the emotional vulnerability that this 
engenders may mean that subjects want to protect themselves by not 
sharing what is happening.  Women who decided not to tell their friends and 
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family sometimes were motivated by the shame that either partner felt about 
their infertility: 
 
 I have chosen not to tell many people because I do not think people 
understand unless they have had to deal with IF themselves. DH struggles to 
talk about it although he does talk more since the IVF. But I do not think men 
have the same need to talk as we do and of course Male Factor IF does 
have a big impact on the male ego. 
 
Not telling friends and family provided privacy but it also has the effect of 
isolating women from potential sources of support or understanding, a low 
risk but low reward approach: 
 
He on the other hand refused to discuss any of it, completely shut me out of 
everything and stuck his head in the sand (plus he didnt want me to talk to 
anyone either, got very upset if i mentioned wanting to speak to any family or 
friends and all but forbid me to even speak to my mum!!).  Eventually the 
strain became too much and we split.  I am in my Mid thirties….Can anyone 
help me in my isolation , i have had to carry out all past procedures in secret 
apart from a few close friends and family members 
 
The benefits of disclosing their infertility status to friends and family were that 
it created an additional source of support, but at the risk of losing privacy or 
status, this could be seen as a high risk but high reward strategy: 
 
We finally told our families and very close friends what was going on.  We'd 
wanted to keep it private but actually telling others was helpful - especially 
my family… I've told a few close friends but not a wide circle of people that 
we're ttc. In a way the more people you tell the more pressure you put on 
yourself. After all  the end of your story to conceive might (sadly) be a bit of a 
way off.  Telling my friends was hard (silly pride) but having one of two 
people you can really open up to aside from your partner I think is a real 
comfort… 
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There is also the risk that family or friends will not provide the expected 
support: 
I told my mum who is quite ill herself and she was naturally very upset but 
instead of the support I thought I'd get she said "if you're trying again please 
don't tell me until you've had the all clear ad it's too upsetting for me"!!!  
 
The benefits of using the forum as a means of disclosure were that privacy 
was protected by using an online identity but they were guaraneeted a 
sympathetic and receptive audience as a source of support and so this was 
seen as a low risk, high reward strategy: 
 
We haven't told friends or family, we are quite private and want to do this our 
way. This site really is an outlet for me to share and understand others 
experiences, even more so for us… We havent told anybody about our if so 
when we found this website it was a godsend and provides the needed 
support although to date we havent come across anyone in the exactly the 
same position….We've had three cycles in all now, ending in BFNs, but 
we've really kept everything to ourselves since that first time, which I don't 
think is healthy - hence finally, so very late in the day, joining in the forums, 
although I have been reading your posts and thoughts and feelings. I can't 
say how much they have helped me through some dark times 
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STRATEGY RISKS BENEFITS 
TELLING F & F 
Being misunderstood 
Emotional pain to self and 
others 
Disappointment at 
treatment failure 
Loss of privacy 
Receiving support 
and 
understanding 
NOT TELLING F & F 
Not receiving support and 
understanding 
Creates a sense of 
isolation 
Protects privacy 
TELLING WORK 
Loss of earnings 
Disapproval from 
manager 
Career prospects 
damaged 
Discrimination 
Being misunderstood 
Loss of privacy 
Support and 
understanding 
Flexibility for time 
to attend 
treatment 
NOT TELLING WORK 
Disciplinary action and 
Loss of earnings for time 
off 
Not receiving support and 
understanding 
Maintain privacy 
and professional 
role 
TELLING VIA FORUM 
Negative experiences 
reported by others might 
be overwhelming. 
Support and 
understanding 
with privacy due 
to anonymity 
Table 27 The Risk Benefit Model of Disclosure 
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Triangulation of data  
Source One 
The forum administrator from IFNUK had previously collected some data on 
the concerns of working women and these were shared as amalgamated 
extracts with the researcher: 
 
TELLING YOUR EMPLOYER EXAMPLES 
1. I've chosen not to tell my work about my IVF journey- I felt too 
vulnerable. My firm has suffered badly with the recession in the 
last few years, and still makes regular redundancies. I feel that 
them knowing that I am trying to get pregnant will put me in line 
for the next redundancy  
 
2. I work as an Accountant and have a great career with my 
current employer.  I am in the Top 20% of my current band, 
which means promotion within the next 12 months from 
Management to Senior Management.  If I had discussed with 
my Manager, I would be discriminated against with regard to 
next job moves and promotion.   
 
3. The CFO of the business is basically 'leader of the boys club' 
and has made particularly unprofessional remarks about 
women in Finance who go on maternity leave. Whereas I have 
the added stress of trying to be discreet and take time off sick, 
my husband has the full support of his male boss and everyone 
in his office.  When really it is I, who need the stress taking 
away so that I have less to worry about whilst waiting for 
results. 
 
4. I told my employer that I was going to be doing IVF, but in my 
case, I only told my immediate manager (a man) who was very 
understanding, having had a very close friend go through IVF 
treatment and so was aware of the stress and trauma that 
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could arise.. However, I believe that a lot of the trust and 
support he gave me had been earned through the years, as I 
was very good at my job, hugely reliable, and dedicated to still 
meeting deadlines and responsibilities even throughout IVF 
treatment. This meant that I could take some time off  etc 
without questions being raised, and also so I could avoid some 
foreign travel which I would have normally done very frequently. 
He treated me very fairly and it was my own choice to book 
some days off as annual leave rather than using sick days, 
although in hindsight I should probably have used sick days. 
My manager didn’t ask too many questions – but asked just 
enough to make sure I was OK.  
 
5. I wanted to pass this on as I think there’s a big difference in 
telling the ‘company’ you work for – as opposed to just telling 
your manager. Unfortunately, not everyone will have such an 
understanding person as a manager!  
 
WHAT TO TELL YOUR EMPLOYER EXAMPLES 
6. I'm the first person at my company to go through ivf although I 
know a few colleagues have had time off for miscarriages. 
There are no policies at all in place and it's quite obvious my 
boss and manager (both mums) haven't a clue about what ivf 
entails and how much of a strain it is not only physically but 
emotionally. This round they have kindly agreed I can take time 
off for stimming and collection and transfer as unpaid and then 
I'm taking holiday for my 2ww. However, they cannot 
understand why I do not want other members of staff knowing 
what I'm going through and give me the impression I'm being 
awkward and a bit precious by saying it all must remain 
confidential. They also do not understand why I'm finding it all 
so hard emotionally. This then adds to my stress as I'm 
worrying about my job as well as the ivf. . 
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7. My husband works for a very large global finance and business 
advice company with offices in London but also across the 
world. He spoke to his HR dept about accompanying me to 
appts and collection/transfer who said "the company does not 
support IVF"! I guess it just shows even big well known 
companies just are not up to date with fertility treatment and 
how to manage the situation.  It's also a company which entitles 
employees to up to six months paid sick leave a year, so if my 
husband was going through depression etc he would get the 
time off with full pay.  
 
8. My company does not have an IVF policy and like many other 
companies decisions are made by line managers about how 
IVF is dealt with. I didn't tell my boss until I felt like I had to. I 
increasingly needed to take time off for appointments, often at 
short notice, and due to it being an NHS cycle I was often 
waiting for 1-2 hours before I was actually seen so it didn't 
seem like an option not to tell her. She had started to worry that 
I was looking for another job! 
 
MANAGING TIME OFF EXAMPLES 
9. I opted to tell my boss before my 1st cycle, and gave 
suggestions about how I could best manage things. I manage a 
team of people, and was keen to ensure I was as stress free as 
possible.  I also confided in a friend at work which was 
invaluable as a sounding board when needed. if your boss 
knows, then it may be possible to keep your diary more open 
and flexible during this time and maybe you could work from 
home around appointments on the days you have to go to the 
clinic 
 
10. I had a chat with my boss and she told me that she doesn't 
want to set a precedent of people working from home, but she 
will give me a few days of compassionate leave and I can take 
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the rest as holiday - so I don't need to go into the office and 
juggle/rush backwards and forwards from meetings during this 
time (which was my biggest worry 
11. The further into this process I get, the more that I really feel that 
the law has to change to give women going through IVF more 
support. It's just ridiculous in this day and age that we have to 
go through all this worry of trying to negotiate days off and 
having to juggle sick leave and holiday. For most other serious 
health conditions - and IF is a serious health condition - there 
would be no question about taking time off for treatment 
 
12. I was lucky and my boss was fine about time off. This may be 
because I'd already worked at the company for 6 years when I 
started treatment and had had no other sickness and always 
worked hard. My boss's attitude may have been different if I 
often took time off or wasn't fully commited to my work. 
 
13. Prior to my second cycle I was told that I needed to stay as 
stress-free as possible and ideally reduce my hours of work. 
This is not practical in my job but I spoke to my boss and 
suggested that I work from home a couple of days a week 
which she agreed to. Reducing my hours would only have 
stressed me out as I'd have the same work to do in less time! 
 
The extracts are included, despite the lack of knowledge about the sampling, 
because they form a useful comparison with this analysis but were not used 
to create the codes or themes in this analysis as there was no indication of 
the method used to obtain them.  Permission was granted by the forum 
administrator to include them in the thesis. 
 
Extract 1 relates to the decision not to disclose treatment because their 
identity as an employee will suffer, they will be at risk of losing their job 
because their company is making people redundant.  This is despite the fact 
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that her company would not be allowed to discriminate against her during IVF 
treatment without laying themselves open to sexual discrimination charges. 
 
Extract 2 is also an illustration of someone who has chosen not to disclose 
their status but for the reason that they are doing well in their career and 
want to be considered for promotion.  They are illustrating the basic conflict 
between identity as a treatment seeker and identity as an employee as being 
mutually incompatible.  Both examples of disclosure are perceived as being 
high risk decisions because the identity as an employee is uppermost. 
 
Extracts 3 and 11 are examples of the injustice felt by women who face 
sexism at work and are distressed by the fact that they need emotional 
support more than ever during treatment.  They are forced to conceal their 
status as a treatment seeker by being ‘discrete’ and taking sick leave.  
Women would like to be able to reconcile their identities as being both 
employees and treatment seekers by seeing them as belong to different 
domains, one is about their health and the other one is about their work. 
 
Extract 4 shows the benefits of disclosure at work if there is a supportive 
manager or company policy leading to a mutual negotiation of flexible time 
off and empathy.  Extract 12 implies that this employer goodwill has to be 
‘earned’ by being a good employee rather than having a legal right to sick 
leave or pay. 
 
Extract 5 is an example of how the personal relationship with the manager 
can lead to a ‘partial’ disclosure to the ‘person’ rather than the company.  
This illustrates the empathy theme and also shows that not all female 
managers are more empathetic than male managers. 
 
Extract 6 describes the emotional stress caused by lack of empathy from 
managers even when they have agreed to be flexible.  There are no 
company policies in place so protect the privacy of the treatment seeker. 
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Extract 7 highlights the way that infertility and infertility treatment are not 
recognised by some companies as a legitimate reason for men and/or  
women to take time off work. This lack of recognition of their condition means 
that the legitimacy of their identity as a treatment seeker (as a health issue)  
is also being challenged at work, this is why the identity as a treatment 
seeker conflicts with their identity as an employee as they are contained 
within the same domain of ‘work’. 
 
Extract 8 shows how the decision not to disclose is sometimes pragmatic 
because of the demands of treatments and the need for flexible working 
arrangements and the fact that the company has not clear policy. 
 
Extracts 9 & 13 provide a positive picture of the benefits of disclosure at 
work and to a friend in order to receive support and flexibility in return.  The 
identity as a treatment seeker and as an employee are integrated and the 
tone of the extract is positive. 
 
Extract 10 illustrates the theme that time off has to be taken from holiday 
time or as compassionate leave because the company has no clear policy 
and doesn’t want to set a precedent, again denying the legitimacy of the 
‘treatment seeker’ role. 
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Triangulation Source Two 
Another source of data that could be used to check the credibility of this 
analysis was the work being conducted at Middlesex University by Nicola 
Payne (Payne, 2014)  During the time period that data was being sought on 
the online infertility forums another research group were also posting a 
request asking women to come forward and be interviewed about their work-
life balance.   
 
Nicola Payne was kind enough to correspond with me and we exchange 
several emails about our projects.  In March 2014 we discussed our progress 
and she shared her slides for a conference of the European Academy of 
Occupational Health Psychology.  The data analysis is not based on her full 
data (31 women and 6 men) set but on 15 women with a mean age of 35 (SD 
=5).  They used semi-structured interviews to collect the data, which was 
then analysed thematically. 
 
The framework for their literature search used role conflict theory (Greenhaus 
and Beutell, 1985) as this is common approach for research on work-life 
balance.  The aim of their project was to explore the experiences of Medically 
Assisted Reproduction, (MAR), users of combining work and MAR.  They 
hoped to be able to identify barriers as well as support mechanisms that 
people used. 
 
The themes that they identified were presented as summary slides and are 
shown below as a list: 
 
MAR-Work conflict 
 
1. Time- and strain-based conflict, which included worrying about the 
results of treatment and the practical issues around taking time off. 
 
2. Work providing a distraction from the anxiety and allowing you to carry 
on as ‘normal’ 
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3. The impact of identity 
4. A shift in anchor identity to ‘becoming a parent’ and work being put on 
the back burner 
5. Resentment towards work if it was perceived to be getting in the way. 
 
Support for MAR use 
 
6. Manager support 
7. Most women experienced some degree of support from practical only 
to also including emotional support 
8. This enabled women to priories MAR, so supported their anchor 
identity and reduced conflict 
9. Shared understanding of the experience helped 
10. Job flexibility also helped reduce conflict 
 
The pros and cons of a specific policy 
 
11. Policy is needed but few workplaces had a specific policy and where it 
existed it was limited, so policy or guidance is needed. 
12. Constraints might include working for a smaller company where the 
absence has a greater impact on the company. 
13. There may be mutual benefits to working for a company that has been 
really good to you and therefore created a loyalty. 
(Payne, 2014) 
 
They concluded that MAR users experience a shift in identity to 
parenthood and so experience a ‘spillover’ conflict.  Line manager support 
and job flexibility can help to reduce this conflict.   The existence of a 
specific policy or guidance is relatively rare but necessary and while there 
are constraints to providing support this may be mutually beneficial. 
 
My own analysis also showed time and strain based conflict (1) which 
centred around the impact of the conflict of identity (3) as either a 
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treatment seeker or an employee.  Payne identified the desire for 
parenthood as an issue of identity rather than ‘treatment seeking’ 
because she has focused on the outcome of treatment (4).    My own 
analysis did not bring out the theme of work providing a distraction from 
anxiety (2) as strongly as hers and I have used ‘injustice’ rather than 
‘resentment’ to describe the conflict of roles (5).  The role of supportive 
managers (6) was also found in my analysis with the same theme that 
support might be emotional or practical (7) depending on company policy 
and the levels of empathy.  I did not find that most women experienced 
some degree of support (7) or that women were able to reduce their 
stress by prioritising their treatments (8). 
 
My study did find that shared understanding of the experience (9) 
particularly through social support including the forum helped women 
cope and that job flexibility (10) was an advantage that could be gained 
by disclosure. 
 
The idea that a specific policy and guidance about how to implement it 
(11) would create a more equalble access to treatment for all women was 
certainly reflected in my analysis as well as the idea that smaller 
companies may have difficult accompodating employees who need time 
off for treatment (12).  The final point that a mutually beneficial 
relationship can be achieved was also found in my analysis (13). 
 
Conclusion. 
There was a high level of agreement between the themes found by (Payne, 
2014) and by myself suggesting that these themes are credible and 
authentic.  The main differences were that most of her women had 
experience some degree of support and the reason for that difference may lie 
in the sampling techniques used especially in the biased form of my posting 
on the forum and the use of naturalistic data.   
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In the final chapter of this thesis I attempt to draw together the philosophical 
worldview, the choice of methodology, the theoretical framework and the 
results of the four strands, before this discussion I present a brief summary of 
the main findings of this thesis below: 
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Conclusion And An Overview Of The Main Findings 
Strand 1 The Practitioner Survey 
 
• Homotoxicology practitioners perceive infertility to have both 
exogenous causes such as stress and toxins as well as endogenous 
causes such as reproductive pathology or hormonal imbalance. 
 
• Unlike classical homeopathy the use of complex homotoxicological 
preparations such as Ovarium compositum are prescribed on clinical 
indications rather than individual case histories and would be suitable 
for use in a randomised controlled trial where the sample of patients 
are being recruited by the clinic for a specific clinical indication. 
 
Strand 2 The Discussion Group and Questionnaire Survey of Staff at 
The Bridge Centre 
 
• The nurses at the clinic provided a perspective that appeared to 
bridge the dismissal of homeopathy by some medical practitioners and 
the personal choice to use homeopathy made by some patients 
 
• They were open to the idea and potential benefits and could also see 
practical challenges to implementing a trial.   
 
• Their support would be necessary to run such a trial and would need 
to be fostered by the researcher.   
 
• They would like to receive more training and information so that they 
could advise patients and colleagues and this would need to be 
planned into the trial schedules.   
• They recognised that their patients often suffer emotional distress and 
disappointment at treatment failure and for that reason may not wish 
to take part in a trial where they could be randomised to placebo.   
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• The other issue raised was that it would not be ethical to delay any 
conventional treatment as women’s fertility outcomes decline with age. 
 
Strand 2   The Questionnaire Survey of Patients at The Bridge Centre 
• The response rate to this questionnaire was 19% but it was not 
possible to record the number of patients who did not choose to take a 
questionnaire from reception.  
• 91% of respondents were motivated by the desire to take part in a trial 
that would help other infertile couples in the future 
• 85% were motivated to increase our knowledge about homotoxicology 
and homeopathy. 
• 88% had not tried this therapy before.  
• A high level of interest (92%) was shown in trying homotoxicology in 
the future.  
• 83%, would be willing to pay for treatment if homotoxicology was 
shown to be effective.  
• 2% indicated that they would consider homotoxicology because they 
were considering stopping IVF/ART. 
• 62% would be prepared to take part in a trial where they may receive 
a placebo.  
• 95% would be prepared to take their medication at home.  
• 100% would be happy to give up peppermint and coffee.  
Strand 3 A Randomised Controlled Trial of Ovarian Compositum 
versus placebo at Jersey General Hospital 
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Over a period of nine months (November 2011 – July 2012) unit staff 
identified suitable patients who attended the ARU.  Four patients agreed to 
take part and three of them were consented. Of the 3 patients that were 
consented 1 withdrew after initial screening as she became pregnant before 
she started the trial medication.  1 patient completed 6 months of treatment, 
1 patient withdrew after 1 month due to compliance issues and 1 patient 
withdrew after 2 months after compliance issues. 
Recruitment and retention rates were low due to a combination of reported 
circumstances: 
• A higher than expected pregnancy rate at the clinic left fewer eligible 
subjects. 
• The difficulty of attending additional appointments for working women 
who are wary of disclosing their treatment to colleagues, family or 
friends 
• The burden of extra work on the ARU staff who did not feel any 
‘ownership’ for this trial as they had not been involved in the planning 
stages. 
• Patient perceptions of the impact of taking part in a trial on their 
treatment progression or outcomes 
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Strand 4 A Qualitative Analysis Of The Concerns Of Infertile 
Women 
 
A thematic analysis (Braun and Clarke, 2006a) and an iterative cycle of 
reading, writing and reflecting, led to the development of two themes found in 
the experiences of infertile women undergoing treatment: firstly the 
conflicting identities of the respondent as both an employee and an infertile 
treatment seeker, and secondly, the emotional distress caused by infertility 
and infertility treatment.  Linking these was a further theme about the 
legitimacy of their condition that was dependent upon the existence or 
absence of a clear company policy on infertility treatment. Consideration of 
the subthemes within these led to development of a higher order thematic 
map as shown in Figure 7 Thematic Map. 
 
The themes were further developed on a conceptual level into a theory of 
‘telling others: Risk Vs. Benefit identity model’ where disclosure of infertility 
treatment status to their work, friends, family or forum could be made on the 
basis of anticipated gains (support, flexibility, empathy) compared to potential 
losses (job security, friendships, emotional rejection/lack of empathy, loss of 
privacy), all of which had an effect on identity, see Figure 8 Risk vrs Benefit 
Theory of Disclosure.   
The development of these themes was aided by the literature on identity 
conflict in chronic disease (Charmaz, 2010, Charmaz, 2006, Charmaz, 1983) 
and disclosure theories from the field of HIV research (Serovich, 2001), 
(Serovich et al., 2008, Rouleau et al., 2012). 
The literature on stress and infertility was also revisited in order to include 
findings from the field of psycho-neuro-endocrine-immunology being used to 
elucidate the biological pathways by which stress may affect adverse 
pregnancy outcomes, maternal health, and fetal development (Christian, 
2012).   
 
  
RESULTS 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   381	  
 
 RISKS BENEFITS 
TELLING F & F 
Being misunderstood 
Emotional pain to self and 
others 
Disappointment at 
treatment failure 
Loss of privacy 
Receiving support 
and 
understanding 
NOT TELLING F & F 
Not receiving support and 
understanding 
Creates a sense of 
isolation 
Protects privacy 
TELLING WORK 
Loss of earnings 
Disapproval from 
manager 
Career prospects 
damaged 
Discrimination 
Being misunderstood 
Loss of privacy 
Support and 
understanding 
Flexibility for time 
to attend 
treatment 
NOT TELLING WORK 
Disciplinary action and 
Loss of earnings for time 
off 
Not receiving support and 
understanding 
Maintain privacy 
and professional 
role 
TELLING VIA FORUM 
Negative experiences 
reported by others might 
be overwhelming. 
Support and 
understanding 
with privacy due 
to anonymity 
Figure 8 Risk vrs Benefit Theory of Disclosure 
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Chapter 5 Discussion and Conclusions. 
Integration with prior work, implications, transferability, and 
contributions to the field 
 
The aim of this final chapter is to review the philosophical and theoretical 
frameworks, methodology, and results of this thesis and comment on how 
they integrate with prior work; to explore their implications and transferability; 
and to reflect on how I have contributed to the field of study which is finding 
appropriate trial designs for the effects of homotoxicology to treat female 
infertility.  There were two main research objectives for this thesis: 
 
 
Research Question 1 (Strand 1,2,3) 
 
Does Ovarium compositum improve the fertility outcomes of women 
undergoing infertility treatment at the Assisted Reproduction Unit of 
Jersey General Hospital? 
 
Research Question 2  (Strand 4) 
 
What are the reasons for recruitment failure to a trial of Ovarium 
compositum (strand 3) to improve the fertility outcomes of women 
undergoing infertility treatment at the Assisted Reproduction Unit of 
Jersey General Hospital? 
 
The rest of the chapter is structured around these with reference to the 
earlier chapters in this thesis as summarised in the preceding section. 
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Research	  Question	  1	  
Does Ovarium compositum improve the fertility outcomes of women 
undergoing infertility treatment at the Assisted Reproduction Unit of 
Jersey General Hospital? 
 
A review of the literature showed that there was a knowledge gap about 
safety of CAM therapies (Fields et al., 2013) and for a methodologically 
sound, well-reported trial, to investigate the use of homotoxicology in infertile 
women. The use of both systematic and non systematic qualitative narrative 
reviews is discussed in the literature review chapter and it is acknowledged 
that a systematic review is a higher level of evidence for making clinical 
decisions but that a non systematic review may provide a stimulus for 
philosophical and scholarly discourse, hypothesis generation or for an 
iterative cycle of rewriting and reading. 
 
‘Methodologically sound’ refers to the need for any trial of homoeopathy or 
homotoxicology to demonstrate model validity (Mathie et al., 2012) and to 
address the so-called ‘efficacy paradox’ where the use of quantitative trial 
designs lead to a situation where internal validity is emphasised to the 
detriment of external validity.  This problem was encountered in existing 
studies of homotoxicology in infertility where successful clinical experiences 
were not easily translated into either clinical trial design or results (Gerhard I, 
1997, Bergmann et al., 2000, Lai, 2000).    
 
My study design was a development on these studies; I included blinding, 
randomisation and rigorous allocation to randomisation procedures.  No 
existing treatment was withheld from women, unlike the Lai study in which 
homotoxicology was an alternative to conventional treatment, something 
that has ethical issues. 
 
DISCUSSION 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   385	  
However my study, like Gerhard’s, also failed to recruit sufficient women and 
although I carried out a qualitative analysis in Strand 4 this might instead 
have been undertaken as a preliminary to recruitment and might have 
improved the outcome. 
 
 
A systematic review (Mathie et al., 2013) has identified 96 studies of placebo 
controlled, non-individualised homeopathy including two records for the 
condition of female infertility: A52 (Bergmann et al., 2000); A74 (Gerhard et 
al., 1998). These existing trials had methodological shortcomings as well as 
being poorly reported.  However it is shown that a randomised placebo 
controlled trial would be the most effective method for establishing the 
specific effect of Ovarium compositum compared to both placebo and non-
participation.   
 
There is also a ‘paucity’ of research using positive emotional outcome 
measures (e.g. well-being, positive affect, happiness or life satisfaction) for 
women undergoing fertility treatment (Rockliff et al., 2014) and so the 
measurement of the quality of life of women taking part in the trial was 
intended to go some way to rectifying this, by using both a validated (Mark 
Oppe, 2007) but generic and non-validated (but specific) (Farmer, 2007) QoL 
instrument. 
 
This study was intended to test the feasibility of measuring a specific effect in 
a homeopathic/homotoxicological product as well as the feasibility of 
recruiting women to such a trial.  The negative results from the trial should 
not be interpreted, as a failure of homotoxicology and the trial design itself 
ought to have been sufficient to measure a specific remedy effect if 
recruitment targets had been achieved.   
 
This study did demonstrate that the nature of homotoxicology as a complex 
formulation means that it can be prescribed on clinical indications rather than 
a single remedy prescribed on an individualised symptom picture.  
Homotoxicology can therefore be administered to a homogenous group of 
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patients with similar clinical indications and compared to a placebo and future 
trials could be planned using a similar protocol to strand 3.   The limitations of 
this attempt were acknowledged, particularly the lack of homogeneity in the 
women attending the ARU and the lack of communication with site staff when 
planning and implementing the trial. 
 
The finding that it is not feasible to plan a trial where recruitment is left to 
clinical staff was an important one and would need to be addressed if this 
pilot study was to be used as the blueprint for a full-scale clinical trial. This 
conclusion is based on the survey findings showing doctors tending to a bias 
to conventional medicine and nurse perspectives bridging doctor and patient 
views and with nurses needing ownership in a study.  Thus a clinician as 
study champion might be helpful, as in any clinical trial, but in a 
homotoxicology trial is unlikely to be sufficient. 
 
The difficulties in recruitment led to several hypotheses by site staff about the 
emotional stresses faced by women attending their unit, the importance of 
investigating these further led to a deeper understanding of the importance of 
attending to the data from the earlier, qualitative aspects of the project.  
 
The qualitative results from strand 1 were used to design the quantitative trial 
design by helping select the medication used as well as the RCT trial design.  
The qualitative results from strand 2 were used to inform the feasibility of the 
RCT trial but the results would have been even more valuable if more 
attention should have been paid to some of the concerns expressed by the 
nurses at The Bridge Centre about hosting a trial from an ARU unit. 
 
They had identified practical difficulties, such as the appointment times that 
would need to be extended, and the need to get a large sample size to 
create a credible result. 
 
These ideas were explored in more detail during the fourth strand of the 
study and during the writing and rewriting of the thesis. 
DISCUSSION 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   387	  
Research	  Question	  2	  
What are the reasons for recruitment failure to a trial of Ovarium 
compositum (strand 3) to improve the fertility outcomes of women 
undergoing infertility treatment at the Assisted Reproduction Unit of 
Jersey General Hospital? 
 
The nurses who cared for women undergoing treatment in both London and 
Jersey reported this patient group to be vulnerable to stress and a review of 
the literature also highlighted that the prognosis of the couples who 
discontinued fertility care because of emotional distress would have been 
better if they had continued with treatment (Brandes et al., 2009). 
 
More recent studies such as (Boivin et al., 2012) recognise that in order to 
retain women in treatment cycles the emotional and psychological aspects of 
infertility treatment need to be recognised and addressed:  
 
Reducing the burden of treatment should lead to improved outcomes, namely 
better quality of life during treatment and lower discontinuation rates. (Boivin 
et al., 2012) 
 
The relationship between stress and infertility was seen to be implicit in the 
earlier papers reviewed (Brandes et al., 2009, Finamore et al., 2007) and 
more recent papers have been able to connect this implied relationship to 
more explicit findings from the emerging field of PNEI (Christian, 2012). 
 
This thesis seeks to understand the mind-body connection that is central to 
both homotoxicology and pragmatism and apply it to the context of stress 
and infertility, this synthesis of concepts represents one of the unique 
contributions made to the field and will explored in more detail below. 
From the results of this qualitative analysis it is possible that women 
attending the ARU unit in Jersey were experiencing difficulty in disclosing 
their treatment status at work in order to attend appointments and that taking 
part in the trial might be a distressing reminder of their condition.  It was clear 
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from the thematic analysis that infertile working women experience a conflict 
between their psychological identities as both treatment seekers and 
employees. 
My theory explores this conflict in more detail and examines the relative risks 
and benefits of disclosing to different audiences.  The risks of disclosing at 
work are exacerbated by the lack of a legal status for treatment seekers and 
the dependence upon the empathy or goodwill of the employer to support the 
treatment seeker.   
It is concluded that women could be spared some of this additional distress if 
there was a clear policy for companies to follow regarding women seeking 
treatment for infertility and a legal framework that offered protection and 
guidance for all parties. 
 
Anonymous disclosure via a forum can help women forge an identity as a 
treatment seeker and express their emotional distress, but does not 
necessarily resolve the identity conflict at work.  Empathy and support from 
employers, colleagues, friends, family and fellow forum posters are highly 
valued by infertile women and help to combat the emotional distress and 
sense of isolation caused by their situation.  The ownership of data posted on 
public forums by patients is debated and is an intended area for my further 
research and publication. 
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Reflections On The Methodology 
Mixed Methods studies are not the most common form of CAM publication, 
some authors reporting that they make up only 4% of papers (Bishop and 
Holmes, 2013), this thesis was an exploration of the use of MMR.  It is 
important to ensure that it met the criteria for mixed methods research so that 
this thesis can make a solid contribution to the literature around the use of 
MMR in CAM (Pace et al., 2012). Its fit to the criteria is now discussed. 
 
At the start of the study design the use of mixed methods was both planned 
(as in strand 1 and 2 as well as the embedded aspect of strand 3) and 
unplanned (as in strand 4).   The emergent nature of the design was shaped 
by the results of strand three as well as the increasingly pragmatist worldview 
of the researcher whose thinking followed: 
 
…A dynamic homeostatic process of belief, doubt, inquiry, modified belief, 
new doubt, new inquiry…in an infinite loop, where the person or researcher 
(and research community) constantly tries to improve upon past 
understandings in a way that fits and works in the world in which he or she 
operates.  The present is always a new starting point. (Johnson and 
Onwuegbuzie, 2004) 
 
When trial recruitment failed (strand 3) there was the option to abandon the 
study altogether, but perhaps because the researcher has a background as a 
homotoxicological practitioner, there remained an interest in how the 
experiences of the infertile women had influenced their choices about trial 
participation.  This moved the research question from a quantitative 
approach to a qualitative approach based upon the existence and importance 
of the natural or physical world as well as the emergent social and 
psychological world that includes language, culture, human institutions, and 
subjective thoughts (Johnson and Onwuegbuzie, 2004). 
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The MMR approach was used to plan the quantitative strand (3) and to 
address the research question: What are the reasons for recruitment 
failure to a trial of Ovarium compositum (strand 3) to improve the 
fertility outcomes of women undergoing infertility treatment at the 
Assisted Reproduction Unit of Jersey General Hospital? 
 
Including the perspective of practitioners, nursing staff and patients was 
intended to make the study design more feasible and effective in answering 
the research objectives. 
 
An example of this would be strand 1, where the therapists who participated 
were using homotoxicology to treat patients for infertility; the questionnaire 
was designed to capture two kinds of data, firstly on the specific kind of 
infertility case that would be the focus of the trial (a patient attending an ARU 
for IVF due to failure to ovulate).   
 
Secondly, the questionnaire also asked about general attitudes and 
approaches to infertility treatment in order to explore the perceptions, 
knowledge and experiences of the prescribers.  This was important to inform 
the trial design for the quantitative phase, especially the exclusion factors 
and the use of a placebo and the intention to have a non-participating control 
group in normal care. 
 
The data collection needs to be suitable to address the research objectives 
or questions; model validity requires that the follow-up period is long enough 
for the outcome to occur. In strand 1 and strand 2 sufficient time was allowed 
to collect in the questionnaires, in Strand 3 recruitment attempts took place 
over 8 months and was stopped so that any patient who did enrol was 
guaranteed was 12 month supply of medication. In strand 4 the time needed 
to complete the qualitative analysis was provided by the thesis rewrite period. 
 
The qualitative data from the small sample of direct responses that were 
used in strand 4 were not the ideal choice but a pragmatic choice.  It would 
have improved the study if there had been a larger sample of responses to 
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the invitation to share their experiences of working and undergoing infertility 
treatment so that saturation of themes could have been achieved.  The small 
sample has been triangulated with other data, from the forum administrator 
and from another similar concurrent study (Payne, 2014) in order to check for 
missing themes and to compensate for this small sample size. 
 
The data from the forum users was also a pragmatic choice but it did allow 
the researcher to seek for the themes in a larger sample of naturalistic data 
and to explore how themes might be interrelated.  If there had been a forum 
just for infertile women in Jersey then that would have been helpful when 
forming a conclusion about the uniqueness of findings at the clinic.  
Pragmatism takes a naturalistic view of man and therefore naturalistic data is 
an appropriate choice. 
 
Thematic analysis  (TA) was a good choice for this study because it is 
relatively simple for a new researcher to use and the process of using it has 
been well described (Braun and Clarke, 2006b).  The flexibility of TA allowed 
me to apply it to different data sets from strands 1,2 and 4 and develop my 
understanding of how to seek for themes in the data at an increasingly 
conceptual depth.   
 
I was able to use it to categorise social data as well as data obtained from 
my questionnaires and discussion groups.  This plurality of use is possible 
because it is not automatically linked to any pre-existing theoretical 
framework and so can be used to do different things within different 
frameworks.  The flexibility of TA also means that as a researcher I had to be 
explicit about my methods, theoretical framework and philosophical 
worldview. 
 
The randomisation of the patients in the quantitative strand (3) was clearly 
described.  The patients were to be randomised, to treatment, using a 
randomisation sequence designed by Heel, in blocks of four.  They were to 
be stratified according to chronological age and treatment group.  The 
randomisation sequence was designed by Heel (manufacturer) who provided 
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sealed envelopes for the codes they had generated.  A template was 
provided for the generation of labels so that clinic staff in Jersey could label 
patient files. The randomisation allocation was captured by the unit staff and 
site pharmacy on a word document provided by the investigator. 
 
The methodology section also clearly describes how the consulting physician 
who allocated the patient to the next number in the approach age and 
treatment group controlled allocation of the study drug.   The allocation code 
was passed to pharmacy that held the medication labelled with the allocation 
codes.  The sealed envelope was added to the patient’s file of notes and a 
sticker was attached to the front of the file to identify them as a trial 
participant and included their allocation code.  In the event of an adverse 
event the envelope could be opened and the code broken.  Patients, 
researchers, doctors and pharmacy were all blinded as to the allocation of 
patients to active drug or placebo. 
 
The selected outcomes and associated measurements in the quantitative 
strand were appropriate to capture both small and large changes in the 
patient group, for example blood tests of hormonal levels are a sensitive 
measure of small changes compared to pregnancy tests.  The trial design 
was checked against the criteria for the MVHT method (Mathie et al., 2012) 
to make sure that there was a concordance between the trial study design 
and “state of the art” practice for the intervention under investigation.  
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Philosophical Worldview 
The integration of both the qualitative (1 & 2) and quantitative strands (3) was 
made possible by the philosophical worldview.  Pragmatism which is a 
pluralistic philosophy provides a framework for reconciling the dualistic views 
originating from quantitative and qualitative research traditions (Mesel, 2013).  
This thesis values the knowledge that can be gained from conducting both 
quantitative and qualitative methods in order to gain a wider, more complete 
perspective on the research question. 
 
The need to report philosophical orientation when writing up a mixed 
methods study was highlighted by (Bishop and Holmes, 2013) who reviewed 
articles from the field of CAM and found that only 5% of studies 
acknowledged or reflected on the limitations of their mixed methods design.   
None of the studies they reviewed acknowledged or addressed the 
philosophical tensions involved in a mixed methods research project.  This 
study seeks to make a contribution to the field by reporting with transparency 
both the pragmatic philosophical framework and the process through which it 
was developed. 
 
The lack of quantitative data meant that there was not a problem with 
divergence of results from qualitative and quantitative sources, but if a 
complete data set had been collected it would have answered the 
quantitative research question: What is the specific effect of Ovarian 
compositum on the fertility outcomes of women attending an ARU at Jersey 
General Hospital? 
 
The decision to then further investigate the work related concerns of women 
attending treatment would have been seen as an extension to the study 
rather than an integral part of the initial design.  The actual study design was 
a pragmatist response to the problems and challenges encountered along 
the way and in turn led to an understanding of the pragmatist foundations for 
MMR.   
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Practicalities (in the collection of data) led to a deeper understanding of 
philosophy.  A deeper understanding of the philosophy led in turn to a more 
informed approach to methodology. The adoption of pragmatism meant that 
this researcher’s journey from post positivist to pragmatist worldview was 
informed by a philosophical worldview, that the decisions made were 
purposeful and it bought a sense of cohesion to the project as a whole. 
 
Pragmatism replaces the need to view the mind and body as separate by 
viewing human beings in naturalistic way as biological organisms in constant 
transaction with their environment.  
 
One of the ideas expressed at the start of this thesis was that it was an 
exploration of the reconciliation of dualisms that exist between conventional 
medicine and complementary medicine and that these originate from the 
Cartesian legacy of mind-body dualism (Shelton, 2013).  
 
Pragmatism views man as a biological organism in constant transaction with 
its environment.  This is in direct contrast with the narrowly focused scientific 
perspective which cuts off mind from the individual human being and cuts off 
the environment from behavior by seeing environment as a purely external 
occasion from which behavior proceeds (Shelton, 2013). 
 
The role of pragmatism as a philosophical framework for uniting dualisms 
has been described in the literature review (Shelton, 2013, Mehta, 2011), 
and the link to mixed methods research designs is described by several 
authors (Bishop and Holmes, 2013, Creswell and Clark, 2007b).  My own 
analysis seeks to build on this existing knowledge by describing some of the 
similarities between the scientific model of PNEI and the CAM model of 
homotoxicology and their links with pragmatism as a philosophical worldview. 
 
So if we take Pragmatism as a starting point, this leads to a view of mankind 
as the organism, which as long as it is alive is always in constant dynamic 
transaction with the environment, (Dewey, 1896). 
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For Dewey the biological theory of stimulus and response was dualistic as it 
assumed a gap between the organism and it’s external environment.  The 
stimulus that caused a response was external to the organism. He replaced 
this dualistic notion with a dynamic model of continuous readjustment where 
the selection and assimilation of information leads to a dynamic coordination 
with the environment (Dewey, 1896).  The stimulus can only be said to have 
been found at the moment that the (adequate) response has been found, it is 
not a prior condition of stimulus leading to a response. (Biesta and Burbules, 
2003). 
 
Dewey postulated two possible states: firstly where the connection between 
stimulus and response has already been made (an accomplished adaptation) 
and secondly where the connection has not yet been made and the organism 
is searching for a stimulus (Dewey, 1896, Biesta and Burbules, 2003).  This 
earlier open phase in which there is a tension, need or conflict resolves into a 
later closed phase described as an integrated interaction of organism and 
environment. 
 
Dewey linked this idea of the construction of a stimulus through experimental 
action to the acquisition of knowledge and habit.  This was not seen as the 
acquisition of information about the world ‘out there’ but learning in the sense 
of the acquisition of a complex set of predispositions to act.  Knowledge is 
seen as becoming gradually more useful and intelligent through experience, 
without the need to attribute reality to an independent entity, essence or 
external reality. (Biesta and Burbules, 2003).  The adoption of this model 
would naturally lead to a constructionist perspective of knowledge and 
learning theory. 
 
Homotoxicology also views man as both and open and closed system that is 
constantly influenced by the surrounding environment.  Interactions between 
the inner and outer environments trigger correcting processes 
(autoregulation) in order to maintain the homeostatic balance necessary for 
life (Smit A, 2009).  Cannon defined the word homeostasis in 1932, deriving 
it from the Greek words homoios  (the same) and stais (stance or posture).  
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Homeostasis thus means to stay in the same condition or position (Smit A, 
2009) but today the understanding would be that this is a dynamic 
equilibrium or steady state.   
 
This steady state is achieved by the workings of the Greater Defence 
System, a model postulated by Reckeweg (Reckeweg, 1984) made up of six 
subsystems working together to eliminate toxins from the body and restore 
tissue damage.  Detoxification and drainage as well as immunomodulation 
are the main treatment pillars in homotoxicology.   
 
The six systems all merge into each other and have a synergist effect, 
working actively together to defend the body and maintain homeostasis.  As 
can be seen from the table below the components of the Greater Defence 
System are consistent with the immune regulation system as seen in modern 
medicine. 
 
The positivist perspective can be found in pyscho-neuro-endocrine-
immunology (PNEI), a multidisciplinary medical approach. PNEI describes 
this active maintenance of internal homeostasis and health by the 
interactions of the neurological, endocrine and immune systems under 
genetic, epigenetic and psychological influences.  
 
Homotoxicology would describe these genetic and epigenetic influences as a 
concept called Miasm. The role of stress as describe by Selye (Selye, 1936) 
in health and disease is another central concept shared by both 
homotoxicology (Smit A, 2009) and PNEI (Campagne, 2006) theoretical 
frameworks. 
 
 
Table 28 Comparison of the Greater Defence System with PNEI 
 Component of the Greater 
Defence System (Smit A, 2009) 
Component of PNEI systems 
1. The reticuloendothelial system Cells of the immune system 
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(macrophages, monocytes, dendritic 
cells, lymphatic system)(Steinman 
and Cohn, 1973), (Sallusto and 
Lanzavecchia, 2002) 
2. The hypothalamus-hypophysis-
suprarenal axis 
The hypothalamus-hypophysis-
suprarenal axis(Campagne, 2006) 
3. 
The neural reflex system 
Neural reflex regulation (Vasquez et 
al., 1997) 
4. 
Detoxification by the liver 
Physiological functions and local 
immunity (Knolle and Gerken, 2000) 
5. 
Detoxification of the matrix 
Structural, transport and immune 
functions of the extracellular matrix 
(Bonnans et al., 2014) 
6. 
The mucous membranes 
Immune functions and stress 
(Papadopoulos et al., 2014) 
 
The concept of an ‘intelligent’ system that is reacting continuously to respond 
to it’s external environment and create a homeostatic internal reality is found 
in pragmatism, homotoxicology and the medical field of PNEI as well some of 
the nursing theories explored in strand 3 (Masters, 2014).  By taking this 
pragmatist viewpoint the basic dualism between quantitative and qualitative 
approaches to research is reconciled, the theoretical framework of 
homotoxicology offers a way to reconcile the mind body connection because 
of it’s similarity with PNEI.  
 
There does however remain the question of what to measure and how to 
measure it.  If a quantitative perspective is taken of the phenomenon then a 
quantitative answer will be produced, the same phenomenon studied using a 
qualitative technique will produce a qualitative answer and the so dualism is 
still present in the results and interpretation of the results.  It is argued in this 
thesis that mixed methods research would allow both perspectives to be 
integrated and allow a more complete, credible and nuanced understanding 
of the phenomenon. 
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Figure 9 The similarities between homotoxicology, pragmatism and PNEI 
  
UniRied	  Mind	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  Body	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  organism	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  transaction	  with	  the	  environment	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  and	  the	  organism	  in	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  the	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  of	  psycho-­‐neuro-­‐immunological	  and	  endocrine	  feedback	  systems	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Limitations 
An important lesson was that a systematic approach to the literature can 
ensure the credibility and utility of the results and conclusions based upon 
the results. It was also recognised post-viva that it is especially important to 
conduct a systematic literature review in this field (CAM) because it works as 
a mechanism to facilitate interdisciplinary collaboration and a more integrated 
understanding of health (Karunananthan et al., 2009). 	  
Strand	  One	  
In the early strands of the study there was the possibility that my familiarity 
with the homotoxicology community and my known associations and 
friendship with the suppliers and producers of products may well have biased 
the responses of the participants in Strand 1.  It is difficult to say where 
goodwill begins and where it turns into bias.  It is hoped that participants 
were motivated to respond to the questionnaire but as professionals were 
responding with an unbiased view of the subject.  The possibility of this bias 
is reported as part of the methodology so that it can be taken into account. 
 
It is acknowledged that the two versions of the questionnaires for the 
practitioners should have been analysed separately.  The earlier version 
could have been treated as a pilot in order to refine the questions.  The 
reason for the change of questionnaire was the change in potential study 
sponsor and therefore remedy choice but they should not have been 
combined in the analysis stage. 
  
The initial analysis claimed to use Grounded Theory but this 
misunderstanding of the depth of analysis needed to meet that claim was 
corrected after the first viva.  During rewriting it was realised that what I had 
actually used was thematic analysis and a section on this method was added 
to the literature review. 
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The methodology chosen was appropriate to answer the research questions 
but it was not systematic enough in the way it was applied to the situation. 
 
Strand	  2	  
In strand 2, the researcher had direct contact with the nurses and matron at 
The Bridge Centre but no contact with the patients.  This was reflected in the 
thematic analysis where the nursing staff were seen as a ‘bridge’ (no pun 
intended) between the public and the therapies or treatments on offer.  The 
nurses were under no obligation to support the study by attending the 
discussion group but were motivated by their own interest in the subject.  It is 
noted in the methodology section that this was therefore a self-selected 
sample that might be biased towards an acceptance of the homotoxicology 
and in turn may pass on that bias to their patients.   
 
Results generated at a clinic in London are not necessarily applicable to a 
clinic in Jersey.  It is always important to take the social and cultural context 
into account, the methodology should have been changed to sample the 
population of infertile women seeking treatment in Jersey and I might have 
done this through my existing private patient network. 
 
Patient questionnaires that are returned on a voluntary basis are susceptible 
to bias as only those patients interested are likely to take part and return 
them.  The methodology did generate some useful results and greater 
attention could have been paid to these when designing the methodology for 
Strand 3. 
 
Strand	  3.	  
Strand 3 (quantitative) did not have a complete data outcome and the major 
limitation of this research study was the lack of quantitative outcome data as 
only 4 out the anticipated 90 participants were enrolled (0.04%) 
	  
Another limitation was the sampling strategy of the quantitative phase.  The 
women attending the ARU were a heterogeneous population in terms of their 
DISCUSSION 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   401	  
infertility reasons, ages and treatments.  The trial design was designed to 
accommodate this but the feedback at the end of the trial was that it a clinic 
with a higher input of a more homogenous patient group would make 
recruitment easier and they suggested that future trials should focus on one 
subgroup with a specific definition of infertility.  The difficulty is that the clinic 
would not generate sufficient numbers of women to create a large sample of 
one subgroup so an alternative site or sites would have to be considered. 
 
It would have been helpful, prior to study design, to carry out research 
regarding the social and legal implications of choosing Jersey as the study 
site.  A lot of time was spent trying to establish the requirement for mainland 
ethics and this delayed the time available for recruitment before the study 
drug expired. 
 
Greater participation from the study site unit staff in the design of the Case 
Report Form would have resulted in a methodology that was easier to 
implement and therefore more ownership, goodwill, and support for 
recruitment. 
 
However the trial design was appropriate for the research question and had 
the necessary level of model validity for investigating a homeopathic 
substance.   
 
Strand	  4	  
From the new perspective of a pragmatist worldview this strand could have 
been carried out as strand one and informed the design of the rest of the 
study.  This would still have been a mixed methods study but greater priority 
could have been given to the role of qualitative data, sourced from the patient 
forums, in an early exploratory phase of the study. 
 
In strand 4 a posting was made on the infertility forum and it was noted that 
this was biased towards the problematic nature of working and having 
infertility treatment, this influenced the responses and the themes emerging 
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from those responses.  The bias was noted by a supervisor and made 
explicit in the methodology reporting.  The bias was somewhat balanced by 
the use of naturalistic data from the My Story section for the analysis but the 
themes had already been largely identified from the smaller sample. 
 
One of the major lessons from this thesis is biased questions can lead to 
results that are less credible and therefore less useful in trial design.  The 
increased attention to theory helped to balance this tendency in the early 
stages of the project.   
 
The small sample size of the direct responses to the question posted on the 
forum (n=7),  is acknowledged as a limitation, but the close attention to 
theory, adherence to the guidelines for good thematic analysis and cross 
referencing with other researchers/sources of data  helps to improve the 
credibility of the conclusions drawn using this method. 
 
The initial methods (ranking of responses and keyword frequency) used to 
analyse the qualitative patient data were not appropriate to answer the 
research question.  The rewritten thesis used thematic analysis to explore 
the attitudes of women towards disclosing their treatment and this led to 
useful insights that could have been used to plan the methodology in Strand 
3. 
 
 
 
 
 
 
 
 
 
 
The choice of a forum for the data for strand four made it necessary to 
explore the ethics of using data that has been posted by private individuals, 
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as well as recognising that those postings were written for a particular reason 
and for a particular audience.  It did have the advantage of offering the 
researcher an ‘insider’ perspective on the process of undergoing infertility 
treatment. 
 
If it had been possible to interview the women from Jersey who had taken 
part in the study or decided not to take part in the study that would have 
created a closer fit between strands three and four.  One form of data that is 
reported but perhaps not analysed sufficiently is the feedback from the unit 
staff in Jersey.  It was necessary to make a decision to either investigate the 
reported reasons for patients not wishing to take part or to investigate the 
possibility that the difficulties faced by the unit staff were largely responsible 
for poor recruitment.  At the time it was deemed more appropriate to take 
their reported reasons for trial failure at face value:  
 
Conclusion  
If we conclude with the idea that this thesis is led by pragmatist thinking then 
the knowledge gained should be useful for creating more intelligent activity 
and should seek to make a contribution in line with democratic values. 
The perceived injustices and emotional distress of women undertaking 
infertility treatment such as the inequality of treatment at work, access to 
treatment and high failure rates have all been explored using thematic 
analysis as a qualitative methodology in Strand 4.  These insights could have 
been used at the start of the research project to plan a better pilot study with 
a successful recruitment rate.  
A positive outcome of this study would be to use the results and the lessons 
learned to try and improve the benefits to women of disclosing their 
treatment status compared to the risks.  For example women taking part in 
the trial could be encouraged to create an identity as a community of trial 
participants with their own forum.   
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This would allow their anonymity could be preserved but it would give them 
an opportunity to increase their sense of identity as a treatment seeker and 
receive support and encouragement without losing privacy or dignity.  
Belonging to a community of treatment seekers would help to validate their 
identity and legitimise their status particularly if their infertility is not 
recognised at work as a legitimate reason for time off. 
As well as supporting the psychological identity of the women they are 
seeking to recruit researchers interested in working with infertile women 
could offer a flexible appointment system to help women avoid the conflict 
between their roles as employees and treatment seekers.   
A major lesson learned from this trial would be to include the ARU staff at an 
early stage not as ‘participants’ taking part in a research study by completing 
a questionnaire or participating in a focus group but with true ‘involvement’ 
(INVOLVE, 2015). If they had been actively involved as co-applicants on the 
research project and their role included identifying research priorities, 
commenting and developing patient information leaflets or other research 
materials there might have been a different outcome from the recruitment 
process.  From the researchers pragmatist point of view it is also true to say 
that if the ARU staff had been consulted at an earlier stage the whole project 
might have been deemed too arduous for them to host and therefore been 
abandoned before it began. 
 
A final point would be that this thesis has demonstrated both in practice and 
through an exploration of theory, that a pragmatist philosophical worldview 
can help to bring conceptual meaning to a difficult process of change, 
structure to an evolving and dynamic study and can allow the researcher to 
reconcile the use of data from both quantitative and qualitative paradigms 
within a constructionist framework. 
 
The use of mixed methods research with a ‘pragmatic’ design exploring both 
qualitative and quantitative data, was found to be suitable to inform the 
design of a valid clinical trial model to establish the specific effects of 
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Ovarium compositum and investigate the problems encountered during 
recruitment.  This pragmatic approach needs to be balanced with a 
systematic approach to both data and literature in my future work. 
 
The use of a pragmatic worldview ensured that the focus was kept on 
seeking practical solutions to these challenges.  The final test of value of 
these finding will be if they can inform future trials that seek to work with 
infertile women.  Perhaps it is appropriate to let John Dewey have the last 
word, he was writing about education but the concepts can equally apply to 
medicine without losing their meaning: 
To suppose that scientific findings decide the value of educational 
undertakings is to reverse the real case.  Actual activities in educating test 
work of scientific results.  They may be scientific in some other field, but not 
in education until they serve educational purposes, and whether they really 
serve or not can be found out only in practice. (Dewey, 1929) 
 
 
 
. 
 
Conflicts of interests 
The researcher has used products supplied by Heel GmbH in her private 
practice, attending their training workshops, and provided freelance 
training/education and consultancy services to BioPathica Ltd, Ashford Kent. 
 
Funding 
This study was supported by an educational research grant from Heel GmbH 
and the researcher tuition fees were paid by Mr Roger Wilson, BioPathica 
Ltd, Ashford Kent.  I would like to express my gratitude to both parties for 
making it possible for me to complete this thesis. 
REFERENCES 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   406	  
 
 
BIBLIOGRAPHY	  
	  2012.	  Smoking	  and	  infertility:	  a	  committee	  opinion.	  Fertil	  Steril,	  98,	  1400-­‐6.	  AKANDE,	  V.	  A.,	  FLEMING,	  C.	  F.,	  HUNT,	  L.	  P.,	  KEAY,	  S.	  D.	  &	   JENKINS,	   J.	  M.	  2002.	  Biological	   versus	   chronological	   ageing	   of	   oocytes,	   distinguishable	   by	  raised	   FSH	   levels	   in	   relation	   to	   the	   success	   of	   IVF	   treatment.	   Human	  
Reproduction,	  17,	  2003-­‐2008.	  AKHTAR,	  M.	  A.,	  SUR,	  S.,	  RAINE-­‐FENNING,	  N.,	  JAYAPRAKASAN,	  K.,	  THORNTON,	  J.,	  QUENBY,	   S.	   &	   MARJORIBANKS,	   J.	   2015.	   Heparin	   for	   assisted	  reproduction:	  summary	  of	  a	  Cochrane	  review.	  Fertil	  Steril,	  103,	  33-­‐4.	  AKTAS,	   M.,	   BECKERS,	   N.	   G.,	   VAN	   INZEN,	  W.	   G.,	   VERHOEFF,	   A.	   &	   DE	   JONG,	   D.	  2005.	   Oocytes	   in	   the	   empty	   follicle:	   a	   controversial	   syndrome.	   Fertil	  
Steril,	  84,	  1643-­‐8.	  AL-­‐JAROUDI,	   D.	   &	   HUSSAIN,	   T.	   Z.	   2010.	   Prevalence	   of	   abnormal	   cervical	  cytology	  among	  subfertile	  Saudi	  women.	  Ann	  Saudi	  Med,	  30,	  397-­‐400.	  ALBAYRAK,	   E.	   &	   GUNAY,	   O.	   2007.	   State	   and	   trait	   anxiety	   levels	   of	   childless	  women	  in	  Kayseri,	  Turkey.	  Eur	  J	  Contracept	  Reprod	  Health	  Care,	  12,	  385-­‐90.	  ALVAREZ,	  S.	  2015.	  Do	  some	  addictions	  interfere	  with	  fertility?	  Fertil	  Steril,	  103,	  22-­‐6.	  ARTINI,	  P.	  G.,	  UCCELLI,	  A.,	  PAPINI,	  F.,	  SIMI,	  G.,	  DI	  BERARDINO,	  O.	  M.,	  RUGGIERO,	  M.	  &	  CELA,	  V.	  2013.	   Infertility	  and	  pregnancy	   loss	   in	  euthyroid	  women	  with	  thyroid	  autoimmunity.	  Gynecol	  Endocrinol,	  29,	  36-­‐41.	  AUDU,	  B.	  M.,	  MASSA,	  A.	  A.,	   BUKAR,	  M.,	   EL-­‐NAFATY,	  A.	  U.	  &	   SA'AD,	   S.	   T.	   2009.	  Prevalence	  of	  utero-­‐tubal	  infertility.	  J	  Obstet	  Gynaecol,	  29,	  326-­‐8.	  BADLEY,	   G.	   2009.	   Academic	   writing	   as	   shaping	   and	   re-­‐shaping.	   Teaching	   in	  
Higher	  Education,	  14,	  209-­‐219.	  BALCEREK,	  M.,	  REINMUTH,	  S.,	  HOHMANN,	  C.,	  KEIL,	  T.	  &	  BORGMANN-­‐STAUDT,	  A.	   2012.	   Suspected	   infertility	   after	   treatment	   for	   leukemia	   and	   solid	  tumors	  in	  childhood	  and	  adolescence.	  Dtsch	  Arztebl	  Int,	  109,	  126-­‐31.	  BALDWIN,	  E.	  2003.	  Time	  for	  a	  fresh	  look	  at	  complementary	  medicine.	  BARAITSER,	   P.,	   ALEXANDER,	   S.	   &	   SHERINGHAM,	   J.	   2011.	   Chlamydia	  trachomatis	   screening	   in	   young	   women.	   Curr	   Opin	   Obstet	   Gynecol,	   23,	  315-­‐20.	  BARNHART,	  K.	   T.	   2006.	   The	   challenge	   and	   enjoyment	   of	   the	   interpretation	   of	  epidemiologic	  data.	  Fertility	  and	  sterility,	  86,	  527-­‐528.	  BENEDETTI,	   F.,	   CARLINO,	   E.	   &	   POLLO,	   A.	   2011.	   How	   placebos	   change	   the	  patient's	  brain.	  Neuropsychopharmacology,	  36,	  339-­‐54.	  BERGMANN,	  J.,	  LUFT,	  B.,	  BOEHMANN,	  S.,	  RUNNEBAUM,	  B.	  &	  GERHARD,	  I.	  2000.	  [The	  efficacy	  of	  the	  complex	  medication	  Phyto-­‐Hypophyson	  L	  in	  female,	  hormone-­‐related	   sterility.	   A	   randomized,	   placebo-­‐controlled	   clinical	  double-­‐blind	  study].	  Forsch	  Komplementarmed	  Klass	  Naturheilkd,	  7,	  190-­‐9.	  
REFERENCES 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   407	  
BHATTACHARYA,	  S.,	  PORTER,	  M.,	  AMALRAJ,	  E.,	  TEMPLETON,	  A.,	  HAMILTON,	  M.,	  LEE,	  A.	  J.	  &	  KURINCZUK,	  J.	  J.	  2009.	  The	  epidemiology	  of	  infertility	  in	  the	  North	  East	  of	  Scotland.	  Hum	  Reprod,	  24,	  3096-­‐107.	  BIER,	   A.	   1926.	   Gedanken	   eines	   Arztes	   über	   die	   Medizin.	   Münch.	   med.	  
Wochenschrift,	  73,	  1163.	  BIER,	  A.	  1930.	  Beitrage	  zur	  Heilkunde	  aus	  der	  chirurgischen	  Universi-­‐tatsklinik	  in	  
Berlin,	  4.	  Abhandlung:	  Homoopathie.	  Miinch.	  med.	  Wsehr.	  BIESTA,	   G.	   &	   BURBULES,	   N.	   C.	   2003.	   Pragmatism	   and	   educational	   research,	  Rowman	  &	  Littlefield	  Lanham,	  MD.	  BISHOP,	   F.	   L.	   &	   HOLMES,	   M.	   M.	   2013.	   Mixed	   Methods	   in	   CAM	   Research:	   A	  Systematic	  Review	  of	  Studies	  Published	  in	  2012.	  Evid	  Based	  Complement	  
Alternat	  Med,	  2013,	  187365.	  BOIVIN,	   J.,	   BUNTING,	   L.,	   COLLINS,	   J.	   A.	   &	   NYGREN,	   K.	   G.	   2007.	   International	  estimates	  of	  infertility	  prevalence	  and	  treatment-­‐seeking:	  potential	  need	  and	  demand	  for	  infertility	  medical	  care.	  Hum	  Reprod,	  22,	  1506-­‐12.	  BOIVIN,	  J.,	  DOMAR,	  A.	  D.,	  SHAPIRO,	  D.	  B.,	  WISCHMANN,	  T.	  H.,	  FAUSER,	  B.	  C.	  J.	  M.	  &	  VERHAAK,	   C.	   2012.	   Tackling	   burden	   in	  ART:	   an	   integrated	   approach	  for	  medical	  staff.	  Human	  Reproduction,	  27,	  941-­‐950.	  BOIVIN,	   J.	   &	   SCHMIDT,	   L.	   2005.	   Infertility-­‐related	   stress	   in	   men	   and	   women	  predicts	  treatment	  outcome	  1	  year	  later.	  Fertility	  and	  sterility,	  83,	  1745-­‐1752.	  BOND,	  C.	  S.,	  AHMED,	  O.	  H.,	  HIND,	  M.,	  THOMAS,	  B.	  &	  HEWITT-­‐TAYLOR,	   J.	  2013.	  The	  conceptual	  and	  practical	  ethical	  dilemmas	  of	  using	  health	  discussion	  board	  posts	  as	  research	  data.	  J	  Med	  Internet	  Res,	  15,	  e112.	  BONNANS,	  C.,	  CHOU,	  J.	  &	  WERB,	  Z.	  2014.	  Remodelling	  the	  extracellular	  matrix	  in	  development	  and	  disease.	  Nat	  Rev	  Mol	  Cell	  Biol,	  15,	  786-­‐801.	  BOOTS,	   C.	   E.,	   GUSTOFSON,	   R.	   L.	   &	   FEINBERG,	   E.	   C.	   2013.	   Does	   methotrexate	  administration	   for	   ectopic	   pregnancy	   after	   in	   vitro	   fertilization	   impact	  ovarian	  reserve	  or	  ovarian	  responsiveness?	  Fertil	  Steril,	  100,	  1590-­‐3.	  BOWLING,	  A.	  2011.	  Research	  Methods	  in	  Health.	  Investigating	  Health	  and	  Health	  
Services,	  Berkshire	  England,	  Open	  University	  Press.	  BOYATZIS,	   R.	   E.	   1998.	  Transforming	  qualitative	   information:	  Thematic	  analysis	  
and	  code	  development,	  Sage.	  BRANDES,	  M.,	  VAN	  DER	  STEEN,	  J.	  O.,	  BOKDAM,	  S.	  B.,	  HAMILTON,	  C.	  J.,	  DE	  BRUIN,	  J.	   P.,	  NELEN,	  W.	   L.	  &	  KREMER,	   J.	   A.	   2009.	  When	   and	  why	  do	   subfertile	  couples	  discontinue	  their	  fertility	  care?	  A	  longitudinal	  cohort	  study	  in	  a	  secondary	  care	  subfertility	  population.	  Hum	  Reprod,	  24,	  3127-­‐35.	  BRAUN,	   V.	   &	   CLARKE,	   V.	   2006a.	   Using	   thematic	   analysis	   in	   psychology.	  
Qualtitative	  Research	  in	  Psychology,	  3,	  77-­‐101.	  BRAUN,	   V.	   &	   CLARKE,	   V.	   2006b.	   Using	   thematic	   analysis	   in	   psychology.	  
Qualitative	  research	  in	  psychology	  	  3.2	  (2006),	  77-­‐101.	  BRAZIER,	   J.,	   DEVERILL,	   M.	   &	   GREEN,	   C.	   1999.	   A	   review	   of	   the	   use	   of	   health	  status	   measures	   in	   economic	   evaluation.	   Journal	   of	   health	   services	  
research	  &	  policy,	  4,	  174-­‐184.	  BROWN,	   K.,	   APUZZIO,	   J.	   &	   WEISS,	   G.	   2010.	   Maternal	   obesity	   and	   associated	  reproductive	  consequences.	  Womens	  Health	  (Lond	  Engl),	  6,	  197-­‐203.	  BRYMAN,	  A.	  2006a.	  Integrating	  quantitative	  and	  qualitative	  research:	  how	  is	  it	  done?	  Qualitative	  Research,	  6.	  
REFERENCES 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   408	  
BRYMAN,	  A.	  2006b.	  Integrating	  quantitative	  and	  qualitative	  research:	  how	  is	  it	  done?	  Qualitative	  research,	  6,	  97-­‐113.	  BUCKMAN,	  R.	  &	  LEWITH,	  G.	  1994.	  What	  does	  homoeopathy	  do-­‐-­‐and	  how?	  BMJ,	  309,	  103-­‐6.	  BUSHNIK,	  T.,	  COOK,	  J.	  L.,	  YUZPE,	  A.	  A.,	  TOUGH,	  S.	  &	  COLLINS,	  J.	  2012.	  Estimating	  the	  prevalence	  of	  infertility	  in	  Canada.	  Hum	  Reprod,	  27,	  738-­‐46.	  BUTTS,	   S.	   F.,	   RATCLIFFE,	   S.,	   DOKRAS,	   A.	   &	   SEIFER,	   D.	   B.	   2013.	   Diagnosis	   and	  treatment	   of	   diminished	   ovarian	   reserve	   in	   assisted	   reproductive	  technology	   cycles	   of	   women	   up	   to	   age	   40	   years:	   the	   role	   of	   insurance	  mandates.	  Fertil	  Steril,	  99,	  382-­‐8.	  BUYALOS,	  R.	  P.,	  DANESHMAND,	  S.	  &	  BRZECHFFA,	  P.	  R.	  1997.	  Basal	  estradiol	  and	  follicle-­‐stimulating	   hormone	   predict	   fecundity	   in	   women	   of	   advanced	  reproductive	   age	   undergoing	   ovulation	   induction	   therapy.	   Fertility	   and	  
Sterility,	  68,	  272-­‐277.	  CAMPAGNE,	   D.	   M.	   2006.	   Should	   fertilization	   treatment	   start	   with	   reducing	  stress?	  Hum	  Reprod,	  21,	  1651-­‐8.	  CANNON,	  W.	  B.	  1916.	  Bodily	  changes	  in	  pain,	  hunger,	  fear,	  and	  rage:	  An	  account	  
of	   recent	   researches	   into	   the	   function	   of	   emotional	   excitement,	   D.	  Appleton.	  CASADEI,	  L.,	  PUCA,	  F.,	  PRIVITERA,	  L.,	  ZAMARO,	  V.	  &	  EMIDI,	  E.	  2010.	   Inherited	  thrombophilia	  in	  infertile	  women:	  implication	  in	  unexplained	  infertility.	  
Fertil	  Steril,	  94,	  755-­‐7.	  CEDARS,	   M.	   I.	   2015.	   Introduction:	   Childhood	   implications	   of	   parental	   aging.	  
Fertil	  Steril,	  103,	  1379-­‐80.	  CERQUAGLIA,	  C.,	  VERRECCHIA,	  E.,	  FONNESU,	  C.,	  GIOVINALE,	  G.,	  MARINARO,	  A.,	  DE	   SOCIO,	   G.	   &	   MANNA,	   R.	   2010.	   Female	   reproductive	   dysfunction	   in	  familial	   Mediterranean	   fever	   patients	   with	   and	   without	   colchicine	  treatment.	  Clin	  Exp	  Rheumatol,	  28,	  S101.	  CHARMAZ,	   K.	   1983.	   Loss	   of	   self:	   a	   fundamental	   form	   of	   suffering	   in	   the	  chronically	  ill.	  Sociol	  Health	  Illn,	  5,	  168-­‐95.	  CHARMAZ,	  K.	  1990.	  'Discovering'	  chronic	  illness:	  using	  grounded	  theory.	  Soc	  Sci	  
Med,	  30,	  1161-­‐72.	  CHARMAZ,	   K.	   2006.	   Constructing	   Grounded	   Theory	   A	   Practical	   Guide	   Through	  
Qualitative	  Research,	  SAGE.	  CHARMAZ,	  K.	  2010.	  Disclosing	  illness	  and	  disability	  in	  the	  workplace.	  Journal	  of	  
International	  Education	  in	  Business,	  ,	  Vol.	  3,	  ,	  pp.6	  -­‐	  19.	  CHOI,	   J.	  M.,	   LEBWOHL,	  B.,	  WANG,	   J.,	   LEE,	   S.	  K.,	  MURRAY,	   J.	  A.,	   SAUER,	  M.	  V.	  &	  GREEN,	   P.	   H.	   2011.	   Increased	   prevalence	   of	   celiac	   disease	   in	   patients	  with	  unexplained	   infertility	   in	   the	  United	  States.	   J	  Reprod	  Med,	  56,	  199-­‐203.	  CHRISTIAN,	   L.	   M.	   2012.	   Psychoneuroimmunology	   in	   pregnancy:	   immune	  pathways	   linking	   stress	  with	  maternal	   health,	   adverse	   birth	   outcomes,	  and	  fetal	  development.	  Neurosci	  Biobehav	  Rev,	  36,	  350-­‐61.	  CLARKE	  A	  Dictionary	  of	  Practical	  Materia	  Medica,	  B	  Jain	  Publishers	  Ltd.	  CLAYTON,	  H.	  B.,	  SCHIEVE,	  L.	  A.,	  PETERSON,	  H.	  B.,	  JAMIESON,	  D.	  J.,	  REYNOLDS,	  M.	  A.	  &	  WRIGHT,	  V.	  C.	  2007.	  A	  comparison	  of	  heterotopic	  and	  intrauterine-­‐only	  pregnancy	  outcomes	  after	  assisted	  reproductive	  technologies	  in	  the	  United	  States	  from	  1999	  to	  2002.	  Fertil	  Steril,	  87,	  303-­‐9.	  
REFERENCES 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   409	  
COHEN,	   S.,	   KAMARCK,	   T.	   &	   MERMELSTEIN,	   R.	   1983.	   A	   global	   measure	   of	  perceived	  stress.	  Journal	  of	  health	  and	  social	  behavior,	  385-­‐396.	  COLQUHOUN,	  D.	  2009.	  Secret	  remedies:	  100	  years	  on.	  BMJ,	  339.	  CORNISH,	   F.	   &	   GILLESPIE,	   A.	   2009.	   A	   pragmatist	   approach	   to	   the	   problem	   of	  knowledge	   in	   health	   psychology.	   Journal	  of	  Health	  Psychology,	   14,	   800-­‐809.	  CORRIGAN,	  P.	  W.,	  LARSON,	  J.	  E.,	  HAUTAMAKI,	  J.,	  MATTHEWS,	  A.,	  KUWABARA,	  S.,	  RAFACZ,	   J.,	  WALTON,	   J.,	  WASSEL,	   A.	  &	  O'SHAUGHNESSY,	   J.	   2009.	  What	  lessons	   do	   coming	   out	   as	   gay	   men	   or	   lesbians	   have	   for	   people	  stigmatized	  by	  mental	  illness?	  Community	  Ment	  Health	  J,	  45,	  366-­‐74.	  COUSINEAU,	  T.	  M.	  &	  DOMAR,	  A.	  D.	  2007.	  Psychological	  impact	  of	  infertility.	  Best	  
Practice	  &	  Research	  Clinical	  Obstetrics	  &	  Gynaecology,	  21,	  293-­‐308.	  COUSINEAU,	  T.	  M.,	  GREEN,	  T.	  C.,	  CORSINI,	  E.	  A.,	  BARNARD,	  T.,	  SEIBRING,	  A.	  R.	  &	  DOMAR,	   A.	   D.	   2006.	   Development	   and	   validation	   of	   the	   Infertility	   Self-­‐Efficacy	  scale.	  Fertility	  and	  sterility,	  85,	  1684-­‐1696.	  CRANDALL,	   C.	   S.	   &	   COLEMAN,	   R.	   1992.	   AIDS-­‐related	   stigmatization	   and	   the	  disruption	   of	   social	   relationships.	   Journal	   of	   Social	   and	   Personal	  
Relationships,	  9,	  163-­‐177.	  CRESWELL,	   J.	   W.	   &	   CLARK,	   V.	   L.	   P.	   2007a.	   Designing	   and	   conducting	   mixed	  
methods	  research,	  Wiley	  Online	  Library.	  CRESWELL,	   J.	   W.	   &	   CLARK,	   V.	   L.	   P.	   2007b.	   Designing	   and	   conducting	   mixed	  methods	  research.	  CROMI,	  A.,	  SERATI,	  M.,	  CANDELORO,	  I.,	  UCCELLA,	  S.,	  SCANDROGLIO,	  S.,	  AGOSTI,	  M.	   &	   GHEZZI,	   F.	   2015.	   Assisted	   reproductive	   technology	   and	  breastfeeding	  outcomes:	  a	  case-­‐control	  study.	  Fertil	  Steril,	  103,	  89-­‐94.	  DATTA,	   S.	   D.,	   TORRONE,	   E.,	   KRUSZON-­‐MORAN,	   D.,	   BERMAN,	   S.,	   JOHNSON,	   R.,	  SATTERWHITE,	   C.	   L.,	   PAPP,	   J.	   &	   WEINSTOCK,	   H.	   2012.	   Chlamydia	  trachomatis	  trends	  in	  the	  United	  States	  among	  persons	  14	  to	  39	  years	  of	  age,	  1999-­‐2008.	  Sex	  Transm	  Dis,	  39,	  92-­‐6.	  DEAN,	   M.	   E.,	   COULTER,	   M.	   K.,	   FISHER,	   P.,	   JOBST,	   K.	   A.	   &	   WALACH,	   H.	   2007.	  Reporting	   data	   on	   homeopathic	   treatments	   (RedHot):	   a	   supplement	   to	  CONSORT.	  J	  Altern	  Complement	  Med,	  13,	  19-­‐23.	  DELANEY,	  A.	  M.,	  JANI	  R.	  JENSEN,	  MD,	  AND	  DEAN	  MORBECK,	  PHD	  	  2012.	  Fertility	  
Testing.	   	   How	   Laboratory	   Tests	   Contribute	   to	   Successful	   Infertility	  
Treatments	  [Online].	  //	  Date:	  NOV.1.2012	  	  //	  Source:	  Clinical	  Laboratory	  News.	   Available:	  https://www.aacc.org/publications/cln/articles/2012/november/fertility-­‐testing	  [Accessed	  27.12.14	  2014].	  DELAUNAY,	  P.,	  CUA,	  E.,	  LUCAS,	  P.	  &	  MARTY,	  P.	  2000.	  Homoeopathy	  may	  not	  be	  
effective	  in	  preventing	  malaria.	  DEMYTTENAERE,	   K.,	   NIJS,	   P.,	   EVERS-­‐KIEBOOMS,	   G.	   &	   KONINCKX,	   P.	   1994.	  Personality	   characteristics,	   psychoendocrinological	   stress	   and	   outcome	  of	   IVF	   depend	   upon	   the	   etiology	   of	   infertility.	   Gynecological	  
Endocrinology,	  8,	  233-­‐240.	  DENZIN,	  N.	  K.	  &	  LINCOLN,	  Y.	  S.	  2011.	  The	  SAGE	  handbook	  of	  qualitative	  research,	  Sage.	  DERLEGA,	   V.	   J.	   &	   CHAIKIN,	   A.	   L.	   1977.	   Privacy	   and	   self‐disclosure	   in	   social	  relationships.	  Journal	  of	  Social	  Issues,	  33,	  102-­‐115.	  
REFERENCES 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   410	  
DEWEY,	   J.	   1896.	  The	   reflex	  arc	   concept	   in	  psychology.	  Psychological	  review,	   3,	  357.	  DEWEY,	   J.	   1910a.	   1991,	   How	   We	   Think.	   Prometheus	   Books,	   Ameherst,	   New	  York.	  DEWEY,	  J.	  1910b.	  How	  we	  think.	  Heat.	  New	  York.	  DEWEY,	  J.	  1916.	  Democracy	  and	  education.	  Macmillan	  Press	  Limited.	  DEWEY,	  J.	  1920.	  Reconstruction	  in	  philosophy.	  DEWEY,	   J.	  1925.	  Logic:	  The	  theory	  of	   inquiry	  (1938).	  The	  later	  works,	  1953,	  1-­‐549.	  DEWEY,	  J.	  1928.	  Body	  and	  mind.	  Bulletin	  of	  the	  New	  York	  Academy	  of	  Medicine,	  4,	  3.	  DEWEY,	   J.	   1929.	   The	   Sources	   of	   a	   Science	   of	   Education.	   New	   York:	   Liveright	  
1929.	  DEWEY,	  J.	  1938a.	  Experience	  and	  Education,	  New	  York,	  Touchstone	  	  DEWEY,	  J.	  1938b.	  Logic:	  The	  Theory	  of	  Inquiry.	  DEWEY,	  J.	  1958.	  Experience	  and	  Nature	  (1925).	  New	  York	  City:	  Dover.	  DEWEY,	   J.	   2008.	   The	   Later	  Works	   of	   John	   Dewey,	   Volume	   7,	   1925-­‐1953:	   1932,	  
Ethics,	  SIU	  Press.	  DHALWANI,	  N.	  N.,	  WEST,	   J.,	  SULTAN,	  A.	  A.,	  BAN,	  L.,	  TATA,	  L.	   J.,	  SCHLIEP,	  K.	  C.,	  MUMFORD	  SL	  FAU	  -­‐	  HAMMOUD,	  A.	  O.,	  HAMMOUD	  AO	  FAU	  -­‐	  STANFORD,	  J.	  B.,	  STANFORD	  JB	  FAU	  -­‐	  KISSELL,	  K.	  A.,	  KISSELL	  KA	  FAU	  -­‐	  SJAARDA,	  L.	  A.,	  SJAARDA	  LA	  FAU	  -­‐	  PERKINS,	  N.	   J.,	  PERKINS	  NJ	  FAU	  -­‐	  AHRENS,	  K.	  A.,	  AHRENS	  KA	  FAU	  -­‐	  WACTAWSKI-­‐WENDE,	  J.,	  WACTAWSKI-­‐WENDE	  J	  FAU	  -­‐	  MENDOLA,	  P.,	  MENDOLA	  P	  FAU	  -­‐	  SCHISTERMAN,	  E.	  F.,	  SCHISTERMAN,	  E.	  F.,	  RASHEED,	  S.	  M.,	  AMIN,	  M.	  M.,	  ABD	  ELLAH,	  A.	  H.,	  ABO	  ELHASSAN,	  A.	  M.,	   EL	   ZAHRY,	   M.	   A.,	  WAHAB,	   H.	   A.,	   PETRAGLIA,	   F.,	   SEROUR	   GI	   FAU	   -­‐	  CHAPRON,	  C.,	  CHAPRON,	  C.,	  TURAN,	  V.,	  BEDOSCHI	  G	  FAU	  -­‐	  MOY,	  F.,	  MOY	  F	   FAU	   -­‐	   OKTAY,	   K.,	   OKTAY,	   K.,	   MALLOCH,	   L.,	   RHOTON-­‐VLASAK,	   A.,	  TIMBERLAKE,	   K.	   S.,	   FOLEY	   KL	   FAU	   -­‐	   HURST,	   B.	   S.,	   HURST	   BS	   FAU	   -­‐	  MATTHEWS,	  M.	  L.,	  MATTHEWS	  ML	  FAU	  -­‐	  USADI,	  R.	  S.,	  USADI	  RS	  FAU	  -­‐	  MARSHBURN,	  P.	  B.,	  MARSHBURN,	  P.	  B.,	  XIAO,	  J.,	  CHANG	  S	  FAU	  -­‐	  CHEN,	  S.,	  CHEN,	  S.,	  BOOTS,	  C.	  E.,	  GUSTOFSON	  RL	  FAU	  -­‐	  FEINBERG,	  E.	  C.,	  FEINBERG,	  E.	  C.,	  LI,	  Z.,	  YU	  J	  FAU	  -­‐	  ZHANG,	  T.,	  ZHANG	  T	  FAU	  -­‐	  LI,	  H.,	  LI	  H	  FAU	  -­‐	  NI,	  Y.	  &	  NI,	  Y.	  Women	  with	  celiac	  disease	  present	  with	  fertility	  problems	  no	  more	  often	  than	  women	  in	  the	  general	  population	  Luteal	   phase	   deficiency	   in	   regularly	   menstruating	   women:	   prevalence	   and	  overlap	   in	   identification	   based	   on	   clinical	   and	   biochemical	   diagnostic	  criteria	  Reproductive	  performance	  after	  conservative	  surgical	  treatment	  of	  postpartum	  hemorrhage	  The	  changing	  prevalence	  of	  infertility	  Safety	  and	  feasibility	  of	  performing	  two	  consecutive	  ovarian	  stimulation	  cycles	  with	  the	  use	  of	  letrozole-­‐gonadotropin	  protocol	  for	  fertility	  preservation	  in	  breast	  cancer	  patients	  An	  assessment	  of	  current	  clinical	  attitudes	  toward	  letrozole	  use	  in	  reproductive	  endocrinology	  practices	  Association	  of	  blood	  type	  and	  patient	  characteristics	  with	  ovarian	  reserve	  
REFERENCES 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   411	  
The	   effectiveness	   of	   gonadotropin-­‐releasing	   hormone	   antagonist	   in	   poor	  ovarian	  responders	  undergoing	  in	  vitro	  fertilization:	  a	  systematic	  review	  and	  meta-­‐analysis	  Does	   methotrexate	   administration	   for	   ectopic	   pregnancy	   after	   in	   vitro	  fertilization	  impact	  ovarian	  reserve	  or	  ovarian	  responsiveness?	  rs189037,	   a	   functional	   variant	   in	   ATM	   gene	   promoter,	   is	   associated	   with	  idiopathic	  nonobstructive	  azoospermia.	  DHONT,	  N.,	  MUVUNYI,	  C.,	  LUCHTERS,	  S.,	  VYANKANDONDERA,	  J.,	  DE	  NAEYER,	  L.,	  TEMMERMAN,	  M.	  &	  VAN	  DE	  WIJGERT,	  J.	  2011.	  HIV	  infection	  and	  sexual	  behaviour	   in	   primary	   and	   secondary	   infertile	   relationships:	   a	   case-­‐-­‐control	  study	  in	  Kigali,	  Rwanda.	  Sex	  Transm	  Infect,	  87,	  28-­‐34.	  DINELLI,	   L.,	   COURBIERE,	   B.,	   ACHARD,	   V.,	   JOUVE,	   E.,	   DEVEZE,	   C.,	   GNISCI,	   A.,	  GRILLO,	   J.	   M.	   &	   PAULMYER-­‐LACROIX,	   O.	   2014.	   Prognosis	   factors	   of	  pregnancy	   after	   intrauterine	   insemination	   with	   the	   husband's	   sperm:	  conclusions	  of	  an	  analysis	  of	  2,019	  cycles.	  Fertil	  Steril,	  101,	  994-­‐1000.	  DOBSON,	   R.	   2006.	   No	   evidence	   found	   that	   homoeopathy	   is	   effective	   against	  
cancer.	  DOLGIN,	   E.	   2013.	   Publication	   checklist	   proposed	   to	   boost	   rigor	   of	   pilot	   trials.	  
Nat	  Med,	  19,	  795-­‐796.	  DOOLEY,	  M.	   2006.	   Complementary	   therapy	   and	   obstetrics	   and	   gynaecology:	   a	  time	  to	  integrate.	  Curr	  Opin	  Obstet	  Gynecol,	  18,	  648-­‐52.	  DU	  BOIS,	  A.,	  HEITZ,	  F.	  &	  HARTER,	  P.	  2013.	  Fertility-­‐sparing	  surgery	  in	  ovarian	  cancer:	  a	  systematic	  review.	  Onkologie,	  36,	  436-­‐43.	  DYER,	  S.	  J.	  2009.	  International	  estimates	  on	  infertility	  prevalence	  and	  treatment	  seeking:	   potential	   need	   and	  demand	   for	  medical	   care.	  Hum	  Reprod,	   24,	  2379-­‐80;	  author	  reply	  2380-­‐3.	  EEC	   1965.	   Council	   Directive	   65/65/EEC	   of	   26	   January	   1965	   on	   the	  approximation	   of	   provisions	   laid	   down	   by	   law,	   regulation	   or	  administrative	  action	  relating	  to	  medicinal	  products.	  ELLISON.	  Date:	  29	  May	  2012	  13:29:09	  GMT+01:00	  201.	  RE:	  Subject:	  Re:	  Jersey	  
Site.	  Type	  to	  C.HARESNAPE.	  ERIN,	  O.,	  SEVIGNY,	  M.,	  SABARRE,	  K.-­‐A.	  &	  PHILLIPS,	  K.	  P.	  2014.	  Perspectives	  of	  complementary	   and	   alternative	   medicine	   (CAM)	   practitioners	   in	   the	  support	  and	  treatment	  of	  infertility.	  BMC	  complementary	  and	  alternative	  
medicine,	  14,	  394.	  ESMAEILZADEH,	   S.,	   DELAVAR,	   M.	   A.,	   ZEINALZADEH,	   M.	   &	   MIR,	   M.	   R.	   2012.	  Epidemiology	   of	   infertility:	   a	   population-­‐based	   study	   in	   Babol,	   Iran.	  
Women	  Health,	  52,	  744-­‐54.	  FARMER,	  G.	  2007.	  Nuffield	  Department	  of	  Obstetrics	  and	  Gynaecology,	  The	  Women's	  Centre,	  John	  Radcliffe	  Hospital,	  Oxford,	  OX3	  9DU.	  	  Tel	  01865	  221907	  Fax	  01865	  769141.	  FENTIMEN,	   I.	   26th	   July	   2012	   12.33pm	   2012.	   RE:	   Re	   Jersey	   Site.	   Type	   to	  C.HARESNAPE.	  
REFERENCES 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   412	  
FERIN,	   M.	   1999.	   Stress	   and	   the	   reproductive	   cycle.	   The	   Journal	   of	   Clinical	  
Endocrinology	  &	  Metabolism,	  84,	  1768-­‐1774.	  FIELDING,	  N.	  &	  FIELDING,	  J.	  L.	  1986.	  Linking	  data,	  Sage	  Beverly	  Hills,	  CA.	  FIELDS,	   E.,	   CHARD,	   J.,	   JAMES,	   D.	   &	   TREASURE,	   T.	   2013.	   Fertility	   (update):	  
summary	  of	  NICE	  guidance.	  FINAMORE,	   P.	   S.,	   SEIFER,	   D.	   B.,	   ANANTH,	   C.	   V.	   &	   LEIBLUM,	   S.	   R.	   2007.	   Social	  concerns	   of	   women	   undergoing	   infertility	   treatment.	   Fertil	   Steril,	   88,	  817-­‐21.	  FINE,	  M.	  1992.	  Disruptive	  voices.	  Ann	  Arbor:	  University	  of	  Michigan	  Press,	  149.	  FIROUZNIA,	  K.,	  GHANAATI,	  H.,	  SANAATI,	  M.,	  JALALI,	  A.	  H.	  &	  SHAKIBA,	  M.	  2009.	  Pregnancy	  after	  uterine	  artery	  embolization	  for	  symptomatic	  fibroids:	  a	  series	  of	  15	  pregnancies.	  AJR	  Am	  J	  Roentgenol,	  192,	  1588-­‐92.	  FISHER,	   P.	   &	   EDEN,	   A.	   1995a.	   Commissioning	   complementary	   medicine.	  Homoeopathic	   hospitals	   have	   unique	   skill.	  BMJ:	  British	  Medical	   Journal,	  311,	  809.	  FISHER,	  P.	  &	  EDEN,	  A.	  1995b.	  Homoeopathic	  hospitals	  have	  unique	  skill.	  FISHER,	   P.	   &	  WARD,	   A.	   1994.	  Medicine	   in	  Europe:	   Complementary	  medicine	   in	  
Europe.	  FISHER,	  P.	  A.	  2010.	  Editorial	  ignores	  evidence.	  FISKEN,	   R.	   A.	   1996a.	  Complementary	  medicine	  must	  be	  based	  on	   sound	   science	  
and	  well	  conducted	  research.	  FISKEN,	  R.	  A.	  1996b.	  Complementary	  medicine	  must	  be	  based	  on	  sound	  science	  and	  well	  conducted	  research.	  BMJ:	  British	  Medical	  Journal,	  313,	  882.	  FORUM,	   I.	   N.	   U.	   M.	   S.	   Available:	  (http://www.infertilitynetworkuk.com/forums/250/My	   Story)	  [Accessed].	  FREIZINGER,	  M.,	  FRANKO,	  D.	  L.,	  DACEY,	  M.,	  OKUN,	  B.	  &	  DOMAR,	  A.	  D.	  2010.	  The	  prevalence	  of	  eating	  disorders	  in	  infertile	  women.	  Fertil	  Steril,	  93,	  72-­‐8.	  FRIEDLAND,	   D.,	   SHLIPAK,	   M.,	   SUBAK,	   L.,	   BENT,	   S.	   &	   MENDELSON,	   T.	   1998.	  Evaluating	   integrative	   literature.	  Evidence-­‐based	  medicine:	  a	   framework	  
for	  clinincal	  practice.	  Stamford,	  CT:	  Appleton	  &	  Lange,	  221-­‐46.	  FRIENDS,	   F.	   2012.	   Available:	  http://www.fertilityfriends.co.uk/forum/index.php?topic=297458.0	  [Accessed].	  FUGH-­‐BERMAN,	   A.	   &	   KRONENBERG,	   F.	   2003.	   Complementary	   and	   alternative	  medicine	   (CAM)	   in	   reproductive-­‐age	   women:	   a	   review	   of	   randomized	  controlled	  trials.	  Reproductive	  Toxicology,	  17,	  137-­‐152.	  GALLINELLI,	   A.,	   RONCAGLIA,	   R.,	   MATTEO,	   M.	   L.,	   CIACCIO,	   I.,	   VOLPE,	   A.	   &	  FACCHINETTI,	  F.	  2001.	  Immunological	  changes	  and	  stress	  are	  associated	  with	   different	   implantation	   rates	   in	   patients	   undergoing	   in	   vitro	  fertilization–embryo	  transfer.	  Fertility	  and	  sterility,	  76,	  85-­‐91.	  GERHARD	  I,	  M.	  B.,	  ROEBRUCK	  P,	  RUNNEBAUM	  B.	  1997.	  Homoeo-­‐	  pathy	  versus	  conventional	   therapy	   in	   female	   infertility:	   Interim	   analysis	   of	   a	  randomized	  study.	  Forsch	  Komplemen-­‐	  tarmed,	  5,	  262–269.	  GERHARD,	  I.,	  MONGA,	  B.,	  ROEBRUCK,	  P.	  &	  RUNNEBAUM,	  B.	  1997.	  Homöopathie	  versus	   konventionelle	   Therapie	   bei	   weiblicher	   Unfruchtbarkeit:	  Zwischenbericht	   einer	   randomisierten	   Studie.	   Forschende	  
Komplementärmedizin	   /	   Research	   in	   Complementary	   Medicine,	   4,	   262-­‐269.	  
REFERENCES 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   413	  
GERHARD,	   I.,	   PATEK,	   A.,	   MONGA,	   B.,	   BLANK,	   A.	   &	   GORKOW,	   C.	   1998.	  Mastodynon	   (R)	   for	   female	   infertility.	   Randomized,	   placebo-­‐controlled	  clinical	   double-­‐blind	   study.	   Forschende	   Komplementarmedizin,	   5,	   272-­‐278.	  GHAZIZADEH,	  S.,	   LESSAN-­‐PEZESHKI,	  M.,	  KHATAMI,	  M.	  R.,	  MAHDAVI-­‐MAZDEH,	  M.,	  ABBASI,	  M.	  R.,	  AZMANDIAN,	   J.,	  RAZEGHI,	  E.,	   SEIFI,	   S.,	  AHMADI,	  F.	  &	  MAZIAR,	   S.	   2007.	   Infertility	   among	   female	   renal	   transplant	   recipients.	  
Saudi	  J	  Kidney	  Dis	  Transpl,	  18,	  387-­‐90.	  GOUIN,	   J.	  P.	  &	  KIECOLT-­‐GLASER,	   J.	  K.	  2011.	  The	  impact	  of	  psychological	  stress	  on	  wound	  healing:	  methods	  and	  mechanisms.	  Immunol	  Allergy	  Clin	  North	  
Am,	  31,	  81-­‐93.	  GREEN,	  B.	  N.,	  JOHNSON,	  C.	  D.	  &	  ADAMS,	  A.	  Writing	  narrative	  literature	  reviews	  for	   peer-­‐reviewed	   journals:	   secrets	   of	   the	   trade.	   Journal	  of	  Chiropractic	  
Medicine,	  5,	  101-­‐117.	  GREENE,	   J.	   &	   HALL,	   J.	   N.	   2010.	   Dialectics	   and	   pragmatism.	   Sage	   handbook	   of	  
mixed	  methods	  in	  social	  and	  behavioral	  research,	  119-­‐67.	  GREENE,	  J.	  C.	  2007.	  Mixed	  methods	  in	  social	  inquiry,	  John	  Wiley	  &	  Sons.	  GREENE,	   J.	   C.,	   CARACELLI,	   V.	   J.	   &	   GRAHAM,	  W.	   F.	   1989.	   Toward	   a	   conceptual	  framework	  for	  mixed-­‐method	  evaluation	  designs.	  Educational	  evaluation	  
and	  policy	  analysis,	  11,	  255-­‐274.	  GREENHAUS,	  J.	  H.	  &	  BEUTELL,	  N.	  J.	  1985.	  Sources	  of	  conflict	  between	  work	  and	  family	  roles.	  Academy	  of	  management	  review,	  10,	  76-­‐88.	  GRUNFELD,	   L.,	   LUNA,	   M.,	   MUKHERJEE,	   T.,	   SANDLER,	   B.,	   NAGASHIMA,	   Y.	   &	  COPPERMAN,	  A.	  B.	  2008.	  Redefining	  in	  vitro	  fertilization	  success:	  should	  triplets	  be	  considered	  failures?	  Fertil	  Steril,	  90,	  1064-­‐8.	  GUBA,	  E.	  G.	  1990.	  The	  paradigm	  dialog,	  Sage	  Publications.	  GUO,	   S.	   W.	   &	   WANG,	   Y.	   2006.	   Sources	   of	   heterogeneities	   in	   estimating	   the	  prevalence	   of	   endometriosis	   in	   infertile	   and	   previously	   fertile	   women.	  
Fertil	  Steril,	  86,	  1584-­‐95.	  GURUNATH,	   S.,	   PANDIAN,	   Z.,	   ANDERSON,	   R.	   A.	   &	   BHATTACHARYA,	   S.	   2011.	  Defining	   infertility-­‐-­‐a	   systematic	   review	   of	   prevalence	   studies.	   Hum	  
Reprod	  Update,	  17,	  575-­‐88.	  GUZICK,	  D.	  S.	  &	  SWAN,	  S.	  2006.	  The	  decline	  of	  infertility:	  apparent	  or	  real?	  Fertil	  
Steril,	  86,	  524-­‐6;	  discussion	  534.	  HAGEN,	  C.	  P.,	  VESTERGAARD,	  S.,	   JUUL,	  A.,	  SKAKKEBAEK,	  N.	  E.,	  ANDERSSON,	  A.	  M.,	  MAIN,	  K.	  M.,	  HJOLLUND,	  N.	  H.,	  ERNST,	  E.,	  BONDE,	  J.	  P.,	  ANDERSON,	  R.	  A.	  &	  JENSEN,	  T.	  K.	  2012.	  Low	  concentration	  of	  circulating	  antimullerian	  hormone	   is	   not	   predictive	   of	   reduced	   fecundability	   in	   young	   healthy	  women:	  a	  prospective	  cohort	  study.	  Fertil	  Steril,	  98,	  1602-­‐8.e2.	  HAIMOV-­‐KOCHMAN,	  R.,	   ADLER,	   C.,	   EIN-­‐MOR,	  E.,	   ROSENAK,	  D.	  &	  HURWITZ,	  A.	  2012.	  Infertility	  associated	  with	  precoital	  ovulation	  in	  observant	  Jewish	  couples;	  prevalence,	   treatment,	  efficacy	  and	  side	  effects.	  Isr	  Med	  Assoc	  J,	  14,	  100-­‐3.	  HAMMOND,	  C.	  T.,	  BECKJORD,	  E.	  B.,	  ARORA,	  N.	  K.,	  BELLIZZI,	  K.	  M.,	  JEFFERY,	  D.	  D.	  &	   AZIZ,	   N.	   M.	   2008.	   Non-­‐Hodgkin's	   lymphoma	   survivors'	   fertility	   and	  sexual	  function-­‐related	  information	  needs.	  Fertil	  Steril,	  90,	  1256-­‐8.	  HANRAHAN,	   M.,	   COOPER,	   T.	   &	   BURROUGHS-­‐LANGE,	   S.	   1999.	   The	   place	   of	  personal	   writing	   in	   a	   PhD	   thesis:	   epistemological	   and	   methodological	  
REFERENCES 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   414	  
considerations.	   International	   Journal	  of	  Qualitative	  Studies	   in	  Education,	  12,	  401-­‐416.	  HARESNAPE,	   C.	   2013a.	   The	   challenges	   of	   obtaining	   ethics	   approval	   for	   a	  randomized,	   double-­‐blind,	   placebo-­‐controlled	   research	   study	   in	   Jersey.	  
JRSM	  short	  reports,	  4,	  2042533313492513.	  HARESNAPE,	  C.	  2013b.	  An	  exploration	  of	  the	  relationship	  between	  placebo	  and	  homeopathy	  and	  the	  implications	  for	  clinical	  trial	  design.	  JRSM	  Short	  Rep,	  4,	  2042533313490927.	  HARRITS,	  G.	  S.	  2011.	  More	  than	  method?	  A	  discussion	  of	  paradigm	  differences	  within	   mixed	   methods	   research.	   Journal	   of	   Mixed	   Methods	   Research,	  1558689811402506.	  HASELEN,	   D.	   R.	   V.	   12/09/07	   2007.	   RE:	   Re:	   Ovarium	   Compositum.	   Type	   to	  CLAIRE	  HARESNAPE,	  C.	  D.	  A.	  S.,	  YVAN	  BOURGAULT.	  HAWKSWORTH,	  E.	  Taking	  time	  off	  work	  for	  IVF	  treatment	  -­‐	  know	  your	  rights.	  
In:	  WALKER,	  E.	  L.	  T.	  A.	  R.	  J.	  (ed.).	  HAWKSWORTH,	   E.	   4th	   September	   2012	   2012.	   RE:	   RE:	   Disclosure	   of	   Fertility	  
Treatment.	  Type	  to	  HARESNAPE,	  C.	  HEEL,	  B.	  H.	  Suis	  Organ	  Preparations	  Therapy	  in	  Practice.	  In:	  HEEL,	  B.	  H.	  (ed.).	  HEEL,	  B.	  H.	  1986.	  Biotherapeutic	  Index.	  In:	  HEEL,	  B.	  H.	  (ed.)	  5th	  revised	  English	  edition	  ed.	  HEEL,	  B.	  H.	  1997.	  Biotherapeutic	  Index.	  In:	  GMBH,	  M.-­‐S.	  D.	  O.	  B.	  H.	  H.	  (ed.)	  4th	  revised	  English	  Edition	  ed.	  Baden-­‐Baden	  Germany.	  HEEL,	  B.	  H.	  2012.	  Disease	  Evolution	  Table.	  19	  	  ed.	  Pretoria,	  South	  Africa:	  Briza	  Publications.	  HEYVAERT,	  M.,	  HANNES,	  K.,	  MAES,	  B.	  &	  ONGHENA,	  P.	  2013.	  Critical	  appraisal	  of	  mixed	   methods	   studies.	   Journal	   of	   mixed	   methods	   research,	  1558689813479449.	  HFEA.	   Latest	   UK	   fertility	   treatment	   data	   and	   figures:	   2011-­‐2012	   [Online].	  Available:	  http://www.hfea.gov.uk/104.html	  [Accessed].	  HFEA	  2008.	   Facts	   and	   Figures	   2006–Fertility	   Problems	   and	  Treatment.	  Table,	  13,	  18.	  HILL,	   S.	   12th	   October	   2009	   2009.	  RE:	  A	  Pilot	   Study	  of	   ovarium	  compositum	   in	  
infertile	  women	  Type	  to	  HARESNAPE,	  C.	  HIRAMOTO,	  R.	  N.,	  ROGERS,	  C.	  F.,	  DEMISSIE,	  S.,	  HSUEH,	  C.	  M.,	  HIRAMOTO,	  N.	  S.,	  LORDEN,	   J.	   F.	   &	   GHANTA,	   V.	   K.	   1997.	   Psychoneuroendocrine	  immunology:	   site	   of	   recognition,	   learning	   and	  memory	   in	   the	   immune	  system	  and	  the	  brain.	  Int	  J	  Neurosci,	  92,	  259-­‐85.	  HOLLOWAY,	  I.	  &	  TODRES,	  L.	  2003.	  The	  status	  of	  method:	  flexibility,	  consistency	  and	  coherence.	  Qualitative	  research,	  3,	  345-­‐357.	  HOPEWELL,	  S.,	  CLARKE,	  M.,	  MOHER,	  D.,	  WAGER,	  E.,	  MIDDLETON,	  P.,	  ALTMAN,	  D.	  G.	  &	  SCHULZ,	  K.	  F.	  2008.	  CONSORT	  for	  reporting	  randomised	  trials	  in	  journal	  and	  conference	  abstracts.	  The	  Lancet,	  371,	  281-­‐283.	  HOWE,	  K.	  R.	  1988.	  Against	  the	  quantitative-­‐qualitative	  incompatibility	  thesis	  or	  dogmas	  die	  hard.	  Educational	  researcher,	  17,	  10-­‐16.	  HUDDLESTON,	  H.	  G.,	  CEDARS,	  M.	  I.,	  SOHN,	  S.	  H.,	  GIUDICE,	  L.	  C.	  &	  FUJIMOTO,	  V.	  Y.	  2010.	   Racial	   and	   ethnic	   disparities	   in	   reproductive	   endocrinology	   and	  infertility.	  Am	  J	  Obstet	  Gynecol,	  202,	  413-­‐9.	  
REFERENCES 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   415	  
HUISMAN,	  D.,	  RAYMAKERS,	  X.	  &	  HOOMANS,	  E.	  H.	  M.	  2009.	  Understanding	   the	  burden	   of	   ovarian	   stimulation:	   fertility	   expert	   and	   patient	   perceptions.	  
Reproductive	  BioMedicine	  Online,	  19,	  Supplement	  2,	  5-­‐10.	  ILANGAVAN,	  K.	  &	  KALU,	  E.	  2010.	  High	  prevalence	  of	  endometriosis	   in	  infertile	  women	  with	  normal	  ovulation	  and	  normospermic	  partners.	  Fertil	  Steril,	  93,	  e10;	  author	  reply	  e12.	  INVOLVE.	   2015.	   Available:	   http://www.peopleinresearch.org/public-­‐involvement/	  [Accessed	  18th	  February	  2015	  2015].	  IWH.	   2009.	   cross-­‐sectional	   vs.	   longitudinal	   studies	   [Online].	  http://www.iwh.on.ca/at-­‐work/55:	   The	   Institute	   for	   work	   and	   health.	  Available:	   http://www.iwh.on.ca/wrmb/cross-­‐sectional-­‐vs-­‐longitudinal-­‐studies	  [Accessed	  27.12.14	  2014].	  JACKSON,	  J.	  E.,	  ROSEN,	  M.,	  MCLEAN,	  T.,	  MORO,	  J.,	  CROUGHAN,	  M.	  &	  CEDARS,	  M.	  I.	  2008.	   Prevalence	   of	   celiac	   disease	   in	   a	   cohort	   of	   women	   with	  unexplained	  infertility.	  Fertil	  Steril,	  89,	  1002-­‐4.	  JACKSON,	   S.,	   HONG,	   C.,	   WANG,	   E.	   T.,	   ALEXANDER,	   C.,	   GREGORY,	   K.	   D.	   &	  PISARSKA,	  M.	  D.	  2015.	  Pregnancy	  outcomes	   in	  very	  advanced	  maternal	  age	   pregnancies:	   the	   impact	   of	   assisted	   reproductive	   technology.	  Fertil	  
Steril,	  103,	  76-­‐80.	  JERSEY,	  S.	  O.	  2012.	  Online	  information	  and	  public	  services	  for	  the	  island	  of	  Jersey	  [Online].	   Available:	   http://www.gov.je/Jersey/Pages/Profile.aspx	  [Accessed	  May	  4th	  2013].	  JOHAM,	   A.	   E.,	   TEEDE,	   H.	   J.,	   RANASINHA,	   S.,	   ZOUNGAS,	   S.	   &	   BOYLE,	   J.	   2015.	  Prevalence	   of	   infertility	   and	   use	   of	   fertility	   treatment	   in	   women	   with	  polycystic	   ovary	   syndrome:	   data	   from	  a	   large	   community-­‐based	   cohort	  study.	  J	  Womens	  Health	  (Larchmt),	  24,	  299-­‐307.	  JOHNSON,	   R.	   B.	   &	   ONWUEGBUZIE,	   A.	   J.	   2004.	   Mixed	   methods	   research:	   A	  research	  paradigm	  whose	  time	  has	  come.	  Educational	  researcher,	  33,	  14-­‐26.	  JOHNSTON,	   P.	   A.	   18th	   March	   2008	   2008.	   RE:	   Homoeopathic	   and	  
Homotoxicological	  Remedies.	  Type	  to	  DR	  MALCOLM	  BARRATT-­‐JOHNSON,	  M.	  A.,	  CLINICAL	  TRIALS	  UNIT	  AND	  LICENSING	  DIVISION.	  JOHNSTON,	   P.	   A.	   14th	   September	   2009	   2009.	   RE:	   A	   pilot	   study	   of	   Ovarium	  
compositum	  in	  infertile	  women.	  Type	  to	  MR	  M	  ENTWISTLE,	  S.-­‐H.	  A.	  S.	  S.,	  ETHICS	  COMMITTEE,	  ST	  HELIER,	  JERSEY.	  JOHNSTON,	  P.	  A.	  12	  August	  2013	  09:39	  2013.	  RE:	  RE:	  Ethical	  Approval	  Needed	  ?	  Type	  to	  A.T.TUCKER@QMUL.AC.UK,	  C.	  H.	  Q.	  A.	  U.	  C.	  R.	  Q.	  A.	  U.	  JOY,	   T.	   R.	   &	   HEGELE,	   R.	   A.	   2008.	   Prevalence	   of	   reproductive	   abnormalities	  among	   women	   with	   familial	   partial	   lipodystrophy.	   Endocr	   Pract,	   14,	  1126-­‐32.	  JÜTTE,	   R.	  &	  RILEY,	  D.	   2005.	   A	   review	  of	   the	   use	   and	   role	   of	   low	  potencies	   in	  homeopathy.	  Complementary	  therapies	  in	  medicine,	  13,	  291-­‐296.	  KARUNANANTHAN,	  S.,	  WOLFSON,	  C.,	  BERGMAN,	  H.,	  BÉLAND,	  F.	  &	  HOGAN,	  D.	  B.	  2009.	   A	   multidisciplinary	   systematic	   literature	   review	   on	   frailty:	  Overview	  of	  the	  methodology	  used	  by	  the	  Canadian	  Initiative	  on	  Frailty	  and	  Aging.	  BMC	  Medical	  Research	  Methodology,	  9,	  1-­‐11.	  KATTAL,	  N.,	  COHEN,	  J.	  &	  BARMAT,	  L.	  I.	  2008.	  Role	  of	  coculture	  in	  human	  in	  vitro	  fertilization:	  a	  meta-­‐analysis.	  Fertil	  Steril,	  90,	  1069-­‐76.	  
REFERENCES 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   416	  
KAYNE,	   S.	   B.	   2006.	   Homeopathic	   Pharmacy	   Theory	   and	   Practice,	   Elsevier	  Churchill	  Livingstone.	  KELLY,	   M.	   2009.	   The	   role	   of	   theory	   in	   qualitative	   health	   research.	   Family	  
practice,	  cmp077.	  KENTENICH,	   H.,	   SIBOLD,	   C.	   &	   TANDLER-­‐SCHNEIDER,	   A.	   2013.	   [In	   vitro	  fertilization	   and	   intracytoplasmic	   sperm	   injection:	   current	   medical	  aspects].	   Bundesgesundheitsblatt	   Gesundheitsforschung	  
Gesundheitsschutz,	  56,	  1653-­‐61.	  KESKIN,	  U.,	  COKSUER,	  H.,	  GUNGOR,	  S.,	  ERCAN,	  C.	  M.,	  KARASAHIN,	  K.	  E.	  &	  BASER,	  I.	  2011.	  Differences	  in	  prevalence	  of	  sexual	  dysfunction	  between	  primary	  and	  secondary	  infertile	  women.	  Fertil	  Steril,	  96,	  1213-­‐7.	  KHADEMI,	   A.,	   ALLEYASSIN,	   A.,	   AMINI,	   M.	   &	   GHAEMI,	   M.	   2008.	   Evaluation	   of	  sexual	  dysfunction	  prevalence	  in	  infertile	  couples.	  J	  Sex	  Med,	  5,	  1402-­‐10.	  KHAWAJA,	  U.	  B.,	  KHAWAJA,	  A.	  A.,	  GOWANI,	  S.	  A.,	  SHOUKAT,	  S.,	  EJAZ,	  S.,	  ALI,	  F.	  N.,	  RIZVI,	   J.	   &	   NAWAZ,	   F.	   H.	   2009.	   Frequency	   of	   endometriosis	   among	  infertile	  women	  and	  association	  of	  clinical	  signs	  and	  symptoms	  with	  the	  laparoscopic	  staging	  of	  endometriosis.	  J	  Pak	  Med	  Assoc,	  59,	  30-­‐4.	  KHOSHBATEN,	  M.,	  ROSTAMI	  NEJAD,	  M.,	  FARZADY,	  L.,	  SHARIFI,	  N.,	  HASHEMI,	  S.	  H.	  &	  ROSTAMI,	  K.	  2011.	  Fertility	  disorder	  associated	  with	  celiac	  disease	  in	  males	  and	  females:	  fact	  or	  fiction?	  J	  Obstet	  Gynaecol	  Res,	  37,	  1308-­‐12.	  KMIETOWICZ,	  Z.	  2010.	  NHS	  should	  stop	  funding	  homoeopathy,	  MPs	  say.	  KNOLLE,	  P.	  A.	  &	  GERKEN,	  G.	  2000.	  Local	  control	  of	  the	  immune	  response	  in	  the	  liver.	  Immunol	  Rev,	  174,	  21-­‐34.	  KRAFT,	  K.	  2001.	  Commentary:	  a	  questionably	  positive	  effect	  of	  a	  homoeopathic	  complex	  medication	   in	   female	   infertility.	  Focus	  Altern	  Complement	  Ther,	  6,	  23.	  KUMAR,	  D.	  2007.	  Prevalence	  of	  female	  infertility	  and	  its	  socio-­‐economic	  factors	  in	  tribal	  communities	  of	  Central	  India.	  Rural	  Remote	  Health,	  7,	  456.	  KUNZ,	  G.,	  BEIL,	  D.,	  HUPPERT,	  P.,	  NOE,	  M.,	  KISSLER,	  S.	  &	  LEYENDECKER,	  G.	  2005.	  Adenomyosis	   in	   endometriosis-­‐-­‐prevalence	   and	   impact	   on	   fertility.	  Evidence	  from	  magnetic	  resonance	  imaging.	  Hum	  Reprod,	  20,	  2309-­‐16.	  LAI,	   G.	   2000.	   Homotoxicological	   treatment	   of	   female	   functional	   infertility:	  clinical	  trial.	  La	  Med	  Biol.	  ,	  4,	  81–86.	  LAMAS,	  C.,	  CHAMBRY,	  J.,	  NICOLAS,	  I.,	  FRYDMAN,	  R.,	  JEAMMET,	  P.	  &	  CORCOS,	  M.	  2006.	   Alexithymia	   in	   infertile	  women.	   J	  Psychosom	  Obstet	  Gynaecol,	   27,	  23-­‐30.	  LARSEN,	  U.	  2005.	  Research	  on	  infertility:	  which	  definition	  should	  we	  use?	  Fertil	  
Steril,	  83,	  846-­‐52.	  LARSEN,	  U.,	  MLAY,	  J.,	  ABOUD,	  S.,	  BALLARD,	  R.,	  SAM,	  N.	  E.,	  SHAO,	  J.	  F.	  &	  KAPIGA,	  S.	  H.	   2007.	  Design	  of	   a	   community-­‐based	   study	  of	   sexually	   transmitted	  infections/HIV	  and	  infertility	  in	  an	  urban	  area	  of	  northern	  Tanzania.	  Sex	  
Transm	  Dis,	  34,	  20-­‐4.	  LASS,	   A.	   &	   BRINSDEN,	   P.	   1999.	   The	   role	   of	   ovarian	   volume	   in	   reproductive	  medicine.	  Human	  Reproduction	  Update,	  5,	  256-­‐266.	  LEE,	  R.	  C.	  &	  FAWCETT,	  J.	  2013.	  The	  influence	  of	  the	  metaparadigm	  of	  nursing	  on	  professional	   identity	   development	   among	  RN-­‐BSN	   students.	  Nurs	  Sci	  Q,	  26,	  96-­‐8.	  
REFERENCES 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   417	  
LEECH,	   N.	   2010.	   Interviews	   with	   the	   early	   developers	   of	   mixed	   methods	  research.	   Mixed	   methodology:	   Combining	   qualitative	   and	   quantitative	  
approaches.	  LEVIN,	   K.	   A.	   2006.	   Study	   design	   III:	   Cross-­‐sectional	   studies.	   Evidence-­‐based	  
dentistry,	  7,	  24-­‐25.	  LEWITH,	   G.	   T.,	   JONAS,	   W.	   B.	   &	   WALACH,	   H.	   2010.	   Clinical	   Research	   in	  
Complementary	   Therapies:	   Principles,	   Problems	   and	   Solutions,	   Elsevier	  Health	  Sciences	  UK.	  LI,	  X.,	  KNOX,	  A.	  &	  O'BYRNE,	  K.	  2010.	  Corticotrophin-­‐releasing	  factor	  and	  stress-­‐induced	   inhibition	   of	   the	   gonadotrophin-­‐releasing	   hormone	   pulse	  generator	  in	  the	  female.	  Brain	  research,	  1364,	  153-­‐163.	  LIBERTY,	   G.,	   HYMAN,	   J.	   H.,	   ELDAR-­‐GEVA,	   T.,	   LATINSKY,	   B.,	   GAL,	   M.	   &	  MARGALIOTH,	   E.	   J.	   2010.	   Ovarian	   hemorrhage	   after	   transvaginal	  ultrasonographically	  guided	  oocyte	  aspiration:	  a	  potentially	  catastrophic	  and	  not	  so	  rare	  complication	  among	  lean	  patients	  with	  polycystic	  ovary	  syndrome.	  Fertil	  Steril,	  93,	  874-­‐9.	  LINCOLN,	  Y.	  S.	  1989.	  Fourth	  generation	  evaluation,	  Sage.	  LINE,	  N.	  Q.	  2009.	  RE:	  RE:	  Study	  in	  Jersey.	  Type	  to	  HARESNAPE,	  C.	  LISSONI,	   P.	   2012.	   A	   reinterpretation	   of	   the	   pathogenesis	   and	   cure	   of	   cancer	  according	   to	   the	   psychoneuroimmunological	   discoveries.	  Methods	   Mol	  
Biol,	  934,	  183-­‐92.	  LLOYD-­‐JONES,	   G.	   2008.	   Design	   and	   control	   issues	   in	   qualitative	   case	   study	  research.	  International	  Journal	  of	  Qualitative	  Methods,	  2,	  33-­‐42.	  LONDON,	   Q.	   M.	   U.	   O.	   2015.	   Available:	   http://blizard.qmul.ac.uk/research-­‐generation/834-­‐consort-­‐reporting-­‐guidance-­‐for-­‐pilot-­‐studies.html)	  [Accessed	  6th	  March	  2015	  2015].	  LOUIS,	   G.	   M.,	   LUM,	   K.	   J.,	   SUNDARAM,	   R.,	   CHEN,	   Z.,	   KIM,	   S.,	   LYNCH,	   C.	   D.,	  SCHISTERMAN,	   E.	   F.	   &	   PYPER,	   C.	   2011.	   Stress	   reduces	   conception	  probabilities	   across	   the	   fertile	   window:	   evidence	   in	   support	   of	  relaxation.	  Fertil	  Steril,	  95,	  2184-­‐9.	  LYNCH,	  C.	  D.,	  SUNDARAM,	  R.,	  MAISOG,	  J.	  M.,	  SWEENEY,	  A.	  M.	  &	  BUCK	  LOUIS,	  G.	  M.	   2014.	   Preconception	   stress	   increases	   the	   risk	   of	   infertility:	   results	  from	   a	   couple-­‐based	   prospective	   cohort	   study-­‐-­‐the	   LIFE	   study.	   Hum	  
Reprod,	  29,	  1067-­‐75.	  M'RABET,	  N.,	  MOFFAT,	  R.,	  HELBLING,	  S.,	  KAECH,	  A.,	  ZHANG,	  H.	  &	  DE	  GEYTER,	  C.	  2012.	  The	  CC-­‐allele	  of	   the	  PvuII	  polymorphic	   variant	   in	   intron	  1	  of	   the	  alpha-­‐estrogen	   receptor	   gene	   is	   significantly	   more	   prevalent	   among	  infertile	  women	  at	  risk	  of	  premature	  ovarian	  aging.	  Fertil	  Steril,	  98,	  965-­‐72.e1-­‐5.	  MACLACHLAN,	  N.	   22nd	  March	  2012.	   16.37	  2012a.	  RE:	  Fw:	  Hi	  no	  sorry	   little	  to	  
feedback.	  Type	  to	  HARESNAPE,	  C.	  MACLACHLAN,	   N.	   26th	   June	   2012	   2012b.	   RE:	   OCVT-­‐001	   Informal	   notice	   of	  
intention.	  Type	  to	  CLAIRE	  HARESNAPE.	  MACLACHLAN,	   N.	   March	   23rd	   2012,	   7.27	   2012c.	   RE:	   RE:	   Supporting	  
Recruitment.	  Type	  to	  HARESNAPE,	  C.	  MAHESHWARI,	   A.,	   GURUNATH,	   S.,	   FATIMA,	   F.	   &	   BHATTACHARYA,	   S.	   2012.	  Adenomyosis	   and	   subfertility:	   a	   systematic	   review	   of	   prevalence,	  diagnosis,	   treatment	   and	   fertility	   outcomes.	   Hum	   Reprod	   Update,	   18,	  374-­‐92.	  
REFERENCES 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   418	  
MALIK,	   A.,	   JAIN,	   S.,	   HAKIM,	   S.,	   SHUKLA,	   I.	   &	   RIZVI,	   M.	   2006.	   Chlamydia	  trachomatis	  infection	  &	  female	  infertility.	  Indian	  J	  Med	  Res,	  123,	  770-­‐5.	  MALIZIA,	   B.	   A.,	   DODGE,	   L.	   E.,	   PENZIAS,	   A.	   S.	   &	   HACKER,	   M.	   R.	   2013.	   The	  cumulative	  probability	  of	  liveborn	  multiples	  after	  in	  vitro	  fertilization:	  a	  cohort	  study	  of	  more	  than	  10,000	  women.	  Fertil	  Steril,	  99,	  393-­‐9.	  MALLOCH,	   L.	   &	   RHOTON-­‐VLASAK,	   A.	   2013.	   An	   assessment	   of	   current	   clinical	  attitudes	   toward	   letrozole	  use	   in	   reproductive	   endocrinology	  practices.	  
Fertil	  Steril,	  100,	  1740-­‐4.	  MANN,	   C.	   2003.	   Observational	   research	   methods.	   Research	   design	   II:	   cohort,	  cross	  sectional,	  and	  case-­‐control	  studies.	  Emergency	  Medicine	  Journal,	  20,	  54-­‐60.	  MARCI,	   R.,	   MARCUCCI,	   I.,	   MARCUCCI,	   A.	   A.,	   PACINI,	   N.,	   SALACONE,	   P.,	  SEBASTIANELLI,	  A.,	  CAPONECCHIA,	  L.,	  LO	  MONTE,	  G.	  &	  RAGO,	  R.	  2013.	  Hysterosalpingocontrast	   sonography	   (HyCoSy):	   evaluation	   of	   the	   pain	  perception,	  side	  effects	  and	  complications.	  BMC	  Med	  Imaging,	  13,	  28.	  MARK	   OPPE,	   R.	   R.,	   FRANK	   DE	   CHARRO	   2007.	   EQ-­‐5D	   User	   Guide	   Version	  1.0:2007.	   In:	   GROUP,	   E.	   (ed.)	   http://www.euroqol.org.	  http://www.euroqol.org.	  MASCARENHAS,	  M.	  N.,	   CHEUNG,	  H.,	  MATHERS,	   C.	   D.	  &	   STEVENS,	   G.	   A.	   2012a.	  Measuring	   infertility	   in	   populations:	   constructing	   a	   standard	   definition	  for	  use	  with	  demographic	  and	  reproductive	  health	  surveys.	  Popul	  Health	  
Metr,	  10,	  17.	  MASCARENHAS,	   M.	   N.,	   FLAXMAN,	   S.	   R.,	   BOERMA,	   T.,	   VANDERPOEL,	   S.	   &	  STEVENS,	  G.	  A.	  2012b.	  National,	  Regional,	  and	  Global	  Trends	  in	  Infertility	  Prevalence	   Since	   1990:	   A	   Systematic	   Analysis	   of	   277	   Health	   Surveys.	  
PLoS	  Med,	  9,	  e1001356.	  MASHTA,	   O.	   2009.	   WHO	   warns	   against	   using	   homoeopathy	   to	   treat	   serious	  
diseases.	  MASTERS,	  K.	  2014.	  Nursing	  theories:	  a	  framework	  for	  professional	  practice,	  Jones	  &	  Bartlett	  Publishers.	  MATHIE,	  R.	   T.,	  HACKE,	  D.,	   CLAUSEN,	   J.,	  NICOLAI,	   T.,	   RILEY,	  D.	   S.	  &	   FISHER,	   P.	  2013.	   Randomised	   controlled	   trials	   of	   homeopathy	   in	   humans:	  characterising	   the	   research	   journal	   literature	   for	   systematic	   review.	  
Homeopathy,	  102,	  3-­‐24.	  MATHIE,	   R.	   T.,	   RONIGER,	   H.,	   VAN	   WASSENHOVEN,	   M.,	   FRYE,	   J.,	   JACOBS,	   J.,	  OBERBAUM,	  M.,	  BORDET,	  M.	  F.,	  NAYAK,	  C.,	  CHAUFFERIN,	  G.,	   IVES,	   J.	  A.,	  DANTAS,	  F.	  &	  FISHER,	  P.	  2012.	  Method	  for	  appraising	  model	  validity	  of	  randomised	   controlled	   trials	   of	   homeopathic	   treatment:	   multi-­‐rater	  concordance	  study.	  BMC	  Med	  Res	  Methodol,	  12,	  49.	  MCCABE,	  P.	  2009.	  RE:	  RE:	  Ethics	  Application.	  Type	  to	  HARESNAPE,	  C.	  MCCABE,	   P.	   24th	   March	   2010	   March	   2010.	   RE:	   A	   pilot	   study	   of	   Ovarium	  
compositum	  in	  infertile	  women.	  Type	  to	  HARESNAPE,	  C.	  MCGOVERN,	  P.	  G.,	  LEGRO,	  R.	  S.,	  MYERS,	  E.	  R.,	  BARNHART,	  H.	  X.,	  CARSON,	  S.	  A.,	  DIAMOND,	   M.	   P.,	   CARR,	   B.	   R.,	   SCHLAFF,	   W.	   D.,	   COUTIFARIS,	   C.,	  STEINKAMPF,	   M.	   P.,	   NESTLER,	   J.	   E.,	   GOSMAN,	   G.,	   LEPPERT,	   P.	   C.	   &	  GIUDICE,	  L.	  C.	  2007.	  Utility	  of	  screening	  for	  other	  causes	  of	  infertility	  in	  women	  with	  "known"	  polycystic	  ovary	  syndrome.	  Fertil	  Steril,	  87,	  442-­‐4.	  MEDICINE,	   U.	   S.	   N.	   L.	   O.	   2015.	   Emotions	   and	   Disease	   Homepage,	   Stress	   and	  
Deprivation	   [Online].	  
REFERENCES 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   419	  
http://www.nlm.nih.gov/exhibition/emotions/stress.html.	   Available:	  http://www.nlm.nih.gov/exhibition/emotions/stress.html	  [Accessed].	  MEHTA,	  N.	  2011.	  Mind-­‐body	  dualism:	  A	  critique	  from	  a	  health	  perspective.	  Mens	  
sana	  monographs,	  9,	  202.	  MESEL,	   T.	   2013.	   The	   necessary	   distinction	   between	   methodology	   and	  philosophical	  assumptions	  in	  healthcare	  research.	  Scand	  J	  Caring	  Sci,	  27,	  750-­‐756.	  MITTELMANN,	   B.,	   WOLFF,	   H.	   G.	   &	   SCHARF,	   M.	   P.	   1942.	   Emotions	   and	  gastroduodenal	  function:	  experimental	  studies	  on	  patients	  with	  gastritis,	  duodenitis	  and	  peptic	  ulcer.	  Psychosomatic	  Medicine,	  4,	  5-­‐61.	  MOCKFORD,	   C.,	   STANISZEWSKA,	   S.,	   GRIFFITHS,	   F.	   &	  HERRON-­‐MARX,	   S.	   2012.	  
The	   impact	   of	   patient	   and	   public	   involvement	   on	  UK	  NHS	   health	   care:	   a	  
systematic	  review.	  MOHER,	   D.,	   LIBERATI,	   A.,	   TETZLAFF,	   J.	   &	   ALTMAN,	   D.	   G.	   2009.	   Preferred	  
reporting	   items	   for	   systematic	   reviews	   and	   meta-­‐analyses:	   the	   PRISMA	  
statement.	  MOINI,	   A.,	   MOHAMMADI,	   S.,	   HOSSEINI,	   R.,	   ESLAMI,	   B.	   &	   AHMADI,	   F.	   2013.	  Accuracy	  of	  3-­‐dimensional	  sonography	  for	  diagnosis	  and	  classification	  of	  congenital	  uterine	  anomalies.	  J	  Ultrasound	  Med,	  32,	  923-­‐7.	  MORGAN,	  D.	  L.	  2007.	  Paradigms	  lost	  and	  pragmatism	  regained	  methodological	  implications	  of	  combining	  qualitative	  and	  quantitative	  methods.	   Journal	  
of	  mixed	  methods	  research,	  1,	  48-­‐76.	  MORSE,	   J.	   M.	   &	   NIEHAUS,	   L.	   2009.	   Mixed	   method	   design:	   Principles	   and	  
procedures,	  Left	  Coast	  Pr.	  MUIR	  GRAY,	  J.	  1997.	  Evidence-­‐based	  healthcare:	  how	  to	  make	  health	  policy	  and	  management	  decisions.	  London:	  Churchill	  Livingstone,	  53.	  MURRAY,	   M.	   &	   PIZZORNO,	   J.	   1998.	   Encyclopaedia	   of	   Natural	   Medicine	   Little	  Brown	  &	  Co.	  London.	  MURTO,	   T.,	   BJURESTEN,	   K.,	   LANDGREN,	   B.-­‐M.	   &	   STAVREUS-­‐EVERS,	   A.	   2013.	  Predictive	   value	   of	   hormonal	   parameters	   for	   live	   birth	   in	  women	  with	  unexplained	   infertility	   and	   male	   infertility.	   Reproductive	   Biology	   and	  
Endocrinology,	  11,	  61.	  NAIRN,	   S.	   2012.	   A	   critical	   realist	   approach	   to	   knowledge:	   implications	   for	  evidence-­‐based	   practice	   in	   and	   beyond	   nursing.	  Nursing	   Inquiry,	   19,	   6-­‐17.	  NAKASHIMA,	  A.,	  ARAKI,	  R.,	  TANI,	  H.,	   ISHIHARA,	  O.,	  KUWAHARA,	  A.,	   IRAHARA,	  M.,	   YOSHIMURA,	   Y.,	   KURAMOTO,	   T.,	   SAITO,	   H.,	   NAKAZA,	   A.	   &	  SAKUMOTO,	  T.	  2013.	  Implications	  of	  assisted	  reproductive	  technologies	  on	   term	   singleton	   birth	   weight:	   an	   analysis	   of	   25,777	   children	   in	   the	  national	  assisted	  reproduction	  registry	  of	  Japan.	  Fertil	  Steril,	  99,	  450-­‐5.	  NEAL,	  M.	  S.,	  HUGHES,	  E.	  G.,	  HOLLOWAY,	  A.	  C.	  &	  FOSTER,	  W.	  G.	  2005.	  Sidestream	  smoking	   is	   equally	   as	   damaging	   as	   mainstream	   smoking	   on	   IVF	  outcomes.	  Hum	  Reprod,	  20,	  2531-­‐5.	  NEALE,	   D.	   10th	   December	   2010	   2010.	   RE:	   Deputy	   Director	   NRES.	   Type	   to	  TUCKER,	  D.	  A.	  NEWMAN,	   J.	   2001.	   Modernizing	   governance:	   New	   Labour,	   policy	   and	   society,	  Sage.	  
REFERENCES 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   420	  
NEWTON,	   C.	   R.,	   SHERRARD,	   W.	   &	   GLAVAC,	   I.	   1999.	   The	   Fertility	   Problem	  Inventory:	   measuring	   perceived	   infertility-­‐related	   stress.	   Fertility	   and	  
sterility,	  72,	  54-­‐62.	  NOORBALA,	   A.	   A.,	   RAMEZANZADEH,	   F.,	   ABEDINIA,	   N.	   &	   NAGHIZADEH,	   M.	   M.	  2009.	   Psychiatric	   disorders	   among	   infertile	   and	   fertile	   women.	   Soc	  
Psychiatry	  Psychiatr	  Epidemiol,	  44,	  587-­‐91.	  O’BRIEN,	  B.	  C.,	  HARRIS,	  I.	  B.,	  BECKMAN,	  T.	  J.,	  REED,	  D.	  A.	  &	  COOK,	  D.	  A.	  2014a.	  Standards	   for	   Reporting	   Qualitative	   Research:	   A	   Synthesis	   of	  Recommendations.	   Academic	   Medicine,	   89,	   1245-­‐1251	  10.1097/ACM.0000000000000388.	  O’BRIEN,	  B.	  C.,	  HARRIS,	  I.	  B.,	  BECKMAN,	  T.	  J.,	  REED,	  D.	  A.	  &	  COOK,	  D.	  A.	  2014b.	  Standards	   for	   Reporting	   Qualitative	   Research:	   A	   Synthesis	   of	  Recommendations.	  Academic	  Medicine,	  89,	  1245-­‐1251.	  OAKLEY,	   L.,	   DOYLE,	   P.	   &	   MACONOCHIE,	   N.	   2008.	   Lifetime	   prevalence	   of	  infertility	  and	  infertility	  treatment	  in	  the	  UK:	  results	  from	  a	  population-­‐based	  survey	  of	  reproduction.	  Hum	  Reprod,	  23,	  447-­‐50.	  OH,	   V.	   1998.	   The	   Powerful	   Placebo:	   From	   Ancient	   Priest	   to	   Modern	   Physician;	  
Complementary	  Medicine:	  A	  Research	  Perspective.	  OLIVE,	   D.	   L.	   &	   PRITTS,	   E.	   A.	   2006.	   Estimating	   infertility:	   the	   devil	   is	   in	   the	  details.	  Fertil	  Steril,	  86,	  529-­‐30;	  discussion	  534.	  OLIVER,	   C.	   2012.	   The	   relationship	   between	   symbolic	   interactionism	   and	  interpretive	  description.	  Qual	  Health	  Res,	  22,	  409-­‐15.	  OMBELET,	  W.,	  COOKE,	  I.,	  DYER,	  S.,	  SEROUR,	  G.	  &	  DEVROEY,	  P.	  2008.	  Infertility	  and	  the	  provision	  of	  infertility	  medical	  services	  in	  developing	  countries.	  
Hum	  Reprod	  Update,	  14,	  605-­‐21.	  ORON,	   G.,	   ESH-­‐BRODER,	   E.,	   SON,	   W.	   Y.,	   HOLZER,	   H.	   &	   TULANDI,	   T.	   2015.	  Predictive	  value	  of	  maternal	  serum	  human	  chorionic	  gonadotropin	  levels	  in	  pregnancies	  achieved	  by	  in	  vitro	  fertilization	  with	  single	  cleavage	  and	  single	  blastocyst	  embryo	  transfers.	  Fertil	  Steril,	  103,	  1526-­‐31.e1-­‐2.	  OZKAN,	   S.,	   MURK,	   W.	   &	   ARICI,	   A.	   2008.	   Endometriosis	   and	   infertility:	  epidemiology	   and	   evidence-­‐based	   treatments.	   Ann	  N	   Y	   Acad	   Sci,	   1127,	  92-­‐100.	  PACE,	  R.,	  PLUYE,	  P.,	  BARTLETT,	  G.,	  MACAULAY,	  A.	  C.,	  SALSBERG,	  J.,	  JAGOSH,	  J.	  &	  SELLER,	  R.	  2012.	  Testing	  the	  reliability	  and	  efficiency	  of	  the	  pilot	  Mixed	  Methods	   Appraisal	   Tool	   (MMAT)	   for	   systematic	   mixed	   studies	   review.	  
International	  journal	  of	  nursing	  studies,	  49,	  47-­‐53.	  PACE,	  T.	  W.	  &	  HEIM,	  C.	  M.	  2011.	  A	  short	  review	  on	  the	  psychoneuroimmunology	  of	   posttraumatic	   stress	   disorder:	   from	   risk	   factors	   to	   medical	  comorbidities.	  Brain	  Behav	  Immun,	  25,	  6-­‐13.	  PAKPOUR,	  A.	  H.,	  YEKANINEJAD,	  M.	  S.,	  ZEIDI,	  I.	  M.	  &	  BURRI,	  A.	  2012.	  Prevalence	  and	  risk	  factors	  of	  the	  female	  sexual	  dysfunction	  in	  a	  sample	  of	  infertile	  Iranian	  women.	  Arch	  Gynecol	  Obstet,	  286,	  1589-­‐96.	  PAPADOPOULOS,	   E.,	   MUIR,	   C.,	   RUSSELL,	   C.,	   TIMMONS,	   B.	   W.,	   FALK,	   B.	   &	  KLENTROU,	  P.	  2014.	  Markers	  of	  biological	  stress	  and	  mucosal	  immunity	  during	  a	  week	  leading	  to	  competition	  in	  adolescent	  swimmers.	  J	  Immunol	  
Res,	  2014,	  234565.	  PARIS,	  K.	  &	  ARIS,	  A.	  2010.	  Endometriosis-­‐associated	  infertility:	  a	  decade's	  trend	  study	   of	   women	   from	   the	   Estrie	   region	   of	   Quebec,	   Canada.	   Gynecol	  
Endocrinol,	  26,	  838-­‐42.	  
REFERENCES 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   421	  
PATRICIA	   ROWAN,	   S.	   A.	   A.	   C.	   O.	   8th	   August	   2012	   2012.	  RE:	  RE:	  Disclosure	   of	  
fertility	  treatment.	  Type	  to	  HARESNAPE,	  C.	  PAYNE,	  N.	   V.	   D.	   A.,	   O.,	   CONSTANTINOU,	   C.	   &	   LEWIS,	   S.	  WORK-­‐LIFE	  BALANCE	  AND	   MEDICALLY	   ASSISTED	   REPRODUCTION	   (MAR):	   MAR	   USES	  EXPERIENCES	   OF	   WORKPLACE	   SUPPORT.	   PRESENTED	   AT	   THE	   11TH	  CONFERENCE	   OF	   THE	   EUROPEAN	   ACADEMY	   OF	   OCCUPATIONAL	  PSYCHOLOGY,	  14-­‐16	  APRIL	  2014,	  SENATE	  HOUSE,	  LONDON	  2014.	  PERT,	  C.	  B.	  1997.	  Molecules	  of	  emotion:	  Why	  you	  feel	  the	  way	  you	  feel,	  Simon	  and	  Schuster.	  PETRAGLIA,	  F.,	  SEROUR,	  G.	  I.	  &	  CHAPRON,	  C.	  2013.	  The	  changing	  prevalence	  of	  infertility.	  Int	  J	  Gynaecol	  Obstet,	  123	  Suppl	  2,	  S4-­‐8.	  PHILLIPS,	  B.,	  BALL,	  C.,	  SACKETT,	  D.,	  BADENOCH,	  D.,	  STRAUS,	  S.,	  HAYNES,	  B.	  &	  DAWES,	   M.	   2001.	   Levels	   of	   evidence	   and	   grades	   of	   recommendation.	  
Available	  for	  URL:	  http://www.	  cebm.	  net.	  POPE,	   C.,	   ZIEBLAND,	   S.	   &	  MAYS,	   N.	   2000.	   Qualitative	   research	   in	   health	   care.	  Analysing	  qualitative	  data.	  BMJ,	  320,	  114-­‐6.	  RABIN,	  R.	  &	  CHARRO,	   F.	  D.	   2001.	   EQ-­‐SD:	   a	  measure	  of	   health	   status	   from	   the	  EuroQol	  Group.	  Annals	  of	  medicine,	  33,	  337-­‐343.	  RASHEED,	   S.	   M.,	   AMIN,	   M.	   M.,	   ABD	   ELLAH,	   A.	   H.,	   ABO	   ELHASSAN,	   A.	   M.,	   EL	  ZAHRY,	   M.	   A.	   &	   WAHAB,	   H.	   A.	   2014.	   Reproductive	   performance	   after	  conservative	   surgical	   treatment	   of	   postpartum	   hemorrhage.	   Int	   J	  
Gynaecol	  Obstet,	  124,	  248-­‐52.	  RECKEWEG,	   H.	   1952.	   [Vicariation	   homotoxins	   and	   pathological	   phases	   in	  tissues	   developed	   from	   the	   three	   germinal	   layers.].	   Munchener	  
medizinische	  Wochenschrift	  (1950),	  94,	  549-­‐555.	  RECKEWEG,	   H.-­‐H.	   1955.	   Homotoxine	   und	   homotoxikosen:	   grundlagen	   einer	  
synthese	  der	  medizin,	  Aurelia.	  RECKEWEG,	   H.-­‐H.	   1984.	   Homotoxicology:	   illness	   and	   healing	   through	   anti-­‐
homotoxic	  therapy,	  Menaco	  Publishing	  Company.	  RECKEWEG,	   H.-­‐H.	   2002.	  Materia	  Medica	  Homeopathica	  Antihomotoxica,	  Baden	  Baden,	  Aurelia-­‐Verlag	  GmbH.	  REH,	  A.,	  CHAUDHRY,	  S.,	  MENDELSOHN,	  F.,	  IM,	  S.,	  ROLNITZKY,	  L.,	  AMAROSA,	  A.,	  LEVITZ,	   M.,	   SRINIVASA,	   S.,	   KREY,	   L.,	   BERKELEY,	   A.	   S.,	   GRIFO,	   J.	   A.	   &	  DANOFF,	   A.	   2011.	   Effect	   of	   autoimmune	   thyroid	   disease	   in	   older	  euthyroid	  infertile	  woman	  during	  the	  first	  35	  days	  of	  an	  IVF	  cycle.	  Fertil	  
Steril,	  95,	  1178-­‐81.	  REICHELT,	   J.,	   KYVERNITAKIS,	   I.,	   MISSELWITZ,	   B.,	   HADJI,	   P.,	   SCHMIDT,	   S.	   &	  KALDER,	  M.	  2015.	  A	  population	  based	  evaluation	  of	  the	  mode	  of	  delivery	  in	   association	  with	   infertility	   treatment	   from	  1990-­‐2012.	  Z	  Geburtshilfe	  
Neonatol,	  219,	  37-­‐44.	  REICHER,	  S.	  &	  TAYLOR,	  S.	  2005.	  Similarities	  and	  differences	  between	  traditions.	  
Psychologist,	  18,	  547-­‐549.	  REILLY,	  D.	  2001.	  Enhancing	  human	  healing.	  REYES-­‐MUNOZ,	   E.,	   CASTELLANOS-­‐BARROSO,	   G.,	   RAMIREZ-­‐EUGENIO,	   B.	   Y.,	  ORTEGA-­‐GONZALEZ,	  C.,	  PARRA,	  A.,	  CASTILLO-­‐MORA,	  A.	  &	  DE	  LA	   JARA-­‐DIAZ,	  J.	  F.	  2012.	  The	  risk	  of	  gestational	  diabetes	  mellitus	  among	  Mexican	  women	  with	  a	  history	  of	  infertility	  and	  polycystic	  ovary	  syndrome.	  Fertil	  
Steril,	  97,	  1467-­‐71.	  
REFERENCES 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   422	  
ROBERTS	   PJ,	   R.	   C.,	   SIBBALD	   B,	   TORGERSON	  DJ.	   I.	   	   2002.	   Increasing	   response	  rates	   to	   postal	   questionnaires.	   Effect	   of	   incentives	   on	   response	   rates	  must	  be	  considered.	  BMJ	  325(7361):444.	  ROBINSON,	  M.	  13th	  November	  2009	  2009.	  RE:	  RE:	  CTIMP	  outside	  the	  UK.	  Type	  to	  BURKE,	  S.	  ROCKLIFF,	  H.	  E.,	  LIGHTMAN,	  S.	  L.,	  RHIDIAN,	  E.,	  BUCHANAN,	  H.,	  GORDON,	  U.	  &	  VEDHARA,	   K.	   2014.	   A	   systematic	   review	   of	   psychosocial	   factors	  associated	   with	   emotional	   adjustment	   in	   in	   vitro	   fertilization	   patients.	  
Human	  Reproduction	  Update.	  RONDA,	   E.,	   GARCIA,	   A.	  M.,	   SANCHEZ-­‐PAYA,	   J.	   &	  MOEN,	   B.	   E.	   2009.	  Menstrual	  disorders	   and	   subfertility	   in	   Spanish	   hairdressers.	  Eur	   J	  Obstet	  Gynecol	  
Reprod	  Biol,	  147,	  61-­‐4.	  ROULEAU,	  G.,	  COTE,	  J.	  &	  CARA,	  C.	  2012.	  Disclosure	  experience	  in	  a	  convenience	  sample	   of	   Quebec-­‐born	   women	   living	   with	   HIV:	   a	   phenomenological	  study.	  BMC	  Womens	  Health,	  12,	  37.	  ROY,	   C.,	   WHETSELL,	   M.	   V.	   &	   FREDERICKSON,	   K.	   2009.	   The	   Roy	   Adaptation	  Model	   and	   Research	   Global	   Perspective.	   Nursing	   science	   quarterly,	   22,	  209-­‐211.	  SAFARINEJAD,	  M.	  R.	  2008.	  Infertility	  among	  couples	  in	  a	  population-­‐based	  study	  in	  Iran:	  prevalence	  and	  associated	  risk	  factors.	  Int	  J	  Androl,	  31,	  303-­‐14.	  SALLUSTO,	  F.	  &	  LANZAVECCHIA,	  A.	  2002.	  The	  instructive	  role	  of	  dendritic	  cells	  on	  T-­‐cell	  responses.	  Arthritis	  Res,	  4,	  S127-­‐S132.	  SCHENKER,	   J.	   G.,	   MEIROW,	   D.	   &	   SCHENKER,	   E.	   1992.	   Stress	   and	   human	  reproduction.	   European	   Journal	   of	   Obstetrics	   &	   Gynecology	   and	  
Reproductive	  Biology,	  45,	  1-­‐8.	  SCHLIEP,	  K.	  C.,	  MUMFORD,	  S.	  L.,	  HAMMOUD,	  A.	  O.,	  STANFORD,	  J.	  B.,	  KISSELL,	  K.	  A.,	  SJAARDA,	  L.	  A.,	  PERKINS,	  N.	  J.,	  AHRENS,	  K.	  A.,	  WACTAWSKI-­‐WENDE,	  J.,	  MENDOLA,	   P.	   &	   SCHISTERMAN,	   E.	   F.	   2014.	   Luteal	   phase	   deficiency	   in	  regularly	  menstruating	  women:	  prevalence	  and	  overlap	  in	  identification	  based	   on	   clinical	   and	   biochemical	   diagnostic	   criteria.	   J	   Clin	   Endocrinol	  
Metab,	  99,	  E1007-­‐14.	  SCHULZ,	   K.	   F.,	   ALTMAN,	   D.	   G.	   &	   MOHER,	   D.	   2010.	   CONSORT	   2010	   Statement:	  
updated	  guidelines	  for	  reporting	  parallel	  group	  randomised	  trials.	  SCHWEIGER,	   U.,	   WISCHMANN,	   T.	   &	   STROWITZKI,	   T.	   2012.	   [Mental	   disorders	  and	  female	  infertility].	  Nervenarzt,	  83,	  1442-­‐7.	  SEALE,	   C.,	   ZIEBLAND,	   S.	   &	   CHARTERIS-­‐BLACK,	   J.	   2006.	   Gender,	   cancer	  experience	   and	   internet	   use:	   a	   comparative	   keyword	   analysis	   of	  interviews	  and	  online	   cancer	   support	  groups.	  Social	  science	  &	  medicine,	  62,	  2577-­‐2590.	  SELYE,	   H.	   1936.	   Thymus	   and	   adrenals	   in	   the	   response	   of	   the	   organism	   to	  injuries	  and	   intoxications.	  British	  Journal	  of	  Experimental	  Pathology,	   17,	  234.	  SELYE,	   H.	   1973.	   The	   Evolution	   of	   the	   Stress	   Concept:	   The	   originator	   of	   the	  concept	  traces	  its	  development	  from	  the	  discovery	  in	  1936	  of	  the	  alarm	  reaction	   to	   modern	   therapeutic	   applications	   of	   syntoxic	   and	   catatoxic	  hormones.	  American	  scientist,	  692-­‐699.	  SEROVICH,	  J.	  M.	  2001.	  A	  test	  of	  two	  HIV	  disclosure	  theories.	  AIDS	  Educ	  Prev,	  13,	  355-­‐64.	  
REFERENCES 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   423	  
SEROVICH,	  J.	  M.,	  LIM,	  J.-­‐Y.	  &	  MASON,	  T.	  L.	  2008.	  A	  retest	  of	  two	  HIV	  disclosure	  theories:	  The	  women's	  story.	  Health	  &	  social	  work,	  33,	  23-­‐31.	  SHAPIRO,	  B.	  S.,	  DANESHMAND,	  S.	  T.,	  RESTREPO,	  H.,	  GARNER,	  F.	  C.,	  AGUIRRE,	  M.	  &	   HUDSON,	   C.	   2013.	   Matched-­‐cohort	   comparison	   of	   single-­‐embryo	  transfers	  in	  fresh	  and	  frozen-­‐thawed	  embryo	  transfer	  cycles.	  Fertil	  Steril,	  99,	  389-­‐92.	  SHARMA,	  S.,	  MITTAL,	  S.	  &	  AGGARWAL,	  P.	  2009.	  Management	  of	  infertility	  in	  low	  resource	  countries.	  Bjog,	  116	  Suppl	  1,	  77-­‐83.	  SHELTON,	  W.	  2013.	  A	  new	   look	  at	  medicine	   and	   the	  mind-­‐body	  problem:	   can	  Dewey's	   pragmatism	   help	  medicine	   connect	  with	   its	  mission?	  Perspect	  
Biol	  Med,	  56,	  422-­‐41.	  SHELTON,	   W.	   19th	   December	   2014	   2014.	   RE:	   RE:	   Pragmatism	   and	   Medicine.	  Type	  to	  C.HARESNAPE.	  SHEN,	  L.,	  WANG,	  Q.,	  HUANG,	  W.,	  WANG,	  Q.,	  YUAN,	  Q.,	  HUANG,	  Y.	  &	  LEI,	  H.	  2011.	  High	   prevalence	   of	   endometrial	   polyps	   in	   endometriosis-­‐associated	  infertility.	  Fertil	  Steril,	  95,	  2722-­‐4.e1.	  SHINDEL,	   A.	   W.,	   NELSON,	   C.	   J.,	   NAUGHTON,	   C.	   K.	   &	   MULHALL,	   J.	   P.	   2008.	  Premature	   ejaculation	   in	   infertile	   couples:	   prevalence	   and	   correlates.	   J	  
Sex	  Med,	  5,	  485-­‐91.	  SILVERMAN,	  D.	  2013.	  Doing	  Qualitative	  Research,	  SAGE	  Publications	  Ltd.	  SIMONI,	   P.	   S.	   1981.	   The	   nurse	   educator:	   change	   agent	   for	   medical	   student	  attitudes.	  Int	  J	  Nurs	  Stud,	  18,	  107-­‐13.	  SIMUNIC,	   V.,	   TOMIC,	   V.,	   TOMIC,	   J.	  &	  NIZIC,	  D.	   2007.	   Comparative	   study	   of	   the	  efficacy	   and	   tolerability	   of	   two	   vaginal	   progesterone	   formulations,	  Crinone	  8%	  gel	   and	  Utrogestan	   capsules,	  used	   for	   luteal	   support.	  Fertil	  
Steril,	  87,	  83-­‐7.	  SKINNER,	  B.	  F.	  2011.	  About	  behaviorism,	  Vintage.	  SLAMA,	  R.,	  BOUTOU,	  O.,	  DUCOT,	  B.	  &	  SPIRA,	  A.	  2008.	  Reproductive	  life	  events	  in	  the	   population	   living	   in	   the	   vicinity	   of	   a	   nuclear	   waste	   reprocessing	  plant.	  J	  Epidemiol	  Community	  Health,	  62,	  513-­‐21.	  SMIT,	  A.,	  O'BYRNE,	  A.,	  VAN	  BRANDT,	  B.,	  BIANCHI,	  I.	  &	  KUESTERMANN,	  K.	  2010.	  Disease	  development.	  Altern	  Ther	  Health	  Med,	  16,	  20-­‐6.	  SMIT	   A,	   O.	   B.	   A.,	   VAN	   BRANDT	   B,	   BIANCHI	   I,	   	   KUESTERMANN	   K	   2009.	  
Introduction	  to	  bioregulatory	  medicine,	  New	  York,	  Thieme	  New	  York.	  SMITH,	   C.	   A.,	   USSHER,	   J.	  M.,	   PERZ,	   J.,	   CARMADY,	  B.	  &	  DE	   LACEY,	   S.	   2011.	   The	  Effect	   of	   Acupuncture	   on	   Psychosocial	   Outcomes	   for	   Women	  Experiencing	   Infertility:	  A	  Pilot	  Randomized	  Controlled	  Trial.	   Journal	  of	  
Alternative	  &	  Complementary	  Medicine,	  17,	  923-­‐930.	  SMITH,	   I.	   1995.	  Commissioning	   complementary	  medicine.	  BMJ:	  British	  Medical	  
Journal,	  310,	  1151.	  SOARES,	  S.,	  RODRIGUES,	  T.	  &	  BARROS,	  H.	  2011.	  [Infertility	  prevalence	  in	  the	  city	  of	  Porto].	  Acta	  Med	  Port,	  24,	  699-­‐706.	  SOMIGLIANA,	  E.,	  INFANTINO,	  M.,	  BENEDETTI,	  F.,	  ARNOLDI,	  M.,	  CALANNA,	  G.	  &	  RAGNI,	   G.	   2006.	   The	   presence	   of	   ovarian	   endometriomas	   is	   associated	  with	  a	  reduced	  responsiveness	  to	  gonadotropins.	  Fertil	  Steril,	  86,	  192-­‐6.	  SONG,	  S.	  2013.	  Assessing	  the	  impact	  of	  in	  utero	  exposure	  to	  famine	  on	  fecundity:	  evidence	  from	  the	  1959-­‐61	  famine	  in	  China.	  Popul	  Stud	  (Camb),	  67,	  293-­‐308.	  
REFERENCES 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   424	  
SOUTER,	   I.,	  BALTAGI,	  L.	  M.,	  TOTH,	  T.	  L.	  &	  PETROZZA,	   J.	  C.	  2010.	  Prevalence	  of	  hyperprolactinemia	  and	  abnormal	  magnetic	  resonance	  imaging	  findings	  in	  a	  population	  with	  infertility.	  Fertil	  Steril,	  94,	  1159-­‐62.	  SPANDORFER,	   S.	   D.,	   BONGIOVANNI,	   A.	   M.,	   FASIOULOTIS,	   S.,	   ROSENWAKS,	   Z.,	  LEDGER,	   W.	   J.	   &	   WITKIN,	   S.	   S.	   2006.	   Prevalence	   of	   cervical	   human	  papillomavirus	   in	   women	   undergoing	   in	   vitro	   fertilization	   and	  association	  with	  outcome.	  Fertil	  Steril,	  86,	  765-­‐7.	  SPIELBERGER,	   C.	   D.,	   GORSUCH,	   R.	   L.	   &	   LUSHENE,	   R.	   E.	   1970.	   Manual	   for	   the	  state-­‐trait	  anxiety	  inventory.	  SRIVASTAVA,	  P.	  H.,	  N	  2009.	  A	  Practical	  Iterative	  Framework	  for	  Qualitative	  Data	  Analysi.	  International	  Journal	  of	  Qualitative	  Methods	  8(1),	  76-­‐84.	  STEINMAN,	   R.	   M.	   &	   COHN,	   Z.	   A.	   1973.	   Identification	   of	   a	   novel	   cell	   type	   in	  peripheral	   lymphoid	   organs	   of	  mice	   I.	  Morphology,	   quantitation,	   tissue	  distribution.	  The	  Journal	  of	  experimental	  medicine,	  137,	  1142-­‐1162.	  STEPHEN,	   E.	  H.	  &	   CHANDRA,	   A.	   2006.	  Declining	   estimates	   of	   infertility	   in	   the	  United	  States:	  1982-­‐2002.	  Fertil	  Steril,	  86,	  516-­‐23.	  STERN,	   J.	   E.,	   LUKE,	   B.,	   TOBIAS,	   M.,	   GOPAL,	   D.,	   HORNSTEIN,	   M.	   D.	   &	   DIOP,	   H.	  2015.	  Adverse	  pregnancy	  and	  birth	  outcomes	  associated	  with	  underlying	  diagnosis	  with	  and	  without	  assisted	  reproductive	  technology	  treatment.	  
Fertil	  Steril,	  103,	  1438-­‐45.	  STERNBERG,	   S.	   A.,	   SCHWARTZ,	   A.	  W.,	   KARUNANANTHAN,	   S.,	   BERGMAN,	  H.	   &	  MARK	   CLARFIELD,	   A.	   2011.	   The	   Identification	   of	   Frailty:	   A	   Systematic	  Literature	   Review.	   Journal	  of	   the	  American	  Geriatrics	   Society,	   59,	   2129-­‐2138.	  STEVENSON,	  T.	  L.	  &	  LASHEN,	  H.	  2008.	  Empty	  follicle	  syndrome:	  the	  reality	  of	  a	  controversial	  syndrome,	  a	  systematic	  review.	  Fertil	  Steril,	  90,	  691-­‐8.	  STOLERU,	  S.,	  CORNET,	  D.,	  VAUGEOIS,	  P.,	  FERMANIAN,	  J.,	  MAGNIN,	  F.,	  ZERAH,	  S.	  &	  SPIRA,	  A.	  1997.	  The	  influence	  of	  psychological	  factors	  on	  the	  outcome	  of	   the	   fertilization	  step	  of	   in	  vitro	   fertilization.	   Journal	  of	  Psychosomatic	  
Obstetrics	  &	  Gynecology,	  18,	  189-­‐202.	  SVENSSON,	   A.	   C.,	   LICHTENSTEIN,	   P.,	   SANDIN,	   S.	   &	   HULTMAN,	   C.	   M.	   2007.	  Fertility	  of	   first-­‐degree	  relatives	  of	  patients	  with	  schizophrenia:	  a	   three	  generation	  perspective.	  Schizophr	  Res,	  91,	  238-­‐45.	  SVENSTRUP,	  H.	  F.,	  FEDDER,	  J.,	  KRISTOFFERSEN,	  S.	  E.,	  TROLLE,	  B.,	  BIRKELUND,	  S.	   &	   CHRISTIANSEN,	   G.	   2008.	   Mycoplasma	   genitalium,	   Chlamydia	  trachomatis,	  and	  tubal	  factor	  infertility-­‐-­‐a	  prospective	  study.	  Fertil	  Steril,	  90,	  513-­‐20.	  TASHAKKORI,	  A.	  &	  TEDDLIE,	  C.	  1998.	  Mixed	  methodology:	  Combining	  qualitative	  
and	  quantitative	  approaches,	  Sage.	  TAUBER,	  A.	   I.	  2009.	  Science	  and	  the	  Quest	  for	  Meaning,	  Baylor	  University	  Press	  Waco,	  TX.	  TEDDLIE,	   C.	  &	  TASHAKKORI,	  A.	   2009.	  Foundations	  of	  mixed	  methods	  research:	  
Integrating	   quantitative	   and	   qualitative	   approaches	   in	   the	   social	   and	  
behavioral	  sciences,	  Sage	  Publications	  Inc.	  TEDDLIE,	   C.	   &	   TASHAKKORI,	   A.	   2010.	   Overview	   of	   contemporary	   issues	   in	  mixed	  methods	   research.	  Sage	  handbook	  of	  mixed	  methods	  in	  social	  and	  
behavioral	  research,	  2,	  1-­‐44.	  
REFERENCES 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   425	  
TEDDLIE,	  C.	  &	  TASHAKKORI,	  A.	  2012.	  Common	  “Core”	  Characteristics	  of	  Mixed	  Methods	   Research	   A	   Review	   of	   Critical	   Issues	   and	   Call	   for	   Greater	  Convergence.	  American	  Behavioral	  Scientist,	  56,	  774-­‐788.	  THELWALL,	  M.	  2009.	  Introduction	  to	  Webometrics:	  quantitative	  web	  research	  for	  
the	   social	   sciences.	   [Online].	   Available:	  http://www.scit.wlv.ac.uk/~cm1993/papers/IntroductionToWebometricsAndSocialWebAnalysis.pdf	  	  [Accessed	  2013].	  THOMA,	   M.	   E.,	   MCLAIN,	   A.	   C.,	   LOUIS,	   J.	   F.,	   KING,	   R.	   B.,	   TRUMBLE,	   A.	   C.,	  SUNDARAM,	  R.	  &	  BUCK	  LOUIS,	  G.	  M.	  2013.	  Prevalence	  of	  infertility	  in	  the	  United	   States	   as	   estimated	   by	   the	   current	   duration	   approach	   and	   a	  traditional	  constructed	  approach.	  Fertil	  Steril,	  99,	  1324-­‐1331.e1.	  THOMAS,	  M.	  28th	  November	  2011	  13.24	  	  2011.	  RE:	  Re:	  Update	  3	  potential	  clients.	  Type	  to	  CLAIRE	  HARESNAPE,	  P.	  M.	  THOMAS,	  M.	  28th	  February	  2012.	  	  10.27	  2012.	  RE:	  RE;	  New	  Protocol	  and	  Patient	  
Information	  Sheet.	  Type	  to	  HARESNAPE,	  C.	  THOMPSON,	  T.	  &	  FEDER,	  G.	  2005.	  Complementary	  therapies	  and	  the	  NHS.	  THORNE,	  S.,	  KIRKHAM,	  S.	  R.	  &	  MACDONALD-­‐EMES,	  J.	  1997.	  Focus	  on	  qualitative	  methods.	   Interpretive	   description:	   a	   noncategorical	   qualitative	  alternative	   for	   developing	   nursing	   knowledge.	   Research	   in	   nursing	   &	  
health,	  20,	  169-­‐177.	  THORNTON,	   K.	   L.	   &	   GOLDMAN,	   M.	   B.	   2006.	   Impact	   of	   subgroup	   analysis	   on	  estimates	  of	  infertility.	  Fertil	  Steril,	  86,	  531-­‐3;	  discussion	  534.	  TIBONI,	  G.	  M.,	  VERNA,	   I.,	  GIAMPIETRO,	  F.,	  LEONZIO,	  E.	  &	   IMPICCIATORE,	  G.	  G.	  2011.	  Cytogenetic	  findings	  and	  reproductive	  outcome	  of	  infertile	  couples	  referred	   to	   an	   assisted	   reproduction	   program.	   Gynecol	   Endocrinol,	   27,	  669-­‐74.	  TIMBERLAKE,	  K.	  S.,	  FOLEY,	  K.	  L.,	  HURST,	  B.	  S.,	  MATTHEWS,	  M.	  L.,	  USADI,	  R.	  S.	  &	  MARSHBURN,	   P.	   B.	   2013.	   Association	   of	   blood	   type	   and	   patient	  characteristics	  with	  ovarian	  reserve.	  Fertil	  Steril,	  100,	  1735-­‐9.	  TITCHENER,	   E.	   B.	   1898.	   The	   postulates	   of	   a	   structural	   psychology.	   The	  
Philosophical	  Review,	  7,	  449-­‐465.	  TOMAO,	   F.,	   LO	   RUSSO,	   G.,	   SPINELLI,	   G.	   P.,	   STATI,	   V.,	   PRETE,	   A.	   A.,	   PRINZI,	   N.,	  SINJARI,	  M.,	  VICI,	  P.,	  PAPA,	  A.,	  CHIOTTI,	  M.	  S.,	  PANICI,	  P.	  B.	  &	  TOMAO,	  S.	  2014.	   Fertility	   drugs,	   reproductive	   strategies	   and	   ovarian	   cancer	   risk.	  
Journal	  of	  Ovarian	  Research,	  7,	  1-­‐19.	  TOMASSETTI,	   C.,	   MEULEMAN,	   C.,	   TIMMERMAN,	   D.	   &	   D'HOOGHE,	   T.	   2013.	  Adenomyosis	   and	   subfertility:	   evidence	   of	   association	   and	   causation.	  
Semin	  Reprod	  Med,	  31,	  101-­‐8.	  TSAI,	  Y.	  R.,	  HUANG,	  F.	  J.,	  LIN,	  P.	  Y.,	  KUNG,	  F.	  T.,	  LIN,	  Y.	  J.,	  LIN,	  Y.	  C.	  &	  LAN,	  K.	  C.	  2015.	   Progesterone	   elevation	   on	   the	   day	   of	   human	   chorionic	  gonadotropin	   administration	   is	   not	   the	   only	   factor	   determining	  outcomes	  of	  in	  vitro	  fertilization.	  Fertil	  Steril,	  103,	  106-­‐11.	  TUIL,	  W.	  S.,	  VERHAAK,	  C.	  M.,	  DE	  VRIES	  ROBBE,	  P.	  F.	  &	  KREMER,	  J.	  A.	  2008.	  IVF	  patients	  show	  three	  types	  of	  online	  behaviour.	  Hum	  Reprod,	  23,	  2501-­‐5.	  TURAN,	  V.,	   BEDOSCHI,	  G.,	  MOY,	   F.	  &	  OKTAY,	  K.	   2013.	   Safety	   and	   feasibility	   of	  performing	   two	   consecutive	   ovarian	   stimulation	   cycles	  with	   the	   use	   of	  letrozole-­‐gonadotropin	   protocol	   for	   fertility	   preservation	   in	   breast	  cancer	  patients.	  Fertil	  Steril,	  100,	  1681-­‐5.e1.	  
REFERENCES 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   426	  
TURAN,	  V.,	  KOPUZ,	  A.,	  OZCAN,	  A.,	  KOCAKAYA,	  B.,	  SAHIN,	  C.	  &	  SOLMAZ,	  U.	  2014.	  Sexual	   dysfunction	   in	   infertile	   Turkish	   females:	   prevalence	   and	   risk	  factors.	  Eur	  J	  Obstet	  Gynecol	  Reprod	  Biol,	  182,	  128-­‐31.	  UK,	  I.	  VAN	   WASSENHOVEN,	   M.	   2005.	   Priorities	   and	   methods	   for	   developing	   the	  evidence	   profile	   of	   homeopathy	   Recommendations	   of	   the	   ECH	   General	  Assembly	  and	  XVIII	  Symposium	  of	  GIRI.	  Homeopathy,	  94,	  107-­‐124.	  VASQUEZ,	   E.	   C.,	   MEYRELLES,	   S.	   D.	   S.,	   MAUAD,	   H.	   &	   CABRAL,	   A.	   D.	   M.	   1997.	  Neural	   reflex	   regulation	   of	   arterial	   pressure	   in	   pathophysiological	  conditions:	   interplay	   among	   the	   baroreflex,	   the	   cardiopulmonary	  reflexes	  and	  the	  chemoreflex.	  Brazilian	  journal	  of	  medical	  and	  biological	  
research,	  30,	  521-­‐532.	  VERU,	   F.,	   LAPLANTE,	   D.	   P.,	   LUHESHI,	   G.	   &	   KING,	   S.	   2014.	   Prenatal	   maternal	  stress	  exposure	  and	  immune	  function	  in	  the	  offspring.	  Stress,	  17,	  133-­‐48.	  VOGELER,	  K.	  T.	  1942.	  August	  Bier,	  Leben	  und	  Werk,	  Lehmann.	  WAN,	  G.	  H.	  &	  CHUNG,	   F.	   F.	   2012.	  Working	   conditions	   associated	  with	   ovarian	  cycle	  in	  a	  medical	  center	  nurses:	  a	  Taiwan	  study.	  Jpn	  J	  Nurs	  Sci,	  9,	  112-­‐8.	  WARD,	   M.	   18th	   November	   2008	   2008.	   RE:	   Re	   Status	   of	   Jersey.	   Type	   to	  JOHNSTON,	  P.	  A.	  WATSON,	  J.	  1979.	  The	  philosophy	  and	  science	  of	  caring.	  Boston:	  Little	  Brown.	  WEIGENT,	   D.,	   KRANEVELD,	   A.	   &	   BLALOCK,	   J.	   E.	   2011.	   A11	  Neuroimmunoendocrinology.	  In:	  NIJKAMP,	  F.	  P.	  &	  PARNHAM,	  M.	  J.	  (eds.)	  
Principles	  of	  Immunopharmacology.	  Birkhäuser	  Basel.	  WEIL,	   E.,	   SIBONY,	   C.,	   CORNET,	   D.,	   RAVEL,	   C.,	   FIORI,	   O.,	   BERTHAUT,	   I.,	   DE	  LAROUZIERE,	   V.	   &	   MANDELBAUM,	   J.	   Session	   57:	   Psychology	   and	  counselling	  2.	  	  Abstracts	  of	  the	  23rd	  Annual	  Meeting	  of	  the	  ESHRE,	  2007.	  ESHRE,	  4.	  WEISS,	  D.	  A.,	  HARRIS,	  C.	  R.	  &	  SMITH,	  J.	  F.	  2011.	  The	  use	  of	  complementary	  and	  alternative	   fertility	   treatments.	   Current	   Opinion	   in	   Obstetrics	   and	  
Gynecology,	  23,	  195-­‐199.	  WERBROUCK,	   E.,	   SPIESSENS,	   C.,	   MEULEMAN,	   C.	   &	   D'HOOGHE,	   T.	   2006.	   No	  difference	   in	   cycle	   pregnancy	   rate	   and	   in	   cumulative	   live-­‐birth	   rate	  between	  women	  with	  surgically	   treated	  minimal	   to	  mild	  endometriosis	  and	   women	   with	   unexplained	   infertility	   after	   controlled	   ovarian	  hyperstimulation	  and	  intrauterine	  insemination.	  Fertil	  Steril,	  86,	  566-­‐71.	  WESTMAN,	  M.	  2005.	  The	  Crossover	  of	  Work‐Family	  Conflict	  From	  One	  Spouse	  to	  the	  Other1.	  Journal	  of	  Applied	  Social	  Psychology,	  35,	  1936-­‐1957.	  WHITEHEAD,	  A.	  L.,	  SULLY,	  B.	  G.	  O.	  &	  CAMPBELL,	  M.	  J.	  2014.	  Pilot	  and	  feasibility	  studies:	   Is	   there	   a	   difference	   from	   each	   other	   and	   from	   a	   randomised	  controlled	  trial?	  Contemporary	  Clinical	  Trials,	  38,	  130-­‐133.	  WIESENFELD,	  H.	  C.,	  HILLIER,	  S.	  L.,	  MEYN,	  L.	  A.,	  AMORTEGUI,	  A.	  J.	  &	  SWEET,	  R.	  L.	  2012.	   Subclinical	   pelvic	   inflammatory	   disease	   and	   infertility.	   Obstet	  
Gynecol,	  120,	  37-­‐43.	  WILDING,	  D.	  G.	  14th	  July	  2012	  2012.	  RE:	  Subject:	  Re:	  Your	  perspective	  on	  CAM	  on	  
Jersey.	  Type	  to	  TYSON,	  C.	  H.	  WILLIAM	   M.K.	   TROCHIM.	   2006.	   Available:	  http://www.socialresearchmethods.net/kb/positvsm.php	   [Accessed	  21st	  Ocotober	  2014	  2014].	  
REFERENCES 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   427	  
WISE,	  J.	  1997.	  Health	  authority	  stops	  buying	  homoeopathy.	  BMJ:	  British	  Medical	  
Journal,	  314,	  1574.	  WOLCOTT,	   H.	   F.	   1990.	  Writing	   Up	   Qualitative	   Research	   (Qualitative	   Research	  Methods).	  Sage	  Publications	  (USA).	  WOLFF,	  H.	  G.	  1953.	  Stress	  and	  disease.	  XIAO,	  J.,	  CHANG,	  S.	  &	  CHEN,	  S.	  2013.	  The	  effectiveness	  of	  gonadotropin-­‐releasing	  hormone	   antagonist	   in	   poor	   ovarian	   responders	   undergoing	   in	   vitro	  fertilization:	   a	   systematic	   review	   and	   meta-­‐analysis.	   Fertil	   Steril,	   100,	  1594-­‐601.e1-­‐9.	  XPERTHR.	   2012.	   Available:	   http://www.xperthr.co.uk/faqs/topics/4,46/time-­‐off-­‐work.aspx?articleid=68720&mode=open	  	  	  [Accessed].	  ZHANG,	  H.,	  WANG,	  S.,	  ZHANG,	  S.,	  WANG,	  T.	  &	  DENG,	  X.	  2014.	  Increasing	  trend	  of	  prevalence	  of	  infertility	  in	  Beijing.	  Chin	  Med	  J	  (Engl),	  127,	  691-­‐5.	  ZILLER,	   V.,	   HADJI,	   P.,	   THIELSCHER,	   C.,	   ZILLER,	   M.	   &	   KOSTEV,	   K.	   2013.	  Prevalence	   of	   female	   subfertility	   in	   German	   gynecological	   practices.	  
Gynecol	  Endocrinol,	  29,	  767-­‐70.	  
 
REFERENCES 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   428	  
REFERENCES 
Claire	  Haresnape.	  	  The	  Challenges	  of	  Designing	  and	  Implementing	  a	  Pilot	  Study	  of	  Ovarium	  Compositum	  in	  Infertile	  Women	   	   429	  
APPENDICES 
	   430	  
VOLUME TWO - THE APPENDICES 
 
 
William Harvey Research Institute 
PhD 
The Challenges of Designing and Implementing a Pilot 
Study of Ovarium Compositum in Infertile Women 
 
Claire Haresnape Tyson 
 
059570532 
25th March 2015 
 
Supervisor: Professor Atholl 
Johnston 
 
APPENDICES 
	   431	  
 
 
  
APPENDICES 
	   432	  
 
Contents 
 
 
APPENDIX 1 The Literature Review ........................................................... 443	  
APPENDIX 2 Copy of questionnaires sent to therapists in Strand One.
 ............................................................................................................. cdlxxxiv	  
APPENDIX 3 Strand 2 The Study At The Bridge Centre .......................... cdxci	  
APPENDIX 4 Protocol for Pilot Study from Strand 3 ..................................... dx	  
APPENDIX 5 Documentation from Pilot Study ........................................... 617	  
APPENDIX 6 The Study Drug ..................................................................... 676	  
APPENDIX 7 Qualitative Data .................................................................... 685	  
APPENDIX 8 – Results and Data ............................................................... 711	  
APPENDIX 9 Damage To Trial Medication ................................................. 739	  
APPENDIX 10 Data collected from Jersey General Hospital participants in 
pilot study .................................................................................................... 742	  
APPENDIX 11 Qualitative Data From Strand 4 .......................................... 757	  
APPENDIX 12 memos written during thematic analysis of strand 4 ........... 971	  
APPENDIX 13 The References for Protocol for OVCT-001 Strand 3 ....... 1015	  
 
 
 
Acknowledgments ........................................................................................ 2 
Abstract .......................................................................................................... 4 
Table of Contents ........................................................................................ 13 
Introduction ................................................................................................. 22 
Background ........................................................................................................ 36 
The Social Environment Of This Study ............................................................. 36 
Chapter 1 Literature Review ....................................................................... 40 
Introduction To The Literature Review ............................................................. 40 
Section 1 The Definitions, Prevalence and Treatment of Female 
Infertility ....................................................................................................... 67 
The Definition And Treatment Of Infertility ............ Error! Bookmark not defined. 
The Definition Of Infertility ...................................... Error! Bookmark not defined. 
The Prevalence of Infertility .................................... Error! Bookmark not defined. 
The Treatment Of Infertility ..................................... Error! Bookmark not defined. 
APPENDICES 
	   433	  
Summary ................................................................... Error! Bookmark not defined. 
Section 2 The Treatment Of Infertility Using Homeopathy Or 
Homotoxicology ........................................................................................ 104 
The Definition of Homotoxicology .................................................................. 107 
The Development of Homotoxicology ............................................................ 108 
The Classification of Homotoxicology as a Homeotherapeutic System ..... 110 
Homeopathy versus conventional therapy for female infertility: Intermediate 
report from a randomized study. .................................................................... 111 
The Homotoxicological Treatment Of Female Functional Infertility: A Clinical 
Trial (Lai, 2000). Translated From Italian By Professional Translator. ........ 116 
The efficacy of the complex medication Phyto-Hypophyson L in female, 
hormone related sterility. A randomized, placebo-controlled clinical double 
blind study. (Bergmann et al., 2000) ............................................................... 120 
Complementary and Alternative Medicine (CAM) in reproductive-age 
women: a review of randomized controlled trials (Fugh-Berman and 
Kronenberg, 2003) ............................................................................................ 122 
Complementary therapy and obstetrics and gynaecology: a time to integrate 
(Dooley, 2006) ................................................................................................... 124 
Discussion of Section 2 ................................................................................... 126 
Section 3 The Use Of RCT To Investigate Homeopathy/Homotoxicology
 .................................................................................................................... 129 
Method for appraising model validity of randomized controlled trials of 
homeopathic treatment: multi-rater concordance study (Mathie et al., 2012)
 ........................................................................................................................... 130 
Randomized controlled trials of homeopathy in humans: characterizing the 
research journal literature for systematic review (Mathie et al., 2013) ....... 140 
Summary ........................................................................................................... 142 
Section 4 The Concerns of Infertile Women. .......................................... 143 
The Legal Position In Jersey ........................................................................... 145 
Social Concerns of Women Undergoing Infertility Treatment (Finamore et 
al., 2007) ............................................................................................................ 146 
Disclosure at work and self-identity ............................................................... 151 
Work-Life balance & Medically Assisted Reproduction (MAR): MAR users - 
experiences of workplace support (Payne, 2014) ......................................... 153 
APPENDICES 
	   434	  
When And Where Do Sub fertile Couples Discontinue Their Fertility Care? A 
Longitudinal Cohort Study In A Secondary Care Subfertility Population. 
(Brandes et al., 2009) ....................................................................................... 156 
Section 5 - Thematic Analysis ................................................................. 163 
Using Thematic Analysis in psychology. ........................................................ 163 
An Example Of Thematic Analysis ................................................................. 169 
The Effect Of Acupuncture On Psychosocial Outcomes For Women 
Experiencing Infertility: A Pilot Randomized Controlled Trial. (Smith et al., 
2011) .............................................................................................................. 169 
Section 6 The Ethics of using Internet Data Sources ............................ 176 
The Conceptual And Practical Ethical Dilemmas Of Using Health Discussion 
Board Posts As Research Data. ...................................................................... 178 
Section 7 – Qualitative Research ............................................................. 184 
Section 8 Mixed Methods Research ........................................................ 192 
The Paradigm Wars .......................................................................................... 194 
Table to show the simplified comparison of typical characteristics of 
quantitative and qualitative approaches to research adapted from (Bishop and 
Holmes, 2013). ............................................................................................... 194 
Descriptions of MMR ...................................................................................... 197 
Table To Show The Summary Of Notations Used To Describe Mixed Methods 
Designs adapted from (Creswell and Clark, 2007a) ....................................... 197 
Table to show the Contemporary “Core” Characteristics of Mixed 
Methods Research. (Teddlie and Tashakkori, 2012)  .......................... 199 
The Critical Appraisal of Mixed Methods Studies ......................................... 200 
The Critical Appraisal of Mixed Methods Studies (Heyvaert et al., 2013) ...... 200 
Mixed Methods in CAM Research: A Systematic Review of Studies 
Published in 2012 (Bishop and Holmes, 2013). ............................................. 204 
Section 9 – The Pragmatic World View ........... Error! Bookmark not defined. 
A New Look at Medicine and the Mind-Body Problem: Can Dewey’s 
Pragmatism Help Medicine Connect with Its Mission? (Shelton, 2013) ... Error! 
Bookmark not defined. 
Chapter 2 Methodology ............................................................................ 212 
Introduction ....................................................................................................... 212 
Section 1 ............................................................ Error! Bookmark not defined. 
APPENDICES 
	   435	  
Pragmatism ........................................................ Error! Bookmark not defined. 
The World View Adopted In This Study ................. Error! Bookmark not defined. 
Section 2 ............................................................ Error! Bookmark not defined. 
Mixed Methods Research ......................................................................... 214 
The reasons for choosing MMR for this thesis. .............................................. 214 
Description Of The Structure Of MMR Used In This Thesis ......................... 219 
Introduction ....................................................................................................... 219 
Section 3 The Methods Used In Each Strand. ........................................ 225 
Strand One  (2006) .................................................................................... 225 
Section 4 .................................................................................................... 236 
Strand Two (2006-2007) ............................................................................ 236 
Section 5 .................................................................................................... 244 
Strand Three (2007 – 2012) ....................................................................... 244 
Title: A Pilot Study Of Ovarium Compositum In Infertile Women. ............... 244 
Introduction ..................................................................................................... 244 
Research Question ......................................................................................... 246 
Methods .......................................................................................................... 246 
Researcher characteristics and reflexivity ...................................................... 247 
Context ........................................................................................................... 248 
Ethics .............................................................................................................. 248 
Sampling strategy ........................................................................................... 251 
Data collection methods ................................................................................. 252 
Data collection instruments and technologies ................................................ 252 
Units of study .................................................................................................. 253 
Recruitment .................................................................................................... 255 
Randomisation and Allocation ........................................................................ 256 
Study Procedures ........................................................................................... 258 
Schedule of Visits. .......................................................................................... 258 
Parameters for evaluation .............................................................................. 259 
Adverse Events .............................................................................................. 260 
Qualitative Data Collection in Strand Three ........................................... 261 
The EQ-5D ..................................................................................................... 262 
The EHIQ ........................................................................................................ 263 
APPENDICES 
	   436	  
Section 6 Study Drug ................................................................................ 265 
Ovarium Compositum ...................................................................................... 265 
Homeopathic Medicinal Products ................................................................... 268 
Preparation of remedies .................................................................................. 269 
Extraction ........................................................................................................ 269 
Potentization ..................................................................................................... 270 
Safety & Tolerability ......................................................................................... 273 
Discussion ................................................................................................. 275 
Section 7 .................................................................................................... 277 
Strand Four (2012 -2015) .......................................................................... 277 
Title An Investigation Into The Work-Related Concerns Faced By Women 
Seeking Infertility Treatment In The British Isles .......................................... 277 
Chapter 3 Results for Strands 1, 2 & 3 .................................................... 288 
Introduction ............................................................................................... 288 
Strand one ................................................................................................. 289 
The Results Of The Practitioner Questionnaire ............................................ 289 
Thematic Analysis of Questions 2,3,4 ............................................................ 294 
The Role Of The Practitioner ........................................................................... 294 
Endogenous Influences ................................................................................... 297 
Exogenous Influences ..................................................................................... 298 
Discussion ........................................................................................................ 299 
Strand 2 - The Bridge Centre ................................................................... 301 
Themes From The Staff Questionnaire And Discussion Group ..................... 301 
Units of study .................................................................................................. 301 
Theory ............................................................................................................... 301 
Themes .............................................................................................................. 302 
Nurses As A Bridge for patients between CAM and IVF. ............................... 302 
Caring For The Patient ................................................................................... 303 
Boundaries Of Professional Role ................................................................... 304 
The Need For A Theoretical Perspective ....................................................... 304 
Discussion of Results ..................................................................................... 305 
The Patient Questionnaire from The Bridge Centre ....................................... 307 
Discussion of results from the patient questionnaire .................................. 307 
Limitations ...................................................................................................... 309 
APPENDICES 
	   437	  
Summary ........................................................................................................... 309 
Strand 3 - A Double Blind, Randomised Controlled Trial of Ovarian 
Compositum in Infertile Women .............................................................. 310 
THE RECRUITMENT TO STUDY OVCT-001 .................................................... 310 
Introduction ....................................................................................................... 310 
Delays To Recruitment Caused By Damage To Trial Medication ................ 311 
Timeline of recruitment. ................................................................................... 311 
Discussion points arising from recruitment ..................................................... 314 
Compliance. .................................................................................................... 314 
Frequent blood testing and USS (Ultrasound Scan). ..................................... 314 
High Expectations ........................................................................................... 314 
Coincidental Issues ........................................................................................ 314 
The Recruitment process - Reflection and feedback from clinic staff. ............ 315 
Summary ........................................................................................................... 315 
Chapter 3 Results for Strand 4 ................................................................ 318 
Strand 4 - A Qualitative Analysis Of The Work Related Concerns Of 
Infertile Women ......................................................................................... 318 
Theory ........................................................................................................ 318 
Summary ........................................................................................................... 323 
Results ....................................................................................................... 324 
Charmaz - Disclosure At Work And Self-Identity .......................................... 324 
Models From HIV Theory ................................................................................. 326 
Thematic Analysis ..................................................................................... 327 
Themes .............................................................................................................. 328 
Theme One - The Psychological Identity Of The Respondent As An 
Employee Or A Treatment Seeker ........................................................... 330 
Psychological Identity ..................................................................................... 330 
Identity as Infertile ............................................................................................ 330 
Secondary Infertility ........................................................................................ 331 
Company Has A Clear Supportive Policy ...................................................... 332 
Practical Issues ................................................................................................ 335 
Proximity of treatment centre to work ............................................................. 335 
Flexible working arrangements ....................................................................... 336 
APPENDICES 
	   438	  
Sexual Discrimination For Time Taken Off ..................................................... 337 
Disclosure And Non-Disclosure ..................................................................... 338 
Theme Two - Emotional Distress ............................................................. 340 
Subtheme Devastation and Injustice .............................................................. 341 
Subtheme Access To Treatment .................................................................... 342 
Subtheme Treatment Failure .......................................................................... 342 
Subtheme Grief And Loss At Her Infertility ..................................................... 344 
Subtheme It’s Ok For Him .............................................................................. 348 
It’s His Fault .................................................................................................... 348 
Subtheme Isolation ......................................................................................... 350 
Subtheme Getting Help .................................................................................. 353 
Subtheme Out Of My Control ......................................................................... 356 
Conceptual Model The Risks and Benefits of Disclosure and Non-Disclosure
 ........................................................................................................................... 360 
Triangulation of data ........................................................................................ 367 
Source One ....................................................................................................... 367 
Triangulation Source Two ............................................................................... 373 
Conclusion. ....................................................................................................... 375 
An Overview Of The Main Findings ......................................................... 377 
Strand 1 The Practitioner Survey ................................................................... 377 
Strand 2 The Discussion Group and Questionnaire Survey of Staff at The 
Bridge Centre ................................................................................................. 377 
Strand 2   The Questionnaire Survey of Patients at The Bridge Centre ......... 378 
Strand 3 A Randomised Controlled Trial of Ovarian Compositum versus 
placebo at Jersey General Hospital ................................................................ 378 
Strand 4 A Qualitative Analysis Of The Concerns Of Infertile Women ....... 380 
Chapter 5 Discussion ............................................................................... 383 
Integration with prior work, implications, transferability, and contributions 
to the field ......................................................................................................... 383 
Research Question 1 (Strand 1,2,3) ............................................................... 383 
Research Question 2  (Strand 4) .................................................................... 383 
Research Question 1 ................................................................................ 384 
Reflections On The Methodology ................................................................... 389 
Philosophical Worldview ................................................................................. 393 
Limitations ........................................................................................................ 399 
APPENDICES 
	   439	  
Conclusion ........................................................................................................ 403 
Conflicts of interests ........................................................................................ 405 
Funding ............................................................................................................. 405 
VOLUME TWO - THE APPENDICES ......................................................... 430 
Contents ..................................................................................................... 432 
Appendix 1 Evaluation Frameworks Used In The Literature Review .......... 443 
Homeopathy versus conventional therapy for female infertility: Intermediate 
report from a randomized study. .................................................................... 443 
(Gerhard et al., 1997) ..................................................................................... 443 
Evaluation against CONSORT ....................................................................... 443 
Homeopathy versus conventional therapy for female infertility: Intermediate 
report from a randomized study. ..................................................................... 445 
(Gerhard et al., 1997) ..................................................................................... 445 
Evaluation against REDHOT .......................................................................... 445 
Homeopathy versus conventional therapy for female infertility: Intermediate 
report from a randomized study. ..................................................................... 448 
(Gerhard et al., 1997) ..................................................................................... 448 
Evaluation against the MVHT ......................................................................... 448 
The Homotoxicological Treatment Of Female Functional Infertility: A Clinical 
Trial (Lai, 2000). Translated From Italian By Professional Translator. ........... 451 
Evaluated against CONSORT  (Schulz et al., 2010) ...................................... 451 
The Homotoxicological Treatment Of Female Functional Infertility: A Clinical 
Trial (Lai, 2000). Translated From Italian By Professional Translator. ........... 455 
Evaluated against RedHot .............................................................................. 455 
The Homotoxicological Treatment Of Female Functional Infertility: A Clinical 
Trial (Lai, 2000). Translated From Italian By Professional Translator. ........... 458 
Evaluated against the MVHT .......................................................................... 458 
The efficacy of the complex medication Phyto-Hypophyson L in female, 
hormone related sterility. A randomized, placebo-controlled clinical double blind 
study. (Bergmann et al., 2000) ....................................................................... 461 
The efficacy of the complex medication Phyto-Hypophyson L in female, 
hormone related sterility. A randomized, placebo-controlled clinical double blind 
study. (Bergmann et al., 2000) ....................................................................... 462 
The efficacy of the complex medication Phyto-Hypophyson L in female, 
hormone related sterility. A randomized, placebo-controlled clinical double blind 
study. (Bergmann et al., 2000) ....................................................................... 465 
APPENDICES 
	   440	  
Evaluated against MVHT ................................................................................ 465 
Complementary and Alternative Medicine (CAM) in reproductive-age 
women: a review of randomized controlled trials (Fugh-Berman and 
Kronenberg, 2003) evaluated using PRISMA. ................................................ 467 
Randomized controlled trials of homeopathy in humans: characterizing the 
research journal literature for systematic review (Mathie et al., 2013) ........... 470 
Evaluated using PRISMA ................................................................................. 470 
Table to show the Standards for Reporting Qualitative Research (SRQR) .... 474 
Fax: 01435 867518 Telephone 0772 006 0116 ............................... cdlxxxv 
Data collection instruments and technologies .................................................. d 
Questionnaire for nurses at The Bridge Centre ................................................ d 
Questionnaire for Patients at The Bridge Centre ............................................. di 
A PILOT STUDY OF OVARIUM COMPOSITUM IN INFERTILE WOMEN. dxi 
Protocol No.: OVCT-001 ............................................................................ dxi 
Table One ....................................................................................................... 518 
Table Two ....................................................................................................... 524 
Progression of Infertility Treatment according to NICE guidelines. .... 524 
Table Three Proposed Treatment Groups .............................................. 527 
Table Four:  Age Stratification Bands ..................................................... 528 
Table Six: Decimal potencies ................................................................... 539 
Glossary of Terms ..................................................................................... 562 
Appendices for Protocol .................................................................................. 563 
Appendix 1 ........................................................................................................ 564 
Reporting Adverse Events .............................................................................. 564 
Appendix 2 for Protocol ................................................................................... 571 
Disease Evolution Table .................................................................................. 571 
Appendix 3 for Protocol ................................................................................... 575 
Expert Report on Ovarium Compositum ........................................................ 575 
1 INTRODUCTION ................................................................................... 576 
Emotional health and infertility questionnaire .............................................. 595 
Appendix 5 for Protocol ................................................................................... 603 
Certificate of Good Manufacturing Standards ............................................... 603 
Appendix 7 Protocol Amendments ................................................................. 615 
APPENDICES 
	   441	  
Protocol No OVCT-001 .............................................................................. 615 
Consent Forms for Non-Participants in OVCT-001 ....................................... 618 
Letter of Invitation to Trial Participants .................................................. 628 
Case Report Form For OVCT-001 Data Collection ................................. 630 
CASE REPORT FORM ...................................................................................... 632 
STUDY TITLE .................................................................................................... 632 
Adverse Events ......................................................................................... 654 
Medication Labels for OVCT-001 – Single Dose .................................... 657 
Medication Labels for OVCT-001 – Patient Package ............................. 664 
Template for Labels with The Randomisation Codes for OVCT-001 .... 669 
The Randomisation Codes As Generated By Heel And For Use On Site.
 .................................................................................................................... 671 
Homeopathic Indications for the Individual Constituents of Ovarium 
Compositum .............................................................................................. 676 
CODED DATA FROM DIRECT RESPONDENTS FROM THE FORUM FOR 
MANUAL SORTING INTO THEMES .......................................................... 685 
MIND MAP OF INTIAL CODES AND THEMES ......................................... 710 
Results from Strand 1 ............................................................................... 711 
Summary of results for Question Two .................................................... 711 
Question Three .......................................................................................... 713 
Question Four ............................................................................................ 715 
Results from Strand 2 ............................................................................... 718 
Coded Data from Staff Questionnaire and Discussion Group ........................ 718 
Damage to Trial Medication ............................................................................. 739 
The Data Collected From The Jersey General Hospital For Trial OVCT-001
 ........................................................................................................................... 742 
Analysis ............................................................................................................. 744 
Summary ........................................................................................................... 744 
The Results Per Subject ........................................................................... 746 
Subject 1201 ..................................................................................................... 746 
APPENDICES 
	   442	  
The EHIQ for subject 1201 ............................................................................. 746 
The EQ-5D for subject 1201 ........................................................................... 747 
Subject 1202 ..................................................................................................... 748 
Summary of CRF for subject 1202 ................................................................. 748 
The EQ-5D for subject 1202 ........................................................................... 749 
Subject 1301 ..................................................................................................... 750 
Summary of CRF for subject 1301 ................................................................. 750 
Summary ........................................................................................................... 754 
Strand 4 ...................................................................................................... 757 
The Work Related Concerns Of Infertile Women ................................... 757 
Coded data from Part 1 .................................................................................... 757 
2. Emotional Distress ....................................................................................... 763 
3. Trust and Support ........................................................................................ 766 
5.  The legal position ........................................................................................ 778 
6. The demands of treatment .......................................................................... 780 
7. Confidentiality .............................................................................................. 781 
8. Career Prospects .......................................................................................... 782 
Coded Data from Forum ........................................................................... 783 
Memo’s Written During Thematic Analysis Of Forum Data .................. 971 
 
 
 
 
 
 
APPENDICES 
Appendix	  1	  The	  Literature	  Review	   443	  
 
APPENDIX 1 The Literature 
Review 
Appendix 1 Evaluation Frameworks Used In 
The Literature Review 
Homeopathy versus conventional therapy for female infertility: 
Intermediate report from a randomized study.  
(Gerhard et al., 1997) 
Evaluation against CONSORT 
(Hopewell et al., 2008) 
 
The original article being published in German the review has been based 
upon the CONSORT guidelines (Hopewell et al., 2008) for assessing 
abstracts of randomised trials.  An English translation was provided by a non-
specialist in the field and checked against an English translation provided by 
Robert Mathie (Mathie et al., 2013) to ensure accuracy and consistency. 
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Table 29 Gerhard 1997 evaluated against Consort 
Item Description Reported on 
line number 
Title  Identification of the study as randomized 2 
Authors * Contact details for the corresponding author In German 
abstract 
Trial design Description of the trial design (e.g. parallel, cluster, non-
inferiority) 
3 
Methods   
  Participants Eligibility criteria for participants and the settings where 
the data were collected 
4 
  Interventions Interventions intended for each group 3-4 
  Objective Specific objective or hypothesis 3 
  Outcome Clearly defined primary outcome for this report 4 
  Randomization How participants were allocated to interventions  
  Blinding 
(masking) 
Whether or not participants, care givers, and those 
assessing the outcomes were blinded to group 
assignment 
5 
Results   
  Numbers 
randomized 
Number of participants randomized to each group 6 
  Recruitment Trial status 10-11 
  Numbers 
analysed 
Number of participants analysed in each group 7 
  Outcome For the primary outcome, a result for each group and the 
estimated effect size and its precision 
 
  Harms Important adverse events or side effects  
Conclusions General interpretation of the results  
Trial registration Registration number and name of trial register  
Funding Source of funding 11, 9 
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Homeopathy versus conventional therapy for female infertility: 
Intermediate report from a randomized study.  
(Gerhard et al., 1997) 
Evaluation against REDHOT 
 
Table 30 Gerhard et al 1997 evaluated against REDHOT 
Checklist for Reporting Data on Homeopathic Treatments (REDHOT) 
(Dean et al., 2007) 
Item Treatment 
(CONSORT item 
number) 
Description Reported on 
page number 
1 Rationale (2) Type of homeopathy 
Individualized (aka 
classical, 
constitutional) 
 
4 of 
translation 
2 Participants (3) Knowledge Condition 
Baseline health definition in 
provings 
10 
3 Medications (4) Manufacture 
Manufacturer, 
pharmacopoeia (or 
process), references. 
Potency and scale 
Dilution Method 
Nomenclature 
Individualised: list or 
frequency table 
Formula: 
Constituents, trade 
name 
Dosage 
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Dose, timing, form 
 
 
 
4 Consultations (4)  Setting 
Clinical history detail 
Duration, frequency 
Number needed to agree 
prescription 
Group process or expert 
consultation 
Confidence in prescriptions 
 
Setting 4-5 
Clinical History 
6,8 
Frequency of 
consultations p9 
5 Practitioners (4) Number in Study 
Experience, accreditation, 
qualifications 
Current schools or styles of 
homeopathy 
9 
  
6 Co-interventions 
(4) 
Included 
Rationale, intended 
effect, references 
Duration, frequency 
Excluded 
Stopping of 
mainstream 
interventions 
Antidotes 
 
 
7 Control 
interventions (4) 
Active 
Rationale, references 
Placebo 
Manufacturing 
process 
 
 
Placebo p5 
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8 Adverse events 
(19)  
Aggravations  
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Homeopathy versus conventional therapy for female infertility: 
Intermediate report from a randomized study.  
(Gerhard et al., 1997) 
Evaluation against the MVHT 
(Mathie et al., 2012) 
Table 31 Gerhard et al 1997 evaluated against MVHT 
Table:  Verdicts for domains 1-6, indicating rating for ‘Yes’, ‘No’ and ‘Unclear’ (Mathie et al., 2012) 
Paper (Gerhard I, 1997) 
 Yes Uncertain No 
1 Rationale 
Clinical knowledge and 
practice inform that, for 
the condition under 
investigation, the health of 
patients may be benefited 
by homeopathic 
intervention. 
Author quotes figures 
from his clinic showing 
good results with 
women with 
amenorrhoea and 
sterility through 
hormonal causes. 
 
 
A substantial number of 
experienced homeopaths 
would support the choice 
of this intervention for this 
type of patient. 
The patients are divided 
into three subgroups 
and it is not clear if 
homeopathy is suitable 
for all three 
groups/pathologies 
 
 
 
 
2 Principles 
One or both of the 
following: 
The intervention used is 
based on the principle of 
‘like treats like’ or is based 
on the principle of 
isopathy. 
 
Literature sources 
(material medica, 
repertory etc.) are 
available that convincingly 
justify the specific 
intervention. 
 
Patients were given 
individually prescribed 
homeopathic remedies 
They received single 
homeopathic remedies 
according to 
  
APPENDICES 
Appendix	  1	  The	  Literature	  Review	   449	  
Table:  Verdicts for domains 1-6, indicating rating for ‘Yes’, ‘No’ and ‘Unclear’ (Mathie et al., 2012) 
Paper (Gerhard I, 1997) 
 Yes Uncertain No 
repertorisation with 
regard to the Similar 
principle. 
3 Practitioner 
Individualised 
homeopathy: Those who 
have prescribed the 
homeopathic medicine(s) 
are suitably trained and 
experienced in 
homeopathy to manage 
the condition under 
investigation 
Authors worked as 
doctors using Integrated 
Medicine at a University 
Clinic in Germany 
 
  
4 Outcome Measures 
The main clinical effect 
expected of the 
intervention is adequately 
measured by the main 
outcome used. 
Hormone levels and 
patient attitudes would 
be a good indicator of 
clinical effect as 
functional change 
precedes structural 
change. 
  
5 Sensitivity 
All of the following: 
The main outcome 
measure is sensitive to 
changes of the magnitude 
expected in the patients 
under investigation. 
Yes. Patients treated for 
hormonal disturbance 
with classical 
homeopathy would 
expect to see some 
changes in mood or 
symptoms after 3 
months of treatment 
The main outcome 
measure is capable of 
determining both 
improvement and 
The main outcome 
measure shows no 
evidence of a ‘floor effect’ 
and/or ‘ceiling effect’ 
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Table:  Verdicts for domains 1-6, indicating rating for ‘Yes’, ‘No’ and ‘Unclear’ (Mathie et al., 2012) 
Paper (Gerhard I, 1997) 
 Yes Uncertain No 
deterioration. 
Yes – Hormone levels 
can go up or down. 
 
 
6 Follow up 
The time-point selected for 
main follow-up 
measurement provides 
sufficient opportunity for a 
clinical change to be 
observed. 
Yes the 3,6,9 month time 
periods would have 
been sufficient to see 
clinical change.  It was 
acknowledged in the 
study that some patients 
took longer to recruit 
and treat because they 
required detoxification 
treatment first.  
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The Homotoxicological Treatment Of Female Functional Infertility: A 
Clinical Trial (Lai, 2000). Translated From Italian By Professional 
Translator. 
Evaluated against CONSORT  (Schulz et al., 2010) 
Table 32 Lai 2000 evaluated against CONSORT 
Section/Topic 
Item 
No Checklist item 
Reported 
on page 
No 
Title and abstract 
 1a Identification as a randomised trial in the title  
1b Structured summary of trial design, methods, 
results, and conclusions (for specific guidance see 
CONSORT for abstracts) 
 
Introduction 
Background 
and objectives 
2a Scientific background and explanation of 
rationale 
1-2 
2b Specific objectives or hypotheses  
Methods 
Trial design 3a Description of trial design (such as parallel, 
factorial) including allocation ratio 
3 
3b Important changes to methods after trial 
commencement (such as eligibility criteria), 
with reasons 
 
Participants 4a Eligibility criteria for participants 2-3 
4b Settings and locations where the data were 
collected 
3 
Interventions 5 The interventions for each group with 
sufficient details to allow replication, including 
how and when they were actually 
administered 
3 
Outcomes 6a Completely defined pre-specified primary and 
secondary outcome measures, including how 
and when they were assessed 
3-7 
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6b Any changes to trial outcomes after the trial 
commenced, with reasons 
 
Sample size 7a How sample size was determined  
7b When applicable, explanation of any interim 
analyses and stopping guidelines 
 
Randomisation:    
 Sequence 
generatio
n 
8a Method used to generate the random 
allocation sequence 
 
8b Type of randomisation; details of any 
restriction (such as blocking and block size) 
 
 Allocation 
concealm
ent 
mechanis
m 
9 Mechanism used to implement the random 
allocation sequence (such as sequentially 
numbered containers), describing any steps 
taken to conceal the sequence until 
interventions were assigned 
 
 
Implementation 
10 Who generated the random allocation 
sequence, who enrolled participants, and 
who assigned participants to interventions 
 
Blinding 11a If done, who was blinded after assignment to 
interventions (for example, participants, care 
providers, those assessing outcomes) and 
how 
 
11b If relevant, description of the similarity of 
interventions 
 
Statistical 
methods 
12a Statistical methods used to compare groups 
for primary and secondary outcomes 
 
12b Methods for additional analyses, such as 
subgroup analyses and adjusted analyses 
 
Results 
Participant flow 
(a diagram is 
strongly 
recommended) 
13a For each group, the numbers of participants 
who were randomly assigned, received 
intended treatment, and were analysed for 
the primary outcome 
 
13b For each group, losses and exclusions after 
randomisation, together with reasons 
 
Recruitment 14a Dates defining the periods of recruitment and  
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follow-up 
14b Why the trial ended or was stopped  
Baseline data 15 A table showing baseline demographic and 
clinical characteristics for each group 
 
Numbers 
analysed 
16 For each group, number of participants 
(denominator) included in each analysis and 
whether the analysis was by original 
assigned groups 
 
Outcomes and 
estimation 
17a For each primary and secondary outcome, 
results for each group, and the estimated 
effect size and its precision (such as 95% 
confidence interval) 
3-7 
17b For binary outcomes, presentation of both 
absolute and relative effect sizes is 
recommended 
 
Ancillary 
analyses 
18 Results of any other analyses performed, 
including subgroup analyses and adjusted 
analyses, distinguishing pre-specified from 
exploratory 
 
Harms 19 All important harms or unintended effects in 
each group (for specific guidance see CONSORT for 
harms) 
8 
Discussion 
Limitations 20 Trial limitations, addressing sources of 
potential bias, imprecision, and, if relevant, 
multiplicity of analyses 
7-9 
Generalizability 21 Generalizability (external validity, 
applicability) of the trial findings 
 
Interpretation 22 Interpretation consistent with results, 
balancing benefits and harms, and 
considering other relevant evidence 
 
Other information  
Registration 23 Registration number and name of trial 
registry 
 
Protocol 24 Where the full trial protocol can be accessed, 
if available 
 
APPENDICES 
Appendix	  1	  The	  Literature	  Review	   454	  
Funding 25 Sources of funding and other support (such 
as supply of drugs), role of funders 
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The Homotoxicological Treatment Of Female Functional Infertility: A 
Clinical Trial (Lai, 2000). Translated From Italian By Professional 
Translator. 
Evaluated against RedHot 
Table 33 Lai, 2000 evaluated against REDHOT 
Checklist for Reporting Data on Homeopathic Treatments (REDHOT) 
(Dean et al., 2007) 
Item Treatment 
(CONSORT item 
number) 
Description Reported 
on page 
number 
1 Rationale (2) Type of homeopathy 
Individualized (aka 
classical, constitutional) 
Formula (aka clinical = 
single constituent or   
complex = multi 
constituent) 
Isopathy 
Evidence base 
Sources, references 
3 
2 Participants (3) Knowledge Condition 
Baseline health definition in 
provings 
 
3 Medications (4) Manufacture 
Manufacturer, 
pharmacopoeia (or 
process), references. 
Potency and scale 
Dilution Method 
Nomenclature 
Individualised: list or 
frequency table 
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Formula: Constituents, 
trade name 
Dosage 
Dose, timing, form 
 
 
 
3,5 trade 
name 
only, 
dose and 
timing  
4 Consultations (4)  Setting 
Clinical history detail 
Duration, frequency 
Number needed to agree 
prescription 
Group process or expert 
consultation 
Confidence in prescriptions 
 
Setting 
assumed 
as clinic 
p3 
5 Practitioners (4) Number in Study  
  Experience, accreditation, 
qualifications 
Current schools or styles of 
homeopathy 
 
6 Co-interventions (4) Included 
Rationale, intended effect, 
references 
Duration, frequency 
Excluded 
Stopping of mainstream 
interventions 
Antidotes 
 
3-5, 6 
(diet) 
7 Control interventions 
(4) 
Active 
Rationale, references 
Placebo 
3-5 
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Manufacturing process 
8 Adverse events (19)  Aggravations 8 
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The Homotoxicological Treatment Of Female Functional Infertility: A 
Clinical Trial (Lai, 2000). Translated From Italian By Professional 
Translator. 
Evaluated against the MVHT  
Table 34 Lai, 2000 evaluated against MVHT 
Table:  Verdicts for domains 1-6, indicating rating for ‘Yes’, ‘No’ and ‘Unclear’ (Mathie et al., 2012) 
Paper  
(Lai, 2000) 
 Yes Uncertain No 
1 Rationale 
Clinical knowledge 
and practice inform 
that, for the condition 
under investigation, 
the health of patients 
may be benefited by 
homeopathic 
intervention. 
References the Lai 
Study (Lai, 2000)  
 
 
A substantial number 
of experienced 
homeopaths would 
support the choice of 
this intervention for 
this type of patient. 
Does not make 
clear the clinical 
success 
experienced 
previously at the 
same clinic that led 
to this trial. 
 
2 Principles 
One or both of the 
following: 
The intervention 
used is based on the 
principle of ‘like 
treats like’ or is 
based on the 
principle of isopathy. 
Literature sources 
(material medica, 
repertory etc.) are 
available that 
convincingly justify 
the specific 
intervention 
Remedies used 
were Heel remedies 
that are formulated 
using homeopathic 
and isopathic 
principles and the 
prescription of 
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these remedies for 
these conditions is 
found in the 
literature published 
by Heel (Heel, 1986) 
 
3 Practitioner 
Non-Individualised 
homeopathy: There 
is evidence that 
experienced 
homeopathic input 
(and/or a suitable 
literature source) has 
been involved in 
informing the choice 
of medicine(s) used 
commonly for all 
patients in the study. 
Author is listed as 
Specialist in 
Obstetrics and 
Gynaecology, 
Managing Doctor at 
the Centre for the 
Study and 
Treatment of the 
Menopause.  
National Secretary 
for the Italian 
College of 
Biological 
Obstetricians and 
Gynaecologists 
 
4 Outcome Measures 
The main clinical 
effect expected of the 
intervention is 
adequately 
measured by the 
main outcome used. 
Yes each sub group 
was assessed 
using a variety of 
outcomes that 
indicate changes to 
the clinical picture 
such as ovulation 
rate, progesterone 
levels, and 
endometrial 
thickness. 
  
5 Sensitivity 
All of the following: 
The main outcome 
measure is sensitive 
to changes of the 
magnitude expected 
in the patients under 
investigation. 
yes 
The main outcome 
measure is capable 
of determining both 
improvement and 
The main outcome 
measure shows no 
evidence of a ‘floor 
effect’ and/or ‘ceiling 
effect’. 
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deterioration. 
yes 
 
6 Follow up  
The time-point 
selected for main 
follow-up 
measurement 
provides sufficient 
opportunity for a 
clinical change to be 
observed. 
 
It is not clear how 
long individual 
patients were treated 
for.  It is suggested 
that the trial 
recruited 
(assessed) women 
between June 1998 
and January 1999.  
Subset B was 
assessed for 8 
monthly cycles.   And 
Subset C underwent 
allopathic treatment 
that was subdivided 
into two 4-month 
cycles. 
~The results tables 
seem to indicate that 
data was collected 
for 8 months 
 
HTX group remedies 
were prescribe twice 
weekly so sufficient 
time would be 
needed to complete 
the task 
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The efficacy of the complex medication Phyto-Hypophyson L in female, 
hormone related sterility. A randomized, placebo-controlled clinical 
double blind study. (Bergmann et al., 2000) 
The original article being published in German only the review has been based upon 
the CONSORT guidelines (Hopewell et al., 2008) for assessing abstracts of 
randomised trials. 
Table 35 Bergman et al 2000 evaluated against CONSORT 
Item Description Reported on 
line number 
Title  Identification of the study as randomized 1 
Authors * Contact details for the corresponding author Names only 
Trial design Description of the trial design (e.g. parallel, cluster, non-
inferiority) 
2 
Methods   
  Participants Eligibility criteria for participants and the settings where 
the data were collected 
8 
  Interventions Interventions intended for each group 9 
  Objective Specific objective or hypothesis 8 
  Outcome Clearly defined primary outcome for this report 10-11 
  Randomization How participants were allocated to interventions  
  Blinding 
(masking) 
Whether or not participants, care givers, and those 
assessing the outcomes were blinded to group 
assignment 
 
Results   
  Numbers 
randomized 
Number of participants randomized to each group  
  Recruitment Trial status  
  Numbers 
analysed 
Number of participants analysed in each group  
  Outcome For the primary outcome, a result for each group and the 
estimated effect size and its precision 
 
  Harms Important adverse events or side effects 16-17 
Conclusions General interpretation of the results 10-16 
Trial registration Registration number and name of trial register  
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Funding Source of funding  
 
The efficacy of the complex medication Phyto-Hypophyson L in female, 
hormone related sterility. A randomized, placebo-controlled clinical 
double blind study. (Bergmann et al., 2000) 
Table 36 Bergman 2000 evaluated against REDHOT 
Checklist for Reporting Data on Homeopathic Treatments (REDHOT) 
(Dean et al., 2007) 
Item Treatment 
(CONSORT item 
number) 
Description Reported on 
page number 
1 Rationale (2) Type of homeopathy 
Individualized (aka 
classical, 
constitutional) 
Formula (aka clinical = 
single constituent or   
complex = multi 
constituent) 
Isopathy 
Evidence base 
Sources, references 
 
Abstract 
2 Participants (3) Knowledge Condition 
Baseline health definition in 
provings 
 
3 Medications (4) Manufacture 
Manufacturer, 
pharmacopoeia (or 
process), references. 
Potency and scale 
Dilution Method 
Nomenclature 
Manufacturer 
is named in 
abstract 
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Individualised: list or 
frequency table 
Formula: Constituents, 
trade name 
Dosage 
Dose, timing, form 
 
 
 
One 
constituent is 
named 
 
 
Dose is shown 
in abstract 
4 Consultations (4)  Setting 
Clinical history detail 
Duration, frequency 
Number needed to agree 
prescription 
Group process or expert 
consultation 
Confidence in prescriptions 
 
 
Clinical 
classification 
in abstract 
5 Practitioners (4) Number in Study  
  Experience, accreditation, 
qualifications 
Current schools or styles of 
homeopathy 
 
6 Co-interventions (4) Included 
Rationale, intended 
effect, references 
Duration, frequency 
Excluded 
Stopping of 
mainstream 
interventions 
Antidotes 
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7 Control 
interventions (4) 
Active 
Rationale, references 
Placebo 
Manufacturing process 
 
 
Placebo is not 
explained 
8 Adverse events (19)  Aggravations Mentioned but 
not described 
in abstract 
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The efficacy of the complex medication Phyto-Hypophyson L in female, 
hormone related sterility. A randomized, placebo-controlled clinical 
double blind study. (Bergmann et al., 2000) 
Evaluated against MVHT 
Table 37 Bergman et al 2000 evaluated against MVHT 
Table:  Verdicts for domains 1-6, indicating rating for ‘Yes’, ‘No’ and ‘Unclear’ 
(Mathie et al., 2012) 
Paper  
 Yes Uncertain No 
1 Rationale 
. 
 
Both of the 
following: 
 
Clinical 
knowledge and 
practice inform 
that, for the 
condition under 
investigation, the 
health of patients 
may be benefited 
by homeopathic 
intervention. 
A substantial number 
of experienced 
homeopaths would 
support the choice of 
this intervention for 
this type of patient 
No discussed in 
abstract but 
context of trial is a 
clinical setting 
 
2 Principles 
One or both of 
the following: 
The intervention 
used is based on 
the principle of 
One or both of 
the following: 
The intervention 
used is based on 
the principle of 
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‘like treats like’ or 
is based on the 
principle of 
isopathy. 
Literature sources 
(material medica, 
repertory etc.) are 
available that 
convincingly justify 
the specific 
intervention 
‘like treats like’ or 
is based on the 
principle of 
isopathy. 
Literature sources 
(material medica, 
repertory etc.) are 
available that 
convincingly justify 
the specific 
intervention 
3 Practitioner    
4 Outcome 
Measures 
   
5 Sensitivity    
6 Follow up    
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Complementary and Alternative Medicine (CAM) in reproductive-
age women: a review of randomized controlled trials (Fugh-
Berman and Kronenberg, 2003) evaluated using PRISMA. 
Table 38 Fugh-Berman and Kronenberg, 2003 evaluated against PRISMA 
Section/topic  # Checklist item  
Reported 
on page 
#  
TITLE: Complementary and Alternative Medicine (CAM) in 
reproductive-age women: a review of randomized controlled trials  
 
Title  1 Identify the report as a systematic review, meta-
analysis, or both.  
Review 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: 
background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal 
and synthesis methods; results; limitations; conclusions 
and implications of key findings; systematic review 
registration number.  
137 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of 
what is already known.  
137-138 
Objectives  4 Provide an explicit statement of questions being 
addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
137 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can 
be accessed (e.g., Web address), and, if available, 
provide registration information including registration 
number.  
 
Eligibility 
criteria  
6 Specify study characteristics (e.g., PICOS, length of 
follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as 
criteria for eligibility, giving rationale.  
 
Information 
sources  
7 Describe all information sources (e.g., databases with 
dates of coverage, contact with study authors to identify 
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additional studies) in the search and date last searched.  
Search  8 Present full electronic search strategy for at least one 
database, including any limits used, such that it could be 
repeated.  
 
Study selection  9 State the process for selecting studies (i.e., screening, 
eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., 
piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from 
investigators.  
 
Data items  11 List and define all variables for which data were sought 
(e.g., PICOS, funding sources) and any assumptions 
and simplifications made.  
 
Risk of bias in 
individual 
studies  
12 Describe methods used for assessing risk of bias of 
individual studies (including specification of whether this 
was done at the study or outcome level), and how this 
information is to be used in any data synthesis.  
 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, 
difference in means).  
 
Synthesis of 
results  
14 Describe the methods of handling data and combining 
results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
 
 
Page 1 of 2  
Section/topic  # Checklist item  
Reported 
on page 
#  
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect 
the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., 
sensitivity or subgroup analyses, meta-regression), if 
done, indicating, which were pre-specified.  
 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for 
eligibility, and included in the review, with reasons for 
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exclusions at each stage, ideally with a flow diagram.  
Study 
characteristics  
18 For each study, present characteristics for which data 
were extracted (e.g., study size, PICOS, follow-up 
period) and provide the citations.  
 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if 
available, any outcome level assessment (see item 12).  
 
Results of 
individual 
studies  
20 For all outcomes considered (benefits or harms), 
present, for each study: (a) simple summary data for 
each intervention group (b) effect estimates and 
confidence intervals, ideally with a forest plot.  
 
Synthesis of 
results  
21 Present results of each meta-analysis done, including 
confidence intervals and measures of consistency.  
 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across 
studies (see Item 15).  
 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., 
sensitivity or subgroup analyses, meta-regression [see 
Item 16]).  
 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of 
evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, 
users, and policy makers).  
 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk 
of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
 
Conclusions  26 Provide a general interpretation of the results in the 
context of other evidence, and implications for future 
research.  
 
FUNDING   
Funding  27 Describe sources of funding for the systematic review 
and other support (e.g., supply of data); role of funders 
for the systematic review.  
 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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Page 2 of 2  
Randomized controlled trials of homeopathy in humans: characterizing 
the research journal literature for systematic review (Mathie et al., 2013) 
Evaluated using PRISMA 
Table 39 Mathie et al 2013 evaluated against PRISMA 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE- Randomized controlled trials of homeopathy in humans: 
characterizing the research journal literature for systematic 
review (Mathie et al., 2013) 
 
 
Title  1 Identify the report as a systematic review, meta-
analysis, or both.  
3 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as 
applicable: background; objectives; data sources; 
study eligibility criteria, participants, and interventions; 
study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key 
findings; systematic review registration number.  
3 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of 
what is already known.  
4 
Objectives  4 Provide an explicit statement of questions being 
addressed with reference to participants, 
interventions, comparisons, outcomes, and study 
design (PICOS).  
4-6 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can 
be accessed (e.g., Web address), and, if available, 
provide registration information including registration 
number.  
 
Eligibility 
criteria  
6 Specify study characteristics (e.g., PICOS, length of 
follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as 
5-6 
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criteria for eligibility, giving rationale.  
Information 
sources  
7 Describe all information sources (e.g., databases with 
dates of coverage, contact with study authors to 
identify additional studies) in the search and date last 
searched.  
4 
Search  8 Present full electronic search strategy for at least one 
database, including any limits used, such that it could 
be repeated.  
4 
Study selection  9 State the process for selecting studies (i.e., 
screening, eligibility, included in systematic review, 
and, if applicable, included in the meta-analysis).  
5-6 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., 
piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from 
investigators.  
5 & In a 
report to 
follow (p4) 
Data items  11 List and define all variables for which data were 
sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
4-5-6 
Risk of bias in 
individual 
studies  
12 Describe methods used for assessing risk of bias of 
individual studies (including specification of whether 
this was done at the study or outcome level), and how 
this information is to be used in any data synthesis.  
 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, 
difference in means).  
Categories 
Synthesis of 
results  
14 Describe the methods of handling data and combining 
results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
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Page 1 of 2  
Section/topic  # Checklist item  
Reported 
on page 
#  
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect 
the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
n/a 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., 
sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified.  
n/a 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for 
eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
7 
Study 
characteristics  
18 For each study, present characteristics for which data 
were extracted (e.g., study size, PICOS, follow-up 
period) and provide the citations.  
8-20 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if 
available, any outcome level assessment (see item 12).  
 
Results of 
individual 
studies  
20 For all outcomes considered (benefits or harms), 
present, for each study: (a) simple summary data for 
each intervention group (b) effect estimates and 
confidence intervals, ideally with a forest plot.  
 
Synthesis of 
results  
21 Present results of each meta-analysis done, including 
confidence intervals and measures of consistency.  
 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across 
studies (see Item 15).  
 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., 
sensitivity or subgroup analyses, meta-regression [see 
Item 16]).  
 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of 
evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, 
users, and policy makers).  
23 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk 23 
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of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
Conclusions  26 Provide a general interpretation of the results in the 
context of other evidence, and implications for future 
research.  
23-24 
FUNDING   
Funding  27 Describe sources of funding for the systematic review 
and other support (e.g., supply of data); role of funders 
for the systematic review.  
24 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
Page 2 of 2  
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Table to show the Standards for Reporting Qualitative Research 
(SRQR) 
(O’Brien et al., 2014a) 
Table 40 Standards for Reporting Qualitative Research 
 
 
Topic Item 
1 Title Concise description of the nature and topic of 
the study identifying the study as qualitative 
or quantitative or indicating the approach or 
data collection method is recommended. 
2 Abstract Summary of key elements of the study using 
the abstract format of the intended 
publication; typically includes background, 
purpose, methods, results and conclusions. 
 Introduction  
3  Problem formulation Description and significance of the 
problem/phenomenon studied; review of 
relevant theory and empirical work; problem 
state 
4 Purpose or Research 
Question 
Purpose of the study and specific objectives 
or questions 
 Methods  
5 Qualitative approach 
and research 
paradigm 
Qualitative approach (e.g. ethnography, grounded theory, narrative 
research) and guiding theory if appropriate; identifying the research 
paradigm (e.g. post positivist, constructivist/interpretivist) is also 
recommended; rationale that briefly discusses the justification for 
choosing that approach; the assumptions and limitations implicit in 
that choice and how those choices influence study conclusions and 
transferability. 
6 Researcher 
characteristics and 
reflexivity 
Researchers’ characteristics that may 
influence the research, including personal 
attributes, qualifications/experience, 
relationships with participants, assumptions, 
and/or presuppositions; potential or actual 
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interaction between researchers 
characteristics and the research question, 
approach, methods, results, and/or 
transferability. 
7 Context Setting/Site and salient contextual factors, 
rationale. 
8 Sampling strategy How and why research participants, 
documents and events were selected, criteria 
for deciding when no further sampling was 
necessary (sampling saturation), rationale. 
9 Ethical issues 
pertaining to human 
subjects 
Documentation of approval by an appropriate 
ethics review board and participant consent, 
or explanation for lack thereof; other 
confidentiality and data security issues. 
 
10  Data collection 
methods 
Types of data collected; details of data 
collection procedures including start and stop 
dates of data collection and analysis, iterative 
process, triangulation of sources/methods, 
and modification of procedures in response to 
evolving study findings, rationale. 
11 Data collection 
instruments and 
technologies 
Description of instruments (e.g. interview 
guides, questionnaires) and devices (e.g. 
audio recorders used for data collection; 
if/how the instruments changed over the 
course of the study. 
12 Units of study Number and relevant characteristics of 
participants, documents or events included in 
the study, level of participation (could be 
recorded in results). 
13  Data processing Methods for processing data prior to and 
during analysis, including transcription, data 
entry, data management and security, 
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verification of data integrity, data coding, and 
anonymization/deidentification of excerpts 
14 Data analysis Process by which inferences, themes, etc. 
were identified and developed including the 
researchers involved in data analysis, usually 
references to a specific paradigm or 
approach, rationale. 
15 Techniques to 
enhance 
trustworthiness 
Techniques to enhance trustworthiness and 
credibility of data analysis 9e.g member 
checking, audit trail, triangulation), rationale. 
 
 Results/Findings  
16 Synthesis and 
interpretation 
Main findings (e.g. interpretations, inferences, 
and themes); might include development of a 
theory or model, or integration with prior 
research or theory. 
17 Links to empirical data Evidence (e.g. quotes, field notes, text 
excerpts, photographs) to substantiate 
analytic findings. 
 Discussion  
18 Integration with prior 
work, implications, 
transferability, and 
contributions to the 
field 
Short summary of main findings; explanation 
of how findings and conclusions connect to, 
support, elaborate on, or challenge 
conclusions of earlier scholarship; discussion 
of scope of application/generalizability; 
identification of unique contribution(s) to 
scholarship in a discipline or field. 
19 Limitations Trustworthiness and limitations of findings 
20 Conflicts of interests Potential source of influence or perceived 
influence on study conduct and conclusions, 
how these were managed 
21 Funding Sources of funding and other support; role of 
funders in data collection, interpretation and 
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reporting. 
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Table 41 External peer review of the protocol for strand 3 
Review of the protocol: 
A PILOT STUDY OF OVARIUM COMPOSITUM IN INFERTILE WOMEN. 
By Claire Haresnape 
 
Reviewer: Dr Alexander Tournier, PhD 
Research Fellow Cancer Research UK and practitioner specialised in 
Homeopathy, practicing in Covent Garden and Southfields. 
30 October 2008 
The appropriateness of the study design in relation to the objectives of 
the study, the statistical methodology, and the potential for reaching 
sound conclusions with the smallest number of research participants 
necessary.  Feasibility and Deliverability. 
The protocol as it stands appears appropriate in terms of the objectives of 
the study, namely to measure the effectiveness of Ovarium Co. as an adjunct 
to conventional treatment in dealing with female infertility.  
The study uses a number of measures: experimental (endometrial thickness, 
nber of follicles progesterone levels) as well as the Quality of Life measure. 
These measures seem appropriate and adapted to capture any significant 
difference between the two groups, as well as offering room for interpretation 
of the results in terms of possible mechanisms of action. 
The number of participants seems to be adapted. A small concern is that the 
study might not have enough statistical power to resolve between the 
different arms: Clomid + Ov. Co. vs Clomid + Placebo (similarly for the FSH 
and IVF groups). This is not a serious limitation of the design as this is not 
the main question of the study. The results of the study should nevertheless 
offer interesting insights in terms of these three conventional treatment 
groups. Overall, N=90 is a reasonable number for this type of study and is 
likely to provide adequate statistical power for the aims of the trials. 
A 3rd arm of the study is mentioned several times as ‘a group that has been 
consented to allow access to their data’. Comparisons with this 3rd group 
could yield interesting results in terms of the effect of placebo, also it is quite 
a cost effective way of doing so. The present protocol gives little indication as 
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to how this 3rd group is going to be populated so as to guarantee that the 
populations of the three groups will indeed be comparable. As small note 
about this would resolve the issue. It is unclear from the present text whether 
this 3rd group is actually part of the design, this should be clarified one way or 
the other.  
The justification of predictable risks and inconveniences weighed 
against the anticipated benefits for the research participants, other 
present and future patients, and the concerned communities. 
There being no known toxicity associated with Ovarium Co., I see no risk in 
the participation in this trial. 
The intervention being an adjunct to conventional treatment I see no 
inconvenience for the participants. 
The study should yield interesting and useful results for future patients. 
Assessment for broad ethical concerns, which may result in harm to the participants. 
 
The participants will follow their conventional treatment all through the trial 
and therefore will not miss out on validated conventional treatment.  
The safety of the participants is appropriately taken care of in this design. 
 
Value for Money: e.g. not addressing the most important question, 
leading to low impact or otherwise poor value for users of research; 
unrealistic targets for recruitment of clinical centres and participants, 
leading to a likelihood of cost over-runs.  Identification of funding 
processes and administration. 
The most important question is well defined and the tools chosen adapted to 
answering it. The results will be useful to both researchers and patients. 
Recruitment criteria appear realistic and the location appropriate for this trial. 
 
Impact to Service:  Affordability of extra clinical 
interventions/processes/visits, which are not covered in the funding, 
cost breakdown.  Impact on service capacity including affiliated 
services such as pharmacy, pathology, imaging, etc.  
Acceptable. 
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Small note: 
Important typo on page 24, ‘succussion’ has been replaced by ‘succession’, it 
seems MS Word does it automatically.  
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Table 42 WHRI internal review of trial from strand 3 
WHRI RESEARCH GOVERNANCE 
COMPLIANCE CERTIFICATE 
Queen Mary, University of London 
 
1. Project Title 
 
A pilot study of ovarium compositum in infertile women 
 
 
 
2. Project Start  
    Date 
 
 
1st November 2008 
  Expected Project 
  End Date 
 
1st May 2010 
 
 
 
3. Details of Contact Person(s) 
 
Lead Investigator 
 
Co-Investigators (list all) 
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Surname(s) and Title  
Ms Haresnape 
 
 1. Name and Address 
Professor Atholl Johnston 
Clinical Pharmacology 
First Name 
Claire 
 
 
Barts and the London 
Charterhouse Square EC1M 6BQ 
 
Address 
Petrona 
Foords Lane 
Vines Cross TN21 9ER 
 2. Name and Address 
Dr. Art Tucker 
The Ernest Cooke Vascular & 
Microvascular Unit 
St. Barts, EC1A 7BE 
 
Telephone no.:  07720060116 
Fax no.:  
 
E-mail address: 
c.haresnape@qmul.ac.uk 
 
 3.  Name and Address 
 
 
 
 
4. Detail of Referees 
Comments and Review 
 
It is encouraging to see a proper randomised placebo controlled trial for complementary 
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therapies as there is a dearth of robust studies in the literature upon which the clinical 
and scientific community can judge the effectiveness of such treatments.  The protocol 
is well planned although I cannot judge whether adequate recruitment levels can be 
achieved as the study will not take place within Barts and the London NHS Trust.  My 
major concern is that there are no statistical power calculations to estimate whether the 
recruitment numbers are adequate to resolve the effects of OC.  I acknowledge 
improvements in study design over that of Gerard et al but am unconvinced that 90 
patients will be adequate. 
 
 
 
5.  Date of Certification 6th August 2008  
 ___________________________ 
         Signature of 
Research Governance Lead 
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APPENDIX 2 Copy of questionnaires 
sent to therapists in Strand One. 
Letter of Invitation and Questionnaire sent  to Therapists Taking Part in Practitioner Survey 
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Please return to Claire Dadswell 
Registered Homoeopath 
Email: Claire@clairedadswell.co.uk 
Fax: 01435 867518 Telephone 0772 006 0116 
 
RESEARCH PROJECT; Homoeopathy and Infertility.  
Supervised by Prof Atholl Johnston, Clinical Pharmacology, 
Barts and The London, Queen Mary’s School of Medicine and 
Dentistry. 
 
Question One: 
 
Please would you read the following summary of an infertility case and 
indicate which of the suggested protocols would, in your opinion, be 
appropriate.  You may tick more than one option. 
 
Case Details:  
Sex: Female, Date of Birth 13th April 1962, Age at first consultation 42 years 
old 
Marital Status: Married (happily) 
Appearance: Dark haired, athletic build. 
Family history: Not available as patient was adopted.  She has undertaken 
psycho-emotional therapy regarding her adoption and is actively tracing her 
birth mother. 
Presenting condition:  Failure to respond to Gonadotrophin injections for 
IVF treatment.  An earlier IVF treatment had resulted in a successful 
pregnancy but the pregnancy was terminated following tests for Downs 
Syndrome. 
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General Health is good, no menstrual difficulties, few acute infections, and 
infrequent headaches.  No financial anxieties. Regular exercise (horse 
riding), but some pain from muscles, diagnosed as lactic acid build-up. 
Vaccination: Hepatitis; Yellow fever, Typhoid.  Malaria treatment. 1998 
Other Health Choices: Hypnosis and Herbal treatment for high mercury 
levels. 
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Please tick the options that in your opinion are appropriate, you may chose 
more than one: 
 
q Option 1: Treatment of the vaccinations using potentised vaccines, 
Silica and Thuja. 
 
q Option 2: Treatment of the hormone balance using potentised 
hormones (GUNA):  
§ FSH D6 20 drops three times a day from the 1st to the 3rd 
day of the menstrual cycle. 
§ Beta Estradiol D6 20 drops three times a day from the 4th 
to the 14th day of the menstrual cycle. 
§ Luteinizing Hormone D6 20 drops three times a day from 
the 4th to the 15th day of the menstrual cycle. 
§ Progesterone D6 20 drops three times a day from the 
14th to the 24th day of the menstrual cycle.  
 
q Option 3: Use of the indicated remedies: Nat Mur 6 and Sepia 6 
daily for two weeks. 
 
q Option 4: Treatment of Miasmatic ‘Psoric’ tendency with Psorinum 
nosode and drainages. 
 
 
q Option 5: Treatment of Pituitary-Ovarian feedback mechanism 
using complex remedy ‘G3’ (GUNA): Composition: Ovarium 
D8/D12/D30, Corpus Luteum D8/D12/D30, Pulsatilla D6/D8/D30, Kali 
Carb 6CH/30CH. 
 
 
 
Question Two  
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What would you use in your practice as a well indicated 
homoeopathic/ homotoxicological protocol for treating 
female infertility due to declining hormone levels? 
 
 
 
 
Question Three 
 
 What would you use in your practice as a well indicated 
homoeopathic/homotoxicological protocol for treating male 
infertility due to low sperm count? 
 
 
 
 
 
 
 
 
 
 
 
 
 
Question Four 
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Are there any other lifestyle choices or changes that you 
would recommend to a patient seeking advice regarding 
infertility? 
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APPENDIX 3 Strand 2 The Study 
At The Bridge Centre 
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Strand Two The Study at The Bridge Centre 
Data collection instruments and technologies 
Questionnaire for nurses at The Bridge Centre 
1. What are your experiences of Homeopathy? 
2. What are your expectations of Homeopathy? 
3. How do you feel about clients who have tried alternative and 
complementary medicine? 
4. How much time do you get with clients to go over consent forms and 
dispense medicine? 
5. How do you feel about being asked to do this study? 
6. What is the most difficult part of your role? 
7. What is the most rewarding aspect of your role? 
8. What problems can you foresee with the proposed project? 
9. What benefits to the patients and the clinic can you foresee with the 
proposed project? 
 
APPENDICES 
Appendix	  3	  Strand	  2	  The	  Study	  at	  The	  Bridge	  Centre	   di	  
Questionnaire for Patients at The Bridge Centre 
 
12 
Would you like to do something to help research into the 
potential benefits of Homotoxicology for infertile women? 
 
The Bridge Centre is assisting research into the use of complex 
homoeopathy (Homotoxicology – see Page 4).  If you would like to 
help then please complete this questionnaire and return it in the 
S.A.E. to: 
 
Ms Pauline Wright, Matron 
The Bridge Centre 
One St Thomas Street 
London Bridge 
London 
SE1 9RY 
 
 
Your answers will be analysed to find out if it is feasible to plan a trial of 
Homotoxicology.  The aim of the trial to see if the use of Homotoxicology 
remedies can increase the number and quality of eggs produced during 
ovulation induction.  If complex homoeopathy is shown to have an effect then 
this may mean that older women, or women who have failed to respond to 
the ovulation induction drugs, have a higher chance of ovulating using 
Assisted Reproduction. 
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Please only answer those questions that you are happy and comfortable to 
answer.  You are not under any obligation to complete this questionnaire, it is 
entirely voluntary. 
 
This project is supervised by a senior academic at a leading London medical 
school. 
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Question One. 
Have you ever tried Homotoxicology as a therapy? 
           yes    no 
  
 
 
Question Two. 
Have you tried Homotoxicology as part of your 
treatment for infertility?       yes    no 
 
 
 
 
Question Three. 
Would you consider trying Homotoxicology in  
the future as part of your treatment for 
Infertility?         yes    no  
 
 
 
 
Question Four. 
Would you be prepared to take part in a clinical trial 
where you may receive a placebo or no medication  
instead of the active remedy?     
           
    yes    no 
 
 
Question Five. 
Would you be willing to take your medication 
daily at home, as drops or tablets?      yes    
no 
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Question Six. 
Would you be willing to give up  
peppermint and coffee?        yes    
no 
 
 
 
 
 
Question Seven. 
What would be your motivation to take 
part in a clinical trial of Homotoxicology? 
(You may tick more than one answer). 
 
(i) To increase my chances of ovulating     yes    
no 
(ii) To help other couples in the future     yes    
no 
(iii) To increase knowledge about homoeopathy    yes    
no 
(iv) Deciding to stop trying with IVF/ART     yes    
no 
(v) Other reasons. (Please specify them below if you wish).   yes 
   no 
 
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
……………………………………………….. 
 
Question Eight. 
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Would you be happy to pay for homotoxicology 
Treatment in the future, if this was shown to be an effective therapy? 
          
  yes    no. 
 
Question Nine. 
Would you be prepared to take homotoxicology remedies 
at the same time as your conventional medication? 
           yes    
no. 
 
 
 
Thank you for taking the time to complete this survey.  You do not need to 
supply your name and address but for research purposes it would be helpful 
to know your date of birth:  
 
 
 
D.O.B ____/____/________(dd/mm/yyyy).  12 
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Patient Information Sheet included with questionnaires 
 
What is Homotoxicology?   
 
o A German Doctor called Hans-Heinrich Reckeweg established 
Homotoxicology 50 years ago. 
 
o Sometimes it is called Anti-Homotoxic Therapy or Complex 
Homoeopathy. 
 
o It is similar to Homoeopathy but not the same. 
 
o Homoeopathy makes use of single remedies carefully chosen to 
match the symptoms of the individual person. 
 
o Homotoxicology makes use of combinations of remedies chosen to 
match the nature and severity of the disease that the person is 
suffering from. 
 
o As well as using the traditional remedies made from plants, animals 
and minerals, Homotoxicology uses preparations made from very 
diluted hormones and other chemicals found naturally in the human 
body.   
 
o By giving remedies made from very diluted hormones Homotoxicology 
aims to bring about a regulation of hormone levels in the body. 
 
o There are other kinds of preparations made from very dilute amounts 
of cells and tissues of healthy pigs.  These are believed to stimulate 
and regenerate the body’s systems that regulate our health. 
 
 
Conclusion 
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Homotoxicology makes use of remedies derived from natural sources to 
bring about a return to a health.  It aims to correct the control systems of 
the body, which sometimes become disturbed.  It works by gently 
stimulating these control systems.  
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APPENDIX 4 Protocol for Pilot 
Study from Strand 3  
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PRIVATE & CONFIDENTIAL 
 
A PILOT STUDY OF OVARIUM COMPOSITUM IN 
INFERTILE WOMEN. 
 
Protocol No.: OVCT-001 
Version 5.3 
4th February 2012 
 
 
 
 
SPONSOR: 
 
 
 
 
William Harvey Research Institute 
Barts and the London School of Medicine & Dentistry 
Queen Mary University of London 
London 
EC1M 6BQ 
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AMENDMENTS: 
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1.  
4.11.10  Sponsor changed from Seahorse Scientific Services to 
 
William Harvey Research Institute 
Barts and the London School of Medicine & Dentistry 
Queen Mary University of London 
London 
EC1M 6BQ 
 
22.01.11  
1. Exclusion Factors changed to remove previous pregnancy and other CAM 
therapies 
2. Quality of Life Questionnaires to be completed on stimulation phase of the 
cycle 
3. Follicular tracking charts to be photocopied and attached to CRF 
4. Primary outcome changed to ovulatory response and secondary outcome 
changed to length of time to pregnancy 
04.02.12 
1.  Amendment to Patient Information Sheet to inform patients that they can take the 
medication +\- one hour either side of stated time and that if they miss a dose then 
they continue with the next dose. 
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 A PILOT STUDY OF OVARIUM COMPOSITUM IN INFERTILE 
WOMEN. 
Claire Haresnape 
 
 
Abstract 
Persistent treatment failure may encourage women to seek out help using 
complementary and alternative medicine (CAM).  There is a need for further 
research to provide an evidence base for the safety, efficacy and cost 
effectiveness of CAM.  Ovarium compositum is a preparation of homeopathic 
ingredients purporting to treat female infertility.  It is prescribed in the UK by 
registered Homotoxicologists and other clinicians.  The aim of this pilot study 
is to evaluate the effectiveness of Ovarium compositum vrs placebo in a 
randomised trial of 90 women attending an infertility clinic for ovarian 
stimulation and assisted reproduction.  The outcomes to be evaluated are 
both quantitative (response to ovulation drugs, length of time to pregnancy) 
and qualitative (quality of life).  
APPENDICES 
Appendix	  4	  The	  Protocol	  for	  The	  Pilot	  Study	  Strand	  3.	   515	  
  
 
  
APPENDICES 
Appendix	  4	  The	  Protocol	  for	  The	  Pilot	  Study	  Strand	  3.	   516	  
1. Synopsis 
 
Study Title A pilot study of the use of Ovarium Compositum  
  as an adjunct treatment for infertile women in an assisted 
reproduction unit. 
Sponsor  
 
 
William Harvey Research Institute 
Barts and the London School of Medicine & Dentistry 
Queen Mary University of London 
London 
EC1M 6BQ 
 
 
Funder:  Heel GmB 
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OBJECTIVES:  
The primary objective is to assess whether the administration of Ovarium 
Compositum as an adjunct therapy can make a significant difference to 
fertility outcomes in infertile women seeking medical intervention. 
The second objective is to measure quality of life in women undergoing 
treatment for infertility and using Ovarium compositum. 
Study Design:  One centre, double blind placebo randomised 
controlled trial 
Study Location: Department of Obstetrics and Gynaecology 
   Jersey General Hospital 
   Gloucester Street, St Helier 
   Jersey, JE1 3QS 
   Telephone 01534 622 660 
 
Study Period:   12 Months 
 
Pharmaceutical Agents: Subjects will be randomised to one of the 
following agents 
 
    Ovarium Compositum vrs Placebo 
 
Route of Administration: Oral Tablet, one tablet three times a day to be 
dissolved in the mouth 
Duration of administration:  Daily, ongoing until positive pregnancy test 
or trial ends 
Study Duration:  Expected to take 12 months 
Sample Size:   45 active plus 45 placebo N=90 
    Non participating women at clinic to be consented 
for access to data for comparison. 
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2. Introduction 
2.1 BACKGROUND 
It has been estimated that at some time in their reproductive lives at least a 
quarter of couples experience a period of infertility (inability to conceive) 
lasting over 1 year. Some of these couples continue to be unable to 
conceive, leading to at least 1 in 6 couples seeing an infertility specialist at a 
hospital In the clinic setting ovulation induction problems are some of the 
commonest problem encountered. Anovulation is the failure to ovulate 
(expel a mature oocyte) owing to dysfunction of the ovary or suppression by 
drug treatment. Anovulation is a common cause of female infertility. Most 
often, women who do not ovulate also do not menstruate (amenorrhea).  
Table One 
 
 
If a woman is not ovulating by herself then ovulation induction may be 
required. The most common causes of failure to ovulate are stress, weight 
fluctuations and Polycystic Ovarian Syndrome (P.C.O.S.). Other causes may 
include disorders of the pituitary gland, thyroid gland and raised prolactin 
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levels. In some cases failure of ovulation is due to the ovarian failure. This 
may occur following treatment for cancer or may be the start of the 
menopause - premature ovarian failurei.  
Many couples may therefore require some form of medical treatment to 
induce ovulation and assist with conception. Ovulation induction aims to 
achieve repeated unifollicular ovulation in the correction of anovulatory 
infertility.  Therapies to induce ovulation first involve the use of the anti-
oestrogen clomiphene citrate.  
If ovulation is not occurring, then drugs may be administered with the onset 
of menstruation to stimulate egg production.  If tablets are not effective then 
more powerful fertility injections may be necessary to stimulate egg 
production in the ovaries. Ovulation is induced using one of two main drug 
regimens: 
Clomiphene or Clomid tablets increase the production of follicle stimulating 
hormone (FSH) by the pituitary gland, thereby stimulating follicles and hence 
egg growth. This tablet is normally given in a starting dose of 50 mgs (1 
tablet) taken from the 2nd to the 6th day of the period. If the periods are very 
infrequent then it may be necessary to induce a period by giving a different 
type o tablet called Nor-ethisterone.  
Gonadotrophins: these are given by injection. Their active ingredient is 
follicle stimulating hormone. Examples are: Menopur, Ronal F and Puregon. 
These injections are given on a daily basis and start at a dose of 75 i.u. each 
day.  
The response to any drugs given is monitored by ultrasound scans. When 
follicles have reached an appropriate size intercourse is advised, or an 
injection of hCG is given to facilitate the timing of intercourse or IUI. 
Individual responses to treatment can be unpredictable and if, during the 
monitoring, the response is insufficient or too strong, the cycle may have to 
be cancelled and restarted as appropriate. If the response to the drugs is 
satisfactory, treatment usually continues for 6 cycles; treatment cycles can be 
carried out consecutively without a break.  
Potential side effects are mainly related to the drugs. Multiple pregnancies 
are a risk of ovulation induction treatments. Twins can result in up to 10% of 
cases with clomiphene treatment, and 20% with gonadotrophins. Triplets 
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may also occur in around 1% of cases. With careful monitoring the risk of 
multiple pregnancies is reduced but not eliminated. Gonadotrophophin 
releasing hormone antagonists (GnRHantag) are increasingly used in In-vitro 
fertilisation/Intra Cytoplasmic Sperm Injection (IVF/ICSI) treatment cycles.  
With their use, however, there are concerns of reduced pregnancy rates.ii  
A study from ESHRE LYON 2007 iii concludes that natural ICSI cycles with 
minimal stimulation in poor responder patients represents a cheap and easy 
approach which offer significantly higher implantation rates compared to 
conventionally stimulated cycles.  The use of Ovarium compositum may 
potentially represent a form of minimal stimulation and an alternative to the 
administration of high levels of gonadotrophins. 
 
 
 
2.2 NICE GUIDELINES FOR THE TREATMENT OF INFERTILE 
WOMEN. 
NICE Guidelines for the treatment of infertility suggest that a couple should 
seek help after 2 years of unprotected sexual intercourse.  However where 
the women are aged 35 or more then assessment and referral to a specialist 
team should take place earlier. 
Women with WHO group II ovulation disorder (hypothalamic-pituitary 
dysfunction) should be offered treatment with comifene citrate as a first line 
of treatment for up to 12 months because it is likely to induce ovulation 
(1.6.1.1) 
Women with WHO group II ovulation disorders who do not ovulate with 
clomiphene citrate can be offered treatment with Gonadotrophins such as 
FSH. (1.6.4.1). 
One of the key priorities of the NICE guidelines is that after 3 years of 
infertility couples should be offered 3 cycles of IVF.  For pituitary down 
regulation as part of IVF treatment using gonadotrophins releasing hormone 
agonist in addition to gonadotrophins stimulation facilitates cycle control and 
results in higher pregnancy rates than the use of gonadotrophins alone 
(1.6.7.1) 
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The effectiveness of complementary therapies for fertility problems has not 
been properly evaluated and further research is needed so that such 
interventions can be integrated. The use of homotoxicology is not currently 
part of the conventional approach to treating infertility as insufficient data 
exists as to both the efficacy and cost effectiveness.  However, according to 
a spokesperson for Clarence House commenting on the Smallwood Report, 
past research indicates that as many as 16 million people in the UK have 
used complementary treatments and so there is a clear need for reliable 
information on this subject).  
M Dooleyiv has reviewed the background to complementary and alternative 
medicine and the evidence for its introduction into mainstream obstetrics and 
gynaecology.  He discusses the difficult of obtaining good evidence and 
concludes that the need to develop an integrated approach to healthcare is 
particularly relevant and important in obstetrics and gynaecology.  With this 
integration in mind he emphasises the need to encourage clinical research in 
this area. 
In my unpublished studyv of UK practitioners using homotoxicology to treat 
infertility, registered Homotoxicologists and practitioners attending the annual 
symposium were asked to complete a questionnaire.. The primary aim of this 
questionnaire was to find out how Homotoxicologist currently practising in the 
UK would treat infertility.  The need to obtain a consensus of opinion was 
highlighted by Professor Edzard Ernst, Director of Complementary Medicine, 
Peninsula Medical School, Universities of Exeter & Plymouth, who kindly 
advised the author in a personal interview.  
 The Questionnaire was designed to firstly establish their opinions regarding 
a specific case study and then to investigate their approach towards treating 
infertility in general.  The specific case study in question one was 
characteristic of the patient group that will be enrolled in the pilot study.  60 
questionnaires were distributed and a total of 20 questionnaires were 
returned.  Four had chosen not to participate and of the remaining 16 
practitioners, five had a medical/dentistry qualification.  For 6 of the therapists 
Homotoxicology is a core skill, they have a recognised qualification in 
Homotoxicology and able to register as Homotoxicologists with the British 
Register of Complementary Practitioners.   
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The results showed that in cases of female infertility the professional 
clinicians and registered practitioners are willing to recommend preparations 
such as Ovarium compositum, purporting to stimulate the Ovarium-Pituitary 
feedback mechanism.  The therapeutic indications for Ovarium compositum 
are listed in the BioTherapeutic Index as:  
‘Stimulation of the glandular and defensive functions, as well of those of the 
connective tissue, in dysmenorrhoea, endometritis, metritis, parametritis, 
enuresis (in young girls), in the climacteric, hyperemesis, insufficiency of the 
anterior lobe of the pituitary gland in females, craurosis vulvae, mastodynia, 
osteomalacia, menorrhagia, as well as in various disturbances of 
metabolism, including those arising in geriatrics. (Page 379). 
The therapeutic use is listed according to the homeopathic drug proving.  
Approximately 2000 units have been prescribed in the UK over the last 3 
years.  European Sales are in the region of 150,000 in the same time period.  
Each unit represents a box of 10 ampoules which is a five week course.1 
 
2.3 RATIONALE 
In the context of assisted reproductive technology, effective strategies to 
overcome the impact of ovarian aging and diminished ovarian reserve on 
pregnancy remain elusive.  This study aims to investigate the impact of 
Ovarium compositum on the success rates of ART in a group of women who 
attend an assisted reproduction unit. The effectiveness of complementary 
therapies for fertility problems has not been properly evaluated and further 
research is needed so that such interventions can be integrated if they prove 
to be cost effective and safe. 
Infertile women will frequently seek out a holistic approach to overcoming 
their infertility.  Infertility Clinics sometimes offer access to advice on 
integrating acupuncture, nutrition, psychological and emotional health, but 
there is little or no available information about interventions using 
homotoxicology.  The NICE guidelines list one study of homeopathic 
treatment in their table of evidence vi  Gerhard et al (1999) recruited 77 
women.  43 were offered individualised homeopathic treatment (sepia, 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 Sales figures quoted by Mr Roger Wilson, UK agent, BioPathica Ltd. 
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pulsatilla, thuja phosphorous etc) and 34 were offered conventional treatment 
(IVF, Clomifene-hCG, and FSH).  The outcomes that were measured were 
live birth rate and pregnancy rate. The results were not considered 
statistically significant and the dropout rate was 34%.  The editors of the 
report comment on the fact that the patients were allowed to change groups 
and that the method of randomisation, allocation, concealment and blinding 
were unclear. 
My pilot study seeks to improve upon this trial design in several important 
ways: firstly the use of a combination homeopathic preparation means that 
treatment does not have to be individualised.  All patients will receive 
Ovarium compositum or Placebo as well as their conventional treatment.  
Secondly, Patients will not be able to change groups.  Thirdly the 
methodology of blinding, randomisation and allocation will be made explicit in 
the study design documentation.  Fourthly we are looking at several 
additional outcomes that may be more sensitive indicators of change such as 
the response to doses of ovulation induction drugs in all groups and Quality 
of Life (QOL) in both groups. 
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Table Two 
Progression of Infertility Treatment according to NICE 
guidelines. 
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A recent paper vii suggests that persistent treatment failure encourages 
women to seek out complementary therapies. Qualitative studies suggest 
that infertility can be a devastating experience especially for women.  This 
pilot study offers an opportunity to collect data on the quality of life for women 
undergoing treatment.  
Making the positive changes suggested by these therapists may generate a 
clinically significant placebo effect through reducing stress. The 
measurement of the Quality of Life of trial participants may yield data on this 
area. Comparison of data between blinded participant groups and none 
participating, consented patients at the same clinic may allow quantitative 
data to be collected on the placebo effect 
The new infertility-specific tool being developed at University of Oxford is 
called the EHIQ (Emotional Health in Infertility Questionnaire) viii  this 
measures emotional strain in healthy individuals, rather than psychopathy.  
(See Appendix 4).  It is a potentially useful tool in studying the emotional 
effects of infertility and the effectiveness of interventions to reduce emotional 
distress in this population and the influence of emotional health on treatment 
perseverance and treatment outcomes. 
The Questionnaire ixhas nine domains: 
1. Personal Strain 
2. Partner relationship strain 
3. Sexuality 
4. Social support 
5. Confidence in treatment 
6. Guilt and blame 
7. Financial strain 
8. Need for privacy 
9. Couple concordance (where appropriate). 
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As this is a new tool that has not been fully validated the EQ5D will be used 
as well (Appendix 6). 
There are two categories of women that are of interest to this trial: firstly 
those that respond very poorly to standard ovulation induction agents and 
secondly those anovulatory women who are being given ovulation induction 
agents  Chronological age is an important predictor of outcome and so each 
group will be stratified for chronological age.  Women presenting at the clinic 
will be offered the opportunity to take part in the trial.  Those who fulfil the 
selection criteria will be consented and then allocated a protocol on a 
randomised basis.  The principal investigator will assign them, blinded to 
everything except their age.  
3. Objectives 
1. To measure the response to doses of ovulation induction drugs in all 
groups: 
1.1 Measuring endometrial thickness at ovulation/mid cycle 
1.2 Measure the number of follicles 
2. Progesterone level on day 21 mid luteal phase (>35 means you have 
ovulated) 1. To measure the length of time to pregnancy in all groups 
3. To measure the Quality of Life (QOL) in both groups using the EHIQ 
and EQ5D (See Appendix 4) 
 
4. Subjects 
Female patients will be recruited via the infertility clinic consultant.  Previous 
use of homeopathic remedies is not considered to be an exclusion factor.  
However a washout period of one month will be necessary if they are taking 
any homeopathic remedies. 
Volunteers will be provided with a full explanation of the nature, purpose and 
requirements of the study including Information Sheets and Informed 
Consent Forms.  The trial design will need to include an active group, a 
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control group and a group that has been consented to allow access to their 
data.  This means that we could compare outcomes in a group that was not 
experiencing a placebo response to those taking both the placebo and the 
active trial medication. 
The Investigators will enrol up to ninety (90) female volunteers into the study 
who will be randomised into six treatment groups.   
Table Three Proposed Treatment Groups 
 Given Plus 
Group one 
N=15 
Clomid Placebo 
Group two 
N=15 
Clomid Ovarium 
Compositum 
Group three 
N=15 
FSH Placebo 
Group four 
N=15 
FSH Ovarium  
Compositum 
Group five 
N =15 
IVF Placebo 
Group six 
N=15 
IVF Ovarium 
Compositum 
 
 
The specific inclusion and exclusion criteria are indicated below: 
4.1 INCLUSION CRITERIA 
In order to be eligible to enter the study, volunteers must meet the following 
criteria: 
1. Female  
2. Age stratified in active and placebo groups (see Table Four). 
3. Diagnosed with poor response to ovulation induction or anovulatory( 
WHO Group2) 
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4. Absence of other significant endocrine dysfunction including diabetes 
4.2 EXCLUSION CRITERIA 
1. Taking medication for other medical conditions that may affect 
ovulation  
2. Pregnancy 
3. BMI   <20kg/m2 and >35kg/m2 x 
4. Use of peppermint, caffeine, nicotine, recreational drugs or alcohol 
 
Table Four:  Age Stratification Bands 
Medica
tion 
 
 
 
Clom
id 
Vrs 
Place
bo 
 
Clom
id 
Vrs 
Place
bo 
 
Clom
id  
Vrs 
Place
bo 
 
FSH  
Vrs 
Place
bo 
 
FSH  
Vrs 
Place
bo 
 
FSH 
Vrs 
Place
bo 
 
IVF  
Vrs 
Place
bo 
 
IVF  
Vrs 
Place
bo 
 
IVF  
Vrs 
Place
bo 
 
Years 
of age 
on date 
of trial 
entry 
<30 30-
35 
>35 
 
<30 30-
35 
>35 <30 30-
35 
 
>35 
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5. Study Methodology 
Up to ninety (90) subjects are planned to be enrolled.  
5.1 DESIGN 
One-centre, randomised, double blind trial in female volunteers who meet the 
inclusion criteria. 
Allocation to treatment will be controlled by the principal investigator and the 
fertility consultant at study site.  The usual blood tests and clinical evaluations 
will be made by the fertility clinic and no additional or specific tests are 
required for this study.   
 
5.2 SCREENING EVALUATION 
Prospective subjects will attend the study site for their routine screening visit. 
They will have the nature of the study, the procedures and the risks fully 
explained. 
Before any screening procedures occur they must sign an Informed Consent 
Form in which they acknowledge that they are willing to be assessed for 
enrolment in the study; that they agree to providing personal particulars to 
the investigators and recognise that these may be available to non-medical 
investigators and may be sighted by the Sponsor; that they agree to having 
the biochemistry; haematology, and urinary tests conducted.   
During the screening evaluation the following procedures will be conducted 
and recorded for all volunteers: 
• Informed Consent 
• Evaluation of compliance with inclusion and exclusion criteria 
• Access to Demography and Medical History 
• No additional Laboratory Tests except as required for their infertility 
treatment 
• Assessment of any concurrent medications 
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Volunteers who satisfy all of the inclusion and exclusion criteria, who sign the 
Informed Consent Form for Study Participation and who agree to the 
conditions of the study, will be eligible to enter the study. 
 
5.2.1 The Randomisation and Allocation Procedure. 
The patients will be randomised, in blocks of four.  They will be stratified 
according to chronological age and treatment group.(see Table Four).   
 
 
5.3 STUDY PROCEDURES 
5.3.1 Treatment Procedures 
Prior to the study, the Investigator shall review all Volunteers’ check-in 
details, consent documents and indicate whether each volunteer has been 
accepted into the study. 
 
Schedule of Visits. 
Visit One:  
• The Volunteers will report to the Study Centre at a pre-agreed time. 
• The active agent will be randomly distributed and 100 tablets 
dispensed to the Subject by the responsible administering Clinician 
with full instructions on frequency and timing of dosages.  
• Dose frequency and timing: one tablet dissolved in the mouth three 
times a day, at least 15 minutes before or after meals.  Dose to be 
taken at 9am, 12 noon and 9pm, plus or minus one hour. 
• If a dose is missed then subjects will take the next dose as normal 
• Subjects will at all times continue with their conventional infertility 
treatment as prescribed by the Consultant.   
 
Visits 2 - 12 
• On completion of this dose for 30 days Subjects are expected to 
attend an evaluation session and if they still fulfil the criteria of the trial 
the dose can be repeated. 
• A further 100 tablets will be dispensed.   
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• Volunteers will be evaluated in this way every 30 days. 
• Unused tablets to be returned to the Principal Investigator in a sealed 
bag, labelled with Subjects name and date of birth for counting. 
• Subjects will be instructed to discontinue trial drug after an ART 
intervention and wait until a pregnancy test is performed. 
• The maximum length of trial is 12 months, however most patients will 
be prescribed their fertility treatment for a 6 month period.  For 
example failure to ovulate is treated with Clomid for 6 months, FSH 
stimulation would follow for 6 months and then IVF would be started.   
• The patients in the trial group for Clomid, for example, would 
discontinue their trial medication when they discontinue their Clomid 
treatment.  They would not automatically be assigned to the next trial 
group. 
• Patients will be discharged when the trial ends (12 months) or on a 
positive pregnancy test. 
 
5.4 RESTRICTIONS: 
5.4.1 Dietary 
Subjects will be free to consume normal meals at all times. 
Peppermint and coffee are to be excluded from the diet but the use of mint 
flavoured toothpaste is allowed. 
No food or drink to be consumed or teeth cleaned within 15 minutes of dose 
of study drug. 
 
5.4.2 Smoking 
Smoking and tobacco consumption are exclusion criteria due to the harmful 
effects in pregnancy. 
 
5.4.3 Concurrent Medication 
Subjects who meet the inclusion criteria will not be asked to abstain from 
prescribed medications. 
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The Subject must inform Study Personnel if any additional medication is 
required.  If drug therapy or medication is required during the study, a 
decision to continue or discontinue the subject will be made by the principal 
Investigator based on the time the medication was administered and its 
pharmacology and pharmacokinetics.  All details of concomitant medications 
will be recorded in the Subject’s Diary and Case Report Form (CRF). 
 
5.5 PARAMETERS FOR EVALUATION 
5. 5.1 Demography, Medical History 
Includes initials, date of birth, BMI, race, height and weight.  A full medical 
and surgical history will also be evaluated including previous pregnancies or 
treatments for infertility. 
 
5.5.2 EHIQ (Emotional Health in Infertility Questionnaire) 
Subjects will be asked to complete an EHIQ   (See Appendix 4) 
 
5.5.3 Vital Signs 
Vital signs, including body temperature, sitting radial pulse and blood 
pressure will be performed at the screening visit. 
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5.5.4 Adverse Events 
Subjects will be monitored for adverse events throughout the study.  Adverse 
events may be spontaneously reported by the subject, observed by the study 
personnel or elicited by the study personnel, who should ask subjects the 
following non-leading question: ‘How do you feel?’ or ‘How have you been 
feeling since I last asked you?’  The same questions will be used throughout 
the study. 
 
Serious Adverse Events will be reported to the Sponsor, the COREC 
recognised Research Ethics Committee and the MHRA.  If a Grade 3 r 4 
toxicity (based on the Common Toxicity Criteria (CTCv3.0)) or other serious 
adverse events occurs, no further dosing of the subjects will occur until the 
cause of the event and its relationship to the study drug has been clarified.  
Continuation of the trial will be contingent upon approval by the Sponsor. 
There is a database for ADRs at Heel’s Safety Departement (only one ADR 
listet for Ovarium Comp) 
 
5.6 STUDY DRUGS 
Ovarium compositum is manufactured in Germany according to Good 
Manufacturing Standards and the certificate is attached (Appendix 5)  
Ovarium compositum is on the market in 20 different countries.  It is on the 
market with an import licence,with a registration or with a marketing 
authorization (Russia, Poland, Latvia). Figures of sales show 700.000 - 
900.000 Ampoules per year 
In the countries where the product is on the market you find as indication on 
the leaflet: "Stimulation of the glandular and defensive functions, as well as 
those of the connective tissue, in dysmenorrhoea, endometritis, metritis, 
parametritis, enuresis (in young girls), in the climacteric, hyperemesis, 
insufficiency of the anterior lobe of the pituitary gland in females, craurosis 
vulvae, mastodynia, osteomalacia, menorrhagia, as well as in various 
disturbances of metabolism, including those arising in geriatrics." 
Due to its individual homeopathic constituents Ovarian Compositum has an 
application in the homeopathic treatment of hormonal disturbances, 
menopausal syndromes and Insufficiency of the pituitary gland. 
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5.6.1 Treatment Formulations Table Five 
The preparation is formulated as follows: 
Ovarium suis     D8 1mg 
Placenta suis     D10 1mg 
Uterus suis    D10 1mg 
Salpinx suis    D10  1mg 
Cypripedium    D6 1mg 
Lilium tigrinum   D4 1mg 
Pulsatilla    D18 1mg 
Aquilegia vulgaris   D4 1mg 
Sepia     D10 1mg 
Lachesis    D10 1mg 
Apisnum    D8 1mg 
Kreosotum    D8 1mg 
Bovista    D6 1mg 
Ipecacuanha    D6 1mg 
Mercurius solubilis Hahnemanni D10 1mg 
Hydrastis    D4 1mg 
Acidum cis-aconiticum  D10 1mg 
Magnesium phosphoricum  D10 1mg 
 
Carrier 
Lactose-Monohydrat   297mg 
Magnesium stearate   1.5mg 
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5.6.2 Homeopathic Medicinal Products 
Modern definitions of homeopathic remedies tend to focus on what remedies 
are rather than how they are used.xiThe definition given in both the EU 
Directive for Medicinal Products (1992) and UK Statutory Instrument (SI 
1995/308) is as follows:xii 
 
Homeopathic medicinal product means a medicinal product (which may 
contain a number of principles) prepared from products, substances or 
compositions called homeopathic stocks in accordance with a homeopathic 
manufacturing procedure described by the European Pharmacopoeia or, in 
the absence thereof, by any pharmacopoeia used officially in an (EU) 
member state. 
 
The UK Medicines and Healthcare Products Regulation Authority (MHRA) 
and other European regulatory bodies use the term stocks for the starting 
solutions, usually mother tinctures, from which homeopathic potencies are 
prepared. 
 
In 1988 The German Health Ministry took the initiative to establish standards 
for the manufacture of homeopathic medicines and this led to the production 
of a European Pharmacopoeia in 2002. 
 
About 65% of all remedies are prepared from extracts of plant materials, and 
because of this homeopathy is often confused with herbalism by many 
people.  The difference lies in the manner of producing the two types of 
medicine.  Herbal products are generally the result of an aqueous or 
alcoholic extraction alone, whereas in homoeopathy an additional dilution 
process is involved.  Either the whole plant may be used or only the leaves, 
stems, flowers or roots as specified in the pharmacopoeia monographs.  The 
species of plants, the parts taken, the time of collection and the extraction 
procedures may well differ according to the particular pharmacopoeia being 
consulted.xiii 
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Animal and insect material must be obtained from healthy specimens.  
Biological materials from healthy animal or vegetable secretions or from 
bacterial cultures are made into remedies known as sarcodes.  If the remedy 
is derived from diseased tissue then the finished remedy is known as a 
nosode. 
 
‘Suis organ preparations (sarcodes) are homeopathic attenuations of 
wholesome organs or tissues obtained from healthy animals, in this case 
pigs.’ xiv 
 
Suis organs are said to act like ‘organ specific nosodes’ to create a 
stimulative treatment where damage has occurred to the organs and tissues 
in question.  These medications are claimed to be ‘particularly successful in 
treatment of degenerative damage as well as functional insufficiency of the 
organs.’ xv  The Suis organ preparations are said to ‘guide’ other active 
homeopathic substances in their presence to the corresponding targeted 
organ, thereby intensifying their efficacy. 
5.6.3 Preparation of remedies: 
5.6.3.1 Extraction 
Mother tinctures are the liquid preparations resulting from the extraction of 
suitable source material with alcohol/water mixtures which form the starting 
point for the production of most homeopathic remedies.  Comminution 
followed by standard percolation, maceration and squeezing techniques are 
used on fresh plants and succulents while dried specimens are subjected to 
percolation with alcohol. 
The resulting solutions are strained and can contain one part drug to three 
parts mother tincture, when the final tincture represents one tenth of the 
concentration of the original drug it is in effect a 1x dilution. 
With insoluble chemicals such as Aurum (gold), Plumbum (lead) or Sulphur 
the solid material must be triturated and serially diluted with lactose powder 
using a pestle and mortar in a precise and documented manner.xvi 
 
5.6.3.2 Potentisation 
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Most mother tinctures are subjected to a two stage process involving dilution 
and succussion, this process is known as potentisation.  The Hahnemanian 
method offers two scales of dilution, centesimal and decimal.  The remedies 
that make up Ovarium Compositum are in the decimal scales of dilution.  In 
modern pharmaceutical practice it is common to use a triple distilled alcohol 
and water system, the strength of which varies from 20 – 60%, in the 
preparation of homeopathic dilutions.  The solution resulting from a mixture of 
the two liquids is subjected to the vigorous shaking with impact known as 
succussion.   
After the initial processes, successive serial dilutions follow, using fresh glass 
vials at each stage, until the solution reaches 6x for example.  The process 
involves adding one drop to nine drops of dilutent.  The potencies are 
designated by a number with the letter ‘x’ following it.  Thus 6x represents a 1 
in 10 dilution carried out serially six times, each with a burst of succussion. 
In large scale manufacture homeopathic granules are medicated and then 
compressed to form the tablets in a process similar to allopathic 
manufacture. 
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Table Six: Decimal potencies 
Dilution Concentration Decimal Potency 
1:10 10-1 1x or D1 
1:100 10 -2 2x or D2 
1:1000 10 -3 3x or D3 
1:10 000 10 -4 4x or D4 
1:100 000 10 -5 5x or D5 
1: 1000 000 10 -6 6x or D6 
1: 10 30 10 -30 30x or D30 
 
5.6.4 Homeopathic Indications for the Individual Constituents 
 
Ovarium suis (ovary)   
 
The Biotherpeutic Index entry for Ovarium Compositum includes Ovarium 
suis with the following symptoms:  Disturbances of the ovarian function e.g. 
dysmenorrhoea, metrorrhagia, climacteric disorders. 
 
These indications are also found in the homeopathic literature xvii : 
‘Disturbances of the ovarian function, dysmenorrhoea, amenorrhoea, 
climacteric with manifestations of ovarian endocrine deficiency; 
hypermenorrhhoea, metrorrhagia, female sterility, climacteric neurosis with 
depression, nymphomania, delusional ideas of jealousy, kraurosis vulvae, 
mastodynia, and osteomalacia’. 
 
Placenta Suis (entire placenta)  
 
The Biotherpeutic Index entry for Ovarium Compositum includes Placenta 
Suis with the following symptoms:  Dysmenorrhoea, peripheral circulatory 
disturbances. 
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The attenuations of this sarcode are prepared using the whole placenta from 
the uterus of a healthy female pig (sus scrofa domesticus) with young.xviii  
 
Indications xix for use: Peripheral circulatory disorders, cutis marmorata, 
decubiutus, pernios, Buerger’s disease, ulcus cruris, rhagades, eczema, 
infolding of skin, sclerodermia, dysbasia intermittens, dysmenorrhoea, sural 
spasms, muscular rheumatism. 
A proving of this substance was conducted in the fall of 1994 by Dr David 
Riley.  Congruent Symptoms with Dr Reckeweg: 
• Disorders of the peripheral circulation 
• Prostration 
• Rheumatism 
• Cramps of the calf muscles 
 
 
Uterus Suis (uterus)  
 
The Biotherpeutic Index entry for Ovarium Compositum includes Uterus Suis 
with the following symptoms:  Dysmenorrhoea. 
 
The attenuations of this sarcode are prepared from the womb removed from 
healthy pigs (Sus scrofa domesticus).xx 
The main indications are: 
Uterine prolapsed.  Uterine fibroids.  Dysmenorrhoea.  Pre-cancerous state 
of the uterus.  Cervical erosion.  Female sterility.  Other degenerative 
diseases of the uterus. 
   
Salpinx Uteri Suis (Fallopian Tube)  
 
The Biotherpeutic Index entry for Ovarium Compositum includes Salpinx Suis 
with the following symptoms:  Dysmenorrhoea, sterility through inflammatory 
diseases of the salpinx uteri 
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The attenuations of this sarcode are prepared from the Fallopian tube 
removed from healthy pigs (Sus scrofa domesticus). 
The main indications are: 
Female sterility resulting from inflammatory disease of the Fallopian tube, 
(consequences of gonorrhoea, etc).  Disorders of ovulation, Dysmenorrhoea.  
Menopausal problems.xxi  
 
 
Cypripedium Pubescens - Lady’s Slipper  
 
The Biotherpeutic Index entry for Ovarium Compositum includes 
Cypripedium with the following symptoms:  Conditions of nervous irritability, 
insomnia with restlessness and twitching of the body. 
 
The mother tincture is prepared from the fresh rootstock, gathered in autumn, 
of the plant Cypripedium calceolus, var. Pubescens (Willd.) Corell., a native 
of North America. N.O. Orchidaceae. 
 
The main indications for the homeopathic dilution are: Abuse of Coffee.  
States of nervous irritation.  It’s listing as an ingredient of Ovarium 
Compositum states: Conditions of nervous irritation, insomnia with 
restlessness and twitching of the body.xxii  
 
Cypripedium is said to be particularly effective in nervous women, whose 
nerves are affected by illness or by abuse of tea or coffee.  (Impregnation 
phases according to the Disease Evolution Table see Appendix 2).  However 
it is also recommended in consequences of mental over-exertion, night 
watching and exhaustion of the nervous system in influenza. 
The German Monograph-Preparation Commission for the Homeopathic Field 
of Therapy has, under the Preparation Monograph for Cypripedium calceolus 
var. Pubescens, published the following indication in the German 
Bundesanzeiger (German Federal Gazette): Insomnia 
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Clarkexxiii  has the following information: Cypripedium has great repute as a 
‘nervine’ among eclectics, and in domestic practice.  For the female sphere it 
is indicated for Amenorrhoea, with hysterics, Great nervous debility and 
despondency, Irritability of vagina; hysterical symptoms, sleeplessness and 
agitation. 
 
 
 
Lilium tigrinum (Tiger Lily)  
 
The Biotherpeutic Index entry for Ovarium Compositum includes Lilium 
tigrinum with the following symptoms:  Uterus descensus, dysmenorrhoea, 
and nervous cardiac disturbances with anxiety, fluor albus. 
 
The mother tincture is prepared from the fresh aerial parts in flower of Lilium 
lancifolium Thunb., a native of China and Japan and often cultivated for 
decorative purposes. N.O. Liliaceae. 
 
The main indications arexxiv : Palpitations, squeezed sensation (similar to 
Cactus). Leucorrhoea.  Dysmenorrhoea.  Uterine prolapsed.  Left sided 
ophoritis.  Bearing down sensation.  Burning and heat in the palms of the 
hands and soles of the feet.  Pulsations throughout the body.  The German 
Monograph-Preparation Commission for the Homeopathic Field of Therapy 
has, under the Preparation Monograph for Lilium lancifolium, published the 
following indications in the German Federal Gazette) for lilium tigrinum: 
complaints associated with prolapsed of the uterus during menopause; 
inflammations and painful conditions of the female reproductive organs; 
nervous cardio circulatory complaints; irritable emotional discord or upset. 
 
 
Pulsatilla – Wind Flower/Meadow Anemone 
The Biotherpeutic Index entry for Ovarium Compositum includes Pulsatilla 
with the following symptoms:  Migrating Disorders (worse before menses), 
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delayed menses, dysmenorrhoea, remedy for affections of the mucosa, 
venous statis. 
 
The Mother Tincture is prepared from the whole fresh plant, gathered while in 
flower, of Pulsatilla pratensis Miller, which occurs in the mountains of Europe 
and Russia.  N.O. Ranunculaceae.xxv 
The tincture prepared from the Wind Flower, Pulsatilla Pratensis, contains 
protoanemonin (an antibiotic substance), tannin, resin and saponin, and 
shows typical therapeutic indications, which cover both psychic and somatic 
symptoms.   
Hans-Heinrich Reckeweg lists the following typical symptoms and 
indications: 
1. Aggravation in a warm room and in hot weather, amelioration in fresh air 
and waling about gently. 
2. Pulsatilla is usually indicated for female patients who are full of 
complaints. Inflammations and disorders of the female reproductive 
organs, vaginitis accompanied by purulent discharge. 
3. Disorders experienced during pregnancy and nursing. 
4. Consequences of suppressed gonorrhoea, or of suppressed leucorrhoea 
with orchitis or oophoritis. 
5. Concomitant catarrh of the bladder, cystitis. 
 
Aquilegia vulgaris (columbine)  
The Biotherpeutic Index entry for Ovarium Compositum includes Aqilegia 
with the following symptoms:  Disturbances of the menses, climacteric 
disorders. 
The mother tincture is prepared from the whole fresh plant in bloom.  
Aquilegia vulgaris L. N.O. Ranunculaceae. xxvi Menstrual disturbances, 
functional amenorrhoea, menopausal problems, depression during the 
menses. 
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Sepia (cuttlefish)  
The Biotherpeutic Index entry for Ovarium Compositum includes Sepia with 
the following symptoms:  Climacteric disorders, nervous exhaustion, 
depression, chronic inflammation of the uterus and adnexa. 
The attenuations are prepared from the dried secretion of the ink gland of the 
cuttlefish, Sepia officinalis L., which inhabits the Mediterranean, the North 
Sea and the Atlantic Ocean. N.O.Sepiidae.xxviiMenopausal complaints with 
hot flushes, emotional depression and irritability (alternating).  Tearfulness, 
hypersensitivity and indifference (to business and family).  General 
weakness, every movement causing outbreaks of sweating.  Feeling of 
faintness.  Yellowish-green leucorrhoea, offensive and excoriating in cervical 
erosion, menses mostly late and scanty, menopause.  
 
Lachesis (bushmaster)  
The Biotherpeutic Index entry for Ovarium Compositum includes Lachesis 
with the following symptoms:  Climacteric disorders (hot flushes) 
dysmenorrhoea. 
The attenuations are prepared from the careful dried venom of the snake, 
Lachesis mutus L., which occurs in Central and South America. N.O. 
Crotalidae.xxviiiThe homoeopath Dr. Constantine Hering investigated venom 
of Lachesis muta in 1892 in South America combining the known toxicology 
with a homeopathic proving.  It is used by homoeopaths as an ovarian 
remedy indicated for endometritis worse on the left side, menopause, ovarian 
dysfunction and especially hot flushes.     
Apisnum (bee venom)  
The Biotherpeutic Index entry for Ovarium Compositum includes Apisnum 
with the following symptoms:  Oedema, Ovarian cysts, dysmenorrhoea, 
ovarialgia, and metrorrhagia. 
The mother tincture is prepared from the whole honey bee, Apis mellifica L. 
N.O. Apidae.xxix 
Apis is indicated for right sided adnexitis and other kinds of right-sided 
inflammatory illnesses, inflammations and disorders with collection of fluid in 
tissues and cavities of the body. 
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Kreosotum (beech tar creosote)  
The Biotherpeutic Index entry for Ovarium Compositum includes Kreosotum 
with the following symptoms:  Catarrh of the mucosa with acrid secretions, 
pruritus vulvae, menorrhagia, metrorrhagia, hyperemesis. 
The attenuations are prepared from Cresosote, a mixture of Guaiacol, Cresol 
and Cresolene obtained by distillation of beechwood tar.xxx Creosote was 
formerly used allopathically as an anti-tubercular, antiseptic and styptic and 
especially in dyspepsia.  In dentistry creosote was used to serve as an 
additive to arsenic paste for the devitalisation of dental pulp.   Homoeopaths 
employ the homeopathic dilution of Kreosotum to treat widely varying 
mucosal conditions with offensive, acrid, excoriating discharges, carcinoma 
of the uterus, general haemorrhagic tendency and inflammations of the 
urinary and reproductive organs. 
 
 
Bovista  (Warted Puff-ball)   
The Biotherpeutic Index entry for Ovarium Compositum includes Bovista with 
the following symptoms:  Menorrhagia, dysmenorrhoea, venous 
haemorrhages. 
The attenuations are prepared from the dried ripe fungus Calvatia gigantean 
without its peridia, which grows in Central Europe in pastures and dry 
meadows everywhere.  N.O. Lycoperdaceae.xxxi  
Employed homeopathically to treat Menorrhagia, menses come too early, 
uterine bleeding. 
 
Ipecacuanha (ipecacuanha)  
The Biotherpeutic Index entry for Ovarium Compositum includes 
Ipecacuanha with the following symptoms:  Uterine haemorrhages, 
hyperemesis  
The mother tincture is prepared from the dried underground parts of 
Cephaelis ipecacuanha (Brot.) A. Rich., a plant growing in Brazil, India and 
Malaysia. N.O. Rubiaceaexxxii  
It is used to treat bright red gushing haemorrhages, menorrhagia and 
metrorrhagia. 
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Mercurius solubilis Hahnemanni (mixture containing essentially 
mercuroamidonitrate)  
The Biotherpeutic Index entry for Ovarium Compositum includes Mercurius 
with the following symptoms:  suppurations, acute and chronic affections of 
the connective tissue. 
The attenuations are prepared from mixture consisting essentially of mercury 
(II)-amidonitrate and metallic mercury xxxiii  it is used for the following 
indications: mucosal inflammations of the respiratory passages, the 
gastrointestinal tract, and the urinary and reproductive organs; skin diseases; 
inflammations of the tonsils, lymph glands, liver, and kidneys; inflammations 
of other glandular organs. 
 
Hydrastis Canadensis (golden seal)  
The Biotherpeutic Index entry for Ovarium Compositum includes Hydrastis 
with the following symptoms:  remedy for affectations of the mucosa; thick, 
ropy, yellowish-white secretions, menorrhagia, viscid, metrorrhagia, 
myomatous haemorrhages. 
The mother tincture is prepared from the dried rootstock, with roots attached, 
of the plant, Hydrastis Canadensis L., which occurs in shady mountain 
forests of Atlantic North America. N.O. Ranunculaceae. xxxiv  The preparation 
contains three alkaloids: hydrastine, berberine and meconin, apart from 
phytosterin, volatile oil and resins.  It is used by homoeopaths in diseases of 
the uterus with vaginal discharge. 
 
Acidum cis-aconiticum  (aconitic acid)  
The Biotherpeutic Index entry for Ovarium Compositum includes Acidum cis 
–acniticum with the following symptoms:  active factor of the citric acid cycle 
and of redox systems. 
The attenuations are prepared from cis-aconitic acid, 
COOHCHC(COOH)CH2COOH.  
M.W: 174.2xxxv  
As with all catalysts of the citric acid cycle, aconitic acid too shows and 
affinity for internal respiration.  The drug picture of cis-Aconiticum Acidum 
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was composed in September 1996 by David Riley, M.D., Santa Fe (New 
Mexico), USA and includes: Pain at menses improving, sensation as if 
menses would come on. 
 
Magnesium phosphoricum (magnesium phosphate)  
The Biotherpeutic Index entry for Ovarium Compositum includes Magnesium 
phosphoricum with the following symptoms:  dysmenorrhoea, tendency to 
cramps and neuralgia. 
The attenuations are prepared from Magnesium hydrogen phosphate 
trihydrate. MgHPO4.3H2O, MW:174.3xxxvi  The triturations and liquid potencies 
prepared from magnesium phosphate are according to Heinigke, ‘one of our 
most important pain remedies..’,. 
Magnesium phosphoricum is also an important remedy in dysmenorrhoea 
and when the menses arrive too early, especially when there is swelling and 
sensitivity of the vagina and so called ovarian neuralgia. 
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5.7 SAFETY & TOLERABILITY 
5.7.1 Global evaluation of toxicity 
The manufacturer (Heel) commissioned an expert report on Ovarium Compositum, this 
report concluded that ‘The current scientific fundamentals and the clinical experiences did 
not reveal serious signs to suspect the containing amount of all homeopathic dilutions for 
causing toxicological risks.’xxxvii  The following data is from that report, (Appendix 3). 
 
5.7.2 Reproductive Function  
Results from direct studies of reproductive or teratogenic toxicity as well as 
fetotoxic side effects influencing fertility are not available. Researching the 
literature produced no hint for such risks 
5.7.3 Embryo-Foetal and Peri-Postnatal Toxicity  
6. Results from direct studies of embryo toxic/ fetotoxic or peril-, postnatal toxicity are 
not available. Researching the literature produced no suggestion of such risks. 
 
5.7.4 Mutagenic Potential  
Results from direct studies of mutagenic toxicity are not available. 
Researching the literature produced no hint for such risks. 
 
5.7.5 Carcinogenic Potential  
Results from direct studies of carcinogenicity are not available. Researching 
the literature produced no hint for such risks. 
 
5.7.6 Immunotoxicity  
No indications show that the effects of single components of Ovarium 
Compositum injection are sensitising or will provoke allergic reactions by the 
parenteral application. Possible risks or adverse drug reactions of parts or 
components of the plants have not been observed regarding the 
pharmacovigilance of the compounds of Ovarium Compositum or similar 
composed drugs. 
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5.7.7 Interactions  
There are no hints that the effects of single components of the incorporated 
homeopathic dilutions and substances may be enhanced or inhibited by 
incorporated drugs or substances which interfere with their characteristic 
pharmacodynamic or toxicologic effects. Potential risks or interactive effects 
associated with the combined administration of the incorporated homeopathic 
dilutions have not been substantiated in drug surveillance studies and 
pharmacovigilance on the use of the incorporated drugs in human. 
 
5.7.8 Pharmacovigilance 
 The drug safety of Ovarium Compositum tablet can also be shown by 
observing pharmacovigilance data, which have been determined by a 
dispensing of a formula with the same composition. The components showed 
identical finishing dilutions. Consequently the dispensing carried the same 
risk potential.  
 
 Within the framework of the supervision of drug safety no adverse event was 
reported since 1998 (745.510 ampoules delivered only in Germany), globally 
seen. This result is striking for the good safety profile of Ovarium 
Compositum. This result of the pharmacovigilance points out that adverse 
drug reactions after parenteral application of the homeopathic dilution in 
Ovarium Compositum tablet are a rarity and that this preparation cannot be 
related to an increased risk especially concerning the gastro-intestinal, 
cardiovascular or central-neurogenic body organ system or the skin. 
 
5.7.9 Conclusions 
  The scientific findings material and the clinical experiences do not reveal any 
indications concerning toxicological risks caused by components of the 
homeopathic drug Ovarium Compositum if the speciality is applied 
according to a recommended dosage of the manufacturer. 
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  Components of an immunotoxicological potential are included with a very 
small concentration. Consequently, a corresponding risk during treatment 
does not need to be taken into account.  
 
5.8. ADVERSE EVENTS 
During a clinical study, onset of Adverse Events may occur.  An AE is defined as any 
untoward medical occurrence in a patient or clinical investigation subject administered a 
pharmaceutical product and that does not necessarily have a causal relationship with this 
treatment (where ‘treatment’ includes also all investigational agents such as comparative 
agents and placebo).  An adverse event can therefore be any unfavourable and unintended 
sign (including abnormal laboratory finding, see Section 5.7.2), symptom, or disease.  
All adverse events encountered during the clinical study are to be reported on the Adverse 
Event Forms contained in the Case Report Form (CRF).  For each adverse event which 
occurs during the clinical study the Principal Investigator will give a judgment on its severity 
and make a causality assessment of the treatment using one of the four given definitions: 
certainly related, probably related, possibly related and definitely unrelated.  Moreover, the 
Principal Investigator will indicate the action to be taken for the adverse event that has 
occurred and its outcome.  In the case of an adverse event, the trained medical personnel 
will act with appropriate diagnostic and therapeutic measures until the subject has 
recovered.  Adverse events will be classified as ‘serious’ and ‘non serious’.  All this 
information will be recorded for each adverse event on the Adverse Event Form of the CRF.  
Detailed information on the compilation of the Adverse Event Form is available in Appendix 
1. 
 
5.8.1 Serious Adverse Events 
A Serious Adverse Event is defined as any untoward medical occurrence that at any dose: 
results in death; is life-threatening; requires inpatient hospitalisation or prolongation of 
existing hospitalisation; results in persistent or significant disability/incapacity; is a congenital 
anomaly/birth defect or any other event which is considered clinically/medically significant. 
As Grade 3 or 4 toxicities (based on the Common Toxicity Criteria (CTC v3.0) are 
considered clinically/medically significant, they will be classified as serious adverse events. 
 
Serious adverse events will be reported to the Principal Investigator and the Sponsor (see 
Section 8) within 24 hours. The 24 hours emergency contact numbers are listed on page iii 
of this protocol.   
 
Serious adverse events will also be reported to: 
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Barts & The London School of Medicine and Dentistry, Joint Research Office. 
Central Office for Research Ethics Committees (COREC) approved 
Research Ethics Committee (the responsibility of the investigator) as soon as 
possible, but in any case within 72 hours.  
 
All available information will be provided, referring to the Serious Adverse Event paragraph 
of the Reporting Adverse Events document (Appendix 1). The Investigator will complete the 
Serious Adverse Event Form by carefully following the relevant instructions (Appendix 1) and 
will fax it within 24 hours to the Sponsor. 
The Investigator, and others responsible for subject care, should institute any supplementary 
investigations of serious adverse events based on their clinical judgment of the likely 
causative factors. This may include seeking further opinion from a specialist in the field of the 
adverse event. The Sponsor may also request extra tests. If a subject dies, any post-mortem 
findings (including histopathology) if available, will be provided to the Sponsor. No medical 
help, diagnosis, or advice, should be withheld from the subject due to an inability to contact 
the Sponsor. 
If a serious adverse event (including a Grade 3 or 4 toxicity), occurs, no further dosing of the 
subjects will occur until the cause of the event and its relationship to the study drug has been 
clarified. Continuation of the trial will be contingent upon approval from an independent 
safety review Committee. 
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5.8.2 Non Serious Adverse Events 
A non-serious adverse event is one, which does not meet any of the criteria listed in the 
Section 5.7.1.1 defining serious adverse events, which is otherwise judged by the 
Investigators as significant. 
If a non-serious adverse event occurs, the Investigator will fill in one Adverse Event Form for 
each adverse event describing its complete evolution to the outcome. Therefore the 
assessment of severity, frequency and causality will be given at the event outcome. The 
completed Adverse Event Form will be sent to the Sponsor. 
During a clinical study, an adverse event previously reported as a non-serious event may 
change becoming, upon the Investigator’s clinical judgment, a serious adverse event (i.e. 
dramatic worsening with hospitalisation etc.). At this moment, the Investigator will follow 
directions for reporting a serious adverse event. 
 
 
5.9 WITHDRAWALS AND DROP-OUTS 
During the study, treatment may be discontinued for many reasons such as the occurrence 
of a disease, an adverse event that could interfere with the subject’s evaluation, or simply 
upon the subject’s request to discontinue for any reason. Intercurrent medical events that do 
not interfere with either continued administration of study drug or scheduled testing, and that 
are judged by the Investigator to not have an effect on the outcome measures will not 
disqualify a subject from continuing in the study. If a subject is withdrawn from the study 
because of an adverse event, treatment discontinuation must be explained on the Adverse 
Event Form of the CRF, and this subject will be followed-up to the satisfaction of the 
Principal Investigator, and a withdrawal visit scheduled where possible. 
Subjects will be advised that they are free to withdraw from the study at any time for any 
reason or, if necessary, the Investigator may withdraw a subject from the study to protect the 
subject’s health. The Investigator may withdraw a subject from the study if it is considered 
that the scientific, and therefore, ethical standards of the study are compromised.  Subjects 
may also be withdrawn for not complying with study procedures.  The reasons for withdrawal 
will be fully recorded on the CRF. Subjects who withdraw or are withdrawn from the study for 
any reason other than toxicity will be replaced to ensure sixty (60) subjects. Subjects who 
are withdrawn because of serious adverse events (including a Grade 3 or 4 toxicity (based 
on the Common Toxicity Criteria (CTC) version 3.0) will not be replaced. The Ethics 
Committee will be notified in writing of any study withdrawals that may occur as a result of 
toxicity.  
 
6. Case Report Form (CRF) 
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6.1 PRESENTATION OF THE CRF 
The CRF to be used for the study consists of pages that contain within the header or footer 
the Protocol number, subject initials, subject number and other relevant information. It is 
composed of an introductory section for the selection and inclusion of subjects in the study 
and a section for the treatment period. Contained within the treatment period section are the 
forms for registration of possible adverse events and for any suspension of the study. 
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6.2 HOW TO USE THE CRF 
All CRFs will be completed using a ball-point pen with black ink. All unused CRFs for drop-
outs must be retained. 
 
All requested information must be entered on the CRFs. If an item is not available or is not 
applicable, this fact should be indicated; there should be no blank spaces. Corrections 
should be made by striking through the incorrect entry with a single line and by entering the 
correct information adjacent to it. The correction must be initialled and dated by an 
Investigator or a designated qualified individual. Each set of completed CRFs must be 
reviewed, signed and dated by an Investigator. The completed original CRFs are to be 
returned to the Sponsor as soon as is practicable after completion and review. A photocopy 
of each completed CRF is to be retained by the Investigator. 
 
7. Data Management 
All data management procedures will be detailed and referred to as the Data Management 
Plan. All data will be entered and checked by a second person.  
The database will be designed and built by research team using Microsoft Excel. Appropriate 
Case Report Forms (CRFs) will be prepared for the collection of the data requested by the 
Protocol. All response variables will be entered into the database by the data management 
personnel. 
 
8. Monitoring & Quality Assurance 
The conduct of the study will be monitored by the Investigators, and if 
required by a representative of the sponsor in accordance with the GCP 
Guidelines. The investigator will co-operate fully with any study monitors and 
auditors. 
The organisation, monitoring, and quality assurance of the present clinical study is the 
responsibility of the Sponsor. 
 
In order to ensure the accuracy of data, direct access to source documents by the 
representatives of both the Sponsor is mandatory. Anonymity of the subject will be 
maintained at all times. 
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9. Study Completion or 
Discontinuation 
Upon completion of the study, the following activities, when applicable, must be conducted 
by the Investigator Investigators, as appropriate: 
• Return of all study data to William Harvey Research Institute. 
• Data clarifications and/or resolutions. 
• Accounting, reconciliation, and final disposition of used and unused study drugs.  
• Unused investigational product will be returned destroyed in line with local policy.  
• Review of site study records for completeness. 
In addition, Barts & The London School of Medicine and Dentistry and the Principal 
Investigator reserve the right to temporarily suspend or prematurely discontinue this study for 
any reason. If such action is taken, Barts & The London School of Medicine and Dentistry 
will discuss this with the Investigator (including the reasons for taking such action) at that 
time. If the study is terminated for safety reasons, Barts & The London School of Medicine 
and Dentistry will promptly inform the regulatory authorities of the suspension or termination 
of the study and the reason(s) for the action. The Investigator must inform the Ethics 
Committee promptly and provide the reason for the suspension or termination. After such a 
decision, the investigator must call in all participating subjects within a reasonable time 
period. At this visit all Medical Files and Case Report Forms must be completed as far as 
possible. 
If the study is prematurely discontinued, all study data must be returned to William Harvey 
Research Institute. In addition, the site must conduct final disposition of all unused study 
drugs in accordance with Barts & The London School of Medicine and Dentistry procedures 
for the study. 
 
10. Investigator Responsibility 
Except where the Principal Investigator’s signature is specifically required, it is understood 
that the term ‘Investigator’ as used in this Protocol and on the CRFs refers to the Principal 
Investigator or a designated member of the staff that the Principal Investigator designates to 
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perform specified duties of the Protocol. The Principal Investigator is ultimately responsible 
for the conduct of all aspects of the study.  
 
 
11. Study Report 
The Final Report shall include the data from the Clinical Summary prepared by the statistical 
data.  The Final Report will be reviewed and signed by the Investigator(s). 
 
12. Administrative Procedures 
12.1 ETHICAL CONSIDERATIONS 
The study will be conducted in accordance with the principles of the 
Declaration of Helsinki (Recommendations guiding Medical Doctors in 
Biomedical Research Involving Human Subjects). 
 
12.2 ETHICAL REVIEW COMMITTEE 
The Protocol, Consent Forms and Subject Information Sheet will be submitted to a Central 
Office for Research Ethics Committees (COREC) approved Research Ethics Committee 
before volunteers are recruited and subjects are enrolled. The Investigators will receive all 
the documentation needed for submitting the present Protocol to the Ethics Committee. No 
study activities will be initiated until the written approval of that Committee is received. A 
copy of the respective approval letters will be transmitted to the Sponsor before starting the 
study.  The composition of the Ethics Committee will also be provided to the Sponsor.  If 
approval is suspended or terminated by the Ethics Committee, the Investigator will notify the 
Sponsor immediately. 
It is the responsibility of the Investigator to report study progress to the Ethics Committee as 
required or at intervals not greater than one year. 
The Investigator will be responsible for reporting any serious adverse events to the Ethics 
Committee as soon as possible and in any event within 72 hours. 
 
12.3  REGULATORY AUTHORITIES 
The Clinical Trial Authorisation (CTA) requirements of the Medicines and Healthcare 
Products Regulatory Authority (MHRA) will be met before commencement of the study.  
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The Principal Investigator will report all serious adverse events to the Sponsor. The Sponsor 
will be responsible for reporting all serious adverse events to the MHRA and other 
appropriate agencies. The MHRA only requires notification of serious adverse events which 
are unexpected and deemed to be related to the study medication.  Fatal or life-threatening 
unexpected adverse events will be notified to the Sponsor and MHRA as soon as possible 
but no later than 7 calendar days after first knowledge by the Sponsor that a case qualifies, 
followed by as complete a report as possible within 8 additional calendar days.  Serious, 
unexpected adverse events that are not fatal or life threatening shall be filed as soon as 
possible but no later than 15 calendar days. Serious adverse events that are unrelated to the 
study medication shall be included in the end of study report. 
 
12.4  INFORMED CONSENT  
Before enrolment into the study, subjects will be fully informed of the nature of the study, the 
properties and side effects of the study drug, and all relevant aspects of study procedures. 
Subject information is provided predominantly by the medical investigator during recruitment. 
Each prospective candidate will be provided with the Privacy Information and the Information 
for Volunteers Sheet and Informed Consent Forms. At the pre-study screening evaluation 
visit, volunteers will be required to sign an Informed Consent Form. Consent Forms shall be 
signed and dated by the appropriate parties. A notation that written informed consent has 
been obtained will be made on the subject’s CRF. Completed Consent Forms will be 
retained by the Investigator and a copy of this will be provided by the Investigator to the 
subject. The Informed Consent Form is included as part of the submission to the Ethics 
Committee. 
 
12.5 SUBJECT DATA PROTECTION 
Subjects will be informed that their data are held on file, that these data may be viewed by 
Sponsor on behalf of the sponsor and by external auditors on behalf of either the sponsor or 
regulatory agencies. They will similarly be informed that this data and a report of the study 
will be submitted to the Sponsor and may also be submitted to government agencies and 
perhaps for publication, but that they will only be identified in such reports by their study 
identification number, initials and perhaps their gender and age. The investigators undertake 
to hold all personal information in confidence 
Investigator(s).  
12.6 EMERGENCY CONTACT WITH INVESTIGATORS  
Suitable arrangements will be made for subjects to contact the Investigators in the event of 
an emergency. All subjects will be provided with a telephone number with details of whom to 
contact in the case of an emergency. 
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12.7 NOTIFICATION OF PRIMARY CARE PHYSICIAN  
With the consent of the volunteer, it is the Investigator’s responsibility to notify the primary 
care physician (if applicable) of the subject’s participation in the study by sending a letter 
stating the nature of the study, the treatment, expected benefits, the most common adverse 
drug events observed in previous studies and concomitant drugs to be avoided. A copy shall 
be retained by the study site for verification by the Sponsor. The primary care physician may 
contact the Investigator for any further information regarding the subject’s participation in the 
study.  
 
12.8 INVESTIGATOR INDEMNIFICATION  
Indemnity will be provided by Queen Mary, University of London and the Barts & The London 
NHS Trust. 
 
 
The study Sponsor will ensure sufficient insurance is available to enable it to indemnify and 
hold the investigator(s) and relevant staff as well as any hospital, institution, ethics 
committee or the like, harmless from any claims for damages for unexpected injuries, 
including death, that may be caused by the study drug but only to the extent that the claim is 
not caused by the fault or negligence of the subjects or investigator(s). 
   
12.9 FINANCIAL ASPECTS  
The conduct of the study is subject to financial support from  
 
Biologische Heilmitte Heel GmbH 
Dr Reckeweg-Str.2-4 
76532 Baden-Baden 
Deutschland 
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12.10 INFORMATION DISCLOSURE AND INVENTIONS 
12.10.1 Ownership 
All data and records provided by the William Harvey Research Institute or generated during 
the study (other than a subject’s medical records) and all inventions discovered in the course 
of conducting the study are the property of the William Harvey Research Institute. If a written 
contract for the conduct of the study, which includes ownership provisions inconsistent with 
this statement is executed, that contract’s ownership provisions shall apply rather than this 
statement. 
 
12.10.2 Confidentiality 
The Investigator and other study site personnel will keep confidential any information 
provided by the William Harvey Research Institute (including this protocol) related to this 
study and all data and records generated in the course of conducting the study, and will not 
use the information, data, or records for any purpose other than conducting the study. These 
restrictions do not apply to: information which becomes publicly available through no fault of 
the investigator or study site personnel; information which it is necessary to disclose in 
confidence to an Ethics Committee solely for the evaluation of the study; information which it 
is necessary to disclose in order to provide appropriate medical care to a study subject, or 
study results which may be published as described in Section (x) If a written contract for the 
conduct of the study, which includes confidentiality provisions inconsistent with this 
statement, is executed then that contract’s confidentiality provisions shall apply rather than 
this statement. 
 
12.10.3 Publication 
Prior to submitting for publication, presenting, using for instructional purposes or otherwise 
disclosing the results of the study, the Investigator requires written permission from the 
William Harvey Research Institute.  Following permission for publication, presenting, using 
for instructional purposes or otherwise disclosing the results of the study, the Investigator 
shall allow a period of at least sixty (60) days (or, for abstracts, at least fifteen (15) working 
days) to review the proposed publication or disclosure prior to its submission for publication 
or other disclosure.  The William Harvey Research Institute must approve final copies of 
publications, presentations, and uses for instructional purposes or otherwise disclosing the 
results of the study prior to submission.  Publications or disclosures of study results shall not 
include other, confidential information of the William Harvey Research Institute. If the 
proposed publication/disclosure risks the William Harvey Research Institute’s ability to patent 
any invention related to the study, the publication or disclosure will be modified or delayed, at 
the William Harvey Research Institute’s option, to allow the William Harvey Research’s to 
seek patent protection of the invention. If a written contract for the conduct of the study which 
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includes publication provisions inconsistent with this statement is executed, that contract’s 
publication provisions shall apply rather than this statement. 
 
12.11 PROTOCOL AMENDMENTS  
Neither the Investigator nor the William Harvey Research Institute will modify the Protocol 
without first obtaining the concurrence of the other in writing. Protocol modifications that 
impact on subject safety or the validity of the study will be approved by the Ethics 
Committee. No changes (amendments) to the Protocol may be implemented without prior 
approval from the Sponsor and the appropriate Ethics Committee. If a Protocol amendment 
requires changes in an informed consent form, the revised informed consent form prepared 
by the Investigator must be approved by the Ethics Committee. 
 
Once the final Protocol has been issued and signed by the Investigator and the authorized 
signatories, it shall not be informally altered. Protocol amendments are alterations to a legal 
document and have the same legal status. Therefore they must pass through appropriate 
steps before being implemented.  In general, any important change which theoretically 
increases risk to subjects constitutes an amendment. Minor changes of a purely 
administrative nature need documentation and advice to the committee, but may be 
implemented without prior approval. 
 
It is the responsibility of the Investigator to submit the amendment to the Ethics Committee 
for their approval; written approval should be obtained and a copy provided to the Sponsor. 
The Sponsor is responsible for determining whether or not the local regulatory authority must 
be notified of the Protocol change. Completed and signed Protocol amendments will be 
circulated to all those who were on the circulation list for the original Protocol. 
 
The original signed copy of amendments will be kept in the Study File with the original 
Protocol. It should be noted that where an amendment to the Protocol substantially alters the 
study design or the potential risks to the subjects, each subject’s consent to continue 
participation should be obtained. 
 
12.12 PROTOCOL COMPLIANCE 
The instructions and procedures specified in this Protocol require diligent attention to their 
execution. Should there be questions or consideration of deviation from the Protocol, 
clarification will be sought from the Principal Investigator and Sponsor. Any subject treated in 
a manner that deviates from the Protocol, or who is admitted into the study but is not 
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qualified according to the Protocol as amended by the William Harvey Research Institute and 
the Investigator, may be ineligible for analysis and thereby compromise the study. 
 
Only when an emergency occurs that requires a departure from the Protocol for an individual 
will there be such a departure.  The nature and reasons for the Protocol violation shall be 
recorded in the CRF. 
 
The Investigator and designees will comply with all applicable federal, state and local laws. 
 
12.13 ARCHIVES: RETENTION OF STUDY RECORDS 
All source documents, CRFs and trial documentation will be kept by the Investigator for at 
least 15 years after the study completion. 
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Glossary of Terms 
 
 
FSH   Follicle Stimulating Hormone 
LH   Luteinizing Hormone 
IUI   Interuterine insemination 
PCOS   Polycystic Ovary Syndrome 
ICSI   Intra-cytoplasmic sperm injection 
IVF   Invitro fertilisation 
GnRH   Gonadotrophin releasing hormone 
GnRHantag  Gonadotrophin releasing hormone agonist 
CAM   Complementary and Alternative Medicine 
EHIQ   Emotional health in infertility questionnaire 
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Appendices for Protocol 
Appendix 1: Reporting Adverse Events 
Appendix 2: The Disease Evolution Table 
Appendix 3:  Expert Report on Ovarium Compositum 
Appendix 4: Oxford Fertility Questionnaire 
Appendix 5: Certificate of Good Manufacturing Standards 
Appendix 6: The EQ-5D 
Appendix 7 Protocol Amendments 
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Appendix 1 
Reporting Adverse Events 
All Serious Adverse Events will be reported in accordance with the 
local policies of the Sponsor organisation. 
DEFINITIONS 
 
ADVERSE EVENT/ADVERSE DRUG REACTION 
 
An adverse event (AE) is defined as any untoward medical occurrence in a 
patient or clinical investigational subject administered a pharmaceutical 
product and that does not necessarily have a causal relationship with this 
treatment (where ‘treatment’ includes also all investigational agents such as 
comparative agents and placebo).  An AE can therefore be any unfavourable 
and unintended sign (including abnormal laboratory finding), symptom, or 
disease temporally associated with the use of a medicinal (investigational) 
product, whether or not related to the medicinal (investigational) product. 
 
In the case of an investigational medicinal product, worsening of the 
pathology under study must be considered an AE only if unexpected in terms 
of timing or severity; in such a case, the AE form will be filled as usual.  If on 
the contrary, the worsening is considered an expected episode of the natural 
history of the disorder, it will be reported as a treatment failure.   
 
Worsening of a concurrent or pre-existing disorder will be reported as an AE.   
 
All noxious and unintended responses to a medicinal product related to any 
dose should be considered an Adverse Drug Reaction (ADR).  The phrase 
‘responses to a medicinal product’ means that a causal relationship between 
a medicinal product and an AE is at least a reasonable possibility, i.e. the 
relationship cannot be ruled out. 
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UNEXPECTED ADVERSE DRUG REACTION 
 
An unexpected adverse reaction is one for which the nature of its severity is 
not consistent with the applicable product information (e.g. Investigator’s 
Brochure for an unapproved investigational medicinal product).  Therefore, 
this definition involves events previously unobserved or undocumented, i.e. 
expected/unexpected from the perspective of previous observations, not only 
on the basis of what might be anticipated from the pharmacological 
properties of a medicinal product. 
 
SERIOUS ADVERSE EVENTS 
 
A Serious Adverse Event (SAE) is defined as any untoward medical 
occurrence that at any dose: results in death; is life-threatening; requires 
inpatient hospitalisation or prolongation of existing hospitalisation; results in 
persistent or significant disability/incapacity; is a congenital anomaly/birth 
defect or any other event which is considered clinically/medically significant. 
As a Grade 3 or 4 toxicity (based on the Common Toxicity Criteria (CTCv3.0) 
is considered clinically/medically significant, they will be classified as serious 
adverse events. 
 
The term ‘life-threatening’ refers to an event in which the patient is at real risk 
of death at the time of the event, it does not refer to an event, which 
hypothetically might have caused death if it were more severe. 
 
Medical and scientific judgment should be exercised in deciding whether 
other situations, such as important medical events that may not be 
immediately life-threatening or result in death or hospitalisation, but may 
jeopardise the patient or may require intervention to prevent one of the other 
outcomes listed in the definition above should also usually be considered 
serious.  Examples of such events are intensive treatment in an emergency 
room or at home for allergic bronchospasm, blood dyscrasias, or convulsions 
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that do not result in hospitalisation, or development of drug dependency or 
drug abuse. 
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INSTRUCTIONS FOR COMPLETING THE ADVERSE EVENTS FORM 
 
The Adverse Events Form must be fully reviewed by the Principal 
Investigator. 
For each AE the following information must be entered in the AE Form by the 
Principal Investigator or his/her designated nominee (including nursing staff): 
subject initials; subject number; treatment at the time of event; description of 
the event; source; onset; frequency; severity; action taken; outcome; 
duration; resolution or death and duration. 
 
 
DESCRIPTION 
Record a clear and concise description of the AE. 
 
SOURCE 
Record from whom the AE has been reported. 
 
ONSET OF THE AE 
Record both the time and date of the onset of the AE. Time shall be recorded 
in 24 hour time, and date in DD/MMM/YY format. 
 
FREQUENCY 
Record the frequency of the AE as either a single episode, intermittent or 
continuous. 
 
SEVERITY 
In order to indicate the severity of the event, the following guidelines should 
be followed: 
Mild: if well tolerated by the patient; patient is capable of carrying out 
everyday activities without any reduction in posology, or interruption or 
discontinuation of the study drug, or necessity of specific treatment of the 
event.  
Moderate: if poorly tolerated by the patient; patient has difficulty in carrying 
out day-to-day activities; it may be necessary to reduce the posology of the 
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study drug, or to interrupt or discontinue its administration, or to initiate 
specific treatment for the event. 
Severe: if it is impossible for the patient to carry out everyday activities, 
imposes discontinuation of the study drug and the implementation of specific 
therapy for the event.  The term ‘severe’ refers to the intensity of the event, 
not to its seriousness.   
 
ACTION TAKEN 
Any action taken in response to the AE shall be documented (none, study 
drug dose adjusted, study drug interrupted, study drug discontinued, 
concomitant medication administered, other). Any changes to the study 
treatment should be recorded in the ‘Additional Comments’ section, in which 
all dates, times and doses shall be reported. All entries in the ‘Additional 
Comments’ section shall be initialled and dated.  
 
OUTCOME OF THE EVENT 
Document whether the AE has been resolved, unresolved, or resulted in 
death. 
 
RESOLUTION OR DEATH 
Record both the time and date of the resolution of the AE or death. Time 
shall be recorded in 24 hour time, and date in DD/MMM/YY format. In the 
case of death a specific form must be completed 
 
a. If death is the outcome of an AE, it must be clearly defined and 
exhaustively described. 
b. If death is not related to an already-known event, the Investigator must 
report the supposed or ascertained cause(s). 
c. If autopsy has been carried out, the findings must be reported. 
d. If the test drug was administered at the time of death, this must be 
recorded or the precise time prior to death when treatment with study 
drug ended. 
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e. The Investigator must make a judgment as to the relationship between 
death and the test drug (certainly, probably, possibly, definitely 
unrelated). 
 
 
DURATION 
The duration of the AE shall be recorded in days, hours, minutes and 
seconds. In the case of an intermittent AE, the mean duration of each 
episode should be reported. 
 
REVIEW OF THE EVENT 
The Principal Investigator may complete the interim review, if required, and 
must conduct a final review of the AE. 
 
If possible, the Principal Investigator should indicate the AE as a diagnosis 
rather than a description. The Principal Investigator shall also include the 
affected body system in the final review section, and complete the sections: 
‘Event Expectation’ and ‘Relationship to Study Treatment’. 
 
 
EVENT EXPECTATION 
An unexpected AE, is one for which the nature of its severity is not consistent 
with the applicable product information (e.g., Investigator’s Brochure or 
Product Information sheet), and includes AEs that have not been previously 
documented or observed. 
 
 
RELATIONSHIP TO STUDY TREATMENT  
The correlation between the AE observed and the drug administered before 
onset is to be annotated according to the following evaluations: 
 
Certainly Related:  
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a) the event is observed within a reasonable time period after administration 
of the drug; 
b) the event occurs with a clinical presentation already known for the drug 
under study; 
c) suspension of the drug is followed by resolution or improvement in the 
event (positive dechallenge);  
d) After renewed administration of the drug, signs and symptoms previously 
observed reappear (positive rechallenge). 
 
Probably Related:  
a) the event is observed within a reasonable time period after administration 
of the drug; 
b) the event occurs with a clinical presentation already known for the drug 
under study; 
c) suspension of the drug is followed by resolution or improvement in the 
event (positive dechallenge); 
d) The event cannot be satisfactorily explained by the clinical condition of 
the patient, by concomitant drug treatment, or by any other factor. 
 
Possibly Related: 
a) the event is observed within a reasonable time period after administration 
of the drug; 
b) the event occurs with a clinical presentation already known for the drug 
under study; 
c) The event can be satisfactorily explained by the clinical condition of the 
patient, by concomitant drug treatment, or by any other factor. 
 
Definitely Unrelated:  
a) An event can be considered definitely unrelated to the drug when none of 
the above referenced criteria is satisfied. 
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Appendix 2 for Protocol 
Disease Evolution Table 
 
The Six Phase Table of homotoxicosis, first developed by Reckeweg and later expanded to 
include more detail (Disease Evolution Table)  is a coordinate system showing the 
relationship between the degree of ‘clogging’ of the intercellular matrix and possible health 
consequences.  The Table’s six columns show increasing toxin loads (on the vertical axis) in 
relationship to the disturbance they cause in the different organs (on the horizontal axis).  
Progression of the patient’s illness (progressive vicariation) is tracked from left to right, 
improvement (regressive vicariation) from right to left.  xxxviii  
 
To better understand the rationale and methods for Homotoxicology it is helpful to define 
what toxins are: Any agent (physical, chemical, microbial, etc.) that adversely modifies or 
damages a balanced biological system is considered a ‘toxin’.xxxix   Toxins may originate from 
within or without the body.  Examples of exogenous toxins are recreational drugs, cosmetics, 
food additives, gaseous pollutants, metals, agricultural chemicals, plasticizers and PBBE’s.  
Examples of endogenous toxins include accumulations of adrenalin and histamine. 
 
Modern medicine is successful in diagnosing and treating acute intoxications as medical 
emergencies for heavy metal poisoning, drug poisoning etc.  However subclinical states of 
chronic intoxications are not recognised. 
 
Subclinical states of intoxication are of great importance to biological medicine, as well as 
recognition of the variation in individual’s susceptibility to specific toxins. 
 
‘The clinical manifestations of biological effects of toxins depend upon the physical and 
chemical properties of the toxin itself, but also on the duration and route of exposure, it’s 
mechanism of action, and obviously on the individual susceptibility..'xl 
 
 
According to the theory of Homotoxicology the body deals with homotoxins essentially in six 
different ways.  The six phases are assigned to three groups of two (the humoral, the matrix 
and the cellular phases), which are divided halfway through the matrix phase by the 
regulation/compensation division.  Once this division is crossed, it indicates that the toxins or 
their effects are evolving from extracellular to intracellular. 
 
The humoral phases include the excretion and the inflammation phases.  They are 
characterised by repeated attempts by the body to achieve elimination.  The intracellular 
structures remain intact; although we see that numerous cells may be lost in the 
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inflammation process but will later be replaced by intact, healthy cells.  There is a 
spontaneous trend towards improvement. 
 
The matrix phases include the deposition and impregnation phases.  The diseases in these 
phases occur at the basic substance level (Ground Regulation System or Extra Cellular 
Matrix). 
It is in these phases that the step from extra cellular to intra cellular homotoxin presence or 
effect occurs.  The properly regulated extra cellular matrix is seen as fundamental in the 
promotion of health and the protection against an evolution into chronic disease. 
 
The cellular phases consist of the degeneration and neoplasm phases or dedifferentiation 
phases.  They are on the other side of the biological division.  This means that intoxication 
has taken place not only between the cells but also inside the cells.  Cellular functions are 
progressively inhibited up to the point of destruction. 
 
 
The Disease Evolution Table (DET) allows us to form a conceptual model for understanding 
the severity of a disease (level of intoxication) and the body’s reaction to this intoxication. 
 HUMORAL PHASES MATRIX PHASES CELLULAR PHASES 
Organ system Excretion 
Phases 
Inflammation 
Phases 
Deposition 
Phases 
 
Impregnation 
Phases 
Degeneration 
Phases 
Dedifferentiation 
Phases 
Skin Episodes of 
sweating 
Acne Naevi Allergy Scleroderma Melanoma 
Nervous 
system 
Difficulty 
concentrating 
Meningitis Cerebrosclerosis Migraine Alzheimer’s 
disease 
Gliosarcoma 
Sensory 
System 
Tears, 
otorrhea 
Conjunctivitis, 
otitis media 
Chalazion, 
cholesteatoma 
Iridocyclitis, 
tinnitus 
Macular 
degeneration, 
anosmia 
Amaurosis, 
malignant tumor 
Locomotor 
System 
Joint pains Epicondylitis Exostosis Chronic 
rheumatoid 
arthritis 
Spondylosis Sarcoma, 
chondroma 
Respiratory 
Tract 
Cough, 
expectoration 
Bronchitis, 
acute 
Silicosis, 
smoker’s lung 
Chronic 
(obstructive) 
bronchitis 
Bronchiectasia, 
emphysema 
Bronchial 
carcinoma 
Cardiovascular 
System 
Functional 
heart 
complaint 
Endocarditis, 
pericarditis, 
myocarditis 
Coronary heart 
disease 
Heart failure Myocardial 
infarction 
Endothelioma 
Gastrointestina
l 
System 
Heartburn Gastroenteritis, 
gastritis 
Hyperplastic 
gastritis 
Chronic gastritis, 
malabsorption 
Atrophic gastritis, 
liver cirrhosis 
Stomach cancer, colon 
cancer 
Urogenital 
System 
Polyuria Urinary tract 
infection 
Bladder stones, 
kidney stones 
Chronic urinary 
tract infection 
Renal atrophy Cancer 
Blood Reticulocytosis Leucocytosis, 
suppuration 
Polycythaemia, 
thrombocytosis 
Aggregation 
disturbance 
Anemia, 
thrombocytopenia 
Leukemia 
Lymph System Lymphedema Lymphangitis, 
tonsillitis, 
lymphadenitis 
Lymph-node 
swelling 
Insufficiency of 
the lymph system 
Fibrosis Lymphoma, 
Hodgkin-/non- 
Hodgkin-lymphoma 
Metabolism Electrolyte 
shift 
Lipid 
metabolism 
disturbance 
Gout, obesity Metabolic 
syndrome 
Diabetes mellitus Slow reactions 
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Hormone 
System 
Globus 
sensation 
Thyroiditis Goitre, 
adenoma 
Hyperthyroidism, 
glucose 
intolerance 
Menopausal 
symptoms 
Thyroid cancer 
Immune 
System 
Susceptibility 
to infection 
Weak immune 
system, acute 
infection 
Weak reactions Autoimmune 
disease, 
immunodeficiency, 
chronic infections 
AIDS Slow reactions 
  Alteration* Reaction* Fixation* Chronic Forms* Deficits* Decoupling* 
Psyche Functional 
psychological 
disturbance, 
«nervousness» 
Reactive 
depressive 
syndromes, 
hyperkinetic 
syndrome 
Psychosomatic 
manifestation, 
neuroses, 
phobias, 
neurotic 
depression 
Endogenous 
depression, 
psychosis, 
anxiety neurosis, 
organic 
psychosyndrome 
Schizophrenic 
defective states, 
mental deficiency 
Mania, catatonia 
 
Biological Division 
 
Note: The six-phase table is a field matrix reflecting medical experience based on careful observation and 
empirical learning. It is a phase-by-phase arrangement of disorders with no direct relationship between them. 
No causal pathogenetic link between disorders can be inferred. The structure of the table makes it suitable for 
developing a prediction system giving a better assessment of the possibilities for a vicariation effect. 
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Appendix 3 for Protocol 
Expert Report on Ovarium Compositum 
 
 
 
 
 
 
HEEL GmbH 
 
 
 
 
Part I C2 – Expert Report to Part III 
 
According to Notice to Applicants (NTA) 
 
- Toxicological and Pharmacological Documentation 
 
 
Ovarium Compositum Injection 
Bulk-No.: 8527 
Figure 10 The Expert Report on Ovarium Compositum
APPENDICES 
Appendix	  4	  The	  Protocol	  for	  The	  Pilot	  Study	  Strand	  3.	   576	  
  
 
Part III – Toxicological and Pharmacological Documentation 
 
1 INTRODUCTION 
 
    The presented homeopathic combination remedy Ovarium 
Compositum injection is composed of the following components: 
 
     One ampoule (2.2 ml) Ovarium 
Compositum contains: 
 
Aquilegia vulgaris D 4 22 µl 
Hydrastis canadensis D 4 22 µl 
Lilium tigrinum D 4 22 µl 
Bovista D 6 22 µl 
Cypripedium calceolus var. 
pubescens 
D 6 22 µl 
Ipecacuanha D 6 22 µl 
Apisinum D 8 22 µl 
Kreosotum D 8 22 µl 
Ovarium suis D 8 22 µl 
Acidum cis-aconitum D 10 22 µl 
Lachesis mutus D 10 22 µl 
Magnesium phosphoricum D 10 22 µl 
Mercurius solubilis Hahnemanni D 10 22 µl 
Placenta suis D 10 22 µl 
Salpinx suis D 10 22 µl 
Sepia officinalis D 10 22 µl 
Uterus suis D 10 22 µl 
Hypophysis suis D 13 22 µl 
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Pulsatilla pratensis D 18 22 µl 
 
The scientific findings material on all the active agents has been evaluated 
and an expert opinion delivered on it by Committee D appointed by the 
Federal Health Office and published in Monographs in the Bundesanzeiger 
[Federal Gazette]. 
 
The present Expert Opinion was drawn up to provide information in 
accordance with the EU Commission’s 'Notice to Applicants' on possible 
toxicological risks of the drug being assessed. 
 
Information on the pharmacodynamics (Part III F under the NTA) and 
pharmacokinetics (Part III G under the NTA) of the homeopathic dilutions is 
quoted and discussed in connection with possible toxicological data. Instead 
of drawing up my own view of pharmacodynamic and pharmacokinetic 
findings in the Expert Opinion assessment of the homeopathic drug based on 
the particularities of the treatment orientation, I have referred to Part I C 3 – 
Expert Opinion on Part IV – Clinical Documentation. 
 
Each component entailing a risk has been appraised with regard to its 
toxicological potential. In this appraisal the classification has followed that of 
the Notice to Applicants; the identification letters are each found in the title of 
the chapter. It is of further interest to answer the question of whether the 
dose and duration of treatment admit a safety margin between the dose 
administered and the possible risks; if on the basis of the bibliography there 
were no restrictions on the duration of treatment with the dose used, a time 
limitation on treatment was not deemed necessary. 
 
 
 
 
 
2 TOXICOLOGY 
 
APPENDICES 
Appendix	  4	  The	  Protocol	  for	  The	  Pilot	  Study	  Strand	  3.	   578	  
The assessment follows standard practice and knowledge applied to 
allopathic drugs with the same constituents. The homeopathic dosage is 
comparable in part to the usual recommendations in drug therapy. In addition 
to the medical and toxicological profile of the substance already known, 
research was also carried out in a few special databases of the chemical or 
cosmetic industry or other health organisations. 
 
7. In general, on the one hand the toxicological risks have been specified by means of 
precisely defined limits, e.g. the minimum workplace concentrations [MAC] or short-term use 
limits [SEL] of the WHO, the Food Additives Organisation [FAO] and the International 
Agency for Cancer Research [IACR]; on the other hand the quantities required for 
homeopathic treatment have been evaluated. The therapeutic requirements and the 
tolerable levels for chronic exposure have been proportioned in order to determine the 
therapeutic applicability of the substances. 
 
It is seldom that the question of the exact concentration in drugs can be 
answered for homeopathic finished products, unless they contain highly 
active components. That is why in principle no content assays of the main 
constituents were carried out by the pharmaceutical manufacturer on the end 
products or mother tinctures. Since the HAB likewise requires no values for 
the content assay of each individual substance, the quantitative 
determination of individual constituents were worked out by own calculations. 
 
The constituents or main components are well documented by type and 
quantity in the pharmacopoeia, which means that the characteristic content 
can be determined by DAB 10 or EUAB, for example. 
 
One way of acquiring a notion of the content of the substance in plant 
components when there are no exact control data extant for the mother 
tincture, is to calculate the corresponding quantities back using the 
Manufacturing Specifications in the HAB. 
 
Hahnemann in his day regarded the system of potentisation as a safety 
factor to minimise the risk of homeopathic drugs. Nowadays data from 
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experiments on animals during toxicological studies sometimes help to 
establish guide values for human application, and to decide whether 
administering a mother tincture or the subsequent attenuations of a plant or 
animal drug poses a toxicological risk or the toxicological effects can be 
disregarded. With many components of homeopathic tinctures and dilutions 
however this knowledge is very fragmentary and incomplete. 
 
If the homeopathic dilution is above the toxicological limit and no interaction 
with other constituents has to be considered for the assessment, the safety of 
the drug is discussed in the SURVEYS in the Appendix. 
 
The manufacturer itself conducted no toxicological studies with the 
preparation submitted. The comments below were drawn up on the basis of 
extant documentation, supported by a pool of bibliography constantly 
updated by half-yearly research. 
 
2.1 TOXICITY (III A) 
 
Given the low toxicity or low concentrations of the constituents, in the evaluation of Bovista 
(D6), Cypripedium calceolus var. pubescens (D6), Apisinum (D8), Kreosotum (D8), 
Acidum cis-aconitum (D10), Lachesis mutus (D10), Magnesium phosphoricum (D10), 
Mercurius solubilis (D10), Sepia officinalis (D10), Pulsatilla pratensis (D18) and of all 
Suis extract dilutions in an end concentration between D10 and D15 (s. Chapter 2.1.1) no 
toxicological aspects that would have to be taken into account in the Ovarium Compositum 
ampoules speciality come into consideration for the risk/benefit ratio (s. following table).  
 
 
Homeopathic dilution 
 
Concentratio
n 
End 
concentration 
Bovista D 6 D 8 
Cypripedium calceolus var. pubescens D 6 D 8 
Apisinum D 8 D 10 
Kreosotum D 8 D 10 
Ovarium suis D 8 D 10 
Acidum cis-aconitum D 10 D 12 
Lachesis mutus D 10 D 12 
Magnesium phosphoricum D 10 D 12 
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Mercurius solubilis Hahnemanni D 10 D 12 
Placenta suis D 10 D 12 
Salpinx suis D 10 D 12 
Sepia officinalis D 10 D 12 
Uterus suis D 10 D 12 
Hypophysis suis D 13 D 15 
Pulsatilla pratensis D 18 D 20 
 
For a more detailed study of the relevant toxicological data, refer to the SURVEYS in the 
Appendix compiled from the bibliography. 
 
On the other hand, the constituents of the officinal plants used Aquilegia vulgaris; 
Hydrastis canadensis, Lilium tigrinum and Ipecacuanha require closer inspection at least 
in special risk discussions. The aforementioned drugs are so well documented in 
pharmacopoeia and botanical lexicons that the pharmacodynamic/toxicological effects can 
be derived at least approximately from known data. 
 
 
2.1.1 Extracts of suis organs 
 
Extracts of suis organs are homeopathic preparations from parts of the body 
of a pig. The manufacturing process is conducted in a way that the infectious 
nature and an immunotoxicological risk (Hypophysis, Ovarium, Placenta, 
Salpinx, and Uterus suis) seem to be completely suppressed. In suis 
xenoprotein sensitised guinea pigs test dilutions >1O5 of the glycerol extract 
gave no positive challenge reactions in the skin sensitisation test (Dermal 
Sensitisation called Maximisation Test according to Magnusson and Kligman) 
and according to the conducted quality control [OECD Guideline No. 406, 
Stahl 1991]. Taking into account an additional security margin of a 3 log 
dilution regarding eventual species differences between guinea pigs and 
man, the suis organ extracts should have no immunogenic xenoprotein risk 
potential for humans at >D8. All preparations to the method described in the 
official homeopathic pharmacopoeia resulted also in a virus inactivation. 
 
The composition Ovarium Compositum injection (2.2 ml) contains an amount 
of 22 mg of Ovarium suis (D8). Due to the pharmaceutical formulation the 
quantitative amount i.e. homeopathic potency decreases from the resulted 
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extract to its final concentration within the composition of the remedy 
(corresponding with ≥D10). According to the manufacturing process the 
toxicology of xenoproteins can be regarded as negligible. This evaluation 
complies also with the assessment of the immunotoxicological risks of 
Hypophysis, Placenta, Salpinx, and Uterus suis in which attenuations of 
different parts of the body are incorporated. To characterise their 
toxicological profiles the surveys can be found in Appendix 5.1. 
 
No toxic effects have been described in the literature. The common 
toxicology of the incorporated dilution can be evaluated as very slight. The 
low doses of the composition provide evidence that preparation risks are 
absent or negligible.  
 
 
2.1.2 Aquilegia vulgaris 
8.  
Besides different fatty acids some cyanogenic glycosides of the trigloquinine-
type were found as components in the fresh subterranean and above ground 
organs of Aquilegia vulgaris, a plant which is native in the moderate areas 
of Europe, Africa, and North America [Hager-ROM 2002]; more exact data 
are not found in the literature. The only existing pharmacodynamic data of 
acylated and non-acylated derivatives of 3-mono-glucosides and 3,5-
diglucosides of delphinidine, pelargonidine and cyanidine, the 
anthocyanidines extracted of the flowers describe chemotaxonomic 
measurements. Extracts of the roots shall be applied as stone-dissolving 
drugs and diuretic by Paracelsus; in the Middle Ages Aquilegia was praised 
as medicinal plant against icterus as well as against liver and spleen 
disorders [Madaus]. Scientific articles describing appropriate experiences 
cannot be found.  
 
The extract of the fresh above ground organs of Aquilegia vulgaris was 
neither analysed pharmacologically nor toxicologically. Observations from the 
European popular medicine led to the assumption that it has internal 
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therapeutic effects in scurvy and icterus, and due to its tranquilizing qualities 
is able to improve excitation [HagerRom 2002]. 
 
The available literature and all information gathered from diverse data 
systems about the basis material applied, which is used to produce the 
Aquilegia vulgaris dilution D4 and an end concentration of D6 do not give any 
proof of a toxic potential [Teuscher/Lindequist 1994, von Mühlendahl et al., 
1995, Hager-ROM 2002]. 
 
To produce Ovarium Compositum ampoules Aquilegia vulgaris is used in a dilution D4 that 
corresponds to a finishing dilution D=6. Due to the available data, a toxicological valuation of 
the employed proportion of the glucosides of  delphinidine, pelargonidine and cyanidine and 
some others contained in the available finished preparation is not possible regarding 
quantitative standard measures. The available literature and all information gathered from 
diverse data systems about the basis material applied do not give any proof of a toxic 
potential [Teuscher/Lindequist 1994, von Mühlendahl et al., 1995]. The low end 
concentration of the possibly pharmacodynamic-working alkaloids reveals that, during a 
therapeutical application of Ovarium Compositum ampoules, a risk of an unexpected toxic 
event caused by the named components is not expectable.  
 
 
2.1.3 Alkaloids of Lilium tigrinum 
 
Some species of the plant family Liliaceae are toxic and contain steroid 
saponins which can lead to disorders of the liver and to photosensibilization 
e.g. by Narthecine or Colchicine with typical zyto-toxic qualities. Others were 
found to be derivatives of the cardenolids and bufadienolids with cardiotoxic 
effects. Besides the immuno-toxic acting tulipalins and allylsulfides as Allicin, 
cardenolids and buffadienolids shall be found in Lilium tigrinum [Frohne]. 
Obviously, there is a strong relationship to the effects of other liliaceae 
species like Allium sativa and Allium cepae. 
 
Whether there are intolerance reactions after the oral application of high doses of Lilium 
tigrinum is not known. Reports of intoxications cannot be found in the literature. 
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There are no previous reports validating the pharmacological and 
toxicological effects of this herbal remedy. Neither Teuscher/Lindequist nor 
Mühlendahl mentioned intoxications with parts or extracts of Lilium tigrinum 
during the last decade [Teuscher/Mühlendahl]. To produce Ovarium 
Compositum injection Lilium tigrinum is used in a dilution D4 that 
corresponds to the finishing dilution D6. Due to the available data, a 
toxicological valuation of the employed quality and proportion of the drug 
components contained in the available finished preparation is not possible 
regarding quantitative standard measures. Though, the low end 
concentration reveals that, during a therapeutical application of Ovarium 
Compositum injection, a risk of an unexpected toxic event caused by Lilium 
tigrinum is not expectable. 
 
 
2.1.4 Benzylisoquinoline-alkaloids from Hydrastis canadensis 
 
 The benzyl isoquinoline derivatives of benzophenanthridin-, protoberberin-
, rhoeadin- and protopin type as well as the phthalidisoquinoline-type 
Chelidonine, Chelerythrine, Sanguinarine, Berberine, Coptisin, 
Sanguinarine and Protopin as well as Hydrastine belong to a group of 
alkaloids that are – orally applied - known for their spasmolytic effects on the 
smooth muscles of the gastro-intestinal system and the biliary tract as well as 
for their centrally sedative effects besides their stimulating effects on heart 
rate and blood pressure (see toxicological profile of Hydrastis canadensis in 
the Appendix). Hydrastine can lead to anaesthesia and mydriasis and in 
higher doses extracts of hydrastis canadensis tend to lead to convulsions. In 
rabbits the mean convulsive dose shall be 100 times higher than after the 
intravenous application dose of 0,2 mg/kg bw (+)-Bicucullin-hydrochlorid 
[Hager 1992], that is approx. 20 mg/kg bw. In neurological research (+)-
Bicucullin-hydrochlorid represents the most used kompetitive antagonist of 
the inhibiting neurotransmitter γ-aminobutyric acid (GABA) of the A-receptor 
and shows within a group of 45 phthalidisoquinoline alkaloids in rats on 
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synaptic membrane of the brain the strongest inhibiting effect on the 
receptor. 
 
 In the past intoxications after using or consuming parts of Sanguinaria 
canadensis or Chelidonium majus were reported though, but cannot be 
confirmed in the current literature. Occasional complaints of the gastro-
intestinal system after internal application were only reported once 
[Roth/Daunderer 1987, Schilcher 1997, Teuscher 1994]. Due to the 
increasing activity of microsomal enzymes in hepatocytes of rats suspects of 
a toxic risk were focussed on sanguinarine. Whether this can be transferred 
to the area of human medicine and especially on hdrastine cannot be 
determined precisely enough due to the experimental character of the 
previous literature as there are no reliable data to this [Dalvi 1981, Dalvi 
1985]. 
 
The alkaloids coptisin, chelerythrine and sanguinarine proved to be highly 
toxic combinations in examinations on the comparative determination of the 
cytotoxicity of the different Schöllkraut-alkaloids in primary cultures of 
hepatocytes of rats. Gebhardt and Gaunitz could show that the median of 
EC50-values for the cytotoxicity amounted to approximately 5 mg/ml in 34 
Schöllkraut extracts and preparations. The EC50-values of garlic preparations 
or rather artichoke extracts in comparison to this do not show a value lower 
than 50 mg/ml or rather 10 mg/ml [Gebhardt/Gaunitz 1999]. The resulting 
toxicity though strongly depends on the choice of the plant parts, the 
extraction procedure and similar parameters. The results confirm Dalvi’s 
works, who used doses in his damage model though that meet a limiting 
value 250 times as high. What becomes quite clearly discernible on the other 
hand is that a dose of 0.2 mg/kg/day over a period of 56 days could not be 
able to cause visible damages [Ulrichová et al., 1996].  
 
 In what way hydrastine will be involved in these results and whether they 
can be transferred to humans, remains difficult to assess. With this 
background the following model is calculated by Gebhardt and Gaunitz 
assuming the most inconvenient conditions [Gebhardt/Gaunitz, 1999]: 
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 Taking the average liver weight of 2 kg as a basis an alkaloid amount of 8 
µg/ml coptisin, usually occurring as main alkaloid of Schöllkraut extracts, 
could be able to exert an acute cytotoxic effect, which could thus have an 
effect on some few cells already. This again would correspond to an average 
alkaloid amount of 8 mg daily. Therefore a total amount of 2.5 mg alkaloids 
per day should be acceptable as maximal daily dose. 
 
 Due to the structural differences of the alkaloids of the 
phthalidisoquinoline-type as hydrastine and the alkaloids of the 
benzophenantridin-, protoberberin- and protopin-type as sanguinarine there 
may be concluded that the above mentioned toxic effects on the hepatocytes 
cannot be shown by phthalidisoquinolines because no cases are reported of 
therapeutically often used drugs as noscapine which belongs to the same 
group of alkaloids. 
 
 The question is whether these results have an impact to the application of 
Hydrastis canadensis which does not contain the components sanguinarine, 
chelerythrine or coptisin (see toxicological profile of Hydrastis canadensis in 
the appendix). According to the D monograph an oral application of Hydrastis 
canadensis is possible from the dilution D4. Hydrastis canadensis is added to 
the dilutions potentised as D4 to manufacture Ovarium Compositum injection 
corresponding arithmetically to an end dilution D=6. The mother tincture of 
Hydrastis canadensis contains at least 0.27 % alkaloids and 0.50 % at most, 
calculated as berberine [C20H19NO5]. That means that the average alkaloid 
content of one ampoule is 110 ng, calculated as berberine. This low amount 
indicates that the final drug does not show any toxicological risk regarding 
the berberine concentration. 
 
 
2.1.5 Isoquinoline alkaloids from Cephaelis ipecacuanha 
 
The derivatives of isoquinoline emetine and cephaeline of cephaelis 
ipecacuanha are part of a group of alkaloids, whose oral application was 
appreciated by the natives of South America in the 17th century due its 
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antibiotic effect in dysenteric diseases. Nowadays the drug is primarily used 
to extract emetine, which is used as an expectorant as well as to fight 
amoebiasis evoked by Entamoeba histolytica. The method, which was 
originally employed in the states and advised to administer a syrup of ipecac 
as an emetic agent in poisoning of children, is also quite customary in Europe 
[Teuscher/Lindequist 1994]. 
 
The dried subterranean organs of cephaelis ipecacuanha contain 1,8-3,5 % 
alkaloids, where approximately 40-80 % of emetine and 25-55 % of cephaelin 
are involved as main alkaloids. Furthermore, the secondary alkaloids 
psychotrine, emetamine, ipecoside and proto-emetine can be found, too 
[Teuscher/Lindequist 1994]. 
 
Intoxications with cephaelis ipecacuanha can occur as severe vomiting, 
diarrhoea, tachycardia, cardiac dysrhythmia, hypotension, leucocytosis as 
well as dysfunction of the respiratory activity [Andersen et al. 1997, Saincher 
et al. 1997]. The symptoms possibly last for weeks (see toxicological profile 
of cephaelis ipecacuanha in the appendix). In the past intoxications after the 
administration of herbal parts were reported but the applications were of a 
mere medical nature [Saincher et al. 1997, Mühlendahl 1994]. Severe 
intoxications in infants after the intake of 100 mg alkaloids were observed 
[Rechling et al. 1984]. There is a report about a lethal outcome of an 
intoxication after the intake of 200 mg in a 4-year old child [Adler 1980]. 
 
The acute toxicity of emetine was determined in animal experiments with 
12.1 mg/kg injected intraperitoneally in rats and 32 mg/kg injected 
subcutaneously in mice. The oral administration of 30 mg/kg body weight is 
considered to be the lethal dosage for children [Teuscher/Lindequist 1994, 
Hager 1998]. 
 
According to the preparation monography an oral application of cephaelis 
ipecacuanha is possible from D2 for globules and D4 for other oral and the 
parenteral administration forms. The composition of Ovarium Compositum 
injectable solution contains 22 mg of cephaelis ipecacuanha dilution D6 in 
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2.2 ml, which corresponds arithmetically to a final dilution of approximately 
D8. 
 
The mother tincture of cephaelis ipecacuanha contains maximal 0.18 % 
alkaloids, i. e. 1.0 ml D4 correspond to an approximate proportion of 0.18 µg 
alkaloids; 22 mg cephaelis ipecacuanha D6 do therefore contain 
approximately 0.396 ng alkaloids meaning that the average content of one 
ampoule, calculated as emetine, relates to approximately 396 pg. Within the 
proposed dosage for Ovarium Compositum injectable solution the weekly 
dose for adults corresponds up to three times one ampoule, which would be 
equivalent to an alkaloid proportion of approximately 1.188 ng per week, 
calculated as emetine (see toxicological profile). This low amount indicates 
that the ready-to-use remedy does not carry any toxicological risk regarding 
the concentration calculated as emetine. 
 
 
2.1.6 Global evaluation of toxicity 
 
By means of presented documentation and with respect to the application form all 
homeopathic dilutions of the composition Ovarium Compositum injection are recommended 
by the commission D at the German Health Authority (Farm, former BGA). The current 
scientific fundamentals and the clinical experiences did not reveal serious signs to suspect 
the containing amount of all homeopathic dilutions for causing toxicological risks.  
 
 
2.2 REPRODUCTIVE FUNCTION (III B) 
 
Results from direct studies of reproductive or teratogenic toxicity as well as 
fetotoxic side effects influencing fertility are not available. Researching the 
literature produced no hint for such risks 
 
 
2.3 EMBRYO-FOETAL AND PERI-POSTNATAL TOXICITY (III C) 
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9. Results from direct studies of embryo toxic/ fetotoxic or peri-, postnatal toxicity are 
not available. Researching the literature produced no suggestion of such risks. 
 
 
2.4 MUTAGENIC POTENTIAL (III D) 
 
Results from direct studies of mutagenic toxicity are not available. 
Researching the literature produced no hint for such risks. 
 
 
2.5 CANCEROGENIC POTENTIAL (III E) 
 
Results from direct studies of carcinogenicity are not available. Researching 
the literature produced no hint for such risks. 
 
 
2.6 IMMUNOTOXICITY (III Q) 
 
No indications show that the effects of single components of Ovarium 
Compositum injection are sensitising or will provoke allergic reactions by the 
parenteral application. Possible risks or adverse drug reactions of parts or 
components of the plants have not been observed regarding the 
pharmacovigilance of the compounds of Ovarium Compositum or similar 
composed drugs. 
 
 
2.7 INTERACTIONS (III H) 
 
There are no hints that the effects of single components of the incorporated 
homeopathic dilutions and substances may be enhanced or inhibited by 
incorporated drugs or substances which interfere with their characteristic 
pharmacodynamic or toxicologic effects. Potential risks or interactive effects 
associated with the combined administration of the incorporated homeopathic 
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dilutions have not been substantiated in drug surveillance studies and 
pharmacovigilance on the use of the incorporated drugs in human. 
 
 
 
3 OTHER INFORMATION 
3.1 Pharmacovigilance 
 
The drug safety of Ovarium Compositum injectable solution can also be 
shown by observing pharmacovigilance data, which have been determined 
by a dispensing of a formula with the same composition. The components 
showed identical finishing dilutions. Consequently the dispensing carried the 
same risk potential.  
 
Within the framework of the supervision of drug safety no adverse event was 
reported since 1998 (745.510 ampoules delivered only in Germany), globally 
seen. This result is striking for the good safety profile of Ovarium 
Compositum injectable solution. This result of the pharmacovigilance points 
out that adverse drug reactions after parenteral application of the 
homeopathic dilution in Ovarium Compositum injectable solution are a rarity 
and that this preparation cannot be related to an increased risk especially 
concerning the gastro-intestinal, cardiovascular or central-neurogenic body 
organ system or the skin. 
4 CONCLUSIONS 
 
 The scientific findings material and the clinical experiences do 
not reveal any indications concerning toxicological risks caused by 
components of the homeopathic drug Ovarium Compositum 
injectable solution if the speciality is applied according to a 
recommended dosage of the manufacturer. 
 
 Components of an immunotoxicological potential are included 
with a very small concentration. Consequently, a corresponding 
risk during treatment does not need to be taken into account.  
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 It is recommendable to grant the application for registration of 
Ovarium Compositum injectable solution. 
    Bergisch Gladbach, 12.12.2003 
 
    Wolfgang Strösser, MD, PhD 
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Figure 11 The Oxford Fertility Questionnaire EHIQ 
 
 
 
 
Oxford Fertility Unit                                                                      University 
of Oxford 
 
Emotional health and infertility questionnaire  
 
Please answer each of the questions indicating the response that 
applies best to how you have felt over the past four weeks. Do not 
spend too much time considering your answer; your immediate 
response is likely to be more accurate. 
 
These questions ask about your overall health. 
 
In general would you say your health has 
been:  
 
Please circle one number only 
Excellent   ……………………………     1               
Very good ……………………………     2               
Good …………………………………     3                       
Fair …………………………………..     4                         
Poor ………………………………….     5                         
  
How much have you been 
bothered by  
emotional problems such as 
feeling  
anxious, depressed, irritable or  
Not at all ……………………………..    1 
Slightly ………………………………    2 
Moderately …………………………..    3 
Quite a lot ……………………………    4 
Extremely ……………………………    5 
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down-hearted and sad? 
 
Please circle one number only 
 
 
 
 
These questions ask you how you have felt about your fertility problem 
over the past four weeks. 
Frequently we have used the term “our fertility problem”. This relates to 
your problem in trying to conceive as a couple, regardless of what that 
problem is. 
 
 
How true are each of the following statements for you?  Please tick the 
box that best applies.  
 
   
 
                              
I feel that information given by staff is 
sometimes inadequate. 
               
               
                              
2.  I feel upset when people make 
insensitive comments about childless 
couples.  
               
               
                              
                              
3.  I get upset when family and/or 
friends talk about their children.. 
               
               
                              
Definitel
y 
true 
Mostly 
true 
Not 
sure 
Mostly 
untrue 
Definitel
y untrue 
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4. I may have to stop treatment sooner 
than I would like because of the 
financial cost. 
               
               
                              
5. My life is on hold because of fertility 
treatment. 
               
               
                              
6.  I find it hard to share my feelings 
about infertility with my family 
and/or friends. 
               
               
                              
7. I feel my partner blames me for our 
fertility problem. 
               
               
                              
8. I find it hard to cope with our fertility 
problem. 
               
               
                              
9. Trying to maintain privacy during 
treatment is stressful. 
               
               
                              
10. At times I feel we are not getting 
the best treatment. 
               
               
                              
11. I resent having to put other 
aspects of my life on hold because 
of infertility. 
               
               
                              
12.  I find it hard to help my partner 
cope with our fertility problem. 
               
               
                              
13. I avoid seeing family and/or friends 
who have children. 
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14. Infertility strains my relationship 
with my partner. 
               
               
                              
15. I feel that decisions about 
treatment are out of my control. 
               
               
                              
16.  I feel pressured to have sex at the 
‘right time’ even when I don’t feel 
like it. 
               
               
 
17.  Infertility has taken over my life. 
               
               
                              
18.  I feel unsupported by family 
and/or friends. 
               
               
                
Definitely 
true 
Mostly 
true 
Not 
sure 
Mostl
y 
untru
e 
Definitel
y untrue 
                              
19. I feel that sex is more about 
conceiving than expressing our 
love for each other. 
               
               
                              
20.  Fertility treatment makes me feel 
like a ‘thing’ rather than a person. 
               
               
                              
21. I find it difficult to talk to my partner 
about our fertility problem without 
one of us getting upset or angry. 
               
               
               
                              
22.  I find it painful when family                
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members and/or friends become 
pregnant. 
               
                              
23.  I will feel incomplete as a person if 
I cannot have my own child. 
               
               
                              
24.  Sometimes I think that infertility 
could lead to us separating. 
               
               
                              
25.  Infertility makes me feel I have 
lost control of my life. 
               
               
                              
26. I disagree with my partner about 
how much money to spend on 
treatment. 
               
               
                              
27.  I avoid places where there might 
be pregnant women or children. 
               
               
                              
28.  I feel my partner is obsessed with 
trying to have children. 
               
               
                               
29.  Sex is less enjoyable now that I 
know about our fertility problem. 
               
               
                              
 
30.  I blame myself for our fertility 
problem. 
               
               
                              
31. I feel my partner is not as 
committed to having children as I 
am. 
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32.  I find it hard to agree with my 
partner whether to tell family and/or 
friends about our fertility problem. 
               
               
               
                              
33.  I am exhausted by the emotional 
roller coaster of infertility. 
               
               
                              
Definitely 
true 
Mostly 
true 
Not 
sure 
Mostl
y 
untru
e 
Definitel
y untrue 
                
34.  I find trying to balance fertility 
treatment with my other 
commitments stressful. 
               
               
                              
35.  I feel less sexually attractive since 
discovering our fertility problem. 
               
               
                              
36.  I feel angry that I may not be able 
to have a / another child. 
               
               
                              
37.  Each birthday without a / 
another child is more upsetting. 
               
               
                              
38.  I feel guilty that my past actions 
may have affected my fertility. 
               
               
                              
39.  Having a fertility problem makes 
me feel inadequate. 
               
               
                              
40.  Finding the money for treatment 
is a constant worry. 
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If you would like to add anything further please do so here. 
 
…………………………………………………………………………………………
………… 
 
…………………………………………………………………………………………
………… 
 
…………………………………………………………………………………………
………… 
 
…………………………………………………………………………………………
………… 
 
…………………………………………………………………………………………
………… 
 
…………………………………………………………………………………………
…………. 
 
…………………………………………………………………………………………
………… 
 
…………………………………………………………………………………………
………… 
 
…………………………………………………………………………………………
………… 
 
…………………………………………………………………………………………
………… 
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Thank you for your help. 
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Appendix 5 for Protocol 
Certificate of Good Manufacturing Standards 
Figure 12 Certificate of Good Manufacturing Standards for Ovarium compositum 
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Figure 13 The EQ-5D 
Appendix 6 for Protocol The EQ-5D 
© EuroQoL Group 1990 
 
 
EQ-5D Health Questionnaire 
 
(English version for the UK) 
(validated for use in Eire) 
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By placing a tick in one box in each group below, please indicate 
which statements best describe your own health state today. 
 
Mobility 
I have no problems in walking about q 
I have some problems in walking about q 
I am confined to bed q 
 
Self-Care 
I have no problems with self-care q 
I have some problems washing or dressing myself q 
I am unable to wash or dress myself q 
 
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
I have no problems with performing my usual activities q 
I have some problems with performing my usual activities q 
I am unable to perform my usual activities q 
 
Pain/Discomfort 
I have no pain or discomfort q 
I have moderate pain or discomfort q 
I have extreme pain or discomfort q 
 
Anxiety/Depression 
I am not anxious or depressed q 
I am moderately anxious or depressed q 
I am extremely anxious or depressed q 
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To help people say how good or bad a 
health state is, we have drawn a scale 
(rather like a thermometer) on which 
the best state you can imagine is 
marked 100 and the worst state you 
can imagine is marked 0. 
 
9	   0	  
8	   0	  
7	   0	  
6	   0	  
5	   0	  
4	   0	  
3	   0	  
2	   0	  
1	   0	  
100	  
Worst	  imaginable	  health	  state	  
0	  
Best	  	  imaginable	  health	  state	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We would like you to indicate on this 
scale how good or bad your own 
health is today, in your opinion. Please 
do this by drawing a line from the box 
below to whichever point on the scale 
indicates how good or bad your health 
state is today. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Your	  own	  
health	  state	  
today	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Appendix 7 Protocol Amendments 
 Protocol No OVCT-001 
Number of Protocol amendments issued: 
( ) 1 Version 4 – 1st September 2008  
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APPENDIX 5 Documentation from 
Pilot Study 
Figure 14 Consent forms for participants in pilot study 
Consent Forms for Participants in OVCT-001 
Title of research proposal: A pilot study of Ovarium compositum in 
infertile women (OVCT-001) 
Name of Researchers: Mr Neil MacLachlan, Ms Claire Haresnape, Prof Atholl Johnston and Dr Arthur T. Tucker 
 
Name of Patient / Volunteer (Block Capitals): 
Address: 
 
STUDY CONSENT FORM 
 
(Initial boxes to agree with statement) 
 
1. I confirm that I have read and understand the information 
sheet dated 23rd, July 2009, version 4, for the above study. I 
have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
  2. I confirm that I have decided NOT to actively participate in 
this study of Ovarium compositum. 
 
  3. I give permission for details of my routine treatment to be 
used in the observational part of this study. 
 
  4. I understand that relevant sections of any of my medical 
records generated during my routine and planned treatment 
for infertility may be looked at by responsible individuals 
from Queen Mary University of London Medical School.  I 
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________________________  ____________ 
 ______________________ 
Name of Patient     Date   
 Signature 
 
_______________________  ____________ 
 ______________________ 
Name of Person taking consent  Date    Signature 
(if different from researcher) 
 
________________________  ____________ 
 ______________________ 
Researcher     Date    Signature 
 
 
 
Figure 15 Consent forms for non participants in pilot study 
Consent Forms for Non-Participants in OVCT-001 
Title of research proposal: A pilot study of Ovarium compositum in 
infertile women (OVCT-001) 
Name of Researchers: Mr Neil MacLachlan, Ms Claire Haresnape, Prof Atholl Johnston and Dr Arthur T. Tucker 
 
Name of Patient / Volunteer (Block Capitals): 
Address: 
 
 
STUDY CONSENT FORM 
 
(Initial boxes to agree with statement) 
 
give permission for these individuals to have access to my 
records. 
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________________________  ____________ 
 ______________________ 
Name of Patient     Date   
 Signature 
 
_______________________  ____________ 
 ______________________ 
Name of Person taking consent  Date    Signature 
(if different from researcher) 
 
________________________  ____________ 
 ______________________ 
Researcher 
  
5. I confirm that I have read and understand the information 
sheet dated 23rd, July 2009, version 4, for the above study. I 
have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
  6. I confirm that I have decided NOT to actively participate in 
this study of Ovarium compositum. 
 
  7. I give permission for details of my routine treatment to be 
used in the observational part of this study. 
 
  8. I understand that relevant sections of any of my medical 
records generated during my routine and planned treatment 
for infertility may be looked at by responsible individuals 
from Queen Mary University of London Medical School.  I 
give permission for these individuals to have access to my 
records. 
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Figure 16 Patient Information Sheets for Pilot Study 
Patient Information Sheet for OVCT-001 
Study Number:  OVCT-001 
Study title:  A Pilot study of Ovarium compositum in Infertile Women 
Sponsor: Clinical Pharmacology, Barts and The London, Queen Mary's 
School of Medicine and Dentistry, Charterhouse Square, London, EC1M 
6BQ, UK , Tel:  +44 (20) 7882 3404, Fax: +44 (20) 7882 3408 
Part 1 
Invitation 
You are being invited to take part in a research study.  Before you decide it is 
important for you to understand why the research is being done and what it 
will involve.  Please take time to read the following information carefully. Talk 
to others about the study if you wish.  
Part 1 tells you the purpose of this study and what will happen to you if you 
take part.   
Part 2 gives you more detailed information about the design of the study.  
Ask us if there is anything that is not clear or if you would like more 
information.  Take time to decide whether or not you wish to take part. 
Seahorse Scientific Services is the sponsor of this research. 
What is the purpose of the study?  
The purpose of this study is to find out if Ovarium compositum is more 
effective than placebo in supporting the treatment of women for female 
infertility, caused by the failure to ovulate.  This is to be taken in addition to 
your normal treatment, not as an alternative.  We would also like to measure 
your quality of life (QoL) during your infertility treatment to find out how it 
affects your sense of wellbeing.  We propose to use two questionnaires to do 
this.  Because this is a double blind trial you may receive either Ovarium 
compositum or a placebo.  Placebo means a dummy drug that has no active 
ingredients. 
Ovarium compositum is a homoeopathic product that is prescribed by holistic 
therapists working with female infertility.  Infertile women will frequently seek 
out a holistic approach in support of their medical treatment to overcoming 
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their infertility and more information about the effectiveness of CAM 
(complementary and alternative medicine) would be helpful. 
 This drug is routinely prescribed by Homotoxicologists in the United 
Kingdom and Europe for female infertility and will be taken exactly as 
normally prescribed.   
Why have I been chosen? 
You are being asked to take part in this study because you are a woman 
seeking treatment for infertility due to problems with ovulation. 
Do I have to take part? 
No.  It is up to you to decide whether or not to take part.  If you do, you will 
be given this information sheet to keep and be asked to sign a consent form. 
You are still free to withdraw at any time and do not have to give a reason.   
Before you can begin the study 
You are welcome to read the full study protocol, as well as this Information 
Sheet. This gives many details about Ovarium compositum (the study 
preparation) and the study. The recruiting investigator will tell you about the 
study and any adverse events (reactions) that could potentially occur. You 
will be told exactly what the study entails and what will be required of you. 
You are encouraged to ask the Investigators conducting the recruitment 
interview, questions until you are satisfied that you fully understand the 
nature of the study and what will be required of you. 
What will happen to me if I take part? 
If you agree to take part and to sign a Consent for Study Screening Form, 
you will be invited to a selection session. 
Screening Visit 
This will occur no more than 28 days before the first administration of study 
medication. 
You will be examined by your infertility consultant who will assess your 
suitability for this study based upon the normal procedures for your 
conventional treatment. 
With your permission we may contact your General Practitioner to advise 
them of your potential participation in this study. If during the health 
screening tests any abnormal results are found, you will be immediately 
referred for clinical review as appropriate. 
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Visit 2  
Once accepted onto the study, we will ask you to come to the Department of 
Obstetrics and Gynaecology, Jersey General Hospital, Gloucester Street, St 
Helier, Jersey, JE1 3QS.  
At this time you will undergo a check-in procedure and sign Consent for 
Study Participation Form. 
One of the study Doctors will give you thirty (30) days of the preparation 
(active or placebo) that you were recruited for and instructions for the timing 
of each dose.  You will be asked to complete two questionnaires that are 
designed to measure your quality of life (QoL). 
Visits 3 to 13 
Thirty days later you will be asked to attend for the third visit   if you are 
happy to continue with the study you will be given a further 100 tablets and 
asked to complete the two questionnaires again.  This procedure will be 
repeated every 30 days until you chose to leave the study or become 
pregnant or the study ends (after 12 months) 
Expenses and payments: 
There is no payment for taking part in this study.  The indirect benefits of 
taking part may include a sense of satisfaction at taking part in a study that 
may help other couples in the future.  
What do I have to do? 
If you choose to take part in this study you must not be taking part in any 
other study.  You must also not have taken part in any other study within the 
last four months. 
In addition to your planned infertility treatment, you will need to come to the 
clinics at the times requested and remain there for the duration of time 
required for each visit; this will be about half an hour.  
From the screening to the end of the study, you should not take any other 
homoeopathic medicines or take part in acupuncture treatments.  You should 
also abstain from drinking coffee and eating peppermints during this whole 
study period as some people believe that these can antidote homoeopathic 
medicines.   You must inform your research doctor of all other medications 
you are taking including over the counter medications. You should not take 
any medications without first consulting the research team. 
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If you experience any changes in your health whether or not you feel that this 
is related to your study medication then you must inform your research 
doctor, we will tell you how to do this. 
What are the possible benefits of taking part? 
The indirect benefits of taking part in this study include the knowledge that 
you are making a contribution to our knowledge about complementary 
medicine which may help other infertile couples in the future.  It has not yet 
been proved that taking supplements of this kind can increase fertility rates 
but it may be that there is some direct benefit to taking the active preparation.   
What happens when the research study stops? 
You will continue with your conventional fertility treatments 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or 
any possible harm you might suffer will be addressed.  The detailed 
information on this is given in Part 2. 
If you have a complaint please contact the following in the first instance: 
Claire Haresnape or Dr Arthur Tucker. 
If you feel any discomfort or distress during the investigations, you must say 
so and we will stop the test medicine immediately at any time. 
Any complaint about the way you have been dealt with during the study or 
any possible harm you might suffer will be addressed.  A contact number for 
complaints will be given. 
Will my taking part in the study be kept confidential?  
Yes. All the information about your participation in this study will be kept 
confidential.  
Contact Details: 
If you require any further information please contact:   
Ms Claire Haresnape 
Research Student 
Barts and the London 
Clinical Pharmacology 
Charterhouse Square 
London, EC1M 6BQ 
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Telephone and Fax 01435 813 101 
Mobile/Cell phone  07720 060 116 
 
Or: 
 
Dr Arthur Tucker 
The Ernest Cooke Vascular & Microvascular Unit, 
4th Floor Dominion House, 
St. Bartholomew’s Hospital, 
West Smithfield. 
London, EC1A 7BE. 
Telephone: 020 7601 8498 
This completes Part 1 of the Information Sheet. 
If the information in Part 1 has interested you and you are considering 
participation, please continue to read the additional information in Part 2 
before making any decision. 
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Part 2  
What if relevant new information becomes available?   
Sometimes during the course of a research project, new information 
becomes available about the treatment/drug that is being studied.  If this 
happens, your research doctor will tell you about it and discuss whether you 
want to or should continue in the study.  If you decide not to carry on, your 
research doctor will make arrangements for your care to continue.  If you 
decide to continue in the study you will be asked to sign an updated consent 
form. 
Also, on receiving new information your research doctor might consider it to 
be in your best interests to withdraw you from the study.  He/she will explain 
the reasons and arrange for your care to continue. If the study is stopped for 
any other reason, you will be told why and your continuing care will be 
arranged. 
What will happen if I don’t want to carry on with the study? 
If you withdraw from the study we will need to use the data collected up to 
your withdrawal.  
If your participation in the study is discontinued after you have received the 
study drug you will be asked to undergo a final examination for your own 
safety. If the reason for ending the study is, for example, an adverse event or 
a side-effect of the drug, you will be asked to give information on these in 
order to protect the other patients taking part in this clinical study. 
What if there is a problem? 
We would not expect you to suffer any harm or injury because of your 
participation in this study. If you are harmed by taking part in this study, there 
is no special compensation arrangement. If you are harmed due to 
someone’s negligence, then you may have grounds for legal action but you 
may have to pay your legal costs. Regardless of this, if you wish to complain 
or have any concerns about any aspect of the way you have been 
approached or treated during the course of this study, the normal National 
Health Service complaints mechanisms should be available to you. These 
arrangements do not affect your right to pursue a claim through legal action. 
Complaints 
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If you have a concern about any aspect of this study, you should ask to 
speak with the Research Team who will do their best to answer your 
questions (Claire Haresnape mobile telephone 0772 006 0116 or landline 
01435 813 101; Dr Arthur Tucker, telephone 020 7601 8498).  
If you remain unhappy and wish to complain formally you can do this by 
contacting: The Complaints Officer, c/o The Chief Operating Officer for 
Seahorse Scientific Services, ‘Nonsuch’ House, 21, Rhodesia Road, 
Leytonstone, London, E11 4DF, UK. (:020 8257 8412 
Will my taking part in this study be kept confidential? 
All the information obtained about you in the course of the study is 
confidential and will be kept in a secure locked room. The investigators 
performing the study and a study Monitor will have access to the data 
collected in this study.  They may also be looked at by representatives of 
regulatory authorities and by authorised people from Seahorse Scientific 
Services to check that the study is being carried out correctly. All will have a 
duty of confidentiality to you as a research participant and nothing that could 
reveal your identity will be disclosed outside the research site. 
Involvement of the General Practitioner/Family doctor (GP)  
With your permission we may contact your General Practitioner to advise 
them of your potential participation in this study. 
What will happen to the results of the research study? 
The results of this study may be published or presented at meetings.  You 
will not be identified in any report / publication or presentation. 
Who is organising and funding the research?   
This research is being sponsored by Seahorse Scientific Services funded by 
an unrestricted educational grant from Heel GmbH. 
Who has reviewed the study?  
This study has been given a favourable ethical opinion for conduct in the 
XXXXXX Research Ethics Committee reference  
Before you sign this consent form please ask any questions you have about 
the study. 
Thank you for taking the time to read this information sheet. 
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Figure 17 Letter of Invitation to Trial Participants 
Letter of Invitation to Trial Participants  
On Jersey General Hospital letterhead  
Dear 
I would like to invite you to participate in a clinical trial that is taking place at 
the Jersey General Hospital.  The purpose of this study is to find out if 
Ovarium compositum is more effective than placebo in supporting the 
treatment of women for female infertility, caused by the failure to ovulate.   
This is to be taken in addition to your normal treatment, not as an 
alternative.  We would also like to measure your quality of life (QoL) during 
your infertility treatment to find out how it affects your sense of wellbeing.  
We propose to use two questionnaires to do this.  Because this is a double 
blind trial you may receive either Ovarium compositum or a placebo.  
Placebo means a dummy drug that has no active ingredients. 
Ovarium compositum is a homoeopathic product that is prescribed by 
holistic therapists working with female infertility.  Infertile women will 
frequently seek out a holistic approach in support of their medical treatment 
to overcoming their infertility and more information about the effectiveness 
of CAM (complementary and alternative medicine) would be helpful. 
This drug is routinely prescribed by Homotoxicologists in the United 
Kingdom and Europe for female infertility and will be taken exactly as 
normally prescribed.   
If you would like to find out more about the trial then please read the 
enclosed Patient Information Sheet. 
Yours sincerely, 
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Mr Neil MacLachlan FRCOG 
Consultant Gynaecologist and Obstetrician 
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Figure 18 Case report form for pilot study 
Case Report Form For OVCT-001 Data Collection  
Available as a pdf document, working draft shown on next page. 
 
     Date    Signature 
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Study Code: OVCT-001 Randomisation no:    Subject initials:     
 
 
 
1 
 
 
 
 
CASE REPORT FORM 
STUDY TITLE 
A Pilot Study of Ovarium Compositum in Infertile Women 
Study reference number OVCT-001 
 
CLINICAL TRIAL SITE/UNIT:   Jersey General Hospital 
PRINCIPAL INVESTIGATOR:   Claire Haresnape 
 
 
Subject Initials:    
 
Subject Randomisation Number:     
 
 
 
I am confident that the information supplied in this case record form is complete and 
accurate data.  I confirm that the study was conducted in accordance with the protocol 
and any protocol amendments and that written informed consent was obtained prior to 
the study. 
 
 
 
Investigator’s Signature: 
  
 
Print Name: 
 
 
Date of signature: 
 
          
 d d m m m y y y y  
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CASE REPORT FORM 
STUDY TITLE 
A Pilot Study of Ovarium Compositum in Infertile Women 
Study reference number OVCT-001 
 
CLINICAL TRIAL SITE/UNIT:   Jersey General Hospital 
PRINCIPAL INVESTIGATOR:   Claire Haresnape 
 
 
Subject Initials:    
 
Subject Randomisation Number:     
 
 
 
I am confident that the information supplied in this case record form is complete and 
accurate data.  I confirm that the study was conducted in accordance with the protocol 
and any protocol amendments and that written informed consent was obtained prior to 
the study. 
 
Investigator’s Signature:   
 
Date of signature: 
 
          
 D d m m m y y y y  
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Inclusion Criteria Yes  No* 
1 Is the subject a healthy female aged between 18 and 60 years?    
     
2 Has the subject willingly given written informed consent?    
     
3 Has the subject been diagnosed with poor response to ovulation induction or is 
anovulatory? 
   
     
4 Has the subject an absence of other significant endocrine dysfunction including 
diabetes? 
   
     
5 Has the subject an absence of other known causes of infertility?    
 
*If any inclusion criteria are ticked no then the patient is not eligible for the study. 
 
   
Exclusion Criteria Yes*  No 
1 Is the subject taking medication , for any other condition, that may affect ovulation?    
    
     
2 Is the subject pregnant?    
     
3 Has the subject been diagnosed with tubal infertility?    
     
4 Has the subject had a previous pregnancy?    
     
5 Has  the subject a BM1 <20kg/m2 or >35kg/m2 ?    
     
6 Does the subject have concomitant use of any other complementary or alternative 
therapies? 
   
     
7 Does the subject ingest  strong peppermint or caffeine?    
     
8     
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9     
 
* If any exclusion criteria are ticked yes then the patient is not eligible for the study. 
   
 
 
 
 
 
 
 
 
 
 
 
VISIT 1 (SCREENING) 
 Date:  
_______________ 
          DD       MMM      YYYY 
 
 
 
 
DEMOGRAPHIC DATA 
Age (yrs):    Sex: Female  Male   
 
Height (m):  •        
 
Weight (Kg):   •       
 
INFORMED CONSENT 
Please note: written informed consent must be given before any study specific procedures take 
place or any current therapy is discontinued for the purposes of participation in this study. 
 
Has the subject freely given written informed consent? Yes  No   
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Body Mass Index (BMI = Wt (kg)/H2 (M):   •       
 
 
SMOKING HABITS 
Does the subject smoke or use tobacco products? *Yes  No   
 
* How many cigarettes per day?    
 
Other, specify -------------------------------------------------------------- 
  
 
ALCOHOL CONSUMPTION 
Does the subject consume alcohol?   Yes  No   
 
If yes, how many units per week?            
 
 
MEDICATIONS TAKEN 
Is the subject currently or previously taking any medication including OTC, vitamins and/or 
supplements?        Yes           No   
*Record all medication on Concomitant Medications page 
VISIT 1 (SCREENING) 
 
PREVIOUS MEDICAL HISTORY 
Is there any relevant medical history in the following systems? 
Code System *Yes No  Code System *Yes No 
1 Cardiovascular    9 Neoplasia   
2 Respiratory    10 Neurological   
3 Hepato-biliary    11 Psychological   
4 Gastro-intestinal    12 Immunological   
5 Genito-urinary    13 Dermatological   
6 Endocrine    14 Allergies   
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7 Haematological    15 Eyes, ear, nose, throat   
8 Musculo-skeletal    00 Other   
*If YES for any of the above, enter the code for each condition in the boxes 
below, give further details (including dates) and state if the condition is 
currently or potentially active.  If giving details of surgery please specify the 
underlying cause.  Use a separate line for each condition. 
 Currently Active? 
Code Details (including dates) 
Ye
s 
No 
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VISIT 1 (SCREENING) 
 
PHYSICAL EXAMINATION (to be carried out by medical staff only) 
Code System *Abnormal Normal 
1 General Appearance   
2 Heart   
3 Lungs   
4 Abdomen   
5 Extremities   
 
* If ABNORMAL enter the code for each condition in the boxes below and give brief 
details.  Please use a separate line for each condition. 
 
Code Details 
  
  
  
  
  
 
 
 
 
VITAL SIGNS 
 Pulse rate    Bpm 
 Blood pressure (seated)    /  
  
 mmHg  
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ECG 
Is the 
ECG: 
Normal             Abnormal   ** 
**Description
: 
__________________________________________________________
__ Retain signed and dated trace in the plastic sleeve at back of CRF  
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VISIT 1 (SCREENING) 
 
LABORATORY ANALYSIS  Initials 
   
Blood for haematology and biochemistry Taken by  
 ü  Repeat Sample Required? Date Taken (dd mmm yyyy)  
 Haematology             
 Clinical Chemistry             
               
 
Please insert a copy of all results in the plastic sleeve at the back of the CRF. 
 
Are all final 
results: 
Normal  Abnormal NCS  **Abnormal CS  
**Description: Ovarian Function Investigations 
Endometrial 
thickness at 
ovulation/midcycle 
 
Ovarian volume of  
both ovaries 
Left Right 
Antral follicle count 
day 3-5 at 
beginning of 
treatment cycle 
Left Right 
Progesterone level 
on day 21 mid-
luteal phase. 
 
 
 
Does any result contradict study entry? *Yes  No   
 
Initials:  
 
*If YES, subject must not continue.  Please complete off study page. 
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VISIT 1 (SCREENING) 
  
End of Visit Checklist: to be completed by Investigator  
  Yes  No 
1 Does the subject satisfy the inclusion and exclusion criteria to date?    
     
2 Have all screening procedures been completed?    
     
3 Has the concomitant medication page been completed?    
     
4 Is the subject willing to proceed?    
 
Investigator 
 Yes  No 
Is the subject to continue?    
 
Has medication been collected from Pharmacy?    
 
Have the dosing instructions been explained to the patient?    
 
Signature:  Date:          
   d d m m m y y y y 
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If ‘Yes’ please: 
Complete details of next visit and any other needed instructions on the instruction card. 
Give the subject the instruction card 
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VISIT 2 (WEEK 1)         
Date:______________ 
          DD       MMM      YYYY 
 
PHYSICAL EXAMINATION (to be carried out by medical staff only) 
Code System *Abnormal Normal 
1 General Appearance   
2 Heart   
3 Lungs   
4 Abdomen   
5 Extremities   
 
* If any changes from baseline, complete adverse event page. 
 
 
 
VITAL SIGNS 
 Pulse rate    Bpm 
 Blood pressure (seated)    /  
  
 mmHg  
 
 
 
 
LABORATORY ANALYSIS  Initials 
   
Blood for haematology and biochemistry Taken by  
 ü  Repeat Sample Required? Date Taken (dd mmm yyyy)  
 Haematology             
 Clinical Chemistry             
               
Please insert a copy of all results in the plastic sleeve at the back of the CRF. 
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Are all final 
results: 
Normal  Abnormal NCS  **Abnormal CS  
**Description
: 
 
  
 
Does any result contradict continuation in the study? *Yes  No   
 
*If YES, subject must not continue.  Please complete off study page. 
 
 
 
Are all final 
results: 
Normal  Abnormal NCS  **Abnormal CS  
**Description: Ovarian Function Investigations 
Endometrial 
thickness at 
ovulation/midcycle 
 
Ovarian volume of  
both ovaries 
Left Right 
Antral follicle count 
day 3-5 at 
beginning of 
treatment cycle 
Left Right 
Progesterone level 
on day 21 mid-
luteal phase. 
 
 
 
Does any result contradict study entry? *Yes  No   
 
Initials:  
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*If YES, subject must not continue.  Please complete off study page. 
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VISIT 3 (WEEK ?)         
Date:______________ 
          DD       MMM      YYYY 
 
PHYSICAL EXAMINATION (to be carried out by medical staff only) 
Code System *Abnormal Normal 
1 General Appearance   
2 Heart   
3 Lungs   
4 Abdomen   
5 Extremities   
 
* If any changes from baseline, complete adverse event page. 
 
 
 
VITAL SIGNS 
 Pulse rate    Bpm 
 Blood pressure (seated)    /  
  
 mmHg  
 
 
 
 
LABORATORY ANALYSIS  Initials 
   
Blood for haematology and biochemistry Taken by  
 ü  Repeat Sample Required? Date Taken (dd mmm yyyy)  
 Haematology             
 Clinical Chemistry             
               
Please insert a copy of all results in the plastic sleeve at the back of the CRF. 
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Are all final 
results: 
Normal  Abnormal NCS  **Abnormal CS  
**Description
: 
 
  
 
Does any result contradict continuation in the study? *Yes  No   
 
*If YES, subject must not continue.  Please complete off study page. 
 
 
 
 
 
 
 
 
Are all final 
results: 
Normal  Abnormal NCS  **Abnormal CS  
**Description: Ovarian Function Investigations 
Endometrial 
thickness at 
ovulation/midcycle 
 
Ovarian volume of  
both ovaries 
Left Right 
Antral follicle count 
day 3-5 at 
beginning of 
treatment cycle 
Left Right 
Progesterone level 
on day 21 mid-
luteal phase. 
 
 
 
Does any result contradict study entry? *Yes  No   
 
Initials:  
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*If YES, subject must not continue.  Please complete off study page. 
 
 
VISIT 4 (WEEK ?)         
Date:______________ 
          DD       MMM      YYYY 
 
PHYSICAL EXAMINATION (to be carried out by medical staff only) 
Code System *Abnormal Normal 
1 General Appearance   
2 Heart   
3 Lungs   
4 Abdomen   
5 Extremities   
 
* If any changes from baseline, complete adverse event page. 
 
 
 
VITAL SIGNS 
 Pulse rate    Bpm 
 Blood pressure (seated)    /  
  
 mmHg  
 
 
 
 
LABORATORY ANALYSIS  Initials 
   
Blood for haematology and biochemistry Taken by  
 ü  Repeat Sample Required? Date Taken (dd mmm yyyy)  
 Haematology             
 Clinical Chemistry             
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Please insert a copy of all results in the plastic sleeve at the back of the CRF. 
 
Are all final 
results: 
Normal  Abnormal NCS  **Abnormal CS  
**Description
: 
 
  
 
Does any result contradict continuation in the study? *Yes  No   
 
*If YES, subject must not continue.  Please complete off study page. 
 
 
 
 
Are all final 
results: 
Normal  Abnormal NCS  **Abnormal CS  
**Description: Ovarian Function Investigations 
Endometrial 
thickness at 
ovulation/midcycle 
 
Ovarian volume of  
both ovaries 
Left Right 
Antral follicle count 
day 3-5 at 
beginning of 
treatment cycle 
Left Right 
Progesterone level 
on day 21 mid-
luteal phase. 
 
 
 
Does any result contradict study entry? *Yes  No   
 
Initials:  
 
APPENDICES 
Appendix	  5	  Documentation	  for	  the	  Pilot	  Study	  in	  Strand	  3	   651	  
*If YES, subject must not continue.  Please complete off study page. 
 
 
 
 
VISIT 5 (WEEK ?)         
Date:______________ 
          DD       MMM      YYYY 
 
PHYSICAL EXAMINATION (to be carried out by medical staff only) 
Code System *Abnormal Normal 
1 General Appearance   
2 Heart   
3 Lungs   
4 Abdomen   
5 Extremities   
 
* If any changes from baseline, complete adverse event page. 
 
 
 
VITAL SIGNS 
 Pulse rate    Bpm 
 Blood pressure (seated)    /  
  
 mmHg  
 
 
 
 
LABORATORY ANALYSIS  Initials 
   
Blood for  U+Es Taken by  
 ü  Repeat Sample Required? Date Taken (dd mmm yyyy)  
 Clinical Chemistry             
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Please insert a copy of all results in the plastic sleeve at the back of the CRF. 
 
Are all final 
results: 
Normal  Abnormal NCS  **Abnormal CS  
**Description
: 
 
  
 
Has renal function remained stable? Yes  *No   
 
*If No, record on adverse event page. 
 
 
Are all final 
results: 
Normal  Abnormal NCS  **Abnormal CS  
**Description: Ovarian Function Investigations 
Endometrial 
thickness at 
ovulation/midcycle 
 
Ovarian volume of  
both ovaries 
Left Right 
Antral follicle count 
day 3-5 at 
beginning of 
treatment cycle 
Left Right 
Progesterone level 
on day 21 mid-
luteal phase. 
 
 
 
Does any result contradict study entry? *Yes  No   
 
Initials:  
 
*If YES, subject must not continue.  Please complete off study page. 
 
 
	  	  
CONCOMITANT MEDICATIONS 
 
 
  
Medication 
Total 
Daily 
Dose 
Units Reason 
Start Date  
(MM/DD/YYYY) 
Stop Date  
(MM/DD/YYYY) 
C
on
tin
ui
ng
 
    ___ ___ / ___ ___ / ___ ___ ___ ___ ___ ___ / ___ ___ / ___ ___ ___ ___  
    ___ ___ / ___ ___ / ___ ___ ___ ___ ___ ___ / ___ ___ / ___ ___ ___ ___  
    ___ ___ / ___ ___ / ___ ___ ___ ___ ___ ___ / ___ ___ / ___ ___ ___ ___  
    ___ ___ / ___ ___ / ___ ___ ___ ___ ___ ___ / ___ ___ / ___ ___ ___ ___  
    ___ ___ / ___ ___ / ___ ___ ___ ___ ___ ___ / ___ ___ / ___ ___ ___ ___  
    ___ ___ / ___ ___ / ___ ___ ___ ___ ___ ___ / ___ ___ / ___ ___ ___ ___  
    ___ ___ / ___ ___ / ___ ___ ___ ___ ___ ___ / ___ ___ / ___ ___ ___ ___  
    ___ ___ / ___ ___ / ___ ___ ___ ___ ___ ___ / ___ ___ / ___ ___ ___ ___  
    ___ ___ / ___ ___ / ___ ___ ___ ___ ___ ___ / ___ ___ / ___ ___ ___ ___  
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Adverse Events                                                                                                                                                                              
     
Has the patient experienced any Adverse Events since signing the 
Informed Consent? 
 Yes, specify below  No 
 
AE 
no. 
Adverse Event (diagnosis (if known) 
or signs/symptoms) 
Start 
Date 
dd/mmm/yy
yy 
and 
Time 
(24 hour 
clock) 
Stop 
Date 
dd/mmm/yy
yy 
and 
Time 
(24 hour 
clock) 
Outcome 
1=Recovered 
2=Recovered 
with sequelae 
3=Continuing 
4=Patient 
Died 
5=Change in 
AE 
6=unknown 
Severity 
1=Mild 
2=Modera
te 
3=Severe 
Plausible 
relationshi
p to Study 
Drug 
Action taken 
with Study 
Drug 
1=None 
2=Dose 
Reduction 
Temporarily 
3=Dose Reduced 
4=Discontinued 
Temporarily 
5=Discontinued 
Withdrawn 
due to AE? 
Serious AE 
(SAE)? 
If SAE does 
it require 
immediate 
reporting?  
(see 
Protocol)? 
  
  
  
   
 
         
/     / /     /   Yes   Yes   Yes   Yes 
              
: :   No   No   No   No 
              
  
  
  
   
 
         
/     / /     /   Yes   Yes   Yes   Yes 
              
: :   No   No   No   No 
              
  
  
  
   
 
         
/     / /     /   Yes   Yes   Yes   Yes 
              
: :   No   No   No   No 
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 OFF STUDY FORM 
 
Date Off Study:  ___ ___ / ___ ___ / ___ ___ ___ ___ 
(MM/DD/YYYY) 
Date Last Study Medication Taken:  ___ ___ / ___ ___ / ___ ___ ___ ___ 
(MM/DD/YYYY) 
 
Reason Off Study (Please mark only the primary reason. Reasons other 
than Completed Study require explanation next to the 
response) 
 Completed study  
 AE/SAE (complete AE CRF & SAE form, if applicable) 
_________________________________________________________________ 
 Lost to follow-up
 ___________________________________________________________________
____________________________ 
 Non-compliant participant
 _________________________________________________________
____________________________ 
 Concomitant medication
 __________________________________________________________
____________________________ 
 Medical contraindication
 __________________________________________________________
____________________________ 
 Withdraw consent
 _________________________________________________________________
____________________________ 
 Death (complete SAE form) 
______________________________________________________________________ 
 Other 
 ______________________________________________________________________________
____________________________ 
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Figure 19 Medication labels for pilot study 
Medication Labels for OVCT-001 – Single Dose 
 
Subject No.: 1101 - 1120 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject No.: 1201 - 1220 
 
 
 
 
 
 
 
 
 
 
 
Department of Obstetrics and Gynaecology, Jersey 
General Hospital,  Gloucester Street, St Helier, Jersey, 
JE1 3QS, Phone: 01534 622 660 
Study-Code: OVCT-001   Clomid treatment, age < 30 
yrs  
Subject-No.: 00 
EudraCT-No.: 2008-005858-20 
100 tablets for oral use 
Directions for use: 1 tablet, 3 times daily; 15 min before 
or after meals; at 9 am, 12 noon and 9 pm 
  
Batch-no.:           Expiry date:  
Storage conditions: room temperature 
For clinical trial use only. Keep out of reach of children. 
Please return unused medication to your doctor. 
Department of Obstetrics and Gynaecology, Jersey 
General Hospital,  Gloucester Street, St Helier, Jersey, JE1 
3QS, Phone: 01534 622 660 
Study-Code: OVCT-001   Clomid treatment, age 30 -35 
yrs 
Subject-No.: 00 
EudraCT-No.:2008-005858-20 
100 tablets for oral use 
Directions for use: 1 tablet, 3 times daily; 15 min before 
or after meals; at 9 am, 12 noon and 9 pm 
  
Batch-no.:           Expiry date:  
Storage conditions: room temperature 
For clinical trial use only. Keep out of reach of children. 
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Subject No.: 1301 - 1320 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject No.: 2101 - 2120 
 
Department of Obstetrics and Gynaecology, Jersey 
General Hospital,  Gloucester Street, St Helier, Jersey, JE1 
3QS, Phone: 01534 622 660 
Study-Code: OVCT-001   Clomid treatment, age > 35 yrs 
Subject-No.: 00 
EudraCT-No.:2008-005858-20 
100 tablets for oral use 
Directions for use: 1 tablet, 3 times daily; 15 min before 
or after meals; at 9 am, 12 noon and 9 pm 
  
Batch-no.:           Expiry date:  
Storage conditions: room temperature 
For clinical trial use only. Keep out of reach of children. 
Please return unused medication to your doctor. 
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Department of Obstetrics and Gynaecology, Jersey 
General Hospital,  Gloucester Street, St Helier, Jersey, 
JE1 3QS, Phone: 01534 622 660 
Study-Code: OVCT-001   FSH treatment, age < 30 yrs  
Subject-No.: 00 
EudraCT-No.: 2008-005858-20 
100 tablets for oral use 
Directions for use: 1 tablet, 3 times daily; 15 min before 
or after meals; at 9 am, 12 noon and 9 pm 
  
Batch-no.:           Expiry date:  
Storage conditions: room temperature 
For clinical trial use only. Keep out of reach of children. 
Please return unused medication to your doctor. 
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Subject No.: 2201 – 2220 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject No.: 2301 - 2320 
 
 
Department of Obstetrics and Gynaecology, Jersey 
General Hospital,  Gloucester Street, St Helier, Jersey, 
JE1 3QS, Phone: 01534 622 660 
Study-Code: OVCT-001    FSH treatment, age 30 -35 
yrs  
Subject-No.: 00 
EudraCT-No.: 2008-005858-20 
100 tablets for oral use 
Directions for use: 1 tablet, 3 times daily; 15 min before 
or after meals; at 9 am, 12 noon and 9 pm 
  
Batch-no.:           Expiry date:  
Storage conditions: room temperature 
For clinical trial use only. Keep out of reach of children. 
Please return unused medication to your doctor. 
Department of Obstetrics and Gynaecology, Jersey 
General Hospital,  Gloucester Street, St Helier, Jersey, 
JE1 3QS, Phone: 01534 622 660 
Study-Code: OVCT-001   FSH treatment, age > 35 yrs  
Subject-No.: 00 
EudraCT-No.: 2008-005858-20 
100 tablets for oral use 
Directions for use: 1 tablet, 3 times daily; 15 min before 
or after meals; at 9 am, 12 noon and 9 pm 
  
Batch-no.:           Expiry date:  
Storage conditions: room temperature 
For clinical trial use only. Keep out of reach of children. 
Please return unused medication to your doctor. 
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Subject No.: 3101 - 3120 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject No.: 3201 - 3220 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Department of Obstetrics and Gynaecology, Jersey 
General Hospital,  Gloucester Street, St Helier, Jersey, 
JE1 3QS, Phone: 01534 622 660 
Study-Code: OVCT-001   IVF treatment, age < 30 yrs  
Subject-No.: 00 
EudraCT-No.: 2008-005858-20 
100 tablets for oral use 
Directions for use: 1 tablet, 3 times daily; 15 min before 
or after meals; at 9 am, 12 noon and 9 pm 
  
Batch-no.:           Expiry date:  
Storage conditions: room temperature 
For clinical trial use only. Keep out of reach of children. 
Please return unused medication to your doctor. 
Department of Obstetrics and Gynaecology, Jersey 
General Hospital,  Gloucester Street, St Helier, Jersey, 
JE1 3QS, Phone: 01534 622 660 
Study-Code: OVCT-001    IVF treatment, age 30 -35 yrs  
Subject-No.: 00 
EudraCT-No.: 2008-005858-20 
100 tablets for oral use 
Directions for use: 1 tablet, 3 times daily; 15 min before 
or after meals; at 9 am, 12 noon and 9 pm 
  
Batch-no.:           Expiry date:  
Storage conditions: room temperature 
For clinical trial use only. Keep out of reach of children. 
Please return unused medication to your doctor. 
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Subject No.: 3301 - 3320 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Department of Obstetrics and Gynaecology, Jersey 
General Hospital,  Gloucester Street, St Helier, Jersey, 
JE1 3QS, Phone: 01534 622 660 
Study-Code: OVCT-001   IVF treatment, age > 35 yrs  
Subject-No.: 00 
EudraCT-No.: 2008-005858-20 
100 tablets for oral use 
Directions for use: 1 tablet, 3 times daily; 15 min before 
or after meals; at 9 am, 12 noon and 9 pm 
  
Batch-no.:           Expiry date:  
Storage conditions: room temperature 
For clinical trial use only. Keep out of reach of children. 
Please return unused medication to your doctor. 
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Medication Labels for OVCT-001 – Patient Package 
 
 
Subject No.: 1101 - 1120 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject No.: 1201 - 1220 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Department of Obstetrics and Gynaecology, Jersey 
General Hospital,  Gloucester Street, St Helier, Jersey, 
JE1 3QS, Phone: 01534 622 660 
Study-Code: OVCT-001   Clomid treatment, age < 30 
yrs  
Subject-No.: 00 
EudraCT-No.: 2008-005858-20 
12 x 100 tablets for oral use 
Directions for use: 1 tablet, 3 times daily; 15 min before 
or after meals; at 9 am, 12 noon and 9 pm 
  
Batch-no.:           Expiry date:  
Storage conditions: room temperature 
For clinical trial use only. Keep out of reach of children. 
Please return unused medication to your doctor. 
Department of Obstetrics and Gynaecology, Jersey 
General Hospital,  Gloucester Street, St Helier, Jersey, JE1 
3QS, Phone: 01534 622 660 
Study-Code: OVCT-001   Clomid treatment, age 30 -35 
yrs 
Subject-No.: 00 
EudraCT-No.:2008-005858-20 
12 x 100 tablets for oral use 
Directions for use: 1 tablet, 3 times daily; 15 min before 
or after meals; at 9 am, 12 noon and 9 pm 
  
Batch-no.:           Expiry date:  
Storage conditions: room temperature 
For clinical trial use only. Keep out of reach of children. 
Please return unused medication to your doctor. 
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Subject No.: 1301 - 1320 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject No.: 2101 - 2120 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Department of Obstetrics and Gynaecology, Jersey 
General Hospital,  Gloucester Street, St Helier, Jersey, JE1 
3QS, Phone: 01534 622 660 
Study-Code: OVCT-001   Clomid treatment, age > 35 yrs 
Subject-No.: 00 
EudraCT-No.:2008-005858-20 
12 x 100 tablets for oral use 
Directions for use: 1 tablet, 3 times daily; 15 min before 
or after meals; at 9 am, 12 noon and 9 pm 
  
Batch-no.:           Expiry date:  
Storage conditions: room temperature 
For clinical trial use only. Keep out of reach of children. 
Please return unused medication to your doctor. 
Department of Obstetrics and Gynaecology, Jersey 
General Hospital,  Gloucester Street, St Helier, Jersey, 
JE1 3QS, Phone: 01534 622 660 
Study-Code: OVCT-001   FSH treatment, age < 30 yrs  
Subject-No.: 00 
EudraCT-No.: 2008-005858-20 
12 x 100 tablets for oral use 
Directions for use: 1 tablet, 3 times daily; 15 min before 
or after meals; at 9 am, 12 noon and 9 pm 
  
Batch-no.:           Expiry date:  
Storage conditions: room temperature 
For clinical trial use only. Keep out of reach of children. 
Please return unused medication to your doctor. 
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Subject No.: 2201 - 2220 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject No.: 2301 - 2320 
 
 
Department of Obstetrics and Gynaecology, Jersey 
General Hospital,  Gloucester Street, St Helier, Jersey, 
JE1 3QS, Phone: 01534 622 660 
Study-Code: OVCT-001    FSH treatment, age 30 -35 
yrs  
Subject-No.: 00 
EudraCT-No.: 2008-005858-20 
12 x 100 tablets for oral use 
Directions for use: 1 tablet, 3 times daily; 15 min before 
or after meals; at 9 am, 12 noon and 9 pm 
  
Batch-no.:           Expiry date:  
Storage conditions: room temperature 
For clinical trial use only. Keep out of reach of children. 
Please return unused medication to your doctor. 
Department of Obstetrics and Gynaecology, Jersey 
General Hospital,  Gloucester Street, St Helier, Jersey, 
JE1 3QS, Phone: 01534 622 660 
Study-Code: OVCT-001   FSH treatment, age > 35 yrs  
Subject-No.: 00 
EudraCT-No.: 2008-005858-20 
12 x 100 tablets for oral use 
Directions for use: 1 tablet, 3 times daily; 15 min before 
or after meals; at 9 am, 12 noon and 9 pm 
  
Batch-no.:           Expiry date:  
Storage conditions: room temperature 
For clinical trial use only. Keep out of reach of children. 
Please return unused medication to your doctor. 
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Subject No.: 3101 - 3120 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject No.: 3201 - 3220 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Department of Obstetrics and Gynaecology, Jersey 
General Hospital,  Gloucester Street, St Helier, Jersey, 
JE1 3QS, Phone: 01534 622 660 
Study-Code: OVCT-001   IVF treatment, age < 30 yrs  
Subject-No.: 00 
EudraCT-No.: 2008-005858-20 
12 x 100 tablets for oral use 
Directions for use: 1 tablet, 3 times daily; 15 min before 
or after meals; at 9 am, 12 noon and 9 pm 
  
Batch-no.:           Expiry date:  
Storage conditions: room temperature 
For clinical trial use only. Keep out of reach of children. 
Please return unused medication to your doctor. 
Department of Obstetrics and Gynaecology, Jersey 
General Hospital,  Gloucester Street, St Helier, Jersey, 
JE1 3QS, Phone: 01534 622 660 
Study-Code: OVCT-001    IVF treatment, age 30 -35 yrs  
Subject-No.: 00 
EudraCT-No.: 2008-005858-20 
12 x 100 tablets for oral use 
Directions for use: 1 tablet, 3 times daily; 15 min before 
or after meals; at 9 am, 12 noon and 9 pm 
  
Batch-no.:           Expiry date:  
Storage conditions: room temperature 
For clinical trial use only. Keep out of reach of children. 
Please return unused medication to your doctor. 
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Subject No.: 3301 - 3320 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Labeling For Trial Medication  
 
 
Department of Obstetrics and Gynaecology, Jersey 
General Hospital,  Gloucester Street, St Helier, 
Jersey, JE1 3QS 
Phone: 01534 622 660 
Study-Code:           Subject-No.: 00 
EudraCT-No.:? 
100 tablets for oral use 
Directions for use: 3 times daily; 15 min before or 
after  meals; at 9 am, 12 noon and 9 pm 
  
Batch-no.:  /  Expiry date:  
Storage conditions: room temperature 
For clinical trial use ly. Keep out of reach of 
children. Please return unused medication to your 
doctor. 
 
 
Department of Obstetrics and Gynaecology, Jersey 
General Hospital,  Gloucester Street, St Helier, Jersey, 
JE1 3QS, Phone: 01534 622 660 
Study-Code: OVCT-001   IVF treatment, age > 35 yrs  
Subject-No.: 00 
EudraCT-No.: 2008-005858-20 
12 x 100 tablets for oral use 
Directions for use: 1 tablet, 3 times daily; 15 min before 
or after meals; at 9 am, 12 noon and 9 pm 
  
Batch-no.:           Expiry date:  
Storage conditions: room temperature 
For clinical trial use only. Keep out of reach of children. 
Please return unused medication to your doctor. 
APPENDICES 
Appendix	  5	  Documentation	  for	  the	  Pilot	  Study	  in	  Strand	  3	   669	  
Template for Labels with The Randomisation Codes 
for OVCT-001 
 
OVCT-001 
Subject Randomisation 
3301 
 
OVCT-001 
Subject Randomisation 
3301 
 
OVCT-001 
Subject Randomisation 
3301 
 
OVCT-001 
Subject Randomisation 
3301 
 
OVCT-001 
Subject Randomisation 
3301 
 
OVCT-001 
Subject Randomisation 
3301 
 
OVCT-001 
Subject Randomisation 
3301 
 
OVCT-001 
Subject Randomisation 
3301 
 
OVCT-001 
Subject Randomisation 
3301 
 
OVCT-001 
Subject Randomisation 
3301 
 
OVCT-001 
Subject Randomisation 
3301 
 
OVCT-001 
Subject Randomisation 
3301 
 
OVCT-001 
Subject Randomisation 
3301 
 
OVCT-001 
Subject Randomisation 
3301 
 
OVCT-001 
Subject Randomisation 
3301 
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OVCT-001 
Subject Randomisation 
3301 
 
OVCT-001 
Subject Randomisation 
3301 
 
OVCT-001 
Subject Randomisation 
3301 
 
OVCT-001 
Subject Randomisation 
3301 
 
OVCT-001 
Subject Randomisation 
3301 
 
OVCT-001 
Subject Randomisation 
3301 
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Figure 20 Randomisation Codes for Pilot Study 
The Randomisation Codes As Generated By Heel And 
For Use On Site. 
 
Randomisation Lists for Trial OVCT-001 
Clomid age < 
30 
Clomid age 
30-35 
Clomid age 
>35 
Medicatio
n number 
Patient 
numbe
r 
Medicatio
n number 
Patient 
numbe
r 
Medicatio
n number 
Patient 
numbe
r 
1101  1201  1301  
1102  1202  1302  
1103  1203  1303  
1104  1204  1304  
1105  1205  1305  
1106  1206  1306  
1107  1207  1307  
1108  1208  1308  
1109  1209  1309  
1110  1210  1310  
1111  1211  1311  
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1112  1212  1312  
1113  1213  1313  
1114  1214  1314  
1115  1215  1315  
1116  1216  1316  
1117  1217  1317  
1118  1218  1318  
1119  1219  1319  
1120  1220  1320  
 
 
 
 
FSH age < 30 FSH age 30-
35 
FSH age >35 
Medication 
number 
Patient 
number 
Medication 
number 
Patient 
number 
Medication 
number 
Patient 
number 
2101  2201  2301  
2102  2202  2302  
2103  2203  2303  
2104  2204  2304  
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2105  2205  2305  
2106  2206  2306  
2107  2207  2307  
2108  2208  2308  
2109  2209  2309  
2110  2210  2310  
2111  2211  2311  
2112  2212  2312  
2113  2213  2313  
2114  2214  2314  
2115  2215  2315  
2116  2216  2316  
2117  2217  2317  
2118  2218  2318  
2119  2219  2319  
2120  2220  2320  
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IVF age < 30 IVF age 30-35 IVF age >35 
Medicatio
n number 
Patient 
numbe
r 
Medicatio
n number 
Patient 
numbe
r 
Medicatio
n number 
Patient 
numbe
r 
3101  3201  3301  
3102  3202  3302  
3103  3203  3303  
3104  3204  3304  
3105  3205  3305  
3106  3206  3306  
3107  3207  3307  
3108  3208  3308  
3109  3209  3309  
3110  3210  3310  
3111  3211  3311  
3112  3212  3312  
3113  3213  3313  
3114  3214  3314  
3115  3215  3315  
APPENDICES 
Appendix	  5	  Documentation	  for	  the	  Pilot	  Study	  in	  Strand	  3	   675	  
3116  3216  3316  
3117  3217  3317  
3118  3218  3318  
3119  3219  3319  
3120  3220  3320  
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APPENDIX 6 The Study Drug 
Homeopathic Indications for the Individual 
Constituents of Ovarium Compositum 
Ovarium suis (ovary)   
The Biotherpeutic Index (Heel, 1986) entry for Ovarium Compositum includes 
Ovarium suis with the following symptoms:  Disturbances of the ovarian 
function e.g. dysmenorrhoea, metrorrhagia, climacteric disorders. 
 
These indications are also found in the homeopathic literature (Heel): 
‘Disturbances of the ovarian function, dysmenorrhoea, amenorrhoea, 
climacteric with manifestations of ovarian endocrine deficiency; 
hypermenorrhhoea, metrorrhagia, female sterility, climacteric neurosis with 
depression, nymphomania, delusional ideas of jealousy, kraurosis vulvae, 
mastodynia, and osteomalacia’. 
 
Placenta Suis (entire placenta)  
The Biotherapeutic Index (Heel, 1986) entry for Ovarium Compositum 
includes Placenta Suis with the following symptoms:  Dysmenorrhoea, 
peripheral circulatory disturbances.  The attenuations of this sarcode are 
prepared using the whole placenta from the uterus of a healthy female pig 
(sus scrofa domesticus) with young.(Reckeweg, 2002).   Indications for use: 
Peripheral circulatory disorders, cutis marmorata, decubiutus, pernios, 
Buerger’s disease, ulcus cruris, rhagades, eczema, infolding of skin, 
sclerodermia, dysbasia intermittens, dysmenorrhoea, sural spasms, 
muscular rheumatism (Heel). 
 
A proving of this substance was conducted in the fall of 1994 by Dr David 
Riley (Reckeweg, 2002).  Congruent Symptoms with Dr Reckeweg: disorders 
of the peripheral circulation, prostration, rheumatism, and cramps of the calf 
muscles. 
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Uterus Suis (uterus)  
The Biotherapeutic Index entry for Ovarium Compositum includes Uterus 
Suis with the following symptoms:  Dysmenorrhoea. 
The attenuations of this sarcode are prepared from the womb removed from 
healthy pigs (Sus scrofa domesticus) (Reckeweg, 2002).  The main 
indications are: Uterine prolapsed, uterine fibroids, Dysmenorrhoea, Pre-
cancerous state of the uterus, cervical erosion.  Female sterility.  Other 
degenerative diseases of the uterus 
 
Salpinx Uteri Suis (Fallopian Tube)  
The Biotherapeutic Index entry (Heel, 1986) for Ovarium Compositum 
includes Salpinx Suis with the following symptoms:  Dysmenorrhoea, sterility 
through inflammatory diseases of the salpinx uteri. 
The attenuations of this sarcode are prepared from the Fallopian tube 
removed from healthy pigs (Sus scrofa domesticus).  The main indications 
are: 
Female sterility resulting from inflammatory disease of the fallopian tube, 
(consequences of gonorrhoea, etc.), disorders of ovulation, dysmenorrhea, 
menopausal problems (Reckeweg, 2002). 
 
Cypripedium Pubescens – (Lady’s Slipper)  
The Biotherapeutic Index entry (Heel, 1986) for Ovarium Compositum 
includes Cypripedium with the following symptoms:  Conditions of nervous 
irritability, insomnia with restlessness and twitching of the body. 
The mother tincture is prepared from the fresh rootstock, gathered in autumn, 
of the plant Cypripedium calceolus, var. Pubescens (Wild.) Corell., a native 
of North America. N.O. Orchidaceae.  The main indications for the 
homeopathic dilution are: abuse of coffee, states of nervous irritation.  Its 
listing as an ingredient of Ovarium Compositum states: conditions of nervous 
irritation, insomnia with restlessness and twitching of the body (Heel, 1986).  
Cypripedium is said to be particularly effective in nervous women, whose 
nerves are affected by illness or by abuse of tea or coffee.  (Impregnation 
phases according to the Disease Evolution Table (Heel, 2012).  However it is 
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also recommended in consequences of mental over-exertion, night watching 
and exhaustion of the nervous system in influenza. 
 
The German Monograph-Preparation Commission for the Homeopathic Field 
of Therapy has, under the Preparation Monograph for Cypripedium calceolus 
var. Pubescens, published the following indication in the German 
Bundesanzeiger (German Federal Gazette): Insomnia 
 
Clarke (Clarke)has the following information: Cypripedium has great repute 
as a ‘nervine’ among eclectics, and in domestic practice.  For the female 
sphere it is indicated for Amenorrhoea, with hysterics, Great nervous debility 
and despondency, Irritability of vagina; hysterical symptoms, sleeplessness 
and agitation. 
 
Lilium tigrinum (Tiger Lily)  
 
The Biotherapeutic Index entry (Heel, 1986) for Ovarium Compositum 
includes Lilium tigrinum with the following symptoms:  Uterus descensus,  
dysmenorrhoea, and nervous cardiac disturbances with anxiety, fluor albus. 
The mother tincture is prepared from the fresh aerial parts in flower of Lilium 
lancifolium Thunb, a native of China and Japan and often cultivated for 
decorative purposes. N.O. Liliaceae. 
 
The main indications (Reckeweg, 2002) are: palpitations, squeezed 
sensation (similar to cactus), leucorrhoea.  Dysmenorrhea, uterine prolapsed, 
left sided ophoritis, bearing down sensation, burning and heat in the palms of 
the hands and soles of the feet, pulsations throughout the body.   
 
The German Monograph-Preparation Commission for the Homeopathic Field 
of Therapy has, under the Preparation Monograph for Lilium lancifolium, 
published the following indications in the German Federal Gazette) for lilium 
tigrinum: complaints associated with prolapsed of the uterus during 
menopause; inflammations and painful conditions of the female reproductive 
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organs; nervous cardio circulatory complaints; irritable emotional discord or 
upset. 
 
Pulsatilla – Wind Flower/Meadow Anemone 
The Biotherapeutic Index entry (Heel, 1986) for Ovarium Compositum 
includes Pulsatilla with the following symptoms: migrating Disorders (worse 
before menses), delayed menses, dysmenorrhoea, remedy for affections of 
the mucosa, venous stasis. 
 
The Mother Tincture is prepared from the whole fresh plant, gathered while in 
flower, of Pulsatilla pratensis Miller, which occurs in the mountains of Europe 
and Russia.  N.O. Ranunculaceae.(Reckeweg, 2002).  The tincture contains 
protoanemonin (an antibiotic substance), tannin, resin and saponin, and 
shows typical therapeutic indications, which cover both psychic and somatic 
symptoms.   
Hans-Heinrich Reckeweg lists the following typical symptoms and 
indications: aggravation in a warm room and in hot weather, amelioration in 
fresh air and walking about gently. 
 
Pulsatilla is usually indicated for female patients who are full of complaints. 
Inflammations and disorders of the female reproductive organs, vaginitis 
accompanied by purulent discharge.  Disorders experienced during 
pregnancy and nursing; consequences of suppressed gonorrhoea, or of 
suppressed leucorrhoea with orchitis or oophoritis; concomitant catarrh of the 
bladder, cystitis. 
 
Aquilegia vulgaris (columbine)  
The Biotherapeutic Index entry (Heel, 1986) for Ovarium Compositum 
includes Aquilegia with the following symptoms:  Disturbances of the 
menses, climacteric disorders. 
The mother tincture is prepared from the whole fresh plant in bloom.  
Aquilegia vulgaris L. N.O. Ranunculaceae.(Reckeweg, 2002) Menstrual 
disturbances, functional amenorrhoea, menopausal problems, depression 
during the menses. 
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Sepia (cuttlefish)  
The Biotherapeutic Index entry (Heel, 1986)for Ovarium Compositum 
includes Sepia with the following symptoms:  Climacteric disorders, nervous 
exhaustion, depression, chronic inflammation of the uterus and adnexa. 
 
The attenuations are prepared from the dried secretion of the ink gland of the 
cuttlefish, Sepia officinalis L., which inhabits the Mediterranean, the North 
Sea and the Atlantic Ocean. N.O.Sepiidae. (Reckeweg, 2002)  
 
Menopausal complaints with hot flushes, emotional depression and irritability 
(alternating).  Tearfulness, hypersensitivity and indifference (to business and 
family), general weakness, every movement causing outbreaks of sweating, 
feeling of faintness, yellowish-green leucorrhoea, offensive and excoriating in 
cervical erosion, menses mostly late and scanty, menopause.  
 
Lachesis (bushmaster)  
The Biotherapeutic Index entry (Heel, 1986) for Ovarium Compositum 
includes Lachesis with the following symptoms: Climacteric disorders (hot 
flushes) dysmenorrhoea. 
 
The attenuations are prepared from the careful dried venom of the snake, 
Lachesis mutus L., which occurs in Central and South America. N.O. 
Crotalidae.(Reckeweg, 2002) The homoeopath Dr. Constantine Hering 
investigated venom of Lachesis muta in 1892 in South America combining 
the known toxicology with a homeopathic proving.  It is used by 
homoeopaths as an ovarian remedy indicated for endometritis worse on the 
left side, menopause, ovarian dysfunction and especially hot flushes.   
   
Apisnum (bee venom)  
The Biotherapeutic Index entry (Heel, 1986)for Ovarium Compositum 
includes Apisnum with the following symptoms:  Oedema, Ovarian cysts, 
dysmenorrhoea, ovarialgia, and metrorrhagia.  The mother tincture is 
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prepared from the whole honey bee, Apis mellifica L. N.O. Apidae 
(Reckeweg, 2002). 
 
Apis is indicated for right-sided adnexitis and other kinds of right-sided 
inflammatory illnesses, inflammations and disorders with collection of fluid in 
tissues and cavities of the body. 
 
Kreosotum (beech tar creosote)  
The Biotherapeutic Index entry (Heel, 1986) for Ovarium Compositum 
includes Kreosotum with the following symptoms: Catarrh of the mucosa with 
acrid secretions, pruritus vulvae, menorrhagia, metrorrhagia, hyperemesis. 
 
The attenuations are prepared from Creosote, a mixture of Guaiacol, Cresol 
and Cresolene obtained by distillation of beech wood tar(Reckeweg, 2002). 
Creosote was formerly used allopathically as an anti-tubercular, antiseptic 
and styptic and especially in dyspepsia.  In dentistry creosote was used to 
serve as an additive to arsenic paste for the devitalisation of dental pulp.   
Homoeopaths employ the homeopathic dilution of Kreosotum to treat widely 
varying mucosal conditions with offensive, acrid, excoriating discharges, 
carcinoma of the uterus, general haemorrhagic tendency and inflammations 
of the urinary and reproductive organs. 
 
Bovista  (Warted Puff-ball)   
The Biotherapeutic Index entry (Heel, 1986) for Ovarium Compositum 
includes Bovista with the following symptoms:  Menorrhagia, dysmenorrhoea, 
venous haemorrhages. 
The attenuations are prepared from the dried ripe fungus Calvatia gigantean 
without its peridia, which grows in Central Europe in pastures and dry 
meadows everywhere. N.O. Lycoperdaceae (Reckeweg, 2002).  It is 
employed homeopathically to treat Menorrhagia, menses come too early, 
uterine bleeding. 
 
Ipecacuanha   
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The Biotherapeutic Index entry (Heel, 1986) for Ovarium Compositum 
includes Ipecacuanha with the following symptoms:  Uterine haemorrhages, 
hyperemesis. 
The mother tincture is prepared from the dried underground parts of 
Cephaelis ipecacuanha (Brot.) A. Rich., a plant growing in Brazil, India and 
Malaysia. N.O. Rubiaceae (Reckeweg, 2002). It is used to treat bright red 
gushing haemorrhages, menorrhagia and metrorrhagia. 
 
Mercurius solubilis Hahnemanni (mixture containing essentially 
mercuroamidonitrate)  
 
The Biotherapeutic Index entry (Heel, 1986) for Ovarium Compositum 
includes Mercurius with the following symptoms:  suppurations, acute and 
chronic affections of the connective tissue. 
 
The attenuations are prepared from mixture consisting essentially of mercury 
(II)-amidonitrate and metallic mercury (Reckeweg, 2002)it is used for the 
following indications: mucosal inflammations of the respiratory passages, the 
gastrointestinal tract, and the urinary and reproductive organs; skin diseases; 
inflammations of the tonsils, lymph glands, liver, and kidneys; inflammations 
of other glandular organs. 
 
Hydrastis Canadensis (golden seal)  
The Biotherapeutic Index entry (Heel, 1986) for Ovarium Compositum 
includes Hydrastis with the following symptoms:  remedy for affectations of 
the mucosa; thick, ropy, yellowish-white secretions, menorrhagia, viscid, 
metrorrhagia, myomatous haemorrhages. 
 
The mother tincture is prepared from the dried rootstock, with roots attached, 
of the plant, Hydrastis Canadensis L., which occurs in shady mountain 
forests of Atlantic North America. N.O. Ranunculaceae. (Reckeweg, 2002). 
The preparation contains three alkaloids: hydrastine, berberine and meconin, 
apart from phytosterin, volatile oil and resins.  It is used by homoeopaths in 
diseases of the uterus with vaginal discharge. 
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Acidum cis-aconiticum  (aconitic acid)  
The Biotherapeutic Index entry (Heel, 1986) for Ovarium Compositum 
includes Acidum cis –acniticum with the following symptoms:  active factor of 
the citric acid cycle and of redox systems. 
The attenuations are prepared from cis-aconitic acid, 
COOHCHC(COOH)CH2COOH.  M.W: 174.2(Reckeweg, 2002)  As with all 
catalysts of the citric acid cycle, aconitic acid too shows and affinity for 
internal respiration.  The drug picture of cis-Aconiticum Acidum was 
composed in September 1996 by David Riley, M.D., Santa Fe (New Mexico), 
USA and includes: Pain at menses improving, sensation as if menses would 
come on. 
 
Magnesium phosphoricum (magnesium phosphate)  
The Biotheraeutic Index entry (Heel, 1986) for Ovarium Compositum includes 
Magnesium phosphoricum with the following symptoms:  dysmenorrhoea, 
tendency to cramps and neuralgia. 
 
The attenuations are prepared from Magnesium hydrogen phosphate 
trihydrate. MgHPO4.3H2O, MW: 174.3 (Reckeweg, 2002). The trituration and 
liquid potencies prepared from magnesium phosphate are according to 
Heinigke, ‘one of our most important pain remedies.’ 
 
Magnesium phosphoricum is also an important remedy in dysmenorrhoea 
and when the menses arrive too early, especially when there is swelling and 
sensitivity of the vagina and so called ovarian neuralgia. 
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APPENDIX 7 Qualitative Data 
Table 44 Coded data segments from direct forum participants who responded to my posting 
CODED DATA FROM DIRECT RESPONDENTS FROM 
THE FORUM FOR MANUAL SORTING INTO THEMES 
Doc Code Segment 
TH Identity as a 
treatment 
seeker or 
employee\proxi
mity of clinic to 
work 
P I had a good number of blood tests over the next few 
months. I was a nursery manager and at that point I 
worked in a nursery on a hospital site so didn't really 
need to say much as it was easy to fit in 
TH Identity as a 
treatment 
seeker or 
employee\gend
er of boss 
She was fine about it, chatty, agreed the time I needed 
TH Identity as a 
treatment 
seeker or 
employee\flexibi
lity 
Any hospital appointments that followed I emailed her 
about to let her know, and she was happy for me to 
attend. 
TH Identity as a 
treatment 
seeker or 
I was honest about my appointments, if they were in 
the middle of the day I took holiday so as not to be a 
complete pain, if they were early or late I worked 
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Doc Code Segment 
employee\flexibi
lity 
around them. 
TH Identity as a 
treatment 
seeker or 
employee\flexibi
lity 
He said he appreciated my being open and that I could 
just let the manager know when my appointments 
were, that was fine. 
TH Identity as a 
treatment 
seeker or 
employee\flexibi
lity 
The manager and director happily accommodated my 
appointments 
TH Identity as a 
treatment 
seeker or 
employee\Using 
annual leave for 
treatment time 
They let me book the Monday as annual leave for the 
IUI, and then we waited. 
TH Identity as a 
treatment 
seeker or 
employee 
(and even though that day he was telling us  
about how the business was developing and how our 
roles could grow and change within it) he made it very 
clear that even though it put a spanner in the works 
from a professional point of view, on a personal level 
he was really pleased. 
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Doc Code Segment 
TC Identity as a 
treatment 
seeker or 
employee\comp
any has clear 
policy on IVF 
We have it written in our t&c that females having Ivf 
are allowed an extra 5 days leave in a rolling 12 mths, 
so  
if you had 1 cycle every year you can claim the extra 5 
days leave, men and civil partners are allowed 2 days 
in a rolling 12 mths. 
TC Identity as a 
treatment 
seeker or 
employee\Using 
annual leave for 
treatment time 
I have requested my 5 days together as I am going 
abroad and have taken a weeks leave before and a 
weeks leave after. 
SW Identity as a 
treatment 
seeker or 
employee\flexibi
lity 
Yes, I got the job on merit, I had no problems 
whatsoever with having time off; working for a large 
organisation, with a terrific foundation on offering staff 
a good work / life balance – I  
was allowed time off for egg collection and embryo 
transfer… 
SW Identity as a 
treatment 
seeker or 
employee\comp
any has clear 
policy on IVF 
– I was allowed time off for egg collection and embryo 
transfer… 
SW Identity as a I was able to take a combination of flexi and holiday  
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Doc Code Segment 
treatment 
seeker or 
employee\Using 
annual leave for 
treatment time 
as I felt necessary. 
SOC Identity as a 
treatment 
seeker or 
employee\gend
er of boss 
luckily it was a female manager who dealt with it 
ND Identity as a 
treatment 
seeker or 
employee\proxi
mity of clinic to 
work 
As we chose a clinic some distance from our home, 
this led to quite a lot of time off 
RBI Identity as a 
treatment 
seeker or 
employee\proxi
mity of clinic to 
work 
Luckily my clinic was only 20 minutes from the office 
and my scans and blood tests were always first thing 
RBI Identity as a 
treatment 
seeker or 
employee\Using 
have now been to Cyprus twice without anyone at  
work having any idea of the reasons behind our trip – 
just a last minute holiday. 
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Doc Code Segment 
annual leave for 
treatment time 
AJ 
 
 
 
Identity as a 
treatment 
seeker or 
employee 
When i 1st started my journey I was an assistant 
manager in a well know retail store. My store manager 
and area manager, at first, were quite sympathetic. 
This soon changed  
when i needed to go for daily bloods and scans. I was 
made aware that this was very inconvenient to the 
business and sometimes I was made to still let the 
cleaners in the  
store at 7 am and wait until another manager arrived to 
relieve me from my duties. 
AJ Identity as a 
treatment 
seeker or 
employee\proxi
mity of clinic to 
work 
This made me feel anxious as I had to then travel 8  
miles to the hospital, get parked up and be there 
before 9. Whilst in the waiting area I was constantly 
aware of the time as they needed me back asap. 
Sometimes 2 hours would  
pass waiting from bloods and then onto scans, 
depending on how many patients were in that day. O 
AJ Identity as a 
treatment 
seeker or 
employee 
I was very upset in front of the nurses as I knew that it 
would be frowned upon as saturdays are our busiest 
day and my area manager was visiting too. 
AJ Identity as a 
treatment 
seeker or 
She was very annoyed and her words were "Andrea. I 
am very sympathetic regarding your needs but I have 
a  
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Doc Code Segment 
employee business to run and your wanting to leave on a 
Saturday afternoon?! 
AJ Identity as a 
treatment 
seeker or 
employee 
attitude changed towards my treatment but then from 
then on i thought, stuff it, they don't care about me, Im 
just a number and instead of having the odd day off 
after embyo transfer  
etc, i had more time off to suit my needs and not of 
that of the business! 
 
 
Doc Code Retrieved Segment 
TH Emotional 
distress 
and to be honest I was not much fun, sometimes I'd 
come back to work on a high because I'd had good 
news,  
sometimes in pieces because it was not the news I'd 
hoped for. 
TH Emotional 
distress 
I was absolutely broken to find out that there was only 
one follicle that had grown large enough and on that 
basis we needed to cancel my cycle. The centre 
suggested to give that follicle a chance and not waste 
the whole cycle, we could convert it to IUI. We decided 
to do that, and I went back to work in pieces 
TH Emotional 
distress\b
They offered to send me home but I stayed and 
finished  
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Doc Code Retrieved Segment 
eing 
worthy 
the day 
SOC Emotional 
distress 
I had to take a day off one day because I was so upset 
after a terrible appointment with a gynaecologist and 
having to explain why was awful, 
SOC Emotional 
distress\fi
nancial 
loss 
so I have that stress plus the stress of not getting paid 
for any  
time off I take for appointments.  
SOC Emotional 
distress\fi
nancial 
loss 
proof to show work, that's also about 4 hours of wages 
a month I am missing out on, which doesn't sound like 
much but really it's the principle and I don't exactly get 
paid very much anyway 
AJ Emotional 
distress 
I have been trying assisted conception now for four 
years. 3 failed iuis, 7 ivf with 2 pregnancies which 
sadly ended in miscarraige. my words that could only 
describe this process is its like being on an emotional 
roller coaster. Very stressful at times and I felt like a 
was the only person that understood what I was going 
through. 
AJ Emotional 
distress\fe
eling 
isolated 
My partner had 2 children to a previous relation ship 
which made things more difficult for me to cope with, 
and at times i thought that he didn't even 
understand,as after all he had 2 children,so how could 
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Doc Code Retrieved Segment 
he?  
AJ Emotional 
distress\c
ounselling 
In time counselling helped me to see things differently 
AJ Emotional 
distress\b
eing 
worthy 
On my return i felt that guilty that i often missed my 
break or lunch break as i felt i and to make the time 
back.  
AJ Emotional 
distress 
At this point i went on to the sales floor and cried my 
heart ou 
AJ Emotional 
distress 
She did her floor walk with the store manager looked 
at me and ignored me.  
AJ Emotional 
distress 
I felt hurt and anxious.  
AJ Emotional 
distress 
Whilst typing it up i was sobbing as i felt humiliated 
and in disbelieve that i had to do it 
AJ Emotional 
distress 
My 1st failed ivf attempt i was that upset that my 
partner rang in work for me to say that i wouldn't be in 
work the following day. I was hysterical during the 
conversation 
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Doc Code Retrieved Segment 
AJ Emotional 
distress\fi
nancial 
loss 
wouldn't be in work the following day. I was hysterical 
during the conversation and my manager could hear 
me in the background but because the company policy 
is to ring in yourself I didn't get paid. 
AJ Emotional 
distress 
This made me feel angry and i spoke to the store 
manager about it saying that i felt sick and really upset 
AJ Emotional 
distress\p
utting you 
first 
attitude changed towards my treatment but then from 
then on i thought, stuff it, they don't care about me,Im 
just a number and instead of having the odd day off 
after embyo transfer etc, i had more time off to suit my 
needs and not of that of the business! 
 
 
Doc Code Segment 
TH Trust and 
Support from 
Manager 
She was fine about it, chatty, agreed the time I 
needed, and knowing my tendancy to push myself 
a bit hard sometimes came and did a 'welfare 
check' on my first day back at work.  
TH Trust and 
Support from 
Manager\empa
thy from boss 
both the owner and the manager have two young  
children and understood that much as I wanted 
this to happen, didn't mean it ever would and did 
not impair my ability to do my job in the meantime.  
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Doc Code Segment 
TH Trust and 
Support from 
Manager\empa
thy from boss 
We got the green light to go, and my manager was 
almost as excited as we were, possibly more 
because she didn't have the fear to deal with that 
came with it. 
TH Trust and 
Support from 
Manager\empa
thy from boss 
My drugs were delivered to work, she signed for 
them and we both squeaked with excitement, like 
we had just signed for a baby in a box. 
TH Trust and 
Support from 
Manager\empa
thy from boss 
we all jumped up and down about the result. Even 
the director  
TH Trust and 
Support from 
Manager 
d I have done this with the goodwill, support, 
compassion and empathy of my employer. 
SW Trust and 
Support from 
Manager\empa
thy from boss 
I have fabulous understanding bosses 
SW Trust and 
Support from 
Manager 
work for a forward thinking organisation – 
ND Trust and tive secondary school and we have an assistant 
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Doc Code Segment 
Support from 
Manager\empa
thy from boss 
head who is  
responsible for staff welfare. When I told her about 
our IVF she was incredibly supportive and told me 
that I could take whatever time I needed and not to 
worry if appointments  
were sometimes at the last minute as that was the 
"nature of the beast". 
RBI Trust and 
Support from 
Manager\lack 
of empathy 
 
  
I am a branch manager and have had to tell my 
MD on a couple of occasions about employees 
being pregnant. HER (the MD’s) response has 
always been very negative –  
what it will cost the company for cover, training 
requirements when employees’ return to work etc. 
She did at one point tell me she hated pregnant 
women! (She does have children of her own.) 
RBI Trust and 
Support from 
Manager\lack 
of empathy 
I do not know what the response from my MD 
would be if I told her I was having fertility 
treatment.  
AJ Trust and 
Support from 
Manager\lack 
of empathy 
This was done on a rota basis and made me feel 
upset as to why the store manager couldn't get the 
others to do it to help me out 
AJ Trust and 
Support from 
Manager\feelin
The 1st time i felt let down and resentful 
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Doc Code Segment 
g let down 
AJ Trust and 
Support from 
Manager\empa
thy from boss 
The nurses were very sympathetic  
and apperently hear about these work related 
stories all of the time. 
AJ Trust and 
Support from 
Manager\lack 
of empathy 
After that she was quite horrible about my 
treatment 
AJ Trust and 
Support from 
Manager\lack 
of empathy 
that rules could be bent and that she should have 
had more empathy. 
AJ Trust and 
Support from 
Manager\empa
thy from boss 
but I wonder to myself if he is more empathetic as 
he himself has friends who have had ivf treatment 
so he understands how difficult it can be.  
 
Doc Code Retrieved Segment 
TH 
 
Being open but I was open with my deputy manager as he and I 
worked very closely together and I'm not great at 
hiding things. 
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TH Being open My first real discussion with my line manager 
(Regional Operations Manager) about this was when I 
recieved an appointment for a laparoscopy and dye 
test. My letter came just before my annual appraisal, 
so once we had agreed our business targets etc, we  
discussed on a personal level that we had been trying 
for a year and a half for 'number 2' at that point and 
that this is where I was at with investigating our 
infertility 
TH Being open I explained we had been trying for a second child for 
some time, that at this point we didn't think it would be 
possible but that I was taking a drug (clomid) that 
impacts on your hormones and I would need a blood 
test at day 21. They were fine with this and I think 
appreciated that I could have completely kept this to 
myself 
TH Being open I was honest about my appointments, if they were in 
the middle of the day I took holiday so as not to be a 
complete pain, if they were early or late I worked 
around them. 
TH Being open I had spoken to the owner/ director about the fact that 
we were waiting to find out if we  
could have IVF when we had been making an off site 
visit to another setting, and we had a lengthy car 
journey because I had an opportunity to instigate this 
when there was a  
good couple of hours available. I said I was speaking 
to him about this because there would be periods of 
time that it would be time consuming and I really 
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Doc Code Retrieved Segment 
TH 
 
Being open but I was open with my deputy manager as he and I 
worked very closely together and I'm not great at 
hiding things. 
TH Being open My first real discussion with my line manager 
(Regional Operations Manager) about this was when I 
recieved an appointment for a laparoscopy and dye 
test. My letter came just before my annual appraisal, 
so once we had agreed our business targets etc, we  
discussed on a personal level that we had been trying 
for a year and a half for 'number 2' at that point and 
that this is where I was at with investigating our 
infertility 
TH Being open I explained we had been trying for a second child for 
some time, that at this point we didn't think it would be 
possible but that I was taking a drug (clomid) that 
impacts on your hormones and I would need a blood 
test at day 21. They were fine with this and I think 
appreciated that I could have completely kept this to 
myself 
needed his goodwill to be able to do it without 
compromising my position 
TH Being open but safe in the knowledge that I have no big secret 
SW Being open I had a job interview in October 2009, one of the 
questions that I was asked was “would you consider 
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Doc Code Retrieved Segment 
TH 
 
Being open but I was open with my deputy manager as he and I 
worked very closely together and I'm not great at 
hiding things. 
TH Being open My first real discussion with my line manager 
(Regional Operations Manager) about this was when I 
recieved an appointment for a laparoscopy and dye 
test. My letter came just before my annual appraisal, 
so once we had agreed our business targets etc, we  
discussed on a personal level that we had been trying 
for a year and a half for 'number 2' at that point and 
that this is where I was at with investigating our 
infertility 
TH Being open I explained we had been trying for a second child for 
some time, that at this point we didn't think it would be 
possible but that I was taking a drug (clomid) that 
impacts on your hormones and I would need a blood 
test at day 21. They were fine with this and I think 
appreciated that I could have completely kept this to 
myself 
job-share?”  to which I responded that I was 
specifically looking at a full-time role at the time, but 
wouldn’t rule out the possibility of being a job sharer in 
the future.   I was asked to elaborate further!  I advised 
the interview panel that I was hoping to undergo 
fertility treatment in the future, and if successful, I 
would like to take up a part-time role to spend as much 
time as possible at home. 
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Doc Code Retrieved Segment 
TH 
 
Being open but I was open with my deputy manager as he and I 
worked very closely together and I'm not great at 
hiding things. 
TH Being open My first real discussion with my line manager 
(Regional Operations Manager) about this was when I 
recieved an appointment for a laparoscopy and dye 
test. My letter came just before my annual appraisal, 
so once we had agreed our business targets etc, we  
discussed on a personal level that we had been trying 
for a year and a half for 'number 2' at that point and 
that this is where I was at with investigating our 
infertility 
TH Being open I explained we had been trying for a second child for 
some time, that at this point we didn't think it would be 
possible but that I was taking a drug (clomid) that 
impacts on your hormones and I would need a blood 
test at day 21. They were fine with this and I think 
appreciated that I could have completely kept this to 
myself 
SW Being open I wasn’t expecting to be handed the job on a plate, but 
I would have felt guilty if I had been offered the job, 
then handing my employers a schedule of treatment to 
arrange the time off.  But by the same token, I wanted 
to be upfront and honest 
RBI Being 
open\non 
When I discovered I would need IVF treatment, I made 
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Doc Code Retrieved Segment 
TH 
 
Being open but I was open with my deputy manager as he and I 
worked very closely together and I'm not great at 
hiding things. 
TH Being open My first real discussion with my line manager 
(Regional Operations Manager) about this was when I 
recieved an appointment for a laparoscopy and dye 
test. My letter came just before my annual appraisal, 
so once we had agreed our business targets etc, we  
discussed on a personal level that we had been trying 
for a year and a half for 'number 2' at that point and 
that this is where I was at with investigating our 
infertility 
TH Being open I explained we had been trying for a second child for 
some time, that at this point we didn't think it would be 
possible but that I was taking a drug (clomid) that 
impacts on your hormones and I would need a blood 
test at day 21. They were fine with this and I think 
appreciated that I could have completely kept this to 
myself 
disclosure the decision not to tell 
RBI Being open I told one employee who would be covering for me 
while I attended appointments. 
RBI Being 
open\non 
I will admit I did come up with some ridiculous ‘white 
lies’ to tell to other members of staff. 
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Doc Code Retrieved Segment 
TH 
 
Being open but I was open with my deputy manager as he and I 
worked very closely together and I'm not great at 
hiding things. 
TH Being open My first real discussion with my line manager 
(Regional Operations Manager) about this was when I 
recieved an appointment for a laparoscopy and dye 
test. My letter came just before my annual appraisal, 
so once we had agreed our business targets etc, we  
discussed on a personal level that we had been trying 
for a year and a half for 'number 2' at that point and 
that this is where I was at with investigating our 
infertility 
TH Being open I explained we had been trying for a second child for 
some time, that at this point we didn't think it would be 
possible but that I was taking a drug (clomid) that 
impacts on your hormones and I would need a blood 
test at day 21. They were fine with this and I think 
appreciated that I could have completely kept this to 
myself 
disclosure 
RBI Being 
open\non 
disclosure 
When my IVF didn’t work and I was told I would 
require donor eggs I decided I didn’t want anyone in 
my employment to know a 
AJ Being open When I arrived at work that morning I had a quiet word 
with the area manager and explained that depending 
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Doc Code Retrieved Segment 
TH 
 
Being open but I was open with my deputy manager as he and I 
worked very closely together and I'm not great at 
hiding things. 
TH Being open My first real discussion with my line manager 
(Regional Operations Manager) about this was when I 
recieved an appointment for a laparoscopy and dye 
test. My letter came just before my annual appraisal, 
so once we had agreed our business targets etc, we  
discussed on a personal level that we had been trying 
for a year and a half for 'number 2' at that point and 
that this is where I was at with investigating our 
infertility 
TH Being open I explained we had been trying for a second child for 
some time, that at this point we didn't think it would be 
possible but that I was taking a drug (clomid) that 
impacts on your hormones and I would need a blood 
test at day 21. They were fine with this and I think 
appreciated that I could have completely kept this to 
myself 
on my blood results that afternoon I may need to go 
infer treatment. 
 
 
Doc Code Segment 
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TC The legal 
position\sexua
l 
discrimination 
men and civil partners  
are allowed 2 days in a rolling 12 mths. 
SW The legal 
position\sexua
l 
discrimination 
maybe I would have kept quiet if I was employed by 
a smaller company – certainly in previous jobs I was 
told quite candidly that they would no longer employ 
ladies of ‘child bearing age’ 
SOC The legal 
position\discli
pinary action 
at work 
but I had disciplinary action as a result of being off 
that day 
SOC The legal 
position\discli
pinary action 
at work 
The worst thing is that people with children are 
allowed time off for 'dependant care', I know more 
than a few people who abuse this and take days off 
pretending that they can't get child care and they're 
not disciplined for it but when I had to take a day off 
because I was so distressed it went through as 
'sickness' and I was given a verbal warning which 
stays on my file for a year. 
AJ The legal 
position\sexua
l 
discrimination 
and hurt i rang the union who gave me some really 
good advise and they told me what she was doing 
was more of sexual discrimination rather than 
victimisation.  
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AJ The legal 
position 
After getting advise i sort of knew where i stood, 
although there are no laws in place for ivf and just 
pregnancy  
laws, the advise given made me feel better.   
 
Doc Code Segment 
TH The 
demands of 
treatment 
Possible but that I was taking a drug (clomid) 
that impacts on your hormones and I would 
need a blood test at day 21. 
SW The 
demands of 
treatment 
as the travelling alone would be a minimum of 2 
hours each time. 
SOC The 
demands of 
treatment 
Now I'm going to need time off twice a month for 
ultrasounds and blood tests and it will be extra 
stressful because these appointments will be 
made over the phone 
AJ The 
demands of 
treatment 
They said that I may need to go back that day 
for my treatment. 
AJ The 
demands of 
treatment 
This was really frustrating as it is not an exact 
science and all depends on your body clock 
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Documen
t 
Code Segment 
TC Confidentiality My company have been fantastic and 
haven't even asked to see any evidence of 
treatment.  
SOC Confidentiality I had no choice but to tell work because I 
work in a call centre and can't just come in 
and leave when I like, i have to show proof 
and they have to photocopy everything and 
time off  
has to be approved depending on the 
staffing.  
SOC Confidentiality it took me about 5 weeks to pluck up the 
courage to show a manager my letter from 
assisted conception with my first 
appointment on it because I was so 
embarrassed, my boyfriend also works in 
here so that makes me feel even more  
embarrassed - I really wish that managers in 
here didn't know so much about my personal 
life.  
AJ Confidentiality Whislt typing it up i was sobbing as i felt 
humiliated and in disbelieve that i had to do 
it 
Docume
nt 
Code Segment 
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Doc Code Segment 
TH The 
demands of 
treatment 
Possible but that I was taking a drug (clomid) 
that impacts on your hormones and I would 
need a blood test at day 21. 
SW The 
demands of 
treatment 
as the travelling alone would be a minimum of 2 
hours each time. 
SOC The 
demands of 
treatment 
Now I'm going to need time off twice a month for 
ultrasounds and blood tests and it will be extra 
stressful because these appointments will be 
made over the phone 
AJ The 
demands of 
treatment 
They said that I may need to go back that day 
for my treatment. 
AJ The 
demands of 
treatment 
This was really frustrating as it is not an exact 
science and all depends on your body clock 
Documen
t 
Code Segment 
RBI career prospects I do not know what the response 
from my MD would be if I told her I 
was having fertility treatment. It is so 
expensive though I cannot take the 
risk of letting on and then losing my 
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Doc Code Segment 
TH The 
demands of 
treatment 
Possible but that I was taking a drug (clomid) 
that impacts on your hormones and I would 
need a blood test at day 21. 
SW The 
demands of 
treatment 
as the travelling alone would be a minimum of 2 
hours each time. 
SOC The 
demands of 
treatment 
Now I'm going to need time off twice a month for 
ultrasounds and blood tests and it will be extra 
stressful because these appointments will be 
made over the phone 
AJ The 
demands of 
treatment 
They said that I may need to go back that day 
for my treatment. 
AJ The 
demands of 
treatment 
This was really frustrating as it is not an exact 
science and all depends on your body clock 
Documen
t 
Code Segment 
job because of it – through work life 
just being made generally difficult, 
so forced out. 
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Figure 21 Mind map from early coding memo 
MIND MAP OF INTIAL CODES AND THEMES  
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APPENDIX 8 – Results and Data 
Results from Strand 1 
Summary of results for Question Two  
What would you use in your practice as a well indicated homoeopathic/ 
homotoxicological protocol for treating female infertility due to 
declining hormone levels? 
A table showing the practitioner responses to question two is shown in 
appendix three. 
   
Table 45 Summary of Practitioner Responses to Question Two 
 (A) Homotoxicology (B) Other Measures (C) 
Methodology 
Mercury Removal (1) Chinese Herbal 
Medicine (1) 
Need to 
individualise the 
treatment (1) 
 
Nosode Therapy (4) Basal Temperature 
chart (1) 
Need to identify 
causative agent 
(1) 
Regulation of Flower Essence  
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Endocrine System (9) Remedies (1) 
Detoxification (3) Check for Ovarian 
Cysts (1) 
Use of machine 
based diagnosis 
(4) 
Organ Support (2) Referral to another 
practitioner (2) 
 
Ovarian Stimulation (3) Mineral and Nutritional 
supplementation (2) 
 
Miasmatic Treatment 
(1) 
 
 
Total statements 23 
Holistic Dentistry (1) 
 
 
Total statements 9 
 
 
 
Total 
statements 6 
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Question Three 
 What would you use in your practice as a well indicated 
homoeopathic/homotoxicological protocol for treating male infertility 
due to low sperm count? 
A table showing the practitioner responses is shown in appendix five and the 
subsequent coding in appendix six. 
Table 46 Summary of Practitioner Responses to Question Three 
 (A) Homotoxicology (B) Other Measures (C) 
Methodology 
 
Detoxification (5) 
 
Identification of 
environmental factors 
such as mobile phone 
radiation and toxic 
exposure (3) 
 
Vega testing (1) 
Miasmatic Treatment 
(2) 
Reflexology  (1)  
Mumps nosode (2) Chinese Herbal 
Medicine (1) 
 
Testis compositum (6) Classical homoeopathy 
(1) 
Nutrition and Diet (8) 
 
K2M (2) 
Thalamus compositum 
(1) 
Other lifestyle choices 
(1) 
 
 
 
 
APPENDICES 
Appendix	  8	  Results	   714	  
 
Therefore suis organ 
therapy = 10 
 
Total number of 
statements 18 
 
Total number of 
statements = 15 
Total number of 
statements = 1 
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Question Four 
Are there any other lifestyle choices or changes that you would recommend 
to a patient seeking advice regarding infertility?   
The practitioner responses are shown in appendix 7 and the coded data in 
appendix 8. 
Table 47 Analysis of Practitioner Responses to Question Four 
Suggestions Sub-group Number of 
statements 
Identify Causative agents Allergies 1 
 Hyperthyroidism 1 
Subtotal  2 
Environmental factors Tested via machine 
based testing such as 
EAV 
1 
 Avoid ‘chemicals’ 3 
 Exposure to pollution 1 
 Exposure to 
EMF/microwaves 
2 
 Exposure to 
chemicals found in 
household products 
2 
 Water Quality 1 
 Endocrine disruptors 
such as plastics 
2 
 Fungus and 
mycotoxins 
1 
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Suggestions Sub-group Number of 
statements 
Subtotal  13 
Diet and Lifestyle   
Diet  6 
Nutritional 
Supplementation 
 6 
Avoidance of caffeine, 
alcohol and nicotine 
 7 
Subtotal  19 
Other holistic therapies Reflexology 1 
 Flower essences 1 
Subtotal  2 
Detoxification Dental amalgam 2 
 Environmental factors 1 
Subtotal  3 
   
Stress reduction Yoga /exercise 3 
 Psycho-dynamic work 7 
Subtotal  10 
   
Total number of  49 
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Suggestions Sub-group Number of 
statements 
statements 
 
  
APPENDICES 
Appendix	  8	  Results	   718	  
Results from Strand 2 
Coded Data from Staff Questionnaire and Discussion Group 
Table 48 Coded Data from Staff Questionnaire at The Bridge Centre 
 
CODE USED RETRIEVED SEGMENT OF QUOTE 
Concerns about randomisation to placebo 
OK just hope we can recruit enough women to get results 
Q5, 6 
 
Asking women if they are willing to delay treatment with a 
50% chance they will be on a placebo 
Q6, 6 
 
Lack of knowledge on Doctors behalf, unwilling to believe, 
patients not wanting to go on a placebo, patients not 
wanting to delay treatment 
Q8, 3 
 
Patients not wanting to try the homeopathy, patients 
getting angry or upset because trial hasn’t worked or no 
benefits 
Q8, 4 
 
Consent from women and compliance 
Q8, 6 
 
 
Scepticism 
I’m interested but sometimes sceptic, I like the idea of 
research and proof if scientific research can justify then 
Q3, 6 
 
Lack of knowledge on Doctors behalf, unwilling to believe, 
patients not wanting to go on a placebo, patients not 
wanting to delay treatment 
Q8, 3 
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CODE USED RETRIEVED SEGMENT OF QUOTE 
Not enough time 
Talk 30 mins to one hour, probably best to organise further 
talk 
Q4, 3 
 
Not long enough, 5-8 minutes approx. 
Q4, 4 
 
More 
Q4, 5 
 
Not enough with nurses talks up to one hour 
Q4, 6 
 
 
Request for more information or training 
Need more information 
Q2, 3 
 
Fine with more training re homeopathy 
Q5, 3 
 
To explain the mechanism to clients 
Q6, 7 
 
Knowledge, actually understanding everything I’m telling 
patients before I talk with them 
Q6, 4 
 
 
Belief in benefit 
African background way back, I think believing in rx will 
make someone to use them with a hope of success and 
belief = success 
Q1, 6 
 
Not a quick cure but something that can help/ease illness 
Q2, 6 
 
General wellbeing, find treatment less stressful, patients 
able to move on with life re deciding not to continue with 
treatment 
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CODE USED RETRIEVED SEGMENT OF QUOTE 
Q9, 3 
 
More pregnancies 
More relaxed patients 
Q9, 4-5 
 
For certain patients with problems like overweight which may affect their chances of having children I think they will benefit from the project.  Relaxes the body and minds as well as relieves their stresses therefore promote health thus 
success in their treatment 
 
Q9, 6 
 
Potentially it could be of great benefit to clinic if we can sell 
the clinic as having an option of IVF or IVF plus 
homeopathy 
Q9, 7 
 
 
No comment or no entry 
None 
Q1, 9 
 
No experience 
Q1, 5 
 
 
Q1, 2 
 
 
Q2, 2 
 
blank 
Q3, 7 
 
blank 
Q4, 7 
 
 
Q4, 2 
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CODE USED RETRIEVED SEGMENT OF QUOTE 
Q5, 2 
 
 
Caution due to unknown interactions 
Professional, patients, drugs not known so tend to stop 
Q1, 4 
 
 
Some previous knowledge or experience 
Echinacea with colds, rescue remedy with stress, gingko 
balboa for memory, I’ve never seen a homeopath but as a 
midwife I’ve cared for many women using remedies so I’ve 
gained some knowledge 
Q1, 8 
 
Personal Hay fever 
Q1, 3 
 
 
Seen as more natural 
To be an alternative if applicable for conventional medicine 
and to be more of a natural medicine 
Q2, 4 
 
 
Let them try 
I don’t know of any but if I did I would probably say try 
anything (safe) once if it will help you get pregnant or have 
another postitive effect on your health. 
Q3, 4 
 
It is their choice, if it is beneficial then let them try 
Q3, 5 
 
 
Cautious but positive 
It’s a very good idea but not enough to impart knowledge 
Q3, 3 
 
I’m interested but sometimes sceptic, I like the idea of 
research and proof if scientific  research can justify then 
fantastic 
Q3, 6 
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CODE USED RETRIEVED SEGMENT OF QUOTE 
Not bad but I just don’t know how the patients will respond 
to it 
Q5, 4 
 
 
Willing to take part 
Fine with more training re homeopathy 
Q5, 3 
 
postive 
Q5, 5 
 
Happy 
Q5, 7 
 
 
Unwilling to take part  
Ethical issues 
Ethical dilemmas – consider!!! 
Q8, 5 
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Table 49 Bridge Centre discussion group responses to questionnaire 
 Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 
Resp
onden
ts 
         
1 Perso
nal 
Hay 
fever 
Profe
ssion
al, 
patien
ts, 
drugs 
not 
know
n so 
tend 
to 
stop 
Need 
more 
infor
matio
n 
It’s a 
very 
good 
idea 
but 
not 
enou
gh to 
impa
rt 
know
ledg
e 
Tal
k 
30 
min
s to 
one 
hou
r, 
pro
bab
ly 
bes
t to 
org
anis
e 
furt
her 
talk 
Fine 
with 
more 
traini
ng re 
home
opath
y 
blank Deali
ng 
with 
patie
nts 
Lack 
of 
knowl
edge 
on 
Docto
rs 
behalf
, 
unwilli
ng to 
believ
e, 
patien
ts not 
wanti
ng to 
go on 
a 
place
bo, 
patien
ts not 
wanti
ng to 
Gene
ral 
wellb
eing, 
find 
treat
ment 
less 
stres
sful, 
patie
nts 
able 
to 
move 
on 
with 
life re 
decidi
ng 
not to 
conti
nue 
with 
treat
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 Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 
Resp
onden
ts 
         
delay 
treat
ment 
ment 
2 No 
experi
ence 
To be 
an 
altern
ative 
if 
applic
able 
for 
conve
ntion
al 
medic
ine 
and 
to be 
more 
of a 
natur
al 
medic
ine 
I 
don’t 
know 
of 
any 
but if 
I did 
I 
woul
d 
prob
ably 
say 
try 
anyt
hing 
(safe
) 
once 
if it 
will 
help 
Not 
lon
g 
eno
ugh
, 5-
8 
min
ute
s 
app
rox. 
Not 
bad 
but I 
just 
don’t 
know 
how 
the 
patie
nts 
will 
respo
nd to 
it 
Knowl
edge, 
actuall
y 
unders
tandin
g 
everyt
hing 
I’m 
telling 
patient
s 
before 
I talk 
with 
them 
Seei
ng 
patie
nts 
plea
sed 
with 
what 
I 
have 
expl
aine
d to 
them 
and 
happ
y 
with 
their 
treat
ment
. And 
Patie
nts 
not 
wanti
ng to 
try the 
home
opath
y, 
patien
ts 
gettin
g 
angry 
or 
upset 
becau
se 
trial 
hasn’t 
worke
d or 
More 
pregn
ancie
s 
More 
relax
ed 
patie
nts 
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 Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 
Resp
onden
ts 
         
you 
get 
preg
nant 
or 
have 
anot
her 
positi
ve 
effec
t on 
your 
healt
h. 
(obvi
ously
) 
seei
ng 
the 
wom
en 
get 
preg
nant 
no 
benefi
ts 
3 Africa
n 
backg
round 
way 
back, 
I think 
believ
ing in 
rx will 
make 
50% 
chanc
e of 
succe
ss 
It is 
their 
choic
e, if 
it is 
bene
ficial 
then 
let 
them 
Mor
e 
Positi
ve 
To 
take 
site/ 
decisi
on for 
patient
s 
Whe
n 
havi
ng 
positi
ve 
resul
ts 
then 
“chil
d” at 
Ethica
l 
dilem
mas – 
consi
der!!! 
For 
certai
n 
patie
nts 
with 
probl
ems 
like 
over
weigh
APPENDICES 
Appendix	  8	  Results	   726	  
 Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 
Resp
onden
ts 
         
some
one to 
use 
them 
with a 
hope 
of 
succe
ss 
and 
belief 
= 
succe
ss 
 
try the 
end 
or 
com
plete
d 
famil
y 
t 
which 
may 
affect 
their 
chan
ces 
of 
havin
g 
childr
en I 
think 
they 
will 
benef
it 
from 
the 
proje
ct.  
Relax
es 
the 
body 
and 
mind
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 Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 
Resp
onden
ts 
         
s as 
well 
as 
reliev
es 
their 
stres
ses 
theref
ore 
prom
ote 
healt
h 
thus 
succe
ss in 
their 
treat
ment 
4 Echin
acea 
with 
colds, 
rescu
e 
Not a 
quick 
cure 
but 
some
thing 
I’m 
inter
este
d but 
som
etim
Not 
eno
ugh 
with 
nur
ses 
OK 
just 
hope 
we 
can 
recrui
Asking 
wome
n if 
they 
are 
willing 
Getti
ng 
feed
back 
from 
wom
Cons
ent 
from 
wome
n and 
compl
Poten
tially 
it 
could 
be of 
great 
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 Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 
Resp
onden
ts 
         
reme
dy 
with 
stress
, 
gingk
o 
balbo
a for 
memo
ry, 
I’ve 
never 
seen 
a 
home
opath 
but as 
a 
midwi
fe I’ve 
cared 
for 
many 
wome
n 
using 
that 
can 
help/
ease 
illnes
s 
es 
scep
tic, I 
like 
the 
idea 
of 
rese
arch 
and 
proof 
if 
scien
tific 
rese
arch 
can 
justif
y 
then 
fanta
stic 
talk
s 
up 
to 
one 
hou
r 
t 
enou
gh 
wom
en to 
get 
result
s 
to 
delay 
treatm
ent 
with a 
50% 
chanc
e they 
will be 
on a 
placeb
o 
en 
who 
you 
have 
care
d for 
and 
who
m 
have 
got 
preg
nant 
iance benef
it to 
clinic 
if we 
can 
sell 
the 
clinic 
as 
havin
g an 
optio
n of 
IVF 
or 
IVF 
plus 
home
opath
y 
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 Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 
Resp
onden
ts 
         
reme
dies 
so 
I’ve 
gaine
d 
some 
knowl
edge  
5 None It is 
effecti
ve for 
Inferti
le 
wome
n 
Blan
k 
Bla
nk 
Happ
y 
To 
explai
n the 
mecha
nism 
to 
clients 
Blan
k  
Blank Blank 
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Codes used to organise the data from the Nurse’s at The Bridge Centre  
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CODE USED RETRIEVED SEGMENT OF QUOTE 
Concerns about randomisation to placebo 
OK just hope we can recruit enough women to get results 
Q5, 6 
 
Asking women if they are willing to delay treatment with a 
50% chance they will be on a placebo 
Q6, 6 
 
Lack of knowledge on Doctors behalf, unwilling to believe, 
patients not wanting to go on a placebo, patients not 
wanting to delay treatment 
Q8, 3 
 
Patients not wanting to try the homeopathy, patients 
getting angry or upset because trial hasn’t worked or no 
benefits 
Q8, 4 
 
Consent from women and compliance 
Q8, 6 
 
 
Scepticism 
I’m interested but sometimes sceptic, I like the idea of 
research and proof if scientific research can justify then 
Q3, 6 
 
Lack of knowledge on Doctors behalf, unwilling to believe, 
patients not wanting to go on a placebo, patients not 
wanting to delay treatment 
Q8, 3 
 
 
Not enough time 
Talk 30 mins to one hour, probably best to organise further 
talk 
Q4, 3 
 
Not long enough, 5-8 minutes approx. 
Q4, 4 
 
More 
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CODE USED RETRIEVED SEGMENT OF QUOTE 
Q4, 5 
 
Not enough with nurses talks up to one hour 
Q4, 6 
 
 
Request for more information or training 
Need more information 
Q2, 3 
 
Fine with more training re homeopathy 
Q5, 3 
 
To explain the mechanism to clients 
Q6, 7 
 
Knowledge, actually understanding everything I’m telling 
patients before I talk with them 
Q6, 4 
 
 
Belief in benefit 
African background way back, I think believing in rx will 
make someone to use them with a hope of success and 
belief = success 
Q1, 6 
 
Not a quick cure but something that can help/ease illness 
Q2, 6 
 
General wellbeing, find treatment less stressful, patients 
able to move on with life re deciding not to continue with 
treatment 
Q9, 3 
 
More pregnancies 
More relaxed patients 
Q9, 4-5 
 
For certain patients with problems like overweight which may affect their chances of having children I think they will benefit from the project.  Relaxes the body and minds as well as relieves their stresses therefore promote health thus 
success in their treatment 
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CODE USED RETRIEVED SEGMENT OF QUOTE 
 
Q9, 6 
 
Potentially it could be of great benefit to clinic if we can sell 
the clinic as having an option of IVF or IVF plus 
homeopathy 
Q9, 7 
 
 
No comment or no entry 
None 
Q1, 9 
 
No experience 
Q1, 5 
 
 
Q1, 2 
 
 
Q2, 2 
 
blank 
Q3, 7 
 
blank 
Q4, 7 
 
 
Q4, 2 
 
 
Q5, 2 
 
 
Caution due to unknown interactions 
Professional, patients, drugs not known so tend to stop 
Q1, 4 
 
 
Some previous knowledge or experience Echinacea with colds, rescue remedy with stress, gingko 
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CODE USED RETRIEVED SEGMENT OF QUOTE 
balboa for memory, I’ve never seen a homeopath but as a 
midwife I’ve cared for many women using remedies so I’ve 
gained some knowledge 
Q1, 8 
 
Personal Hay fever 
Q1, 3 
 
 
Seen as more natural 
To be an alternative if applicable for conventional medicine 
and to be more of a natural medicine 
Q2, 4 
 
 
Let them try 
I don’t know of any but if I did I would probably say try 
anything (safe) once if it will help you get pregnant or have 
another postitive effect on your health. 
Q3, 4 
 
It is their choice, if it is beneficial then let them try 
Q3, 5 
 
 
Cautious but positive 
It’s a very good idea but not enough to impart knowledge 
Q3, 3 
 
I’m interested but sometimes sceptic, I like the idea of 
research and proof if scientific  research can justify then 
fantastic 
Q3, 6 
 
Not bad but I just don’t know how the patients will respond 
to it 
Q5, 4 
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CODE USED RETRIEVED SEGMENT OF QUOTE 
Willing to take part 
Fine with more training re homeopathy 
Q5, 3 
 
postive 
Q5, 5 
 
Happy 
Q5, 7 
 
 
Unwilling to take part  
Ethical issues 
Ethical dilemmas – consider!!! 
Q8, 5 
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Figure 22 Poster 
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Poster that was accepted for display at the William Harvey Day 16th October 2007
  
APPENDICES 
Appendix	  8	  Results	   738	  
 
 
 
 
APPENDICES 
Appendix	  9	  Damage	  to	  Trial	  Medication	   739	  
APPENDIX 9 Damage To Trial 
Medication 
Damage to Trial Medication 
Upon inspection it was found that the following containers were broken open 
and the tablets were found in the bottom of the white boxes (some tablets 
were also found in the outer brown boxes): 
Subject 1202:    Containers 6 & 10 
Subject 1320:    Container 8 
Subject 2116:    Container 10 
Subject 3216:    Container 10 
Subject 1305:    Container 6 
Subject 1316:    Containers 4 & 6 
Subject 1313:    Container 6 
Subject 1207:    Container 6 
Subject 2219:    Container 6 
Subject 2218:    Container 11 
 
The following containers had broken seals: 
Subject 3215:    Container 7 
Subject 2205:    Container 8 
Subject 3216:    Container 8 
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Subject 2304:    Container 2 
Subject 2220:    Container 1 
Subject 3308:    Container 4 
Subject 3209:    Container 4 
Subject 2113:    Containers 6 & 7 
Subject 3316:    Container 2 
Subject 2117:    Container 4 
Subject 1320:    Container 10 
Subject 1207:    Containers 4 & 8 
Subject 1202:    Container 8 
Subject 2101:    Container 4 
Subject 3208:    Containe 
Subject 1316:    Container 9 
Subject 1203:    Containers 6 & 9 
Subject 1216:    Container 6 
Subject 1313:    Container 3 & 4 
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APPENDIX 10 Data collected from 
Jersey General Hospital 
participants in pilot study 
The Data Collected From The Jersey General Hospital For Trial 
OVCT-001 
The quantitative data regarding clinical outcomes was collected via a 
specially designed case report form (CRF) and comprised of the following 
variables per cycle/visit: 
• Age 
• BMI 
• Endometrial thickness (mm) 
• Ovarium volume (cm3 ) for left and right ovaries 
• Antral follicle count for left and right ovaries 
• Progesterone level on day 21 (nmol/L) 
• Prescribed Treatment 
• Dose of prescribed treatment 
• FSH level day 3-5 (iu/L) 
• Estradiol  level (pmol/L) 
• HCG Mediation  
• HCG medication dose 
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• Pregnancy test  
: 
 
 
 
Figure 23 Snapshot of The Information From The Case Report Forms (CRF) 
 
 
 
 
Figure 24 Snapshot of data from the EHIQ 
The two domains that are of particular interest to this study are: 
9. Trying to maintain privacy during treatment is stressful. 
 
34.  I find trying to balance fertility treatment with my other commitments stressful. 
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Figure 25 Table to show the results for domains 9 and 34 of the EHIQ 
Analysis 
Subject 1301 showed the highest possible score for cycles one and five 
showing that it was definitely untrue that they had problems with maintaining 
privacy and with balancing other commitments with their treatment.   
Subject 1201 scored 3 for question 9 and 2 for question 34 indicating that 
they were not sure if they found trying to maintain privacy during treatment 
stressful and that it was mostly true that they found find trying to balance 
fertility treatment with their other commitments stressful. 
Subject 1202 scored 2 for question 9 and 2 for question 34 indicating that it 
was mostly true that they found trying to maintain privacy during treatment 
stressful and that it was mostly true that they found find trying to balance 
fertility treatment with their other commitments stressful. 
Summary 
Due to the small sample size it is unclear if there is a general trend for the 
two questions that relate to privacy and balancing commitments.  There is not 
enough evidence to prove or disprove the hypothesis suggested by the ARU 
APPENDICES 
Appendix	  	  10	  Patient	  Data	  from	  Strand	  3	   745	  
nurse that women were reluctant to attend appointments due to the stress 
caused by forced disclosure of their treatment at work. 
 
 
 
Figure 26 Snapshot to show the results of the EQ-5D  
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The Results Per Subject 
 
Subject 1201 
 
Randomisation 
number 
Age 
band 
(years) 
Treatment 
Group 
Trial medication 
group 
Outcome 
1201 30-35 Clomid Ovarium 
compositum 
Treatment 
stopped after 2 
months 
Table 50 Subject 1202 
Summary of CRF for subject 1201 
The differences that were observed between cycle one and cycle two were 
that the endometrial thickness diminished by 3mm, the progesterone level on 
day 21 declined by 15.5 nm/l and there was no change in follicle count or 
ovarian volume. 
The EHIQ for subject 1201 
 
 
Figure 27 Snapshot of EHIQ for subject 1201 
The baseline measurement for Emotional Health in Infertility was a total 
score of 160.  They rated themselves as being in excellent health with no 
emotional problems at that time.  No further measurements were taken for 
this subject.  
This respondent scored 3 for question 9 and 2 for question 34 indicating that 
they were not sure if they found trying to maintain privacy during treatment 
stressful and that it was mostly true that they found find trying to balance 
fertility treatment with their other commitments stressful. 
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The EQ-5D for subject 1201 
 
Subject 1201 rated themselves as 11111 which indicates no problems with 
mobility, self-care, activity, pain and anxiety.  On the VAS she rated herself 
as 95/100 indicating that they see themselves in an almost optimal health 
state. 
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Subject 1202 
 
1202 30-35  Clomid Ovarium 
compositum 
Treatment 
stopped after 1 
months 
Figure 28 Subject 1202 
Summary of CRF for subject 1202 
Subject 1202 shows a decrease of 1.1cm3 in left Ovarium volume and a 
decrease in right Ovarium volume of 2.8 cm3 between visit one and visit two.  
The follicle count increased by one follicle on both the left and the right 
ovaries between visit one and visit two.  The progesterone level increased by 
35.8 nmol/l between visit one and visit two. 
 
 
 
Figure 29 Snapshot of The EHIQ for subject 1202 
The baseline measurement for Emotional Health in Infertility was a total 
score of 160.  They rated themselves as being in good health with quite a lot 
of emotional problems at that time.  No further measurements were taken for 
this subject.  
Subject 1202 scored 2 for question 9 and 2 for question 34 indicating that it 
was mostly true that they found trying to maintain privacy during treatment 
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stressful and that it was mostly true that they found find trying to balance 
fertility treatment with their other commitments stressful. 
 
The EQ-5D for subject 1202 
 
The subject rated herself as 11111 which indicates no problems with mobility, 
self-care, activity, pain and anxiety.  On the VAS she rated herself as 78/100 
indicating that she perceived herself to be in a good health state 
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Subject 1301 
 
1301 >35 Clomid Placebo Completed 6 
months of 
treatment 
Table 51 Subject 1301 
Summary of CRF for subject 1301 
 
There were seven visits for subject 1301 which makes it possible to 
represent the collected data in a graphic form: 
 
 
Figure 30 Graph to show the changes in endometrial thickness for subject 1301 
 
 
 
Figure 31 Graph to show the changes in ovarium volume in subject 1301 
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Figure 32 graph to show antral volume count for subject 1301 
 
 
Figure 33 graph to show progesterone levels for subject 1301 
 
Figure 34 Graph to show FSH levels for subject 1301 
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Figure 35 Graph to show Estradiol levels for subject 1301 
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The EHIQ for subject 1301 
 
 
Figure 36 The EHIQ for subject 1301 
 
The EQ-5D for subject 1301 
 
 
Figure 37 The EQ-5D for subject 1301 
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Summary 
The low number of subjects recruited and the low number of appointments 
that they attended means that it has not been possible to perform a statistical 
analysis.  We can see that we were able to capture both quality of life 
measurements and fertility outcomes with the trial design. 
We are able to show changes over time for one patient and differences 
between each subject. 
We are not able to comment on a trend or correlation as insufficient data was 
captured and a high degree of variation between both subjects and visits is to 
be expected in this clinical situation. 
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APPENDIX 11 Qualitative Data 
From Strand 4 
Strand 4 
The Work Related Concerns Of Infertile Women 
 
Coded data from Part 1 
 
Table 52 Table to show the quotes relating to the codes ‘identity as an employee or treatment 
seeker’ with associated sub codes 
 
 
Doc Code Segment 
TH Identity as a 
treatment 
seeker or 
employee\proxi
mity of clinic to 
work 
P I had a good number of blood tests over the next few 
months. I was a nursery manager and at that point I 
worked in a nursery on a hospital site so didn't really 
need to say much as it was easy to fit in 
TH Identity as a 
treatment 
She was fine about it, chatty, agreed the time I needed 
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Doc Code Segment 
seeker or 
employee\gend
er of boss 
TH Identity as a 
treatment 
seeker or 
employee\flexibi
lity 
Any hospital appointments that followed I emailed her 
about to let her know, and she was happy for me to 
attend. 
TH Identity as a 
treatment 
seeker or 
employee\flexibi
lity 
I was honest about my appointments, if they were in 
the middle of the day I took holiday so as not to be a 
complete pain, if they were early or late I worked 
around them. 
TH Identity as a 
treatment 
seeker or 
employee\flexibi
lity 
He said he appreciated my being open and that I could 
just let the manager know when my appointments 
were, that was fine. 
TH Identity as a 
treatment 
seeker or 
employee\flexibi
lity 
The manager and director happily accommodated my 
appointments 
TH Identity as a They let me book the Monday as annual leave for the 
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Doc Code Segment 
treatment 
seeker or 
employee\Using 
annual leave for 
treatment time 
IUI, and then we waited. 
TH Identity as a 
treatment 
seeker or 
employee 
(and even though that day he was telling us  
about how the business was developing and how our 
roles could grow and change within it) he made it very 
clear that even though it put a spanner in the works 
from a professional point of view, on a personal level 
he was really pleased. 
TC Identity as a 
treatment 
seeker or 
employee\comp
any has clear 
policy on IVF 
We have it written in our t&c that females having Ivf 
are allowed an extra 5 days leave in a rolling 12 mths, 
so  
if you had 1 cycle every year you can claim the extra 5 
days leave, men and civil partners are allowed 2 days 
in a rolling 12 mths. 
TC Identity as a 
treatment 
seeker or 
employee\Using 
annual leave for 
treatment time 
I have requested my 5 days together as I am going 
abroad and have taken a weeks leave before and a 
weeks leave after. 
SW Identity as a 
treatment 
seeker or 
Yes, I got the job on merit, I had no problems 
whatsoever with having time off; working for a large 
organisation, with a terrific foundation on offering staff 
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Doc Code Segment 
employee\flexibi
lity 
a good work / life balance – I  
was allowed time off for egg collection and embryo 
transfer… 
SW Identity as a 
treatment 
seeker or 
employee\comp
any has clear 
policy on IVF 
– I was allowed time off for egg collection and embryo 
transfer… 
SW Identity as a 
treatment 
seeker or 
employee\Using 
annual leave for 
treatment time 
I was able to take a combination of flexi and holiday  
as I felt necessary. 
SOC Identity as a 
treatment 
seeker or 
employee\gend
er of boss 
luckily it was a female manager who dealt with it 
ND Identity as a 
treatment 
seeker or 
employee\proxi
mity of clinic to 
As we chose a clinic some distance from our home, 
this led to quite a lot of time off 
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Doc Code Segment 
work 
RBI Identity as a 
treatment 
seeker or 
employee\proxi
mity of clinic to 
work 
Luckily my clinic was only 20 minutes from the office 
and my scans and blood tests were always first thing 
RBI Identity as a 
treatment 
seeker or 
employee\Using 
annual leave for 
treatment time 
have now been to Cyprus twice without anyone at  
work having any idea of the reasons behind our trip – 
just a last minute holiday. 
AJ 
 
 
 
Identity as a 
treatment 
seeker or 
employee 
When i 1st started my journey I was an assistant 
manager in a well know retail store. My store manager 
and area manager, at first, were quite sympathetic. 
This soon changed  
when i needed to go for daily bloods and scans. I was 
made aware that this was very inconvenient to the 
business and sometimes I was made to still let the 
cleaners in the  
store at 7 am and wait until another manager arrived to 
relieve me from my duties. 
AJ Identity as a 
treatment 
seeker or 
This made me feel anxious as I had to then travel 8  
miles to the hospital, get parked up and be there 
before 9. Whilst in the waiting area I was constantly 
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Doc Code Segment 
employee\proxi
mity of clinic to 
work 
aware of the time as they needed me back asap. 
Sometimes 2 hours would  
pass waiting from bloods and then onto scans, 
depending on how many patients were in that day. O 
AJ Identity as a 
treatment 
seeker or 
employee 
I was very upset in front of the nurses as I knew that it 
would be frowned upon as saturdays are our busiest 
day and my area manager was visiting too. 
AJ Identity as a 
treatment 
seeker or 
employee 
She was very annoyed and her words were "Andrea. I 
am very sympathetic regarding your needs but I have 
a  
business to run and your wanting to leave on a 
Saturday afternoon?! 
AJ Identity as a 
treatment 
seeker or 
employee 
attitude changed towards my treatment but then from 
then on i thought, stuff it, they don't care about me, Im 
just a number and instead of having the odd day off 
after embyo transfer  
etc, i had more time off to suit my needs and not of 
that of the business! 
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2. Emotional Distress 
 
Table 53 Table to show retrieved segments of data relating to emotional distress in the seven 
direct responses to forum posting 
 
Doc Code Retrieved Segment 
TH Emotional 
distress 
and to be honest I was not much fun, sometimes I'd 
come back to work on a high because I'd had good 
news,  
sometimes in pieces because it was not the news I'd 
hoped for. 
TH Emotional 
distress 
I was absolutely broken to find out that there was only 
one follicle that had grown large enough and on that 
basis we needed to cancel my cycle. The centre 
suggested to give that follicle a chance and not waste 
the whole cycle, we could convert it to IUI. We decided 
to do that, and I went back to work in pieces 
TH Emotional 
distress\b
eing 
worthy 
They offered to send me home but I stayed and 
finished  
the day 
SOC Emotional 
distress 
I had to take a day off one day because I was so upset 
after a terrible appointment with a gynaecologist and 
having to explain why was awful, 
SOC Emotional 
distress\fi
so I have that stress plus the stress of not getting paid 
for any  
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Doc Code Retrieved Segment 
nancial 
loss 
time off I take for appointments.  
SOC Emotional 
distress\fi
nancial 
loss 
proof to show work, that's also about 4 hours of wages 
a month I am missing out on, which doesn't sound like 
much but really it's the principle and I don't exactly get 
paid very much anyway 
AJ Emotional 
distress 
I have been trying assisted conception now for four 
years. 3 failed iuis, 7 ivf with 2 pregnancies which 
sadly ended in miscarraige. my words that could only 
describe this process is its like being on an emotional 
roller coaster. Very stressful at times and I felt like a 
was the only person that understood what I was going 
through. 
AJ Emotional 
distress\fe
eling 
isolated 
My partner had 2 children to a previous relation ship 
which made things more difficult for me to cope with, 
and at times i thought that he didn't even 
understand,as after all he had 2 children,so how could 
he?  
AJ Emotional 
distress\c
ounselling 
In time counselling helped me to see things differently 
AJ Emotional 
distress\b
eing 
On my return i felt that guilty that i often missed my 
break or lunch break as i felt i and to make the time 
back.  
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Doc Code Retrieved Segment 
worthy 
AJ Emotional 
distress 
At this point i went on to the sales floor and cried my 
heart ou 
AJ Emotional 
distress 
She did her floor walk with the store manager looked 
at me and ignored me.  
AJ Emotional 
distress 
I felt hurt and anxious.  
AJ Emotional 
distress 
Whilst typing it up i was sobbing as i felt humiliated 
and in disbelieve that i had to do it 
AJ Emotional 
distress 
My 1st failed ivf attempt i was that upset that my 
partner rang in work for me to say that i wouldn't be in 
work the following day. I was hysterical during the 
conversation 
AJ Emotional 
distress\fi
nancial 
loss 
wouldn't be in work the following day. I was hysterical 
during the conversation and my manager could hear 
me in the background but because the company policy 
is to ring in yourself I didn't get paid. 
AJ Emotional 
distress 
This made me feel angry and i spoke to the store 
manager about it saying that i felt sick and really upset 
AJ Emotional 
distress\p
utting you 
attitude changed towards my treatment but then from 
then on i thought, stuff it, they don't care about me,Im 
just a number and instead of having the odd day off 
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Doc Code Retrieved Segment 
first after embyo transfer etc, i had more time off to suit my 
needs and not of that of the business! 
3. Trust and Support 
 Table 54 Table to show the retrieved code segments for Trust and Support in the seven direct 
responses from the forum 
 
Doc Code Segment 
TH Trust and 
Support from 
Manager 
She was fine about it, chatty, agreed the time I 
needed, and knowing my tendancy to push myself 
a bit hard sometimes came and did a 'welfare 
check' on my first day back at work.  
TH Trust and 
Support from 
Manager\empa
thy from boss 
both the owner and the manager have two young  
children and understood that much as I wanted 
this to happen, didn't mean it ever would and did 
not impair my ability to do my job in the meantime.  
TH Trust and 
Support from 
Manager\empa
thy from boss 
We got the green light to go, and my manager was 
almost as excited as we were, possibly more 
because she didn't have the fear to deal with that 
came with it. 
TH Trust and 
Support from 
Manager\empa
thy from boss 
My drugs were delivered to work, she signed for 
them and we both squeaked with excitement, like 
we had just signed for a baby in a box. 
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Doc Code Segment 
TH Trust and 
Support from 
Manager\empa
thy from boss 
we all jumped up and down about the result. Even 
the director  
TH Trust and 
Support from 
Manager 
d I have done this with the goodwill, support, 
compassion and empathy of my employer. 
SW Trust and 
Support from 
Manager\empa
thy from boss 
I have fabulous understanding bosses 
SW Trust and 
Support from 
Manager 
work for a forward thinking organisation – 
ND Trust and 
Support from 
Manager\empa
thy from boss 
tive secondary school and we have an assistant 
head who is  
responsible for staff welfare. When I told her about 
our IVF she was incredibly supportive and told me 
that I could take whatever time I needed and not to 
worry if appointments  
were sometimes at the last minute as that was the 
"nature of the beast". 
RBI Trust and 
Support from 
I am a branch manager and have had to tell my 
MD on a couple of occasions about employees 
APPENDICES 
Appendix	  	  11	  	  Qualitative	  Data	  from	  Strand	  4	   768	  
Doc Code Segment 
Manager\lack 
of empathy 
 
  
being pregnant. HER (the MD’s) response has 
always been very negative –  
what it will cost the company for cover, training 
requirements when employees’ return to work etc. 
She did at one point tell me she hated pregnant 
women! (She does have children of her own.) 
RBI Trust and 
Support from 
Manager\lack 
of empathy 
I do not know what the response from my MD 
would be if I told her I was having fertility 
treatment.  
AJ Trust and 
Support from 
Manager\lack 
of empathy 
This was done on a rota basis and made me feel 
upset as to why the store manager couldn't get the 
others to do it to help me out 
AJ Trust and 
Support from 
Manager\feelin
g let down 
The 1st time i felt let down and resentful 
AJ Trust and 
Support from 
Manager\empa
thy from boss 
The nurses were very sympathetic  
and apperently hear about these work related 
stories all of the time. 
AJ Trust and 
Support from 
Manager\lack 
After that she was quite horrible about my 
treatment 
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Doc Code Segment 
of empathy 
AJ Trust and 
Support from 
Manager\lack 
of empathy 
that rules could be bent and that she should have 
had more empathy. 
AJ Trust and 
Support from 
Manager\empa
thy from boss 
but I wonder to myself if he is more empathetic as 
he himself has friends who have had ivf treatment 
so he understands how difficult it can be.  
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Table 55 Table to show the retrieved quotes coded for ‘being open’ and ‘non-disclosure’ by the 
seven direct responses from the forum 
 
Doc Code Retrieved Segment 
TH 
 
Being open but I was open with my deputy manager as he and I 
worked very closely together and I'm not great at 
hiding things. 
TH Being open My first real discussion with my line manager 
(Regional Operations Manager) about this was when I 
recieved an appointment for a laparoscopy and dye 
test. My letter came just before my annual appraisal, 
so once we had agreed our business targets etc, we  
discussed on a personal level that we had been trying 
for a year and a half for 'number 2' at that point and 
that this is where I was at with investigating our 
infertility 
TH Being open I explained we had been trying for a second child for 
some time, that at this point we didn't think it would be 
possible but that I was taking a drug (clomid) that 
impacts on your hormones and I would need a blood 
test at day 21. They were fine with this and I think 
appreciated that I could have completely kept this to 
myself 
TH Being open I was honest about my appointments, if they were in 
the middle of the day I took holiday so as not to be a 
complete pain, if they were early or late I worked 
around them. 
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Doc Code Retrieved Segment 
TH 
 
Being open but I was open with my deputy manager as he and I 
worked very closely together and I'm not great at 
hiding things. 
TH Being open My first real discussion with my line manager 
(Regional Operations Manager) about this was when I 
recieved an appointment for a laparoscopy and dye 
test. My letter came just before my annual appraisal, 
so once we had agreed our business targets etc, we  
discussed on a personal level that we had been trying 
for a year and a half for 'number 2' at that point and 
that this is where I was at with investigating our 
infertility 
TH Being open I explained we had been trying for a second child for 
some time, that at this point we didn't think it would be 
possible but that I was taking a drug (clomid) that 
impacts on your hormones and I would need a blood 
test at day 21. They were fine with this and I think 
appreciated that I could have completely kept this to 
myself 
TH Being open I had spoken to the owner/ director about the fact that 
we were waiting to find out if we  
could have IVF when we had been making an off site 
visit to another setting, and we had a lengthy car 
journey because I had an opportunity to instigate this 
when there was a  
good couple of hours available. I said I was speaking 
to him about this because there would be periods of 
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Doc Code Retrieved Segment 
TH 
 
Being open but I was open with my deputy manager as he and I 
worked very closely together and I'm not great at 
hiding things. 
TH Being open My first real discussion with my line manager 
(Regional Operations Manager) about this was when I 
recieved an appointment for a laparoscopy and dye 
test. My letter came just before my annual appraisal, 
so once we had agreed our business targets etc, we  
discussed on a personal level that we had been trying 
for a year and a half for 'number 2' at that point and 
that this is where I was at with investigating our 
infertility 
TH Being open I explained we had been trying for a second child for 
some time, that at this point we didn't think it would be 
possible but that I was taking a drug (clomid) that 
impacts on your hormones and I would need a blood 
test at day 21. They were fine with this and I think 
appreciated that I could have completely kept this to 
myself 
time that it would be time consuming and I really 
needed his goodwill to be able to do it without 
compromising my position 
TH Being open but safe in the knowledge that I have no big secret 
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Doc Code Retrieved Segment 
TH 
 
Being open but I was open with my deputy manager as he and I 
worked very closely together and I'm not great at 
hiding things. 
TH Being open My first real discussion with my line manager 
(Regional Operations Manager) about this was when I 
recieved an appointment for a laparoscopy and dye 
test. My letter came just before my annual appraisal, 
so once we had agreed our business targets etc, we  
discussed on a personal level that we had been trying 
for a year and a half for 'number 2' at that point and 
that this is where I was at with investigating our 
infertility 
TH Being open I explained we had been trying for a second child for 
some time, that at this point we didn't think it would be 
possible but that I was taking a drug (clomid) that 
impacts on your hormones and I would need a blood 
test at day 21. They were fine with this and I think 
appreciated that I could have completely kept this to 
myself 
SW Being open I had a job interview in October 2009, one of the 
questions that I was asked was “would you consider 
job-share?”  to which I responded that I was 
specifically looking at a full-time role at the time, but 
wouldn’t rule out the possibility of being a job sharer in 
the future.   I was asked to elaborate further!  I advised 
the interview panel that I was hoping to undergo 
fertility treatment in the future, and if successful, I 
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Doc Code Retrieved Segment 
TH 
 
Being open but I was open with my deputy manager as he and I 
worked very closely together and I'm not great at 
hiding things. 
TH Being open My first real discussion with my line manager 
(Regional Operations Manager) about this was when I 
recieved an appointment for a laparoscopy and dye 
test. My letter came just before my annual appraisal, 
so once we had agreed our business targets etc, we  
discussed on a personal level that we had been trying 
for a year and a half for 'number 2' at that point and 
that this is where I was at with investigating our 
infertility 
TH Being open I explained we had been trying for a second child for 
some time, that at this point we didn't think it would be 
possible but that I was taking a drug (clomid) that 
impacts on your hormones and I would need a blood 
test at day 21. They were fine with this and I think 
appreciated that I could have completely kept this to 
myself 
would like to take up a part-time role to spend as much 
time as possible at home. 
SW Being open I wasn’t expecting to be handed the job on a plate, but 
I would have felt guilty if I had been offered the job, 
then handing my employers a schedule of treatment to 
arrange the time off.  But by the same token, I wanted 
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Doc Code Retrieved Segment 
TH 
 
Being open but I was open with my deputy manager as he and I 
worked very closely together and I'm not great at 
hiding things. 
TH Being open My first real discussion with my line manager 
(Regional Operations Manager) about this was when I 
recieved an appointment for a laparoscopy and dye 
test. My letter came just before my annual appraisal, 
so once we had agreed our business targets etc, we  
discussed on a personal level that we had been trying 
for a year and a half for 'number 2' at that point and 
that this is where I was at with investigating our 
infertility 
TH Being open I explained we had been trying for a second child for 
some time, that at this point we didn't think it would be 
possible but that I was taking a drug (clomid) that 
impacts on your hormones and I would need a blood 
test at day 21. They were fine with this and I think 
appreciated that I could have completely kept this to 
myself 
to be upfront and honest 
RBI Being 
open\non 
disclosure 
When I discovered I would need IVF treatment, I made 
the decision not to tell 
RBI Being open I told one employee who would be covering for me 
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Doc Code Retrieved Segment 
TH 
 
Being open but I was open with my deputy manager as he and I 
worked very closely together and I'm not great at 
hiding things. 
TH Being open My first real discussion with my line manager 
(Regional Operations Manager) about this was when I 
recieved an appointment for a laparoscopy and dye 
test. My letter came just before my annual appraisal, 
so once we had agreed our business targets etc, we  
discussed on a personal level that we had been trying 
for a year and a half for 'number 2' at that point and 
that this is where I was at with investigating our 
infertility 
TH Being open I explained we had been trying for a second child for 
some time, that at this point we didn't think it would be 
possible but that I was taking a drug (clomid) that 
impacts on your hormones and I would need a blood 
test at day 21. They were fine with this and I think 
appreciated that I could have completely kept this to 
myself 
while I attended appointments. 
RBI Being 
open\non 
disclosure 
I will admit I did come up with some ridiculous ‘white 
lies’ to tell to other members of staff. 
RBI Being 
open\non 
When my IVF didn’t work and I was told I would 
require donor eggs I decided I didn’t want anyone in 
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Doc Code Retrieved Segment 
TH 
 
Being open but I was open with my deputy manager as he and I 
worked very closely together and I'm not great at 
hiding things. 
TH Being open My first real discussion with my line manager 
(Regional Operations Manager) about this was when I 
recieved an appointment for a laparoscopy and dye 
test. My letter came just before my annual appraisal, 
so once we had agreed our business targets etc, we  
discussed on a personal level that we had been trying 
for a year and a half for 'number 2' at that point and 
that this is where I was at with investigating our 
infertility 
TH Being open I explained we had been trying for a second child for 
some time, that at this point we didn't think it would be 
possible but that I was taking a drug (clomid) that 
impacts on your hormones and I would need a blood 
test at day 21. They were fine with this and I think 
appreciated that I could have completely kept this to 
myself 
disclosure my employment to know a 
AJ Being open When I arrived at work that morning I had a quiet word 
with the area manager and explained that depending 
on my blood results that afternoon I may need to go 
infer treatment. 
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5.  The legal position 
 
Doc Code Segment 
TC The legal 
position\sexua
l 
discrimination 
men and civil partners  
are allowed 2 days in a rolling 12 mths. 
SW The legal 
position\sexua
l 
discrimination 
maybe I would have kept quiet if I was employed by 
a smaller company – certainly in previous jobs I was 
told quite candidly that they would no longer employ 
ladies of ‘child bearing age’ 
SOC The legal 
position\discli
pinary action 
at work 
but I had disciplinary action as a result of being off 
that day 
SOC The legal 
position\discli
pinary action 
at work 
The worst thing is that people with children are 
allowed time off for 'dependant care', I know more 
than a few people who abuse this and take days off 
pretending that they can't get child care and they're 
not disciplined for it but when I had to take a day off 
because I was so distressed it went through as 
'sickness' and I was given a verbal warning which 
stays on my file for a year. 
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AJ The legal 
position\sexua
l 
discrimination 
and hurt i rang the union who gave me some really 
good advise and they told me what she was doing 
was more of sexual discrimination rather than 
victimisation.  
AJ The legal 
position 
After getting advise i sort of knew where i stood, 
although there are no laws in place for ivf and just 
pregnancy  
laws, the advise given made me feel better.   
 
Table 56 Table to show the retrieved segments for the legal position and sexual discrimination 
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6. The demands of treatment 
 
Doc Code Segment 
TH The 
demands of 
treatment 
Possible but that I was taking a drug (clomid) 
that impacts on your hormones and I would 
need a blood test at day 21. 
SW The 
demands of 
treatment 
as the travelling alone would be a minimum of 2 
hours each time. 
SOC The 
demands of 
treatment 
Now I'm going to need time off twice a month for 
ultrasounds and blood tests and it will be extra 
stressful because these appointments will be 
made over the phone 
AJ The 
demands of 
treatment 
They said that I may need to go back that day 
for my treatment. 
AJ The 
demands of 
treatment 
This was really frustrating as it is not an exact 
science and all depends on your body clock 
 
Table 57 Table to show the retrieved segments for the code ‘The demands of Treatment’ 
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7. Confidentiality 
 
Document Code Segment 
TC Confidentiality My company have been fantastic and haven't 
even asked to see any evidence of treatment.  
SOC Confidentiality I had no choice but to tell work because I work in 
a call centre and can't just come in and leave 
when I like, i have to show proof and they have to 
photocopy everything and time off  
has to be approved depending on the staffing.  
SOC Confidentiality it took me about 5 weeks to pluck up the courage 
to show a manager my letter from assisted 
conception with my first appointment on it 
because I was so embarrassed, my boyfriend 
also works in here so that makes me feel even 
more  
embarrassed - I really wish that managers in here 
didn't know so much about my personal life.  
AJ Confidentiality Whislt typing it up i was sobbing as i felt 
humiliated and in disbelieve that i had to do it 
 
Table 58 Table to show the retrieved segments for Confidentiality  
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8. Career Prospects 
The concern that career or job might be jeopardized by the choice to 
undertake infertility treatment was only expressed once in one document in 
this sample. 
Docume
nt 
Code Segment 
RBI career prospects I do not know what the response 
from my MD would be if I told her I 
was having fertility treatment. It is so 
expensive though I cannot take the 
risk of letting on and then losing my 
job because of it – through work life 
just being made generally difficult, 
so forced out. 
 
Table 59 Data segments for career prospects
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Table 60 Coded data from forum in strand 4 
Coded Data from Forum 
Comme
nt 
Docume
nt 
Code Begi
n 
En
d 
Weigh
t 
score 
Segment Author Creation 
date 
Docume
nt group 
Pag
e 
 my story 
group\15
4 
Identity as an 
employee or a 
treatment 
seeker 
5 5 0 .  It's not so 
much the cost 
of all this 
treatment but 
the cost to 
me 
emotionally, 
and in time 
off work. 
Claire 
Haresnap
e 
20/37/201
3 
11:37:00 
my story 
group 
1 
 my story 
group\14
8 
Identity as an 
employee or a 
treatment 
seeker\Using 
annual leave 
for treatment 
time 
9 9 0  Thanks to 
Easter I 
have not had 
to take too 
much time off 
work but have 
been back a 
week now. 
Claire 
Haresnap
e 
20/44/201
3 
11:44:00 
my story 
group 
1 
 my story 
group\14
5 
Identity as an 
employee or a 
treatment 
seeker\Using 
annual leave 
for treatment 
time 
4 4 0 Am just 
playing the 
waiting game 
now- was 
hoping to 
start asap 
while I am on 
summer 
holidays (I'm 
a teacher). If 
period arrives 
this week, 
embryo 
collection and 
transfer 
would be in 
the first week 
of the new 
term. Not 
very 
convenient! 
Claire 
Haresnap
e 
20/20/201
3 
12:20:00 
my story 
group 
1 
 my story 
group\14
6 
Identity as an 
employee or a 
treatment 
seeker 
1 1 0 now take the 
pill for 39 
days (my 
choice due to 
Claire 
Haresnap
e 
20/25/201
3 
12:25:00 
my story 
group 
1 
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work and life) 
 my story 
group\13
4 
Identity as an 
employee or a 
treatment 
seeker\medica
l sign off work 
3 3 0 Shortly after 
this 2nd failed 
go I took 
some leave ill 
as I was 
suffering from 
anxiety/stress 
Claire 
Haresnap
e 
20/26/201
3 
12:26:00 
my story 
group 
1 
 my story 
group\17
7 
Identity as an 
employee or a 
treatment 
seeker 
1 1 0 I have elderly 
parents I can't 
burden with 
all this and a 
highflying job( 
means very 
little I know - 
but helped at 
first) that 
means that all 
the friends I 
once had are 
doing bigger 
and better 
things and to 
busy to be 
there even if I 
could bear to 
talk about all 
this 
Claire 
Haresnap
e 
20/36/201
3 
12:36:00 
my story 
group 
1 
 my story 
group\19
2 
Identity as an 
employee or a 
treatment 
seeker\workin
g around 
appointmentns 
4 4 0 we finally told 
our families 
and very 
close friends 
what was 
going 
on.  We'd 
wanted to 
keep it private 
but actually 
telling others 
was helpful - 
especially my 
family.  I 
eventually 
also told work 
too when I 
requested to 
go part time 
which helped 
Claire 
Haresnap
e 
20/27/201
3 
20:27:00 
my story 
group 
1 
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enormously. 
 my story 
group\18
1 
Identity as an 
employee or a 
treatment 
seeker\Using 
annual leave 
for treatment 
time 
12 12 0  Ive taken 
time off work 
and Im being 
very lazy! 
Claire 
Haresnap
e 
20/44/201
3 
20:44:00 
my story 
group 
1 
 my story 
group\12
8 
Identity as an 
employee or a 
treatment 
seeker\proximi
ty of clinic to 
work 
1 1 0   The waiting 
lists for NHS 
funded IVF 
was outside 
of our 
timescales so 
we chose to 
go privately, 
made easy by 
the fact that 
Bourn Hall 
Clinic was 
about 20 
minutes down 
the road. 
Claire 
Haresnap
e 
10/38/201
3 
09:38:00 
my story 
group 
1 
 my story 
group\12
6 
Identity as an 
employee or a 
treatment 
seeker\No 
clear company 
policy in place 
8 8 0 Also not sure 
how much 
time to take 
off from 
work(very 
stressful 
workplace!!) 
What do you 
think is 
acceptable? 
Claire 
Haresnap
e 
10/36/201
3 
09:36:00 
my story 
group 
1 
 my story 
group\12
4 
Identity as an 
employee or a 
treatment 
seeker 
2 2 0 Does anyone 
know how 
long after 
planning how 
long before 
treatment 
starts 
roughly.  How 
much time 
Claire 
Haresnap
e 
10/34/201
3 
09:34:00 
my story 
group 
1 
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will I need off 
work?  I am a 
teacher and it 
obviously has 
a big impact 
on the 
children I 
teach when I 
am 
continually 
out at 
appointments
?  
 my story 
group\12
0 
Identity as an 
employee or a 
treatment 
seeker\medica
l sign off work 
28 30 0 e finally saw 
the Cons 
again whilst I 
was on sick 
leave to talk 
through the 
treatment 
options and 
she told us 
we could start 
as soon as 
possible as 
there was in 
fact DS 
available and 
no waiting list 
Claire 
Haresnap
e 
10/26/201
3 
09:26:00 
my story 
group 
1 
 my story 
group\11
7 
Identity as an 
employee or a 
treatment 
seeker\medica
l sign off work 
15 15 0 I had 
depression 
and anxiety 
and had been 
signed of 
work prior to 
our IUI 
commencing, 
the 
miscarriage 
from our IVF 
just 
compounded 
that 
Claire 
Haresnap
e 
10/22/201
3 
09:22:00 
my story 
group 
1 
 my story 
group\11
3 
Identity as an 
employee or a 
treatment 
seeker\proximi
ty of clinic to 
work 
4 4 0 Anyway fast 
forward a few 
months and 
we have been 
really lucky 
we 
have found a 
Claire 
Haresnap
e 
10/13/201
3 
09:13:00 
my story 
group 
1 
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clinic 30 mins 
from home 
with excellent 
results and 
no NHS 
waiting list. 
 my story 
group\10
2 
Identity as an 
employee or a 
treatment 
seeker\medica
l sign off work 
8 8 0 So, the 
rollercoaster 
began in 
earnest in 
January last 
year.  2006 
ended with 
the start of ivf 
cycle (icsi) 
number 1.  It 
was the 
hardest thing 
i have ever 
done.  Dr'ing 
was horrible, i 
suffered 
badly 
emotionally 
and didnt 
make it very 
long into 
treatment 
before 
needing to be 
signed off 
work. 
Claire 
Haresnap
e 
09/18/201
3 
15:18:00 
my story 
group 
1 
 my story 
group\93 
Identity as an 
employee or a 
treatment 
seeker 
6 6 0 We haven't 
told friends or 
family, we are 
quite private 
and want to 
do this our 
way. This site 
really is an 
outlet for me 
to share and 
understand 
others 
experiences, 
even more so 
for us as our 
decision to 
keep this to 
ourselves will 
Claire 
Haresnap
e 
09/51/201
3 
14:51:00 
my story 
group 
1 
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no doubt be 
difficult. I am 
not telling 
work either, 
my job is 
quite 
pressured 
and I couldn't 
stand the 
speculation. 
They already 
suspect I am 
pregnant as I 
put on weight 
post wedding. 
The irony of it 
isn't lost on 
me!! 
 my story 
group\93 
Identity as an 
employee or a 
treatment 
seeker 
8 8 0  Work is 
crazily manic 
and I worry 
about my 
ability to 
balance the 
relaxed zen 
that I need to 
get through 
the next few 
weeks with 
my need to 
perform and 
not let the 
side down in 
work. 
Claire 
Haresnap
e 
09/53/201
3 
14:53:00 
my story 
group 
1 
 my story 
group\87 
Identity as an 
employee or a 
treatment 
seeker\medica
l sign off work 
8 8 0 At this point 
very 
depressed . 
Hit rock 
bottom. Sure 
we would not 
have children! 
Signed off 
work for 2 
weeks 
Claire 
Haresnap
e 
07/11/201
3 
14:11:00 
my story 
group 
1 
 my story 
group\85 
Identity as an 
employee or a 
treatment 
seeker 
1 1 0  Cycles 
appeared to 
return to 
normal then 
april to june 
cycle 7 weeks 
Claire 
Haresnap
e 
02/25/201
3 
18:25:00 
my story 
group 
1 
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- think this is 
due to huge 
stress and 
unhappiness 
at work 
 my story 
group\85 
Identity as an 
employee or a 
treatment 
seeker\workin
g around 
appointmentns 
1 1 0 luckily I had 
given up work 
in september 
so did not 
have to return 
anywhere. My 
husband did, 
but he has 
suffered as a 
result I 
believe, he is 
very 
depressed 
about the 
situation and 
buries himself 
in work 
Claire 
Haresnap
e 
07/02/201
3 
14:02:00 
my story 
group 
1 
 my story 
group\78 
Identity as an 
employee or a 
treatment 
seeker 
6 6 0 But then the 
stress levels 
seem to 
rise Which 
clinic? How 
long to get 
appointment? 
How much 
time off work? 
(as i work as 
a f/t nanny 
difficult to get 
time off!) 
etc.........I'm 
sure you 
have all faced 
the same 
choices! 
Claire 
Haresnap
e 
02/07/201
3 
18:07:00 
my story 
group 
1 
 my story 
group\77 
Identity as an 
employee or a 
treatment 
seeker 
3 3 0  Work wise, I 
am in the 
middle of an 
intensive 
three year 
training 
course where 
TTC isn’t the 
best idea, but 
at the same 
Claire 
Haresnap
e 
02/06/201
3 
18:06:00 
my story 
group 
1 
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time having a 
family means 
so much to us 
that we want 
all the 
precious time 
on our side 
that we can 
get 
 my story 
group\76 
Identity as an 
employee or a 
treatment 
seeker\Using 
annual leave 
for treatment 
time 
8 8 0 . We have 
decided 
though that 
as we have 
holiday in 
April we are 
going to try 
and tie 
everything in 
with that. 
Claire 
Haresnap
e 
02/02/201
3 
18:02:00 
my story 
group 
1 
 my story 
group\73 
Identity as an 
employee or a 
treatment 
seeker\workin
g around 
appointmentns 
1 1 0  I am 33 and 
DH is 36 - we 
got married in 
2006 and had 
a relaxing 
year when 
first married 
before TTC 
when I came 
off the pill at 
the same 
time that I left 
a busy 
stressful job 
in London 
and began 
working for 
myself at 
home.  So we 
were trying 
but not trying 
too hard 
whilst I 
worked on 
getting the 
business off 
the ground.  
Claire 
Haresnap
e 
02/53/201
3 
17:53:00 
my story 
group 
1 
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 my story 
group\70 
Identity as an 
employee or a 
treatment 
seeker\Using 
annual leave 
for treatment 
time 
1 1 0  I was 
intending on 
working right 
up to EC but I 
really 
struggled with 
the side 
effects, 
mainly the hot 
sweats, very 
emotional 
and tiredness 
like i’ve never 
felt before. I 
decided to 
take leave 
from work 
until after ET 
– my 
manager was 
wonderful, so 
supportive! 
Claire 
Haresnap
e 
02/42/201
3 
17:42:00 
my story 
group 
1 
 my story 
group\67 
Identity as an 
employee or a 
treatment 
seeker\Using 
annual leave 
for treatment 
time 
9 9 0 April 07 - 1st 
IVF - this was 
our private 
one.  Got 11 
eggs, 8 
fertilised.  2 
embies 
transferred 2 
days later 
on 14th 
November - a 
4 cell b & a 3 
cell b. Took 
the 2ww off & 
did all I could 
to optimise 
chances 
Claire 
Haresnap
e 
02/34/201
3 
17:34:00 
my story 
group 
1 
 my story 
group\67 
Identity as an 
employee or a 
treatment 
seeker\Using 
annual leave 
for treatment 
time 
12 12 0  Again I didn't 
work during 
2ww & I did 
all I did last 
time & a few 
extra things 
such as 
acupuncture, 
a 
hypnotherapy 
cd, paraben 
Claire 
Haresnap
e 
02/36/201
3 
17:36:00 
my story 
group 
1 
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free shower 
gel etc, no 
nail polish 
etc.  DH like 
the 1st time 
did ALL 
housework et 
 my story 
group\62 
Identity as an 
employee or a 
treatment 
seeker\workin
g around 
appointmentns 
57 58 0  I can’t get 
time off work 
until July so 
expect to 
start down 
regging June 
ish time. 
Claire 
Haresnap
e 
02/44/201
3 
16:44:00 
my story 
group 
1 
 my story 
group\33 
Identity as an 
employee or a 
treatment 
seeker 
3 3 0 I went to my 
GP last 
monday and 
she signed 
me off for a 
week - i do 
not feel ready 
to go back to 
work yet but 
cannot get 
appointment 
at docs till 
tuesday....so 
what do i do 
re work and 
will docs 
renew sick 
note over 
phone. 
Claire 
Haresnap
e 
24/32/201
3 
14:32:00 
my story 
group 
1 
 my story 
group\29 
Identity as an 
employee or a 
treatment 
seeker\Using 
annual leave 
for treatment 
time 
7 7 0 They have 
provisionally 
booked me in 
for EC and 
ET for week 
beginning feb 
13th and We 
have both 
booked 
off  that week 
Claire 
Haresnap
e 
24/19/201
3 
14:19:00 
my story 
group 
1 
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 my story 
group\29 
Identity as an 
employee or a 
treatment 
seeker 
7 7 0  Hoping that it 
is going to be 
that week as 
will be difficult 
to rearrange 
the time off. 
Plus found 
out recently 
that I am 
moving to a 
new 
department in 
work first 
week in 
March around 
time of end of 
the 2 week 
wait 
(assuming 
the dates 
don't 
change). Not 
the best 
timing! Will 
have to get to 
know new 
staff, new 
boss, 
different way 
of working! 
Not ideal but 
hopefully will 
be ok. 
Claire 
Haresnap
e 
24/19/201
3 
14:19:00 
my story 
group 
1 
 my story 
group\28 
2 
Identity as an 
employee or a 
treatment 
seeker\No 
clear company 
policy in place 
6 6 0  as I am the 
first and only 
woman I 
know they 
haven't had 
to work out 
maternity 
leave before, 
let alone 
whether they 
have a policy 
for people 
going through 
IVF 
treatment. 
Claire 
Haresnap
e 
24/16/201
3 
14:16:00 
my story 
group 
1 
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 my story 
group\28 
2 
Identity as an 
employee or a 
treatment 
seeker 
6 6 0  So just 
hoping things 
will work out 
and I won't 
need too 
much time off 
for treatment. 
I think they 
would be fine 
about it - and 
my line 
manager has 
young 
children of his 
own so 
should 
understand - 
but I wouldn't 
be pleased if I 
was them so 
why should 
they be? 
Claire 
Haresnap
e 
24/16/201
3 
14:16:00 
my story 
group 
1 
 my story 
group\18 
Identity as an 
employee or a 
treatment 
seeker\Using 
annual leave 
for treatment 
time 
6 6 0 3th August 
embryo put 
back, again 
not a nice 
experience 
but copable, 
like an 
extended 
smear test...2 
weeks of 
pessaries, 1 
week at work 
the other one 
on leave at 
M-I-L caravan 
to relax. 
Claire 
Haresnap
e 
24/25/201
3 
12:25:00 
my story 
group 
1 
 my story 
group\9 
Identity as an 
employee or a 
treatment 
seeker\proximi
ty of clinic to 
work 
6 6 0  We have 
found a lovely 
clinic nearby 
with 
Claire 
Haresnap
e 
21/18/201
3 
14:18:00 
my story 
group 
1 
APPENDICES 
Appendix	  	  11	  	  Qualitative	  Data	  from	  Strand	  4	   795	  
 my story 
group\6 
Identity as an 
employee or a 
treatment 
seeker\proximi
ty of clinic to 
work 
15 15 0 In October, it 
was 
announced 
that my office 
was going to 
close, this 
really hit me 
as I moved to 
this office so 
that I could 
have mat 
leave, return 
to work part 
time, and be 
close to 
home, that 
made me 
really sad,  
Claire 
Haresnap
e 
21/13/201
3 
14:13:00 
my story 
group 
1 
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Comme
nt 
Docum
ent 
Code Begi
n 
En
d 
Weig
ht 
score 
Segment Author Creati
on 
date 
Docum
ent 
group 
Pag
e 
 my 
story 
group\1
35 
Emotional 
distress 
6 7 0 I will update this piece by 
piece as there is just too 
much to put down in one 
go. I think I am trying to 
prolong putting it all down 
as once it is written down 
then it becomes real, our 
story, something I 
wouldn't wish on my worst 
enemy 
 
Claire 
Haresna
pe 
20᠋† my 
story 
group 
1 
 my 
story 
group\1
33 
Emotional 
distress\feeling 
isolated 
1 1 0 m fairly new on here and 
joined in the hope that 
some of you are in similar 
situations with male 
infertility.  I feel very 
alone, but know that I'm 
not alone - just don't know 
anyone who is in the 
same situation.  My 
cousin has just had a 
positive pregnancy test 
after her 3 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
33 
Emotional 
distress 
7 7 0 I still feel very , very sad 
that I will never have my 
husbands biological 
children, I will never look 
at them and think they 
have his nose / eyes / 
build etc.  I still feel that I 
don't want another man's 
baby and feel guilty that 
my fertility (as far as we 
know) is fine, and cannot 
imagine how he feel 
Claire 
Haresna
pe 
20᠋† my 
story 
group 
1 
 my 
story 
group\1
57 
Emotional 
distress 
4 4 0  Petrified I went on in, 
braved it but having got 
started it was painful, I 
tightned up and I just 
couldnt let them continue, 
so I never found out if my 
fallopian tubes were 
blocked. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
57 
Emotional 
distress 
6 6 0 From my point of view I 
am petrified of going for 
blood tests, the very 
though of injecting daily, 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
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regular trips to clinics, 
having eggs removed fills 
me with horor, I just cant 
see myself ever going 
along that route.  It is 
expensive but we have 
savings that we could dip 
into but also to me a 25-
30% chance of conceiving 
is still very low.  I know 
people who have said, 
surely its worth the pain if 
you end up with a child, of 
course it is, but the 
heartache continues if 
you are not successful 
and where do you stop? 
 my 
story 
group\1
57 
Emotional 
distress 
7 7 0 I am sad, I feel low, not 
very enthusiatic about 
anything in life at the 
moment and I feel that 
there is something 
missing from me as a 
woman and I know I have 
to deal with my feelings in 
my head.  I am a real 
thinker anyway so at the 
moment I am constanly 
thinking about it all and 
my dreams are terrible at 
the moment. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
59 
Emotional 
distress 
1 2 0 Hi there - not sure where 
this post will take me, but 
here goes.....here is my 
story. 
I've been a member on 
INUK for the last couple 
of months, but have really 
only just managed to start 
responding and posting 
very recently.  Mainly 
because I'm finding the 
reality of IF really painful 
and I guess I'm scared 
that by writing things 
down it makes it all so 
much more real.  I feel 
now that I need to get a 
grip though, for my own 
sanity (and my DH's) as 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
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well as moving forward 
and doing something 
about it.  Since 
September I've not really 
done much else but cry 
buckets and buckets.  I 
still do.  Getting a grip is 
hard - it's easier to stick 
my head in the sand, 
which is probably what 
I've done since 
September 2008 
 my 
story 
group\1
59 
Emotional 
distress 
4 4 0 bout three years ago, we 
decided to start a 
family.  I am near to tears 
now when I think how 
niaive I was in thinking it 
would all happen 
immediately.  I feel guilty 
not just at the fact that it's 
me causing the IF, but 
also because it's because 
of me that we waited so 
long before trying.   
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
59 
Emotional 
distress 
5 5 0   IVF was mentioned.  So 
were donor eggs.  It was 
all a blur - like being hit 
with a juggernaut 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
59 
Emotional 
distress 
6 6 0 I know I'm teetering on 
the edge of depression - I 
suffered from it in June 
2006 following severe 
bullying by a senior 
manager at work (I left the 
organisation as a result ut 
now have my own 
business).  I feel helpless, 
scared and so 
desperately sad. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
59 
Emotional 
distress 
7 7 0  They (my parents) dote 
on him - you'd think he 
was their grandson.  Don't 
want to go into that at the 
moment, but the way they 
are with him and their 
involvement with him, 
makes me angry, sad, 
upset, reclusive towards 
them......for a whole 
number of different 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
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reasons.  I'll no doubt talk 
about that another time, 
because I know it's a 
major cause of my 
sadness and feelings of 
anger and 
helplessness whenever I 
see them. 
 my 
story 
group\1
59 
Emotional 
distress 
10 10 0 Anyway, I don't know how 
to finish this post - it's not 
really something I've done 
before, so I'll leave it for 
now and perhaps add to it 
another time.  Hopefully, 
like anyone who may read 
this, one day the longed 
for result will happen and 
this constant ache and 
emptiness will go away. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
58 
Emotional 
distress 
4 4 0 Specialist asked husband 
to do sp.test - to our 
shock it came back low - 
8ml. Advised to do  a 
secondary swim up 
test.  Returned to the 
hospital in Nov for results, 
devastated to find DH 
result was even worse at 
5ml. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
58 
Emotional 
distress 
6 6 0 I just feel numb 
really.  We haven't 
discussed our IF with 
anyone and when I try 
and discuss it with my DH 
he says everything will be 
ok.  He is so optimistic 
that the results will be 
better in May, and I am 
trying to be but it is 
hard.  Im worried that 
things may not 
improve.  It seems a bit 
surreal that we have 
signed the IVF waiting 
list.  I just have so many 
questions to ask and Im 
not sure where to start or 
who to ask.  Not sure 
where to ask them on 
here either really. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
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 my 
story 
group\1
51 
Emotional 
distress 
1 1 0 Unfortunately, I had a 
BFN in June and was 
utterly devestated.  I 
couldn't believe I could 
feel so sad and empty.  I 
couldn't believe that me, 
someone with nothing 
wrong with them, a 
youngish age and of good 
health, could get a BFN.  I 
did not want to have IVF 
again and be so upset 
again 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
51 
Emotional 
distress\counse
lling 
1 1 0 Everything spiralled 
down, with me pushing 
Matt away at times, it was 
easier to grieve alone, or 
so I thought.Matt decided 
that I needed to speak to 
others so he joined me to 
this site where I have 
read so many stories of 
others, and been lucky 
enough to befriend some 
of you.  On reading some 
of the stories, I decided I 
was strong enough to 
look to the future and I 
booked a counciling 
session for us and an 
appointment with the 
hospital nurses to discuss 
the next steps as I wanted 
to again donate my eggs 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
56 
Emotional 
distress 
4 4 0  We were devastated. We 
didn't realise how much 
we wanted the baby until 
we lost it. If that makes 
sense! It was an awful 
time, but slowly we picked 
ourselves up and 
everyone said at least you 
know you can get PG 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
54 
Emotional 
distress 
2 2 0 On Thursday I had a BFN 
from my 2nd IVF attempt; 
I still in a state of shock 
and feel very panic 
stricken. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
Emotional 
distress 
3 3 0   Since then nothing - 
except a whole heap of 
Claire 
Haresna
20᠋
 
my 
story 
1 
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group\1
54 
further loss and much 
suffering.  Within 4 
months of ttc my 
Grandma died, my 
beloved cat started his 
terminal illness, and then 
my M/C 
pe group 
 my 
story 
group\1
54 
Emotional 
distress 
3 3 0   However, had BFN 
whilst on summer holiday, 
and again I suffered huge 
distress because of the 
timing - precisely 2 years 
since M/C. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
54 
Emotional 
distress 
5 5 0 I am currently suffering 
from major panic attackes 
and a sense of urgency 
as to whether to try again 
using a different drug to 
try get some eggs, or to 
abandon all hope of 
having my own and use a 
donor egg 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
54 
Emotional 
distress 
6 6 0 I haven't mentioned yet 
that my beloved cat 
suffered with his illness 
for 2 years before dying at 
the end of March this 
year, shortly before our 
1st treatment, and DH's 
beloved cat died on the 
day of our 1st IVF scan.  I 
still feel that was so 
outrageous of life and so 
unecessary to take him 
from us in the manner 
and the timing that it 
did.  We have 1 cat and 
our dear little hamster left 
to keep us company. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
52 
Emotional 
distress 
8 10 0 We did conceive back in 
October 2007 only to 
miscarry at 5.5 weeks. 
This was a 
complete accident and 
even though it wasn't 
planned we were of 
course 
devastated 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
Emotional 
distress 
35 36 0  Even though i am 
devastated I take solace 
Claire 
Haresna
20᠋ my 
story 
1 
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group\1
52 
in the fact that i got 
pregnant again. 
pe  group 
 my 
story 
group\1
53 
Emotional 
distress\feeling 
isolated 
1 1 0 , but feel that all other 
family members are really 
negiative and would 
rather not know what is 
going on. No support- I 
get really frustrated by 
this.... and makes me feel 
worse... especially as my 
parents are so supportive 
of my sister and her 3 
children. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
50 
Emotional 
distress\Not 
feeling in 
control 
15 17 0 I had always worked hard 
with determination 
and commitment in 
everything I had done in 
my life...but this..this was 
different. It didn't matter 
what i did I could not 
influence the outcome 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
49 
Emotional 
distress 
3 3 0 l. I would need IVF!! I was 
devastated, I had been 
lead to believe I would 
just need some pills? 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
49 
Emotional 
distress 
3 3 0  I have had to fight and 
got my MP behind me , 
harrassed my poor GP to 
death and it went to the 
Exceptional case panel. I 
have just found out that 
they have approved it and 
I get what I am entitled 
too. Whoopie doo! I 
should be gratefull for 
that! I am SO angry. I was 
living in ignorance, 
thinking that I might just 
need some tablets and 
now I am sterile! My DH is 
trying to understand but 
he has and always will 
have 2 lovely children. 
What about me? I have to 
heal for 3 months now 
before I begin the "real" 
journey but feel like I have 
been through the mill 
already!!! 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my Emotional 4 4 0 I cried and cried and think Claire 20᠋ my 1 
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story 
group\1
49 
distress I lost the plot for a while. 
No-one understands as 
all my family and freinds 
have kids and if anyone 
else says "at least there is 
IVF", I think I wil hit them! 
lol 
Haresna
pe 
 story 
group 
 my 
story 
group\1
49 
Emotional 
distress\feeling 
isolated 
5 5 0  I have to put a smile on 
my face and pretend that I 
am ok to everyone around 
me cos I think they will 
get sick of hearing me 
moaning! It would be 
great to hear back from 
anyone as I feel so very 
alone right now 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
46 
Emotional 
distress 
1 1 0 t.After a long wait of 25 
months, one beautiful 
wedding and both 
brothers having 6 children 
between them and me 
feeling a complete failure 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
46 
Emotional 
distress 
1 1 0  I was given drugs to start 
that day, we were going 
away and my first 
injection ever was done in 
my brother in law's 
bedroom, I cried and 
really cried yet once I did 
it I wondered what I had 
panicked about it was fine 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
46 
Emotional 
distress 
1 1 0 , i started to bleed even 
before the blood results 
came so we knew, yet our 
heart broke when we got 
the phone call with the 
negative result 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
46 
Emotional 
distress 
1 1 0  I was given the option of 
waiting or having an 
injection called 
methotrexate to end it. I 
chose the injection I could 
not wait. The next day it 
happened. I broke my 
heart, I wanted to hide 
away and I did, the 
trouble with losing 
something so wanted and 
precious if it changed you 
forever, I wasn’t sure I 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
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would ever get over this 
but I did with time and 
understanding 
 my 
story 
group\1
34 
Emotional 
distress\counse
lling 
3 3 0 and started to go to the 
clinic counsellor which 
was a great help. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
34 
Emotional 
distress\being 
in control 
6 6 0 During this 3rd cycle I felt 
more positive and more in 
control, I'd continued my 
counselling throughout 
and am sure this helped 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
34 
Emotional 
distress\counse
lling 
6 6 0 During this 3rd cycle I felt 
more positive and more in 
control, I'd continued my 
counselling throughout 
and am sure this helped 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
39 
Emotional 
distress 
1 1 0   I’ve got to the point 
where I have moments 
when I really struggle and 
feel utterly consumed with 
sadness at the thought of 
no baby 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
39 
Emotional 
distress 
1 1 0  I suffer with really bad 
PMS. At least I know from 
all the tests as a result of 
IVF that there appears to 
be nothing serious wrong, 
which is a plus.  But I’ve 
tried pretty much 
everything out there to 
ease it, but you name it, I 
suffer.  Once I’ve 
ovulated, for the next 2 
weeks before my period, I 
have an absolute 
nightmare rollercoaster of 
emotions and cramps.  It 
can put a bit of a strain 
me and DH, who is 
usually thick skinned and 
just goes with the flow or 
ducks for 
cover!  Everything just 
gets so much worse 
during those 2 weeks – 
those of you who suffer 
will know how awful it can 
be.  And dealing with not 
being a mum gets so 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
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much worse. I’m so glad 
I’ve finally joined this 
site.  I dipped in and out 
for so long, but got to the 
point where I really 
needed someone who 
properly 
understood.  Friends and 
family support, but it’s not 
the same.  Knowing that 
what sometimes sounds 
like the “right” thing to say 
is often the worst. From 
feeling so alone with what 
I’m trying to cope with, I 
now feel more reassured 
that I’m not 
alone.   Anyway, that’s 
the end really.  Like I say, 
I know I have a lot to be 
grateful for, and I am, but 
I also have this void, this 
huge emptiness that hits 
me like a kick in the 
stomach when I least 
expect.  News of new 
babies when people seem 
to just blink and get 
pregnant.  The sense of 
failure that I can’t do 
something that to me is 
part of being a woman – 
being able to have 
children, when some 
people find it so, so 
easy.  I used to get really 
stressed about it, but now 
I’m much more relaxed, 
but it’s still something I 
deal with daily.  I feel like 
I’m not living the life I 
thought, naively, that I 
would have by now – with 
a baby – and it’s 
incredibly hard to deal 
with some days and 
sometimes a really good 
sob is what’s needed – 
although DH gets upset 
seeing me upset!   I’m 
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looking forward to hearing 
from you lovely ladies, 
and knowing that I’ve got 
this forum as an outlet 
 my 
story 
group\1
47 
Emotional 
distress 
4 4 0 .! Part of me really wanted 
them to find something 
physical so we could pin 
point it and fix it! Had a 
cry after the procedures 
from all the pent up 
anxiety, frustration and 
much relief that my body 
is in working order. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
43 
Emotional 
distress 
2 2 0  The usual tests and 
scans over 2.5 years 
showed nothing to be 
wrong, incredibly 
frustrating in itself. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
43 
Emotional 
distress 
4 4 0 The stress and strain took 
there toll I on an off over 
the time I suffered from 
depression and anxiety 
caused by the infertility. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
44 
Emotional 
distress 
3 3 0 Married in 1997and 
started ttc in 1999, after 
about 9 months we went 
to the doctors and had all 
the initial blood tests and 
sperm samples were sent 
away but to be honest we 
didnt really think anything 
of it, therefore it came as 
a massive shock when dh 
sperm sample came back 
as no sperm in them, my 
blood tests were all ok. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
71 
Emotional 
distress 
1 1 0   I've been struggling with 
depression for the past 
few years on and off -
since we found out we 
probably couldn't have 
children naturally, and 
then, amazingly did get 
pregnant, only to miscarry 
at 12 weeks. It's nearly 2 
years since then...hence 
the ICSI appt looming in 
April 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
Emotional 
distress\feeling 
1 1 0 Feel very alone with all 
the worry as my partner 
Claire 
Haresna
20᠋ my 
story 
1 
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group\1
71 
isolated gets upset when I get 
tearful about it all, so I try 
to keep as much of the 
black mood to myself as 
possible. Most of my 
friends have kids and say 
they feel guilty if I tell 
them how sad I get...so - 
quite isolated and blue. 
that's why i'm here. 
pe  group 
 my 
story 
group\1
40 
Emotional 
distress 
2 2 0 I've been with my DH for 
9 years, married for 
3.  We've been ttc for 16 
+ months now and the 
anger and upset each 
month when AF arrives 
certainly has not got any 
better over time.  
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
77 
Emotional 
distress\feeling 
isolated 
1 1 0  is the first time I have 
ever really sat down and 
tried to tell anyone about 
all of this....sorry if I go 
on, just don't have anyone 
I can discuss this with and 
to find this network has 
opened my eyes so 
much, hopefully you won't 
judge me. Up until now I 
felt like the loneliest 
person in the world! 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
77 
Emotional 
distress 
1 1 0 I am a selfish, 
spiteful woman for not 
wanting to see him and as 
each day turns to weeks 
and weeks to months I 
find that coping with even 
the most mundane things 
in life is becoming more 
difficult.  
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
77 
Emotional 
distress\feeling 
isolated 
1 1 0 Friends carry on having 
babies, as do family, I 
work in a hospital 
enviroment and and have 
to deal with seeing people 
who are pregnant and 
with children all the time, I 
have created a 
professional and cold 
shell I put up to allow me 
to function but inside I am 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
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screaming, tears come 
late at night after my 
husband sleeps and when 
I am alone - pathetic I 
know, I'm doing it again 
now. I used to like me and 
I am agood person I 
hope, most of the time -I 
am a caring person, now 
all I see is a stressed and 
tired woman looking back 
at me at odds with the 
world wondering when did 
all this take over me and 
when will I ever be able to 
not wake to the thoughts I 
do and drift off to 
sleep without a tear 
stained pillow. Sorry to be 
moaner thanks for 
listening it's helped just to 
put this to paper so to 
speak. Better go and put 
my face on again and 
pretend everything is 
OK... am getting to be 
quite the expert 
 my 
story 
group\1
77 
Emotional 
distress 
1 1 0 Friends carry on having 
babies, as do family, I 
work in a hospital 
enviroment and and have 
to deal with seeing people 
who are pregnant and 
with children all the time, I 
have created a 
professional and cold 
shell I put up to allow me 
to function but inside I am 
screaming, tears come 
late at night after my 
husband sleeps and when 
I am alone - pathetic I 
know, I'm doing it again 
now. I used to like me and 
I am agood person I 
hope, most of the time -I 
am a caring person, now 
all I see is a stressed and 
tired woman looking back 
at me at odds with the 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
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world wondering when did 
all this take over me and 
when will I ever be able to 
not wake to the thoughts I 
do and drift off to 
sleep without a tear 
stained pillow. Sorry to be 
moaner thanks for 
listening it's helped just to 
put this to paper so to 
speak. Better go and put 
my face on again and 
pretend everything is 
OK... am getting to be 
quite the expert 
 my 
story 
group\1
79 
Emotional 
distress 
1 1 0 I've been in tears reading 
some of your 
experiences - thank you 
all so much for sharing as 
it must have been really 
difficult. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
75 
Emotional 
distress\feeling 
isolated 
8 8 0 I think the hardest part for 
me is that three of my four 
closest friends are all 
pregnant and all became 
pregnant in the first month 
of trying.  I feel alienated 
from them as babies and 
pregnancy is all the talk 
about with each 
other.  Sadly I feel I am 
avoiding situations when 
we are all together.  I 
know it has affected my 
friendships with them.  It 
not their fault they are 
pretty sensitive but they 
can never understand the 
frustrations having month 
after month of 
disapointment as then 
didn't even have 
one.  Perhaps I am being 
mean 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
75 
Emotional 
distress 
8 8 0 I think the hardest part for 
me is that three of my four 
closest friends are all 
pregnant and all became 
pregnant in the first month 
of trying.  I feel alienated 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
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from them as babies and 
pregnancy is all the talk 
about with each 
other.  Sadly I feel I am 
avoiding situations when 
we are all together.  I 
know it has affected my 
friendships with them.  It 
not their fault they are 
pretty sensitive but they 
can never understand the 
frustrations having month 
after month of 
disapointment as then 
didn't even have 
one.  Perhaps I am being 
mean 
 my 
story 
group\1
70 
Emotional 
distress 
1 1 0 Well, I picked up a card 
for INUK 2 1/2wks ago at 
the hospital having ET, I 
desperately hoped I'd 
never have the need to 
find out what it was all 
about, but here I am so 
that says alot. I had BFN 
on monday and have 
never felt so alone in this 
whole IF thing, probably 
because this time we told 
no one, which I dont 
regret because I have just 
about had enough of all 
the sympathy and feeling 
sorry for us, especially 
surrounding the birth of 
my brother's beautiful 
baby boy in April - the first 
born in my family. Thats 
been really tough, and I 
have felt every emotion 
under the sun, including 
massive jealousy, anger, 
guilt for those feelings, 
and an overwhelming 
feeling of love and 
protection towards my 
nephew that scares me. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
Emotional 
distress 
5 5 0 The joy and tears from 
both my DH and I was 
overwhelming, but out 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
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70 nurse who we had grown 
to know well, showed no 
emotion, telling us to 
come back a week later to 
look for the heart beat. A 
week later, we saw a 
flicker, but not clear. A 
week later, a little bigger 
but not developing as fast 
as the 7wks I should be. 
A week later, told not to 
get our hopes up, that it 
wasnt looking good. 
Needless to say I had had 
a missed miscarriage and 
my baby had died. Waited 
10 days and couldnt bear 
it any longer, I thought I 
would go out of my mind 
with grief, I cried 24/7 and 
the pain in my chest with 
never leave me. I still cry 
for our baby who would 
have been a year old on 
the 1st July. 
 my 
story 
group\1
70 
Emotional 
distress 
7 7 0 So .......... FE cycle was 
crap. I was evil, felt evil 
and was downright evil 
............ I would have left 
me if I had been DH !!!!! 
The headaches, feeling 
sick all the time and 
irritable and angry. This 
all eased but this time ET 
was really painful too, and 
I do have a high pain 
threshold ! Well, then this 
monday came the BFN, 
I'd already done 4 pg 
tests (even though knew it 
wouldnt work !!!!! Yeah 
but you still have hope 
whatever you say out loud 
!) I have coped this week, 
and I put that down to 
nothing being worse than 
my DH having meningitis 
and losing our darling 
baby, but I feel so low and 
angry. DH isnt coping too 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
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well. He is doing the 
caveman bit and 
retreating. So I thought 
this would be a good way 
for me to get off my chest, 
stuff I know I want to say 
to DH, but cant at the 
moment. I am staying 
busy, went straight back 
to work after the results 
on monday and havent 
stopped, think thats the 
best way for me. 
 my 
story 
group\1
67 
Emotional 
distress 
4 4 0  this time i did nt start my 
period but i still got a 
BFN. after this try i was 
so depressed and 
low and felt awful 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
67 
Emotional 
distress\counse
lling 
4 4 0 .  i even went for 
counselling at the hospital 
but it did nt work. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
66 
Emotional 
distress 
1 1 0  Both DH and I were 
gutted but got through a 
tough few days. 
Claire 
Haresna
pe 
20᠋† my 
story 
group 
1 
 my 
story 
group\1
66 
Emotional 
distress 
2 2 0 The situation really hit me 
last October 4 days 
before my Nieces 1st 
birthday and I turned to 
our senior leader who 
was brilliant and really 
made a tough week as 
easy as it was going to 
be.  It wasn't until end 
January that I started to 
feel better, it was when 
we got our review 
appointment through. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
65 
Emotional 
distress 
2 2 0 I went back to GP who 
then informed us that DH 
did have a problem 
according to the sample 
he had given a year or so 
ago but noone had 
informed him. I was 
devastated as was he. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
Emotional 
distress\feeling 
isolated 
6 6 0 I get very low and 
because so few people 
around me are aware of 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
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65 the problem, I often feel 
misundersood 
 my 
story 
group\1
64 
Emotional 
distress 
7 7 0 We were devastated and 
with my mum's help we 
complained to the GP and 
PCT and after 8 months 
of letters, phone calls, 
crying and appointments, 
we were transferred to 
another clinic. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
64 
Emotional 
distress 
8 8 0 - when on the day we had 
bad news that 
unexpectedly my DH's 
sperm count and motility 
had drastically reduced so 
they couldn't go ahead 
with IUI - we were totally 
devastated and couldn't 
understand it and neither 
could the clinic because 
he was fine a month 
before. It felt like the 
world was falling apart.  
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
64 
Emotional 
distress 
10 10 0 cycle in Feb, ready for 
starting IVF - and I was 
told by the nurse that the 
PCT was cutting our 
funding (along with 17 
other couples) so we 
wouldn't be able to start 
IVF this month. I was so 
shocked and yet again 
devastated and hurt - I 
got straight onto the 
phone to my mum and 
then my GP - they both 
knew the PCT from trying 
to get our funding 
changed before, and it 
took a whole day and lots 
of phone calls for it to be 
agreed. (In the process 
they also managed to get 
all the other 17 couples' 
funding secured too - but 
they won't have known 
that!!) 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
Emotional 
distress 
1 1 0 We started trying to 
conceive in 2004 and fell 
pregnant after about 6 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
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60 months but sadly 
miscarried at 7 
weeks.  This hit me very 
hard and I was desperate 
to get pregnant again as 
soon as possible, 
although in retrospect 
perhaps I didn't allow 
myself time enough to 
grieve properly. 
 my 
story 
group\1
93 
Emotional 
distress 
2 2 0 DH is azoospermic 
(absolutely zilch). He 
dealt with it as only men 
can - very badly. He was 
turning 40 as well, and all 
that turned into a mid-life 
crisis of sorts. Pleased to 
report he's on the up, just 
as I lose my optimism and 
stamp my feet about the 
injustice of it all! 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
93 
Emotional 
distress 
4 4 0  After DH going to pieces 
initially I think he was 
expecting the negative 
result but I was, and still 
am, completely floored. 
My best friend has just 
had her second child and 
the fact I will never have 
DH's baby makes me feel 
sick. I am finding it very, 
very hard to accept. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
93 
Emotional 
distress 
5 5 0 . I feel cheated and 
robbed and all the other 
horrible horrible feelings 
are that all of us here deal 
with on a daily basis. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
94 
Emotional 
distress 
1 1 0 In the past I have had two 
terminations of 
pregnancies with people 
who didn't want to have 
children (or at least not 
mine!). The second of 
these I found 
particularly upsetting at 
the age of 35. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
94 
Emotional 
distress 
3 3 0 After another year of 
trying (and lots of 
tears!)we went back for 
more tests.  
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
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 my 
story 
group\1
92 
Emotional 
distress 
3 3 0 I was devastated as had 
found the drugs and 
process of scans really 
taxing to that point so was 
gutted that the chances of 
it working were even 
more reduced.  We 
weren't surprised that it 
didn't work but was still 
very upsetting.  2 more 
IUI's led to BFNs in Feb 
and March 07 and I found 
it increasingly difficult to 
cope with.  
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
92 
Emotional 
distress\counse
lling 
4 4 0  I found the counsellor at 
our clinic was great  
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
91 
Emotional 
distress 
1 1 0  I'm new to  INUK - I've 
recently 
been unsuccessful at ICSI 
(2nd attempt) and 
miscarried after a short 
time recently - 1 day 
before my 39th birthday 
so hugely disappointed 
and really struggled this 
time round - I feel a mid-
life crisis coming on!  
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
91 
Emotional 
distress\feeling 
isolated 
2 2 0 what I'm struggling with 
the most is how distant I 
now feel from a lot of my 
friends who were once in 
the same boat as me but 
now seem to have got on 
with their lives with their 
new familes and we just 
don't see so much of 
them or it can be a little 
strained - I guess they 
don't know what to say, 
others are just plain 
silent.  It's quite painful to 
think the support I'd 
thought we'd receive just 
hasn't been there 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
88 
Emotional 
distress 
9 9 0 Again we had more tests 
and DH was asked to be 
a sperm donor by this 
clinic to which we said no 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
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to straight away as I just 
couldnt cope with the 
thought of someone else 
having what I longed for 
and as his wife should be 
entiled to. 
 my 
story 
group\1
88 
Emotional 
distress 
13 13 0  BFN followed and I lost 
the plot, was on a plane 
the next day to see my 
parents in Spain and to 
give my DH a breather 
from the mad woman 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
88 
Emotional 
distress 
16 16 0 I am 30 in August and DH 
will be 39, like all of the 
ladies on this wonderful 
site I dread every birthday 
and every Christmas as 
for me it marks yet 
another year of ttc and for 
me it makes me feel a 
failure. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
88 
Emotional 
distress\Not 
feeling in 
control 
17 17 0 I was a successful carrer 
girl and controlled all 
aspects of my life and this 
is the one thing I can't 
control or buy! I 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
90 
Emotional 
distress 
3 3 0 I found out a month after 
my wedding that i was 
unable to have children 
naturally and thought my 
world was ending. I had 
been with my husband for 
three years before we 
married and from the 
moment i met him i hoped 
to have his children one 
day. This news made me 
feel inadequate, a failure 
and less of a women. I 
couldnt understand why 
this was happening to m 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
90 
Emotional 
distress 
3 3 0 On my eight week scan 
there was a problem, 
the baby was not growing 
properly and the doctors 
face started to change, i 
had an agonising two 
week wait only to be told 
that i had had a missed 
miscarriage. I cried so 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
APPENDICES 
Appendix	  	  11	  	  Qualitative	  Data	  from	  Strand	  4	   817	  
hard i couldnt breath and 
carried on crying for two 
weeks. 
 my 
story 
group\1
85 
Emotional 
distress 
1 1 0 ur little girl was born 
asleep on 25th June and 
we miss her so very 
much. She was born at 
36+6 at 6.45pm and just 
looked so perfect and 
beautiful. She was 
conceived on our third 
attempt after many years 
of striving to become 
parents so her loss was 
particularly difficult to 
bear. Our little girl was a 
frozen embryo, created in 
the late summer of 2006, 
and so had already 
overcome being frozen 
and defrosted. We at 
least have the consolation 
that we were able to 
“meet” her when she was 
only 3 cells old 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
85 
Emotional 
distress 
1 1 0  We had lost our darling 
baby. They then brought 
through an ultrasound 
machine and as soon as 
they began you could see 
the chambers of my 
baby’s heart were still. 
There was no movement 
at all. My husband was 
distraught, but I had 
already come to accept 
the fact that my baby was 
gone. We had to wait 
however for a 
Sonographer to come on 
duty to confirm that we 
had lost our child 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
85 
Emotional 
distress 
1 1 0 . She was such a part of 
our lives despite our 
never having met her 
before that hour, and the 
devastation of her loss 
will remain with us for 
ever. We called the 
midwife back into the 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
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room so she could wash 
her, as I was afraid I may 
hurt our little darling. The 
midwife weighed her and 
she was 5lb 10oz, she 
measured her head and 
length and we then had 
an opportunity to take 
some photographs of he 
 my 
story 
group\1
81 
Emotional 
distress 
9 9 0 As you can imagine i was 
devastated, i couldn't get 
my head round why this 
was happening, I've never 
been a bad person or hurt 
anyone why was this 
happening to us! Our 
consultant advised our 
best next option would be 
Embryo Donation. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
81 
Emotional 
distress 
10 10 0 I was finding every day 
life very difficult, i would 
cry on the way to work 
and in work but the one i 
thing i did that did not 
help was i cried alone. I 
never have been very 
good at opening up, so 
everything just came to a 
head. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
81 
Emotional 
distress\counse
lling 
10 10 0  I therefore starting seeing 
my counsellor in 
September 07 & am 
continuing to do so at 
present, i think without 
her help i would not have 
been ready to be where I 
am now. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
80 
Emotional 
distress 
8 8 0 Two days later it is 
sinking in and is very 
painful.  I am all alone 
away from my friends and 
family and honestly dont 
know how to get through 
the next few days. My 
husband is the silent type 
who says he just wants to 
move on...  When I 
suggest getting a second 
opinion (preferably in a 
language we can 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
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understand and in a 
country with few legal 
restrictions) he says I 
must not get scary 
and obsessed. 
 my 
story 
group\1
42 
Emotional 
distress 
7 7 0 Successful transfer then 
spotting 2 days before 
prgnancy test which was 
negative result. My 
husband and I were 
devastated.. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
42 
Emotional 
distress 
8 8 0  My husband and I were 
in shock and disbelief at 
first, I just felt numb - he 
was clearly 
devastated and angry. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
42 
Emotional 
distress 
10 10 0 4 months on my husband 
wanted me to try IVF 
again. 6 weeks ago I told 
him that there is no way 
that I can do this again for 
the moment - if it did not 
work then this would just 
destroy me. I don't know 
when we will do it again 
now, but have said that if 
we do it again then that 
really is the last time I can 
go through this god awful 
process! 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\2
15 
Emotional 
distress 
4 4 0 We had our first 
consultation in Aberdeen 
in August 2005, I was 
utterly shocked to be sent 
away clutching my bag of 
injections and drugs! 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\2
15 
Emotional 
distress 
12 13 0 Fifth cycle in September 
2006 was a natural FET 
with 1 embie. 
Ended up on anti-
depressants, how much 
more pain could I take... 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\2
13 
Emotional 
distress 
1 1 0 and to my shock was told 
I had a probable 
endometrioma on my 
ovary and most likely had 
endometriosis and would 
need a Laparoscopy.I  
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
Emotional 
distress 
4 4 0 we were both devested 
when we was told we 
Claire 
Haresna
20᠋ my 
story 
1 
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group\2
12 
could never conceive 
naturally but was refered 
to another hospital as 
they didnt hold the 
funding for us as we lived 
in a diffrent county 
pe  group 
 my 
story 
group\2
11 
Emotional 
distress 
4 4 0 First IVF attempt in May 
07 - 10 eggs and no 
fertilisation, so advised to 
go for ICSI.  ICSI attempt 
in Aug 07, which resulted 
in 19 eggs and no 
fertilisation again.  Felt 
like the end of the world. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\2
09 
Emotional 
distress 
7 7 0 The pain was beyond 
belief, as we had lost our 
little baby and our dreams 
were shattered. I cried for 
what seemed like weeks. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\2
09 
Emotional 
distress\counse
lling 
11 11 0 . I decided to have some 
counselling which is one 
of the best things I have 
ever done. It was hard, 
very hard. But with time 
really helped to come to 
terms with what had 
happened and got me to 
a place where I am strong 
again and accept that 
there will be times when I 
will feel sad and that's ok 
but that there is much 
hope for the future. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\2
08 
Emotional 
distress 
10 10 0  then my younger, 
unmarried, unattached 
sister announced her pg 
and it felt like a knife in 
the heart. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\2
07 
Emotional 
distress 
1 1 0   Had 7th cycle using 
donor eggs, but donor 
pulled out.  World then fell 
well and truly apart but 
found that leap of faith to 
try using donor eggs just 
once more.  Fell 
pregnant!!!! 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
31 
Emotional 
distress 
1 1 0 ery rapid profound 
depression with 
clomiphene, 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
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 my 
story 
group\1
31 
Emotional 
distress 
1 1 0 With more sadness and 
loss my China adoption 
hopes have died inside, 
although our application is 
still in and we are 
monitoring the timescales.  
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
31 
Emotional 
distress 
1 1 0 I had 3w atrocious 'baby 
blues' 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
30 
Emotional 
distress 
2 2 0 Probably shouldn't be 
writing this today as I'm 
feeling really tired, sore 
and low. But hey, ho, here 
goes! 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
30 
Emotional 
distress 
5 5 0 Meanwhile time is ticking 
and frustration building. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
30 
Emotional 
distress 
10 10 0 I'm also having to cope 
with a difficult family 
situation. My younger (29) 
sister got accidently 
pregnant last year and 
chose to have an 
abortion. She and my 
mother debated not telling 
me, but did. So I had to 
bury all my own feelings 
to support her including 
listening to her complain 
about her pregnancy 
symptoms before the 
procedure. Didn't she 
realise that I'm desperate 
to feel like that? Life is so 
unfair. That little life was 
flushed away. My sister is 
incapable of offering 
support to me so I'm 
feeling angry at her (for 
this more than the 
abortion). We've now 
fallen-out and I don't have 
the emotional energy to 
sort it out. 
Claire 
Haresna
pe 
20᠋
 
my 
story 
group 
1 
 my 
story 
group\1
29 
Emotional 
distress 
5 5 0 In 2009 we started our 
treatment.  It hasn't been 
that bad but the emotional 
journey is quite hard.  I 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
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spend so much time 
trying to convince myself 
that we should just accept 
that we don't have to have 
children and we can get a 
dog or travel again but the 
desire for a family has 
become so great now that 
I can't see how I will 
accept just being the two 
of us. 
 my 
story 
group\1
28 
Emotional 
distress 
1 1 0  I hadn’t had mumps as a 
child, nor had any viruses 
recently so would this be 
a permanent 
condition?  My whole 
world came crashing 
down around me.  
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
28 
Emotional 
distress 
1 1 0  All hope was lost.   We 
were both devastated but 
with the numbness came 
the feeling of relief.  No 
more unknown, no more 
waiting, no more clinging 
to hope; we could now 
move on.   
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
28 
Emotional 
distress 
1 1 0    So how has this been 
emotionally?  We are still 
going through IVF and not 
had much luck, therefore 
my feelings are still fresh 
and quite raw.  When this 
is over I’m sure the 
benefit of hindsight will 
kick in but for the moment 
trying to have a family is 
still very much the focus 
of our lives, and coping is 
sometimes less than 
easy.  My feelings this 
year have ranged from 
anger, upset, self-pity, 
resentment, guilt and 
inadequacy.  On a lucky 
day I’ve felt all of these 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
28 
Emotional 
distress\counse
lling 
1 1 0  From speaking to the 
fertility counsellor I 
realised my feelings were 
normal and as a result I 
haven’t beat myself up 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
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about whether I’m being 
irrational. 
 my 
story 
group\1
28 
Emotional 
distress 
1 1 0   Of course I can’t help 
feeling a little resentment, 
why do other people have 
a baby at the drop of a 
hat I ask?  Likewise I 
know that the occasional 
feeling of self pity is 
normal.  We have tried to 
maintain control of these 
feelings and I think we 
have made a good job of 
being open about all 
aspects of our treatment, 
without becoming 
emotional and showing 
any of these feelings.  On 
the outside we’ve 
probably appeared 
casual, but behind closed 
doors it has been very 
different and we still get 
upset and get strength 
from each other 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
28 
Emotional 
distress\feeling 
isolated 
1 1 0 In an ideal world we 
would be open with those 
closest to us but people 
struggle with 
understanding how we 
feel and find it awkward 
knowing what to 
say.  Listening to 
comments like “you’ll be 
ok in the end” or “relax 
and stay positive” don’t 
help but can understand 
why people say them 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
28 
Emotional 
distress\counse
lling 
1 1 0 The use of donor sperm 
was one of the easier 
things to come to term 
with for me.  The fertility 
counsellor made me 
rethink my original idea of 
the student donor who 
was trying to make an 
easy £20 with a dirty 
magazine.   
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
Emotional 
distress 
5 5 0 . He acted like it was no 
big deal but I know he 
Claire 
Haresna
10᠋
 
my 
story 
1 
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group\1
27 
really felt bad. pe group 
 my 
story 
group\1
27 
Emotional 
distress 
7 8 0 I thought it would get 
easier the closer it got to 
our start date but it just 
gets more terrifying. 
I had depression in my 
teens & am so scared if 
IVF doesn't work history 
may repeat itself. 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
25 
Emotional 
distress 
3 3 0 So went for the scan with 
DH in tow, & the 
sonographer asked me if I 
knew I had ovarian cysts. 
Cue a bit of crying, 
followed by rational 'at 
least we know & can deal 
with it'. 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
25 
Emotional 
distress 
5 5 0  Managed to ask him 
about having children, to 
which he responded IVF 
was only hope. Needless 
to say I became a tad 
hysterical, being told that I 
was infertile at the age of 
27. 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
23 
Emotional 
distress 
8 8 0 We started the attempt for 
number two end 2005, 
and within a few months, I 
started to get a bit 
annoyed when it wasnt 
happening. As the months 
passed, annoyance 
turned to bother, bother 
turned to anger, anger 
turned to confusion, 
confusion turned to worry. 
I just didnt understand 
why it wasn't happening. 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
23 
Emotional 
distress 
10 10 0 I was absolutely 
devastated. I had an 
overwhelming desire for 
another child, my friends 
were all having second or 
third children, and all 
anybody would ask me 
was 'when are you going 
to have another one'. I 
just couldn't believe this 
was happening - and 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
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happening to me. 
 my 
story 
group\1
23 
Emotional 
distress 
12 12 0  was starting to feel 
increasingly depressed 
about it. Grieving for the 
child I couldn't have, 
sorrow for my son not 
having a sibling (I am very 
close to my sibling), pain 
at my incomplete family 
and feeling totally isolated 
dangling somewhere 
between the worlds of 
the fertile and infertile. I 
just didn't belong or fit in 
anywhere. 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
23 
Emotional 
distress\feeling 
isolated 
12 12 0  and feeling totally 
isolated dangling 
somewhere between the 
worlds of the fertile and 
infertile. I just didn't 
belong or fit in anywhere.. 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
23 
Emotional 
distress 
19 19 0 The pain of infertility is so 
intrenched, all consuming 
and inexplicable, it will 
never ever leave me. 
Unless you have been 
there, it is really totally 
impossible to understand. 
I cannot begin to pretend 
to understand the depth 
of pain of total 
childlessness, but I have 
a fair idea of how I felt 
dealing with our infertility. 
I wouldn't wish it on my 
worst enemy. Its unfair, 
cruel and heartbreaking 
and nobody should have 
to suffer it, least of all 
alone 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
21 
Emotional 
distress\feeling 
isolated 
2 2 0 This is my story. I would 
really like to hear back 
from anyone who is in a 
similar position as I don't 
feel there is anyone I 
know who truly 
understands how I feel. I 
found out this week that 
our second attempt at IVF 
didn't work. 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
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 my 
story 
group\1
21 
Emotional 
distress 
6 6 0 motionally I have been 
demented to say the 
least. This is the worst 
experience of my life. 
Every month is a 
bereavement. The 
unexplained element is 
bewildering and not 
understanding why drives 
me demented. The 
prospect of facing a future 
without ever experiencing 
pregnancy and having 
children of my own, is 
horrific. Only in recent 
months have I come in a 
small way to 'accept' that 
this is the way it is for us 
right now. I have been in 
a state of panic and shock 
for most of the last 3 
years. I have deep, deep 
feelings of failure, anger 
and incredulousness at 
our situation. The 
disappointment, injustice, 
lack of understanding I 
feel is overwhelming. 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
21 
Emotional 
distress 
7 7 0 I cannot stand pregnant 
women, especially the 
ones who are oblivious to 
the fact that someone 
around them may not be 
as lucky as them and who 
think everyone should 
fawn all over them and 
make a fuss of them (a so 
called friend who knew 
what I was going through 
thrust her positive 
pregnancy test under my 
nose a week to show me 
her success after I had 
my first failed IVF such 
was her lack of empathy 
and self absorption). I've 
had some pregnant 
friends who have been 
lovely and worked hard to 
not rub my face in it but I 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
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really have difficulty being 
around them. When I cry, 
the grief comes from so 
deep down in my very 
depths and I just howl 
with sorrow 
 my 
story 
group\1
21 
Emotional 
distress\feeling 
isolated 
8 8 0 I could go on and in more 
detail but I think I've 
provided the general 
story. I really just need to 
be in touch with people 
who understand and can 
make me feel less lonely 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
20 
Emotional 
distress 
3 6 0 He 
came home devastated 
and the timing could not 
have been more ironic as 
it was the day before we 
were due to move from 
our little flat to a 
family house that we fully 
intended to fill with 
children! 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
20 
Emotional 
distress 
12 15 0 I literally felt the blood 
drain from my body. I 
think I went 
into a bit of a meltdown 
for the next few months, 
work was unbelievably 
full on, we were told that 
there was no DS on the 
NHS, we were told to 
go to the USA, we were 
told that the wait here 
would be 5 years. 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
20 
Emotional 
distress\being 
in control 
38 43 0 After that appointment we 
decided just to stop 
everything 
for two months, to 
concentrate on each other 
again, go on holiday in 
the sunshine, see our 
friends and find some joy 
in our lives again.  I 
also found a great 
acupuncturist and started 
regular treatments to 
prepare my body, I 
started pilates again and 
did lots and lots of 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
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walking 
 my 
story 
group\1
20 
Emotional 
distress\counse
lling 
43 46 0 We have both been 
having counselling and 
this has helped a 
great deal plus we got to 
talk to a fantastic couple 
from the Donor 
Conception Network and 
it was very reassuring to 
listen to their story 
and ask questions. 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
20 
Emotional 
distress\being 
in control 
46 47 0  have also been making 
efforts to reduce the 
stress at work. 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
19 
Emotional 
distress 
1 1 0 Every month the cycle of 
negative test sticks is 
quite wearing 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
19 
Emotional 
distress 
4 4 0 elt a bit like we were 
going nowhere and the 
constant dissapointment 
is really getting to me, I 
now seem to cry for about 
3 days after my period 
starts.  
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
18 
Emotional 
distress 
2 2 0 My first miscarriage 
happened last year, in 
August 08. I was 
devastated as I had 
thought having a baby 
was easy! How wrong I 
was! It was a blighted 
ovum and I had a D&C 
after hanging on for 
nearly 3 weeks and 
hoping that I'd just got my 
dates wrong. It was 
extremely traumatic as I 
just hadn't expected 
anything like this to 
happen to me. 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
18 
Emotional 
distress 
4 4 0 The very next day I had 
terrible pains at work - I 
was scared but didn't 
think it could be the 
worst.... unfortunately it 
was. A scan that evening 
showed only one 
heartbeat. I was so sad 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
APPENDICES 
Appendix	  	  11	  	  Qualitative	  Data	  from	  Strand	  4	   829	  
for the first twin, afraid 
that something would 
happen to the 2nd twin, 
but at the same time 
hopeful. I had to stay in 
bed for 2 weeks, but after 
just one week I had 
spotting during the night. I 
knew immediately what 
was happening and was 
heartbroken. I had a 
natural miscarriage and 
lost the 2nd twin at 8 
weeks, which was 
completely traumatic and 
devastating. I would not 
ever like to go through 
that again in my life and 
will never forget it. 
 my 
story 
group\1
17 
Emotional 
distress 
4 4 0 fter 6 months of ttc, I 
visited my GP for advice 
and said that the constant 
expectation each month 
was beginning to get me 
down - little did I know 
that was alot more 
expectation ahead and 
devastation in the future 
than the 6 months we had 
been trying for a family. 
The GP told me that most 
couples will conceive 
within the first 6- 8 
months of ttc, and the 
majority by a year. 
Disheartened but hopeful 
at the same time we 
continued for another 3 
months and nothing. I 
became obsessive about 
my cycles and stressed 
each month that passed. 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
17 
Emotional 
distress\feeling 
isolated 
4 4 0 Friends around me didn't 
understand and I felt lost 
and left out the loop or 
club. every 
announcement that was 
made by friends made my 
isolation worse. 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
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 my Emotional 5 5 0  I had been to the hospital Claire 10᠋ my 1 
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story 
group\1
17 
distress in tears and talked to the 
fertility nurse in the 
maternity/Gynae unit. 
Haresna
pe 
 story 
group 
 my 
story 
group\1
17 
Emotional 
distress\feeling 
isolated 
5 5 0  I felt something like this 
may help if I had a focus 
each month where I could 
talk to others in the same 
situation and we could 
swap thoughts. I had felt 
so alone before this. 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
17 
Emotional 
distress 
7 7 0 The cycle was abandoned 
and I was devastated 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
17 
Emotional 
distress 
8 8 0 IUI was abandoned after 
that as a means of 
treatment for us and I was 
desperate to try IVF 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
17 
Emotional 
distress\financi
al loss 
8 8 0 We couldn't afford the 
amount being asked 
privately and didn't yet 
qualify under the NHS 
criteria of 3  yeas ttc, ( we 
were 2.5 yrs) so we 
looked into the private 
system to see if we 
could  in any way afford it 
possibly with some help 
from family. 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
17 
Emotional 
distress 
11 11 0 . My symptoms seemed 
to dwindle around 6 
weeks and I got really 
worried - I was right too, 
on the day before our first 
7 week scan I started to 
loose our precious 
miracle at the very end of 
April and beginning of 
May 07. I was devastated 
beyond belief. How could 
this happen? Why? 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
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 my 
story 
group\1
17 
Emotional 
distress 
12 12 0 After a traumatic wait in A 
and E at our local hospital 
I was told to prepare for 
the worst - How can 
you?? The next day was 
our scan and the clinic 
agreed to go ahead even 
though they were 
reluctant as they feared 
Claire 
Haresna
pe 
10᠋
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what I already knew deep 
down - it was over. No 
picture of a heartbeat and 
a bean like being on the 
screen - nothing. I have 
never felt emotional pain 
like it. DH didn't know 
what to do, it was 
unbearable. 
 my 
story 
group\1
17 
Emotional 
distress 
13 13 0 We grieved and grieved 
and this was added to as 
the hospital thought there 
was concern over a 
second embryo that may 
have implanted in my 
tubes or on my ovary - an 
ectopic.The scans 
continued and more blood 
tests, finally after a few 
weeks they agreed the 
pregnancy was gone and 
I was not in danger as it 
had 'naturally resolved'. I 
was grief stricken. 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
17 
Emotional 
distress\counse
lling 
14 14 0 . I had counselling 
throughout the first cycle 
and through our loss, 
every week. Our 
counsellor was fantastic. 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
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 my 
story 
group\1
17 
Emotional 
distress 
15 15 0 I had depression and 
anxiety and had been 
signed of work prior to our 
IUI commencing, the 
miscarriage from our IVF 
just compounded that 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
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 my 
story 
group\1
17 
Emotional 
distress 
19 19 0 Slowly each week I have 
gained a bit more 
confidence but the anxiety 
is still there, I’m 22 weeks 
+ 2 days pregnant, and 
thrilled, due on 19th May 
2008, with one baby but 
our journey will never 
leave us, nor it's scars. 
I've seen my GP each 
week for anxiety. I'm now 
33 and DH is 37. I am 
well aware some have not 
yet felt the joy of a 
positive test or worst have 
Claire 
Haresna
pe 
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done and lost more than 
we. Infertility hurts, it 
dissolves confidence, it 
rules your life, it isolates 
you and you loose 
elements of your 
personality 
 my 
story 
group\1
15 
Emotional 
distress 
2 2 0 I was devastated because 
losing the baby hadn't 
even entered my head. I 
have been trying again 
since but I had to have 2 
D&C's which delayed 
things and then I was put 
on clomid again in 
September 
Claire 
Haresna
pe 
10᠋
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my 
story 
group 
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 my 
story 
group\1
14 
Emotional 
distress 
1 1 0 This is the first time I have 
written anything about 
what I’m feeling in relation 
to our ‘unexplained’ 
infertility.  I have just 
turned 32 and we have 
been ttc for nearly 2 years 
(I know I’m still relatively 
young and it’s only been 2 
years, but it doesn’t get 
any easier does it…).  I 
never knew what effect 
this would have on our 
lives and on my emotions 
in particular.  I go through 
days when I want to hit 
something with pure 
anger and 
frustration.  And others 
when I just want to curl up 
under the duvet and 
never come out – 
fortunately the good days 
still outweigh the bad 
days, but the 
unpredictability of the bad 
days really gets you 
down. 
Claire 
Haresna
pe 
10᠋
 
my 
story 
group 
1 
 my 
story 
group\1
14 
Emotional 
distress\Not 
feeling in 
control 
1 1 0  And now I feel like I am 
totally failing and there is 
absolutely nothing I can 
do to improve the 
situation – I can’t study 
harder, I can’t work longer 
Claire 
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hours, I can’t be a better 
daughter or wife.  Usually 
I know the answer to 
things and know what I 
have to do to improve the 
situation.  But not about 
this.    I’ve always been 
known as the ‘rational’ 
friend, the person to turn 
to in need, the person 
who can work through 
things logically. 
 my 
story 
group\1
14 
Emotional 
distress 
1 1 0 And now I don’t feel like 
that at all.  In fact on the 
bad days I hate what I 
have become – I hate 
being the whinger, the 
cry-baby, the drama 
queen.  I hate those 
surreptitious thoughts that 
go through my head when 
I see families with lots of 
children and think ‘can’t 
you give me one of 
those?’; or the false smile 
that I have to ensure is on 
my face when someone 
else tells me they are 
pregnant.  I’m not like that 
– I’ve always been told I 
was a good person and 
loyal and a reliable 
friend.  And I just don’t 
feel like that any 
more.   And the clomid is 
making it worse.  My 
goodness!  Talk about 
upsetting my emotional 
balances!  I don’t know 
what it is doing to me (I’m 
on my 5th month of it), but 
I’ll be very glad when I 
can stop taking it.  I feel 
like a loonie!  Only 1 more 
month to go….  And then 
what? Then I get drawn in 
to the world of IUI and IVF 
– oh what joy.  I read 
those other posts that you 
lovely ladies have written, 
Claire 
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and although I’m really 
happy for you guys that 
you are moving forwards, 
I have to say it fills me 
with dread.  I keep 
thinking of all those 
orphaned children in the 
world and wonder 
whether I should just 
accept that we can’t have 
kids and adopt a whole 
host of them.  Anyone 
else ever feel like that?   I 
just read the factsheets 
today that this Network 
provides and they are 
really useful – they made 
me realise that it was ok 
to feel like this was one of 
the worst and hardest 
things I’ve ever had to 
deal with.  And it really is 
like a bereavement – 
every month I feel like a 
little bit of me dies and 
disappears.  Every month 
you have that awful wait, 
knowing in your heart of 
hearts that nothing has 
happened, but still that 
hope until the first signs of 
your period arrive.  One 
friend who has been 
through all this uses one 
word to describe it, and I 
agree with 
her…..Devastating.  Mayb
e I’m being a drama 
queen again, but that’s 
how I quite often feel – 
devastated.   I looked up 
infertility support on the 
website today as yet 
another friend (who got 
married 2 weeks after us) 
told us she was 
pregnant.  
 my 
story 
group\1
Emotional 
distress 
3 3 0 As i'm sure most of you 
will understand we were 
devasted and my DH 
Claire 
Haresna
pe 
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13 feels awful - he even told 
me I should leave him 
and find myself a 'real 
man'. Felt so bad and no 
matter how hard I tried I 
couldn't make him feel 
better. Scary to think of 
the journey ahead but I 
want children with my DH 
not anyone else... 
 my 
story 
group\1
12 
Emotional 
distress 
3 3 0 I miscarried painfully and 
'completely' (as they 
wrote on my medical 
records) on the 8th 
January 2008 at 11 
weeks and 3 days . As I 
lay on the bathroom floor 
waiting for the ambulance 
with T crying next to me I 
had that context for my 
fears and knew without a 
doubt that I would have 
done anything to stop that 
blood flowing so I could 
hold onto our baby. It was 
at that moment that I think 
I truly understood what it 
felt like to want a baby 
with every part of me. 
That feeling just grows 
every m 
Claire 
Haresna
pe 
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my 
story 
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 my 
story 
group\1
12 
Emotional 
distress 
6 6 0 . I remember not really 
understanding what she 
was saying and as soon 
as I heard menopausal I 
felt my heart stop- I tried 
to write things down but 
she spoke so quickly. I 
remember saying 'does 
this mean I will have an 
early menopause?' and 
she said 'yes probably'.... 
and I said 'but I'm 31 
years old'.... then I put the 
phone down 
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12 
Emotional 
distress 
7 7 0 We hardly slept that night 
and tears came and just 
wouldn't stop. A badly 
executed phone call, 
delivered at the wrong 
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time in the wrong way, 
without a good knowledge 
of fertility to inform it left a 
legacy of fear that I don't 
think has left me. We got 
the first appointment with 
'her' the next day and she 
seemed surprised that we 
were so upset and even 
said 'I didn't tell you that 
you had ovarian failure'... 
and so she referred us to 
the fertility clinic 
 my 
story 
group\1
12 
Emotional 
distress 
14 14 0 Friends pregnancies 
came and went, I trod a 
regular path to BabyGap 
and started to noticed 
them looking scared and 
sad when they told me 
they were pregnant and I 
was terrified when they 
told me, because I 
couldn't feel the 
happiness they deserved, 
the jealousy was just too 
strong. I now have a 
pregnancy radar that can 
spot a impending bump 
from a text message 
(How did you know from a 
text that said 'We are 
really well thanks'.. said T 
?) 
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group\1
12 
Emotional 
distress\financi
al loss 
16 16 0 So now we need to 
decide when we start IVF 
with all the financial (not 
eligible despite working 
for the NHS!), physical 
and emotional baggage 
that is wrapped up in that 
package of hope. 
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story 
group\1
11 
Emotional 
distress 
5 5 0 Started to feel really low 
and tearful so went to GP 
who said i was suffering 
with depression but didnt 
want to prescribe 
anything, went home and 
really felt i couldnt cope 
so rang fertility clinic to 
ask for help, the nurse 
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called me back and i 
explained how i felt, she 
replied "dont worry its not 
the end of the road for 
you, your DH can have a 
sperm retrieval opp" i 
explained my husbands 
SA was normal and she 
said " i am afraid not he 
has no sperm at all, the 
GP must have read it 
wrong" I thought i was 
going to faint on the 
phone, i only phoned to 
say i felt low and got this 
news!!!   I had to break 
the news to my DH when 
he got home from work 
and he was devastated. 
We then waited two 
weeks to see a consultant 
to explain things 
 my 
story 
group\1
09 
Emotional 
distress\feeling 
isolated 
8 8 0 Has anybody out there, 
had a similar situation? I 
really feel like I need to 
talk about this, but like 
most people on here none 
of my family or friends 
understand. 
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08 
Emotional 
distress 
1 1 0 It is great to know that I 
am not alone in this 
desperate situation but 
sad that there are so 
many of us out there. 
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group\1
08 
Emotional 
distress 
8 8 0  am SO unbelievably 
happy for her but man 
was it difficult the first few 
months of her starting to 
show. It was just so hard. 
I just wanted to hide. With 
time I am getting better 
about it but it still is just so 
difficult. She is my best 
friend and we depend on 
each other so much as 
our families are far away 
but our friendship is so 
strained right now. She is 
too scared to 
acknowledge that she is 
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pregnant. So afraid she is 
going to lose this one so 
we just don’t talk about it 
at all. As if it’s not there. I 
feel like such a horrible 
friend. I know she doesn’t 
feel that way and she can 
appreciate a bit of what I 
am going through having 
had 2mc’s like me but she 
is now pregnant and I am 
not. I am so angry that it 
all got taken away. 
 my 
story 
group\1
06 
Emotional 
distress 
26 34 0 For the first time in 
my life I was completely 
devastated, I always 
thought I was a strong 
person and able to take 
what life threw at me – I 
had worked for 
many years in rural Africa 
after all – what could be 
worse than 
that!!!! But this complete 
destruction of my dream 
of adopting a 
child was too much. I 
cried solidly for a week – 
Kleenex shares 
soared!!! But there was 
no way we could afford it 
even if we only 
lived on bread and water 
for a year. So adoption is 
on hold until we 
win the Lottery. 
Claire 
Haresna
pe 
9᠋ my 
story 
group 
1 
 my 
story 
group\1
06 
Emotional 
distress 
53 62 0 The world went from 
being unfair for the not 
hugely 
rich to just unfair - full 
stop!!!! Life is unfair - I 
know 
that!!!!! but I´m having a 
really bad time dealing 
with this one 
particular issue. I´m 
surrounded (it feels like) 
by pregnant people 
and I can´t relate to them 
anymore and more 
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importantly feel 
incredibly isolated, as my 
usual sources of help and 
support are 
pregnant and how 
uncomfortable for all 
involved to pour your 
heart 
out about being childless 
to someone heavily 
pregnant!!!! Or my 
mother who talks 
continually about my 
nephew!!!!!!!!!!!! Or my 
sister who conceived the 
first month of trying!!!!!!!! 
 my 
story 
group\1
06 
Emotional 
distress\feeling 
isolated 
53 62 0 The world went from 
being unfair for the not 
hugely 
rich to just unfair - full 
stop!!!! Life is unfair - I 
know 
that!!!!! but I´m having a 
really bad time dealing 
with this one 
particular issue. I´m 
surrounded (it feels like) 
by pregnant people 
and I can´t relate to them 
anymore and more 
importantly feel 
incredibly isolated, as my 
usual sources of help and 
support are 
pregnant and how 
uncomfortable for all 
involved to pour your 
heart 
out about being childless 
to someone heavily 
pregnant!!!! Or my 
mother who talks 
continually about my 
nephew!!!!!!!!!!!! Or my 
sister who conceived the 
first month of trying!!!!!!!! 
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05 
Emotional 
distress 
1 1 0 New to INUK so thought I 
provide some background 
to my story and hope to 
speak to individuals who 
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understand the pain I am 
going through. 
 my 
story 
group\1
05 
Emotional 
distress 
2 2 0  We also had many 
stresses that year, with 
the death of my mother-
in-law, nan & auntie - so 
knew this might be 
effecting things 
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story 
group\1
05 
Emotional 
distress 
3 3 0 Everything looked fine at 
the early 7 week scan and 
there was a lovely tiny 
heartbeat, however that 
very evening I started to 
bleed. I went back 4 days 
later and still everything 
looked fine, but that 
evening I M/C. Thankfully 
my husband was there 
with me and we grieved 
together. 
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story 
group\1
05 
Emotional 
distress\feeling 
isolated 
5 5 0 At the moment I am 
feeling very low and 
lonely. I only have 2 
friends now that don't 
have children and thats 
because they aren't yet 
married and ready. Our 
social life has come to a 
stand still and I really 
miss having girlie chats 
over the phone. It seems 
that everyone else is just 
too busy with their family. 
When people do ring, 
they don't know how to 
speak to me and keep 
saying it will happen or 
making silly little jokes like 
are we doing it right!!! I 
know they are trying to 
help, but really they have 
no idea. It seems that no 
one understands, I did 
have one friend in a 
similar situation but guess 
what! - she fell pregnant 
and now has a lovely 
daughter. 
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story 
Emotional 
distress 
6 6 0 When will it be my 
turn???!!! 
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group\1
05 
pe group 
 my 
story 
group\1
04 
Emotional 
distress 
1 1 0 I'd stopped buying 
pregnancy test kits, but 
this time, I was late. I had 
to be pg - it was poetic 
timing, perfect symmetry 
from the day we came to 
look round the venue. Of 
course, life doesn't work 
like that and I was on the 
edge of tears all day, 
feeling terrible for 
focusing on my own upset 
and not on the couple's 
happy day. It took another 
few months for us to 
finally go to the GP 
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 my 
story 
group\1
04 
Emotional 
distress 
1 1 0 We were really in denial 
and I regret this so much 
now.After initial 
consultations and tests 
with the GP, we were 
referred to our local 
hospital, but the first visit 
was an agonising three 
months later and by now 
the clock and the panic 
were ticking louder and 
louder in our heads 
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 my 
story 
group\1
04 
Emotional 
distress 
1 1 0 We arrived home 
exhausted and tearful, 
took off our coats and the 
phone rang: DH's brother 
telling us we were going 
to have a niece or 
nephew. We had another 
nine months of hospital 
visits and tests, all of 
them involving long waits 
in packed waiting rooms. 
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 my 
story 
group\1
04 
Emotional 
distress 
1 1 0  I felt really hurt, but it's 
hard for other people to 
genuinely understand the 
agony of IF. I know that 
they are probably trying to 
spare our feelings and 
don't like to bring up 
something that must 
upset us, but I wanted to 
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have those conversations 
and to talk with people I 
loved about what we'd 
lost. I at least wanted a 
hug from our parents and 
the chance to cry with 
them, but I don't think 
they knew how to handle 
it. I also think the media 
gives a false impression 
that IVF is an easy option. 
We had lots of comments 
along the lines of "you 
can try again" or "it'll be 
your turn soon". As if it 
was a case of keeping up 
with the Joneses. 
 my 
story 
group\1
02 
Emotional 
distress 
4 4 0 It was almost exactly a 
year from starting to ttc 
that we visited our GP 
and asked the 
questions.  Luckily we 
had a great GP then who 
didnt fob us off with the 
whole "relax and i'm sure 
it'll happen" rubbish, but 
referred us for the inital 
tests straight away.  That 
is when our whole world 
began to crumble.. 
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story 
group\1
02 
Emotional 
distress 
5 5 0  Dh's results however 
were not so reassuring 
and we were given the 
devastating news that he 
has an extremely low 
sperm count which is 
what was accounting for 
our failure thus 
far.  Initially it was our GP 
that delivered the news of 
the result and he did so 
with great compassion 
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story 
group\1
02 
Emotional 
distress 
5 6 0 we were subsequently 
delivered the bombshell 
that in order to stand any 
realistic chance of 
conceiving we would 
need ivf.  
Strangely at this stage i 
dont 
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remember feeling surprise
d or anything other than 
accepting.  Looking back i 
think there was part of us 
that was expecting this, 
after the bad initial result 
and given the fact that my 
dh has a history of 
undescended testes 
(which wasnt identified 
until relatively late in his 
childhood and 
therefore not corrected as 
early as it should have 
been), and another part of 
us that were in shock and 
numb really.  
 my 
story 
group\1
02 
Emotional 
distress 
7 7 0 After the SA results dh 
and i seriously grew 
apart.  I was a like a 
demon possessed, 
desperately searching the 
web for info and stories of 
ivf and reading every 
book going.  He on the 
other hand refused to 
discuss any of it, 
completely shut me out of 
everything and stuck his 
head in the sand (plus he 
didnt want me to talk to 
anyone either, got very 
upset if i mentioned 
wanting to speak to any 
family or friends and all 
but forbid me to even 
speak to my 
mum!!).  Eventually the 
strain became too much 
and we split. 
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 my 
story 
group\1
02 
Emotional 
distress 
9 9 0 We spent a weekend of 
tears and immense stress 
and actually ignored all 
advice to stop the 
medication 
until we were able to 
speak to a consultant at 
the colposcopy clinic, 
which wasnt until the 
Tues (we were 
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originally told all this on 
the Friday mid 
afternoon).  When we 
finally did we discovered it 
wasnt necessary to 
interupt the cycle and any 
treatment for the 
abnormal cells could be 
delayed until we werent 
cycling or pg! 
 my 
story 
group\1
02 
Emotional 
distress 
10 10 0   Luckily my best friend 
came over to be with me 
when the result came 
in.  It wasnt good.  The 
result showed the level 
had dropped drastically 
indicating m/c was 
imminent.  The clinic told 
me to stop taking the 
pessaries and hopefully 
(!!) bleeding would start 
within a few days.  Luckily 
i guess, it did.  Pg for one 
week and only a few 
hours of that being 
excited (the rest stressed 
and anxious)   Not a 
happy time. 
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story 
group\1
02 
Emotional 
distress 
13 13 0 Since then i've gone from 
feeling fine to feeling lost 
and scared, empty and 
devastated all over 
again.  Initially i think i 
dealt with things fairly well 
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story 
group\1
02 
Emotional 
distress\counse
lling 
13 13 0 The counsellor was 
'happy' with how we were 
coping and i felt confident 
in the way forward.  
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 my 
story 
group\1
02 
Emotional 
distress 
13 13 0  The last couple of weeks 
have seen a re-
emergence of the anger 
and frustration, upset and 
tears 
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story 
group\1
01 
Emotional 
distress 
4 4 0 At this point i'd had 2 
years of monthly 
disappointments so said 
to hell with it, we'll just go 
for broke and go to a 
private clinic. Thankfully 
we did and in August 07 
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after an initial meeting we 
started 3 cycles of 
IUI.  Unfortunately we got 
3 BFN's.  After hitting a 
big low point we decided 
to go for IVF and were 
just about to start Nov 07 
when I got 
abnormal results back 
from a smear test and 
had to go in for a biopsy. 
 my 
story 
group\1
01 
Emotional 
distress 
5 5 0  was so shocked and 
hadn't prepared myself at 
all for the outcome.  At 
this point I turned into a 
blubbering mess, it was 
just one set back too 
many.  Thankfully my 
nurse (who is a total 
angel) phoned round all 
her contacts and got me 
booked in the next week 
for the dilitation which 
meant we could crack on 
with the drugs, I went 
from feeling totally 
desperate to being on 
cloud 9 within 24 hrs!!! 
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story 
group\1
00 
Emotional 
distress 
6 6 0 In June 08 we started our 
first IVF cycle. I had just 
started taking the DR 
inhaler when I got a letter 
saying that a smear test I 
had had 3 months before 
showed severe abnormal 
results. We therefore had 
to cancel that cycle whilst 
I had treatment. I was 
devastated. The following 
week one of my closest 
friends announced her 
pregnancy. I was even 
more devastated! Then 
on the day that I got the 
letter saying that they had 
removed all of the 
abnormal cells, had a 
clear margin and there 
was no sign of cancer, my 
parents split up. More 
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devastation. 
 my 
story 
group\9
9 
Emotional 
distress 
3 3 0 I am desperate to know if 
anyone has had the New 
treatment, Array CGH. I 
am due to start the 
treatment in early March. 
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 my 
story 
group\9
7 
Emotional 
distress\being 
in control 
3 3 0 . So I took matters into my 
own hands, did some 
research on the internet 
and started taking 
50mg B6 daily to increase 
my DPO's. This worked 
for 3 months and I got 8/9 
day LP however 
when realised it was 
giving me diarrhoea I 
stoped taking it and my 
DPO's dropped straight 
back down to 7. 
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 my 
story 
group\9
7 
Emotional 
distress 
4 4 0 This time I was told under 
the PCT guidlines for my 
area I have to of been 
trying for 18 months for a 
referral as there are no 
grounds for me to be 
referred. I left very upset, 
without my referral, and 
with most of my questions 
unanswered 
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story 
group\9
7 
Emotional 
distress\being 
in control 
5 5 0 I took matters into my 
own hands again - this 
time consulting a 
proffessional and 
started acupuncture and 
chinese herbal medicine. 
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 my 
story 
group\9
7 
Emotional 
distress 
20 22 0 Over the course of the 
year we've had a roller 
coaster of emotion. If I'm 
honest DH isn't as worried 
as me. He's yonger and in 
less of a rush, he's more 
patient, he can't hear his 
clock ticking, he's more 
worried about  money, 
he's got an exciting new 
job which he's really 
enjoying and if I'm honest 
he was quite dismissive 
and it seemed that he 
was releaved at the start 
Claire 
Haresna
pe 
9᠋ my 
story 
group 
1 
APPENDICES 
Appendix	  	  11	  	  Qualitative	  Data	  from	  Strand	  4	   847	  
of the year when we didn't 
get lucky. I was really 
careful in approaching the 
subject with DH when we 
started out trying. I didn't 
want to push him into 
anything he wasn't ready 
for so I was really hurt 
with his attitude towards 
our failure, when we were 
supposed to be doing this 
together and it was a joint 
decision to start a family. 
Over the year things have 
moved on, I've regularly 
broked down - tears most 
month, the odd hissy fit 
for no reason and a 
couple of good heart to 
hearts. I'm still hurt that 
he never seems upset. 
Does that make me 
weird? It's not that I was 
to see him upset but I 
want to see that he cares. 
He's being more 
supportive as time goes 
on and I'm sure it's just a 
mars venus thing. 
Sometimes it seems he 
just saying the right thing 
but doesn't really feel it 
but then his family are 
dryer than mine 
emotionaly. 
It's not exactly the first 
year of married life we'de 
hoped for. 
 my 
story 
group\9
4 
Emotional 
distress 
3 3 0 . I asked my Dr if I could 
have Luteal Phase 
Defect, but was told such 
a condition did not exist. 
To cut a long story short, 
a series of very difficult 
losses happened in quick 
succession in 2006, 
meaning infertility was 
forced to take a back 
seat, although the pain 
continued to bubble under 
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the surface. In 2007 my 
marriage hit a really rough 
spot. The strain of 
everything was begining 
to take it's toll, and had it 
not of been for how strong 
my DH and I are as a 
couple, I think we could 
have broken up. We've 
managed to get our 
marriage back on track 
and despite the ongoing 
pain of infertility, are 
stronger than ever. We've 
moved from Swindon to 
Oxford, somthing we've 
always wanted to do and 
have built a new life for 
ourselves here. Last year, 
we went to a clinic called 
Viveka in London, which 
takes a holistic approach 
to infertility. It was 
confirmed through a 
hormone profile that I do 
have LPD and when I told 
the Dr in London that I 
had perviously been told it 
did not exist, he was 
horrified.  
 my 
story 
group\9
4 
Emotional 
distress\being 
in control 
3 3 0 I were so hopeful that 
finally we had gotten to 
the bottom of our 
infertility. (I had 
finally spotting).  We have 
changed our lifestyle, I 
am having accupuncture, 
we've cut out the caffeine, 
booze and are eating 
healthily 
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story 
group\9
4 
Emotional 
distress 
3 3 0  Since then there have 
been no more positives 
and I feel like I am loosing 
heart. We are due to have 
our first round of IVF in 
May, but I cannot get my 
hopes up. After 6 and a 
half years of 
dissapointment I feel 
emotionally exausted and 
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despite having a good 
(but v stressful) job, loving 
family and friends, and 
most importantly a 
wonderful husband, I still 
feel very low and lonely. 
It's like I am grieving for 
the child that hasn't been 
born. Each month is an 
emotional rollercoaster 
and I feel like I am 
arriving at the start of IVF 
exausted. 
 my 
story 
group\9
3 
Emotional 
distress 
4 4 0 In February of this year 
we were told that IVF with 
ICSI would be our only 
chance of having a family. 
As I drove home from the 
clinic my sister phoned to 
say she was pregnant 
with her first baby. I was 
overjoyed for her but don't 
mind admitting that I also 
shed a little tear for 
myself 
Claire 
Haresna
pe 
9᠋ my 
story 
group 
1 
 my 
story 
group\9
2 
Emotional 
distress 
1 1 0 failed IUI attempts. We 
have recently had a failed 
IVF cycle. The awful thing 
was, alhtough we had 8 
eggs, only 4 fertilized and 
none divided. The 
Doctors have told us that 
we have poor egg quality. 
Claire 
Haresna
pe 
9᠋ my 
story 
group 
1 
 my 
story 
group\9
1 
Emotional 
distress 
5 6 0 I have revolutionised the 
diet, my partner is taking 
zinc and selenium and 
alcohol is down to a 
minimum. We have 
approx 3 months before 
the next step and I'm 
feeling more than a little 
overwhelmed about 
what's on the horizon 
having read various posts 
on this site and on others. 
I'll keep posting if there's 
anything to report, I'm a 
bit lost at the moment to 
be honest. This wasn't 
part of the plan! 
Claire 
Haresna
pe 
9᠋ my 
story 
group 
1 
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 my 
story 
group\9
1 
Emotional 
distress\being 
in control 
5 5 0 I have revolutionised the 
diet, my partner is taking 
zinc and selenium and 
alcohol is down to a 
minimum. We have 
approx 3 months before 
the next step and I'm 
feeling more than a little 
overwhelmed about 
what's on the horizon 
having read various posts 
on this site and on others. 
Claire 
Haresna
pe 
9᠋ my 
story 
group 
1 
 my 
story 
group\8
9 
Emotional 
distress 
4 4 0 devastated by this blow.  I 
burst into floods of tears 
and dh took me home, 
both of us feeling totally 
numb.  10 days later (July 
2006) I was back in for 
my op.  A different 
surgeon did the 
procedure and told me in 
the recovery room (when I 
was still drowsy from the 
drugs!) what she had 
found.  She had removed 
my polyp but during the 
lap & dye had found that I 
had endometriosis.  The 
dye drained through my 
right tube but my left tube 
was totally blocked and 
would not drain at 
all.  She also found a 
fibroid and lasered off my 
endo.  She said I would 
most likely need IVF but 
that we should keep trying 
for another 3 months 
before being referred for 
treatment!  I just wanted 
to be with my dh - not in 
the recovery room on my 
own - and when I got 
back to the ward he just 
held me in his arms and I 
cried and cried 
Claire 
Haresna
pe 
7᠋ my 
story 
group 
1 
 my 
story 
group\8
7 
Emotional 
distress 
8 8 0 At this point very 
depressed . Hit rock 
bottom. Sure we would 
not have children! Signed 
Claire 
Haresna
pe 
7᠋ my 
story 
group 
1 
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off work for 2 weeks 
 my 
story 
group\8
7 
Emotional 
distress 
10 11 0 Also stopped charting 
cycles as absolutely 
obsessed with it and 
knew my cycles were fine! 
3rd April 2007- DP first 
SA. Stressful++++ 
Claire 
Haresna
pe 
7᠋ my 
story 
group 
1 
 my 
story 
group\8
7 
Emotional 
distress 
15 16 0 22nd Jan 2008- Results 
of SA even lower again. 
Advised by reg that we 
need ICSI, but won't be 
eligible for funding until I 
turn 30. Only 27 at this 
point. Devastated. Cried 
all way home. Poor DP 
didn't know what to do! 
No money so self fund not 
an option! Also getting 
married in 2009! 
Big long 
gap...........continued 
trying. Knew when I was 
ovulating as cycles like 
clockwork by now! Lots of 
hope each month but 
nothing! Threw myself 
into wedding plans but 
hurting lots. Desperate for 
a baby. All my friends 
have at least 1 if not 2 by 
now! Depressed on and 
off over next year. 
Claire 
Haresna
pe 
7᠋ my 
story 
group 
1 
 my 
story 
group\8
7 
Emotional 
distress 
34 36 0 4th Dec 2009- Scan at 
7+4. No heartbeat 
although sac and fetal 
pole evident. Quite likely 
not alive. Wait for further 
scan in 3 days. 
Devastated. Searched 
online+++. Some 
reassuring stories but I 
wouldn't allow myself to 
get hopes up! DH more 
positive than me! 
17th Dec 2009- Our world 
comes crashing down. 
Embie def not alive. Has 
started to 
collapse!  DEVASTATED! 
Stop progesterone and 
Claire 
Haresna
pe 
7᠋ my 
story 
group 
1 
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await m/c over xmas! 
3rd Jan 2010- Still no m/c. 
The wait is now becoming 
unbearable . Will 
 my 
story 
group\8
6 
Emotional 
distress 
1 1 0 We had ICSI and it failed 
in the way it does for the 
majority of women, the 
embryoes failed to 
implant.  I had been so 
optomistic and lost sight 
of us having a one in 
three chance of it 
working.  I was in 
absolute pieces when I 
started bleeding - I hadn't 
even realised that is what 
would happen if it went 
wrong! 
Claire 
Haresna
pe 
7᠋ my 
story 
group 
1 
 my 
story 
group\8
6 
Emotional 
distress\being 
in control 
3 3 0 I've just read a book 
called Taking Charge of 
Your Fertility by Toni 
Weschler - it's an 
International Bestseller. I 
wish I'd read this before 
going to the 
doctor.  There's so much 
useful information in there 
about how to maximise 
your chances of 
conception. I'm going to 
follow it's 
recommendations and if 
they don't work I haven't 
wasted any money or 
taken any drugs - it tells 
you why ovulation tests 
might not work for you 
and says ttc on day 14 of 
your cycle might never 
work for you too - please 
read it if your ttc. It won't 
do you any harm and it's 
very insightful. 
Claire 
Haresna
pe 
7᠋ my 
story 
group 
1 
 my 
story 
group\8
6 
Emotional 
distress 
19 19 0 On our 2nd cycle when 
we went back in for the 
embryo transfer we were 
told three embryos had 
survived.  So they were 
happy to transfer two 
back in and wanted us to 
Claire 
Haresna
pe 
7᠋ my 
story 
group 
1 
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decide there and then 
what to do with the 3rd 
one.  Ie did we want to 
pay for it to go into frozen 
storage - which is costly 
and the chances of it 
surviving all the way 
through to natural birth 
are small - or did we 
consent to it being 
destroyed. We had to 
decide there and then in 
the waiting room (me 
crying and looking 
shocked in a room full of 
strangers looking scared) 
 my 
story 
group\8
5 
Emotional 
distress 
1 1 0  Cycles appeared to 
return to normal then april 
to june cycle 7 weeks - 
think this is due to huge 
stress and unhappiness 
at work 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\8
5 
Emotional 
distress 
1 1 0  Panic set in as thought a 
little bleeding not a 
problem, however, 
apparently it is if you 
haven’t had any bleeding 
at all by this point.   After 
hideous day at 2 A&E 
departments (won’t go 
into that L) at 5.45pm, it is 
confirmed that our baby 
had died at about 8 
weeks and that I had had 
a missed miscarriage i.e. 
your body continues to 
think you are pregnant 
after the baby has died. 
Total and utter 
devastation, I cannot 
describe the grief and 
despair and the complete 
and utter feeling of loss – 
how completely unfair to 
allow us to lose our 
miracle baby. How could 
that happen?   I decided 
to have the surgical 
procedure, Evacuation & 
Removal of Products 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
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related to Conception 
(ERPC) – how heartless a 
term is that? Our baby 
being referred to as a 
“Product related to 
Conception”. This 
happened on the 9th 
October in a Day Unit 
where I was surrounded 
by people killing their 
babies, terminations, all of 
them 
 my 
story 
group\8
5 
Emotional 
distress 
1 1 0 I sobbed and howled, my 
husband and I were 
inconsolable, our hearts 
were broken. Seeing my 
husband cry was also 
extremely distressing.   It 
took a few weeks to get 
back to any sense of 
normality, 
Claire 
Haresna
pe 
7᠋ my 
story 
group 
1 
 my 
story 
group\8
5 
Emotional 
distress 
1 1 0  I am terrified of the failure 
again, although we do 
have enormous faith in 
our doctors this time. 
Claire 
Haresna
pe 
7᠋ my 
story 
group 
1 
 my 
story 
group\8
4 
Emotional 
distress 
3 3 0 I bought a Persona and 
we bought a puppy – we 
thought it would be good 
practice for a baby – I 
have to say I’m so glad 
we did as she is my 
comforter when I have 
dark days and all I want to 
do is curl up and cry 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\8
4 
Emotional 
distress 
5 5 0   This was such a shock, I 
was only 33 and 
otherwise healthy, my 
mum did go through the 
menopause in her early to 
mid forties, but I still 
thought I had a couple of 
years before things got 
difficult. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\8
4 
Emotional 
distress 
7 7 0  I was in shock, I bust into 
tears, my mind raced, did 
I have any eggs, would be 
need to consider a donor 
egg, where did you get 
one from.  Would we ever 
have little Josh?  I admit I 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
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do have a habit of 
jumping to the worse case 
scenario, but when you 
don’t know what is 
happening I think you do 
imagine the worse. 
 my 
story 
group\8
4 
Emotional 
distress\feeling 
isolated 
13 13 0 I joined IFUK to remind 
myself that I’m not alone, 
and I’m encouraged by 
the stories on here.  
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\8
3 
Emotional 
distress 
1 1 0  I have had the barrage of 
poking, probing and tests 
from ultrasounds to HSG 
to a lap last month with 
the dreaded result of 
unexplained infertility. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\8
3 
Emotional 
distress 
1 1 0 Its just starting to get to 
me now, with most of my 
friends and family being 
able to conceive at the 
drop of a hat. They are so 
happy with their babies 
that they are difficult to 
talk to as they don’t really 
understand and you get 
the ‘just relax Im sure it 
will happen soon’ I know 
they mean well but it is 
hard to keep smiling 
sometimes.   The doctors 
can be very insensitive 
and quite dismissive, they 
see you for 5 mins every 
4or5 months and cant 
wait to get you out the 
door. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\8
3 
Emotional 
distress\being 
worthy 
1 1 0 I try to think of the bigger 
picture, there a many 
people in the world a lot 
worse off than me. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\8
2 
Emotional 
distress 
4 4 0 We have 
subsequently had three 
unsuccesful attempts at 
IVF using an English 
clinic.  This was alas a 
really awful experience 
as I was put through 
cycles which were never 
going to work as my 
uterus was once again 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
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being distorted by fibroids 
which had reoccured.  We 
had asked them 
constantly to rescan me 
to check this as I feared 
this had 
happened.  Nobody 
knows your body as you 
do and  my periods had 
become so heavy and 
lengthy that I simply knew 
something wasn't 
right.  The clinic pushed 
these concerns aside 
and  seemed more 
interested in taking our 
money and pushing us 
onto another cycle.   
 my 
story 
group\8
2 
Emotional 
distress 
5 5 0 Alas we found out two 
weeks ago that this 
attempt has also failed 
and to be honest its really 
floored me.  Up until now 
I've managed to keep 
quite positive and hold my 
head up but I really feel 
completely devastated.  I 
don't know if anyone else 
has found this but it 
seems to be getting 
harder the more attempts 
we make. 
Claire 
Haresna
pe 
2᠋† my 
story 
group 
1 
 my 
story 
group\8
1 
Emotional 
distress 
1 1 0 . I decided to take 
progestrone afterwards. 
lack of information caused 
me to believe I was 
pregnent as didn't know 
progesterone stopped 
period. Found out on 
internet. Stopped it and 
period came two days 
later. MASSIVE 
DISAPPOINTMENT and 
deep sorrow. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\8
1 
Emotional 
distress 
1 1 0 feeling too confused and 
also want to give chinese 
herbs more time to work . 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
Emotional 
distress 
4 4 0 The doctor then asked me 
what I would like to do. I 
Claire 
Haresna
2᠋ my 
story 
1 
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group\8
0 
felt under extreme 
pressure to make a 
decision then and there, 
which was impossible to 
do without DH. We hadn't 
really talked about IVF at 
this point and didn't really 
understand what it was all 
about. The doctor told me 
it was a very stressful and 
emotional thing to 
undergo and suggested I 
talk to one of the fertility 
nurses before leaving. 
This I did, and was given 
lots of help and advice 
and support-in fact she 
gave up a whole hour of 
her precious time to talk 
to me as she could see I 
was worried and upset. 
pe group 
 my 
story 
group\8
0 
Emotional 
distress 
5 5 0  The first time I injected I 
was absolutely terrified of 
getting something so 
important wrong. I wished 
they had given us practice 
injections using oranges 
or something. We were 
given a DVD about how to 
inject, but it's one thing 
understanding a DVD and 
another thing actually 
doing the practice! I will 
admit I got myself in a 
right state about it all- 
probably due to the DR 
hormones flying around 
my body and did my first 
injection in floods of tears 
with DH trying to calm  
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\8
0 
Emotional 
distress 
11 12 0 On day11 I was spotting, 
and by day 12 I had a full 
blown heavy AF. I tried to 
stay positive as I knew 
that sometimes you can 
have implantation 
bleeding, but in my heart, 
I knew that AF was too 
heavy and I was losing 
our little "Oreos" 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
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It was at that this point 
that everything hit me and 
I cried unconsolably. I am 
lucky enough not to be 
working at the moment 
and so was able to fall 
apart in the comfort of my 
own home. I texted DH 
throughout the day telling 
him everything as he was 
at work. He kept telling 
me to try to stay positive 
until after the test. I just 
got angry and then said I 
needed sometime to 
myself and that I was 
going for a walk. 
 my 
story 
group\7
9 
Emotional 
distress 
1 1 0 Sadly I am to follow a 
different route to that of 
my friends and family. It 
may sound odd but in a 
way I thought that we may 
have problems but at the 
time I had no reason to 
think this. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
9 
Emotional 
distress 
5 5 0 At first I was excited as 
for the 1st time in years I 
felt like I have a chance of 
becoming a mummy but 
then the anxieties 
followed. I almost had to 
grieve for the fact that we 
cannot have a child 
naturally and I am also 
scared that my chances 
of having a child are now 
so much more limited 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
9 
Emotional 
distress\feeling 
isolated 
5 5 0  Knowing no one who has 
gone through the same 
thing I have found this a 
very lonely time. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
8 
Emotional 
distress 
4 4 0 What a bombshell! And 
what a mixture of 
emotion. I have had many 
ups and downs since we 
were originally told last 
October 09. My husband 
has did not really speak 
about our news and I 
suppose I had to let him 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
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come to terms with it in 
his own way as it's male 
factor infertility, all my 
tests came back normal. 
 my 
story 
group\7
8 
Emotional 
distress 
10 10 0 So how am I feeling??? 
Nervous, anxious, 
excited, frightened, 
hopeful. But mostly a bit 
numb. I really am not sure 
why I am coping with it so 
well. I have bad days, 
where I just start to cry 
but on the whole my 
opinion has been if it is 
going to work it will work 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
8 
Emotional 
distress\financi
al loss 
10 10 0  He said that my mind is 
overactive and no matter 
how many relaxation 
techniques I do will not 
stop that (plus the fact 
that they all cost money 
that we do not ha 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
8 
Emotional 
distress\feeling 
isolated 
12 12 0 It's just nice to have 
somewhere to put my 
thoughts and feelings. It 
just helps me to write 
about it. Can't really 
explain it to my friends 
and some of my family 
have not even asked me 
how things are since the 
day I told them we could 
not have children 
naturally. I suppose it's 
their way and they feel 
they don't want to ask, I 
don't know! I just feel like 
they would not 
understand anyway. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
7 
Emotional 
distress 
2 2 0  We were both very upset 
when the results came 
back; his count and 
progressive motility were 
both low, but what was 
particularly worrying was 
the morphology (0% 
normal, summarised at 
the bottom of the letter as 
severe teratozoospermia). 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
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 my 
story 
group\7
7 
Emotional 
distress 
2 2 0 What alarmed me was his 
advice for us to start 
trying straight away, give 
it 6 months (not long at 
all!) then consider IVF 
with ICSI. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
7 
Emotional 
distress 
3 3 0 This has all happened in 
the space of a month and 
I feel so overwhelmed 
with it all. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
7 
Emotional 
distress 
4 4 0 . She’s always there when 
I need a good cry or to 
rant about how unfair it all 
is. Unfortunately my 
Mother-in-law’s reaction 
“Oh well, it’s not the end 
of the world,” and “well, 
you can always adopt 
then” was very unhelpful 
as I’m really not in a place 
to be thinking this way 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
7 
Emotional 
distress 
4 4 0 Mostly I feel very sad and 
alone, surrounded by 
friends who chat away 
about babies, and more 
and more announcements 
of pregnancies are made. 
Since we got married I 
regularly get asked the 
question, “so when are 
you having a baby?” 
which I never used to 
mind but now makes me 
want to burst into tears. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
7 
Emotional 
distress\feeling 
isolated 
4 4 0 Mostly I feel very sad and 
alone, surrounded by 
friends who chat away 
about babies, and more 
and more announcements 
of pregnancies are made. 
Since we got married I 
regularly get asked the 
question, “so when are 
you having a baby?” 
which I never used to 
mind but now makes me 
want to burst into tears. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
Emotional 
distress 
4 4 0 As you can imagine we 
were devastated and I 
don't think I stopped 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
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6 crying all weekend. Being 
so far away from family 
also was very hard, 
although I've kept all this 
away from my Dad. We 
lost Mum last year and he 
has had a lot to deal with 
and I don't want him 
worrying about me at the 
moment. I could have 
done with a good cry and 
natter with my wonderful 
Mum that day though, I 
can tell you.  
 my 
story 
group\7
6 
Emotional 
distress 
7 7 0  For me, having lost mum, 
I found it devastating that 
nothing of her/me would 
be passed on and that 
made me so very sad. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
6 
Emotional 
distress\being 
worthy 
10 10 0 Gosh this story all sounds 
very blaze, but believe 
me, its all been very bleak 
and a hard decision to 
make. I know I've not 
been through anything 
compared to all you lovely 
ladies, but I'm hoping that 
things work out for us as 
the last couple of years 
have been so horrendous 
for us, that this was the 
final straw and we're just 
hoping that our luck 
changes. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
5 
Emotional 
distress 
4 4 0 Completely freaked out 
that consultant thinks 
there could be a problem.  
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
5 
Emotional 
distress 
4 4 0  Devastated, starting to 
drift apart from DH as he 
wanted me to stop trying.  
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
5 
Emotional 
distress\financi
al loss 
4 4 0 Couldnt afford to do 
private without a loan so 
decided to wait 18mths to 
get to top of waiting list. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
5 
Emotional 
distress 
5 5 0 Spring 2008, IVF 1 used 
buserlin and menopur and 
was devastated again 
when only got 3 follicles 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
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 my 
story 
group\7
5 
Emotional 
distress 
5 5 0 . Had second BFN just 
before Christmas and 
devastated.  DH gutted 
too but not keen to try 
again. Relationship going 
downhill at a very rapid 
rate. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
5 
Emotional 
distress 
6 6 0 2009    A new year 
and relationship at an all 
time low.  At the brink of 
divorce, start to 
communicate better and 
eventually DH agree to 
one final private IVF 
using money saved up. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
5 
Emotional 
distress\counse
lling 
6 6 0 've seen a hospital 
counsellor to help get  my 
head sorted out regarding 
infertility diagnosis, failed 
IVF, dealing with 
family/friends and trying 
to be positive for this last 
treatment and future 
ahead. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
4 
Emotional 
distress 
1 1 0 This was a bit of a 
shocker as I had always 
viewed ICSI as 'the last 
resort' and it took me a 
long time to accept that 
we were going straight 
there without trying 
anything else first. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
4 
Emotional 
distress 
3 3 0 on 29th. First scan 
showed 11 follies which 
increased to 23 by day 
12. Bloods still showed 
relatively low estradiol so 
after a frantic day waiting 
by the phone to hear if we 
were being cancelled we 
got the go ahead and our 
EC was arranged for 13th 
May. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
3 
Emotional 
distress 
1 1 0  On the one hand I felt 
relieved that we had a 
diagnosis and could now 
move forward and on the 
other I felt crushed and 
slightly ashamed that we 
couldn't be 'normal' and 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
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just get pregnant like all 
my friends/sister have 
done etc.  What a horrible 
mix of emotions.  Anyway 
after a week or so I 
picked myself up and 
pulled myself together 
and told myself to stop 
being ridiculous, this 
happens to so many 
people it's just that 
nobody really talks about 
it. 
 my 
story 
group\7
2 
Emotional 
distress 
6 6 0  By this time I was 
seriously depressed so I 
was prescribed anti-
depressants for a while. 
Thankfully i managed to 
come off them a few 
months later. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
2 
Emotional 
distress 
9 9 0 I am trying to remain 
positive and patient but 
it's hard. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
1 
Emotional 
distress 
5 5 0 I have 2 sisters (and 1 
brother but he can't get 
pregnant so is OK) and at 
that stage they both had 
one child each of about 
18 months. I don't think I 
was upset back then as 
I'd only just started trying, 
as time went on I just 
started getting more 
stressed and my endo 
started becoming more 
painful, I got referred to 
specialist and had a 
laparoscopy. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
1 
Emotional 
distress 
5 5 0  That was in febuary this 
year and I'd given myself 
6 months to see if I could 
achieve pregnancy. 
Needless to say - no 
success - it didn't help 
that each of my sisters 
have gone on to have 
another child each, and 
they did it so easily! How 
can three people form the 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
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same gene pool have 
such different 
experiences? 
 my 
story 
group\7
1 
Emotional 
distress 
6 6 0 . I thought I'd been coping 
reasonably well but since 
actually starting infertility 
treatment ( I'm on birth 
control now and have a 
scan booked on Dec 21st) 
I've felt worse not better. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
1 
Emotional 
distress 
6 7 0 I feel like I have a tenuous 
grip on self control, like I 
could cryat any moment. 
Hopefully once I start the 
cycle properly I'll feel 
better but I feel like I'm 
already waiting for it to 
fail. 
Sorry, It turned into a bit 
of an epic but it's so good 
to just be able to let it all 
out to someone who 
understands.  
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
0 
Emotional 
distress 
1 1 0 Like many other couples, 
we were like ‘if it 
happens, it happens’ and 
were trying to get 
pregnant in a very laid 
back way. It wasn’t long 
until we started using 
ovulation kits, trying 
‘properly’ as we called it, 
and it became apparent 
that I wasn’t ovulating at 
the same time each 
month. As the months 
went on, and the feeling 
of disappointment and 
upset grew I began to 
wonder why it wasn’t 
‘happening’ for us 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\7
0 
Emotional 
distress 
1 1 0  Consultant explained the 
only way forward for us 
was ICIS. We had 
received funding for 3 
IUIs and 1 cycle of IVF - 
The news hit us like a ton 
of bricks, all sorts of 
things were racing around 
my head; would I ever be 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
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able to get pregnant? 
would we ever be a 
mummy and 
daddy?  Never before had 
I considered my life 
without a family and 
suddenly we were faced 
with that very possibility. 
 my 
story 
group\7
0 
Emotional 
distress 
1 1 0 week. After hearing the 
news that we couldn’t 
have ET because of this, I 
was completely 
distraught!! Even though I 
knew we had 4 embies I 
felt as if everything we 
had been working 
towards had been pulled 
further away.....yet more 
waiting......was a very 
strange transition 
period.......DP was my 
rock!  
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\6
9 
Emotional 
distress 
1 1 0 My Husband and i have 
been trying for a family for 
the last 4 and half years 
and have gone through 
IVF/icsi in Devon (x2 
rounds) and one round at 
Nottingham Care all with 
painfully negative 
outcomes 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\6
9 
Emotional 
distress 
1 1 0 With this round we had 5 
eggs, 2 were 
fertilized ,  grade 3 quality 
and fragmented, and both 
transfered. They had 
developed to a 3 and 7 
cell division.We are both 
devastated and have a 
huge dilema as to what to 
do next  
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\6
9 
Emotional 
distress\financi
al loss 
1 1 0  remaining funds. We 
have started looking at 
the ARGC clinic in 
London but with the much 
higher costs we would 
only be able to afford one 
cycle 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
Emotional 
distress\feeling 
1 1 0   I am in my Mid 
thirties.Can ayone help 
Claire 
Haresna
2᠋ my 
story 
1 
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group\6
9 
isolated me in my isolation , i have 
had to carry out all past 
procedures in secret apart 
from a few close friends 
and familly members 
pe group 
 my 
story 
group\6
8 
Emotional 
distress 
2 2 0 but slowly it began to get 
quite emotional - month 
by month, it was ovulation 
and then waiting to see if I 
came on or not. Most of 
the time it was on time as 
AF has always been like 
clockwork...then came the 
disappointment and low 
moods. Then poor DH 
would be encouraging me 
to say we'd try next 
month.. It all became 
really draining and 
stressful. At the same 
time the whole world was 
getting pregnant apart 
from me... 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\6
7 
Emotional 
distress 
9 9 0 did all I could to optimise 
chances. 2 days post ET 
ended up in gynae ward 
with OHSS. 30th 
November - did the test - 
BFN - totally 
devastated.  Even worse 
as Christmas 
approaching. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\6
7 
Emotional 
distress 
10 10 0 23rd december - review 
with our consultant - very 
tough as she was 
pregnant with her 3rd 
child & seeing her "bump" 
was such a reminder of 
what should have been 
for us 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\6
7 
Emotional 
distress 
12 12 0 I was crying my eyes out 
as I was worried we 
wouldn't have any embies 
with so few eggs. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\6
7 
Emotional 
distress 
16 16 0  was in bits - Dh was ok 
as we knew that 3 days 
before there was no h/b 
yet Junior now had one.  I 
was worried so we saw 
our private consultant 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
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again on the same day en 
route home.  Again he 
scanned me - no 
problems.  
 my 
story 
group\6
7 
Emotional 
distress 
18 18 0 we did the test our 
dreams ended.  Junior 
has gone & with him/her 
all our hopes & 
dreams.   As I'd had no 
bleeding & pregnancy 
symtoms still there the 
shock was crippling.  Our 
private consultant wants 
to see us next week to 
see what we should do if I 
haven't bled.  I guess I'll 
have to have an ERPC 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\6
7 
Emotional 
distress 
19 21 0 I used to think during 4 
years of ttc that if I ever 
got pregnant that "at least 
I'd know I could conceive" 
What a daft thing to 
think.  Once we got our 
long awaited BFP all I 
wanted was to hold onto 
it.  I did everything to 
keep it but it wasn't to be. 
My Dh feels that he's 
happy we got pregnant & 
it gives us hope.  I just 
feel I'd rather have had a 
BFN than this loss of our 
darling baby.  
Heartbroken we are - 
never knew we could feel 
pain like this.  The bottom 
has fallen out of our 
world.  Our parents & 
family are in pieces 
too.  WHY WHY WHY? 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\6
6 
Emotional 
distress 
1 1 0  After my first 
unsucessesful month I 
started to get terrible 
pains, which gradually 
became unbearable over 
the next month.  I 
contacted the doctor in 
Thailand and he advised 
me to continue as 
planned and if we still had 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
APPENDICES 
Appendix	  	  11	  	  Qualitative	  Data	  from	  Strand	  4	   868	  
no luck with Clomide in 3 
months fly back to 
Thailand to see him.After 
3 very painful months we 
headed back to Thailand 
to be told that I had very 
large cysts on both 
ovaries, which had been 
the reason for the pain 
and had to stop with all 
medication for at least 3 
months!So we traveled 
home in despair as in 
both countries we had 
received little advice and 
spent a fortune 
 my 
story 
group\6
5 
Emotional 
distress 
2 2 0 . But that never 
happened. I found out he 
was having an affair so 
ended the marriage, I 
could never forgive 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\6
5 
Emotional 
distress\being 
in control 
2 2 0 I was now faced with 
making a decision about 
our relationship and after 
a couple of years decided 
that having a family was 
more important to me 
than a flailing relationship 
so ended it. Unfortunately 
he is still living in my 
house and doesn't seem 
to get the hint about 
leaving!I was now 33 
years old and beginning 
to believe that things were 
never going to happen for 
me. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\6
5 
Emotional 
distress 
2 2 0 Only there is a very sad 
twist to this part of the 
story..............my 
gorgeous boyfriend can't 
have children despite 
wanting them so badly. 
He fought a very brave 11 
year battle against 
leukaemia which he 
managed to beat but it left 
him unable to have 
children of his own. Not 
only was he battling the 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
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illness but many other 
illnesses too at the same 
time which nearly killed 
him over and over again. 
 my 
story 
group\6
5 
Emotional 
distress 
2 2 0 It's so sad that finally I 
meet the man of my 
dreams and we can't just 
have a family together the 
way we wanted to. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\6
4 
Emotional 
distress 
3 3 0 I am a successful 
professional and I have 
always held the belief that 
if you want something 
badly enough you will get 
it with determination and 
grit. Whilst that may be 
true of career goals, it 
doesn't seem to be true of 
fertility. I am used to 
being in control and 
calling the shots. This 
infertility experience has 
left me feeling hopelessly 
lost and despondent. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\6
4 
Emotional 
distress\being 
worthy 
4 4 0 People tell me to be 
grateful for what I have 
got...I am! I know that I 
am lucky to have a loving 
relationship, a beautiful 
daughter, a lovely home 
and a great job. But does 
that mean I have no right 
to expect anything else 
from life? 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\6
4 
Emotional 
distress 
5 5 0 Every month I am filled 
with an optimism that 
turns to an overwhelming 
sense of grief and despair 
when I find out I am not 
pregnant AGAIN. I feel 
that I can't go on torturing 
myself and that I have to 
stop tryin, but then I can't 
let go of the dream. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\6
4 
Emotional 
distress 
5 5 0 .I seem to spend a lot of 
time sobbing - mainly in 
the shower so my 
daughter won't hear me -
 and the slightest little 
problem at work brings on 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
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the waterworks again. I 
feel like a failure as a 
woman, as a wife and as 
a mother. It has affected 
my confidence, my 
identity and my world 
belief. 
 my 
story 
group\6
4 
Emotional 
distress\being 
worthy 
6 6 0 orry, I will sto going on 
about it now. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\6
3 
Emotional 
distress 
1 2 0 I have been ttc for six 
months and had a 
miscarriage in Jan after 
taking Clomid. After 17 
years of going back and 
forth to gps/consultants I 
finally was diagnosed with 
pcos/endo and fibroids 
and adhesions and had 
major surgery. Sadly I 
have to abandon the 
Clomid as I have had 
major side-effects and 
have been in hospital. 
Tamoxifen has been 
mentioned and also 
ovarian drilling does 
anyone on the boards 
have any knowledge of 
these? 
I feel pretty crappy at the 
minute six people at work 
are pregnant and when I 
hear about others on 
other boards getting 
results I just burst into 
tears. I feel such a failur 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\6
2 
Emotional 
distress\being 
worthy 
1 2 0 Well it’s a long story so 
will try not to go into loads 
of 
detail and bore anyone 
who reads this! 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\6
2 
Emotional 
distress 
19 20 0 Number 2 was December 
2009. I really wouldn’t 
recommend going 
through ivf this time of 
year. This time I felt 
dreadful 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
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 my 
story 
group\6
2 
Emotional 
distress 
24 54 0 Started bleeding 
about 10 days into the 
2ww, so again no surprise 
bfn, 6 days before Xmas. 
Had a 
really rubbish Xmas. DH 
& I were told by my gay 
brother in law that his 
partner had just 
impregnated one of their 
lesbian friends with a 
turkey baster. 
They used to joke about 
this, and I really couldn’t 
cope with this news as it 
came so out of the blue. 
DH & I had tried so hard 
and spent so money, and 
it works for them with a 
turkey baster! Ahhhhhh! 
  
Number 3 was April 2010. 
Everyone kept telling me 
“3rd 
time lucky”, and because 
the weather was nice and 
everything was springing 
into 
life I felt much more 
positive this time. All 10 of 
my eggs fertilised, and 
this time I stared bleeding 
2 days before my test. 
Again no surprises, bfn 
again. I seemed to be 
getting nowhere, and 
getting really depressed. 
  
Number 4 was August 
2010. My consultant 
recommended I start 
asprin straight away and 
take heparin injections 
and steroids during the 
2ww. 
This is because he thinks 
my nk (natural killer) cells 
in my blood may be too 
high, so were stopping 
embryos from implanting. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
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He decided not to actually 
test 
me for this because the 
results can be 
inconclusive and very 
expensive. We were 
lucky enough to have 2 
goes on the nhs, but were 
rapidly running out of 
cash so 
didn’t want to spend even 
more money on 
something that my be 
inconclusive. During 
the 2nd week of the 2ww I 
turned into a mad anxious 
neurotic cow. I 
symptom spotted all the 
time and was convinced I 
was going to start 
bleeding every 
time I went to the loo. I 
felt horrendous and just 
couldn’t relax, sleep or 
eat! When DH & I did the 
pregnancy test at 5am 
and saw a very faint line 
for a bfp I couldn’t believe 
it. I couldn’t wait for 
Sainsbury’s to open so I 
could 
 buy a digital test 
just to make sure! We had 
less than one day of 
unbelieving elation when I 
started bleeding that 
night. Despite a weekend 
of bed rest, I was told by 
the 
hospital that my 
pregnancy was no more 
after a blood test, the day 
before my 
brother in laws, partner’s 
friends baby was born. 
We were devastated. 
 my 
story 
group\6
2 
Emotional 
distress 
58 63 0  Every 
month that passes I am 
dreading it more and 
more – I thought I would 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
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feel 
better about it by now but 
I don’t. I am absolutely 
dreading the 2ww (the 
injections and flying 
hormones don’t bother 
me at all, just bother DH!). 
If the 
hospital could inject me to 
induce me into a deep 
sleep for the 2nd week 
of the 2ww I’d jump at the 
chance 
 my 
story 
group\6
0 
Emotional 
distress\feeling 
isolated 
1 1 0   It’s nice to find 
somewhere when I can 
finally share how I am 
feeling with people who 
truly understand 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\6
0 
Emotional 
distress 
3 3 0 n the mean time my DH 
went off for his test and 
we were both a little 
shocked at how poor the 
results were – weren’t 
very many, abnormally 
formed, swim in circles, 
get lost and die!  
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\5
9 
Emotional 
distress 
2 2 0 This is my first go, doing 
ivf&icsi, halfway through 
2ww and feeling like a 
complete cliche: finding 
the waiting 
unbearable. How do 
people keep 
going through 
this? I'm panicking about 
every symptom, checking 
the internet too much, 
ringing clinic for 
reassurance, but finding it 
hard to be reassured. H 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\5
8 
Emotional 
distress 
3 3 0 obvious problems and SA 
for DH, which showed 
only 8% right shape.  Our 
GP just said "well I never 
seen anyone get pregnant 
with that count so I'll refer 
you".  DH was gutted to 
say the least. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
Emotional 
distress\feeling 
7 7 0 The feeling of isolation 
and that your whole lives 
Claire 
Haresna
2᠋ my 
story 
1 
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group\5
8 
isolated are on hold while you go 
through this is one that 
only those who have 
experienced it themselves 
will understand.  I am so 
grateful  
pe group 
 my 
story 
group\5
7 
Emotional 
distress\being 
worthy 
3 3 0 Went through IVF in 2007 
in Oxford and conceived 
by beautiful, amazing DD 
first go.  Feel very guilty 
writing that but hopefully it 
gives people 
hope.  Dreams can come 
true. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\5
7 
Emotional 
distress 
4 4 0 Anyway, things have 
been awful since 
then.  Made extra 3 
embryoes with first round 
of IVF.  Had frozen cycle 
a couple of months 
ago.  2 died and 1 was 
'barely there' on day of ET 
so no surprises we ended 
up with a BFN. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\5
7 
Emotional 
distress\financi
al loss 
4 4 0  Things really grim now 
because we are out of 
money and my hormones 
are utterly messed up and 
periods haven't 
returned.  Need to be 
scanned for cysts.  Feel in 
quite a low place now as 
time is ticking, my DD is 
getting older and money 
is very low 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\5
7 
Emotional 
distress 
4 4 0 What an awful business 
this all is!To top it all, my 
brother and sister have 
both announced that they 
are pregnant without even 
trying.  
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\5
6 
Emotional 
distress\feeling 
isolated 
1 1 0 Hi all - I am completely 
new to this and suppose I 
am on here looking for 
some friends who are 
going through the same 
thing.  
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\5
Emotional 
distress 
2 4 0 After 3 m/c's I caught with 
a 4th and after a small 
bleed was told that I was 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
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6 having an ectopic.  I 
questioned this as I didnt 
have any of the 
symptoms - never the 
less, I was rushed into 
surgery (and then waited 
7 hours in a side room 
before going in).  When I 
was taken back to the 
ward I was informed that 
they hadnt used any of 
the 'preventative' methods 
and had just taken out my 
left tube. 
After being discharged, 
and for the next week, I 
looked into this further 
and was so confused by 
every decision made by 
the hospital, I wrote to the 
CEO of the Hospital 
Trust. It was just a short 5 
days late when I received 
a phone call asking me to 
return to the ward asap as 
they thought I may still be 
pregnant.  Confused, we 
went back, to be told the 
worse news of my life - 
they had made a mistake, 
my baby wasnt ectopic - 
they had terminated it in 
error. 
The following month we 
were hit with the final 
blow - my left tube was 
my only 'working' tube 
and therefore - they left 
me infertile. 
 my 
story 
group\5
5 
Emotional 
distress 
3 3 0 his was last week, and I 
have spend most of the 
week crying and trying to 
except that this is it, I will 
never have my own baby. 
I have just joined this 
website to get more of an 
understanding of my 
problem and to talk to 
others that are going 
through this awlful 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
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situation and despair. To 
be updated when I know 
what the hell to do!!!  
 my 
story 
group\5
5 
Emotional 
distress\feeling 
isolated 
3 3 0 his was last week, and I 
have spend most of the 
week crying and trying to 
except that this is it, I will 
never have my own baby. 
I have just joined this 
website to get more of an 
understanding of my 
problem and to talk to 
others that are going 
through this awlful 
situation and despair. To 
be updated when I know 
what the hell to do!!!  
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\5
4 
Emotional 
distress 
1 1 0 I thought I would write 
about my journey as I 
have not posted on this 
section before. I talk 
about ‘my story’ not just 
‘my IVF story’. October 
1990 – DH and I first 
started going out with 
each other. July 1991 – 
DH got diabetes. August 
1998 – got married to DH. 
I got my first teaching job 
and DH got a job with Sky 
TV. August 2001 –DH 
started to get depression 
so was put on anti 
depressants, for the next 
couple of years he was 
on/off antidepressants but 
only took a bit of time off 
work. February 2003 – 
DH’s depression got 
worse; he was having 
longer periods of time 
signed off work. April 
2003 – DH’s last day at 
Sky TV. May 2003 – DH 
admitted to the Priory as 
he was very unwell, had 
had a complete 
breakdown.  Whilst he 
was there I found out a lot 
of things that I did not 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
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know about him and his 
family! August 2003 – DH 
moved out for 2 weeks 
(whilst his parents were 
away – he moved into 
their home) as we were 
under so much pressure, I 
was walking on egg shells 
around DH as I never 
knew how he would be 
and how he would react 
to what I said or did! 
November 2003 – Found 
out SSP was going to end 
this month so we were 
under yet more pressure, 
DH moved out again for a 
month as we were unable 
to cope with the situation. 
June 2004 – DH was 
assigned a ‘vocational 
rehabilitation co-ordinator’ 
to help us try to get him to 
be able to cope with 
life.  She visited every 
month and wrote an 
action plan for what DH 
had to try to achieve by 
the next visit.  Looking 
back at this time it was 
just so scary as DH was 
unable to do anything as 
he just couldn’t cope with 
anything. August 2004 – 
DH admitted as a day 
patient at the Priory for 
next couple of months. 
September 2004 – DH 
and I decided to separate 
as we felt we could not 
carry on emotionally 
hurting the other person 
due to the whole 
situation.  We seriously 
spoke about getting a 
divorce (I saw a solicitor) 
as neither of us could see 
how we could cope with 
our situation.  I still loved 
DH but he was hell to live 
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with! July 2005 – DH 
officially left Sky TV 
(although he had not 
actually been to work 
since April 2003) July 
2005 – DH went to ‘Way 
2Work’, it's run by 
MIND.  They support 
people with mental health 
or emotional problems to 
gain employment.  They 
recognised that taking the 
first steps back to work 
would be daunting.  They 
helped DH think about 
what he could do with his 
life and helped him 
organise a CV. August 
2005 – DH got a part time 
job as a gardener, money 
was cr*p but at least he 
was going out to work. 
March 2006 – Spoke to 
doctor with our concerns 
about not falling pregnant 
yet! As we had tried on 
and off since we got 
married (when things 
were tough for us of 
course we were not trying 
 my 
story 
group\5
4 
Emotional 
distress 
1 1 0 February 2007 – found 
out my Mum had breast 
cancer, it felt as though 
my world had fallen apart. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\5
4 
Emotional 
distress 
1 1 0 une 2007 – DH’s best 
friend died in a motorbike 
accident. O 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\5
4 
Emotional 
distress\counse
lling 
1 1 0 Started having 
counselling at my clinic as 
felt I was not coping at all 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\5
4 
Emotional 
distress 
1 1 0  DH is not coping with the 
result.  October 2008 – 
For the sake of my 
marriage I feel I need to 
take a break from IVF but 
it is just so hard as I just 
want to be a Mum!   26th 
October 2008 - I am 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
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telling everyone that I am 
coping with the last BFN 
but now I am not sure if I 
am; as I burst into tears 
whilst shoppping 
yesterday! This then 
made my DH feel more 
vulnerable and moody as 
I am usually the one who 
copes with everything and 
is the strong one, so 
when I don't cope he of 
course doesn't cope 
 my 
story 
group\5
3 
Emotional 
distress 
2 2 0 . I literally know nothing 
about it and i am very 
scared. I'm hoping to find 
some support and advice 
on this site as it's been a 
very emotional time. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\5
2 
Emotional 
distress 
21 21 0 Treatment showed me to 
be a ‘poor responder’ - we 
only got 3 eggs, 1 
fertilised and our grade 3 
embryo was transferred 
on day 2.  We got a 
devastating BFN and 
found the whole 
experience very 
traumatic. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\5
2 
Emotional 
distress 
35 37 0 January 2010 - our fifth 
(frozen) cycle.  Two of the 
5 survived the freeze and 
we got a BFP but 
miscarried at 6 
weeks.  Completely 
heartbreaking and still 
very difficult to cope with, 
baby would have been 
due within days of DH’s 
birthday. 
      
May 2010 - our sixth cycle 
and feeling pretty dreadful 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\5
2 
Emotional 
distress 
39 39 0 Feeling weary and tired of 
being positive and hopeful 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\5
Emotional 
distress 
4 4 0 The results from all of this 
basically mean i wont 
concieve without IVF and 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
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1 gov wont fund it, but if i 
wait another 2 yrs to 
when gov will fund it my 
FSH level will be too high 
and they wont fund it then 
either, so im now at the 
point where im trying to 
get my head round the 
fact that we wont have 
children and oh im likely 
to start menopause early. 
 my 
story 
group\5
1 
Emotional 
distress\feeling 
isolated 
5 5 0 I would love to hear from 
anyone who can relate, it 
seems like theres no one 
that understands. I am 
dealing with this and living 
my life but it would realy 
help to chat to someone, 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\5
0 
Emotional 
distress 
5 5 0  This was done a fortnight 
ago, and nothing could 
have prepared us for the 
awful shock that awaited 
us that day. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\5
0 
Emotional 
distress 
7 7 0 Two weeks on and I am 
still trying to come to 
terms with it.  I haven't 
even gone back to work 
yet, and I'm so afraid to 
phone them, as I won't 
know what to say to them, 
as I only started the job a 
couple of mths ago.  My 
friends and family don't 
seem to understand, as 
they have children of their 
own, and I come from a 
big family. 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\4
9 
Emotional 
distress 
3 4 0  We were then given 
the devastating news that 
my husband had low 
morphology and as I had 
already been diagnosed 
with PCOS our only hope 
was IVF. 
Just had our second IVF 
atttempt with ICSI, only to 
get the devastating 
news on Friday that our 
second IVF attempt 
failed. I feel so 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
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disappointed and upset 
and a bit of a failure 
really. 
 my 
story 
group\4
9 
Emotional 
distress 
6 8 0 After ET had to endure 
the painful 2ww. I began 
to examine every pain 
and twinge. I was so 
scared that I was getting 
period cramps. We were 
also scared, becuase I 
was told with BFP, I could 
get delayed OHSS, which 
meant I could be 
seriously ill for several 
weeks. 
On the day of the blood 
test, I felt so sick and 
nervous about the 
outcome, although we 
both wanted to feel 
optimisitic that it had 
worked. however, we 
received devastasting 
news of another BFN. 
Just felt so shocked and 
was crying all afternoon. 
Was dreading telling our 
family and friends that the 
IVF had failed again. 
However after the initial 
shock, and because of 
the lovely weather at the 
weekend we went to the 
park to get some fresh air 
and sunshine, although it 
was hard seeing mums 
with their babies, having 
picnics, wishing we were 
in their situation 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\4
7 
Emotional 
distress 
2 2 0 his is my first post, my 
storry well didnt realise 
that there was anyting on 
the web tohelp so I have 
been slient with my story, 
I found put around 2000 
that I couldnt have 
choldren excuess is 
"unexplained" which as 
you know reall doesnt 
help as you can't put 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
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clousure on it I went for 
IVF which was funded 
through the NS then me 
and my husband (ex now) 
went through a really bad 
time and I had to pull out 
since then I have been 
able to semi accepct I will 
never have children after 
findong a new partner in 
2007 we now want to try 
and I would love to try IVF 
but now my docs are not 
funding IVF and Im over 
the big 40 so I can see 
that ifwont happen, the 
only alternitive is to go to 
a d octors who does fund 
the IVF or addoption route 
but obivously I would love 
to have a go myself. Just 
wish I could get an 
answer for why I cant 
have children as I am 
sure we all would like 
that. 
 my 
story 
group\4
7 
Emotional 
distress\being 
worthy 
2 2 0 Thanks for listening hope 
I havent bored you all. 
just wanted to note where 
I am at....I have been 
reading some of the posts 
ans feels nice to know 
there are people worst of 
that me.  
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\4
8 
Emotional 
distress 
3 3 0 I think alot of this has 
been tipped from not 
really being a problem to 
being one due to an 
incredibly awful ex-boss 
for 4 and a half years 
leading to raised stress 
levels most of the time 
(alot of psychological 
bullying), drinking too 
much as a result etc etc 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\4
8 
Emotional 
distress 
6 6 0 We felt better and more 
positive coming out (am a 
bit low today but that's 
due to every flipping time 
I go for tea or lunch it 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
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seems to be at the same 
time as the enormously 
pregnant 3 women being 
there too massaging their 
bellies!!) 
 my 
story 
group\4
8 
Emotional 
distress\being 
in control 
12 12 0  think also would like to 
sort out my nutrition (any 
tips?) and so am going to 
see a nutritionist next 
week who specialises in 
fertility issues etc and 
may be get my weight 
going down a bit. I'd also 
like to ramp up a little my 
exercise - I used to go the 
gym/run 3 or 4 times a 
week and now do nothing 
so that isn't helping and it 
does make me feel better! 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\4
6 
Emotional 
distress 
4 4 0 On Christmas Day I felt 
terrible and just knew it 
wasn't right but couldn't 
get scan until Boxing 
Day.  Long story short I 
had had a missed 
miscarriage baby had 
stopped developing 
weeks ago.  This was my 
worst experience as I 
opted to wait for natural 
miscarriage which never 
happened and one 
evening in January I was 
rushed to hospital 
heamorraging and had to 
have emergency ERPC 
but I had lost so much 
blood, I was anaemic and 
on standby for blood 
transfusion.   
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\4
6 
Emotional 
distress 
6 6 0 Our relationship has 
suffered a lot in the past 
year but we are holding it 
together just about! 
Claire 
Haresna
pe 
2᠋ my 
story 
group 
1 
 my 
story 
group\4
4 
Emotional 
distress\counse
lling 
5 5 0 new and also I'm having a 
bad time with life in 
general  so taking the 
offer of free counselling 
up. 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my Emotional 6 6 0 I'm at the point now of Claire 24᠋ my 1 
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story 
group\4
4 
distress having to try and turn my 
mind to accepting that I 
will not be able to bear 
children, very hard to 
even write this sentance 
down let alone trying to 
start dealing it ! 
Haresna
pe 
 story 
group 
 my 
story 
group\4
3 
Emotional 
distress 
1 1 0 hi there my name is joy 
and i have been with my 
husband for 17years 
married for 15years,, we 
av been trying for a baby 
for 16years after many 
tests we was told that 
there is no way on this 
earth that we will be able 
to have a baby,,, my 
husband has a mental 
illness and is on alot of 
medication which has 
coursed him to have no 
good sperm we was both 
devestated as we both 
really want a baby for me 
as a woman it is really 
hard as i am reminded of 
it every day of my life i 
thought i had dealt with it 
but i recently found out 
that a couple of my mates 
are expecting a baby and 
it has brought back all 
that hurt i want to greive 
but how can you grieve 
for summit that is not 
there,,,, every time i see a 
baby or a young child i 
keep thinking wish it was 
me i am finding things 
really hard to deal with 
right now,,, husband and i 
have spoken bout ivf 
sperm donor but i cant do 
that as i would feel like 
that i have cheated on 
him we have also looked 
into adoption and 
fostering but they wont 
even give us a 2nd look 
cos of my husbands 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
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mental illness which i 
think is wrong cos he 
would make a wonderful 
dad i went to see our 
doctor bout havin a 
histerectamy but he said 
that no surgeon would 
consider me as it is not 
for health reasons i told 
him i need to grieve and 
that is the only way i can 
think of its just so hard we 
you see babies and 
children every day of your 
life and wishing that they 
was yours,,,, any way that 
is my story if any one can 
help me i would be most 
greatful 
 my 
story 
group\4
2 
Emotional 
distress 
5 5 0 We have been referred to 
an infertility clinic (NHS) 
in Chichester, West 
Sussex.  This week has 
seen me hit an all time 
low and I seem to have 
been really angry / 
frustrated.....most unlike 
m 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\4
1 
Emotional 
distress 
6 6 0 but I feel like christmas 
will be ruined, especailly if 
i find out that i am fully 
infertile, or even if they 
dont know what it is, all i 
really want is one, just 
one child, my partner has 
already got a son, 
he doesnt live with us but 
visits on the weekends, i 
know he really wants a 
family, so the pressure is 
so massive! 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\4
0 
Emotional 
distress 
73 74 0  The news that my tubes 
were blocked was a 
devastating blow. That 
was a 
very difficult week; I broke 
down at work, crying 
during a 1-2-1 with my 
boss, 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my Emotional 4 4 0 having SA re done and Claire 24᠋ my 1 
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story 
group\3
9 
distress they we are off to 
Cheltenham Hospital to 
see a fertility specialits, I 
am happy and I am so so 
grateful for this 
opportunity, but at the 
same time I am suffering 
with the fact that I can't 
conceive naturally. 
Haresna
pe 
 story 
group 
 my 
story 
group\3
8 
Emotional 
distress 
5 6 0 I've cried on and off since 
xmas day and am now 
feeling very bitter and 
frustrated. There are 
reminders everywhere!  I 
even had someone tell 
me I should hurry up and 
have children at my age! 
Picking up my partner's 
three children and seeing 
the mother of his children, 
only added insult to 
injury.  They do not know 
about what we are going 
through so there have 
been lots of excuses and 
brave faces, something I 
could have done 
without.  My partner has 
been brilliant and very 
supportive but dare I say, 
this is very different for 
him:  he has three 
children and he is a man 
so I believe his 
understanding is 
limited.  No one can 
understand this unless 
you have been through it 
yourself. 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\3
8 
Emotional 
distress\financi
al loss 
6 6 0 We are trying again at the 
end of this month but I 
worry as my biological 
clock is not getting any 
younger and we do not 
have an endless pot of 
money (nhs will not help) 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\3
6 
Emotional 
distress\financi
al loss 
1 1 0 Hi, My name is sam and 
I am 28. Me and my DH 
have been trying now for 
2yrs since our ectopic in 
Claire 
Haresna
pe 
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 
my 
story 
group 
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2009 which ended up me 
having my left tube 
removed. Since then we 
have been to the doctors 
and they have tested us 
and said we have 
unexplainable infertility 
and then referred us to 
private fertility clinic which 
we can no way afford 
 my 
story 
group\3
5 
Emotional 
distress 
1 1 0 Hi Im Karin (33), and 
together with my fiance 
(DF) (35),  we have been 
trying for what seems like 
forever. Im not sure if i am 
in the right place, as we 
have not embarked on 
IVF.ICSI, but they are the 
considerings we are 
having.  Im in a place 
right now i possibly may 
not come back from.  My 
emotions are all over the 
place and im tired, grump, 
snappy & depressed - 
and no one i know 
understands, they just say 
stop stressing, relax all 
will be fine - nearly 2 
years and im no further! 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\3
4 
Emotional 
distress 
5 5 0  i'm 
so angry,emotional,depre
ssed and the wonderful 
group of friends as i loved 
going out socialising .But i 
feel i can't do that now all 
my wonderful friends are 
still there but they have all 
moved on with there little 
families.I feel very lost 
and alone 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\3
4 
Emotional 
distress\feeling 
isolated 
5 5 0  i'm 
so angry,emotional,depre
ssed and the wonderful 
group of friends as i loved 
going out socialising .But i 
feel i can't do that now all 
my wonderful friends are 
still there but they have all 
moved on with there little 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
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families.I feel very lost 
and alone 
 my 
story 
group\3
2 
Emotional 
distress 
3 3 0 I had 2 separate counts of 
less than 1 million. Other 
tests didn’t reveal any 
identifiable causes. My 
partner and I were 
devastated as it seemed 
that conceiving naturally 
would be almost 
impossible! 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\3
1 
Emotional 
distress 
3 3 0 I got pregnant in October 
2010 - we had been trying 
for a couple of months 
and my family had 
experienced a rather 
traumatic time earlier in 
the year so this was 
perfect. During early days 
I started to experience 
some spotting - I went to 
do hospital and they said 
it was normal for some 
women. I was totally 
distracted by this, and in 
the end of the day on my 
10 week scan I was told I 
had experienced a 
missed miscarriage. We 
were devastated 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\3
1 
Emotional 
distress 
4 5 0 tests, we have had basic 
tests - all came back ok. 
On Thursday of next 
week we are going for 
further tests to make sure 
I don't have any 
blockages. But I still hate 
hearing about people 
being pregnant and taking 
it for granted. I hate 
feeling like this, and I live 
in fear of close friends 
telling me they are 
pregnant because I'll have 
to put on a happy face, 
and I won't be able to 
keep it up.  
Ugh.  
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
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 my 
story 
Emotional 
distress\being 
6 6 0 I don't even know what I 
want to hear! And then I 
Claire 
Haresna
24᠋
 
my 
story 
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group\3
1 
worthy feel guilty about feeling 
like this because it has 
just been over a year 
since my miscarriage, and 
so many women have 
been dealing with this for 
years - but I just don't 
know where to turn. 
pe group 
 my 
story 
group\3
1 
Emotional 
distress 
7 7 0 My husband is amazing, 
and so supportive - he 
would go to the end of the 
earth for me to be happy. 
But over the past year it's 
been more difficult to find 
happiness 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
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 my 
story 
group\2
9 
Emotional 
distress 
1 1 0 I have recently turned 35 
and my DH is 39.  We 
started TTC when we 
were first married in Oct 
2008 (age 31 and 36). 
This I feel was one of the 
most stressful and 
emotional times for both 
of us. Each month was 
passing and I was buying 
PG tests each month and 
OPK's to try and time 
intercourse around 
ovulation. I was getting 
smiley faces on the OPK's 
but no smile on my 
face....just tears. I started 
temping every morning 
and checking cm and 
position of my cervix. 
Spent lots of money on 
registering with 
FertilityFriend and time 
updating all of my details. 
My emotions were all over 
the place and I spent a lot 
of time in tears or on the 
Internet searching for 
information on all sorts of 
fertility/baby sites. 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\2
9 
Emotional 
distress 
2 2 0  We were devastated...my 
poor DH. I decided to 
change GP surgery to 
same as my DH's to make 
things easier. 
Claire 
Haresna
pe 
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my 
story 
group 
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 my 
story 
group\2
9 
Emotional 
distress\being 
in control 
5 5 0  I decided that I would be 
too stressed just before 
Christmas and had 
already arranged to travel 
to see family and that it 
would be too stressful to 
rearrange....so here we 
are now. 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\2
8 2 
Emotional 
distress\putting 
you first 
6 6 0  feel very conflicted a lot 
of the time as in June last 
year I started a new job 
which is basically my 
dream job working for a 
great charity, and don't 
want to be messing them 
around - or to give it up - 
but at the same time I 
know that having a child 
would be the most 
important thing in my life, 
much more important 
than any job 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\2
6 2 
Emotional 
distress 
2 2 0 That was around the time 
DH brother and girlfriend 
announced their 1st 
pregnancy after only 
being together a short 
while straight away i felt a 
pang of jelousy 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\2
6 2 
Emotional 
distress 
4 4 0 I rang my doctors and 
they said we had to be ttc 
for a year before they 
would take us seriously it 
seemed every day more 
and more of our friends 
had happy news i wanted 
to be happy for them but i 
felt like my world was 
falling apar 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\2
6 2 
Emotional 
distress 
5 5 0 DH had perfect fertility 
where as mine was non 
existant i took such a 
confidence knock i felt 
useless but was 
determined i was gonna 
be brave enough to do 
what ever it took to make 
this happen for us 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
Emotional 
distress\financi
7 7 0 I turned 30 and excitedly 
rang the hospital to be 
Claire 
Haresna
24᠋ my 
story 
1 
APPENDICES 
Appendix	  	  11	  	  Qualitative	  Data	  from	  Strand	  4	   891	  
group\2
6 2 
al loss told  i could be put on the 
waiting list now!!!!! i 
couldnt believe it but what 
could i do we couldnt 
afford to go private 
pe  group 
 my 
story 
group\2
6 2 
Emotional 
distress\Not 
feeling in 
control 
7 7 0 at all i struggled with my 
emotions so bad i didnt 
know what was 
happening or what would 
happen nex 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\2
6 2 
Emotional 
distress 
7 7 0 but on the day before test 
i started to bleed at work i 
paniced and left without 
saying a word got home 
and couldnt find the 
words to tell DH it was as 
if if i said it out loud it was 
really happening 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\2
6 2 
Emotional 
distress 
7 7 0 i love my DH my dog and 
my horses but i didnt want 
any of them near me my 
doctor said i had event 
triggured depression i 
think i was in shock i felt 
like my life had ended i 
had panic attacks when 
people came round to see 
me i wouldnt go out i gave 
everyone quite a scare 
things got worse when my 
best friends 2nd child was 
due on my test date made 
things really hard 
between us 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\2
5 
Emotional 
distress 
5 5 0 At the time, DH and me 
were just focussing on my 
recovery which took 
months, but as the weeks 
went on&I began to get 
better it it me that we may 
never have the chance of 
having our own baby, 
something we have 
both desperately wanted 
for so long 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\2
5 
Emotional 
distress 
5 5 0  Now I am really scared 
as I had never worried 
about me producing the 
follicles before as my 
hormone levels have 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
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always been fine, what if 
we fall at the first hurdle? 
I am not sure how we will 
cope. 
 my 
story 
group\2
4 
Emotional 
distress 
3 3 0  I had a 2 day 
transfer.  My period came 
before the pregnancy test, 
which was a BFN.  I was 
utterly 
devastated.  However, the 
recipient had a BFP, 
which gave me loads of 
hope for future cycles 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\2
4 
Emotional 
distress 
5 5 0 I had a 3 day transfer.  I 
was very positive about 
this cycle, but again my 
period came before the 
pregnancy test, which 
was a BFN.  I was really 
upset again, but knew 
that the sooner we tried 
again, the sooner I could 
get over it. 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\2
4 
Emotional 
distress\being 
in control 
8 8 0 I've got lots of questions 
to ask at the review 
meeting, and will also ask 
for a review of my medical 
notes by another clinic, to 
see if there is anything 
that we can change for 
the next time. 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\2
4 
Emotional 
distress 
9 9 0 My husband has been a 
brilliant support 
throughout the process, 
but it is really hard to stay 
positive for the next cycle 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\2
3 
Emotional 
distress 
1 1 0 For the first time in my life 
I want to be pregnant and 
can't get pregnant. Feels 
like I'm being punished. 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\2
3 
Emotional 
distress 
1 1 0 I thought I was going to 
lose my mind. I can't wait 
to find out, I know it's my 
tubes, I'm hoping they can 
be unblocked. I 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\2
3 
Emotional 
distress 
1 1 0 If its not my tubes that are 
the problem I would be 
very surprised. I can feel 
them hurting me some 
times. Since being 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
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infertile my sex drive is 
not the same, I feel to 
broken and sex feels 
pointless. 
 my 
story 
group\2
1 
Emotional 
distress 
2 2 0 Been married since 
2000.  Decided in 2002 
that we were ready to 
have a family (how naive I 
was back 
then).  Conceived 1st 
month of trying, very 
surprised but 
happy.  Went along to 
scan at 9.5 weeks to have 
the devastating news 
that it had not progressed 
beyond the 5 week 
mark.  Hospital gave me 
the choice to stay in or go 
home, opted to go home 
as didn't see the point in 
staying in and having the 
whole world and his wife 
watching my 
miscarriage.  Miscarried 
two days later : ( Then 
had two months of 
bleeding / pain / hospital 
visits and loads of strong 
antibiotics and an awful 
lot of upset and distress 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\2
1 
Emotional 
distress 
3 3 0  It had been a horrible 
year full of pregnancy 
anouncements and 
disappointment each 
month and frustration 
(what had changed from 
1st time?).  All tests said 
we were fine so we 
were another unexplained 
case.  
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\2
0 
Emotional 
distress\being 
worthy 
2 2 0 I am very very lucky to 
have an amazing 
daughter from ivf, she is 
five know and time has 
flown by, sadly her dad 
and I got divorsed a year 
after her birth. 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
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 my 
story 
Emotional 
distress\feeling 
7 8 0 Im sick of the pregnant 
people, sick of new mums 
Claire 
Haresna
24᠋
 
my 
story 
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group\1
9 
isolated with babys forcing theirs 
on me and the pitying 
smile of "it will be you 
soon dont stress it will 
happen!" Im sick of the 
announcements and the " 
i wanted to let you know 
im pregnant and i dont 
want to upset you 
because you cant have 
one!" Ive had enough of it 
all, i hate being the only 
wife alone. They all group 
together for mum and 
baby stuff and im left out 
on the side lines forgotten 
about because i dont fit 
into their group!  
  
pe group 
 my 
story 
group\1
9 
Emotional 
distress\being 
worthy 
9 9 0 It may not be as traumatic 
as some experiences i 
have read but its 
heartbreaking and im on 
the brink of giving up on 
the idea of ever becoming 
a mum and carrying our 
child!!!  
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\1
9 
Emotional 
distress 
9 9 0 Adoption is an idea but so 
difficult for this to be 
agreed with army families 
due to the life style we 
lead! However i cannot be 
apart from my husband 5 
days a week,these last 7 
months have killed us. 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\1
8 
Emotional 
distress 
4 4 0 So back home again, 
tears, ice to numb 
leg/bum, tears, ear 
phones and TV for 
distraction, more tears, 
plasters so i can't see 
needle mark, ...I felt so 
sorry for hubby as he had 
to inject me while I was 
close to hysterical. 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\1
8 
Emotional 
distress 
5 5 0 Egg collection was 
booked for early as 
possible on 11th August, I 
had Emla cream on my 
hand to numb it (usually 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
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used on kids), and i was 
absolutely petrified 
 my 
story 
group\1
8 
Emotional 
distress 
6 6 0 end of 2 weeks 27th 
August 2010... 
NEGATIVE.. 
deverstated...unsure 
whether to get up and get 
on with it or wither and cry 
forever. Having to tell the 
people that knew we were 
having treatment was 
horrendous. 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\1
7 
Emotional 
distress 
3 3 0 Was then advised to try 
short protocol, which I 
preferred, and had 4 
eggs, 2 didn't mature but 
had the other 2 
transferred back. After 
2ww another BFN and 
was/still am gutted. This 
was last week. 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\1
6 
Emotional 
distress\feeling 
isolated 
1 1 0 It has taken me some 
time to join as I thought 'I 
would be ok'!! But there 
comes a point when you 
realise that your friends 
don't understand and you 
cannot keep shouting at 
your husband!!! 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\1
6 
Emotional 
distress 
4 6 0 Things had changed 
dramatically and there 
was no other option other 
then IVF. 
I was deverstated, my 
world fell apart, this is not 
how things are supposed 
to be. 
I feel like something died 
that day and I am trying to 
come to terms with it but I 
am so scared for the 
future and what it will 
bring for us. 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
1 
 my 
story 
group\1
6 
Emotional 
distress 
8 8 0 My DH and I have been 
through some awful times 
and it saddens me to 
think there are more to 
come. 
Claire 
Haresna
pe 
24᠋
 
my 
story 
group 
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 my 
story 
Emotional 
distress\financi
4 4 0 Today 04/09/12 was our 
first appointment at 
Claire 
Haresna
21᠋ my 
story 
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group\1
5 
al loss Ninewells, the doctor 
explained the whole 
procedure and finished off 
with telling us if we 
decided to go with nhs 
funded treatment it would 
be a 3 year waiting list, if 
we pay it will be 8 weeks.. 
gutted was not the word, 
yes I knew there was a 
waiting list but never 
knew this long. 
Unfortunately we don't 
have the money to bring it 
forward. 
pe  group 
 my 
story 
group\1
4 
Emotional 
distress 
1 1 0 Here is the story of the 
worst time of my life, and 
the loss of my son Aidan 
first....Aidan Irving Craig, 
my son, was an 
unexplained stillbirth at 34 
weeks in Aug 23 1996. 
He would be turning a 
teen this year, and it 
hasnt got any easier, I 
was on my own then, and 
now after all these years, 
im now going thru more 
uncertainty and isolation 
with unexplained infertility 
I have no other family to 
remember my child with 
me, as my elderly 
widowed mother has 
suffered from vascular 
dementia the last 9 years, 
(she is now 81, been in a 
care home for 7  years, 
and nearly died this year 
with a severe chest 
infection, I was distraught 
with fear and worry). 
Aidans useless father lost 
touch during my 
pregnancy. I met him in 
Berlin when I played in a 
band I was touring with 
whom I played bass with) 
- he played guitar in 
another band and was 
Claire 
Haresna
pe 
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 
my 
story 
group 
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from Birmingham, so it 
was difficult to begin 
with(as Im in Glasgow), 
but he couldn't even be 
bothered to keep in touch 
even after what 
happened.  I had already 
given up the band after 
this tour to look after 
myself so that was a loss 
in itself, but I was still 
looking forward to being a 
first time Mum at 28.I will 
never know the real 
reason why I lost Aidan, (I 
agreed to a post mortem, 
but they couldnt find 
anything wrong...so 
unexplained),  but I had to 
move because my 
landlord wanted to 
refurbish my top floor flat 
so he could claim more 
rent money and I was up 
and down stairs at 7 and 
half months pregnant, - it 
so happened it was the 
same stressful week I got 
told there was no 
heartbeat during my usual 
routine scan.  I had to be 
taken into the hospital 
that night knowing my 
baby was dead (they 
allowed my mother who 
was still well at the time 
thank God, to stay in the 
ward over night with me). 
The next morning they 
induced me, and I gave 
birth later that night at 
10.31pm. This was when I 
also got told the umbilical 
cord was twisted round 
the neck and 
shoulder(which could 
have been another 
cause). But he weighed 
only 1. 32 kg (34 and half 
weeks).Aidans funeral 
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was a week later on 
Friday 30th August 
1996.  This was painful 
enough, but little did I 
know it was the last time I 
would see one of my new 
found friends Val, who 
commited suicide about 3 
weeks later.The last time I 
saw her alive was Aidan's 
funeral.Then I found out 
another old  friend Jamie 
died about a month after 
that.  Needless to say this 
was the worst year of my 
life.  I thought the year my 
Dad died was in Oct 92, 
but  that comes a close 
second. As at that time, 
my bf then, had dumped 
me, I got chucked out my 
bedsit and had to 
braveface my pals 
wedding all in the same 
month! After losing Aidan, 
I went through several 
years of severe 
depression and chronic 
anxiety (which I was 
already prone to but 
never quite as bad).  I 
also took to drink like 
there was no tommorrow - 
well I used to hope there 
wasn't! Plus I was on anti-
depressants for over 9 
years.  I was just 
beginning to feel a bit 
brighter in 2000 (4 years 
later) but then my mum 
took ill with dementia and 
I became a carer, and this 
made my depression 
worse again. I started 
seeing someone who 
turned out to be a con 
man who took advantage 
and ripped me and my 
mum off - money, her 
engagement/wedding 
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rings, fraud, and my pets 
all mysteriously died and 
other unmentionables- 
another long story - he 
got away with it even 
though police knew! 
 my 
story 
group\1
4 
Emotional 
distress\feeling 
isolated 
1 1 0 im now going thru more 
uncertainty and isolation 
with unexplained infertility 
I have no other family to 
remember my child with 
me, as my elderly 
widowed mother has 
suffered from vascular 
dementia the last 9 years, 
(she is now 81, been in a 
care home for 7  years, 
and nearly died this year 
with a severe chest 
infection 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
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 my 
story 
group\1
4 
Emotional 
distress\putting 
you first 
1 1 0 since I met Graeme, that 
things started to get a bit 
better.  I stopped drinking 
so much and stopped the 
long term anti-deps 
without the doctors help! 
Then started doing short 
courses and eventually 
ended up back at college, 
and now im qualified to do 
swedish massage and 
aromatherapy and 
continuing to learn other 
holistic therapies. 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\1
4 
Emotional 
distress\being 
in control 
1 1 0 since I met Graeme, that 
things started to get a bit 
better.  I stopped drinking 
so much and stopped the 
long term anti-deps 
without the doctors help! 
Then started doing short 
courses and eventually 
ended up back at college, 
and now im qualified to do 
swedish massage and 
aromatherapy and 
continuing to learn other 
holistic therapies. 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
Emotional 
distress 
1 1 0 . I feel that life is passing 
me by and that I am just 
Claire 
Haresna
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group\1
4 
not good enough, its very 
hard to explain. I also feel 
that I may be kidding 
myself on and perhaps 
just wanting to fill the 
terrible gap that not 
having Aidan around left 
behind. And perhaps I am 
being selfish at my age to 
keep trying...(As I know 
only too well what its like 
to be left without a family 
on my own, as I had older 
parents). It is also very 
hard keeping up the 
courage to keep trying 
after the first time that's 
well over 3 years now and 
Ill be 40 next birthday. I 
have to wait months 
inbetween tests and my 
next one is on Jan 21, 
and I think this time its 
about my fallopian tubes 
pe group 
 my 
story 
group\1
4 
Emotional 
distress\financi
al loss 
1 1 0   I am now too old for 
IVFin my area on the 
NHS, unless I go private 
and pay loads of money I 
don't have!  
Claire 
Haresna
pe 
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 my 
story 
group\1
4 
Emotional 
distress 
1 1 0 Im now 40 and its 2009, 
my depression has came 
back with a vengeance 
and after all the years off 
them, im back on these 
damn anti-depressants 
even tho I feel they dont 
work. The last year and 
this xmas and new year 
have been the worst for 
many years since before 
meeting Graeme, as 
nothing has went right 
with a run of major bad 
luck, just feel im cursed in 
this life and in all honesty 
with no future to look 
forward to...still jobless, 
still childless and all my 
savings taken away and 
in massive debt, I cannot 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
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wait to pass on to the next 
life. I even seriously 
thought of 
sectioning  myself cos im 
sick of the suicidal 
thoughts plagueing me. 
 my 
story 
group\1
3 
Emotional 
distress\feeling 
isolated 
1 1 0 I am new to this forum, 
but I have decided to 
reach out as this process 
is so bloomin' isolating 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\1
3 
Emotional 
distress 
6 6 0 I have found this last year 
awfully hard. Two of my 
sisters got pregnant (both 
younger than me), and we 
joked about all three of us 
potentially being pregnant 
at the same time. Well, 
they got on that train and I 
was left in the waiting 
room. My best friend got 
pregnant last summer on 
her very first attempt, 
which was absolutely 
horrible 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\1
3 
Emotional 
distress\feeling 
isolated 
6 6 0 generally happy for her, 
but also very upset for 
several reasons - 
jealousy, but also I felt so 
lonely as her life 
(naturally) completely 
changed whereas mine 
stayed the same. No 
more sharing a bottle of 
wine at the pub over a 
girly chat, etc. I am now 
the Godmother of that 
child, which is lovely but 
at the same time difficult, 
for obvious reasons. 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\1
3 
Emotional 
distress\feeling 
isolated 
7 7 0 Where we live, most of 
our friends now have 
children or are expecting, 
which has left us feeling 
quite isolated - we 
sometimes joke about the 
fact that we need to find 
new friends. Of course we 
still spend time with our 
friends, but their life styles 
have changed and they 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
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cannot do the same 
things as they used to. 
When I feel particularly 
lonely, I even contemplate 
moving, as I can't see a 
reason for us living here. I 
work from home and my 
husband works away 3 
days a week. 
 my 
story 
group\1
3 
Emotional 
distress\feeling 
isolated 
8 8 0  I can't stand the 
loneliness anymore. I was 
initially reluctant to tell 
anyone because I had 
this idea in my head that I 
would get pregnant and it 
would be this amazing 
surprise to everyone 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\1
3 
Emotional 
distress\feeling 
isolated 
8 8 0  but the loneliness was 
just too much to bear. So 
we have gradually starting 
telling people. And this is 
my next step in reaching 
out, writing this 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\1
2 
Emotional 
distress\being 
worthy 
3 3 0 I actually do have one 
child already, a boy who 
is 9 years old.  The first 
time round I was 27 years 
old and got pregnant very 
very easily.  I took it all for 
granted and now realise 
quite what a miracle that 
was 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\1
2 
Emotional 
distress 
4 4 0 .  After 2 solid years of 
trying every cycle we 
went to our GP who 
referred us on to a fertility 
clinic.  It was not a very 
pleasant experience, the 
first time i turned up to the 
clinic the consultant came 
out into the waiting room 
and shouted loudly at me 
that i could not be seen at 
this clinic as 'I already had 
one kid, what more did i 
want?'  It was awful, left 
totally humiliated 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\1
Emotional 
distress 
5 5 0 I'm a pretty healthy 
person, I've never had 
anything seriously wrong 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
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2 with me and i find all this 
a bit shocking. 
 my 
story 
group\1
2 
Emotional 
distress 
6 6 0 I am also struggling to 
cope with the idea that I 
may never have a 
'normal' baby, one that I 
can take home and one 
that has a life expectancy 
beyond his teens. 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\1
2 
Emotional 
distress\being 
worthy 
6 6 0 Some people may think 
that i am being selfish 
wanting another kid but 
my experience with my 
first child has left me 
feeling more like a nurse 
than a mother and i yearn 
to hold a baby, feed a 
baby naturally not through 
a tube, take them home 
without machines etc.  I 
have a feeling it would be 
very healing for us as a 
family to have a 'normal' 
healthy child, and now 
that this seems to be 
difficult its hard to 
consider that my only 
experience of motherhood 
is going to be one of such 
trial and tribulation.  I 
know that many of you 
may not have children 
and I feel awfully guilty 
moaning about the 
experiences I have had, 
but let me tell you its been 
a tough time for my first 
child, and there are no 
guarantees that he will be 
with us for a long time.  
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\1
1 
Emotional 
distress 
4 4 0 t is so frustrating not 
knowing what is wrong, 
it's been 5 yrs since we 
started trying again, my 
son is growing up and I 
really want him to have a 
sibling; 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\1
Emotional 
distress\being 
worthy 
4 4 0  I know we are so lucky 
having him and our family 
of 3 is happy but I feel like 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
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1 I've let him down 
 my 
story 
group\1
0 
Emotional 
distress 
3 3 0  In the next 7 months we 
had various tests done, 
saw an awful consultant 
and at the last 
appointment we saw a 
doctor who was a 
nightmare. We went in 
hoping to get my 
husbands second sperm 
analysis results (the first 
showed a low count & low 
motility)  but the doctor 
said she hadn't got the 
results, when I asked 
when we could get them 
she was really rude, I 
burst into tears and luckily 
at the last minute another 
nurse came in with the 
results. They showed 
slight improvement, but 
when I asked the doctor 
what our chances were 
she just shrugged her 
shoulders. 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\1
0 
Emotional 
distress 
3 3 0 We were both shocked 
and felt really confused. 
We'd had a stressful year 
before for various reasons 
and it continued. We 
everything really hard to 
cope with 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\1
0 
Emotional 
distress\being 
in control 
3 3 0 Since then I've read up on 
what we can do through 
diet and lifestyle to 
improve our chances of 
concieving naturally. I've 
done daily temps etc, we 
had individual lifestyle 
plans,  
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\1
0 
Emotional 
distress 
3 3 0 a house move & lots of 
close friends and family 
falling pregnant, being 
pregnant and having their 
babies and we're still no 
further, we've hit a point 
where we've reached our 
limits 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my Emotional 3 3 0  We're needing to protect Claire 21᠋ my 1 
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story 
group\1
0 
distress ourselves from anymore 
hurt at the moment so its 
hard to see them. My 
husband has been 
depressed, I'm an 
emotional wreck  its come 
to a point where we don't 
know where to tur 
Haresna
pe 
 story 
group 
 my 
story 
group\1
0 
Emotional 
distress\feeling 
isolated 
3 3 0  feel so lonely. So after 
reading about I N UK and 
the support you all give 
eachother I thought  we 
need to join. We've 
booked an appointment at 
the local private hospital 
to have a chat about our 
option 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\1
0 
Emotional 
distress\financi
al loss 
3 3 0  We can't afford private 
treatment  
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\1
0 
Emotional 
distress\being 
worthy 
3 3 0 I feel guilty going on 
about how hard we're 
finding this when I read 
about some of you who 
have tried for much longer 
and have had lots of 
treatment. I admire your 
strength, I don't know if 
I/we can do it.  
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\9 
Emotional 
distress 
5 5 0  I was told to get in touch 
if nothing was happening 
in 6 months time.  I was 
discharged from hospital 
a week later with no 
follow up appointment 
scheduled and no 
acknowledgement of my 
lost baby.  When my 
period returned 7 weeks 
later, after initially being 
unsure if we could go 
through that anguish 
again 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\9 
Emotional 
distress\being 
in control 
6 6 0 Meanwhile, I decided not 
to wait 6 months to speak 
to a doctor and pushed 
for an appointment with 
my gynaecologist.  I had 
that initial appointment in 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
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June 2011 and persuaded 
him to refer me to the 
local fertility clinic.  
 my 
story 
group\9 
Emotional 
distress 
6 6 0 In that time I had had 7 
periods, knew when I was 
ovulating and every 
month have been left with 
the pain of nothing 
happening. 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\9 
Emotional 
distress 
6 6 0  The appointmet in 
Ocotber was both 
encouraging and 
devastating - they agreed 
not to do more surgery 
(no point - natural 
pregnancy is now highly 
unlikely) and have put us 
straight on the list for IVF 
(I have good ovulation 
levels but a low AMH and 
DH has borderline sperm 
results on top of my 
horribly disfigured left 
tube and missing 
right!)  Unfortunately, the 
waiting list in my area is in 
excess of 2.5 years and 
we have been warned 
that in that time, the 
funding is likely to be - at 
best - severely cut, thus 
increasing the waiting 
time further, and at worst 
- withdrawn 
altogether.  That same 
week DH was also made 
redundnat which heaped 
more stress onto the 
situation.  DH found 
another job within a week 
(phew) and as a result, 
we are fortunate that, at 
this poitn in time, we are 
in a position to be able to 
look into private treatment 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\9 
Emotional 
distress\financi
al loss 
6 6 0 That same week DH was 
also made redundnat 
which heaped more 
stress onto the situation.  
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my Emotional 6 6 0   It particularly feels so far Claire 21᠋ my 1 
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story 
group\9 
distress away because this month 
is possibly the worst 
month of my entire 
life.  We would have been 
due to meet our little son 
or daughter around the 
29th of this month and I 
learned on Friday that the 
last of the people who 
were having 
difficulties/suffered a 
miscarriage at the same 
time as us is now nearly 5 
months pregnant again 
and all is well. 
Haresna
pe 
 story 
group 
 my 
story 
group\9 
Emotional 
distress\feeling 
isolated 
6 6 0   I am so pleased for her, 
and my best friend at 
work who is 5 1/2 months 
pregnant with twins but I 
feel so lonely.  Nobody 
else I know is in the same 
position as DH and I.  All 
of our friends are all either 
falling pregnant incredibly 
quickly or are not at the 
stage of starting a 
family.  I guess in 10 
years time we will be 
old hands dishing out the 
advice either way, but 
now it just feels like such 
a lonely world and quite 
frankly I feel like a failure 
as a wife! 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\8 
Emotional 
distress 
2 2 0 We went through our first 
IVF cycle last year and 
unfortunately it didnt work 
and thought at the time 
that I couldnt put myself 
or my husband through 
that again but needless to 
say were are starting 
another cycle and just 
started taking my nasal 
spray this morning. I am 
trying to stay positive but 
its so hard and if it doesnt 
work this time im not sure 
I can go through it again 
and to make things even 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
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worse cause of all the 
operations and endo my 
cervix is in a tilted position 
whichmakes egg 
collection and embryo 
transfer very very painful.  
 my 
story 
group\7 
Emotional 
distress 
3 3 0 Me and my partner had a 
bombshell dropped on us 
only yesterday.  It was our 
second appointment at 
the fertility clinic where 
the results of my day 1-4 
and day 21 bloods and 
his sperm analysis were 
to be reviewed and the 
next steps to be 
discussed. 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\7 
Emotional 
distress 
5 5 0 My partner blames 
himself and is scared I'm 
going to leave him.  I feel 
sad for my body because 
despite my 39 years  my 
body released two eggs 
last cycle, my day 21 
result was in the 80's, 
were we able to conceive 
naturally it would have 
been a multiple 
pregnancy.  I feel like I'm 
grieving for the fact that 
we can't try all those other 
steps and have to go 
straight for the one-shot-
40% chance IXI.  I feel 
robbed, lost and empty.  I 
don't feel positive and I 
am soooooo scared at 
having the face the 
prospect of never having 
a baby.  I have butterflies 
in my stomach that are 
making me feel sick with 
anxiety.  I'm scared at the 
prospects of the drugs, 
egg harvesting, and it just 
not working.  
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\7 
Emotional 
distress\financi
al loss 
5 5 0  We can't afford the 
£5000 that has been 
quoted to us for further 
cycles  
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
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 my 
story 
group\7 
Emotional 
distress 
5 5 0 I still find myself feeling 
sad and depressed. I'm 
grateful that we will get 
that 1 chance but there is 
soooooooooooooooooooo
ooooo much hanging on 
that.   
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\6 
Emotional 
distress\being 
in control 
8 8 0 After 2 1/4 yrs of trying, 
and a nice holiday to the 
Caribbean with no 
success, started looking 
at getting myself some 
further treatment - needed 
to do something. 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\6 
Emotional 
distress 
13 13 0  Due to test on a 
Saturday, on the 
Wednesday before this, I 
noticed a light spotting 
(which is normal before 
AF for me), this was 
worse on  Thursday, 
started biking to work, but 
couldn't see the road for 
my tears, decided in no fit 
state to go to work, 
headed home.  Spoke 
with my clinic, a nurse 
called me back, who said 
I could do the test a day 
early on the Friday, that it 
might not mean the end, 
but it could be.  Terrible 
day, cried all day long.  
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\6 
Emotional 
distress\being 
in control 
14 14 0 So instead, my DH and I 
went for a fab day out at 
Longleat Safari Park, and 
dinner in a really nice 
local pub, which was 
much better than sitting 
around being sad. 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\6 
Emotional 
distress\counse
lling 
15 15 0 so headed back to see 
my counsellor who helped 
me through it.  Feeling a 
lot better at the moment. 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\5 
Emotional 
distress 
1 1 0 . Panic moment, so I got 
the GP to fax the referral 
to them again. Today 
after waiting 2 months 
since the 2nd referral was 
sent, I rang the clinic 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
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again only to be told that 
they have never received 
a referral for me. I feel like 
I'm hitting a brick wall on 
what I know to be a long 
journey of possible brick 
walls. I don't know if my 
GP hasn't been sending 
them, but up to this 
moment they have been 
wonderful, even by 
contacting the community 
mental health team in 
regard to my clinical 
depression and the 
medication that I am on. 
I'm finding everything 
extremely overwhelming 
as I don't know family for 
support. I'm not sure what 
to think anymore, I feel 
like I'm being paranoid, 
but I've heard that the 
waiting times in regard to 
IVF Wales for extremely 
long. 
 my 
story 
group\4 
Emotional 
distress 
1 1 0 At 11weeks and 5 days I 
started having discharge 
and panicked though the 
GP and midwife were 
very matter of fact "it's an 
inevitable miscarriage" my 
world fell apart. 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\4 
Emotional 
distress 
1 1 0 . I went with my full 
bladder in hope, when 
they couldn't see anything 
on the ultra sound I was 
told "go and empty your 
bladder" I had to walk out 
in the waiting room in 
front of all the heavily 
pregnant mums with tears 
streaming down my face 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\4 
Emotional 
distress 
1 1 0  I cried from 7am when I 
went into surgery at 
12am! I was devastated. 
We were referred to the 
NHS IUI clinic, the nurses 
were (and still are 
amazing). As I had clomid 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
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left over we had our first 
couple of goes using that. 
The first attempt I was 
convinced I was going to 
be pregnant, but BFN 
again, we ended up 
having 7 IUI attempts 
some timed, some with 
the overtrile. I always had 
2 lovely follies and was 
hopeful each time but all 
BFN's. its an emotional 
roller coaster doesn't 
even come close !!!! I told 
my mum who is quite ill 
herself and she was 
naturally very upset but 
instead of the support I 
thought I'd get she said "if 
you're trying again please 
don't tell me until you've 
had the all clear ad it's too 
upsetting for me"!!! Ouch. 
Too upsetting for her what 
about me? So I closed up 
and to that day she has 
no idea what we are 
going 
 my 
story 
group\3 
Emotional 
distress\feeling 
isolated 
3 3 0 Feeling quite alone in this 
process  
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\2 
Emotional 
distress 
3 3 0 after several trips to the 
doctor to have various 
blood test which came 
back fine our gp sent my 
partner for a SA which to 
our surprise can back with 
dreaful 
results,  morophology of 
only 3%  we were both in 
total schock! 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
 my 
story 
group\1 
Emotional 
distress 
1 1 0 h and myself have been 
ttc for 5 years-married for 
nearly 7. We have no 
children and I am 38 now 
so running out of time. I 
finally got to ivf stage on 
nhs earlier this year with 5 
eggs at ec. Then the call 
to say I had zero eggs 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
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fertilised I was devasted  
 my 
story 
group\1 
Emotional 
distress 
1 1 0  Devasted as cramps to 
so day 11 which was tues 
this wk I decided to do 
pregnancy test. As 
expected it was negative 
and bleeding heavier. Still 
taking progestrone 
suppositories and will test 
on fri as meant 2. I known 
I am wasting my time but 
can't help hoping for a 
miracle. Just can't stop 
crying so desperate for 
me and dh to have a 
baby. Don't know where 
to go from here. We said 
we wouldn't keep 
throwing money at this 
but I just can't accept we 
won't have children. The 
support and stories on 
here give me hope that 
miracles can happen. Just 
so empty at min and 
finding it had to carry on 
Claire 
Haresna
pe 
21᠋
 
my 
story 
group 
1 
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Commen
t 
Documen
t 
Code Begi
n 
En
d 
Weigh
t 
score 
Segment Author Creatio
n date 
Documen
t group 
Pag
e 
 my story 
group\16
5 
Trust and 
Support from 
Manager\lack of 
empathy 
5 5 0 Work is 
incredibly hard 
at the moment, 
my (female) 
manager does 
not really 
understand 
and my job is 
extremely 
stressful. 
Claire 
Haresnap
e 
20倀 my story 
group 
1 
 my story 
group\10
4 
Trust and 
Support from 
Manager 
1 1 0  I have to say 
though that our 
employers 
have been 
fantastic. My 
boss even 
looked at the 
INUK site and 
fact sheets 
and has been 
great at telling 
me to take as 
much time as I 
need, not to 
rush back to 
work etc. I 
couldn't have 
asked for 
more, so we 
have to count 
our blessings 
on that front. 
They have 
been incredibly 
understanding 
Claire 
Haresnap
e 
9倀 my story 
group 
1 
 my story 
group\10
4 
Trust and 
Support from 
Manager\empath
y from boss 
1 1 0  I have to say 
though that our 
employers 
have been 
fantastic. My 
boss even 
looked at the 
INUK site and 
fact sheets 
and has been 
great at telling 
me to take as 
Claire 
Haresnap
e 
9倀 my story 
group 
1 
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much time as I 
need, not to 
rush back to 
work etc. I 
couldn't have 
asked for 
more, so we 
have to count 
our blessings 
on that front. 
They have 
been incredibly 
understanding 
 my story 
group\70 
Trust and 
Support from 
Manager\empath
y from boss 
1 1 0  I was 
intending on 
working right 
up to EC but I 
really 
struggled with 
the side 
effects, mainly 
the hot sweats, 
very emotional 
and tiredness 
like i’ve never 
felt before. I 
decided to 
take leave 
from work until 
after ET – my 
manager was 
wonderful, so 
supportive! 
Claire 
Haresnap
e 
2倀 my story 
group 
1 
 my story 
group\65 
Trust and 
Support from 
Manager 
2 2 0 24th Septemb
er 2010I was 
at work when I 
found an 
article in our 
Police 
Federation 
magazine (the 
Federation is 
like a civilian's 
union) which 
was about 
officers getting 
support 
through the 
IVF process 
from work. 
Claire 
Haresnap
e 
2倀 my story 
group 
1 
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 my story 
group\65 
Trust and 
Support from 
Manager 
2 2 0 Going to speak 
to my Fed rep 
at work 
tomorrow and 
advise her of 
what we are 
doing so I can 
get some 
guarantees of 
support from 
my bosses 
Claire 
Haresnap
e 
2倀 my story 
group 
1 
 my story 
group\49 
Trust and 
Support from 
Manager\empath
y from boss 
9 9 0 Went back to 
work today, 
which was 
hard, but 
everyone has 
been very 
sympathetic. A 
colleague at 
work, has a 
sister who has 
gone through 
IVF too which 
helps a bit, but 
would love to 
hear from 
anyone with 
words of 
encouragemen
t to keep my 
spirits up and 
to hear your 
own 
experiences of 
IVF. 
Claire 
Haresnap
e 
2倀 my story 
group 
1 
 my story 
group\26 
2 
Trust and 
Support from 
Manager\feeling 
let down 
7 7 0 later in 2010 i 
started my 1st 
cycle of ivf my 
work were 
awfull they 
didnt support 
me at  
Claire 
Haresnap
e 
24倀 my story 
group 
1 
 my story 
group\10 
Trust and 
Support from 
Manager\lack of 
empathy 
3 3 0 But my 
husbands 
family have 
found our 
situation hard. 
They have (not 
conciously) 
made it much 
Claire 
Haresnap
e 
21倀 my story 
group 
1 
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harder, 
especially this 
year since the 
birth of their 
first 
grandchild. 
The comments 
that have been 
made, the 
pressure thats 
put on us to 
attend big 
family get 
togethers and 
the lack of 
understanding 
even though 
we've tried to 
explain is 
proving really 
hard to deal 
with and 
causing us alot 
of distress 
 my story 
group\4 
Trust and 
Support from 
Manager\lack of 
empathy 
1 1 0 I told my mum 
who is quite ill 
herself and 
she was 
naturally very 
upset but 
instead of the 
support I 
thought I'd get 
she said "if 
you're trying 
again please 
don't tell me 
until you've 
had the all 
clear ad it's too 
upsetting for 
me"!!!  
Claire 
Haresnap
e 
21倀 my story 
group 
1 
 my story 
group\2 
Trust and 
Support from 
Manager\lack of 
empathy 
4 4 0 another 4 
month wait to 
see the 
consultant 
again we were 
hit with more 
baffaling 
news... this 
Claire 
Haresnap
e 
21倀 my story 
group 
1 
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time we had a 
differnt 
consultant who 
proceeded to 
tell me the only 
thing would be 
ivf before i'd 
even sat down, 
was told after 
another SA 
partner is the 
problem i 
asked a bout 
my blocked 
tube which i 
had been 
shown to be 
told that that 
was incorrect 
she made me 
feel like i was 
making it up!!! 
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Document 
group 
Page 
 my story 
group\145 
The 
demands 
of 
treatment 
4 4 0 Am just playing 
the waiting game 
now- was hoping 
to start asap while 
I am on summer 
holidays (I'm a 
teacher). If period 
arrives this week, 
embryo collection 
and transfer would 
be in the first week 
of the new term. 
Not very 
convenient! 
Claire 
Haresnape 
20  my story 
group 
1 
 my story 
group\124 
The 
demands 
of 
treatment 
2 2 0 Does anyone 
know how long 
after planning how 
long before 
treatment starts 
roughly.  How 
much time will I 
need off work?  I 
am a teacher and 
it obviously has a 
big impact on the 
children I teach 
when I am 
continually out at 
appointments?  
Claire 
Haresnape 
10  my story 
group 
1 
 my story 
group\102 
The 
demands 
of 
treatment 
8 8 0 So, the 
rollercoaster 
began in earnest 
in January last 
year.  2006 ended 
with the start of ivf 
cycle (icsi) number 
1.  It was the 
hardest thing i 
have ever 
done.  Dr'ing was 
horrible, i suffered 
badly emotionally 
and didnt make it 
very long into 
treatment before 
needing to be 
signed off work. 
Claire 
Haresnape 
9  my story 
group 
1 
 my story The 4 4 0 with us purely so Claire 9  my story 1 
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group\100 demands 
of 
treatment 
that we could take 
a morning off work 
and spend it 
shaking hands 
with him for 5 
minutes whilst he 
repeated 
everything the 
nurses had told us 
the month before. 
Haresnape group 
 my story 
group\6 
The 
demands 
of 
treatment 
11 11 0 That afternoon, I 
felt quite rough, 
curled up on the 
sofa watching 
Twilgiht, insides 
feeling very 
bruised, it hit me 
that afternoon how 
big a thing IVF is.  
Claire 
Haresnape 
21  my story 
group 
1 
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Pag
e 
 my story 
group\15
7 
career 
prospects\stressf
ul job 
2 2 0   I am a 
deputy 
manager in a 
day nursery 
(not the 
easiest job 
during this) 
and my 
husband is a 
bus driver 
Claire 
Haresnap
e 
20䠏 my story 
group 
1 
 my story 
group\15
9 
career 
prospects\stressf
ul job 
6 6 0 severe 
bullying by a 
senior 
manager at 
work (I left the 
organisation 
as a result ut 
now have my 
own business) 
Claire 
Haresnap
e 
20䠏 my story 
group 
1 
 my story 
group\15
8 
career prospects 8 8 0 To top it off 
Ive been 
offered a 
promotion at 
work but don't 
want to accept 
it if im going to 
start IVF this 
year. 
Claire 
Haresnap
e 
20䠏 my story 
group 
1 
 my story 
group\15
4 
career 
prospects\stressf
ul job 
3 3 0  I suffered 
greatly from 
my job change 
as in effect I 
was demoted - 
talking about 
kicking a man 
when he's 
down!  It had a 
terrible effect 
on me as I felt 
I had lost 
everything I 
had worked so 
hard for and 
that was 
so beneficial t
o me 
Claire 
Haresnap
e 
20䠏 my story 
group 
1 
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 my story 
group\15
4 
career prospects 7 7 0 My one good 
luck story in 3 
years has 
been my new 
job, which I 
started 2 
weeks after 
1st IVF 
failure.  So 
now, at least, 
DH and myself 
are both finally 
settled in jobs 
that we love, 
so some 
stability at 
long last. 
Claire 
Haresnap
e 
20䠏 my story 
group 
1 
 my story 
group\15
0 
career prospects 6 8 0  Having 
chased a 
career I finally 
realised I 
wasn't 
such a bad 
person and he 
was certainly 
a great person 
and what we 
had to offer 
to a new life 
Claire 
Haresnap
e 
20䠏 my story 
group 
1 
 my story 
group\14
1 
career 
prospects\stressf
ul job 
1 1 0  Instead I just 
feel 
shattered.  Als
o worried 
about the 
effects of the 
drugs, about 
getting OHSS, 
about it not 
working and 
losing this one 
hope we have, 
whether to go 
for SET or two 
embryos, 
working full-
time whilst this 
is all going on 
(although 
planning on 
taking sick 
Claire 
Haresnap
e 
20䠏 my story 
group 
1 
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leave for 2 
weeks) 
 my story 
group\17
9 
career prospects 7 7 0 I also went on 
a motivational 
course with 
work in 
January and 
had to face up 
to some things 
and be honest 
with myself 
that family is 
more 
important than 
work for me.  I 
think I was 
going for 
promotions as 
some sort of 
displacement 
for how I really 
feel! 
Claire 
Haresnap
e 
20䠏 my story 
group 
1 
 my story 
group\17
0 
career prospects 2 2 0 Both of us 
very career-
minded and 
ambitious and 
never really 
thought about 
children, but 
not long after 
we met, we 
both knew we 
were 
soulmates and 
were engaged 
within a few 
months 
Claire 
Haresnap
e 
20䠏 my story 
group 
1 
 my story 
group\17
0 
career prospects 6 6 0 I got offered 
my boss's job, 
ironically to 
cover her 
maternity 
leave, which I 
started in Jan, 
Claire 
Haresnap
e 
20䠏 my story 
group 
1 
 my story 
group\16
5 
career 
prospects\stressf
ul job 
5 5 0 Work is 
incredibly hard 
at the 
moment, my 
(female) 
manager does 
Claire 
Haresnap
e 
20䠏 my story 
group 
1 
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not really 
understand 
and my job is 
extremely 
stressful. 
 my story 
group\16
4 
career prospects 2 2 0 years - I look 
back now and 
just laugh at 
how careful 
we were with 
contraception 
while we were 
make a go of 
our careers. 
Claire 
Haresnap
e 
20䠏 my story 
group 
1 
 my story 
group\16
4 
career 
prospects\stressf
ul job 
4 4 0  That's when 
all the hassle 
started - 
because we 
were both only 
27 nobody 
took us 
seriously - our 
GP told us to 
go home and 
just relax, our 
parents told us 
to give up our 
stressful jobs 
and have a 
long holiday 
Claire 
Haresnap
e 
20䠏 my story 
group 
1 
 my story 
group\18
8 
career 
prospects\stressf
ul job 
17 17 0 I gave up my 
high flying job 
almost 3 years 
ago now and 
now live and 
work on our 
farm so I 
much more 
chilled and 
less up tight 
but still my 
body isnt 
doing what 
everyone else 
seems to be 
able to 
achieve so 
easily. 
Claire 
Haresnap
e 
20䠏 my story 
group 
1 
 my story 
group\20
career 
prospects\stressf
2 2 0  he set up a 
new business 
Claire 
Haresnap
20䠏 my story 
group 
1 
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8 ul job and I was 
doing a long 
commute to 
work so we 
just thought it 
was nature's 
way of telling 
us that it 
wasn't the 
right time 
e 
 my story 
group\20
8 
career 
prospects\stressf
ul job 
10 10 0 There's been 
lots of stress 
along the way 
- working in a 
workplace 
surrounded by 
30 something 
women, there 
have been a 
lot of 
pregnancies 
this year 
Claire 
Haresnap
e 
20䠏 my story 
group 
1 
 my story 
group\12
6 
career 
prospects\stressf
ul job 
8 8 0 Also not sure 
how much 
time to take off 
from 
work(very 
stressful 
workplace!!) 
What do you 
think is 
acceptable? 
Claire 
Haresnap
e 
10䠏 my story 
group 
1 
 my story 
group\12
0 
career 
prospects\stressf
ul job 
12 15 0 I literally felt 
the blood 
drain from my 
body. I think I 
went 
into a bit of a 
meltdown for 
the next few 
months, work 
was 
unbelievably 
full on, we 
were told that 
there was no 
DS on the 
NHS, we were 
told to 
go to the USA, 
Claire 
Haresnap
e 
10䠏 my story 
group 
1 
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we were told 
that the wait 
here would be 
5 years. 
 my story 
group\12
0 
career 
prospects\stressf
ul job 
26 28 0 At this point I 
was doing 70 
hour weeks at 
work and with 
the stress of 
everything my 
eyesight 
packed 
up. 
Claire 
Haresnap
e 
10䠏 my story 
group 
1 
 my story 
group\12
0 
career 
prospects\stressf
ul job 
46 47 0  have also 
been making 
efforts to 
reduce the 
stress at work. 
Claire 
Haresnap
e 
10䠏 my story 
group 
1 
 my story 
group\94 
career 
prospects\stressf
ul job 
3 3 0  I feel 
emotionally 
exausted and 
despite having 
a good (but v 
stressful) job 
Claire 
Haresnap
e 
9䠏 my story 
group 
1 
 my story 
group\93 
career prospects 4 4 0 . The day after 
our diagnosis I 
started the 
biggest job of 
my career in a 
new company. 
I don't tend to 
do things by 
halves  
Claire 
Haresnap
e 
9䠏 my story 
group 
1 
 my story 
group\93 
career 
prospects\stressf
ul job 
6 6 0 my job is quite 
pressured and 
I 
Claire 
Haresnap
e 
9䠏 my story 
group 
1 
 my story 
group\93 
career 
prospects\stressf
ul job 
8 8 0 Work is crazily 
manic 
Claire 
Haresnap
e 
9䠏 my story 
group 
1 
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Segment Author Creation 
date 
Document 
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Page 
 my story 
group\127 
Confidentiality 4 4 0 After about a 
year I 
persuaded 
DH to come 
along with me 
to our local 
doctors, 
which in itself 
was awkward, 
as I also work 
there 
Claire 
Haresnape 
10랭 my story 
group 
1 
 my story 
group\4 
Confidentiality 1 1 0  At that stage 
I had to tell 
my mother in 
law as DH 
was taking 
me into 
hospital 
Claire 
Haresnape 
21랭 my story 
group 
1 
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Documen
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e 
 my story 
group\14
4 
Being 
Open\no
n 
disclosur
e 
7 7 0 We are optimistic 
about this but age is 
against us, im 36 
and dh is 37.  We 
havent told anybody 
about our if so when 
we found this 
website it was a 
godsend and 
provides the needed 
support although to 
date we havent 
come across 
anyone in the 
exactly the same 
position. 
Claire 
Haresnap
e 
20 ÿ my story 
group 
1 
 my story 
group\17
7 
Being 
Open\no
n 
disclosur
e 
1 1 0 Friends carry on 
having babies, as 
do family, I work in a 
hospital enviroment 
and and have to 
deal with seeing 
people who are 
pregnant and with 
children all the time, 
I have created a 
professional and 
cold shell I put up to 
allow me to function 
but inside I am 
screaming, tears 
come late at night 
after my husband 
sleeps and when I 
am alone - pathetic I 
know, I'm doing it 
again now. 
Claire 
Haresnap
e 
20 ÿ my story 
group 
1 
 my story 
group\17
9 
Being 
Open 
7 7 0 I also went on a 
motivational course 
with work in January 
and had to face up 
to some things and 
be honest with 
myself that family is 
more important than 
work for me.  I think 
I was going for 
promotions as some 
Claire 
Haresnap
e 
20 ÿ my story 
group 
1 
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sort of displacement 
for how I really feel! 
 my story 
group\17
9 
Being 
Open\no
n 
disclosur
e 
10 10 0 I've not really told 
many people and 
D's parents don't 
know.  Not sure 
whether it is easier 
to say or not - will 
have to see what 
I'm like nearer the 
time and decide 
then. 
Claire 
Haresnap
e 
20 ÿ my story 
group 
1 
 my story 
group\16
5 
Being 
Open\no
n 
disclosur
e 
4 4 0 I have chosen not to 
tell many people 
because I do not 
think people 
understand unless 
they have had to 
deal with IF 
themselves. DH 
struggles to talk 
about it although he 
does talk more 
since the IVF. But I 
do not think men 
have the same need 
to talk as we do and 
of course Male 
Factor IF does have 
a big impact on the 
male ego 
Claire 
Haresnap
e 
20 ÿ my story 
group 
1 
 my story 
group\19
2 
Being 
Open 
4 4 0 we finally told our 
families and very 
close friends what 
was going on.  We'd 
wanted to keep it 
private but actually 
telling others was 
helpful - especially 
my family.  I 
eventually also told 
work too when I 
requested to go part 
time which helped 
enormously. 
Claire 
Haresnap
e 
20 ÿ my story 
group 
1 
 my story 
group\12
8 
Being 
Open 
1 1 0 In an ideal world we 
would be open with 
those closest to us 
but people struggle 
with understanding 
Claire 
Haresnap
e 
10 ÿ my story 
group 
1 
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how we feel and find 
it awkward knowing 
what to 
say.  Listening to 
comments like 
“you’ll be ok in the 
end” or “relax and 
stay positive” don’t 
help but can 
understand why 
people say them 
 my story 
group\10
4 
Being 
Open 
1 1 0 .We told lots of 
people about the 
ICSI. We wanted 
people to 
understand and we 
wanted their support 
and help. We knew 
we'd be in pieces if 
it didn't work. And 
people seemed 
surprised, 
particularly by our 
frankness, but 
supportive and 
encouraging 
Claire 
Haresnap
e 
9 ÿ my story 
group 
1 
 my story 
group\10
4 
Being 
Open\no
n 
disclosur
e 
1 1 0 They have been 
incredibly 
understanding.We'v
e had three cycles 
in all now, ending in 
BFNs, but we've 
really kept 
everything to 
ourselves since that 
first time, which I 
don't think is healthy 
- hence finally, so 
very late in the day, 
joining in the 
forums, although I 
have been reading 
your posts and 
thoughts and 
feelings. I can't say 
how much they 
have helped me 
through some dark 
times 
Claire 
Haresnap
e 
9 ÿ my story 
group 
1 
 my story Being 7 7 0 After the SA results Claire 9 ÿ my story 1 
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group\10
2 
Open\no
n 
disclosur
e 
dh and i seriously 
grew apart.  I was a 
like a demon 
possessed, 
desperately 
searching the web 
for info and stories 
of ivf and reading 
every book 
going.  He on the 
other hand refused 
to discuss any of it, 
completely shut me 
out of everything 
and stuck his head 
in the sand (plus he 
didnt want me to 
talk to anyone 
either, got very 
upset if i mentioned 
wanting to speak to 
any family or friends 
and all but forbid me 
to even speak to my 
mum!!).  Eventually 
the strain became 
too much and we 
split. 
Haresnap
e 
group 
 my story 
group\93 
Being 
Open\no
n 
disclosur
e 
6 6 0 We haven't told 
friends or family, we 
are quite private and 
want to do this our 
way. This site really 
is an outlet for me to 
share and 
understand others 
experiences, even 
more so for us as 
our decision to keep 
this to ourselves will 
no doubt be difficult. 
I am not telling work 
either, my job is 
quite pressured and 
I couldn't stand the 
speculation. They 
already suspect I 
am pregnant as I 
put on weight post 
wedding. The irony 
Claire 
Haresnap
e 
9 ÿ my story 
group 
1 
APPENDICES 
Appendix	  	  11	  	  Qualitative	  Data	  from	  Strand	  4	   931	  
of it isn't lost on me!! 
 my story 
group\86 
Being 
Open\no
n 
disclosur
e 
7 9 0 When I was having 
treatment I didn't tell 
anyone at work 
although I was 
tempted on several 
occasions. I'm really 
glad I didn't. It was 
hard getting over 
the disappointment 
privately so dealing 
with other people 
too wouldn't have 
suited me. It also 
meant at work I 
could temporarily 
forget about it. 
I've told a few close 
friends but not a 
wide circle of people 
that we're ttc. In a 
way the more 
people you tell the 
more pressure you 
put on yourself. 
After all the end of 
your story to 
conceive might 
(sadly) be a bit of a 
way off. 
Telling my friends 
was hard (silly 
pride) but having 
one of two people 
you can really open 
up to aside from 
your partner I think 
is a real comfort. 
Claire 
Haresnap
e 
7 ÿ my story 
group 
1 
 my story 
group\76 
Being 
Open\no
n 
disclosur
e 
4 4 0 As you can imagine 
we were devastated 
and I don't think I 
stopped crying all 
weekend. Being so 
far away from family 
also was very hard, 
although I've kept all 
this away from my 
Dad. We lost Mum 
last year and he has 
had a lot to deal 
Claire 
Haresnap
e 
2 ÿ my story 
group 
1 
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with and I don't want 
him worrying about 
me at the moment. I 
could have done 
with a good cry and 
natter with my 
wonderful Mum that 
day though, I can 
tell you.  
 my story 
group\76 
Being 
Open\no
n 
disclosur
e 
8 8 0 So the next step is 
basically doing 
it!  We have to keep 
things very quiet 
here at work, for 
many reasons, so 
getting the 
time/dates to do it is 
proving a bit of a 
nightmar 
Claire 
Haresnap
e 
2 ÿ my story 
group 
1 
 my story 
group\73 
Being 
Open\no
n 
disclosur
e 
1 1 0 Anyway after a 
week or so I picked 
myself up and 
pulled myself 
together and told 
myself to stop being 
ridiculous, this 
happens to so many 
people it's just that 
nobody really talks 
about it. 
Claire 
Haresnap
e 
2 ÿ my story 
group 
1 
 my story 
group\73 
Being 
Open 
1 1 0  I have since 
discovered a couple 
of close friends that 
are going through 
similar problems 
and realised that 
more people share 
this journey than I 
first imagined. 
Claire 
Haresnap
e 
2 ÿ my story 
group 
1 
 my story 
group\69 
Being 
Open\no
n 
disclosur
e 
1 1 0   I am in my Mid 
thirties.Can ayone 
help me in my 
isolation , i have had 
to carry out all past 
procedures in secret 
apart from a few 
close friends and 
familly members 
Claire 
Haresnap
e 
2 ÿ my story 
group 
1 
 my story 
group\65 
Being 
Open 
2 2 0  I've told people, I 
can't keep my 
Claire 
Haresnap
2 ÿ my story 
group 
1 
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mouth shut about 
anything! 
e 
 my story 
group\29 
Being 
Open\no
n 
disclosur
e 
1 1 0 We have decided 
not to tell anyone 
about our situation 
and over time a lot 
of people have 
stopped asking us 
questions. 
Claire 
Haresnap
e 
24 ÿ my story 
group 
1 
 my story 
group\28 
2 
Being 
Open\no
n 
disclosur
e 
6 6 0 I haven't told work 
anything yet - I think 
I may have to but 
very reluctant - 
especially as its 
such a small team, 
there are about 10 
employees 
Claire 
Haresnap
e 
24 ÿ my story 
group 
1 
 my story 
group\13 
Being 
Open 
8 8 0 but I have gradually 
started to open up 
about this  
Claire 
Haresnap
e 
21 ÿ my story 
group 
1 
 my story 
group\13 
Being 
Open 
8 8 0  I was so sad to give 
up on this surprise 
element 
Claire 
Haresnap
e 
21 ÿ my story 
group 
1 
 my story 
group\13 
Being 
Open 
8 8 0  but the loneliness 
was just too much to 
bear. So we have 
gradually starting 
telling people. And 
this is my next step 
in reaching out, 
writing this 
Claire 
Haresnap
e 
21 ÿ my story 
group 
1 
 my story 
group\9 
Being 
Open\no
n 
disclosur
e 
6 6 0  we don't want to tell 
people when we do 
it in case it doesn't 
work 
Claire 
Haresnap
e 
21 ÿ my story 
group 
1 
 my story 
group\6 
Being 
Open 
13 13 0   Had to pop into 
work that afternoon 
for a meeting with 
my boss, let her 
know as best as I 
could. 
Claire 
Haresnap
e 
21 ÿ my story 
group 
1 
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Comment Document Code Begin End Weight 
score 
Segment Author Creation 
date 
Document 
group 
Page 
 my story 
group\159 
Medical Staff 
Interactions\medical 
let down 
8 8 0 We are on the NHS 
waiting list for IVF 
(delayed because of 
my GP acting like 
God - "it's cause 
you're stressed" - 
initially saying we 
had to wait before 
he'd refer us) and 
hopefully it'll be 
sometime in 
September or 
October of this year 
Claire 
Haresnape 
20➘ my story 
group 
1 
 my story 
group\141 
Medical Staff 
Interactions\medical 
let down 
1 1 0  The consultant we 
saw was an odd 
one.  He sat in his 
chair rocking and 
just said everything 
was "fine".  We were 
in shock.  We asked 
him several times to 
perhaps elaborate 
and for the actual 
percentages of the 
sperm morphology, 
actual results of the 
tests, however he is 
very reluctant to go 
into any detail 
whatsoever.  We 
finally managed to 
get out of him that 
normal forms were 
now at 22% 
(although we had to 
do the maths 
ourselves to work 
this out).  He said we 
come under 
“unexplained 
infertility” and offered 
IUI.    Given this 
good news of now 
everything being 
“fine", we decided 
that maybe we 
should try naturally 
for a while longer 
Claire 
Haresnape 
20➘ my story 
group 
1 
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and so decided to 
put the treatment on 
hold for now.   We 
were feeling really 
hopeful 
again.       The “still 
nothing happens” bit 
January 2009 and 
still nothing had 
happened.  We 
booked an 
appointment at the 
clinic to see how 
long they would 
recommend us trying 
for and to ask about 
things like nutrition, 
complimentary 
therapies (very 
naively thinking the 
clinic would offer this 
type of advice!).   On 
the morning of the 
appointment, my DH 
and I decided that 
we would actually try 
the IUI.  We got to 
the appointment and 
there was no expert 
in sight.  Instead we 
waited for 2 hours to 
speak to somebody 
who had no idea 
how to answer any 
of our (let’s be 
honest, my) 
questions, confused 
IVF with IUI and just 
about managed to 
give my DH a sperm 
pot.  Discussing 
nutritional advice etc 
was definitely out the 
window as the man 
didn’t have a clue! 
 my story 
group\140 
Medical Staff 
Interactions\medical 
staff lack of 
empathy 
3 4 0 To get to the fertility 
clinic you had to 
walk through the 
antenatal clinic. And 
then the waiting 
Claire 
Haresnape 
20➘ my story 
group 
1 
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room for the fertility 
clinic was a tiny 
windowless room 
with a load of baby 
toys in it! The fertility 
nurse I saw advised 
to have a 
laparoscopy which 
was an equally 
horrific 
experience.  The 
NHS staff were 
unfortunately very 
unsympathetic and 
uncaring. 
One month after the 
operation I went 
back  
 my story 
group\177 
Medical Staff 
Interactions\medical 
staff lack of 
empathy 
1 1 0 My GP's answer to 
all of this is "just 
adopt, there are 
plenty of children out 
there who need a 
home" nice... The 
consultant's answer 
to my husbands 
azoospermia was in 
the first instance not 
to even offer to help 
him, just use donor 
sperm - the child 
won't be yours but 
you'll bring it up so 
it's as good as! This 
as you can imagine 
has not helped our 
relationship he won't 
talk to me, I am 
scared he will call off 
the whole thing if we 
are offered ICSI/IVF 
through pride, 
selfloathing  and 
anger. 
Claire 
Haresnape 
20➘ my story 
group 
1 
 my story 
group\177 
Medical Staff 
Interactions\medical 
staff lack of 
empathy 
1 1 0  The result came 
back - Azoospermia, 
no sperm in the 
semen at all - we 
where told in a very 
uncaring way, it was 
Claire 
Haresnape 
20➘ my story 
group 
1 
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just announced, my 
husbands face was 
just pure shock, then 
anger 
 my story 
group\173 
Medical Staff 
Interactions\medical 
staff lack of 
empathy 
4 4 0  After a year we 
went to our GP and 
were referred to the 
ACU who tested us 
both and said 
everything was fine 
and we should go 
home and try and 
relax 
(argh!*&^%$£"!!!). 
Claire 
Haresnape 
20➘ my story 
group 
1 
 my story 
group\176 
Medical Staff 
Interactions\medical 
let down 
3 3 0 Our consultant said 
he would refer us for 
IVF at Leeds 
hospital, my hubby 
has a son 17 but our 
cons said that we 
would still get IVF 
free on the NHS 
cause I dont have 
any children, he said 
it wouldnt be a 
problem and he 
would fight our 
case....so we 
thought fantastic 
what a weight off our 
minds...then we got 
word last week that 
we have been 
rejected for IVF 
cause Patrick has a 
son!!, I was 
devastated so i 
phoned my cons 
secrectary and 
explained to her 
what happened, she 
said she would pass 
the info on to him, 
she phoned me back 
3 days later and said 
my consultant 
wouldnt be 
appealing and that 
was that, she also 
said now they was 
Claire 
Haresnape 
20➘ my story 
group 
1 
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nothing more he can 
do but go and see 
our GP for the next 
step 
 my story 
group\162 
Medical Staff 
Interactions\medical 
staff lack of 
empathy 
1 1 0 . I was referred to a 
gynecologist. I feel 
angry when I think of 
him. I have always 
been a very thin 
person – size 8 and 
slightly under weight 
– however, 
throughout the whole 
appointment, he 
talked to me about 
diets and told me 
that I would need to 
cut down on the 
amount of carbs I 
was eating 
Claire 
Haresnape 
20➘ my story 
group 
1 
 my story 
group\165 
Medical Staff 
Interactions\medical 
let down 
2 2 0 I went back to GP 
who then informed 
us that DH did have 
a problem according 
to the sample he had 
given a year or so 
ago but noone had 
informed him. I was 
devastated as was 
he. 
Claire 
Haresnape 
20➘ my story 
group 
1 
 my story 
group\164 
Medical Staff 
Interactions\medical 
let down 
6 6 0 We were referred to 
a clinic and were put 
on the long waiting 
list and were told 
that we could pay for 
IUI before we 
reached the top of 
the IVF waiting list. 
We were all ready, 
and on the first day 
of my cycle, I rang 
up and.... got no 
answer on any of the 
three phone 
numbers. I tried 
again and again, all 
day and still no 
answer. The next 
day, the nurse rang 
and apologized that 
Claire 
Haresnape 
20➘ my story 
group 
1 
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everyone was on a 
course and we had 
missed our chance 
for that cycle! 
 my story 
group\164 
Medical Staff 
Interactions\medical 
let down 
10 10 0 cycle in Feb, ready 
for starting IVF - and 
I was told by the 
nurse that the PCT 
was cutting our 
funding (along with 
17 other couples) so 
we wouldn't be able 
to start IVF this 
month. I was so 
shocked and yet 
again devastated 
and hurt - I got 
straight onto the 
phone to my mum 
and then my GP - 
they both knew the 
PCT from trying to 
get our funding 
changed before, and 
it took a whole day 
and lots of phone 
calls for it to be 
agreed. (In the 
process they also 
managed to get all 
the other 17 couples' 
funding secured too 
- but they won't have 
known that!!) 
Claire 
Haresnape 
20➘ my story 
group 
1 
 my story 
group\196 
Medical Staff 
Interactions\medical 
let down 
1 1 0 My own doctor didn't 
take me seriously as 
all tests were ok.  I 
finally went private in 
2004.  He didn't take 
me seriously either 
Claire 
Haresnape 
20➘ my story 
group 
1 
 my story 
group\192 
Medical Staff 
Interactions\medical 
let down 
3 3 0 We started on our 
1st of 3 IUI's in 
December 06 which 
went wrong when 
the nurse discovered 
that she couldn't get 
the catheter in the 
right place so just 
released it randomly 
Claire 
Haresnape 
20➘ my story 
group 
1 
 my story Medical Staff 1 1 0  I was really Claire 20➘ my story 1 
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group\183 Interactions\medical 
staff lack of 
empathy 
disheartened with 
her lack of 
sympathy, 
explanations and 
proposed treatment 
but I went away and 
did as I was told. 
Haresnape group 
 my story 
group\187 
Medical Staff 
Interactions\medical 
let down 
1 2 0 n Nov 08 I decided 
to go to the GP to 
discuss getting us 
some help in trying 
to conceive.  He 
referred us to the FC 
and our first appt is 
on 7th Apr.  
Unfortunately I have 
no idea how he 
qualified as a GP as 
he hadnt referred us 
for any tests at all 
before sending us 
there and if it wasnt 
for this lifeline of a 
website we wouldnt 
know and would 
have been sent back 
for the initial tests. 
Claire 
Haresnape 
20➘ my story 
group 
1 
 my story 
group\214 
Medical Staff 
Interactions\medical 
staff lack of 
empathy 
1 1 0 uring the 
appointment the 
consultant was 
dreadful, no care, 
compasion, or 
explaination, just 
"well we'll have to 
run more tests" 
Claire 
Haresnape 
20➘ my story 
group 
1 
 my story 
group\212 
Medical Staff 
Interactions\medical 
let down 
4 5 0 At the next hospital 
we were told we 
were also at the 
wrong place and 
reffered to another 
hospital who then 
told us the local pct 
had cut funding and 
we could not have 1 
cycle of icsi on the 
nhs but we could 
have 6 attemps at iui 
using a donor when i 
reached 23 years. 
We went to our local 
Claire 
Haresnape 
20➘ my story 
group 
1 
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newspaper who 
featured our story 
and the pct denied 
they had cut funding 
but coudnt explain 
why the doctors 
thought we could not 
have a cycle after 
trying to sort this but 
with no luck, we 
decided to move 
house to the county 
where we attended 
the first hospital but 
unfortunatley i had 
put the weight back 
on then and they 
refused to treat us 
even though they 
had sent us on a 
wild goose chase for 
12 months. 
Then 6 months later 
they threatened to 
take us to court over 
sperm storage costs 
which they had not 
informed us off. the 
paper got involved 
again and the centre 
addmitted they was 
in the wrong and 
dropped it. 
 my story 
group\211 
Medical Staff 
Interactions\medical 
staff lack of 
empathy 
3 3 0 Had a lap and dye in 
Sep 06 which 
showed that both 
tubes were blocked 
and that I have 
endometriosis (had 
been complaining 
about painful, heavy 
periods form the age 
of 13, but the doctor 
had told me that this 
was the norm and to 
get on with it on 
several 
occasions).  Great!  
Claire 
Haresnape 
20➘ my story 
group 
1 
 my story 
group\130 
Medical Staff 
Interactions\medical 
3 3 0 But classic comment 
from his GP 'I don't 
Claire 
Haresnape 
20➘ my story 
group 
1 
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let down know anything about 
sperm but it should 
be enough'. Thanks 
for that.  
 my story 
group\130 
Medical Staff 
Interactions\medical 
let down 
4 4 0 ook months to get an 
appointment. When I 
phoned up to make 
the appointment the 
secretary told me the 
wrong date. A letter 
arrived the day of 
the appointment 
stating that it was 4 
days before!!! So I 
phoned up - 'don't 
worry make another 
appointment after 
your next cycle'. 
Frustrating. Next 
cycle I phone up, but 
disaster! As I 'didn't 
turn up for the 
original treatment' 
(!!!!) my notes had 
been returned so NO 
procedure. Saw GP, 
made official 
complaint, referred 
to bigger central 
hospital. 
Claire 
Haresnape 
20➘ my story 
group 
1 
 my story 
group\130 
Medical Staff 
Interactions\medical 
staff lack of 
empathy 
8 8 0 I'm feeling very 
confused. She was 
so horrible!  
Claire 
Haresnape 
20➘ my story 
group 
1 
 my story 
group\117 
Medical Staff 
Interactions\medical 
let down 
8 8 0 t. With failure 2 
weeks later and an 
awful experience 
with the technician 
doing the procedure 
Claire 
Haresnape 
10➘ my story 
group 
1 
 my story 
group\116 
Medical Staff 
Interactions\medical 
let down 
6 6 0 most recent outcome 
had laparoscopy on 
7th jan and 
discovered i have 
both tubes 
blocked(which 
should have been 
picked up with 
having dye test 
done)so booked in 
now for tubal 
Claire 
Haresnape 
10➘ my story 
group 
1 
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reconstruction on 
3rd march.. 
 my story 
group\111 
Medical Staff 
Interactions\medical 
let down 
5 5 0 Started to feel really 
low and tearful so 
went to GP who said 
i was suffering with 
depression but didnt 
want to prescribe 
anything, went home 
and really felt i 
couldnt cope so rang 
fertility clinic to ask 
for help, the nurse 
called me back and i 
explained how i felt, 
she replied "dont 
worry its not the end 
of the road for you, 
your DH can have a 
sperm retrieval opp" 
i explained my 
husbands SA was 
normal and she said 
" i am afraid not he 
has no sperm at all, 
the GP must have 
read it wrong" I 
Claire 
Haresnape 
10➘ my story 
group 
1 
 my story 
group\111 
Medical Staff 
Interactions\medical 
let down 
6 6 0  I phoned my clinic 
four times to ask 
them to send both 
our blood test 
results, my DH 
phoned once and 
Addenbrooks 
phoned once, each 
time being made to 
feel a nuisance for 
keeping phoning 
them and when we 
arrived they hadnt 
sent our notes so 
our bloods had to be 
done again!!!   The 
genetic councellor 
along with a top 
Doctor wrote to our 
clinic to tell them that 
there treatment DH 
and I had been 
below acceptable, 
Claire 
Haresnape 
10➘ my story 
group 
1 
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and we also made 
an app to complain 
 my story 
group\109 
Medical Staff 
Interactions\medical 
let down 
6 6 0 I recently asked the 
private clinic for a 
copy of my notes, 
and I think they have 
left me more 
confused, as they 
seem to suggest that 
my husband's sperm 
was ok on our very 
first attempt!!! 
Claire 
Haresnape 
10➘ my story 
group 
1 
 my story 
group\108 
Medical Staff 
Interactions\medical 
staff lack of 
empathy 
6 6 0 Well 9 weeks in she 
lost hers and one 
week later I went for 
a dating scan to be 
asked if I had a 
positive result. I just 
went cold. I knew 
that again I was 
going to have a mc. 
My experience with 
the hospitals is 
absolutely 
despicable! NO 
support at all! I was 
told to go home and 
let nature do it’s 
course. No one to 
call, nothing. 
Claire 
Haresnape 
10➘ my story 
group 
1 
 my story 
group\108 
Medical Staff 
Interactions\medical 
let down 
6 6 0 Well 9 weeks in she 
lost hers and one 
week later I went for 
a dating scan to be 
asked if I had a 
positive result. I just 
went cold. I knew 
that again I was 
going to have a mc. 
My experience with 
the hospitals is 
absolutely 
despicable! NO 
support at all! I was 
told to go home and 
let nature do it’s 
course. No one to 
call, nothing. 
Claire 
Haresnape 
10➘ my story 
group 
1 
 my story 
group\104 
Medical Staff 
Interactions\medical 
1 1 0 After a five hour wait 
in a crowded waiting 
Claire 
Haresnape 
9➘ my story 
group 
1 
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let down room, we went 
through all the same 
questions and same 
answers as we had 
with our GP and 
were referred for the 
some of the same 
tests, which was 
incredibly frustrating.  
 my story 
group\104 
Medical Staff 
Interactions\medical 
let down 
1 1 0 We couldn't believe 
the number of 
people with fertility 
problems. We 
couldn't believe 
there seemed to be 
such a shortage of 
staff to meet their 
needs. At one point, 
some test results got 
lost and there was 
the prospect of 
having to wait 
another six months 
for a new test. I was 
on the phone non-
stop, furious that due 
to their mistake, we 
would have to wait 
even longer to find 
out what was wrong. 
I even composed an 
angry letter to the 
chief  exec of the 
PCT, but didn't have 
to send it as they 
managed to fit us in 
two weeks later. 
Claire 
Haresnape 
9➘ my story 
group 
1 
 my story 
group\102 
Medical Staff 
Interactions\medical 
let down 
6 6 0 Unfortunately on 
returning to our GP 
to discuss where we 
go from there we fell 
foul of a GP who 
was extremely 
compassionate and 
well-meaning but 
who was at the end 
of the day a GP and 
didnt have the 
knowledge that we 
needed at this time 
Claire 
Haresnape 
9➘ my story 
group 
1 
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(altho to his credit he 
always sought out 
the information we 
needed or pointed 
us in the right 
direction), and to this 
end he reassured us 
that there were 
things that could be 
done, it wasnt 
necessarily an 
insurmountable 
problem and that at 
least he had some 
sperm so hopefully 
he would be able to 
use his own sperm 
and not a donor 
(altho he did say he 
wasnt sure how 
many were needed 
for ivf).  It was here 
where dh really 
struggled and from 
this moment on he 
couldnt see past 
where we were at 
and the mention of 
donor sperm 
 my story 
group\100 
Medical Staff 
Interactions\medical 
let down 
2 2 0 Our GP was 
sympathetic, but 
seemed to know less 
than I did about IF 
(from trawling the 
internet), and 
referred us to our 
local hospital, and 
the endless battery 
of tests began. 
Claire 
Haresnape 
9➘ my story 
group 
1 
 my story 
group\100 
Medical Staff 
Interactions\medical 
let down 
4 4 0 with us purely so 
that we could take a 
morning off work and 
spend it shaking 
hands with him for 5 
minutes whilst he 
repeated everything 
the nurses had told 
us the month before. 
Claire 
Haresnape 
9➘ my story 
group 
1 
 my story 
group\100 
Medical Staff 
Interactions\medical 
5 5 0 After the second 
failure I therefore 
Claire 
Haresnape 
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let down asked the nurse if 
she would put our 
name down on the 
IVF waiting list. She 
didn't. After our 4th 
failed cycle she 
finally decided that 
she had better do it 
 my story 
group\97 
Medical Staff 
Interactions\medical 
staff lack of 
empathy 
3 3 0 I had 21 day 
progesterone test in 
April which couldn't 
confirm ovulation but 
the Dr we saw for 
my results was very 
dismissive and told 
me I had to be trying 
for 12 months before 
they can do anything 
Claire 
Haresnape 
9➘ my story 
group 
1 
 my story 
group\97 
Medical Staff 
Interactions\medical 
staff lack of 
empathy 
4 4 0 I took my charts but 
she didn't even look 
at them.  
Claire 
Haresnape 
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 my story 
group\97 
Medical Staff 
Interactions\medical 
staff lack of 
empathy 
4 4 0 This time I was told 
under the PCT 
guidlines for my area 
I have to of been 
trying for 18 months 
for a referral as there 
are no grounds for 
me to be referred. I 
left very upset, 
without my referral, 
and with most of my 
questions 
unanswered 
Claire 
Haresnape 
9➘ my story 
group 
1 
 my story 
group\97 
Medical Staff 
Interactions\medical 
staff lack of 
empathy 
10 10 0 I spent a few weeks 
not understanding if 
we had been 
reffered or not so 
when we went back 
to the Drs to get the 
results of the blood 
test (which again this 
could not confirm 
ovulation) I had 
intended to ask if we 
had been refferred 
but this time she was 
dismissive for a 
different reason  
Claire 
Haresnape 
9➘ my story 
group 
1 
APPENDICES 
Appendix	  	  11	  	  Qualitative	  Data	  from	  Strand	  4	   948	  
 my story 
group\97 
Medical Staff 
Interactions\Feeling 
supported by 
medical staff 
11 11 0 So that was Dec 08. 
I got the phone 
number for the 
fertility clinic to ask 
how long their 
waiting list 
was (thinking it 
would be months 
again) but was 
amazed to here it 
would only be a 
matter of weeks 
before we saw 
someone. The nurse 
I spoke to was 
fantastic - she was 
very reassuring 
about the test results 
to date and was 
willing to listen to all 
of my concerns. 
Claire 
Haresnape 
9➘ my story 
group 
1 
 my story 
group\94 
Medical Staff 
Interactions\medical 
let down 
3 3 0 . I asked my Dr if I 
could have Luteal 
Phase Defect, but 
was told such a 
condition did 
not exist. To cut a 
long story short, a 
series of very difficult 
losses happened in 
quick succession in 
2006, meaning 
infertility was forced 
to take a back seat, 
although the pain 
continued to bubble 
under the surface. In 
2007 my marriage 
hit a really rough 
spot. The strain of 
everything was 
begining to take it's 
toll, and had it not of 
been for how strong 
my DH and I are as 
a couple, I think we 
could have broken 
up. We've managed 
to get our marriage 
back on track and 
Claire 
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despite the ongoing 
pain of infertility, are 
stronger than ever. 
We've moved from 
Swindon to Oxford, 
somthing we've 
always wanted to do 
and have built a new 
life for ourselves 
here. Last year, we 
went to a clinic 
called Viveka in 
London, which takes 
a holistic approach 
to infertility. It was 
confirmed through a 
hormone profile that 
I do have LPD and 
when I told the Dr in 
London that I had 
perviously been told 
it did not exist, he 
was horrified.  
 my story 
group\93 
Medical Staff 
Interactions\medical 
let down 
6 6 0 For the sake of the 
readers of this post I 
will skip all the 
poking and prodding, 
the internals, the 
endless blood tests, 
the HSG and the 
general feeling that 
we were on a 
telecaster with no 
real say in when we 
got on or off. We 
have all been 
through it, been 
endlessly frustrated 
with the system, 
confused and yes 
sometimes very 
angry but lets not 
labour the point!! 
Claire 
Haresnape 
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 my story 
group\89 
Medical Staff 
Interactions\medical 
let down 
4 4 0 I was gowned up, 
ready to go into 
theatre at the end of 
the day and I had a 
sinking feeling that 
something was 
going to go 
Claire 
Haresnape 
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wrong.  Our lovely 
consultant came to 
see me to tell me 
that my op was 
cancelled due to 
complications with 
the previous patient,  
 my story 
group\86 
Medical Staff 
Interactions\medical 
staff lack of 
empathy 
19 19 0 On our 2nd cycle 
when we went back 
in for the embryo 
transfer we were told 
three embryos had 
survived.  So they 
were happy to 
transfer two back in 
and wanted us to 
decide there and 
then what to do with 
the 3rd one.  Ie did 
we want to pay for it 
to go into frozen 
storage - which is 
costly and the 
chances of it 
surviving all the way 
through to natural 
birth are small - or 
did we consent to it 
being destroyed. We 
had to decide there 
and then in the 
waiting room (me 
crying and looking 
shocked in a room 
full of strangers 
looking scared) 
Claire 
Haresnape 
7➘ my story 
group 
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 my story 
group\85 
Medical Staff 
Interactions\medical 
staff lack of 
empathy 
1 1 0  Panic set in as 
thought a little 
bleeding not a 
problem, however, 
apparently it is if you 
haven’t had any 
bleeding at all by this 
point.   After hideous 
day at 2 A&E 
departments (won’t 
go into that L) at 
5.45pm, it is 
confirmed that our 
baby had died at 
Claire 
Haresnape 
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about 8 weeks and 
that I had had a 
missed miscarriage 
i.e. your body 
continues to think 
you are pregnant 
after the baby has 
died. Total and utter 
devastation, I cannot 
describe the grief 
and despair and the 
complete and utter 
feeling of loss – how 
completely unfair to 
allow us to lose our 
miracle baby. How 
could that 
happen?   I decided 
to have the surgical 
procedure, 
Evacuation & 
Removal of Products 
related to 
Conception (ERPC) 
– how heartless a 
term is that? Our 
baby being referred 
to as a “Product 
related to 
Conception”. This 
happened on the 9th 
October in a Day 
Unit where I was 
surrounded by 
people killing their 
babies, terminations, 
all of them 
 my story 
group\85 
Medical Staff 
Interactions\Feeling 
supported by 
medical staff 
1 1 0  I am terrified of the 
failure again, 
although we do have 
enormous faith in 
our doctors this time. 
Claire 
Haresnape 
7➘ my story 
group 
1 
 my story 
group\83 
Medical Staff 
Interactions\medical 
staff lack of 
empathy 
1 1 0  The doctors can be 
very insensitive and 
quite dismissive, 
they see you for 5 
mins every 4or5 
months and cant 
wait to get you out 
the door 
Claire 
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 my story 
group\82 
Medical Staff 
Interactions\medical 
let down 
4 4 0 We have 
subsequently had 
three unsuccesful 
attempts at IVF 
using an English 
clinic.  This was 
alas a really awful 
experience as I 
was put through 
cycles which were 
never going to work 
as my uterus was 
once again being 
distorted by fibroids 
which had 
reoccured.  We had 
asked them 
constantly to rescan 
me to check this as I 
feared this had 
happened.  Nobody 
knows your body as 
you do and  my 
periods had become 
so heavy and 
lengthy that I simply 
knew something 
wasn't right.  The 
clinic pushed these 
concerns aside 
and  seemed more 
interested in taking 
our money and 
pushing us onto 
another cycle.   
Claire 
Haresnape 
2➘ my story 
group 
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 my story 
group\79 
Medical Staff 
Interactions\medical 
let down 
2 2 0 These were not 
really explained to 
us but we did not 
think there was 
anything to be 
concerned about. 
Claire 
Haresnape 
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 my story 
group\76 
Medical Staff 
Interactions\Feeling 
supported by 
medical staff 
9 9 0 Thankfullly my Gyno 
here is lovely and 
has said that he will 
help me with 
anything that is 
needed....I just hope 
he means it ! 
Claire 
Haresnape 
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 my story 
group\75 
Medical Staff 
Interactions\medical 
4 4 0  Couple of months 
later, had lap&dye at 
Claire 
Haresnape 
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staff lack of 
empathy 
another local 
hospital.  Attitude of 
nurses/consultants 
awful and told bad 
news without my DH 
being present. 
Unforgiveable 
 my story 
group\75 
Medical Staff 
Interactions\medical 
let down 
5 5 0  Very confused by 
lack of 
communication, in 
fact, no 
communication, 
between PCT, local 
hospital, regional 
hospitals and GP. 
Guess work on what 
we were getting 
throughout whole 
process. But very 
grateful to get any 
NHS treatment as at 
one point very 
worried we wouldnt 
be eligble due to age 
and stepchild living 
with us.  Prior to 
treatment had to do 
genetic testing 
again, which was 
long and stressful 
and badly organised, 
but eventually got 
complete all clear 
and ok  to proceed 
with treatment. 
Claire 
Haresnape 
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group 
1 
 my story 
group\70 
Medical Staff 
Interactions\Feeling 
supported by 
medical staff 
1 1 0 The anesthetist was 
fab, completely put 
me at ease. He was 
totally right, didn’t 
feel or remember a 
thing! 9 eggs 
collected, 4 eggs 
fertilised 
successfully..... yay!  
Claire 
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 my story 
group\68 
Medical Staff 
Interactions\medical 
let down 
5 5 0 Next appt followed in 
Aug 09 - we were 
told by the 
consultant to take 
vitamins to see if 
they improved the 
Claire 
Haresnape 
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quality of DH's 
sperm. We were 
outraged as we 
could have been told 
this from the start 
instead of being told 
8 months after our 
first visit to the GP. 
 my story 
group\68 
Medical Staff 
Interactions\Feeling 
supported by 
medical staff 
7 7 0 Next hurdle was the 
fact that no NHS IVF 
treatment is offered 
in Essex, so we had 
to choose from 5 
clinics outside 
London. We chose 
Leicester as they 
were the only clinic 
not to have a waiting 
list. LFC have been 
wonderful, we have 
visited a few times, 
filled the forms and 
more tests done etc 
...and now we are in 
a position where we 
start treatment in the 
next 4 days!!! 
Claire 
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 my story 
group\67 
Medical Staff 
Interactions\medical 
staff lack of 
empathy 
15 15 0 3rd May - standard 3 
week post test 
scan with Fertility 
Clinic.  Got the 
consultant from Hell 
who's never seen 
me before. Junior 
has a 
heartbeat!!!! BUT 
consultant there felt 
pregnancy wasn't 
viable as h/b faint & 
wanted us to see 
him again in a week. 
Claire 
Haresnape 
2➘ my story 
group 
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 my story 
group\66 
Medical Staff 
Interactions\medical 
let down 
1 1 0 After TTC for about 
a year we consulted 
a specialist in the 
Maldives who 
eventually (after a 
year of heavy fee's 
and monthly 
appointments) sent 
me for a HSG after 
Claire 
Haresnape 
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which she informed 
me that my tubes 
were blocked and 
recommended that I 
have microsurgery to 
unblock 
them.  Unfortunately 
this procedure is not 
available in the 
Maldives so I 
traveled to Thailand 
with my DH to 
consult another 
specialist.Once in 
Thailand I performed 
another HSG only to 
be informed that my 
tubes were perfectly 
fine!! 
 my story 
group\66 
Medical Staff 
Interactions\medical 
let down 
1 1 0  After my first 
unsucessesful 
month I started to 
get terrible pains, 
which gradually 
became unbearable 
over the next 
month.  I contacted 
the doctor in 
Thailand and he 
advised me to 
continue as planned 
and if we still had no 
luck with Clomide in 
3 months fly back to 
Thailand to see 
him.After 3 very 
painful months we 
headed back to 
Thailand to be told 
that I had very large 
cysts on both 
ovaries, which had 
been the reason for 
the pain and had to 
stop with all 
medication for at 
least 3 months!So 
we traveled home in 
despair as in both 
countries we had 
Claire 
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received little advice 
and spent a fortune 
 my story 
group\66 
Medical Staff 
Interactions\Feeling 
supported by 
medical staff 
1 1 0 From the moment I 
contacted the UK 
clinic I new we had 
made the right 
choice as finally we 
have been inundated 
with so much 
valuable information 
and friendly faces.I 
must admit I was a 
little worried as the 
laws have changed 
in the UK but after I 
was contacted by an 
Indian clinic that 
happily told me that 
they would transfer 
as many embryo’s, 
as I liked up to 12!!!! 
As apposed to the 
UK's max of 2 I new 
I had to come home 
Claire 
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 my story 
group\60 
Medical Staff 
Interactions\medical 
staff lack of 
empathy 
5 5 0 The laparoscopy 
was awful as while in 
gown and waiting to 
go down to theatre a 
flippant comment 
was made about my 
tubes and womb.  
Claire 
Haresnape 
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1 
 my story 
group\58 
Medical Staff 
Interactions\medical 
let down 
5 5 0  But ironically due to 
my 'success' with 
Clomid that put me 
on a dose of 
Puregon that was 
too low and didn't 
stim me enough. 
Claire 
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 my story 
group\56 
Medical Staff 
Interactions\medical 
let down 
2 4 0 After 3 m/c's I 
caught with a 4th 
and after a small 
bleed was told that I 
was having an 
ectopic.  I 
questioned this as I 
didnt have any of the 
symptoms - never 
the less, I was 
rushed into surgery 
(and then waited 7 
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hours in a side room 
before going 
in).  When I was 
taken back to the 
ward I was informed 
that they hadnt used 
any of the 
'preventative' 
methods and had 
just taken out my left 
tube. 
After being 
discharged, and for 
the next week, I 
looked into this 
further and was so 
confused by every 
decision made by 
the hospital, I wrote 
to the CEO of the 
Hospital Trust. It was 
just a short 5 days 
late when I received 
a phone call asking 
me to return to the 
ward asap as they 
thought I may still be 
pregnant.  Confused, 
we went back, to be 
told the worse news 
of my life - they had 
made a mistake, my 
baby wasnt ectopic - 
they had terminated 
it in error. 
The following month 
we were hit with the 
final blow - my left 
tube was my only 
'working' tube and 
therefore - they left 
me infertile. 
 my story 
group\52 
Medical Staff 
Interactions\medical 
let down 
19 19 0 March 2008 - our 
first cycle (free NHS 
one).  Mid way 
through the planning 
appointments they 
realised they hadn’t 
done any tests on 
me!  Blood tests 
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showed high FSH so 
we were switched to 
the short protocol. 
 my story 
group\51 
Medical Staff 
Interactions\medical 
let down 
3 3 0 internals etc etc and 
said my FSH Level 
is too high which 
means my egg 
quality is very poor 
its 13.5 he said only 
hope would be IVF 
but gov wont fund it 
cos ive conceived 
within the last 3 yrs! 
its a joke! 
Claire 
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 my story 
group\48 
Medical Staff 
Interactions\Feeling 
supported by 
medical staff 
5 5 0 We saw the 
consultant yesterday 
for a good hour and 
she was incredibly 
helpful and realistic. 
Claire 
Haresnape 
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1 
 my story 
group\41 
Medical Staff 
Interactions\medical 
let down 
3 3 0  was diagnosed with 
PCOS 5 years ago, 
didnt really know 
much about it, but 
then nor did my DR 
at the time, or any 
since, they were 
pretty damn clueless 
which just made it 
worse!  
Claire 
Haresnape 
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 my story 
group\41 
Medical Staff 
Interactions\Feeling 
supported by 
medical staff 
3 3 0 Luckily i have an 
amazing DR now 
Claire 
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 my story 
group\41 
Medical Staff 
Interactions\medical 
let down 
6 6 0 My doctor has put 
me in for an internal 
scan, and now im a 
sitting duck, 
hospitals take 
forever, especailly 
this time of year. 
Claire 
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 my story 
group\40 
Medical Staff 
Interactions\medical 
let down 
2 13 0 worst part is the 
waiting, waiting to 
see if my period will 
come, waiting to 
see the doctor, 
waiting for the next 
treatment, waiting to 
see if it worked...   
I stated puberty 
about aged 12-13. I 
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was never regular 
and had major 
problems with my 
"monthly" cycle. 
Sometimes I would 
go 4months without 
bleeding, other times 
I would bleed 
constantly for a 
whole month. 
Sometimes I was 
doubled up in pain 
sometimes I 
wasn't. Sometimes it 
would be so heavy I 
had to miss school 
or couldn't go out 
for a meal with my 
family. I knew 
something was 
wrong but 6 different 
GP's told 
me it was nothing. 
They gave pills to 
hide the pain; they 
strongly 
recommended 
I go on the pill, not 
only to mask the 
irregularity but also 
to fix it. Between 
the ages of 15-23 I 
spent most of my 
time on the pill (or 
rather several 
different brands of 
it). 
 my story 
group\39 
Medical Staff 
Interactions\medical 
let down 
3 3 0 Once we got to see 
him he explained 
that we could have 
blocked tubes, 
endometriosis, 
fybroids, polyps etc 
and wanted to do a 
Laparoscopy I found 
this so hard to deal 
with I thought that 
our problem would of 
been resolved 
easily, so he said we 
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could have a HSG 
and 3 more months 
of checking my 
progesterone and 
charting, so we went 
away and did this 
and after 3 months 
we got given the go 
ahead for the 
HSG,  well they lost 
our paper work and I 
ended up waiting for 
another 3 months for 
this to be done, 
despite pestering the 
Dr and Hospital they 
were all happy for 
me to wait, until 
eventually my 
gynea's secretary 
decided to look into 
and realized my 
paper work had 
been lost so finally I 
am at the hospital 
getting into my gown 
ready for the HSG to 
be done, I found 
myself getting upset 
before hand, and 
wandering why we 
were having to go 
through this, it felt so 
unfair.  
 my story 
group\35 
Medical Staff 
Interactions\medical 
let down 
3 3 0 The whole process 
and after math has 
been a living hell, 
first the shambolic 
surgery, major 
swelling,  massive 
lump, an i dont care 
gp, or ultrasound 
doctor, who says all 
he can see were 
varicous veins & 
carry on. 
Claire 
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 my story 
group\34 
Medical Staff 
Interactions\medical 
let down 
4 4 0 It took an age for H 
to back to doctors 
and the hospital took 
another 6 to 9 
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months. Lets just 
make a very long 
story short my 
hospital is awful! 
Brand new super 
hospital and very 
understaffed! There 
was originally two 
nurses running the 
subfertility clinic  but 
one nurse retired 
and they never 
replaced her,if they 
did i never saw her! I 
have had all my 
records lost,the 
nurse has phoned in 
sick and they've had 
to rush a sectarary 
from another 
department 
to  cancel 
appointments ,while 
i'm in reception 
nearly falling asleep 
and a number of 
other delays.So 
upset once phoned 
GP couldn't get to 
speak to him so 
spoke to the 
receptionist ,couldn't 
stop crying and the 
receptionist said if 
you complain they 
may you at back of 
the waitng list and/or 
take you off if i make 
to much fuss! 
 my story 
group\32 
Medical Staff 
Interactions\medical 
let down 
3 3 0 We were just told to 
go for ICSI/IVF and 
weren’t given any 
advice about trying 
to improve my count. 
Claire 
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 my story 
group\29 
Medical Staff 
Interactions\Feeling 
supported by 
medical staff 
3 3 0 Our GP was fab! He 
referred us for 
fertility treatment 
straight away in the 
Summer of 2010 and 
then I had blood 
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tests after. All came 
back normal 
 my story 
group\29 
Medical Staff 
Interactions\medical 
let down 
5 5 0 We were both 
excited and nervous 
and were both 
geared up for it and I 
was just about to 
start down regging 
when I received a 
phone call that day 
informing me that 
our treatment had 
been cancelled due 
to staff sickness and 
that the next 
available time was 
week before 
Christmas for EC 
and ET 
Claire 
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 my story 
group\26 
2 
Medical Staff 
Interactions\Feeling 
supported by 
medical staff 
9 9 0 I had a great doctor 
she signed me off 
work for 6 months 
and saw me 
regulally and 
eventually things got 
better i eventually 
visited my friend and 
2nd baby a beautiful 
boy who is now DH 
and my god son. 
Claire 
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group 
1 
 my story 
group\23 
Medical Staff 
Interactions\medical 
let down 
1 1 0 . I've tried for a year 
to get my GP to give 
me a referral and 
only managed to get 
him to refer me to St 
Thomas hospital 
yesterday. So finally 
I can find our exactly 
what the problem is. 
It's all I've been 
thinking about for 
years. It's been so 
frustrating trying to 
get referred 
Claire 
Haresnape 
24➘ my story 
group 
1 
 my story 
group\19 
Medical Staff 
Interactions\medical 
let down 
5 5 0 Whilst he was gone i 
decided to have 
some further tests 
done! I wasnt 
convinced it was just 
him. I went in alone 
Claire 
Haresnape 
24➘ my story 
group 
1 
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and frightened but 
determined to get 
answers. I woke up 
in recovery and lifted 
my bed sheets up to 
find i was 
heamoragging all 
over the bed.There 
was blood 
everywhere and i sat 
screaming!!! They 
whisked me back 
into surgery for 
internal stitches, 
they had nicked my 
cervix during the first 
op! I woke up 
battered and bruised 
and alone. I 
apparently screamed 
for an hour none 
stop for my husband 
until they sedated 
me!  
 my story 
group\15 
Medical Staff 
Interactions\Feeling 
supported by 
medical staff 
2 2 0 Been with my 
partner 8 years 
and have now been 
ttc for around 4 
years, after 3 years 
of nothing happening 
we went to the 
doctor who was very 
happy to get us help. 
Claire 
Haresnape 
21➘ my story 
group 
1 
 my story 
group\15 
Medical Staff 
Interactions\Feeling 
supported by 
medical staff 
3 3 0 After a year of tests, 
it was confirmed my 
partner had a low 
sperm count and 
that they were going 
to help us, next step 
being Ninewells for 
ivf treatment. Which 
to us was amazing 
news, finally getting 
the help we need. 
Claire 
Haresnape 
21➘ my story 
group 
1 
 my story 
group\12 
Medical Staff 
Interactions\medical 
staff lack of 
empathy 
4 4 0   It was not a very 
pleasant experience, 
the first time i turned 
up to the clinic the 
consultant came out 
into the waiting room 
Claire 
Haresnape 
21➘ my story 
group 
1 
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and shouted loudly 
at me that i could not 
be seen at this clinic 
as 'I already had one 
kid, what more did i 
want?'  It was awful, 
left totally humiliated. 
 my story 
group\12 
Medical Staff 
Interactions\Feeling 
supported by 
medical staff 
4 4 0 .  He was a bit 
furious and wrote a 
letter asking me to 
be seen by someone 
else which i was 
very quickly 
Claire 
Haresnape 
21➘ my story 
group 
1 
 my story 
group\11 
Medical Staff 
Interactions\medical 
let down 
3 4 0 I'm considering 
immune testing but I 
don't know if it would 
help me. My other 
concern is that I 
bleed from day 21 (& 
have done since the 
last m/c). The drs 
don't seem 
concerned by this 
but I am. My period 
cycle is 28 days but I 
start light bleeding 
on day 21 for 5 dys 
then stop for 2 dys 
before my actual 
period starts (lasting 
for 4 dys) - so in all 
bleeding for 10/11 
dys each mth. The 
IVF consultant said it 
looked like there was 
an old follicle that 
hadn't disintegrated 
the previous mth and 
this was the 
additional bleed  - 
but surely this can't 
be every mth?  
It is so frustrating not 
knowing what is 
wrong, 
Claire 
Haresnape 
21➘ my story 
group 
1 
 my story 
group\10 
Medical Staff 
Interactions\Feeling 
supported by 
medical staff 
3 3 0  We saw a lovely 
doctor, he referred 
us to the local 
hospital. 
Claire 
Haresnape 
21➘ my story 
group 
1 
 my story Medical Staff 3 3 0  The consultant was Claire 21➘ my story 1 
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group\10 Interactions\medical 
staff lack of 
empathy 
ok, didn't explain 
anything and 
referred us for 
further tests. In the 
next 7 months we 
had various tests 
done, saw an awful 
consultant and at the 
last appointment we 
saw a doctor who 
was a nightmare. 
We went in hoping to 
get my husbands 
second sperm 
analysis results (the 
first showed a low 
count & low 
motility)  but the 
doctor said she 
hadn't got the 
results, when I 
asked when we 
could get them she 
was really rude, I 
burst into tears and 
luckily at the last 
minute another 
nurse came in with 
the results. They 
showed slight 
improvement, but 
when I asked the 
doctor what our 
chances were she 
just shrugged her 
shoulders. The 
previous doctor told 
us we'd need IVF, 
this one told us she 
wasnt sure, that her 
colleage probably 
knew more, but 
she thought we 
should go for IUI and 
asked if we wanted 
to go on the list. We 
didnt know what IUI 
was!! and weren't 
encouraged by her 
hesitation. We said 
Haresnape group 
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we'd think about it. 
We were both 
shocked and felt 
really confused. 
 my story 
group\10 
Medical Staff 
Interactions\medical 
let down 
3 3 0  The consultant was 
ok, didn't explain 
anything and 
referred us for 
further tests. In the 
next 7 months we 
had various tests 
done, saw an awful 
consultant and at the 
last appointment we 
saw a doctor who 
was a nightmare. 
We went in hoping to 
get my husbands 
second sperm 
analysis results (the 
first showed a low 
count & low 
motility)  but the 
doctor said she 
hadn't got the 
results, when I 
asked when we 
could get them she 
was really rude, I 
burst into tears and 
luckily at the last 
minute another 
nurse came in with 
the results. They 
showed slight 
improvement, but 
when I asked the 
doctor what our 
chances were she 
just shrugged her 
shoulders. The 
previous doctor told 
us we'd need IVF, 
this one told us she 
wasnt sure, that her 
colleage probably 
knew more, but 
she thought we 
should go for IUI and 
asked if we wanted 
Claire 
Haresnape 
21➘ my story 
group 
1 
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to go on the list. We 
didnt know what IUI 
was!! and weren't 
encouraged by her 
hesitation. We said 
we'd think about it. 
We were both 
shocked and felt 
really confused. 
 my story 
group\5 
Medical Staff 
Interactions\medical 
staff lack of 
empathy 
1 1 0  I contacted my GP 
at the year mark of 
trying, only to be told 
to wait a bit longer. I 
changed GPs due to 
this flippant attitude 
and now have what I 
thought to be a 
wonderful GP 
Claire 
Haresnape 
21➘ my story 
group 
1 
 my story 
group\5 
Medical Staff 
Interactions\medical 
let down 
1 1 0 my GP filled in the 
application form for 
IVF Wales with us 
and sent it off, I was 
told that in 6 - 8 
weeks we would 
receive an 
acknowledgement 
letter from them, this 
never arrived so I 
gave it a bit longer, 3 
months later I 
gathered the 
courage to ring IVF 
Wales only to be told 
that never received 
the referral. Panic 
moment, so I got the 
GP to fax the referral 
to them again. 
Today after waiting 2 
months since the 
2nd referral was 
sent, I rang the clinic 
again only to be told 
that they have never 
received a referral 
for me. I feel like I'm 
hitting a brick wall on 
what I know to be a 
long journey of 
possible brick walls. 
Claire 
Haresnape 
21➘ my story 
group 
1 
APPENDICES 
Appendix	  	  11	  	  Qualitative	  Data	  from	  Strand	  4	   968	  
I don't know if my 
GP hasn't been 
sending them, 
 my story 
group\5 
Medical Staff 
Interactions\Feeling 
supported by 
medical staff 
1 1 0 but up to this 
moment they have 
been wonderful, 
even by contacting 
the community 
mental health team 
in regard to my 
clinical depression 
and the medication 
that I am on. 
Claire 
Haresnape 
21➘ my story 
group 
1 
 my story 
group\4 
Medical Staff 
Interactions\medical 
staff lack of 
empathy 
1 1 0 . At 11weeks and 5 
days I started having 
discharge and 
panicked though the 
GP and midwife 
were very matter of 
fact "it's an inevitable 
miscarriage" my 
world fell apart 
Claire 
Haresnape 
21➘ my story 
group 
1 
 my story 
group\4 
Medical Staff 
Interactions\medical 
staff lack of empathy 
1 1 0 help (nobody told 
me this was 
dangerous).. I went 
with my full bladder 
in hope, when they 
couldn't see 
anything on the 
ultra sound I was 
told "go and empty 
your bladder" I had 
to walk out in the 
waiting room in front 
of all the heavily 
pregnant mums with 
tears streaming 
down my face. I 
was given the 
choice of waiting to 
pass "it" naturally or 
tablets to force it or 
"evacuation of 
retained products" 
don't these NHS 
healthcare 
'professionsls' know 
what we go for?  
Claire 
Haresnape 
21➘ my story 
group 
1 
 my story 
group\2 
Medical Staff 
Interactions\medical 
3 3 0 we had to wait 6 
months for our 
Claire 
Haresnape 
21➘ my story 
group 
1 
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let down hospital 
appointment where 
we where told that 
my partners results 
had been read 
wrong, talk about 
emotions being all 
over the place, the 
consultant sent me 
for more bloods and 
a HSG and my 
partner for another 
SA, 
 my story 
group\2 
Medical Staff 
Interactions\medical 
let down 
4 4 0 another 4 month 
wait to see the 
consultant again we 
were hit with more 
baffaling news... 
this time we had a 
differnt consultant 
who proceeded to 
tell me the only 
thing would be ivf 
before i'd even sat 
down, was told after 
another SA partner 
is the problem i 
asked a bout my 
blocked tube which i 
had been shown to 
be told that that was 
incorrect she made 
me feel like i was 
making it up!!! 
Claire 
Haresnape 
21➘ my story 
group 
1 
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APPENDIX 12 memos written 
during thematic analysis of strand 
4 
Memo’s Written During Thematic Analysis Of Forum 
Data 
 
Memos regarding qualitative chapter 
 
1. In vivo coding ((Charmaz, 2006) PAGE 55 that condense meanings 
consist of widely used terms that participants assume everyone shares.   
Codes of participants special terms are in vivo codes. 
Insider shorthand terms specific to this particular group are common due to 
the technical nature of infertility treatment and many procedures are referred 
to with abbreviations. 
 
2. Triangulation was obtained by discussions with acquaintances going 
through infertility treatment at the time and using online forums (SSW).  This 
helped confirm the use of some non technical abbreviations such as DH 
(Dear Husband) which I had assumed to be Donor Husband. 
 
3. The literature search emerged from the coding which is the other way 
round than my quantitative section of the study.  The work on Charmaz on 
identity and disability was suggested by Carol Rivas.  The themes that 
emerged from the first smaller sample suggested the area of literature to 
review. 
 
Is this an acceptable methodology? 
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4. reflection that symbolic interactionism is closely linked to placebo, ‘we 
engage in a constant process of meaning making or mind action (Charon 
2007) 
 
  
Came across idea that Interpretive Description might be linked to my 
methodology.  Paper by Carolyn Oliver 2011 explores the relationships 
between symbolic interactionism and Interpretative Description. 
 
‘An SI study must be about the ways in which people develop their lines of 
action in alignment with, or reaction to, those of others:’ (Oliver, 2012)  This 
quote makes me think of the forum members who are continually receiving 
feedback via the  the reactions to their postings.  There are articles about this 
online also see Wiki entry for SI and New Media 
 
New Media[edit]|]edit source] 
New Media is a term used to define all that is related to the internet and the 
interplay between technology, images and sound.[10] As studies of online 
community proliferate, the concept of online community has become a more 
accepted social construct. Studies encompassed discursive 
communities;[11][12] identity;[13][14] community as social reality;[15] 
networking;[16] the public sphere;[17] ease and anonymity in 
interactions.[18] These studies show that online community is an important 
social construct in terms of its cultural, structural, political and economic 
character. 
It has been demonstrated that people's ideas about community are formed, 
in part, through interactions both in online forums as well as those in face to 
face interactions. As a result, people act in their communities according to 
the meanings they derive about their environment, whether online or offline, 
from those interactions. This perspective reveals that online communication 
may very well take on different meanings for different people depending on 
information, circumstance, relationships, power, and other systems that 
make up communities of practice. People enact community the way it is 
conceived and the meaning of community evolves as they come up with new 
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ways to utilize it. Given this reality, scholars are continually challenged to 
research and understand how online communities are comprised, how they 
function, and how they are connected to offline social life.[19] 
Symbolic Interaction Theory was discussed in “The Cyberself: The Self-ing 
Project goes online, Symbolic Interaction in the Digital Age.” Robinson 
discusses how Symbolic Interaction theory explains the way individuals 
create a sense of self through their interactions with others. However, she 
believes advances in technology have changed this. The article investigates 
the manner in which individuals form their online identity. She uses symbolic 
interaction theory to examine the formation of the cyber “I” and a digital 
“generalized other.” In the article, Robinson suggests individuals form new 
identities on the internet. She argues these cyber identities are not 
necessarily the way the individual would be perceived offline.[20] 
 
5. Inductive reasoning consists of inferring general principles or rules from 
specific facts 
 
6. Notes from Cardiff conference 
 
Critical realism is presently most commonly associated with the work of Roy 
Bhaskar. Bhaskar developed a general philosophy of science that he 
described as transcendental realism, and a special philosophy of the human 
sciences that he called critical naturalism. The two terms were combined by 
other authors to form the umbrella term critical realism. 
Transcendental realism attempts to establish that in order for scientific 
investigation to take place, the object of that investigation must have real, 
manipulable, internal mechanisms that can be actualised to produce 
particular outcomes. This is what we do when we conduct experiments. This 
stands in contrast to empiricist scientists' claim that all scientists can do is 
observe the relationship between cause and effect and impose meaning. 
Whilst empiricism, and positivism more generally, locate causal relationships 
at the level of events, Critical Realism locates them at the level of the 
generative mechanism, arguing that causal relationships are irreducible to 
empirical constant conjunctions of David Hume's doctrine; in other words, a 
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constant conjunctive relationship between events is neither sufficient nor 
even necessary to establish a causal relationship. 
The implication of this is that science should be understood as an ongoing 
process in which scientists improve the concepts they use to understand the 
mechanisms that they study. It should not, in contrast to the claim of 
empiricists, be about the identification of a coincidence between a postulated 
independent variable and dependent variable. 
Positivism/falsification[clarification needed] are also rejected due to the 
observation that it is highly plausible that a mechanism will exist but either a) 
go unactivated, b) be activated, but not perceived, or c) be activated, but 
counteracted by other mechanisms, which results in its having unpredictable 
effects. Thus, non-realisation of a posited mechanism cannot (in contrast to 
the claim of positivists) be taken to signify its non-existence. 
Critical naturalism argues that the transcendental realist model of science is 
equally applicable to both the physical and the human worlds. However, 
when we study the human world we are studying something fundamentally 
different from the physical world and must therefore adapt our strategy to 
studying it. Critical naturalism therefore prescribes social scientific method 
which seeks to identify the mechanisms producing social events, but with a 
recognition that these are in a much greater state of flux than those of the 
physical world (as human structures change much more readily than those 
of, say, a leaf). In particular, we must understand that human agency is made 
possible by social structures that themselves require the reproduction of 
certain actions/pre-conditions. Further, the individuals that inhabit these 
social structures are capable of consciously reflecting upon, and changing, 
the actions that produce them—a practice that is in part facilitated by social 
scientific research. 
Critical realism has become an influential movement in British sociology and 
social science in general as a reaction to, and reconciliation of, so-called 
"postmodern" critiques. 
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270713.  
Inspired by Charmaz model of ways of telling 
Coding data for staging and spontaneous disclosure, notice that where I had 
used ‘being open’ these were quite often staged prononouments not 
spontaneous declarations.  Not being open in the normal everyday sense. 
 
Staging might be formalized such as asking for annual leave in order to 
attend appointments 
 
New code emerging from the data  
 
LOOKING AT SMALLER SAMPLE FIRST 
Spontaneous and staged seemed inadequate to explain how they might be 
forced by circumstances to disclose so I added an extra code  
 
Who did they disclose their treatment to?  Usually owner of business/ 
director/ manager or colleague or during interview.   
Sometimes they were sympathetic and sometimes they were not 
 
No mention of spontaneous disclose to colleagues or friends but that is 
probably due to bias in my question. 
Sometimes forced to disclose their need for treatment because they could 
not leave work easily for appointments. 
What did they tell them? Trying for a baby, waiting for treatment, needing 
time off for treatment, taking a fertility drug, hoping to go part time in the 
future.  The focus is on the demands of treatment rather than internal drivers  
 
Social conditions affecting disclosure:  
It depends on the manager, working in a child centred or friendly 
environment such as school or nursery, working for a forward thinking 
company, all had positive associations 
 
smaller size of company, city worker, call centre, had negative associations 
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How did they tell them? During annual review or job interview, as part of an 
application for annual leave these would be structured and staged 
opportunities.  Also during a car journey and asking for a quiet word show 
premeditated intention to disclose treatment.  Asking for time off to attend 
appointments so the demands of treatment dictate the need for disclosure. 
 
 
THOUGHT 
 
DOES DISCLOSURE WORK DIFFERENTLY AT WORK, ARE PEOPLE 
USING THE FORUM FOR AN OPPORTUNITY TO HAVE SPONTANEOUS 
DISCLSURES BUT AT WORK THEY HAVE TO BE MORE GUARDED AND 
MEASURED. 
 
HOW DOES FLAUNTING FIT IT? CHARMAZ  
 
THE RISK OF TELLING VRS THE POSSIBLE BENEFITS RECEIVED 
FROM TELLING MIGHT EMERGE AS A THEME ON THE LARGER 
SAMPLE (82)  FORUM MINIMISES THIS RISK BY PROVIDING 
ANONYMOUS OUTLET FOR TELLING AND RECEIVING SUPPORT 
 
 
270713 
 
If you look at the quotes for the being open codes from the large sample you 
can divide them into different categories depending on whom they have told: 
 
TELLING WORK (186, 2)  186 was prompted by the need to work part time 
SO NOT SPONTANEOUS 
 
I eventually also told work too when I requested to go part time which helped 
enormously…Had to pop into work that afternoon for a meeting with my 
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boss, let her know as best as I could. 
 
 
NOT TELLING WORK 170,89,82,72,25,24)   and the reasons for not telling 
include (aggregated quote): I work in a hospital environment and have to 
deal with seeing people who are pregnant and with children all the time, I 
have created a professional and cold shell I put up to allow me to function .. I 
am not telling work either, my job is quite pressured and I couldn't stand the 
speculation. When I was having treatment I didn't tell anyone at work 
although I was tempted on several occasions. I'm really glad I didn't. It was 
hard getting over the disappointment privately so dealing with other people 
too wouldn't have suited me. It also meant at work I could temporarily forget 
about it… We have to keep things very quiet here at work, for many reasons, 
so getting the time/dates to do it is proving a bit of a nightmare.. I haven't told 
work anything yet - I think I may have to but very reluctant - especially as its 
such a small team, there are about 10 employees. 
TELLING FRIENDS AND FAMILY: 198, 186,65, 82170,186,82,72,65,100,61 
AGGREGATED QUOTE 
we finally told our families and very close friends what was going on.  We'd 
wanted to keep it private but actually telling others was helpful - especially 
my family.. .We told lots of people about the ICSI. We wanted people to 
understand and we wanted their support and help. We knew we'd be in 
pieces if it didn't work. And people seemed surprised, particularly by our 
frankness, but supportive and encouraging.. I've told people, I can't keep my 
mouth shut about anything!.. but I have gradually started to open up about 
this .. I was so sad to give up on this surprise element.. but the loneliness 
was just too much to bear. So we have gradually starting telling people.. 
….Telling my friends was hard (silly pride) but having one of two people you 
can really open up to aside from your partner I think is a real comfort. , i have 
had to carry out all past procedures in secret apart from a few close friends 
and family members. 
 
NOT TELLING FRIENDS AND/OR FAMILY 144,198,89,25,24,72,65 
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We are optimistic about this but age is against us, im 36 and dh is 37.  We 
havent told anybody about our if so when we found this website it was a 
godsend and provides the needed support although to date we havent come 
across anyone in the exactly the same position…I have chosen not to tell 
many people because I do not think people understand unless they have had 
to deal with IF themselves. DH struggles to talk about it although he does talk 
more since the IVF. But I do not think men have the same need to talk as we 
do and of course Male Factor IF does have a big impact on the male 
ego...We've had three cycles in all now, ending in BFNs, but we've really 
kept everything to ourselves since that first time, which I don't think is healthy 
He on the other hand refused to discuss any of it, completely shut me out of 
everything and stuck his head in the sand (plus he didnt want me to talk to 
anyone either, got very upset if i mentioned wanting to speak to any family or 
friends and all but forbid me to even speak to my mum!!).  Eventually the 
strain became too much and we split…..We haven't told friends or family, we 
are quite private and want to do this our way….I've told a few close friends 
but not a wide circle of people that we're ttc. In a way the more people you 
tell the more pressure you put on yourself. After all the end of your story to 
conceive might (sadly) be a bit of a way off,. Being so far away from family 
also was very hard, although I've kept all this away from my Dad. We lost 
Mum last year and he has had a lot to deal with and I don't want him worrying 
about me at the moment. I could have done with a good cry and natter with 
my wonderful Mum that day though, I can tell you… I have had to carry out 
all past procedures in secret apart from a few close friends and family 
members 
We have decided not to tell anyone about our situation and over time a lot of 
people have stopped asking us questions. we don't want to tell people when 
we do it in case it doesn't work 
. 
 
 
TELLING FORUM 144,100,89,65,9 
We are optimistic about this but age is against us, im 36 and dh is 37.  We 
havent told anybody about our if so when we found this website it was a 
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godsend and provides the needed support although to date we havent come 
across anyone in the exactly the same position… - hence finally, so very late 
in the day, joining in the forums, although I have been reading your posts and 
thoughts and feelings. I can't say how much they have helped me through 
some dark times. This site really is an outlet for me to share and understand 
others experiences, even more so for us as our decision to keep this to 
ourselves will no doubt be difficult.  I am in my Mid thirties.  Can aNyone help 
me in my isolation , i have had to carry out all past procedures in secret apart 
from a few close friends and familly members 
1 
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1 
THIS LED ME  
  RISKS BENEFITS 
TELLING F & F being misunderstood 
emotional pain to self 
and others 
disappointment at 
treatment failure 
loss of privacy 
receiving 
support and 
understanding 
NOT TELLING F & 
F 
not receiving support 
and understanding 
creates a sense of 
isolation 
protects 
privacy  
TELLING WORK loss of earnings  
disapproval from 
manager 
career prospects 
damaged 
discrimination 
being misunderstood 
loss of privacy 
support and 
understanding 
flexibility for 
time to attend 
treatment 
NOT TELLING 
WORK 
disciplinary action 
and  
loss of earnings for 
time off 
not receiving support 
and understanding 
maintain 
privacy and 
professional 
role 
TELLING VIA 
FORUM 
negative experiences 
reported by  
support and 
understanding 
with privacy 
due to 
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anonymity 
 
 
NOTE  SMALL COMPANY CAUSING PROBLEMS MIGHT LINK TO 
JERSEY BEING SMALL COMMUNITY 
Telling or not telling as a form of control 
to our earlier observation, all participants in the present study had access to 
the 28/07/13 A PRACTICAL ITERATIVE FRAMEWORK FOR QUALITATIVE 
DATA ANALYSIS (Srivastava, 2009)  
The role of iteration is to develop a deeply reflexive processs which sparks 
insight and develops meaning.  By visiting and revisiting the data you 
progressively develop refined focus and understanding.  Srivastava has 
developed a framework of three basic questions to engage with the data 
analysis process. 
Question one is WHAT ARE THE DATA TELLING ME? 
Q2 WHAT IS IT I WANT TO KNOW? 
Q3 WHAT IS THE DIALECTICAL RELATIONSHIP BETWEEN WHAT THE 
DATA ARE TELLING ME AND WHAT I WANT TO KNOW? 
 
SO  
Q1 What are the data telling me?  That women who post their story on 
infertility forums are using the forum to share their story without loss of 
privacy.  That the stories contain a lot of emotional distress and not much  
about employment issues.  If you specifically ask for information about work 
stress then a small sample of women will tell you that they have experienced 
conflict between their identity as an employee and as a treatment seeker.   
Where they have chosen to disclose their treatment status or condition they 
have done it in the context of the process they are engaged in and often 
because time was needed off work for treatment or appointments.  
Sometimes it is formalised as part of a performance review or interview. 
If you look at the larger sample and specifically at the codes for being 
open/nondisclosure then you see that the reasons for not telling vary from 
protecting privacy, avoiding emotional pain and disappointment at failed 
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treatment to maintaining a professional role, avoiding additional pressure or 
speculation, working in a small team. 
The reasons for telling work include needing to ask time off but not many 
quotes available 
Question two , what is it I want to find out?  I want to know if pressure of work 
inhibits women from taking part in clinical trials. 
Question three what is the relationship between q1 and q2?  We can see that 
a few women are concerned with the difficulties of managing the conflict 
between work and treatment but that the majority of their concerns are 
around emotional distress and treatment failure. 
 
Discussion 
We could detect three online behavioural styles in IVF patient couples: an 
‘individual information style’, a ‘generic information style’ and a 
‘communication style’. There are only a limited number of correlations 
between these styles and demographics or coping mechanisms: patients 
having paid employment are significantly less attracted to individual 
information and significantly more to communication functions. Patients who 
exhibit the coping mechanism of sharing of emotions show less attraction to 
individual information. Although only a trend was observed, patients with a 
more depressive mood seem less likely to look for information concerning 
their own treatment and more likely to use the website to find generic 
information concerning the IVF treatment. A longitudinal study would explain 
this relationship in more detail. The positive relationship between anxiety at 
the start of the treatment and the ‘communication style’ suggests that more 
anxious patients are more likely to use the bulletin board (which provides 
asynchronous web communication) and the chatroom (for synchronous web 
communication) functions of the website. 
It is possible that they communicate on the website as a way to relieve their 
anxiety. In a larger sample size, it would have been possible to investigate 
possible interaction effects between online behavioural style, coping 
mechanisms and anxiety and depression. 
The lack of correlation between the behavioural styles and the demographic 
variables ‘household income’ and ‘ethnic background’ is notable. In previous 
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research by Haagen et al. (2003), both variables were significant predictors 
of overall internet usage, whereas in the present study, they are not. This can 
be attributed to differences in both study populations. In contrast 
Internet.(Tuil et al., 2008) 
 
 
070813  just realised whilst reading (Silverman, 2013) that my focus on the 
work related concerns of women seeking infertility treatment could also 
reflect my own concerns as a working mother doing a PhD.  There is the 
issue of the need to negotiate time off for non work activities such as Hospital 
appointments for self and child. 
 
 
 
 
 
 
 
 
 
080813  Decided to use itartive analysis and check my model with the forum 
again.  No need to ask administrators for permission as there is a special 
section for research questions so posted my question  at 10.22 on Thursday 
8th August 2013  Screeen shot attached 
 
 
 
Hi, a few months ago I asked for your stories about telling work that you were 
having treatment.  I wanted to say thanks to those people who replied.  I 
have been thinking about their stories and it seems that there are both risks 
and benefits to telling or not telling others about your treatment.  'Others' 
might include work, friends or family.  I wanted to check my ideas with the 
forum and so if anyone would like to comment on the model I have put 
together then please email me on c.haresnape@qmul.ac.uk.  This 
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information is being used as part of my PhD thesis and your information will 
be anonymised if it is used.  Quotes from individual posters can be 
aggregated together to avoid them being tracked back to you via search 
engines.  My model of risk and benefit is as follows: 
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  RISKS BENEFITS 
TELLING F & F Being misunderstood 
Emotional pain to self 
and others 
Disappointment at 
treatment failure 
Loss of privacy 
Receiving 
support and 
understanding 
NOT TELLING F & 
F 
Not receiving support 
and understanding 
Creates a sense of 
isolation 
Protects 
privacy 
TELLING WORK Loss of earnings 
Disapproval from 
manager 
Career prospects 
damaged 
Discrimination 
Being misunderstood 
Loss of privacy 
Support and 
understanding 
Flexibility for 
time to attend 
treatment 
NOT TELLING 
WORK 
Disciplinary action 
and 
Loss of earnings for 
time off 
Not receiving support 
and understanding 
Maintain 
privacy and 
professional 
role 
TELLING VIA 
FORUM 
Negative experiences 
reported by others 
might be 
overwhelming. 
Support and 
understanding 
with privacy 
due to 
anonymity 
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The tables did not come out properly so it appears as a list 
 
The hunch that I am following is that women negotiate between the risks and 
benefits by disclosing information at work in a controlled and premeditated 
way to maximise benefit and minimise risks.  The uncertainty inherent in their 
situation is that there is not legal framework to support their position.  
Perhaps the problem with taking part in a clinical trial is that it forces 
disclosure and maximises risks.  Also the benefits to taking part in a clinical 
trial where they might receive a placebo might not be strong enough to 
balance the risks. 
 
 
 
IDEAS FOR NEW STRUCTURE OF QUALITATIVE CHAPTER SEE RED 
HANDWRITTEN NOTES 
Reflections on David Silverman’s Doing Qualitative Research 
 
2.1 My decision to use qualitative research methodology was because of the 
nature of the research question rather than starting off using qualitative 
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research and thus it influencing the way I defined my research problem.  The 
method emerged from the direction that the project took.  Silverman calls this 
‘how biographical factors play an important role in how students plan their 
research..’ page 8 
 
Exercise 2.2 
Explain why you think a qualitative method is appropriate to your own 
research project? 
 
I was trying to find out how women undergoing infertility treatment feel about 
attending appointments and having to ask for time off work.  We wanted to 
know if this was stopping them being recruited for my trial.  My original trial 
design intended to offset the advantages of a questionnaire and the rct 
design.   I felt it would have more credibility if it included a qol questionnaire 
as well as just their clinical results. 
 I moved to investigate the reasons because I was sampling a new 
population to create completeness in my study.  To some extent the situation 
in Jersey was an unexpected result and new insights needed to be found 
 
Would quantitative methods be more appropriate and if not why not? 
This would mean I needed access to numerical data for example the 
employment records of women showing how many days off they had 
requested or how many appointments were attended at the clinic.  This 
would not answer the question about why they did NOT attend appointments 
due to pressures at work.  It would not tell me how they perceived the trial or 
their feelings about taking part. 
 
Would it make sense to combine qualitative and quantitative methods? 
 
If we could get access to data about the number of appointments attended or 
we could analyse the responses of women in Jersey to a questionnaire (Qual 
or quan?) then that would give me a deeper understanding of the pressures 
they faced and the scale of the issue. 
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Notes on Integrating quantitative and qualitative research: how is it done? 
(Bryman, 2006a) 
The dimensions out of which the different typologies are constructed are 
useful: 
Are the quantitative and qualitative data collected simultaneously or 
sequentially?  In my case the quantitative data was the primary source but 
was insufficient and then we moved to qualitative data as a secondary 
source ( before analysis of the primary data). 
2. Which has priority – the quantitative data or the qualitative data?  In my 
case the qualitative data overtakes because of the failure to recruit sufficient 
women to the study. 
3. What is the function of the integration for example triangulation, 
explanation or exploration.  I would say mine was an exploration as we were 
looking for something that had been suggested.  It was also an attempt to 
develop a theory. 
At what stage in the research process does multi-strategy research occur?  
In my case it occurred after the initial research question  and attempts at data 
collection and it occurred as part of the data analysis. 
Is there more than one data strand?  Yes we had the initial trial, the small 
sample and the larger sample 
What are the justifications for combining quantitative and qualitative 
research?  Greene et al 1989 has a scheme which isolates five justifications: 
Triangulation: convergence, corroboration, correspondence or results from 
different methods.   Seeking corroboration between quantitative and 
qualitative data. 
Complementarity:  seeking elaboration, enhancement, illustration, 
clarification of the results from one method with the results of another 
Development:  seeks to use the results from one method to help develop or 
inform the other method, where development is broadly construed to 
included sampling and implementation as well as measurement decisions. 
Initiation: seeks the discovery of paradox and contradiction, new 
perspectives of frameworks, the recasting of questions or results from one 
method with questions or results from the other method. 
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Expansion : seeks to extend the breadth and range of enquiry by using 
different methods for different inquiry components 
This scheme is parsimonious and so Bryman has devised a more detailed 
scheme based on the extensive review of the kinds of reasons that are 
frequently given for combining research methods: 
1. Triangulation or greater validity refers to the traditional view that 
quantitative and qualitative research might be combined to triangulate 
findings in order that they be mutually corroborated. 
2 Offset: combining methods allows the author to offset the strengths and 
weaknesses of each method. 
3.  Completeness, combining methods means that the researcher can bring 
together a more comprehensive account  
4. Process, quan can provide an account of the structures in social life but 
qual can proved a sense of process. 
5. Different research questions 
6 Explanation one is used to help explain findings by the other 
unexpected results 
Instrument development 
Samplings 
Credibility 
Context 
Utility 
Confirm and discover  use qual data to generate hypotheses and quant 
research to test them 
Diversity of views  
Enhancement 
 
 
Key points from page 41, ‘treat your relations within the field as data’, this 
study was characterised by delays and difficulties in communication with 
supervisor and site staff.  The difficulty in setting up a reliable audit of the 
study via the site nurse and the effect of my expectations of her are an 
example.  I should have made those expectations clear at the earlier 
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meetings with Neil.  If I analyse my research diary how many times do I say 
that I am waiting for a response or that there is no response? 
 
Date Diary Entry 
130310 Waiting for letter of confirmation from JGH Ethics  
000510 Waiting for AJ to arrange patient insurance 
130710 Left message for AJ asking for tutorial 
201010 Meeting with NM at JGH cancelled at short notice as he is flying to 
London to give evidence in a court case 
 
Page 47  I realise that I need to sort out the methodology of using internet 
data, although I have looked at the ethical issues around using it I also need 
to think about the methodological literature on analysing internet data. 
 
http://webometrics.wlv.ac.uk 
 
 
In comparison to content analysis, grounded theory has the advantage that it 
produces theories from the texts and the outcomes can be more interesting 
as a result. A key disadvantage is that the method is non-scientific in the 
sense that the results are not normally based upon random samples of texts 
and there are no real safeguards against researcher bias. In contrast, 
content analysis can use multiple coders to guard against bias. With 
grounded theory the onus is on the researcher to make the case that the 
findings are a valid interpretation of the texts.(Thelwall, 2009) 
Silverman page 57 recommends the work of Helen Snee a British Sociologist 
based at Manchester.  I listened to her youtube video 
http://www.youtube.com/watch?v=k-iBE-CLg2k and found her ideas 
promoted me to think about the differences between my large and small 
samples: 
 
The small sample was constructed because I actively solicited information by 
posting a question on the forum.  I am a participant observer 
APPENDICES 
Appendix	  	  12	  Memos	  Written	  During	  Qualitative	  Data	  Analysis	   992	  
 
The large sample is naturalistic because I viewed the work that members had 
spontaneously posted.  I am unobtrusive and an observer only. 
 
The Methodological issues that she encountered and that resonated with me 
included: 
The biased nature of the sample in that it only captures the views of those 
people who have posted on the forum. 
The ethical challenges of how to view the members of the forum, are they 
private individuals who need to have their identity protected or are they 
authors whose work should be cited?  She resolved this by taking a view that 
it is contextually dependent not black and white … 
One key to this might be that the intended audience for my members is other 
people suffering from the same or similar conditions, who may be unknown 
to them, rather than friends or family known to them.  In her study of gap year 
students the blogs were used to update people they knew about their 
progress. 
 
Using a forum rather than a blog like she did reduces the amount of 
redundant data needing to be trawled through, it was a more focussed 
approach. 
 
It has an interactive element ( I post questions and become a participant 
observer) and also I can chose to look beyond the initial posting to view the 
comments made by members about each others work, (I am observing only) 
 
 
 
10.08.13  gone back to forums to saturate categories with further data 
Tried doing word searches on ‘boss’, ‘job’  saved as separate files.  Also 
looking more closely at the conversations between forum members 
11.08.13  Working on chapter 7 Using Theories of Silverman book 
page 108-109 Grounded Theory 
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a defining strategy of grounded theory is theoretical sampling in order to flesh 
out the properties of a tentative category.  As Charmaz and Bryant put it: 
Theoretical sampling involves gathering new data to check hunches and to 
confirm that the properties of the grounded theorist’s theoretical category are 
filled out…’ 
Theoretical sampling helps develop grounded theories based on situation 
and concepts which are progressively widened by : 
Including social situations very different from those with which one began 
Linking concepts to broader theories 
 
This reflects two key features of the GT approach: 
The constant comparative method as the analyst seeks out settings which 
may modify or broaden her initial categories 
A continual movement between data, memos and theory so that data 
analysis is theoretically based and theory is grounded in data. 
 
Because of the difficulties with my initial thesis draft I have returned to 
theory and returning to theory has stimulated me to revisit the data, the 
literature and the forums in search of theoretical sampling. I have 
become ITERATIVE 
 
I now wonder if the earlier work I did on the homotoxicology treatment and 
the nurses focus group are indeed grounded theory??  I suspect that they do 
not fulfil that criteria and might be better described as a survey. 
 
WATCHING PROF TONY BRYANT ON YOUTUBE AS SUGGESTED ON 
PAGE 109 
Should our methods be prescriptive, advisory or heuristic? 
Crtiques the Corbin book as mechanistic but it made GT popular 
GT is a ‘family of methods’  
Grounded means theory is grounded in the data, get your data from the 
research context.  Discovery or construction?  We prefer constructionalism 
because it takes into account that different people will construct different 
meanings from the same data 
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Peirce the pragmatist, you try and find patterns but how you come across 
those patterns may be suprising (abduction) not induction or dedeuction. 
 
Using the literature is a problem because, Glaser (keeping an open mind 
means don’t engage with the literature).  Quick and Dirty method?   
 
 
110813  Reading through the forum postings one way women negotiate time 
off work is to be signed off for stress. 
Channel Islands? 
Posted by: Research Student - 11 Aug 13 09:08 Send a message to this 
person 
 
Hi, I have already posted some details of my PhD study based at Queen 
Mary University of London. The data I obtained from your responses was 
used to help me understand the experiences of women who have to juggle 
work and treatment commitments.  I would be interested to interview (via 
email) men and women based in the Channel Islands as part of my 
analysis.  Any information provided would be used anonymously.  My study 
has ethical approval from Jersey General Hospital. If you would be interested 
in sharing your experiences with me my email address is 
c.haresnape@qmul.ac.uk   
Thanks and best wishes 
Claire Haresnape 
Post Graduate Research Student 
Queen Mary University of London 
See more at: 
http://www.infertilitynetworkuk.com/forums/topic/18125/Channel%20Islands?
#sthash.nfavOHi9.dpuf 
 
Key points from page 119 
Models provide an overall framework for how we look at reality 
Concepts are clearly specified ideas deriving from a particular model 
Theories arrange sets of concepts to define and explain some phenomenon 
APPENDICES 
Appendix	  	  12	  Memos	  Written	  During	  Qualitative	  Data	  Analysis	   995	  
Methodologies define how  one will go about studying any phenomenon 
Methods are specific research techniques 
 
My Study   
 
 
Model = Constructionism or Naturalism?  If I use thematic analysis I can use 
both methods.  See notes on thematic analysis 
 
 
 
 
Concept = Definitions of the situation, how do women undergoing infertility 
treatment construct their reality in the face of strong emotional pressures and 
a lot of uncertainty about treatment success and the absence of a clear legal 
framework or company policy 
 
 
 
 
Theory = Risks and Benefits of disclosing infertility treatment at work =  
consequence theory. 
 
 
 
 
Hypothesis = Women undergoing infertility treatment are trying to 
minimise the risks of disclosure and taking part in a trial may force 
disclosure without producing additional benefits 
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Methodology =  naturally occurring data ( theoretical thematic analysis), and 
data received in response to posting on forum (theoretical thematic analysis) 
 
 
 
 
Methods = observing, recording, semi structured online interview, analysis of 
text, iterative process of returning to forum with theory or model to share, use 
of theoretical thematic analysis to create a theory (Grounded Theory 
Charmaz style). 
 
 
 
 
Findings = Concerns of women undergoing infertility treatment 
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Chapter 8  Choosing  Methodology 
There are no right or wrong methods there are only methods that are 
appropriate to your research topic  and the model with which you are 
working. 
Observation is fundamental to understanding another culture 
Textual analysis helps understand participant’s categories 
Interviews consist of open ended questions to small samples 
 
 
Method Naturalists Constructionists 
Observation Understanding 
Subcultures 
Asking both ‘what’ and 
‘how’ questions to 
understand how 
interaction is organised 
Texts and Documents Background Material Understanding of 
Language and other 
sign systems 
Interviews Understanding 
experience 
Narrative construction 
 
When we analyse text from the forum how can we be sure that it reflects their 
social or psychological world? 
 
Reflect that I could have approached this study with a naturalistic approach 
by looking at the My Story section of the forum first, immersing myself in that 
data and then looking for categories.  Instead I took a constructionist 
approach because I created data by setting up a research question on the 
forum and then  I imposed these categories on the data from ‘My Story’.  Or 
did I seek to discover them!!  I sought them would be a better description.. 
 
Exercise 8.1 
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The data source open to me are the uk infertility forums online such as INUK 
and Fertility Friends. 
These can give me naturally occurring data that tells participants experiences 
in their own words as well as interactions between different participants as 
they respond to posts from each other. 
They can help me understand the fears and hopes, social pressures, medical 
treatments, relationships and physical effects of those women and men 
undergoing infertility treatment. 
This might help me understand how they construct their reality to cope with 
the success and failure of treatment in a very uncertain arena with high 
failure rates and high expectations\high stakes.   
This could help me understand how they might view taking part in a clinical 
trial where they might receive a placebo, how they view disclosing their 
treatment at work 
 
 
Query: is information from a forum naturally occurring data? 
Query: how might I identify deviant cases when I am trying to saturate my 
data? 
 
 
Query: what other situations might my model fit so that I can create a 
generalised formal theory as opposed to a substantive theory.  What about 
the risks and benefits of disclosing HIV status, disability, homosexuality, 
terminal illness? 
(Rouleau et al., 2012) sheds some light on this idea: 
 
Various conditions can influence disclosure. These include the confidant’s 
ability to keep a secret, whether or not a climate of trust exists, a feeling of 
closeness and intimacy, the nature of the relationship (sexual or non-sexual), 
the consequences anticipated, one’s perception of being stigmatized, and 
prior disclosure experiences [8,20,27,28]. In light of these conditions, 
interpersonal relations are clearly central in the decision to disclose or not. 
HIV-positive persons must choose carefully who they reveal their serostatus 
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to [27,29-31]. Moreover, it appears that there is a prior evaluation of the 
rewards and costs of disclosing to family and friends before disclosure 
occurs, which is supported by Consequence Theory [10,32]. This theoretical 
model proved useful in explaining disclosure in a study involving 125 HIV-
positive women [10]. The principal rewards (benefits) for these WLHIV had 
more to do with the safety of others and their right to be informed than with 
oneself. The perceived costs (negative consequences) were in connection 
with the negative aspects of breaking the news, such as the fact of being 
reprimanded [10]. Disclosure occurs if the person perceives the benefits to 
outweigh the negative consequences and if it can thus avoid situations likely 
to cause harm [32](Rouleau et al., 2012) 
What is consequence theory? How does this fit the theory I have devised? 
 
 
 
(Corrigan et al., 2009)  Table 1 Perceived contingencies affecting coming out 
Benefits 
person to bring together many important people and issues into one’s 
experience. 
Participants also noticed interpersonal costs of coming out to family and 
friends. These are sometimes poignant and may lead people into thinking 
they were better in the closet. ‘‘I am still saddened by my parent’s response. I 
went from being the super-star daughter who does all these wonderful things 
to being, ‘Oh well, we only expect this from you’’ [Suzy]. This forces some 
people back into the closet. ‘‘You know, I didn’t want to hurt my mom, 
because she cried and she didn’t talk to me for a whole month. So, if I were 
to stay in the closet, it would probably be because of family’’ [Betsy]. 
Acceptance may also have meaning at the personal level; namely, 
recognition and acknowledgement that being gay or lesbian is part of what 
significantly defines the person’s identity. This kind of awareness is 
fundamental to his or her identity. 
Well, I know it’s something I can’t change. With enough of a career change I 
could start to feel like a different career person. If I move, I won’t feel like a 
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Chicagoan and if I change religions I won’t feel Jewish. But I think gay is so 
innate and so much a part of me that it’s very close to who I am [James]. 
For some individuals, the many pains of acknowledging or taking on a 
stigmatized identity result in decisions to never come out, to never accept the 
experience for them- selves, and to never obtain solace from others. ‘‘If I 
could choose this life again, I would be wealthy by now and I would not be 
gay... The lifestyle... It’s too much weight for one person to carry’’ [Simon]. 
Suzy said ‘‘But I think at 
 
Acceptance: The place to begin is seeking recognition and support of key 
people in one’s social network, most prominently including family but also 
friends, coworkers, peers in a faith congregation and others. This is social 
acceptance which is distinguished from self-acceptance. Gay men and 
lesbians seek to acknowledge their sexual orientation for themselves without 
disparagement or shame. As people learn to accept themselves, 
opportunities emerge for gay men and lesbians to acknowledge their multi-
faceted and complex self. This kind of honesty opens the person for greater 
acceptance and a more integrated and positive sense of self 
Community: One way in which gay men and lesbians have learned to deal 
with discrimination is through the development of a gay community. As gay 
communities matured, members sought to spread their hegemony. Groups of 
gay men and lesbians organized to address obvious discrimination as well as 
more subtle forms of prejudice. Another goal of actively participating in the 
gay community is to provide opportunities for peers who continue to struggle 
with discrimination. This kind of altruism generalizes to an overall concern 
about the well-being of members of the community 
Comfort and Happiness: Coming out and personal acceptance have the most 
basic of effects on gay men and lesbians. This experience is variably enjoyed 
as relief, freedom, and opportunity. With comfort comes the most deep-
seated experiences of life satisfactions: happiness. One way this emerges is 
a sense of optimism about sexual orientation 
Costs 
Shame and Conformity: This is the sense of failure that results from and the 
stigma of gays and lesbians. One way to protect one’s self from the shame 
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and other egregious effects of public attitudes about being gay is to conform 
sexually, to pass as heterosexual 
Harm and Discrimination: Gay men and lesbians often lose opportunities in 
the world of work, as well in finances, with family, and in health. Moreover, 
many people who are out with their sexual orientation are physically or 
verbally assaulted by the public. Pronounced struggles with coming out and 
being in the closet impact people both psychologically and physically 
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110813 
See below for good example of how you achieve credibility in your study. 
 
 
Credibility is, according to Lincoln and Guba [43], one of the most important 
criteria for establishing trustworthiness. Results are credible when the 
phenomenon under study is recognized by participants and experts and it 
reflects their personal experience [43,44]. The authenticity criterion refers to 
the fact that results must be in line with or reflect the experiences described 
and lived by participants [44]. In the aim of meeting these criteria, the 
principal investigator: used bracketing; read the interviews many times over; 
went back and forth between data collection and analysis; reached data 
saturation; used peer reviewing and held debriefing sessions with the two 
research directors (supervisors) regarding the data collected, analysis and 
interpretation.(Rouleau et al., 2012) 
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Notes on Thematic Analysis (Braun and Clarke, 2006a) 
 
Thematic analysis should be seen as a foundation method for qualitative 
analysis, providing core skills that will be useful for other forms of QA. 
Qualitative methods can be roughly divided into two camps: 
those that are tied to or stemming from a particular theoretical or 
epistemological position.  For example conversational analysis (CA); 
interpretative phenomenological analysis (IPA), Grounded Theory, Discourse 
analysis, Narrative analysis, 
Methods that are essentially independent of theory and epistemology and 
can be applied across a range of theoretical and epistemological 
approaches. 
 
KEY TERMS 
Data corpus refers to all data collected for a particular research project 
Data set refers to all the data from the corpus that is being used for a 
particular analysis 
Your data set might consist of many or all individual items within your data 
corpus or it might be identified by a particular analystic interest 
Data item is used to refer to each individual piece of data collected 
Data extract refers to an individual coded chunk of data that has been 
identified within and extracted from a data item. 
. 
WHAT IS THEMATIC ANALYSIS 
 A method for identifying, analysing and reporting patterns (themes) within 
data.  It minimally organises and describes your data set in (rich) details.  It 
often goes further than this and interprets various aspects of the research 
topic.  The range of different possible thematic analysis relate to a number of 
decisions regarding method. 
 
The language of themes emerging: 
‘can be misinterpreted to mean that themes reside in the data …but if they 
reside anywhere they reside in our heads from our thinking about our data 
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and creating links as we understand them (Ely,Vinz, Downing, & Anzul, 
1997:205-6)  
((taken from page 7 of paper)) 
 
page 8: a named and claimed thematic analysis means researchers need not 
subscribe to the implicit theoretical commitments of a ‘full-fat’ grounded 
theory if they do not wish to produce a fully worked-up grounded theory 
analysis. 
 
IMPLICATIONS FOR MY STUDY, I HAVE ACTUALLY USED THEMATIC 
ANALYSIS TO LOOK AT THE PRACTITIONERS AND NURSES DATA NOT 
GT SO NEED TO CHANGE THAT. 
 
TA can be an essentialist or realist method which reports experiences, 
meanings and the reality of participants or it can be a constructionist method 
which examines the ways in which events, realities, meanings and 
experiences and so on are the effects of a range of discourses operating 
within society. (Page 9).  The important thing is to make your theoretical 
position transparent. 
 
What counts as a theme? 
A theme is something which captures something important about the data in 
relation to the research question and represents some level of patterned 
response or meaning within the data set. 
 
Prevalence of  a theme might refer to the number of participants who 
mention it or to the number of times it appears in the total dataset. 
 
A rich description of the data set, or a detailed account of one particular 
aspect 
  
It is important to decide if you want to provide a rich thematic description of 
your entire data set so your reader gets a sense of the predominant or 
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important themes or you might wish to provide a more detailed and nuanced 
account of one particular theme or group of themes within the data. 
 
Inductive vrs theoretical thematic analysis 
Themes or patterns can be identified in one of two primary ways in thematic 
analysis: 
Inductive or ‘bottom up’ way   this means the themes are strongly linked to 
the data themselves it is a process of coding the data without trying to fit it 
into a pre-existing coding frame or the researches analytical preconceptions 
Theoretical or ‘top down’ way means it is driven by the researchers 
theoretical or analytic interest in the area. 
You can either code for a specific research question (theoretical approach) or 
the specific research question can evolve through the coding process ( 
inductive approach). 
 
Epistemology: essentialist/realist vs constructionist thematic analysis 
The research epistemology guides what you can say about your data and 
informs how you theorise meaning. 
For example with an essentialist/realist approach you can theorise 
motivations, experience and meaning in a straight forward way, because a 
simple, largely unidirectional relationship is assumed between meaning and 
experience a and language (language reflects and enables us to articulate 
meaning and experience). 
In contrast from a constructionist perspective, meaning and experience are 
socially produced, rather than inhering within individuals.  Therefore, 
thematic analysis conducted within a constructionist framework cannot and 
does not seek to focus on motivation or individual psychologies, but instead 
seeks to theorise the socio-cultural contexts and structural conditions that 
enable the individual accounts that are provided.   
 
Doing thematic analysis a step by step guide 
 
The process begins when the analyst starts to look for patterns of meaning 
and issues of potential interest in the data. 
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Writing is an integral part of analysis not something that takes place at the 
end 
Engaging with the literature early on can sensitize you to more subtle 
features of the data or some would argue that it narrows your field of view. 
 
A more inductive approach would be enhanced by not engaging with the 
literature in the early stages of analysis whereas a theoretical approach 
requires engagement with the literature prior to analysis. 
 
question. 
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150813 
the previous posts were removed and this was sent today 
It was approved by Hannah and posted on 160813 
 
Dear Hannah 
 
I would like to post a research question on the INUK forum please.  Last year 
some of your forum members responded to my enquiries about their work 
related stress.  I have been using their responses as part of my PhD project. 
The PhD was initially the design and implementation of a small clinical trial of 
a homeopathic product to support infertility treatment at a unit in Jersey. 
The trial had to be closed down due to poor recruitment. 
I then switched to investigating the reasons for poor recruitment and it was 
most helpful to get feedback from the forum. 
I have used their responses to create a 'risk-benefit' theory that I would like to 
share with forum members for their feedback. 
 
My question would look something like this: 
 
Last year some of the forum members supported by PhD project by sharing 
their experiences of work related stress, I have used the data provided to 
generate the following theory and I would appreciate your feedback about it: 
 
The risks of telling employers about treatment need to be balanced against 
the benefits of disclosure.     
 
The risk of disclosure may include increased stress at work due to 
expectations of treatment success, emotional distress at treatment failure, 
being misunderstood, sexual discrimination for time taken off work for 
treatment, loss of earning or career prospects, having to use annual leave for 
treatment.   
 
The benefits of disclosure at work might include support and understanding 
from colleagues or managers, flexible working arrangements and relief at not 
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having to hide a secret.  Women who disclose their intention to have or 
participation in infertility treatment tend to do so in a controlled way, perhaps 
as part of formal request for time off , job interview or performance review.   
If a company has a clear policy or legal framework exists then the risks of 
disclosure are reduced ( added on 20.08.13) 
 
This allows them to finely balance the risks and benefits of disclosure vs non 
disclosure.  Taking part in a clinical trial that required them to attend 
additional appointments might force them to disclose their treatment and the 
benefits of taking part in a trial may not be worth this risk. Taking part in a 
trial may offer benefits but these are unknown particularly in a randomised 
trial where you might only receive a placebo. 
 
 
Please can you tell me if this is an accurate representation of how you would 
approach the dilemma of telling your employers about your infertility 
treatment 
 
Your réponses will be used as part of my PhD thesis but would be 
anonymised and used as an aggregated quote so that they cannot be traced 
back to you. 
 
Thank you for your help and best wishes 
 
 
Claire Haresnape 
Research Student 
Barts and The London School of Medicine and Dentistry 
Queen Mary University of London 
 
Email: c.haresnape@qmul.ac.uk 
Mobile: 07720060116 
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120813  QUERY TO SELF: SHOULD I BE OBTAINING ETHICAL 
APPROVAL FROM QMUL BEFORE POSTING QUESTIONS ON THE 
INTERNET?  ASK CR AND AT AND AJ?  Although the consensus was yes it 
was ok to proceed I removed the orginaial quotes and approached Hannah 
at INUK on 150813 to create a new post. 
 
 
190813 
 
Looking through my code segments of data for the original small sample I 
need to saturate those categories with more data but where to find it?  I have 
then moved to a small sample of the My Story forum… 
 
Exercise 8.1 
Possible research methods and data source options: 
Interviews with women who attended the clinic in Jersey.  Problems with 
access and ethics 
Questionnaire by post or phone with women who attended the clinic in 
Jersey, problems with access and ethics 
Questionnaire to employers in Jersey, tried to do this through the chamber of 
commerce but no reply or response from companies 
Interviews with women attending UK infertility clinics, need to form a 
relationship with a clinic and get ethics 
Questionnaire by post or phone for women attending UK clinic , access and 
ethics 
Posting questions on UK forum done this  
Contact other researchers who have conducted trials in Jersey or trials with 
infertile women. Doing this already. 
Interviews or questionnaires with HR and Employers 
What data sources and methods of data generation are potentially available 
or appropriate? 
The UK infertility forums 
+ 
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9 How many cases do you need? 
 
The aim  is to try and develop as full an understanding as possible 
Robert Stake has identified three different types of case study 
 
The intrinsic case study where this case is of interest in all its particularity 
and ordinariness.  No attempt is made to generalize beyond a single case or 
even to build theories. 
The instrumental case study in which a case is examined mainly to provide 
insight into an issue or to revise a generalization.  Although the case is 
selected and studied indepth the main focus is on something else. 
The collective case study where a number of cases are studied in depth in 
order to investigate some general phenomenon. 
 
 
Qualitative research should produce explanations which are generalizable in 
some way or which have a wider resonance. 
The Qualitative Model of Generalization 
Generalizability is a standard aim in quantitative research and is normally 
achieved by statistical sampling procedures. Such sampling has two 
functions: it allows you to feel confident about the representativeness of your 
sample and it allows you to make inferences about the broader population. 
 
 
The logic of random sampling may not work in qualitative research see page 
145 
In case study research: 
We generalize to theoretical propositions not populations 
We sample social relations not individuals 
We can test theories by choosing extreme or deviant cases 
We can choose new cases during our research, confident that this is not 
problematic but expected and useful. 
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Purposive sampling is guided by time and resources and researchers seek 
out groups settings and individuals where the processes being studied are 
most likely to occur. 
 
Theoretical sampling means selecting groups or categories to study on the 
basis of their relevance to your research questions, your theoretical position 
and the explanation or account which you are developing.  Theoretical 
sampling is concerned with constructing a sample which is meaningful 
theoretically because it builds in certain characteristics or criteria which help 
to develop and test your theory and explanation (Mason 1996 page 151 of 
Silverman book 
 
Theoretical sampling has three features: 
Choosing cases in terms of your theory 
Choosing deviant cases 
Changing the size of your sample during the research 
Doubt gate keepers on principal! Page 153 
 
Qualitative research can improve the generalizability of our findings by 
allowing us to include new cases after initial findings are satisfied. 
 
Replace ‘case’ with instance and ‘generalisatio’ with ‘extrapolation’. 
 
 
 
10: Ethical Research 
Voluntary participation and the right to withdraw 
Protection of research participants 
Assessment of potential benefit and risks to participants 
Obtaining informed consent 
Not doing harm 
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Complex Ethical Issues: 
Consent to observational research 
Consent to internet research 
Whether there can be an ‘appropriate’ deception 
Paying participants 
The unintended consequences of good ethical practice. 
 
 
Consent to internet research 
Many users perceive publically accessible discourse sites as private 
Anonymity is difficult to guarantee 
Online discussion sites can be highly transient  
Vulnerable persons are difficult to identify (age for example). 
 
 
Claire, 
 
My opinion is that if you are on this forum and you choose to answer a 
question posted to the forum you have consented. If you go further than that 
and approach a respondent outside the confines of the forum then we might 
to think about it. 
 
Best wishes. 
 
Atholl 
 
200813  Realised that I have used the idea of keyword frequency to 
construct my theretical model after reading Clive Seal’s work 
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PART THREE 
Collecting and analysing your data 
12: Collecting your data 
 
 
 
290813 
 
READING THROUGH THE SILVERMAN CHAPTER ON RELIABILITY 
LED ME TO GO BACK TO THE FORUM TO LOOK FOR DEVIANT CASES. 
CAME ACROSS AN ACCOUNT POSTED  BY EMA ON 040110 ABOUT 
TEACHERS HAVING DIFFICULTY ASKING FOR TIME OFF.  LED TO 
THINKING ABOUT NOT FEELING WORTHY WHICH WAS A MINOR CODE 
BEFORE AND HOW TIME OFF IS SANCTIONED BY AN AUTHORITY 
FIGURE SUCH AS BOSS OR DOCTOR.  INCORPORATED THIS INTO 
THE MODEL SUGGESTED BY CAROL RIVAS CTY VERSION 
 
 
 
300813 
Reading charmaz paper on disclosing disability in the work place. Linking 
peoples proclivity to disclose with the amount of legitamancy granted to their 
health condition.  Infertility may not be legitimised as a condition that 
warrents time off work  but GP will validate their desire for time off by signing 
them off with stress or other related conditions. 
 
Also GP is authority figure who sanctions time off and legitimises the 
condition.  
 
Conflict between the role of the doctor and the role of the employer reflects 
the conflict between role as treatment seeker or employee 
 
Could return to my 'medical sign off' codes to look for examples.  
 
APPENDICES 
Appendix	  	  12	  Memos	  Written	  During	  Qualitative	  Data	  Analysis	   1014	  
 
 
 
APPENDICES 
Appendix	  	  13	  References	  for	  Protocol	  for	  Strand	  3	   1015	  
 
APPENDIX 13 The References for 
Protocol for OVCT-001 Strand 3 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
i http://www.uhcw.nhs.uk/ivf/treatments/oi  Website for University 
Hospitals Coventry and Warwickshire, site visited 28.10.07 
 ii	  S.Vani,	  S.	  MacDonald,	  A.R.W	  Williams,	  J.I.	  Mason,	  K.J.Kong,	  H.O.D.	  Critchley.)	  (ESHRE	  LYON	  2007)	  	  
iii Abstract o014 Natural ICSI cycles with minimum stimulation in poor 
responder patients: a prospective study with historical control  (F.Ubaldi, 
L.Rienzi, F. Sapienza, M.Iacobelli, E Baroni, S.Romano, M.G.Minasi, 
S.Ferrero, E. Greco, European Hospital, Centre for Reproductive 
Medicine, Rome, Italy) (ESHRE LYON 2007) 
 
iv M. Dooley  Complementary therapy and obstetrics and gynaecology: a 
time to integrate.  Current Opinion Obstet Gynae, 2006  2006 Dec; 
18(6):648-652. 
 
v C. Haresnape, Unpublished PhD project. A survey of the use of 
homotoxicology to treat infertility in the UK, 2006. 
 
vi Nice  Fertility:assessment and treatment for people with fertility 
problems.  Evidence Tables. February 2004 
 
vii ESHRE LYON 2007 (Biovin and Schmidt) Abstract 0220 ‘’who uses 
complementary therapy? Predictors in an infertile population 
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viii ESHRE LYON 2007, Abstract 0219 ‘The development and initial 
psychometric testing of the Emotional Health in Infertility Questionnaire 
(EHIQ). G.A.Farmer, P.J. Magill, R. Shaw-Smith, J.E. McVeigh, 
S.H.Kennedy, C.Jenkinson 
ix Gail Farmer MSc. BA (Hons) RGN Clinical Research Sister  University of 
Oxford, Nuffield Department of Obstetrics and Gynaecology, John 
Radcliffe Hospital. (MSc Thesis papers currently being written for 
publication). 
 
x ‘Women with a BM! >35kg/m2 a significantly reduced chance of 
conceiving compared with those of normal weight.  Furthermore this 
group also reported a significant correlation between body weight and 
miscarriage after ART ‘page 10 A report of the Impact of obesity on 
female reproductive health: British Fertility Society, Policy and Practice 
Guidelines.  Lead authors: Adam H Balen and Richard A Anderson. 
xi Homeopathic Pharmacy, Theory and Practice.  Steven B Kayne  Second 
Edition  Elsevier ISBN 0-443101604 
 
xii Homeopathic Pharmacy, Theory and Practice.  Steven B Kayne  Second 
Edition  Elsevier ISBN 0-443101604 
Page 82 
xiii Homeopathic Pharmacy, Theory and Practice.  Steven B Kayne  Second 
Edition  Elsevier ISBN 0-443101604;Page 84 
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xiv Suis Organ Preparations  Therapy in Practice Heel 1994 
xv BioTherapeutic Index Heel, Baden Baden,  5th revised English edition 
page 69 
xvi Homeopathic Pharmacy, Theory and Practice.  Steven B Kayne  Second 
Edition  Elsevier ISBN 0-443101604  page 91 
 
 
xvii Suis Organ Preparations Therapy in Practice  Heel, Baden Baden 
Germany 1989 
xviii Materia Medica   Hans –Heinrich Reckeweg  Aureilia 4th edition ISBN 
3-922907-96-2 p492 
xix Suis-Organ Preparations Therapy in Practice.  Heel, Baden Baden 
Germany p18 
xx Materia Medica   Hans –Heinrich Reckeweg  Aureilia 4th edition ISBN 
3-922907-96-2 p587 
xxi Materia Medica   Hans –Heinrich Reckeweg  Aureilia 4th edition ISBN 
3-922907-96-2 p519 
 
xxii Page 380 BioTherapeutic Index.  Heel.  English Version  2000 
 
xxiii Clarke.  A Dictionary of Practical Materia  Medica Volume one B Jain 
Publishers (P) Ltd page653 
xxiv Materia Medica.  Hans-Heinrich Reckeqeg  4th edition Aurelia ISBN 3-
922907-96-2 Page 387  
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xxvi Materia Medica.  Hans-Heinrich Reckeqeg  4th edition Aurelia ISBN 3-
922907-96-2 Page 144 
 
xxvii Materia Medica.  Hans-Heinrich Reckeqeg  4th edition Aurelia ISBN 
3-922907-96-2 Page 531 
 
xxviii Materia Medica.  Hans-Heinrich Reckeqeg  4th edition Aurelia ISBN 
3-922907-96-2 Page 380 
 
xxix Materia Medica.  Hans-Heinrich Reckeqeg  4th edition Aurelia ISBN 3-
922907-96-2 Page 140 
 
xxx Materia Medica.  Hans-Heinrich Reckeqeg  4th edition Aurelia ISBN 3-
922907-96-2 Page 377 
xxxiMateria Medica.  Hans-Heinrich Reckeqeg  4th edition Aurelia ISBN 3-
922907-96-2 Page 185 
xxxii Materia Medica.  Hans-Heinrich Reckeqeg  4th edition Aurelia ISBN 
3-922907-96-2 Page 360 
xxxiii Materia Medica.  Hans-Heinrich Reckeqeg  4th edition Aurelia ISBN 
3-922907-96-2 Page 417 
xxxiv Materia Medica.  Hans-Heinrich Reckeqeg  4th edition Aurelia ISBN 
3-922907-96-2 Page 344 
xxxv Materia Medica.  Hans-Heinrich Reckeqeg  4th edition Aurelia ISBN 
3-922907-96-2 Page 118 
xxxvi Materia Medica.  Hans-Heinrich Reckeqeg  4th edition Aurelia ISBN 
3-922907-96-2 Page 398 
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